activity_comment	activity_id	assay_chembl_id	assay_description	assay_type	canonical_smiles	data_validity_comment	molecule_chembl_id	relation	standard_type	standard_units	standard_value	target_chembl_id	target_organism	type	units	value
	105521	CHEMBL823901	Inhibition of [3H]-phorbol 12,13-dibutyrate (PDBu) binding to human recombinant protein kinase C beta	B	CCCCCCCCC#Cc1ccc2c(c1)[C@](C)(C(C)C)[C@H]1C(=O)N[C@H](CO)[C@@H]21		CHEMBL440201	=	Ki	nM	701.0	CHEMBL3045	Homo sapiens	Ki	nM	701.0
	105521	CHEMBL823901	Inhibition of [3H]-phorbol 12,13-dibutyrate (PDBu) binding to human recombinant protein kinase C beta	B	CCCCCCCCC#Cc1ccc2c(c1)[C@](C)(C(C)C)[C@H]1C(=O)N[C@H](CO)[C@@H]21		CHEMBL440201	=	Ki	nM	701.0	CHEMBL3045	Homo sapiens	Ki	nM	701.0
	119374	CHEMBL823901	Inhibition of [3H]-phorbol 12,13-dibutyrate (PDBu) binding to human recombinant protein kinase C beta	B	CCCCCCCCC#Cc1ccc2c(c1)C[C@@H](CO)NC(=O)[C@H](C(C)C)N2C		CHEMBL6453	=	Ki	nM	70.0	CHEMBL3045	Homo sapiens	Ki	nM	70.0
	121808	CHEMBL823901	Inhibition of [3H]-phorbol 12,13-dibutyrate (PDBu) binding to human recombinant protein kinase C beta	B	CCCCCCCCCCCC(=O)Oc1ccc2c(c1)[C@@](C)(C(C)C)[C@H]1C(=O)N[C@H](CO)[C@@H]21		CHEMBL173348	=	Ki	nM	1052.0	CHEMBL3045	Homo sapiens	Ki	nM	1052.0
	134555	CHEMBL823901	Inhibition of [3H]-phorbol 12,13-dibutyrate (PDBu) binding to human recombinant protein kinase C beta	B	CCCCCCCCCCCC(=O)Oc1ccc2c(c1)[C@](C)(C(C)C)[C@H]1C(=O)N[C@H](CO)[C@@H]21		CHEMBL368720	=	Ki	nM	593.0	CHEMBL3045	Homo sapiens	Ki	nM	593.0
	141696	CHEMBL823901	Inhibition of [3H]-phorbol 12,13-dibutyrate (PDBu) binding to human recombinant protein kinase C beta	B	CCCCCCCCCCCCCC(=O)O[C@@H]1[C@@H](C)[C@@]2(O)[C@@H](C=C(CO)C[C@]3(O)C(=O)C(C)=C[C@@H]23)[C@@H]2C(C)(C)[C@]12OC(C)=O		CHEMBL279115	=	Ki	nM	1.8	CHEMBL3045	Homo sapiens	Ki	nM	1.8
	145866	CHEMBL759475	Inhibitory concentration against human protein kinase C-betaII using histone as substrate	B	COc1ccccc1C1=C(c2cn(CCCO)c3ncccc23)C(=O)NC1=O		CHEMBL111298	=	IC50	nM	1440.0	CHEMBL3045	Homo sapiens	IC50	uM	1.44
	145870	CHEMBL759475	Inhibitory concentration against human protein kinase C-betaII using histone as substrate	B	CN(C)CCCn1cc(C2=C(c3cccc4ccccc34)C(=O)NC2=O)c2cccnc21		CHEMBL326688	=	IC50	nM	240.0	CHEMBL3045	Homo sapiens	IC50	uM	0.24
	147025	CHEMBL759475	Inhibitory concentration against human protein kinase C-betaII using histone as substrate	B	O=C1NC(=O)C(c2cn(CCCO)c3ncccc23)=C1c1ccccc1C(F)(F)F		CHEMBL325817	=	IC50	nM	1850.0	CHEMBL3045	Homo sapiens	IC50	uM	1.85
	147029	CHEMBL759475	Inhibitory concentration against human protein kinase C-betaII using histone as substrate	B	COc1ccccc1C1=C(c2cn(CCCNS(C)(=O)=O)c3ncccc23)C(=O)NC1=O		CHEMBL326208	=	IC50	nM	1880.0	CHEMBL3045	Homo sapiens	IC50	uM	1.88
	157958	CHEMBL759476	Inhibition of protein kinase C-betaII at 10 uM	B	O=C1NC(=O)C(c2cn(CCCO)c3ncccc23)=C1c1cccs1		CHEMBL333829	<	Inhibition	%	50.0	CHEMBL3045	Homo sapiens	Inhibition	%	50.0
	159121	CHEMBL759475	Inhibitory concentration against human protein kinase C-betaII using histone as substrate	B	O=C1NC(=O)C(c2cn(CCCO)c3ncccc23)=C1c1ccc(F)cc1Cl		CHEMBL111005	=	IC50	nM	2380.0	CHEMBL3045	Homo sapiens	IC50	uM	2.38
	161206	CHEMBL762484	Inhibition of Protein kinase C beta	B	CC(C)(C)c1cnc(CSc2cnc(NC(=O)Cc3ccc(CNC(CO)CO)cc3)s2)o1		CHEMBL300936	>	IC50	nM	45000.0	CHEMBL3045	Homo sapiens	IC50	nM	45000.0
	165231	CHEMBL759475	Inhibitory concentration against human protein kinase C-betaII using histone as substrate	B	COc1ccccc1C1=C(c2cn(CCCN)c3ncccc23)C(=O)NC1=O		CHEMBL324268	=	IC50	nM	1100.0	CHEMBL3045	Homo sapiens	IC50	uM	1.1
	170245	CHEMBL759475	Inhibitory concentration against human protein kinase C-betaII using histone as substrate	B	CCn1cc(C2=C(c3cn(CCCO)c4ncccc34)C(=O)NC2=O)c2cccnc21		CHEMBL110000	=	IC50	nM	1070.0	CHEMBL3045	Homo sapiens	IC50	uM	1.07
	171444	CHEMBL759475	Inhibitory concentration against human protein kinase C-betaII using histone as substrate	B	COc1ccccc1C1=C(c2cn(CCCNC=O)c3ncccc23)C(=O)NC1=O		CHEMBL109977	=	IC50	nM	2730.0	CHEMBL3045	Homo sapiens	IC50	uM	2.73
	173753	CHEMBL759475	Inhibitory concentration against human protein kinase C-betaII using histone as substrate	B	CN(C)CCCn1cc(C2=C(c3ccccc3Cl)C(=O)NC2=O)c2cccnc21		CHEMBL109834	=	IC50	nM	1160.0	CHEMBL3045	Homo sapiens	IC50	uM	1.16
	174919	CHEMBL759475	Inhibitory concentration against human protein kinase C-betaII using histone as substrate	B	COc1ccccc1C1=C(c2cn(CCCNS(N)(=O)=O)c3ncccc23)C(=O)NC1=O		CHEMBL423323	=	IC50	nM	890.0	CHEMBL3045	Homo sapiens	IC50	uM	0.89
	177433	CHEMBL759476	Inhibition of protein kinase C-betaII at 10 uM	B	O=C1NC(=O)C(c2cn(CCCO)c3ncccc23)=C1c1ncc(C(F)(F)F)cc1Cl		CHEMBL111620	<	Inhibition	%	50.0	CHEMBL3045	Homo sapiens	Inhibition	%	50.0
	177485	CHEMBL759072	Inhibition of PKCbetaII	B	O=C1NC(=O)C(c2cn(CCCO)c3ncccc23)=C1c1ncc(C(F)(F)F)cc1Cl		CHEMBL111620	=	Activity	%	70.0	CHEMBL3045	Homo sapiens	Activity	%	70.0
	178742	CHEMBL759475	Inhibitory concentration against human protein kinase C-betaII using histone as substrate	B	O=C1NC(=O)C(c2cn(CCCO)c3ncccc23)=C1c1ccccc1Cl		CHEMBL326971	=	IC50	nM	730.0	CHEMBL3045	Homo sapiens	IC50	uM	0.73
	178746	CHEMBL759475	Inhibitory concentration against human protein kinase C-betaII using histone as substrate	B	COCCCn1cc(C2=C(c3ccccc3O)C(=O)NC2=O)c2cccnc21		CHEMBL109944	=	IC50	nM	4360.0	CHEMBL3045	Homo sapiens	IC50	uM	4.36
	178798	CHEMBL759072	Inhibition of PKCbetaII	B	COCCCn1cc(C2=C(c3ccccc3O)C(=O)NC2=O)c2cccnc21		CHEMBL109944	=	Activity	%	32.0	CHEMBL3045	Homo sapiens	Activity	%	32.0
	178824	CHEMBL759476	Inhibition of protein kinase C-betaII at 10 uM	B	O=C1NC(=O)C(c2cn(CCCO)c3ncccc23)=C1c1ccccn1		CHEMBL450340	<	Inhibition	%	50.0	CHEMBL3045	Homo sapiens	Inhibition	%	50.0
	180005	CHEMBL759475	Inhibitory concentration against human protein kinase C-betaII using histone as substrate	B	O=C1NC(=O)C(c2cn(CCCO)c3ncccc23)=C1c1cccc2ccccc12		CHEMBL430694	=	IC50	nM	270.0	CHEMBL3045	Homo sapiens	IC50	uM	0.27
	182057	CHEMBL762484	Inhibition of Protein kinase C beta	B	CN1CC[C@H](c2c(O)cc(O)c3c(=O)cc(-c4ccccc4Cl)oc23)[C@H](O)C1		CHEMBL428690	>	IC50	nM	45000.0	CHEMBL3045	Homo sapiens	IC50	nM	45000.0
	182493	CHEMBL759475	Inhibitory concentration against human protein kinase C-betaII using histone as substrate	B	COc1ccccc1C1=C(c2cn(CCCNC(=O)OC(C)(C)C)c3ncccc23)C(=O)NC1=O		CHEMBL109981	=	IC50	nM	2260.0	CHEMBL3045	Homo sapiens	IC50	uM	2.26
	182545	CHEMBL759072	Inhibition of PKCbetaII	B	COc1ccccc1C1=C(c2cn(CCCNC(=O)OC(C)(C)C)c3ncccc23)C(=O)NC1=O		CHEMBL109981	=	Activity	%	15.0	CHEMBL3045	Homo sapiens	Activity	%	15.0
	192997	CHEMBL761762	Inhibition of human Protein kinase C beta 1	B	O=C(N[C@@H]1CNCCC[C@H]1OC(=O)c1cc(O)c(C(=O)c2c(O)cccc2C(=O)O)c(O)c1)c1ccc(O)cc1		CHEMBL60254	=	IC50	nM	32.0	CHEMBL3045	Homo sapiens	IC50	uM	0.032
	192998	CHEMBL768101	Inhibition of human Protein kinase C beta 2	B	O=C(N[C@@H]1CNCCC[C@H]1OC(=O)c1cc(O)c(C(=O)c2c(O)cccc2C(=O)O)c(O)c1)c1ccc(O)cc1		CHEMBL60254	=	IC50	nM	44.0	CHEMBL3045	Homo sapiens	IC50	uM	0.044
	207171	CHEMBL761762	Inhibition of human Protein kinase C beta 1	B	O=C(N[C@@H]1CNC[C@H]1OC(=O)c1cc(O)c(C(=O)c2c(O)cccc2C(=O)O)c(O)c1)c1ccc(O)cc1		CHEMBL59828	=	IC50	nM	17.0	CHEMBL3045	Homo sapiens	IC50	uM	0.017
	207172	CHEMBL768103	Inhibition of human Protein kinase C beta 2	B	O=C(N[C@@H]1CNC[C@H]1OC(=O)c1cc(O)c(C(=O)c2c(O)cccc2C(=O)O)c(O)c1)c1ccc(O)cc1		CHEMBL59828	=	IC50	nM	33.0	CHEMBL3045	Homo sapiens	IC50	uM	0.033
	217785	CHEMBL761762	Inhibition of human Protein kinase C beta 1	B	O=C(N[C@@H]1CCC[C@H]1OC(=O)c1cc(O)c(C(=O)c2c(O)cccc2C(=O)O)c(O)c1)c1ccc(O)cc1		CHEMBL52529	=	IC50	nM	40.0	CHEMBL3045	Homo sapiens	IC50	uM	0.04
	217786	CHEMBL768103	Inhibition of human Protein kinase C beta 2	B	O=C(N[C@@H]1CCC[C@H]1OC(=O)c1cc(O)c(C(=O)c2c(O)cccc2C(=O)O)c(O)c1)c1ccc(O)cc1		CHEMBL52529	=	IC50	nM	50.0	CHEMBL3045	Homo sapiens	IC50	uM	0.05
	218984	CHEMBL761762	Inhibition of human Protein kinase C beta 1	B	O=C(N[C@@H]1CNCC[C@H]1OC(=O)c1cc(O)c(C(=O)c2c(O)cccc2C(=O)O)c(O)c1)c1ccc(O)cc1		CHEMBL67442	=	IC50	nM	2200.0	CHEMBL3045	Homo sapiens	IC50	uM	2.2
	218985	CHEMBL768103	Inhibition of human Protein kinase C beta 2	B	O=C(N[C@@H]1CNCC[C@H]1OC(=O)c1cc(O)c(C(=O)c2c(O)cccc2C(=O)O)c(O)c1)c1ccc(O)cc1		CHEMBL67442	=	IC50	nM	4700.0	CHEMBL3045	Homo sapiens	IC50	uM	4.7
	221444	CHEMBL761762	Inhibition of human Protein kinase C beta 1	B	O=C(N[C@@H]1CCCCC[C@H]1OC(=O)c1cc(O)c(C(=O)c2c(O)cccc2C(=O)O)c(O)c1)c1ccc(O)cc1		CHEMBL304549	=	IC50	nM	220.0	CHEMBL3045	Homo sapiens	IC50	uM	0.22
	221445	CHEMBL768101	Inhibition of human Protein kinase C beta 2	B	O=C(N[C@@H]1CCCCC[C@H]1OC(=O)c1cc(O)c(C(=O)c2c(O)cccc2C(=O)O)c(O)c1)c1ccc(O)cc1		CHEMBL304549	=	IC50	nM	430.0	CHEMBL3045	Homo sapiens	IC50	uM	0.43
	226773	CHEMBL761758	Inhibition of Protein kinase C beta 1	B	CCN1CCC(n2cc(C3=C(c4cn(C)c5ccccc45)C(=O)NC3=O)c3ccccc32)CC1		CHEMBL54382	=	IC50	nM	20.0	CHEMBL3045	Homo sapiens	IC50	uM	0.02
	226774	CHEMBL764582	Inhibition of Protein kinase C beta 2	B	CCN1CCC(n2cc(C3=C(c4cn(C)c5ccccc45)C(=O)NC3=O)c3ccccc32)CC1		CHEMBL54382	=	IC50	nM	5.0	CHEMBL3045	Homo sapiens	IC50	uM	0.005
	233202	CHEMBL761758	Inhibition of Protein kinase C beta 1	B	CN(C)C[C@@H]1CCn2cc(c3ccccc32)C2=C(C(=O)NC2=O)c2cn(c3ccccc23)CCO1.CS(=O)(=O)O		CHEMBL432130	=	IC50	nM	4.7	CHEMBL3045	Homo sapiens	IC50	uM	0.0047
	233203	CHEMBL764582	Inhibition of Protein kinase C beta 2	B	CN(C)C[C@@H]1CCn2cc(c3ccccc32)C2=C(C(=O)NC2=O)c2cn(c3ccccc23)CCO1.CS(=O)(=O)O		CHEMBL432130	=	IC50	nM	5.9	CHEMBL3045	Homo sapiens	IC50	uM	0.0059
	247734	CHEMBL761758	Inhibition of Protein kinase C beta 1	B	Cn1cc(C2=C(c3cn(C4CCN(Cc5ccccc5)C4)c4ccccc34)C(=O)NC2=O)c2ccccc21		CHEMBL291975	=	IC50	nM	22.0	CHEMBL3045	Homo sapiens	IC50	uM	0.022
	247735	CHEMBL764582	Inhibition of Protein kinase C beta 2	B	Cn1cc(C2=C(c3cn(C4CCN(Cc5ccccc5)C4)c4ccccc34)C(=O)NC2=O)c2ccccc21		CHEMBL291975	=	IC50	nM	24.0	CHEMBL3045	Homo sapiens	IC50	uM	0.024
	249191	CHEMBL761758	Inhibition of Protein kinase C beta 1	B	Cn1cc(C2=C(c3cn(C4CCNCC4)c4ccccc34)C(=O)NC2=O)c2ccccc21		CHEMBL55788	=	IC50	nM	30.0	CHEMBL3045	Homo sapiens	IC50	uM	0.03
	249192	CHEMBL764582	Inhibition of Protein kinase C beta 2	B	Cn1cc(C2=C(c3cn(C4CCNCC4)c4ccccc34)C(=O)NC2=O)c2ccccc21		CHEMBL55788	=	IC50	nM	30.0	CHEMBL3045	Homo sapiens	IC50	uM	0.03
	250564	CHEMBL761758	Inhibition of Protein kinase C beta 1	B	CC(C)N1CCC(n2cc(C3=C(c4cn(C)c5ccccc45)C(=O)NC3=O)c3ccccc32)CC1		CHEMBL301860	=	IC50	nM	19.0	CHEMBL3045	Homo sapiens	IC50	uM	0.019
	250565	CHEMBL764582	Inhibition of Protein kinase C beta 2	B	CC(C)N1CCC(n2cc(C3=C(c4cn(C)c5ccccc45)C(=O)NC3=O)c3ccccc32)CC1		CHEMBL301860	=	IC50	nM	26.0	CHEMBL3045	Homo sapiens	IC50	uM	0.026
	251939	CHEMBL761758	Inhibition of Protein kinase C beta 1	B	CN1CCC(n2cc(C3=C(c4c[nH]c5ccccc45)C(=O)NC3=O)c3ccccc32)CC1		CHEMBL52654	=	IC50	nM	20.0	CHEMBL3045	Homo sapiens	IC50	uM	0.02
	251940	CHEMBL764582	Inhibition of Protein kinase C beta 2	B	CN1CCC(n2cc(C3=C(c4c[nH]c5ccccc45)C(=O)NC3=O)c3ccccc32)CC1		CHEMBL52654	=	IC50	nM	10.0	CHEMBL3045	Homo sapiens	IC50	uM	0.01
	254630	CHEMBL761758	Inhibition of Protein kinase C beta 1	B	Cn1cc(C2=C(c3cn(C4CCN(CC5CC5)CC4)c4ccccc34)C(=O)NC2=O)c2ccccc21		CHEMBL55394	=	IC50	nM	30.0	CHEMBL3045	Homo sapiens	IC50	uM	0.03
	254631	CHEMBL764582	Inhibition of Protein kinase C beta 2	B	Cn1cc(C2=C(c3cn(C4CCN(CC5CC5)CC4)c4ccccc34)C(=O)NC2=O)c2ccccc21		CHEMBL55394	=	IC50	nM	10.0	CHEMBL3045	Homo sapiens	IC50	uM	0.01
	256023	CHEMBL761758	Inhibition of Protein kinase C beta 1	B	Cn1cc(C2=C(c3cn(C4CCN(Cc5ccccn5)CC4)c4ccccc34)C(=O)NC2=O)c2ccccc21		CHEMBL300138	=	IC50	nM	30.0	CHEMBL3045	Homo sapiens	IC50	uM	0.03
	256024	CHEMBL764582	Inhibition of Protein kinase C beta 2	B	Cn1cc(C2=C(c3cn(C4CCN(Cc5ccccn5)CC4)c4ccccc34)C(=O)NC2=O)c2ccccc21		CHEMBL300138	=	IC50	nM	30.0	CHEMBL3045	Homo sapiens	IC50	uM	0.03
	257372	CHEMBL761758	Inhibition of Protein kinase C beta 1	B	Cn1cc(C2=C(c3cn(C4CCN(Cc5ccccc5)CC4)c4ccccc34)C(=O)NC2=O)c2ccccc21		CHEMBL300549	=	IC50	nM	50.0	CHEMBL3045	Homo sapiens	IC50	uM	0.05
	257373	CHEMBL764582	Inhibition of Protein kinase C beta 2	B	Cn1cc(C2=C(c3cn(C4CCN(Cc5ccccc5)CC4)c4ccccc34)C(=O)NC2=O)c2ccccc21		CHEMBL300549	=	IC50	nM	30.0	CHEMBL3045	Homo sapiens	IC50	uM	0.03
	257385	CHEMBL761758	Inhibition of Protein kinase C beta 1	B	CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL388978	=	IC50	nM	23.0	CHEMBL3045	Homo sapiens	IC50	uM	0.023
	257386	CHEMBL764582	Inhibition of Protein kinase C beta 2	B	CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL388978	=	IC50	nM	19.0	CHEMBL3045	Homo sapiens	IC50	uM	0.019
	258769	CHEMBL761758	Inhibition of Protein kinase C beta 1	B	CN1CCC(n2cc(C3=C(c4cn(C)c5ccccc45)C(=O)NC3=O)c3ccccc32)CC1		CHEMBL53596	=	IC50	nM	20.0	CHEMBL3045	Homo sapiens	IC50	uM	0.02
	258770	CHEMBL764582	Inhibition of Protein kinase C beta 2	B	CN1CCC(n2cc(C3=C(c4cn(C)c5ccccc45)C(=O)NC3=O)c3ccccc32)CC1		CHEMBL53596	=	IC50	nM	10.0	CHEMBL3045	Homo sapiens	IC50	uM	0.01
	262661	CHEMBL761758	Inhibition of Protein kinase C beta 1	B	Cn1cc(C2=C(c3cn(C4CCN(C(=O)OC(C)(C)C)CC4)c4ccccc34)C(=O)NC2=O)c2ccccc21		CHEMBL293805	=	IC50	nM	200.0	CHEMBL3045	Homo sapiens	IC50	uM	0.2
	262662	CHEMBL764582	Inhibition of Protein kinase C beta 2	B	Cn1cc(C2=C(c3cn(C4CCN(C(=O)OC(C)(C)C)CC4)c4ccccc34)C(=O)NC2=O)c2ccccc21		CHEMBL293805	=	IC50	nM	80.0	CHEMBL3045	Homo sapiens	IC50	uM	0.08
	265154	CHEMBL761767	Inhibition of Protein kinase C beta 1	B	O=C(N[C@@H]1CNCCC[C@H]1OC(=O)c1cc(O)c(C(=O)c2c(O)cccc2C(=O)O)c(O)c1)c1ccc(O)cc1		CHEMBL60254	=	IC50	nM	10.0	CHEMBL3045	Homo sapiens	IC50	uM	0.01
	265155	CHEMBL768107	Inhibition of Protein kinase C beta 2	B	O=C(N[C@@H]1CNCCC[C@H]1OC(=O)c1cc(O)c(C(=O)c2c(O)cccc2C(=O)O)c(O)c1)c1ccc(O)cc1		CHEMBL60254	=	IC50	nM	10.0	CHEMBL3045	Homo sapiens	IC50	uM	0.01
	273992	CHEMBL761767	Inhibition of Protein kinase C beta 1	B	CN(C(=O)c1cc(O)c(C(=O)c2c(O)cccc2C(=O)O)c(O)c1)[C@H]1CCCNC[C@H]1NC(=O)c1ccc(O)cc1		CHEMBL2310935	>	IC50	nM	50000.0	CHEMBL3045	Homo sapiens	IC50	uM	50.0
	273993	CHEMBL768107	Inhibition of Protein kinase C beta 2	B	CN(C(=O)c1cc(O)c(C(=O)c2c(O)cccc2C(=O)O)c(O)c1)[C@H]1CCCNC[C@H]1NC(=O)c1ccc(O)cc1		CHEMBL2310935	>	IC50	nM	50000.0	CHEMBL3045	Homo sapiens	IC50	uM	50.0
	276554	CHEMBL761767	Inhibition of Protein kinase C beta 1	B	O=C(N[C@@H]1CNC[C@H]1NC(=O)c1cc(O)c(C(=O)c2c(O)cccc2C(=O)O)c(O)c1)c1ccc(O)cc1		CHEMBL59677	=	IC50	nM	220.0	CHEMBL3045	Homo sapiens	IC50	uM	0.22
	276555	CHEMBL768107	Inhibition of Protein kinase C beta 2	B	O=C(N[C@@H]1CNC[C@H]1NC(=O)c1cc(O)c(C(=O)c2c(O)cccc2C(=O)O)c(O)c1)c1ccc(O)cc1		CHEMBL59677	=	IC50	nM	330.0	CHEMBL3045	Homo sapiens	IC50	uM	0.33
	278917	CHEMBL761767	Inhibition of Protein kinase C beta 1	B	O=C(N[C@@H]1CNC[C@H]1OC(=O)c1cc(O)c(C(=O)c2c(O)cccc2C(=O)O)c(O)c1)c1ccc(O)cc1		CHEMBL59828	=	IC50	nM	10.0	CHEMBL3045	Homo sapiens	IC50	uM	0.01
	278918	CHEMBL768107	Inhibition of Protein kinase C beta 2	B	O=C(N[C@@H]1CNC[C@H]1OC(=O)c1cc(O)c(C(=O)c2c(O)cccc2C(=O)O)c(O)c1)c1ccc(O)cc1		CHEMBL59828	=	IC50	nM	33.0	CHEMBL3045	Homo sapiens	IC50	uM	0.033
	284838	CHEMBL761767	Inhibition of Protein kinase C beta 1	B	C[C@@]1(OC(=O)c2cc(O)c(C(=O)c3c(O)cccc3C(=O)O)c(O)c2)CCCNC[C@H]1NC(=O)c1ccc(O)cc1		CHEMBL433101	=	IC50	nM	120.0	CHEMBL3045	Homo sapiens	IC50	uM	0.12
	284839	CHEMBL768107	Inhibition of Protein kinase C beta 2	B	C[C@@]1(OC(=O)c2cc(O)c(C(=O)c3c(O)cccc3C(=O)O)c(O)c2)CCCNC[C@H]1NC(=O)c1ccc(O)cc1		CHEMBL433101	=	IC50	nM	70.0	CHEMBL3045	Homo sapiens	IC50	uM	0.07
	289621	CHEMBL761767	Inhibition of Protein kinase C beta 1	B	O=C(NC[C@@H]1CCC[C@H]1NC(=O)c1ccc(O)cc1)c1cc(O)c(C(=O)c2c(O)cccc2C(=O)O)c(O)c1		CHEMBL293500	=	IC50	nM	17000.0	CHEMBL3045	Homo sapiens	IC50	uM	17.0
	289622	CHEMBL768107	Inhibition of Protein kinase C beta 2	B	O=C(NC[C@@H]1CCC[C@H]1NC(=O)c1ccc(O)cc1)c1cc(O)c(C(=O)c2c(O)cccc2C(=O)O)c(O)c1		CHEMBL293500	=	IC50	nM	4900.0	CHEMBL3045	Homo sapiens	IC50	uM	4.9
	294626	CHEMBL761767	Inhibition of Protein kinase C beta 1	B	O=C(N[C@@H]1CCCNC[C@H]1NC(=O)c1ccc(O)cc1)c1cc(O)c(C(=O)c2c(O)cccc2C(=O)O)c(O)c1		CHEMBL59687	=	IC50	nM	630.0	CHEMBL3045	Homo sapiens	IC50	uM	0.63
	294627	CHEMBL768107	Inhibition of Protein kinase C beta 2	B	O=C(N[C@@H]1CCCNC[C@H]1NC(=O)c1ccc(O)cc1)c1cc(O)c(C(=O)c2c(O)cccc2C(=O)O)c(O)c1		CHEMBL59687	=	IC50	nM	1200.0	CHEMBL3045	Homo sapiens	IC50	uM	1.2
	294634	CHEMBL761767	Inhibition of Protein kinase C beta 1	B	O=C(N[C@@H]1CCC[C@H]1OC(=O)c1cc(O)c(C(=O)c2c(O)cccc2C(=O)O)c(O)c1)c1ccc(O)cc1		CHEMBL52529	=	IC50	nM	40.0	CHEMBL3045	Homo sapiens	IC50	uM	0.04
	294635	CHEMBL768107	Inhibition of Protein kinase C beta 2	B	O=C(N[C@@H]1CCC[C@H]1OC(=O)c1cc(O)c(C(=O)c2c(O)cccc2C(=O)O)c(O)c1)c1ccc(O)cc1		CHEMBL52529	=	IC50	nM	50.0	CHEMBL3045	Homo sapiens	IC50	uM	0.05
	297264	CHEMBL761767	Inhibition of Protein kinase C beta 1	B	O=C(N[C@@H]1CCC[C@H]1OCc1cc(O)c(C(=O)c2c(O)cccc2C(=O)O)c(O)c1)c1ccc(O)cc1		CHEMBL294303	=	IC50	nM	430.0	CHEMBL3045	Homo sapiens	IC50	uM	0.43
	297265	CHEMBL768107	Inhibition of Protein kinase C beta 2	B	O=C(N[C@@H]1CCC[C@H]1OCc1cc(O)c(C(=O)c2c(O)cccc2C(=O)O)c(O)c1)c1ccc(O)cc1		CHEMBL294303	=	IC50	nM	290.0	CHEMBL3045	Homo sapiens	IC50	uM	0.29
	299836	CHEMBL761767	Inhibition of Protein kinase C beta 1	B	O=C(N[C@@H]1CCC[C@H]1COC(=O)c1cc(O)c(C(=O)c2c(O)cccc2C(=O)O)c(O)c1)c1ccc(O)cc1		CHEMBL60455	=	IC50	nM	40.0	CHEMBL3045	Homo sapiens	IC50	uM	0.04
	299837	CHEMBL768107	Inhibition of Protein kinase C beta 2	B	O=C(N[C@@H]1CCC[C@H]1COC(=O)c1cc(O)c(C(=O)c2c(O)cccc2C(=O)O)c(O)c1)c1ccc(O)cc1		CHEMBL60455	=	IC50	nM	30.0	CHEMBL3045	Homo sapiens	IC50	uM	0.03
Not Active	302287	CHEMBL766517	Inhibition of Protein Kinase C beta at 10 uM Histone H1 substrate (Inactive)	B	COn1cc2c3c(cccc31)[C@@H]1C=C(C)CN(C)[C@@H]1C2		CHEMBL435240		Inhibition	%		CHEMBL3045	Homo sapiens	Inhibition	%	
	303404	CHEMBL761767	Inhibition of Protein kinase C beta 1	B	O=C(N[C@@H]1CNCCC[C@H]1OC(=O)c1cc(O)c(C(=O)c2c(O)cccc2C(=O)O)c(O)c1)c1ccc(O)cc1		CHEMBL60254	=	IC50	nM	30.0	CHEMBL3045	Homo sapiens	IC50	uM	0.03
	303405	CHEMBL768107	Inhibition of Protein kinase C beta 2	B	O=C(N[C@@H]1CNCCC[C@H]1OC(=O)c1cc(O)c(C(=O)c2c(O)cccc2C(=O)O)c(O)c1)c1ccc(O)cc1		CHEMBL60254	=	IC50	nM	30.0	CHEMBL3045	Homo sapiens	IC50	uM	0.03
	308748	CHEMBL768247	Displacement of [3H]PDBu from protein kinase C Beta-C1A domain	B	CCCCCCCCCCCN1c2ccccc2C[C@@H](CO)OC(=O)[C@@H]1C(C)C		CHEMBL102991	=	Ki	nM	4690.0	CHEMBL3045	Homo sapiens	Ki	nM	4690.0
	308749	CHEMBL768249	Displacement of [3H]PDBu from protein kinase C Beta-C1B domain	B	CCCCCCCCCCCN1c2ccccc2C[C@@H](CO)OC(=O)[C@@H]1C(C)C		CHEMBL102991	=	Ki	nM	2070.0	CHEMBL3045	Homo sapiens	Ki	nM	2070.0
	308762	CHEMBL768246	Binding affinity for protein kinase C Beta-C1A domain	B	CCCC(=O)O[C@@H]1[C@@H](C)[C@@]2(O)[C@@H](C=C(CO)C[C@]3(O)C(=O)C(C)=C[C@@H]23)[C@@H]2C(C)(C)[C@]12OC(=O)CCC		CHEMBL27768	=	Kd	nM	1.31	CHEMBL3045	Homo sapiens	Kd	nM	1.31
	308763	CHEMBL768248	Binding affinity for protein kinase C Beta-C1B domain	B	CCCC(=O)O[C@@H]1[C@@H](C)[C@@]2(O)[C@@H](C=C(CO)C[C@]3(O)C(=O)C(C)=C[C@@H]23)[C@@H]2C(C)(C)[C@]12OC(=O)CCC		CHEMBL27768	=	Kd	nM	1.34	CHEMBL3045	Homo sapiens	Kd	nM	1.34
	312747	CHEMBL768247	Displacement of [3H]PDBu from protein kinase C Beta-C1A domain	B	CCCCCCCCCCc1ccc2c(c1)N(C)[C@@H](C(C)C)C(=O)O[C@H](CO)C2		CHEMBL102858	=	Ki	nM	1140.0	CHEMBL3045	Homo sapiens	Ki	nM	1140.0
	312748	CHEMBL768249	Displacement of [3H]PDBu from protein kinase C Beta-C1B domain	B	CCCCCCCCCCc1ccc2c(c1)N(C)[C@@H](C(C)C)C(=O)O[C@H](CO)C2		CHEMBL102858	=	Ki	nM	610.0	CHEMBL3045	Homo sapiens	Ki	nM	610.0
	330321	CHEMBL768247	Displacement of [3H]PDBu from protein kinase C Beta-C1A domain	B	CCCCCCCCCCc1cccc2c1C[C@@H](CO)OC(=O)[C@H](C(C)C)N2C		CHEMBL103091	=	Ki	nM	539.0	CHEMBL3045	Homo sapiens	Ki	nM	539.0
	330322	CHEMBL768249	Displacement of [3H]PDBu from protein kinase C Beta-C1B domain	B	CCCCCCCCCCc1cccc2c1C[C@@H](CO)OC(=O)[C@H](C(C)C)N2C		CHEMBL103091	=	Ki	nM	2690.0	CHEMBL3045	Homo sapiens	Ki	nM	2690.0
	330335	CHEMBL768247	Displacement of [3H]PDBu from protein kinase C Beta-C1A domain	B	CCCCCCCCCCc1ccc2c(c1)C[C@@H](CO)OC(=O)[C@H](C(C)C)N2C		CHEMBL318971	>	Ki	nM	10000.0	CHEMBL3045	Homo sapiens	Ki	nM	10000.0
	330336	CHEMBL768249	Displacement of [3H]PDBu from protein kinase C Beta-C1B domain	B	CCCCCCCCCCc1ccc2c(c1)C[C@@H](CO)OC(=O)[C@H](C(C)C)N2C		CHEMBL318971	=	Ki	nM	22000.0	CHEMBL3045	Homo sapiens	Ki	nM	22000.0
	394909	CHEMBL760370	Inhibition of PKC-beta2 kinase	B	COc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCNCC2)n1		CHEMBL95692	=	IC50	nM	17.0	CHEMBL3045	Homo sapiens	IC50	nM	17.0
	395336	CHEMBL761755	Inhibition of Protein kinase C beta	B	CCCCc1c(-c2ccc(O)cc2)[nH]c2nccnc12		CHEMBL75680	>	IC50	nM	100000.0	CHEMBL3045	Homo sapiens	IC50	uM	100.0
	395337	CHEMBL761755	Inhibition of Protein kinase C beta	B	CCCCc1c(-c2ccc(O)cc2)[nH]c2nccnc12		CHEMBL75680	>	IC50	nM	100000.0	CHEMBL3045	Homo sapiens	IC50	uM	100.0
	396153	CHEMBL761760	Inhibition of Protein kinase C beta 1	B	O=C(NC1CN2CCC(CC2)C1OC(=O)c1cc(O)c(C(=O)c2c(O)cccc2C(=O)O)c(O)c1)c1ccc(O)cc1		CHEMBL306884	=	IC50	nM	26.0	CHEMBL3045	Homo sapiens	IC50	uM	0.026
	396154	CHEMBL768099	Inhibition of Protein kinase C beta 2	B	O=C(NC1CN2CCC(CC2)C1OC(=O)c1cc(O)c(C(=O)c2c(O)cccc2C(=O)O)c(O)c1)c1ccc(O)cc1		CHEMBL306884	=	IC50	nM	69.0	CHEMBL3045	Homo sapiens	IC50	uM	0.069
	397392	CHEMBL761760	Inhibition of Protein kinase C beta 1	B	O=C(NC1CCC[C@@H]1OC(=O)c1cc(O)c(C(=O)c2c(O)cccc2C(=O)O)c(O)c1)c1ccc(O)cc1		CHEMBL71331	=	IC50	nM	40.0	CHEMBL3045	Homo sapiens	IC50	uM	0.04
	397393	CHEMBL768099	Inhibition of Protein kinase C beta 2	B	O=C(NC1CCC[C@@H]1OC(=O)c1cc(O)c(C(=O)c2c(O)cccc2C(=O)O)c(O)c1)c1ccc(O)cc1		CHEMBL71331	=	IC50	nM	50.0	CHEMBL3045	Homo sapiens	IC50	uM	0.05
	402628	CHEMBL761760	Inhibition of Protein kinase C beta 1	B	O=C(N[C@@H]1CNCCCC1OC(=O)c1cc(O)c(C(=O)c2c(O)cccc2C(=O)O)c(O)c1)c1ccc(O)cc1		CHEMBL311399	=	IC50	nM	32.0	CHEMBL3045	Homo sapiens	IC50	uM	0.032
	402629	CHEMBL768099	Inhibition of Protein kinase C beta 2	B	O=C(N[C@@H]1CNCCCC1OC(=O)c1cc(O)c(C(=O)c2c(O)cccc2C(=O)O)c(O)c1)c1ccc(O)cc1		CHEMBL311399	=	IC50	nM	44.0	CHEMBL3045	Homo sapiens	IC50	uM	0.044
	403968	CHEMBL761760	Inhibition of Protein kinase C beta 1	B	O=C(NC1C2CCC(C2)C1OC(=O)c1cc(O)c(C(=O)c2c(O)cccc2C(=O)O)c(O)c1)c1ccc(O)cc1		CHEMBL305667	=	IC50	nM	45.0	CHEMBL3045	Homo sapiens	IC50	uM	0.045
	403969	CHEMBL768099	Inhibition of Protein kinase C beta 2	B	O=C(NC1C2CCC(C2)C1OC(=O)c1cc(O)c(C(=O)c2c(O)cccc2C(=O)O)c(O)c1)c1ccc(O)cc1		CHEMBL305667	=	IC50	nM	30.0	CHEMBL3045	Homo sapiens	IC50	uM	0.03
	413927	CHEMBL761760	Inhibition of Protein kinase C beta 1	B	CN1C2CCC1C(NC(=O)c1ccc(O)cc1)C(OC(=O)c1cc(O)c(C(=O)c3c(O)cccc3C(=O)O)c(O)c1)C2		CHEMBL306883	=	IC50	nM	22000.0	CHEMBL3045	Homo sapiens	IC50	uM	22.0
	413928	CHEMBL768099	Inhibition of Protein kinase C beta 2	B	CN1C2CCC1C(NC(=O)c1ccc(O)cc1)C(OC(=O)c1cc(O)c(C(=O)c3c(O)cccc3C(=O)O)c(O)c1)C2		CHEMBL306883	=	IC50	nM	22000.0	CHEMBL3045	Homo sapiens	IC50	uM	22.0
	418750	CHEMBL761760	Inhibition of Protein kinase C beta 1	B	O=C(NC1C2CCC(C2)C1OC(=O)c1cc(O)c(C(=O)c2c(O)cccc2C(=O)O)c(O)c1)c1ccc(O)cc1		CHEMBL305667	=	IC50	nM	17000.0	CHEMBL3045	Homo sapiens	IC50	uM	17.0
	418751	CHEMBL768099	Inhibition of Protein kinase C beta 2	B	O=C(NC1C2CCC(C2)C1OC(=O)c1cc(O)c(C(=O)c2c(O)cccc2C(=O)O)c(O)c1)c1ccc(O)cc1		CHEMBL305667	=	IC50	nM	6900.0	CHEMBL3045	Homo sapiens	IC50	uM	6.9
	418759	CHEMBL761760	Inhibition of Protein kinase C beta 1	B	O=C(NC1C2CC(C3CCCC32)C1OC(=O)c1cc(O)c(C(=O)c2c(O)cccc2C(=O)O)c(O)c1)c1ccc(O)cc1		CHEMBL72480	=	IC50	nM	150.0	CHEMBL3045	Homo sapiens	IC50	uM	0.15
	418760	CHEMBL768099	Inhibition of Protein kinase C beta 2	B	O=C(NC1C2CC(C3CCCC32)C1OC(=O)c1cc(O)c(C(=O)c2c(O)cccc2C(=O)O)c(O)c1)c1ccc(O)cc1		CHEMBL72480	=	IC50	nM	30.0	CHEMBL3045	Homo sapiens	IC50	uM	0.03
Not Determined	418890	CHEMBL760371	Inhibition of PKC-beta2 kinase (Not determined)	B	COc1nccc(-c2c(-c3ccc(F)cc3)ncn2[C@H]2CC[C@H](O)CC2)n1		CHEMBL97162		Inhibition	%		CHEMBL3045	Homo sapiens	Inhibition		
	419946	CHEMBL761760	Inhibition of Protein kinase C beta 1	B	O=C(NC1CN2CCC(CC2)C1OC(=O)c1cc(O)c(C(=O)c2c(O)cccc2C(=O)O)c(O)c1)c1ccc(O)cc1		CHEMBL306884	=	IC50	nM	6300.0	CHEMBL3045	Homo sapiens	IC50	uM	6.3
	419947	CHEMBL768099	Inhibition of Protein kinase C beta 2	B	O=C(NC1CN2CCC(CC2)C1OC(=O)c1cc(O)c(C(=O)c2c(O)cccc2C(=O)O)c(O)c1)c1ccc(O)cc1		CHEMBL306884	=	IC50	nM	34000.0	CHEMBL3045	Homo sapiens	IC50	uM	34.0
	419955	CHEMBL761760	Inhibition of Protein kinase C beta 1	B	O=C(NC1C2CC(C3CCCC32)C1OC(=O)c1cc(O)c(C(=O)c2c(O)cccc2C(=O)O)c(O)c1)c1ccc(O)cc1		CHEMBL72480	=	IC50	nM	3300.0	CHEMBL3045	Homo sapiens	IC50	uM	3.3
	419956	CHEMBL768099	Inhibition of Protein kinase C beta 2	B	O=C(NC1C2CC(C3CCCC32)C1OC(=O)c1cc(O)c(C(=O)c2c(O)cccc2C(=O)O)c(O)c1)c1ccc(O)cc1		CHEMBL72480	=	IC50	nM	2100.0	CHEMBL3045	Homo sapiens	IC50	uM	2.1
	422829	CHEMBL761760	Inhibition of Protein kinase C beta 1	B	CN1C2CCC1C(NC(=O)c1ccc(O)cc1)C(OC(=O)c1cc(O)c(C(=O)c3c(O)cccc3C(=O)O)c(O)c1)C2		CHEMBL306883	=	IC50	nM	4400.0	CHEMBL3045	Homo sapiens	IC50	uM	4.4
	422830	CHEMBL768099	Inhibition of Protein kinase C beta 2	B	CN1C2CCC1C(NC(=O)c1ccc(O)cc1)C(OC(=O)c1cc(O)c(C(=O)c3c(O)cccc3C(=O)O)c(O)c1)C2		CHEMBL306883	=	IC50	nM	14000.0	CHEMBL3045	Homo sapiens	IC50	uM	14.0
	426588	CHEMBL761760	Inhibition of Protein kinase C beta 1	B	O=C(NC1CNC[C@@H]1OC(=O)c1cc(O)c(C(=O)c2c(O)cccc2C(=O)O)c(O)c1)c1ccc(O)cc1		CHEMBL422056	=	IC50	nM	17.0	CHEMBL3045	Homo sapiens	IC50	uM	0.017
	426589	CHEMBL768099	Inhibition of Protein kinase C beta 2	B	O=C(NC1CNC[C@@H]1OC(=O)c1cc(O)c(C(=O)c2c(O)cccc2C(=O)O)c(O)c1)c1ccc(O)cc1		CHEMBL422056	=	IC50	nM	33.0	CHEMBL3045	Homo sapiens	IC50	uM	0.033
	427205	CHEMBL761764	Binding affinity for human PKC beta-1	B	CC(C)[C@H]1C(=O)N[C@H](CO)Cc2cc(NC(=O)CCCCCCCCCCCCC(=O)Nc3ccc4c(c3)N(C)[C@@H](C(C)C)C(=O)N[C@H](CO)C4)ccc2N1C		CHEMBL337834	=	Kd	nM	0.19	CHEMBL3045	Homo sapiens	Kd	nM	0.19
	427210	CHEMBL761765	Inhibition of human PKC beta-1	B	CC(C)[C@H]1C(=O)N[C@H](CO)Cc2cc(NC(=O)CCCCCCCCCCCCC(=O)Nc3ccc4c(c3)N(C)[C@@H](C(C)C)C(=O)N[C@H](CO)C4)ccc2N1C		CHEMBL337834	=	Ki	nM	1.42	CHEMBL3045	Homo sapiens	Ki	nM	1.42
	429119	CHEMBL761760	Inhibition of Protein kinase C beta 1	B	CC1(C)C2CCC1(C)C(OC(=O)c1cc(O)c(C(=O)c3c(O)cccc3C(=O)O)c(O)c1)C2NC(=O)c1ccc(O)cc1		CHEMBL306170	=	IC50	nM	310.0	CHEMBL3045	Homo sapiens	IC50	uM	0.31
	429120	CHEMBL768099	Inhibition of Protein kinase C beta 2	B	CC1(C)C2CCC1(C)C(OC(=O)c1cc(O)c(C(=O)c3c(O)cccc3C(=O)O)c(O)c1)C2NC(=O)c1ccc(O)cc1		CHEMBL306170	=	IC50	nM	80.0	CHEMBL3045	Homo sapiens	IC50	uM	0.08
	475040	CHEMBL764579	Inhibition of Human Protein kinase C beta 2	B	O=C(N[C@@H]1CCC[C@H]1OC(=O)c1cc(O)c(C(=O)c2c(O)cccc2NS(=O)(=O)C(F)(F)F)c(O)c1)c1ccc(O)cc1		CHEMBL52869	=	IC50	nM	50.0	CHEMBL3045	Homo sapiens	IC50	uM	0.05
	478626	CHEMBL764579	Inhibition of Human Protein kinase C beta 2	B	O=C(N[C@@H]1CCC[C@H]1OC(=O)c1cc(O)c(C(=O)c2c(O)cccc2-c2nn[nH]n2)c(O)c1)c1ccc(O)cc1		CHEMBL298872	=	IC50	nM	290.0	CHEMBL3045	Homo sapiens	IC50	uM	0.29
	479801	CHEMBL764579	Inhibition of Human Protein kinase C beta 2	B	CS(=O)(=O)Nc1cccc(O)c1C(=O)c1c(O)cc(C(=O)O[C@@H]2CCC[C@H]2NC(=O)c2ccc(O)cc2)cc1O		CHEMBL294166	=	IC50	nM	150.0	CHEMBL3045	Homo sapiens	IC50	uM	0.15
	479807	CHEMBL764579	Inhibition of Human Protein kinase C beta 2	B	CC(C)(C)C(=O)OCn1nnc(-c2cccc(O)c2C(=O)c2c(O)cc(C(=O)O[C@@H]3CCC[C@H]3NC(=O)c3ccc(O)cc3)cc2O)n1		CHEMBL300658	=	IC50	nM	9100.0	CHEMBL3045	Homo sapiens	IC50	uM	9.1
	482378	CHEMBL764579	Inhibition of Human Protein kinase C beta 2	B	O=C(N[C@@H]1CCC[C@H]1OC(=O)c1cc(O)c(C(=O)c2c(O)cccc2NC(=O)C(F)(F)F)c(O)c1)c1ccc(O)cc1		CHEMBL55890	=	IC50	nM	46000.0	CHEMBL3045	Homo sapiens	IC50	uM	46.0
	484817	CHEMBL764579	Inhibition of Human Protein kinase C beta 2	B	Cn1nnnc1-c1cccc(O)c1C(=O)c1c(O)cc(C(=O)O[C@@H]2CCC[C@H]2NC(=O)c2ccc(O)cc2)cc1O		CHEMBL53025	=	IC50	nM	3500.0	CHEMBL3045	Homo sapiens	IC50	uM	3.5
	487102	CHEMBL764579	Inhibition of Human Protein kinase C beta 2	B	O=C(N[C@@H]1CCC[C@H]1OC(=O)c1cc(O)c(C(=O)c2c(O)cccc2C(=O)O)c(O)c1)c1ccc(O)cc1		CHEMBL52529	=	IC50	nM	50.0	CHEMBL3045	Homo sapiens	IC50	uM	0.05
	489532	CHEMBL768284	Inhibition of [3H]phorbol-12,13-dibutyrate (PDBu) binding to Protein kinase C beta C1a	B	CCCCCCCCCCc1ccc2c(c1)C[C@@H](CO)OC(=O)[C@H](C(C)C)N2C		CHEMBL318971	>	Ki	nM	10000.0	CHEMBL3045	Homo sapiens	Ki	nM	10000.0
	490609	CHEMBL764579	Inhibition of Human Protein kinase C beta 2	B	CC(C)(C)C(=O)OCn1nnnc1-c1cccc(O)c1C(=O)c1c(O)cc(C(=O)O[C@@H]2CCC[C@H]2NC(=O)c2ccc(O)cc2)cc1O		CHEMBL293722	=	IC50	nM	2500.0	CHEMBL3045	Homo sapiens	IC50	uM	2.5
	495314	CHEMBL764579	Inhibition of Human Protein kinase C beta 2	B	CC(=O)Nc1cccc(O)c1C(=O)c1c(O)cc(C(=O)O[C@@H]2CCC[C@H]2NC(=O)c2ccc(O)cc2)cc1O		CHEMBL299987	=	IC50	nM	4800.0	CHEMBL3045	Homo sapiens	IC50	uM	4.8
	495320	CHEMBL764579	Inhibition of Human Protein kinase C beta 2	B	Cn1nnc(-c2cccc(O)c2C(=O)c2c(O)cc(C(=O)O[C@@H]3CCC[C@H]3NC(=O)c3ccc(O)cc3)cc2O)n1		CHEMBL298159	=	IC50	nM	1300.0	CHEMBL3045	Homo sapiens	IC50	uM	1.3
	506206	CHEMBL768284	Inhibition of [3H]phorbol-12,13-dibutyrate (PDBu) binding to Protein kinase C beta C1a	B	CC(C)[C@H]1C(=O)N[C@H](CO)Cc2c[nH]c3cccc(c23)N1C		CHEMBL27266	=	Ki	nM	173.5	CHEMBL3045	Homo sapiens	Ki	nM	173.5
	507435	CHEMBL768284	Inhibition of [3H]phorbol-12,13-dibutyrate (PDBu) binding to Protein kinase C beta C1a	B	CCCCCCCCCCc1ccc2c(c1)C[C@@H](CO)NC(=O)[C@H](C(C)C)N2C		CHEMBL28205	=	Ki	nM	442.4	CHEMBL3045	Homo sapiens	Ki	nM	442.4
	586952	CHEMBL762483	Inhibition of Protein kinase C beta	B	CC(C)(C)c1cnc(CSc2cnc(NC(=O)C3CCNCC3)s2)o1		CHEMBL296468	>	IC50	nM	40000.0	CHEMBL3045	Homo sapiens	IC50	uM	40.0
	611250	CHEMBL761761	Inhibition of human Protein kinase C beta 1	B	O=C(N[C@H]1CNCCC[C@H]1OC(=O)c1cc(O)c(C(=O)c2c(O)cccc2C(=O)O)c(O)c1)c1ccc(O)cc1		CHEMBL307747	=	IC50	nM	32.0	CHEMBL3045	Homo sapiens	IC50	uM	0.032
	611251	CHEMBL768100	Inhibition of human Protein kinase C beta 2	B	O=C(N[C@H]1CNCCC[C@H]1OC(=O)c1cc(O)c(C(=O)c2c(O)cccc2C(=O)O)c(O)c1)c1ccc(O)cc1		CHEMBL307747	=	IC50	nM	44.0	CHEMBL3045	Homo sapiens	IC50	uM	0.044
	615192	CHEMBL761761	Inhibition of human Protein kinase C beta 1	B	O=C(N[C@H]1CSCCC[C@H]1OC(=O)c1cc(O)c(C(=O)c2c(O)cccc2C(=O)O)c(O)c1)c1ccc(O)cc1		CHEMBL67788	=	IC50	nM	3800.0	CHEMBL3045	Homo sapiens	IC50	uM	3.8
	615193	CHEMBL768100	Inhibition of human Protein kinase C beta 2	B	O=C(N[C@H]1CSCCC[C@H]1OC(=O)c1cc(O)c(C(=O)c2c(O)cccc2C(=O)O)c(O)c1)c1ccc(O)cc1		CHEMBL67788	=	IC50	nM	2400.0	CHEMBL3045	Homo sapiens	IC50	uM	2.4
	615200	CHEMBL761761	Inhibition of human Protein kinase C beta 1	B	O=C(N[C@H]1CS(=O)(=O)CCC[C@H]1OC(=O)c1cc(O)c(C(=O)c2c(O)cccc2C(=O)O)c(O)c1)c1ccc(O)cc1		CHEMBL303205	=	IC50	nM	5200.0	CHEMBL3045	Homo sapiens	IC50	uM	5.2
	615201	CHEMBL768100	Inhibition of human Protein kinase C beta 2	B	O=C(N[C@H]1CS(=O)(=O)CCC[C@H]1OC(=O)c1cc(O)c(C(=O)c2c(O)cccc2C(=O)O)c(O)c1)c1ccc(O)cc1		CHEMBL303205	=	IC50	nM	3600.0	CHEMBL3045	Homo sapiens	IC50	uM	3.6
	616485	CHEMBL761761	Inhibition of human Protein kinase C beta 1	B	O=C(N[C@H]1CCCCC[C@H]1OC(=O)c1cc(O)c(C(=O)c2c(O)cccc2C(=O)O)c(O)c1)c1ccc(O)cc1		CHEMBL302998	=	IC50	nM	220.0	CHEMBL3045	Homo sapiens	IC50	uM	0.22
	616486	CHEMBL768100	Inhibition of human Protein kinase C beta 2	B	O=C(N[C@H]1CCCCC[C@H]1OC(=O)c1cc(O)c(C(=O)c2c(O)cccc2C(=O)O)c(O)c1)c1ccc(O)cc1		CHEMBL302998	=	IC50	nM	430.0	CHEMBL3045	Homo sapiens	IC50	uM	0.43
	616543	CHEMBL768105	Inhibition of Protein kinase C beta 2 at 100 nM	B	Cn1ccc2ccc3c4[nH]c5c(CCCN[C@H]6CC[C@H](O)CC6)cccc5c4c4c(c3c21)C(=O)NC4=O		CHEMBL307152	=	Control	%	96.0	CHEMBL3045	Homo sapiens	Control	%	96.0
	616582	CHEMBL768106	Inhibition of Protein kinase C beta 2 at 500 nM	B	Cn1ccc2ccc3c4[nH]c5c(CCCN[C@H]6CC[C@H](O)CC6)cccc5c4c4c(c3c21)C(=O)NC4=O		CHEMBL307152	=	Control	%	59.0	CHEMBL3045	Homo sapiens	Control	%	59.0
	625259	CHEMBL761761	Inhibition of human Protein kinase C beta 1	B	O=C(N[C@H]1COCCC[C@H]1OC(=O)c1cc(O)c(C(=O)c2c(O)cccc2C(=O)O)c(O)c1)c1ccc(O)cc1		CHEMBL70078	=	IC50	nM	2500.0	CHEMBL3045	Homo sapiens	IC50	uM	2.5
	625260	CHEMBL768100	Inhibition of human Protein kinase C beta 2	B	O=C(N[C@H]1COCCC[C@H]1OC(=O)c1cc(O)c(C(=O)c2c(O)cccc2C(=O)O)c(O)c1)c1ccc(O)cc1		CHEMBL70078	=	IC50	nM	3300.0	CHEMBL3045	Homo sapiens	IC50	uM	3.3
	686285	CHEMBL761753	Displacement of [3H]- PDBu from recombinant PKC beta expressed in baculovirus	B	CC(C)[C@H]1C(=O)N[C@H](CO)Cc2c[nH]c3cccc(c23)N1C		CHEMBL27266	=	Ki	nM	6.1	CHEMBL3045	Homo sapiens	Ki	nM	6.1
	698423	CHEMBL761753	Displacement of [3H]- PDBu from recombinant PKC beta expressed in baculovirus	B	CCCCCCCCCCc1ccc2c(c1)C[C@@H](CO)NC(=O)[C@H](C(C)C)N2C		CHEMBL28205	=	Ki	nM	58.2	CHEMBL3045	Homo sapiens	Ki	nM	58.2
	703618	CHEMBL761753	Displacement of [3H]- PDBu from recombinant PKC beta expressed in baculovirus	B	CCCCCCCCc1ccc2c3c(c[nH]c13)C[C@@H](CO)NC(=O)[C@H](C(C)C)N2C		CHEMBL285801	=	Ki	nM	0.4	CHEMBL3045	Homo sapiens	Ki	nM	0.4
	711449	CHEMBL761753	Displacement of [3H]- PDBu from recombinant PKC beta expressed in baculovirus	B	CCCCCCCCC#Cc1ccc2c(c1)C[C@@H](CO)NC(=O)[C@H](C(C)C)N2C		CHEMBL6453	=	Ki	nM	17.4	CHEMBL3045	Homo sapiens	Ki	nM	17.4
	750654	CHEMBL761752	Inhibition of Protein kinase C beta	B	O=C(Cc1ccc2ccccc2c1)Nc1cc(C2CC2)n[nH]1		CHEMBL115220	>	IC50	nM	10000.0	CHEMBL3045	Homo sapiens	IC50	nM	10000.0
	753997	CHEMBL764572	Inhibition of partially purified recombinant human calcium sensitive protein kinase C beta 2	B	O=C(NC1CNCCC[C@H]1OC(=O)c1cc(O)c(C(=O)C2CCCC[C@@H]2C(=O)O)c(O)c1)c1ccc(O)cc1	Outside typical range	CHEMBL88848	=	IC50	nM	124000.0	CHEMBL3045	Homo sapiens	IC50	uM	124.0
	754001	CHEMBL764572	Inhibition of partially purified recombinant human calcium sensitive protein kinase C beta 2	B	O=C(NC1CCCC1OCc1cc(O)c(C(=O)c2c(O)cccc2C(=O)O)c(O)c1)c1ccc(O)cc1		CHEMBL89833	=	IC50	nM	290.0	CHEMBL3045	Homo sapiens	IC50	uM	0.29
	754005	CHEMBL764572	Inhibition of partially purified recombinant human calcium sensitive protein kinase C beta 2	B	O=C(NC1CNCC1OC(=O)c1cc(O)c(-c2ccccc2C(=O)O)c(O)c1)c1ccc(O)cc1		CHEMBL315545	>	IC50	nM	50000.0	CHEMBL3045	Homo sapiens	IC50	uM	50.0
	754007	CHEMBL764572	Inhibition of partially purified recombinant human calcium sensitive protein kinase C beta 2	B	N#Cc1cccc(O)c1C(=O)c1c(O)cc(C(=O)OC2CCCC2NC(=O)c2ccc(O)cc2)cc1O		CHEMBL89280	=	IC50	nM	2100.0	CHEMBL3045	Homo sapiens	IC50	uM	2.1
	754012	CHEMBL764572	Inhibition of partially purified recombinant human calcium sensitive protein kinase C beta 2	B	NCCOc1cccc(O)c1C(=O)c1c(O)cc(C(=O)OC2CCCC2NC(=O)c2ccc(O)cc2)cc1O		CHEMBL316088	=	IC50	nM	24000.0	CHEMBL3045	Homo sapiens	IC50	uM	24.0
	754642	CHEMBL764576	Inhibition of Protein kinase C beta 2 expressed in Sf-9 cells	B	O=C(N[C@@H]1CNCCC[C@H]1OC(=O)c1cc(O)c(C(=O)c2c(O)cccc2C(=O)O)c(O)c1)c1ccc(O)cc1		CHEMBL60254	=	IC50	nM	44.0	CHEMBL3045	Homo sapiens	IC50	uM	0.044
	755045	CHEMBL764572	Inhibition of partially purified recombinant human calcium sensitive protein kinase C beta 2	B	O=C(NC1CNCC1OC(=O)c1ccc(-c2c(O)cccc2C(=O)O)cc1)c1ccc(O)cc1		CHEMBL85129	=	IC50	nM	40000.0	CHEMBL3045	Homo sapiens	IC50	uM	40.0
	755780	CHEMBL764576	Inhibition of Protein kinase C beta 2 expressed in Sf-9 cells	B	COC(=O)c1cccc(O)c1C(=O)c1c(O)cc(C(=O)O[C@@H]2CCC[C@H]2NC(=O)c2ccc(O)cc2)cc1O		CHEMBL66923	=	IC50	nM	40.0	CHEMBL3045	Homo sapiens	IC50	uM	0.04
	755797	CHEMBL764570	Inhibition of Protein kinase C beta 1	B	CN1CCOCCOCCN(C)CCn2cc(c3ccccc32)C2=C(C(=O)NC2=O)c2cn(c3ccccc23)CC1		CHEMBL105620	=	IC50	nM	140.0	CHEMBL3045	Homo sapiens	IC50	uM	0.14
	755798	CHEMBL768280	Inhibition of Protein kinase C beta 2	B	CN1CCOCCOCCN(C)CCn2cc(c3ccccc32)C2=C(C(=O)NC2=O)c2cn(c3ccccc23)CC1		CHEMBL105620	=	IC50	nM	75.0	CHEMBL3045	Homo sapiens	IC50	uM	0.075
	756886	CHEMBL764576	Inhibition of Protein kinase C beta 2 expressed in Sf-9 cells	B	CC(C)(C)C(=O)OCOC(=O)c1cccc(O)c1C(=O)c1c(O)cc(C(=O)O[C@@H]2CNC[C@H]2NC(=O)c2ccc(O)cc2)cc1O		CHEMBL304175	=	IC50	nM	20.0	CHEMBL3045	Homo sapiens	IC50	uM	0.02
	758127	CHEMBL764576	Inhibition of Protein kinase C beta 2 expressed in Sf-9 cells	B	CCOC(=O)c1cccc(O)c1C(=O)c1c(O)cc(C(=O)O[C@@H]2CCC[C@H]2NC(=O)c2ccc(O)cc2)cc1O		CHEMBL66452	=	IC50	nM	1600.0	CHEMBL3045	Homo sapiens	IC50	uM	1.6
	759118	CHEMBL764570	Inhibition of Protein kinase C beta 1	B	CCN1CCOCCOCCn2cc(c3ccccc32)C2=C(C(=O)NC2=O)c2cn(c3ccccc23)CC1		CHEMBL103506	=	IC50	nM	31.0	CHEMBL3045	Homo sapiens	IC50	uM	0.031
	759119	CHEMBL768280	Inhibition of Protein kinase C beta 2	B	CCN1CCOCCOCCn2cc(c3ccccc32)C2=C(C(=O)NC2=O)c2cn(c3ccccc23)CC1		CHEMBL103506	=	IC50	nM	19.0	CHEMBL3045	Homo sapiens	IC50	uM	0.019
	759506	CHEMBL764572	Inhibition of partially purified recombinant human calcium sensitive protein kinase C beta 2	B	COc1cc(C(=O)O[C@@H]2CCCNCC2NC(=O)c2ccc(O)cc2)cc(OC)c1C(=O)c1c(O)cccc1O	Outside typical range	CHEMBL89191	>	IC50	nM	150000.0	CHEMBL3045	Homo sapiens	IC50	uM	150.0
	759510	CHEMBL764572	Inhibition of partially purified recombinant human calcium sensitive protein kinase C beta 2	B	O=C(NC1CCCC1OC(=O)c1cc(O)c(C(=O)c2c(O)cccc2NS(=O)(=O)C(F)(F)F)c(O)c1)c1ccc(O)cc1		CHEMBL312846	=	IC50	nM	50.0	CHEMBL3045	Homo sapiens	IC50	uM	0.05
	760150	CHEMBL764577	Inhibition of Protein kinase C beta 2 expressed in Sf-9 cells	B	O=C(N[C@@H]1CNC[C@H]1OC(=O)c1cc(O)c(C(=O)c2c(O)cccc2C(=O)OCC2CCCCC2)c(O)c1)c1ccc(O)cc1		CHEMBL302304	=	IC50	nM	22000.0	CHEMBL3045	Homo sapiens	IC50	uM	22.0
	760587	CHEMBL764572	Inhibition of partially purified recombinant human calcium sensitive protein kinase C beta 2	B	O=C(NC1CNCCC[C@H]1OC(=O)c1cc(O)c(C(=O)c2ccccc2C(=O)O)c(O)c1)c1ccc(O)cc1		CHEMBL433175	=	IC50	nM	3700.0	CHEMBL3045	Homo sapiens	IC50	uM	3.7
	760592	CHEMBL764572	Inhibition of partially purified recombinant human calcium sensitive protein kinase C beta 2	B	O=C(NC1CNCCC[C@H]1OC(=O)c1cc(O)c(Cc2c(O)cccc2C(=O)O)c(O)c1)c1ccc(O)cc1		CHEMBL313814	>	IC50	nM	5000.0	CHEMBL3045	Homo sapiens	IC50	uM	5.0
	760596	CHEMBL764572	Inhibition of partially purified recombinant human calcium sensitive protein kinase C beta 2	B	O=C(NC1CCCC1OC(=O)c1cc(O)c(C(=O)c2c(O)cccc2-c2nn[nH]n2)c(O)c1)c1ccc(O)cc1		CHEMBL89384	=	IC50	nM	260.0	CHEMBL3045	Homo sapiens	IC50	uM	0.26
	761723	CHEMBL764572	Inhibition of partially purified recombinant human calcium sensitive protein kinase C beta 2	B	O=C(O)CN(C(=O)c1c(O)cc(C(=O)OC2CNCC2NC(=O)c2ccc(O)cc2)cc1O)c1ccccc1	Outside typical range	CHEMBL88962	>	IC50	nM	150000.0	CHEMBL3045	Homo sapiens	IC50	uM	150.0
	762304	CHEMBL764576	Inhibition of Protein kinase C beta 2 expressed in Sf-9 cells	B	O=C(N[C@@H]1CCC[C@H]1OC(=O)c1cc(O)c(C(=O)c2c(O)cccc2C(=O)O)c(O)c1)c1ccc(O)cc1		CHEMBL52529	=	IC50	nM	50.0	CHEMBL3045	Homo sapiens	IC50	uM	0.05
	762677	CHEMBL764572	Inhibition of partially purified recombinant human calcium sensitive protein kinase C beta 2	B	O=C(NC1CNCCC[C@H]1OC(=O)c1cc(O)c(C(=O)C2CCCC[C@H]2C(=O)O)c(O)c1)c1ccc(O)cc1	Outside typical range	CHEMBL313550	>	IC50	nM	150000.0	CHEMBL3045	Homo sapiens	IC50	uM	150.0
Not Active	763420	CHEMBL764578	Inhibition of Protein kinase C beta 2 expressed in Sf-9 cells (inactive)	B	CC(C)(C)C(=O)OCOC(=O)c1cccc(O)c1C(=O)c1c(O)cc(C(=O)O[C@@H]2CCC[C@H]2NC(=O)c2ccc(O)cc2)cc1O		CHEMBL67980		IC50	nM		CHEMBL3045	Homo sapiens	IC50	uM	
	763517	CHEMBL761754	Inhibition of Protein kinase C beta at 10 uM	B	Cn1nc(C(C)(C)C)cc1NC(=O)Nc1ccc(Cc2ccncc2)cc1		CHEMBL288812	=	Inhibition	%	5.0	CHEMBL3045	Homo sapiens	Inhibition	%	5.0
	764584	CHEMBL768282	Binding affinity for Protein kinase C beta C1a domain	B	CCCC(=O)O[C@@H]1[C@@H](C)[C@@]2(O)[C@@H](C=C(CO)C[C@]3(O)C(=O)C(C)=C[C@@H]23)[C@@H]2C(C)(C)[C@]12OC(=O)CCC		CHEMBL27768	=	Kd	nM	1.31	CHEMBL3045	Homo sapiens	Kd	nM	1.31
	764585	CHEMBL768240	Binding affinity for Protein kinase C beta C1b domain	B	CCCC(=O)O[C@@H]1[C@@H](C)[C@@]2(O)[C@@H](C=C(CO)C[C@]3(O)C(=O)C(C)=C[C@@H]23)[C@@H]2C(C)(C)[C@]12OC(=O)CCC		CHEMBL27768	=	Kd	nM	1.34	CHEMBL3045	Homo sapiens	Kd	nM	1.34
	764957	CHEMBL764572	Inhibition of partially purified recombinant human calcium sensitive protein kinase C beta 2	B	Cn1nnc(-c2cccc(O)c2C(=O)c2c(O)cc(C(=O)OC3CCCC3NC(=O)c3ccc(O)cc3)cc2O)n1		CHEMBL89355	=	IC50	nM	1300.0	CHEMBL3045	Homo sapiens	IC50	uM	1.3
	765658	CHEMBL764570	Inhibition of Protein kinase C beta 1	B	CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL388978	=	IC50	nM	63.0	CHEMBL3045	Homo sapiens	IC50	uM	0.063
	765659	CHEMBL768280	Inhibition of Protein kinase C beta 2	B	CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL388978	=	IC50	nM	10.0	CHEMBL3045	Homo sapiens	IC50	uM	0.01
	765665	CHEMBL686884	Inhibition of PKC-beta II mediated IL-8 release from HEK293 cells by ELISA	F	CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL388978	=	IC50	nM	77.0	CHEMBL3045	Homo sapiens	IC50	uM	0.077
	766006	CHEMBL764572	Inhibition of partially purified recombinant human calcium sensitive protein kinase C beta 2	B	O=C(NC1CNCCC[C@H]1OC(=O)c1cc(O)c(C(=O)c2ccc3ccccc3c2O)c(O)c1)c1ccc(O)cc1	Outside typical range	CHEMBL91412	>	IC50	nM	150000.0	CHEMBL3045	Homo sapiens	IC50	uM	150.0
	767060	CHEMBL764572	Inhibition of partially purified recombinant human calcium sensitive protein kinase C beta 2	B	O=C(NC1CCCC1OC(=O)c1cc(O)c(C(=O)c2c(O)cccc2NC(=O)C(F)(F)F)c(O)c1)c1ccc(O)cc1		CHEMBL91932	>	IC50	nM	50000.0	CHEMBL3045	Homo sapiens	IC50	uM	50.0
	768155	CHEMBL764572	Inhibition of partially purified recombinant human calcium sensitive protein kinase C beta 2	B	O=C(NC1CNCCC[C@H]1OC(=O)c1cc(O)c(C(=O)c2c(O)cccc2C(=O)O)c(O)c1)c1ccc(O)cc1		CHEMBL89648	=	IC50	nM	30.0	CHEMBL3045	Homo sapiens	IC50	uM	0.03
	768946	CHEMBL764576	Inhibition of Protein kinase C beta 2 expressed in Sf-9 cells	B	COC(=O)c1cccc(O)c1C(=O)c1c(O)cc(C(=O)O[C@@H]2CNC[C@H]2NC(=O)c2ccc(O)cc2)cc1O		CHEMBL304626	=	IC50	nM	290.0	CHEMBL3045	Homo sapiens	IC50	uM	0.29
	768952	CHEMBL764576	Inhibition of Protein kinase C beta 2 expressed in Sf-9 cells	B	CC(C)COC(=O)c1cccc(O)c1C(=O)c1c(O)cc(C(=O)O[C@@H]2CNC[C@H]2NC(=O)c2ccc(O)cc2)cc1O		CHEMBL68418	=	IC50	nM	20000.0	CHEMBL3045	Homo sapiens	IC50	uM	20.0
	769082	CHEMBL768285	Displacement of [3H]- PDBu from Protein kinase C beta C1a domain	B	CC(C)[C@H]1/C(S)=N/[C@H](CO)Cc2c[nH]c3cccc(c23)N1C		CHEMBL63262	=	Ki	nM	179.5	CHEMBL3045	Homo sapiens	Ki	nM	179.5
	769083	CHEMBL768243	Displacement of [3H]- PDBu from Protein kinase C beta C1b domain	B	CC(C)[C@H]1/C(S)=N/[C@H](CO)Cc2c[nH]c3cccc(c23)N1C		CHEMBL63262	=	Ki	nM	225.9	CHEMBL3045	Homo sapiens	Ki	nM	225.9
	769332	CHEMBL764572	Inhibition of partially purified recombinant human calcium sensitive protein kinase C beta 2	B	CS(=O)(=O)Nc1cccc(O)c1C(=O)c1c(O)cc(C(=O)OC2CCCC2NC(=O)c2ccc(O)cc2)cc1O		CHEMBL88749	=	IC50	nM	110.0	CHEMBL3045	Homo sapiens	IC50	uM	0.11
	770040	CHEMBL768285	Displacement of [3H]- PDBu from Protein kinase C beta C1a domain	B	CC(C)[C@H]1C(=O)N[C@H](CO)Cc2c[nH]c3cccc(c23)N1C		CHEMBL27266	=	Ki	nM	173.5	CHEMBL3045	Homo sapiens	Ki	nM	173.5
	770041	CHEMBL768243	Displacement of [3H]- PDBu from Protein kinase C beta C1b domain	B	CC(C)[C@H]1C(=O)N[C@H](CO)Cc2c[nH]c3cccc(c23)N1C		CHEMBL27266	=	Ki	nM	135.6	CHEMBL3045	Homo sapiens	Ki	nM	135.6
Not Determined	771120	CHEMBL764571	Inhibition of Protein kinase C beta 1 (not determined)	B	CC(C)N1CCOCCn2cc(c3ccccc32)C2=C(C(=O)NC2=O)c2cn(c3ccccc23)CCOCC1		CHEMBL421217		IC50	nM		CHEMBL3045	Homo sapiens	IC50	uM	
	771121	CHEMBL768280	Inhibition of Protein kinase C beta 2	B	CC(C)N1CCOCCn2cc(c3ccccc32)C2=C(C(=O)NC2=O)c2cn(c3ccccc23)CCOCC1		CHEMBL421217	=	IC50	nM	17.0	CHEMBL3045	Homo sapiens	IC50	uM	0.017
	771128	CHEMBL764570	Inhibition of Protein kinase C beta 1	B	CN1CCOCCn2cc(c3ccccc32)C2=C(C(=O)NC2=O)c2cn(c3ccccc23)CCN(C)CC1		CHEMBL106384	=	IC50	nM	10.0	CHEMBL3045	Homo sapiens	IC50	uM	0.01
	771129	CHEMBL768280	Inhibition of Protein kinase C beta 2	B	CN1CCOCCn2cc(c3ccccc32)C2=C(C(=O)NC2=O)c2cn(c3ccccc23)CCN(C)CC1		CHEMBL106384	=	IC50	nM	9.0	CHEMBL3045	Homo sapiens	IC50	uM	0.009
	771135	CHEMBL686884	Inhibition of PKC-beta II mediated IL-8 release from HEK293 cells by ELISA	F	CN1CCOCCn2cc(c3ccccc32)C2=C(C(=O)NC2=O)c2cn(c3ccccc23)CCN(C)CC1		CHEMBL106384	=	IC50	nM	46.0	CHEMBL3045	Homo sapiens	IC50	uM	0.046
	771138	CHEMBL764570	Inhibition of Protein kinase C beta 1	B	CCN1CCOCCN(CC)CCn2cc(c3ccccc32)C2=C(C(=O)NC2=O)c2cn(c3ccccc23)CCOCC1		CHEMBL103421	=	IC50	nM	300.0	CHEMBL3045	Homo sapiens	IC50	uM	0.3
	771139	CHEMBL768280	Inhibition of Protein kinase C beta 2	B	CCN1CCOCCN(CC)CCn2cc(c3ccccc32)C2=C(C(=O)NC2=O)c2cn(c3ccccc23)CCOCC1		CHEMBL103421	=	IC50	nM	110.0	CHEMBL3045	Homo sapiens	IC50	uM	0.11
	771538	CHEMBL764572	Inhibition of partially purified recombinant human calcium sensitive protein kinase C beta 2	B	O=C(NC1CNCCC[C@H]1OC(=O)c1cc(O)c(C2OC(=O)c3cccc(O)c32)c(O)c1)c1ccc(O)cc1		CHEMBL86680	=	IC50	nM	800.0	CHEMBL3045	Homo sapiens	IC50	uM	0.8
	771542	CHEMBL764572	Inhibition of partially purified recombinant human calcium sensitive protein kinase C beta 2	B	O=C(NC1CNCC1OC(=O)c1cc(O)c(C(=O)c2c(O)ccc3c2CCCC3)c(O)c1)c1ccc(O)cc1		CHEMBL91126	=	IC50	nM	260.0	CHEMBL3045	Homo sapiens	IC50	uM	0.26
	772742	CHEMBL764572	Inhibition of partially purified recombinant human calcium sensitive protein kinase C beta 2	B	COc1cccc(OC)c1C(=O)c1c(O)cc(C(=O)O[C@@H]2CCCNCC2NC(=O)c2ccc(O)cc2)cc1O		CHEMBL327994	=	IC50	nM	26000.0	CHEMBL3045	Homo sapiens	IC50	uM	26.0
	772746	CHEMBL764572	Inhibition of partially purified recombinant human calcium sensitive protein kinase C beta 2	B	Cn1nnnc1-c1cccc(O)c1C(=O)c1c(O)cc(C(=O)OC2CCCC2NC(=O)c2ccc(O)cc2)cc1O		CHEMBL89591	=	IC50	nM	3500.0	CHEMBL3045	Homo sapiens	IC50	uM	3.5
	773556	CHEMBL764570	Inhibition of Protein kinase C beta 1	B	CN1CCCn2cc(c3ccccc32)C2=C(C(=O)NC2=O)c2cn(c3ccccc23)CCOCCOCC1		CHEMBL321315	=	IC50	nM	73.0	CHEMBL3045	Homo sapiens	IC50	uM	0.073
	773557	CHEMBL768280	Inhibition of Protein kinase C beta 2	B	CN1CCCn2cc(c3ccccc32)C2=C(C(=O)NC2=O)c2cn(c3ccccc23)CCOCCOCC1		CHEMBL321315	=	IC50	nM	46.0	CHEMBL3045	Homo sapiens	IC50	uM	0.046
	773563	CHEMBL686884	Inhibition of PKC-beta II mediated IL-8 release from HEK293 cells by ELISA	F	CN1CCCn2cc(c3ccccc32)C2=C(C(=O)NC2=O)c2cn(c3ccccc23)CCOCCOCC1		CHEMBL321315	=	IC50	nM	45.0	CHEMBL3045	Homo sapiens	IC50	uM	0.045
Not Determined	773566	CHEMBL878999	Inhibition of Protein kinase C beta 1 (Not determined)	B	Cn1cc(C2=C(c3ccc(Cl)cc3Cl)C(=O)NC2=O)c2ccccc21		CHEMBL102714		IC50	nM		CHEMBL3045	Homo sapiens	IC50	uM	
Not Determined	773567	CHEMBL768281	Inhibition of Protein kinase C beta 2 (Not determined)	B	Cn1cc(C2=C(c3ccc(Cl)cc3Cl)C(=O)NC2=O)c2ccccc21		CHEMBL102714		IC50	nM		CHEMBL3045	Homo sapiens	IC50	uM	
Not Determined	773573	CHEMBL686885	Inhibition of PKC-beta II mediated IL-8 release from HEK293 cells by ELISA (Not determined)	F	Cn1cc(C2=C(c3ccc(Cl)cc3Cl)C(=O)NC2=O)c2ccccc21		CHEMBL102714		IC50	nM		CHEMBL3045	Homo sapiens	IC50	uM	
	774003	CHEMBL764572	Inhibition of partially purified recombinant human calcium sensitive protein kinase C beta 2	B	O=C(NC1CNCC1OC(=O)c1cc(O)c2c(c1)C(=O)c1cccc(O)c1C2=O)c1ccc(O)cc1		CHEMBL88812	=	IC50	nM	25000.0	CHEMBL3045	Homo sapiens	IC50	uM	25.0
	775054	CHEMBL764572	Inhibition of partially purified recombinant human calcium sensitive protein kinase C beta 2	B	O=C(NC1CCCC1OC(=O)c1cc(O)c(-c2nnc(O)c3cccc(O)c23)c(O)c1)c1ccc(O)cc1		CHEMBL313902	>	IC50	nM	50000.0	CHEMBL3045	Homo sapiens	IC50	uM	50.0
	776190	CHEMBL764572	Inhibition of partially purified recombinant human calcium sensitive protein kinase C beta 2	B	O=C(NC1CNCCC[C@H]1OC(=O)c1cc(O)c(C(=O)c2ccccc2O)c(O)c1)c1ccc(O)cc1		CHEMBL88466	=	IC50	nM	38000.0	CHEMBL3045	Homo sapiens	IC50	uM	38.0
	776744	CHEMBL764576	Inhibition of Protein kinase C beta 2 expressed in Sf-9 cells	B	CCOC(=O)c1cccc(O)c1C(=O)c1c(O)cc(C(=O)O[C@@H]2CNC[C@H]2NC(=O)c2ccc(O)cc2)cc1O		CHEMBL307543	=	IC50	nM	1000.0	CHEMBL3045	Homo sapiens	IC50	uM	1.0
	776788	CHEMBL764570	Inhibition of Protein kinase C beta 1	B	CCN1CCOCCn2cc(c3ccccc32)C2=C(C(=O)NC2=O)c2cn(c3ccccc23)CCOCC1		CHEMBL103055	=	IC50	nM	14.0	CHEMBL3045	Homo sapiens	IC50	uM	0.014
	776789	CHEMBL768280	Inhibition of Protein kinase C beta 2	B	CCN1CCOCCn2cc(c3ccccc32)C2=C(C(=O)NC2=O)c2cn(c3ccccc23)CCOCC1		CHEMBL103055	=	IC50	nM	9.0	CHEMBL3045	Homo sapiens	IC50	uM	0.009
	776795	CHEMBL686884	Inhibition of PKC-beta II mediated IL-8 release from HEK293 cells by ELISA	F	CCN1CCOCCn2cc(c3ccccc32)C2=C(C(=O)NC2=O)c2cn(c3ccccc23)CCOCC1		CHEMBL103055	=	IC50	nM	25.0	CHEMBL3045	Homo sapiens	IC50	uM	0.025
	777203	CHEMBL764572	Inhibition of partially purified recombinant human calcium sensitive protein kinase C beta 2	B	O=C(NC1CNCC1OC(=O)c1cc(O)c(C(=O)c2c(C(=O)O)ccc3ccccc23)c(O)c1)c1ccc(O)cc1		CHEMBL421539	=	IC50	nM	8000.0	CHEMBL3045	Homo sapiens	IC50	uM	8.0
	778316	CHEMBL764572	Inhibition of partially purified recombinant human calcium sensitive protein kinase C beta 2	B	O=C(NC1CNCC1OC(=O)c1cc(O)c(C(=O)c2c(O)cccc2C(=O)O)c(O)c1)c1ccc(O)cc1		CHEMBL265559	=	IC50	nM	33.0	CHEMBL3045	Homo sapiens	IC50	uM	0.033
	780229	CHEMBL764576	Inhibition of Protein kinase C beta 2 expressed in Sf-9 cells	B	CCCCOC(=O)c1cccc(O)c1C(=O)c1c(O)cc(C(=O)O[C@@H]2CNC[C@H]2NC(=O)c2ccc(O)cc2)cc1O		CHEMBL66750	=	IC50	nM	2200.0	CHEMBL3045	Homo sapiens	IC50	uM	2.2
	780268	CHEMBL764570	Inhibition of Protein kinase C beta 1	B	O=C1NC(=O)C2=C1c1cn(c3ccccc13)CCOCCN(CCO)CCOCCn1cc2c2ccccc21		CHEMBL321529	=	IC50	nM	68.0	CHEMBL3045	Homo sapiens	IC50	uM	0.068
	780269	CHEMBL768280	Inhibition of Protein kinase C beta 2	B	O=C1NC(=O)C2=C1c1cn(c3ccccc13)CCOCCN(CCO)CCOCCn1cc2c2ccccc21		CHEMBL321529	=	IC50	nM	40.0	CHEMBL3045	Homo sapiens	IC50	uM	0.04
	780275	CHEMBL686884	Inhibition of PKC-beta II mediated IL-8 release from HEK293 cells by ELISA	F	O=C1NC(=O)C2=C1c1cn(c3ccccc13)CCOCCN(CCO)CCOCCn1cc2c2ccccc21		CHEMBL321529	=	IC50	nM	58.0	CHEMBL3045	Homo sapiens	IC50	uM	0.058
	780718	CHEMBL764572	Inhibition of partially purified recombinant human calcium sensitive protein kinase C beta 2	B	O=C(NC1CNCC1OC(=O)c1cc(O)c(C(=O)Nc2ccccc2C(=O)O)c(O)c1)c1ccc(O)cc1	Outside typical range	CHEMBL88454	=	IC50	nM	117000.0	CHEMBL3045	Homo sapiens	IC50	uM	117.0
	781827	CHEMBL764572	Inhibition of partially purified recombinant human calcium sensitive protein kinase C beta 2	B	COc1cccc(O)c1C(=O)c1c(O)cc(C(=O)O[C@@H]2CCCNCC2NC(=O)c2ccc(O)cc2)cc1O		CHEMBL91541	=	IC50	nM	9500.0	CHEMBL3045	Homo sapiens	IC50	uM	9.5
	782445	CHEMBL764570	Inhibition of Protein kinase C beta 1	B	CN1CCOCCN(C)CCn2cc(c3ccccc32)C2=C(C(=O)NC2=O)c2cn(c3ccccc23)CC1		CHEMBL105477	=	IC50	nM	27.0	CHEMBL3045	Homo sapiens	IC50	uM	0.027
	782446	CHEMBL768280	Inhibition of Protein kinase C beta 2	B	CN1CCOCCN(C)CCn2cc(c3ccccc32)C2=C(C(=O)NC2=O)c2cn(c3ccccc23)CC1		CHEMBL105477	=	IC50	nM	41.0	CHEMBL3045	Homo sapiens	IC50	uM	0.041
	782812	CHEMBL764572	Inhibition of partially purified recombinant human calcium sensitive protein kinase C beta 2	B	O=C(NC1CCCC1OC(=O)c1ccc(C(=O)c2c(O)cccc2C(=O)O)cc1)c1ccc(O)cc1		CHEMBL433361	=	IC50	nM	4500.0	CHEMBL3045	Homo sapiens	IC50	uM	4.5
	782870	CHEMBL764572	Inhibition of partially purified recombinant human calcium sensitive protein kinase C beta 2	B	O=C(NC1CNCCC[C@H]1OC(=O)c1cc(O)c(C(=O)c2c(O)cccc2O)c(O)c1)c1ccc(O)cc1		CHEMBL328747	=	IC50	nM	7600.0	CHEMBL3045	Homo sapiens	IC50	uM	7.6
	783559	CHEMBL764570	Inhibition of Protein kinase C beta 1	B	CN1CCOCCn2cc(c3ccccc32)C2=C(C(=O)NC2=O)c2cn(c3ccccc23)CCOCC1		CHEMBL106061	=	IC50	nM	47.0	CHEMBL3045	Homo sapiens	IC50	uM	0.047
	783560	CHEMBL768280	Inhibition of Protein kinase C beta 2	B	CN1CCOCCn2cc(c3ccccc32)C2=C(C(=O)NC2=O)c2cn(c3ccccc23)CCOCC1		CHEMBL106061	=	IC50	nM	41.0	CHEMBL3045	Homo sapiens	IC50	uM	0.041
	783567	CHEMBL764570	Inhibition of Protein kinase C beta 1	B	CN1CCN(C)CCn2cc(c3ccccc32)C2=C(C(=O)NC2=O)c2cn(c3ccccc23)CC1		CHEMBL319265	=	IC50	nM	250.0	CHEMBL3045	Homo sapiens	IC50	uM	0.25
	783568	CHEMBL768280	Inhibition of Protein kinase C beta 2	B	CN1CCN(C)CCn2cc(c3ccccc32)C2=C(C(=O)NC2=O)c2cn(c3ccccc23)CC1		CHEMBL319265	=	IC50	nM	200.0	CHEMBL3045	Homo sapiens	IC50	uM	0.2
	783870	CHEMBL764572	Inhibition of partially purified recombinant human calcium sensitive protein kinase C beta 2	B	O=C(NC1CCCC1OC(=O)c1cc(O)c(C(=O)c2c(O)cccc2C(=O)O)c(O)c1)c1ccc(O)cc1		CHEMBL48636	=	IC50	nM	50.0	CHEMBL3045	Homo sapiens	IC50	uM	0.05
	785842	CHEMBL764576	Inhibition of Protein kinase C beta 2 expressed in Sf-9 cells	B	COC(=O)c1cccc(O)c1C(=O)c1c(O)cc(C(=O)O[C@@H]2CCC[C@H]2NC(=O)c2ccc(O)cc2)cc1O		CHEMBL66923	=	IC50	nM	330.0	CHEMBL3045	Homo sapiens	IC50	uM	0.33
	785849	CHEMBL764576	Inhibition of Protein kinase C beta 2 expressed in Sf-9 cells	B	COC(=O)c1cccc(O)c1C(=O)c1c(O)cc(C(=O)O[C@@H]2CCC[C@H]2NC(=O)c2ccc(O)cc2)cc1O		CHEMBL66923	=	IC50	nM	1800.0	CHEMBL3045	Homo sapiens	IC50	uM	1.8
	785855	CHEMBL764576	Inhibition of Protein kinase C beta 2 expressed in Sf-9 cells	B	CC(C)OC(=O)c1cccc(O)c1C(=O)c1c(O)cc(C(=O)O[C@@H]2CCC[C@H]2NC(=O)c2ccc(O)cc2)cc1O		CHEMBL431568	=	IC50	nM	440.0	CHEMBL3045	Homo sapiens	IC50	uM	0.44
	786278	CHEMBL764572	Inhibition of partially purified recombinant human calcium sensitive protein kinase C beta 2	B	Cc1cc(C(=O)OC2CCCC2NC(=O)c2ccc(O)cc2)cc(C)c1C(=O)c1c(O)cccc1C(=O)O		CHEMBL87075	>	IC50	nM	50000.0	CHEMBL3045	Homo sapiens	IC50	uM	50.0
	786350	CHEMBL764572	Inhibition of partially purified recombinant human calcium sensitive protein kinase C beta 2	B	CC(=O)Nc1cccc(O)c1C(=O)c1c(O)cc(C(=O)OC2CCCC2NC(=O)c2ccc(O)cc2)cc1O		CHEMBL329178	=	IC50	nM	4800.0	CHEMBL3045	Homo sapiens	IC50	uM	4.8
	786996	CHEMBL764576	Inhibition of Protein kinase C beta 2 expressed in Sf-9 cells	B	O=C(N[C@@H]1CNC[C@H]1OC(=O)c1cc(O)c(C(=O)c2c(O)cccc2C(=O)O)c(O)c1)c1ccc(O)cc1		CHEMBL59828	=	IC50	nM	33.0	CHEMBL3045	Homo sapiens	IC50	uM	0.033
	787347	CHEMBL764572	Inhibition of partially purified recombinant human calcium sensitive protein kinase C beta 2	B	O=C(NC1CCCC1OC(=O)c1ccc(C(=O)c2c(O)cccc2C(=O)O)c(O)c1)c1ccc(O)cc1		CHEMBL90330	=	IC50	nM	2700.0	CHEMBL3045	Homo sapiens	IC50	uM	2.7
	787399	CHEMBL764572	Inhibition of partially purified recombinant human calcium sensitive protein kinase C beta 2	B	O=C(NC1CNCC1OC(=O)c1cc(O)c(C(=O)c2c(O)ccc3ccccc23)c(O)c1)c1ccc(O)cc1		CHEMBL89639	=	IC50	nM	5600.0	CHEMBL3045	Homo sapiens	IC50	uM	5.6
	788135	CHEMBL764576	Inhibition of Protein kinase C beta 2 expressed in Sf-9 cells	B	CC(=O)OCOC(=O)c1cccc(O)c1C(=O)c1c(O)cc(C(=O)O[C@@H]2CNC[C@H]2NC(=O)c2ccc(O)cc2)cc1O		CHEMBL67528	=	IC50	nM	20.0	CHEMBL3045	Homo sapiens	IC50	uM	0.02
	788144	CHEMBL764570	Inhibition of Protein kinase C beta 1	B	CN1CCN(C)CCn2cc(c3ccccc32)C2=C(C(=O)NC2=O)c2cn(c3ccccc23)CCN(C)CC1		CHEMBL103628	=	IC50	nM	31.0	CHEMBL3045	Homo sapiens	IC50	uM	0.031
	788145	CHEMBL768280	Inhibition of Protein kinase C beta 2	B	CN1CCN(C)CCn2cc(c3ccccc32)C2=C(C(=O)NC2=O)c2cn(c3ccccc23)CCN(C)CC1		CHEMBL103628	=	IC50	nM	27.0	CHEMBL3045	Homo sapiens	IC50	uM	0.027
	788151	CHEMBL686884	Inhibition of PKC-beta II mediated IL-8 release from HEK293 cells by ELISA	F	CN1CCN(C)CCn2cc(c3ccccc32)C2=C(C(=O)NC2=O)c2cn(c3ccccc23)CCN(C)CC1		CHEMBL103628	=	IC50	nM	82.0	CHEMBL3045	Homo sapiens	IC50	uM	0.082
	788414	CHEMBL764572	Inhibition of partially purified recombinant human calcium sensitive protein kinase C beta 2	B	O=C(NC1CNCCC[C@H]1OC(=O)c1cc(O)c2c(=O)c3c(C(=O)O)cccc3oc2c1)c1ccc(O)cc1	Outside typical range	CHEMBL329437	>	IC50	nM	150000.0	CHEMBL3045	Homo sapiens	IC50	uM	150.0
	788426	CHEMBL764572	Inhibition of partially purified recombinant human calcium sensitive protein kinase C beta 2	B	O=C(NC1CNCCC[C@H]1OC(=O)c1cc(O)c(C(=O)c2ncccc2C(=O)O)c(O)c1)c1ccc(O)cc1		CHEMBL88533	=	IC50	nM	13000.0	CHEMBL3045	Homo sapiens	IC50	uM	13.0
	788429	CHEMBL764572	Inhibition of partially purified recombinant human calcium sensitive protein kinase C beta 2	B	O=C(O)COc1cccc(O)c1C(=O)c1c(O)cc(C(=O)OC2CCCC2NC(=O)c2ccc(O)cc2)cc1O		CHEMBL89210	=	IC50	nM	330.0	CHEMBL3045	Homo sapiens	IC50	uM	0.33
	789700	CHEMBL761759	Inhibitory concentration against recombinant human Protein kinase C beta 1 isozyme	B	N[C@@H]1C[C@@H](NC(=O)c2ccc(O)cc2)[C@H](OC(=O)c2cc(O)c(C(=O)c3c(O)cccc3C(=O)O)c(O)c2)C1		CHEMBL432168	=	IC50	nM	4.0	CHEMBL3045	Homo sapiens	IC50	uM	0.004
	789701	CHEMBL768098	Inhibitory concentration against recombinant human Protein kinase C beta 2 isozyme	B	N[C@@H]1C[C@@H](NC(=O)c2ccc(O)cc2)[C@H](OC(=O)c2cc(O)c(C(=O)c3c(O)cccc3C(=O)O)c(O)c2)C1		CHEMBL432168	=	IC50	nM	2.0	CHEMBL3045	Homo sapiens	IC50	uM	0.002
	793577	CHEMBL761759	Inhibitory concentration against recombinant human Protein kinase C beta 1 isozyme	B	NC[C@H]1C[C@@H](NC(=O)c2ccc(O)cc2)[C@H](OC(=O)c2cc(O)c(C(=O)c3c(O)cccc3C(=O)O)c(O)c2)C1		CHEMBL307708	=	IC50	nM	4.0	CHEMBL3045	Homo sapiens	IC50	uM	0.004
	793578	CHEMBL768098	Inhibitory concentration against recombinant human Protein kinase C beta 2 isozyme	B	NC[C@H]1C[C@@H](NC(=O)c2ccc(O)cc2)[C@H](OC(=O)c2cc(O)c(C(=O)c3c(O)cccc3C(=O)O)c(O)c2)C1		CHEMBL307708	=	IC50	nM	4.0	CHEMBL3045	Homo sapiens	IC50	uM	0.004
	794647	CHEMBL761759	Inhibitory concentration against recombinant human Protein kinase C beta 1 isozyme	B	O=C(N[C@@H]1CN2CCC(CC2)[C@H]1OC(=O)c1cc(O)c(C(=O)c2c(O)cccc2C(=O)O)c(O)c1)c1ccc(O)cc1		CHEMBL78129	=	IC50	nM	26.0	CHEMBL3045	Homo sapiens	IC50	uM	0.026
	794648	CHEMBL768098	Inhibitory concentration against recombinant human Protein kinase C beta 2 isozyme	B	O=C(N[C@@H]1CN2CCC(CC2)[C@H]1OC(=O)c1cc(O)c(C(=O)c2c(O)cccc2C(=O)O)c(O)c1)c1ccc(O)cc1		CHEMBL78129	=	IC50	nM	69.0	CHEMBL3045	Homo sapiens	IC50	uM	0.069
	794656	CHEMBL761759	Inhibitory concentration against recombinant human Protein kinase C beta 1 isozyme	B	O=C(N[C@@H]1CC(C(=O)C(F)(F)F)C[C@H]1OC(=O)c1cc(O)c(C(=O)c2c(O)cccc2C(=O)O)c(O)c1)c1ccc(O)cc1		CHEMBL262980	=	IC50	nM	360.0	CHEMBL3045	Homo sapiens	IC50	uM	0.36
	794657	CHEMBL768098	Inhibitory concentration against recombinant human Protein kinase C beta 2 isozyme	B	O=C(N[C@@H]1CC(C(=O)C(F)(F)F)C[C@H]1OC(=O)c1cc(O)c(C(=O)c2c(O)cccc2C(=O)O)c(O)c1)c1ccc(O)cc1		CHEMBL262980	=	IC50	nM	260.0	CHEMBL3045	Homo sapiens	IC50	uM	0.26
	795782	CHEMBL761759	Inhibitory concentration against recombinant human Protein kinase C beta 1 isozyme	B	CC(=O)C1C[C@@H](NC(=O)c2ccc(O)cc2)[C@H](OC(=O)c2cc(O)c(C(=O)c3c(O)cccc3C(=O)O)c(O)c2)C1		CHEMBL441802	=	IC50	nM	710.0	CHEMBL3045	Homo sapiens	IC50	uM	0.71
	795783	CHEMBL768098	Inhibitory concentration against recombinant human Protein kinase C beta 2 isozyme	B	CC(=O)C1C[C@@H](NC(=O)c2ccc(O)cc2)[C@H](OC(=O)c2cc(O)c(C(=O)c3c(O)cccc3C(=O)O)c(O)c2)C1		CHEMBL441802	=	IC50	nM	820.0	CHEMBL3045	Homo sapiens	IC50	uM	0.82
	797996	CHEMBL761759	Inhibitory concentration against recombinant human Protein kinase C beta 1 isozyme	B	O=C(N[C@@H]1COCCC[C@H]1OC(=O)c1cc(O)c(C(=O)c2c(O)cccc2C(=O)O)c(O)c1)c1ccc(O)cc1		CHEMBL306373	=	IC50	nM	2500.0	CHEMBL3045	Homo sapiens	IC50	uM	2.5
	797997	CHEMBL768098	Inhibitory concentration against recombinant human Protein kinase C beta 2 isozyme	B	O=C(N[C@@H]1COCCC[C@H]1OC(=O)c1cc(O)c(C(=O)c2c(O)cccc2C(=O)O)c(O)c1)c1ccc(O)cc1		CHEMBL306373	=	IC50	nM	3300.0	CHEMBL3045	Homo sapiens	IC50	uM	3.3
	798005	CHEMBL761759	Inhibitory concentration against recombinant human Protein kinase C beta 1 isozyme	B	O=C(N[C@@H]1CNCC[C@H]1OC(=O)c1cc(O)c(C(=O)c2c(O)cccc2C(=O)O)c(O)c1)c1ccc(O)cc1		CHEMBL67442	=	IC50	nM	2200.0	CHEMBL3045	Homo sapiens	IC50	uM	2.2
	798006	CHEMBL768098	Inhibitory concentration against recombinant human Protein kinase C beta 2 isozyme	B	O=C(N[C@@H]1CNCC[C@H]1OC(=O)c1cc(O)c(C(=O)c2c(O)cccc2C(=O)O)c(O)c1)c1ccc(O)cc1		CHEMBL67442	=	IC50	nM	4700.0	CHEMBL3045	Homo sapiens	IC50	uM	4.7
	798014	CHEMBL761759	Inhibitory concentration against recombinant human Protein kinase C beta 1 isozyme	B	O=C(N[C@@H]1C[C@H](CO)C[C@H]1OC(=O)c1cc(O)c(C(=O)c2c(O)cccc2C(=O)O)c(O)c1)c1ccc(O)cc1		CHEMBL75661	=	IC50	nM	4.0	CHEMBL3045	Homo sapiens	IC50	uM	0.004
	798015	CHEMBL768098	Inhibitory concentration against recombinant human Protein kinase C beta 2 isozyme	B	O=C(N[C@@H]1C[C@H](CO)C[C@H]1OC(=O)c1cc(O)c(C(=O)c2c(O)cccc2C(=O)O)c(O)c1)c1ccc(O)cc1		CHEMBL75661	=	IC50	nM	3.0	CHEMBL3045	Homo sapiens	IC50	uM	0.003
	800436	CHEMBL761759	Inhibitory concentration against recombinant human Protein kinase C beta 1 isozyme	B	O=C(N[C@@H]1C[C@@H](CO)C[C@H]1OC(=O)c1cc(O)c(C(=O)c2c(O)cccc2C(=O)O)c(O)c1)c1ccc(O)cc1		CHEMBL75004	=	IC50	nM	60.0	CHEMBL3045	Homo sapiens	IC50	uM	0.06
	800437	CHEMBL768098	Inhibitory concentration against recombinant human Protein kinase C beta 2 isozyme	B	O=C(N[C@@H]1C[C@@H](CO)C[C@H]1OC(=O)c1cc(O)c(C(=O)c2c(O)cccc2C(=O)O)c(O)c1)c1ccc(O)cc1		CHEMBL75004	=	IC50	nM	20.0	CHEMBL3045	Homo sapiens	IC50	uM	0.02
	804149	CHEMBL761759	Inhibitory concentration against recombinant human Protein kinase C beta 1 isozyme	B	O=C(N[C@@H]1CC(O)C[C@H]1OC(=O)c1cc(O)c(C(=O)c2c(O)cccc2C(=O)O)c(O)c1)c1ccc(O)cc1		CHEMBL306580	=	IC50	nM	20.0	CHEMBL3045	Homo sapiens	IC50	uM	0.02
	804150	CHEMBL768098	Inhibitory concentration against recombinant human Protein kinase C beta 2 isozyme	B	O=C(N[C@@H]1CC(O)C[C@H]1OC(=O)c1cc(O)c(C(=O)c2c(O)cccc2C(=O)O)c(O)c1)c1ccc(O)cc1		CHEMBL306580	=	IC50	nM	10.0	CHEMBL3045	Homo sapiens	IC50	uM	0.01
	809505	CHEMBL761759	Inhibitory concentration against recombinant human Protein kinase C beta 1 isozyme	B	O=C(N[C@@H]1CNC[C@H]1OC(=O)c1cc(O)c(C(=O)c2c(O)cccc2C(=O)O)c(O)c1)c1ccc(O)cc1		CHEMBL59828	=	IC50	nM	17.0	CHEMBL3045	Homo sapiens	IC50	uM	0.017
	809506	CHEMBL768098	Inhibitory concentration against recombinant human Protein kinase C beta 2 isozyme	B	O=C(N[C@@H]1CNC[C@H]1OC(=O)c1cc(O)c(C(=O)c2c(O)cccc2C(=O)O)c(O)c1)c1ccc(O)cc1		CHEMBL59828	=	IC50	nM	33.0	CHEMBL3045	Homo sapiens	IC50	uM	0.033
	809514	CHEMBL761759	Inhibitory concentration against recombinant human Protein kinase C beta 1 isozyme	B	CC1(C)C2CCC1(C)[C@@H](OC(=O)c1cc(O)c(C(=O)c3c(O)cccc3C(=O)O)c(O)c1)[C@@H]2NC(=O)c1ccc(O)cc1		CHEMBL309078	=	IC50	nM	310.0	CHEMBL3045	Homo sapiens	IC50	uM	0.31
	809515	CHEMBL768098	Inhibitory concentration against recombinant human Protein kinase C beta 2 isozyme	B	CC1(C)C2CCC1(C)[C@@H](OC(=O)c1cc(O)c(C(=O)c3c(O)cccc3C(=O)O)c(O)c1)[C@@H]2NC(=O)c1ccc(O)cc1		CHEMBL309078	=	IC50	nM	80.0	CHEMBL3045	Homo sapiens	IC50	uM	0.08
	810666	CHEMBL761759	Inhibitory concentration against recombinant human Protein kinase C beta 1 isozyme	B	CN1C2CCC1C(NC(=O)c1ccc(O)cc1)C(OC(=O)c1cc(O)c(C(=O)c3c(O)cccc3C(=O)O)c(O)c1)C2		CHEMBL306883	=	IC50	nM	4400.0	CHEMBL3045	Homo sapiens	IC50	uM	4.4
	810667	CHEMBL768098	Inhibitory concentration against recombinant human Protein kinase C beta 2 isozyme	B	CN1C2CCC1C(NC(=O)c1ccc(O)cc1)C(OC(=O)c1cc(O)c(C(=O)c3c(O)cccc3C(=O)O)c(O)c1)C2		CHEMBL306883	=	IC50	nM	14000.0	CHEMBL3045	Homo sapiens	IC50	uM	14.0
	811835	CHEMBL761759	Inhibitory concentration against recombinant human Protein kinase C beta 1 isozyme	B	O=C(N[C@@H]1CSCCC[C@H]1OC(=O)c1cc(O)c(C(=O)c2c(O)cccc2C(=O)O)c(O)c1)c1ccc(O)cc1		CHEMBL76537	=	IC50	nM	3800.0	CHEMBL3045	Homo sapiens	IC50	uM	3.8
	811836	CHEMBL768098	Inhibitory concentration against recombinant human Protein kinase C beta 2 isozyme	B	O=C(N[C@@H]1CSCCC[C@H]1OC(=O)c1cc(O)c(C(=O)c2c(O)cccc2C(=O)O)c(O)c1)c1ccc(O)cc1		CHEMBL76537	=	IC50	nM	2400.0	CHEMBL3045	Homo sapiens	IC50	uM	2.4
	811844	CHEMBL761759	Inhibitory concentration against recombinant human Protein kinase C beta 1 isozyme	B	O=C(N[C@@H]1CS(=O)(=O)CCC[C@H]1OC(=O)c1cc(O)c(C(=O)c2c(O)cccc2C(=O)O)c(O)c1)c1ccc(O)cc1		CHEMBL305718	=	IC50	nM	5200.0	CHEMBL3045	Homo sapiens	IC50	uM	5.2
	811845	CHEMBL768098	Inhibitory concentration against recombinant human Protein kinase C beta 2 isozyme	B	O=C(N[C@@H]1CS(=O)(=O)CCC[C@H]1OC(=O)c1cc(O)c(C(=O)c2c(O)cccc2C(=O)O)c(O)c1)c1ccc(O)cc1		CHEMBL305718	=	IC50	nM	3600.0	CHEMBL3045	Homo sapiens	IC50	uM	3.6
	813172	CHEMBL761759	Inhibitory concentration against recombinant human Protein kinase C beta 1 isozyme	B	O=C(N[C@H]1CNCCC[C@@H]1OC(=O)c1cc(O)c(C(=O)c2c(O)cccc2C(=O)O)c(O)c1)c1ccc(O)cc1		CHEMBL77970	=	IC50	nM	500.0	CHEMBL3045	Homo sapiens	IC50	uM	0.5
	813173	CHEMBL768098	Inhibitory concentration against recombinant human Protein kinase C beta 2 isozyme	B	O=C(N[C@H]1CNCCC[C@@H]1OC(=O)c1cc(O)c(C(=O)c2c(O)cccc2C(=O)O)c(O)c1)c1ccc(O)cc1		CHEMBL77970	=	IC50	nM	880.0	CHEMBL3045	Homo sapiens	IC50	uM	0.88
	813181	CHEMBL761759	Inhibitory concentration against recombinant human Protein kinase C beta 1 isozyme	B	O=C(N[C@@H]1CCCCC[C@H]1OC(=O)c1cc(O)c(C(=O)c2c(O)cccc2C(=O)O)c(O)c1)c1ccc(O)cc1		CHEMBL304549	=	IC50	nM	220.0	CHEMBL3045	Homo sapiens	IC50	uM	0.22
	813182	CHEMBL768098	Inhibitory concentration against recombinant human Protein kinase C beta 2 isozyme	B	O=C(N[C@@H]1CCCCC[C@H]1OC(=O)c1cc(O)c(C(=O)c2c(O)cccc2C(=O)O)c(O)c1)c1ccc(O)cc1		CHEMBL304549	=	IC50	nM	430.0	CHEMBL3045	Homo sapiens	IC50	uM	0.43
	813190	CHEMBL761759	Inhibitory concentration against recombinant human Protein kinase C beta 1 isozyme	B	COC(=O)C1C[C@@H](NC(=O)c2ccc(O)cc2)[C@H](OC(=O)c2cc(O)c(C(=O)c3c(O)cccc3C(=O)O)c(O)c2)C1		CHEMBL77399	=	IC50	nM	810.0	CHEMBL3045	Homo sapiens	IC50	uM	0.81
	813191	CHEMBL768098	Inhibitory concentration against recombinant human Protein kinase C beta 2 isozyme	B	COC(=O)C1C[C@@H](NC(=O)c2ccc(O)cc2)[C@H](OC(=O)c2cc(O)c(C(=O)c3c(O)cccc3C(=O)O)c(O)c2)C1		CHEMBL77399	=	IC50	nM	2700.0	CHEMBL3045	Homo sapiens	IC50	uM	2.7
	818004	CHEMBL761759	Inhibitory concentration against recombinant human Protein kinase C beta 1 isozyme	B	CC(C)C1C[C@@H](NC(=O)c2ccc(O)cc2)[C@H](OC(=O)c2cc(O)c(C(=O)c3c(O)cccc3C(=O)O)c(O)c2)C1		CHEMBL76920	=	IC50	nM	60.0	CHEMBL3045	Homo sapiens	IC50	uM	0.06
	818005	CHEMBL768098	Inhibitory concentration against recombinant human Protein kinase C beta 2 isozyme	B	CC(C)C1C[C@@H](NC(=O)c2ccc(O)cc2)[C@H](OC(=O)c2cc(O)c(C(=O)c3c(O)cccc3C(=O)O)c(O)c2)C1		CHEMBL76920	=	IC50	nM	70.0	CHEMBL3045	Homo sapiens	IC50	uM	0.07
	818013	CHEMBL761759	Inhibitory concentration against recombinant human Protein kinase C beta 1 isozyme	B	CNC(=O)C1C[C@@H](NC(=O)c2ccc(O)cc2)[C@H](OC(=O)c2cc(O)c(C(=O)c3c(O)cccc3C(=O)O)c(O)c2)C1		CHEMBL312067	=	IC50	nM	680.0	CHEMBL3045	Homo sapiens	IC50	uM	0.68
	818014	CHEMBL768098	Inhibitory concentration against recombinant human Protein kinase C beta 2 isozyme	B	CNC(=O)C1C[C@@H](NC(=O)c2ccc(O)cc2)[C@H](OC(=O)c2cc(O)c(C(=O)c3c(O)cccc3C(=O)O)c(O)c2)C1		CHEMBL312067	=	IC50	nM	1800.0	CHEMBL3045	Homo sapiens	IC50	uM	1.8
	820325	CHEMBL761759	Inhibitory concentration against recombinant human Protein kinase C beta 1 isozyme	B	O=C(N[C@@H]1CCC[C@H]1OC(=O)c1cc(O)c(C(=O)c2c(O)cccc2C(=O)O)c(O)c1)c1ccc(O)cc1		CHEMBL52529	=	IC50	nM	40.0	CHEMBL3045	Homo sapiens	IC50	uM	0.04
	820326	CHEMBL768098	Inhibitory concentration against recombinant human Protein kinase C beta 2 isozyme	B	O=C(N[C@@H]1CCC[C@H]1OC(=O)c1cc(O)c(C(=O)c2c(O)cccc2C(=O)O)c(O)c1)c1ccc(O)cc1		CHEMBL52529	=	IC50	nM	50.0	CHEMBL3045	Homo sapiens	IC50	uM	0.05
	820334	CHEMBL761759	Inhibitory concentration against recombinant human Protein kinase C beta 1 isozyme	B	CS(=O)(=O)C1C[C@@H](NC(=O)c2ccc(O)cc2)[C@H](OC(=O)c2cc(O)c(C(=O)c3c(O)cccc3C(=O)O)c(O)c2)C1		CHEMBL306623	=	IC50	nM	330.0	CHEMBL3045	Homo sapiens	IC50	uM	0.33
	820335	CHEMBL768098	Inhibitory concentration against recombinant human Protein kinase C beta 2 isozyme	B	CS(=O)(=O)C1C[C@@H](NC(=O)c2ccc(O)cc2)[C@H](OC(=O)c2cc(O)c(C(=O)c3c(O)cccc3C(=O)O)c(O)c2)C1		CHEMBL306623	=	IC50	nM	350.0	CHEMBL3045	Homo sapiens	IC50	uM	0.35
	821378	CHEMBL761759	Inhibitory concentration against recombinant human Protein kinase C beta 1 isozyme	B	O=C(N[C@@H]1C2CCC(C2)[C@H]1OC(=O)c1cc(O)c(C(=O)c2c(O)cccc2C(=O)O)c(O)c1)c1ccc(O)cc1		CHEMBL80525	=	IC50	nM	50.0	CHEMBL3045	Homo sapiens	IC50	uM	0.05
	821379	CHEMBL768098	Inhibitory concentration against recombinant human Protein kinase C beta 2 isozyme	B	O=C(N[C@@H]1C2CCC(C2)[C@H]1OC(=O)c1cc(O)c(C(=O)c2c(O)cccc2C(=O)O)c(O)c1)c1ccc(O)cc1		CHEMBL80525	=	IC50	nM	30.0	CHEMBL3045	Homo sapiens	IC50	uM	0.03
	821387	CHEMBL761759	Inhibitory concentration against recombinant human Protein kinase C beta 1 isozyme	B	O=C(N[C@@H]1C2CC(C3CCCC32)[C@H]1OC(=O)c1cc(O)c(C(=O)c2c(O)cccc2C(=O)O)c(O)c1)c1ccc(O)cc1		CHEMBL263910	=	IC50	nM	150.0	CHEMBL3045	Homo sapiens	IC50	uM	0.15
	821388	CHEMBL768098	Inhibitory concentration against recombinant human Protein kinase C beta 2 isozyme	B	O=C(N[C@@H]1C2CC(C3CCCC32)[C@H]1OC(=O)c1cc(O)c(C(=O)c2c(O)cccc2C(=O)O)c(O)c1)c1ccc(O)cc1		CHEMBL263910	=	IC50	nM	30.0	CHEMBL3045	Homo sapiens	IC50	uM	0.03
	822478	CHEMBL761759	Inhibitory concentration against recombinant human Protein kinase C beta 1 isozyme	B	O=C(N[C@@H]1CNCCC[C@H]1OC(=O)c1cc(O)c(C(=O)c2c(O)cccc2C(=O)O)c(O)c1)c1ccc(O)cc1		CHEMBL60254	=	IC50	nM	10.0	CHEMBL3045	Homo sapiens	IC50	uM	0.01
	822479	CHEMBL768098	Inhibitory concentration against recombinant human Protein kinase C beta 2 isozyme	B	O=C(N[C@@H]1CNCCC[C@H]1OC(=O)c1cc(O)c(C(=O)c2c(O)cccc2C(=O)O)c(O)c1)c1ccc(O)cc1		CHEMBL60254	=	IC50	nM	10.0	CHEMBL3045	Homo sapiens	IC50	uM	0.01
	823718	CHEMBL761759	Inhibitory concentration against recombinant human Protein kinase C beta 1 isozyme	B	O=C(N[C@@H]1C[C@@H](O)C[C@H]1OC(=O)c1cc(O)c(C(=O)c2c(O)cccc2C(=O)O)c(O)c1)c1ccc(O)cc1		CHEMBL309034	=	IC50	nM	30.0	CHEMBL3045	Homo sapiens	IC50	uM	0.03
	823719	CHEMBL768098	Inhibitory concentration against recombinant human Protein kinase C beta 2 isozyme	B	O=C(N[C@@H]1C[C@@H](O)C[C@H]1OC(=O)c1cc(O)c(C(=O)c2c(O)cccc2C(=O)O)c(O)c1)c1ccc(O)cc1		CHEMBL309034	=	IC50	nM	20.0	CHEMBL3045	Homo sapiens	IC50	uM	0.02
	826267	CHEMBL761759	Inhibitory concentration against recombinant human Protein kinase C beta 1 isozyme	B	O=C(NC1CNCCCC1OC(=O)c1cc(O)c(C(=O)c2c(O)cccc2C(=O)O)c(O)c1)c1ccc(O)cc1		CHEMBL49354	=	IC50	nM	30.0	CHEMBL3045	Homo sapiens	IC50	uM	0.03
	826268	CHEMBL768098	Inhibitory concentration against recombinant human Protein kinase C beta 2 isozyme	B	O=C(NC1CNCCCC1OC(=O)c1cc(O)c(C(=O)c2c(O)cccc2C(=O)O)c(O)c1)c1ccc(O)cc1		CHEMBL49354	=	IC50	nM	30.0	CHEMBL3045	Homo sapiens	IC50	uM	0.03
	826275	CHEMBL761759	Inhibitory concentration against recombinant human Protein kinase C beta 1 isozyme	B	NC[C@@H]1C[C@@H](NC(=O)c2ccc(O)cc2)[C@H](OC(=O)c2cc(O)c(C(=O)c3c(O)cccc3C(=O)O)c(O)c2)C1		CHEMBL308263	=	IC50	nM	5.0	CHEMBL3045	Homo sapiens	IC50	uM	0.005
	826276	CHEMBL768098	Inhibitory concentration against recombinant human Protein kinase C beta 2 isozyme	B	NC[C@@H]1C[C@@H](NC(=O)c2ccc(O)cc2)[C@H](OC(=O)c2cc(O)c(C(=O)c3c(O)cccc3C(=O)O)c(O)c2)C1		CHEMBL308263	=	IC50	nM	5.0	CHEMBL3045	Homo sapiens	IC50	uM	0.005
	838662	CHEMBL768096	Inhibition of Protein kinase C beta 2	B	O=C1NC(=O)c2c1c1c3ccccc3ccc1c1[nH]c3ccccc3c21		CHEMBL332575	=	IC50	nM	9000.0	CHEMBL3045	Homo sapiens	IC50	uM	9.0
	866916	CHEMBL768283	Displacement of 3[H]PDBu from Protein kinase C beta C1a domain	B	CCCC(=O)O[C@@H]1[C@@H](C)[C@@]2(O)[C@@H](C=C(CO)C[C@@H]3C(=O)C(C)=C[C@H]32)[C@@H]2C(C)(C)[C@]12OC(=O)CCC		CHEMBL265998	=	Ki	nM	2.78	CHEMBL3045	Homo sapiens	Ki	nM	2.78
	866917	CHEMBL768245	Displacement of 3[H]PDBu from Protein kinase C beta C1b domain	B	CCCC(=O)O[C@@H]1[C@@H](C)[C@@]2(O)[C@@H](C=C(CO)C[C@@H]3C(=O)C(C)=C[C@H]32)[C@@H]2C(C)(C)[C@]12OC(=O)CCC		CHEMBL265998	=	Ki	nM	2.23	CHEMBL3045	Homo sapiens	Ki	nM	2.23
	883941	CHEMBL764580	Inhibition of Protein kinase C beta 2	B	O=C1NC(=O)C2=C1c1cn(c3ccccc13)CCO[C@H](CO)CCn1cc2c2ccccc21		CHEMBL292495	=	IC50	nM	32.0	CHEMBL3045	Homo sapiens	IC50	nM	32.0
	899714	CHEMBL764580	Inhibition of Protein kinase C beta 2	B	O=C1NC(=O)C2=C1c1cn(c3ccccc13)CCCOC(CO)CCn1cc2c2ccccc21		CHEMBL294120	=	IC50	nM	270.0	CHEMBL3045	Homo sapiens	IC50	nM	270.0
	902309	CHEMBL768283	Displacement of 3[H]PDBu from Protein kinase C beta C1a domain	B	CCCC(=O)O[C@@H]1[C@@H](C)[C@@]2(O)[C@@H](C=C(CO)C[C@]3(O)C(=O)C(C)=C[C@@H]23)[C@@H]2C(C)(C)[C@]12OC(=O)CCC		CHEMBL27768	=	Ki	nM	1.8	CHEMBL3045	Homo sapiens	Ki	nM	1.8
	902310	CHEMBL768245	Displacement of 3[H]PDBu from Protein kinase C beta C1b domain	B	CCCC(=O)O[C@@H]1[C@@H](C)[C@@]2(O)[C@@H](C=C(CO)C[C@]3(O)C(=O)C(C)=C[C@@H]23)[C@@H]2C(C)(C)[C@]12OC(=O)CCC		CHEMBL27768	=	Ki	nM	1.97	CHEMBL3045	Homo sapiens	Ki	nM	1.97
	907694	CHEMBL761756	Evaluated against recombinant human Protein kinase C beta 1	B	O=C(OC1CCCC1Oc1ccc(O)cc1)c1cc(O)c(C(=O)c2c(O)cccc2C(=O)O)c(O)c1		CHEMBL48988	=	IC50	nM	20.0	CHEMBL3045	Homo sapiens	IC50	uM	0.02
	907695	CHEMBL764574	Evaluated against recombinant human Protein kinase C beta 2	B	O=C(OC1CCCC1Oc1ccc(O)cc1)c1cc(O)c(C(=O)c2c(O)cccc2C(=O)O)c(O)c1		CHEMBL48988	=	IC50	nM	20.0	CHEMBL3045	Homo sapiens	IC50	uM	0.02
	908795	CHEMBL761756	Evaluated against recombinant human Protein kinase C beta 1	B	O=C(OC[C@@H](Cc1ccc(O)cc1)NS(=O)(=O)c1ccccc1)c1cc(O)c(C(=O)c2c(O)cccc2C(=O)O)c(O)c1		CHEMBL345767	=	IC50	nM	30.0	CHEMBL3045	Homo sapiens	IC50	uM	0.03
	908796	CHEMBL764574	Evaluated against recombinant human Protein kinase C beta 2	B	O=C(OC[C@@H](Cc1ccc(O)cc1)NS(=O)(=O)c1ccccc1)c1cc(O)c(C(=O)c2c(O)cccc2C(=O)O)c(O)c1		CHEMBL345767	=	IC50	nM	7.0	CHEMBL3045	Homo sapiens	IC50	uM	0.007
	908803	CHEMBL761756	Evaluated against recombinant human Protein kinase C beta 1	B	O=C(OCCCc1ccc(O)cc1)c1cc(O)c(C(=O)c2c(O)cccc2C(=O)O)c(O)c1		CHEMBL151800	=	IC50	nM	210.0	CHEMBL3045	Homo sapiens	IC50	uM	0.21
	908804	CHEMBL764574	Evaluated against recombinant human Protein kinase C beta 2	B	O=C(OCCCc1ccc(O)cc1)c1cc(O)c(C(=O)c2c(O)cccc2C(=O)O)c(O)c1		CHEMBL151800	=	IC50	nM	270.0	CHEMBL3045	Homo sapiens	IC50	uM	0.27
	910228	CHEMBL761756	Evaluated against recombinant human Protein kinase C beta 1	B	CC(CCc1ccc(O)cc1)OC(=O)c1cc(O)c(C(=O)c2c(O)cccc2C(=O)O)c(O)c1		CHEMBL148745	=	IC50	nM	40.0	CHEMBL3045	Homo sapiens	IC50	uM	0.04
	910229	CHEMBL764574	Evaluated against recombinant human Protein kinase C beta 2	B	CC(CCc1ccc(O)cc1)OC(=O)c1cc(O)c(C(=O)c2c(O)cccc2C(=O)O)c(O)c1		CHEMBL148745	=	IC50	nM	30.0	CHEMBL3045	Homo sapiens	IC50	uM	0.03
	910415	CHEMBL768097	Inhibition of Protein kinase C beta 2	B	O=C1NC(=O)C2=C1c1cn(c3ccccc13)CCOCCOCCOCCn1cc2c2cccnc21		CHEMBL340935	=	IC50	nM	46.0	CHEMBL3045	Homo sapiens	IC50	uM	0.046
	912840	CHEMBL761756	Evaluated against recombinant human Protein kinase C beta 1	B	O=C(OCC(Cc1ccc(O)cc1)NS(=O)(=O)c1ccc2ccccc2c1)c1cc(O)c(C(=O)c2c(O)cccc2C(=O)O)c(O)c1		CHEMBL151823	=	IC50	nM	2800.0	CHEMBL3045	Homo sapiens	IC50	uM	2.8
	912841	CHEMBL764574	Evaluated against recombinant human Protein kinase C beta 2	B	O=C(OCC(Cc1ccc(O)cc1)NS(=O)(=O)c1ccc2ccccc2c1)c1cc(O)c(C(=O)c2c(O)cccc2C(=O)O)c(O)c1		CHEMBL151823	=	IC50	nM	1800.0	CHEMBL3045	Homo sapiens	IC50	uM	1.8
	915722	CHEMBL768097	Inhibition of Protein kinase C beta 2	B	O=C1NC(=O)C2=C1c1cn(c3ncccc13)CCOCCOCCOCCn1cc2c2cccnc21		CHEMBL340776	=	IC50	nM	1163.0	CHEMBL3045	Homo sapiens	IC50	uM	1.163
	915730	CHEMBL764573	Inhibition of human Protein kinase C beta 2 at 10 uM	B	O=C1NC(=O)C2=C1c1cn(c3ncccc13)CCOCCOCCOCCn1cc2c2cccnc21		CHEMBL340776	=	Activity	%	15.0	CHEMBL3045	Homo sapiens	Activity	%	15.0
	918242	CHEMBL768097	Inhibition of Protein kinase C beta 2	B	O=C1NC(=O)C2=C1c1cn(c3ccccc13)CCOCCOCCOCCn1cc2c2ccccc21		CHEMBL340259	=	IC50	nM	6.0	CHEMBL3045	Homo sapiens	IC50	uM	0.006
	920395	CHEMBL761756	Evaluated against recombinant human Protein kinase C beta 1	B	COC(=O)c1cccc(O)c1C(=O)c1c(O)cc(C(=O)OC2CNCC2Cc2ccc(O)cc2)cc1O		CHEMBL48546	=	IC50	nM	110.0	CHEMBL3045	Homo sapiens	IC50	uM	0.11
	920396	CHEMBL764574	Evaluated against recombinant human Protein kinase C beta 2	B	COC(=O)c1cccc(O)c1C(=O)c1c(O)cc(C(=O)OC2CNCC2Cc2ccc(O)cc2)cc1O		CHEMBL48546	=	IC50	nM	250.0	CHEMBL3045	Homo sapiens	IC50	uM	0.25
	921555	CHEMBL761756	Evaluated against recombinant human Protein kinase C beta 1	B	COC(=O)c1cccc(O)c1C(=O)c1c(O)cc(C(=O)OCCCc2ccc(O)cc2)cc1O		CHEMBL149313	=	IC50	nM	460.0	CHEMBL3045	Homo sapiens	IC50	uM	0.46
	921556	CHEMBL764574	Evaluated against recombinant human Protein kinase C beta 2	B	COC(=O)c1cccc(O)c1C(=O)c1c(O)cc(C(=O)OCCCc2ccc(O)cc2)cc1O		CHEMBL149313	=	IC50	nM	750.0	CHEMBL3045	Homo sapiens	IC50	uM	0.75
	924026	CHEMBL761756	Evaluated against recombinant human Protein kinase C beta 1	B	O=C(OC1CNCC1Cc1ccc(O)cc1)c1cc(O)c(C(=O)c2c(O)cccc2C(=O)O)c(O)c1		CHEMBL300422	=	IC50	nM	10.0	CHEMBL3045	Homo sapiens	IC50	uM	0.01
	924027	CHEMBL764574	Evaluated against recombinant human Protein kinase C beta 2	B	O=C(OC1CNCC1Cc1ccc(O)cc1)c1cc(O)c(C(=O)c2c(O)cccc2C(=O)O)c(O)c1		CHEMBL300422	=	IC50	nM	30.0	CHEMBL3045	Homo sapiens	IC50	uM	0.03
	925520	CHEMBL761756	Evaluated against recombinant human Protein kinase C beta 1	B	O=C(OCC(NS(=O)(=O)c1ccccc1)c1ccc(O)cc1)c1cc(O)c(C(=O)c2c(O)cccc2C(=O)O)c(O)c1		CHEMBL150422	=	IC50	nM	11000.0	CHEMBL3045	Homo sapiens	IC50	uM	11.0
	925521	CHEMBL764574	Evaluated against recombinant human Protein kinase C beta 2	B	O=C(OCC(NS(=O)(=O)c1ccccc1)c1ccc(O)cc1)c1cc(O)c(C(=O)c2c(O)cccc2C(=O)O)c(O)c1		CHEMBL150422	=	IC50	nM	2800.0	CHEMBL3045	Homo sapiens	IC50	uM	2.8
	928338	CHEMBL761756	Evaluated against recombinant human Protein kinase C beta 1	B	O=C(NC1CNCCCC1OC(=O)c1cc(O)c(C(=O)c2c(O)cccc2C(=O)O)c(O)c1)c1ccc(O)cc1		CHEMBL49354	=	IC50	nM	30.0	CHEMBL3045	Homo sapiens	IC50	uM	0.03
	928339	CHEMBL764574	Evaluated against recombinant human Protein kinase C beta 2	B	O=C(NC1CNCCCC1OC(=O)c1cc(O)c(C(=O)c2c(O)cccc2C(=O)O)c(O)c1)c1ccc(O)cc1		CHEMBL49354	=	IC50	nM	30.0	CHEMBL3045	Homo sapiens	IC50	uM	0.03
	928346	CHEMBL761756	Evaluated against recombinant human Protein kinase C beta 1	B	Cc1ccc(S(=O)(=O)N2CCC[C@@H](OC(=O)c3cc(O)c(C(=O)c4c(O)cccc4C(=O)O)c(O)c3)[C@H](NC(=O)c3ccc(O)cc3)C2)cc1		CHEMBL146846	=	IC50	nM	70.0	CHEMBL3045	Homo sapiens	IC50	uM	0.07
	928347	CHEMBL764574	Evaluated against recombinant human Protein kinase C beta 2	B	Cc1ccc(S(=O)(=O)N2CCC[C@@H](OC(=O)c3cc(O)c(C(=O)c4c(O)cccc4C(=O)O)c(O)c3)[C@H](NC(=O)c3ccc(O)cc3)C2)cc1		CHEMBL146846	=	IC50	nM	20.0	CHEMBL3045	Homo sapiens	IC50	uM	0.02
	928354	CHEMBL761756	Evaluated against recombinant human Protein kinase C beta 1	B	O=C(OCC(Cc1ccc(O)cc1)NS(=O)(=O)c1ccccc1)c1cc(O)c(C(=O)c2c(O)cccc2C(=O)O)c(O)c1		CHEMBL358264	=	IC50	nM	220.0	CHEMBL3045	Homo sapiens	IC50	uM	0.22
	928355	CHEMBL764574	Evaluated against recombinant human Protein kinase C beta 2	B	O=C(OCC(Cc1ccc(O)cc1)NS(=O)(=O)c1ccccc1)c1cc(O)c(C(=O)c2c(O)cccc2C(=O)O)c(O)c1		CHEMBL358264	=	IC50	nM	30.0	CHEMBL3045	Homo sapiens	IC50	uM	0.03
	930969	CHEMBL761756	Evaluated against recombinant human Protein kinase C beta 1	B	O=C(NC1CCCC1OC(=O)c1cc(O)c(C(=O)c2c(O)cccc2C(=O)O)c(O)c1)c1ccc(O)cc1		CHEMBL48636	=	IC50	nM	40.0	CHEMBL3045	Homo sapiens	IC50	uM	0.04
	930970	CHEMBL764574	Evaluated against recombinant human Protein kinase C beta 2	B	O=C(NC1CCCC1OC(=O)c1cc(O)c(C(=O)c2c(O)cccc2C(=O)O)c(O)c1)c1ccc(O)cc1		CHEMBL48636	=	IC50	nM	50.0	CHEMBL3045	Homo sapiens	IC50	uM	0.05
	930977	CHEMBL761756	Evaluated against recombinant human Protein kinase C beta 1	B	O=C(NC(COC(=O)c1cc(O)c(C(=O)c2c(O)cccc2C(=O)O)c(O)c1)Cc1ccc(O)cc1)c1ccc(O)cc1		CHEMBL151731	=	IC50	nM	3600.0	CHEMBL3045	Homo sapiens	IC50	uM	3.6
	930978	CHEMBL764574	Evaluated against recombinant human Protein kinase C beta 2	B	O=C(NC(COC(=O)c1cc(O)c(C(=O)c2c(O)cccc2C(=O)O)c(O)c1)Cc1ccc(O)cc1)c1ccc(O)cc1		CHEMBL151731	=	IC50	nM	3000.0	CHEMBL3045	Homo sapiens	IC50	uM	3.0
	931183	CHEMBL768097	Inhibition of Protein kinase C beta 2	B	O=C1NC(=O)C2=C1c1cn(c3ncccc13)CCOCCOCCOCCOCCn1cc2c2cccnc21		CHEMBL337642	>	IC50	nM	10000.0	CHEMBL3045	Homo sapiens	IC50	uM	10.0
	931191	CHEMBL764573	Inhibition of human Protein kinase C beta 2 at 10 uM	B	O=C1NC(=O)C2=C1c1cn(c3ncccc13)CCOCCOCCOCCOCCn1cc2c2cccnc21		CHEMBL337642	=	Activity	%	69.0	CHEMBL3045	Homo sapiens	Activity	%	69.0
	932332	CHEMBL761756	Evaluated against recombinant human Protein kinase C beta 1	B	O=C(NC(COC(=O)c1cc(O)c(C(=O)c2c(O)cccc2C(=O)O)c(O)c1)Cc1ccc(O)cc1)c1ccccc1		CHEMBL343362	=	IC50	nM		CHEMBL3045	Homo sapiens	IC50	uM	
	932333	CHEMBL764574	Evaluated against recombinant human Protein kinase C beta 2	B	O=C(NC(COC(=O)c1cc(O)c(C(=O)c2c(O)cccc2C(=O)O)c(O)c1)Cc1ccc(O)cc1)c1ccccc1		CHEMBL343362	=	IC50	nM	2800.0	CHEMBL3045	Homo sapiens	IC50	uM	2.8
	933777	CHEMBL761756	Evaluated against recombinant human Protein kinase C beta 1	B	O=C(OCCCCc1ccc(O)cc1)c1cc(O)c(C(=O)c2c(O)cccc2C(=O)O)c(O)c1		CHEMBL439996	=	IC50	nM	960.0	CHEMBL3045	Homo sapiens	IC50	uM	0.96
	933778	CHEMBL764574	Evaluated against recombinant human Protein kinase C beta 2	B	O=C(OCCCCc1ccc(O)cc1)c1cc(O)c(C(=O)c2c(O)cccc2C(=O)O)c(O)c1		CHEMBL439996	=	IC50	nM	370.0	CHEMBL3045	Homo sapiens	IC50	uM	0.37
	935230	CHEMBL761756	Evaluated against recombinant human Protein kinase C beta 1	B	O=C(NCCOC(=O)c1cc(O)c(C(=O)c2c(O)cccc2C(=O)O)c(O)c1)c1ccc(O)cc1		CHEMBL149873	=	IC50	nM	4500.0	CHEMBL3045	Homo sapiens	IC50	uM	4.5
	935231	CHEMBL764574	Evaluated against recombinant human Protein kinase C beta 2	B	O=C(NCCOC(=O)c1cc(O)c(C(=O)c2c(O)cccc2C(=O)O)c(O)c1)c1ccc(O)cc1		CHEMBL149873	=	IC50	nM	7500.0	CHEMBL3045	Homo sapiens	IC50	uM	7.5
	936655	CHEMBL761756	Evaluated against recombinant human Protein kinase C beta 1	B	O=C(OC1CCCC1Cc1ccc(O)cc1)c1cc(O)c(C(=O)c2c(O)cccc2C(=O)O)c(O)c1		CHEMBL295806	=	IC50	nM	4.0	CHEMBL3045	Homo sapiens	IC50	uM	0.004
	936656	CHEMBL764574	Evaluated against recombinant human Protein kinase C beta 2	B	O=C(OC1CCCC1Cc1ccc(O)cc1)c1cc(O)c(C(=O)c2c(O)cccc2C(=O)O)c(O)c1		CHEMBL295806	=	IC50	nM	3.0	CHEMBL3045	Homo sapiens	IC50	uM	0.003
	938248	CHEMBL761756	Evaluated against recombinant human Protein kinase C beta 1	B	CN(C)C(COC(=O)c1cc(O)c(C(=O)c2c(O)cccc2C(=O)O)c(O)c1)Cc1ccc(O)cc1		CHEMBL421790	=	IC50	nM	880.0	CHEMBL3045	Homo sapiens	IC50	uM	0.88
	938249	CHEMBL764574	Evaluated against recombinant human Protein kinase C beta 2	B	CN(C)C(COC(=O)c1cc(O)c(C(=O)c2c(O)cccc2C(=O)O)c(O)c1)Cc1ccc(O)cc1		CHEMBL421790	=	IC50	nM	500.0	CHEMBL3045	Homo sapiens	IC50	uM	0.5
	938256	CHEMBL761756	Evaluated against recombinant human Protein kinase C beta 1	B	O=C(OCC(COc1ccc(O)cc1)NS(=O)(=O)c1ccccc1)c1cc(O)c(C(=O)c2c(O)cccc2C(=O)O)c(O)c1		CHEMBL150264	=	IC50	nM	1600.0	CHEMBL3045	Homo sapiens	IC50	uM	1.6
	938257	CHEMBL764574	Evaluated against recombinant human Protein kinase C beta 2	B	O=C(OCC(COc1ccc(O)cc1)NS(=O)(=O)c1ccccc1)c1cc(O)c(C(=O)c2c(O)cccc2C(=O)O)c(O)c1		CHEMBL150264	=	IC50	nM	830.0	CHEMBL3045	Homo sapiens	IC50	uM	0.83
	939394	CHEMBL761756	Evaluated against recombinant human Protein kinase C beta 1	B	CS(=O)(=O)NC(COC(=O)c1cc(O)c(C(=O)c2c(O)cccc2C(=O)O)c(O)c1)Cc1ccc(O)cc1		CHEMBL149604	=	IC50	nM	220.0	CHEMBL3045	Homo sapiens	IC50	uM	0.22
	939395	CHEMBL764574	Evaluated against recombinant human Protein kinase C beta 2	B	CS(=O)(=O)NC(COC(=O)c1cc(O)c(C(=O)c2c(O)cccc2C(=O)O)c(O)c1)Cc1ccc(O)cc1		CHEMBL149604	=	IC50	nM	430.0	CHEMBL3045	Homo sapiens	IC50	uM	0.43
	939402	CHEMBL761756	Evaluated against recombinant human Protein kinase C beta 1	B	O=C(OC1CCCC1Cc1ccc(O)cc1)c1cc(O)c(C(=O)c2c(O)cccc2C(=O)O)c(O)c1		CHEMBL295806	=	IC50	nM	20.0	CHEMBL3045	Homo sapiens	IC50	uM	0.02
	939403	CHEMBL764574	Evaluated against recombinant human Protein kinase C beta 2	B	O=C(OC1CCCC1Cc1ccc(O)cc1)c1cc(O)c(C(=O)c2c(O)cccc2C(=O)O)c(O)c1		CHEMBL295806	=	IC50	nM	20.0	CHEMBL3045	Homo sapiens	IC50	uM	0.02
	939410	CHEMBL761756	Evaluated against recombinant human Protein kinase C beta 1	B	COC(=O)c1cccc(O)c1C(=O)c1c(O)cc(C(=O)OC2CCCC2Cc2ccc(O)cc2)cc1O		CHEMBL48665	=	IC50	nM	100.0	CHEMBL3045	Homo sapiens	IC50	uM	0.1
	939411	CHEMBL764574	Evaluated against recombinant human Protein kinase C beta 2	B	COC(=O)c1cccc(O)c1C(=O)c1c(O)cc(C(=O)OC2CCCC2Cc2ccc(O)cc2)cc1O		CHEMBL48665	=	IC50	nM	90.0	CHEMBL3045	Homo sapiens	IC50	uM	0.09
	939420	CHEMBL761756	Evaluated against recombinant human Protein kinase C beta 1	B	O=C(N[C@@H]1CNCCC[C@H]1OC(=O)c1cc(O)c(C(=O)c2c(O)cccc2C(=O)O)c(O)c1)c1ccc(O)cc1		CHEMBL60254	=	IC50	nM	10.0	CHEMBL3045	Homo sapiens	IC50	uM	0.01
	939421	CHEMBL764574	Evaluated against recombinant human Protein kinase C beta 2	B	O=C(N[C@@H]1CNCCC[C@H]1OC(=O)c1cc(O)c(C(=O)c2c(O)cccc2C(=O)O)c(O)c1)c1ccc(O)cc1		CHEMBL60254	=	IC50	nM	10.0	CHEMBL3045	Homo sapiens	IC50	uM	0.01
	939607	CHEMBL768097	Inhibition of Protein kinase C beta 2	B	CN(C)C[C@@H]1CCn2cc(c3ccccc32)C2=C(C(=O)NC2=O)c2cn(c3ccccc23)CCO1		CHEMBL91829	=	IC50	nM	6.0	CHEMBL3045	Homo sapiens	IC50	uM	0.006
	942028	CHEMBL761756	Evaluated against recombinant human Protein kinase C beta 1	B	COC(=O)c1cccc(O)c1C(=O)c1c(O)cc(C(=O)OC[C@@H](Cc2ccc(O)cc2)NS(=O)(=O)c2ccccc2)cc1O		CHEMBL146847	=	IC50	nM	2200.0	CHEMBL3045	Homo sapiens	IC50	uM	2.2
	942029	CHEMBL764574	Evaluated against recombinant human Protein kinase C beta 2	B	COC(=O)c1cccc(O)c1C(=O)c1c(O)cc(C(=O)OC[C@@H](Cc2ccc(O)cc2)NS(=O)(=O)c2ccccc2)cc1O		CHEMBL146847	=	IC50	nM	340.0	CHEMBL3045	Homo sapiens	IC50	uM	0.34
	945933	CHEMBL761756	Evaluated against recombinant human Protein kinase C beta 1	B	O=C(OC[C@H](Cc1ccc(O)cc1)NS(=O)(=O)c1ccccc1)c1cc(O)c(C(=O)c2c(O)cccc2C(=O)O)c(O)c1		CHEMBL151822	=	IC50	nM	230.0	CHEMBL3045	Homo sapiens	IC50	uM	0.23
	945934	CHEMBL764574	Evaluated against recombinant human Protein kinase C beta 2	B	O=C(OC[C@H](Cc1ccc(O)cc1)NS(=O)(=O)c1ccccc1)c1cc(O)c(C(=O)c2c(O)cccc2C(=O)O)c(O)c1		CHEMBL151822	=	IC50	nM	20.0	CHEMBL3045	Homo sapiens	IC50	uM	0.02
	953097	CHEMBL762481	Inhibition of Protein kinase C beta	B	Nc1nccc(-c2c[nH]c3c(Br)ccc(O)c23)n1		CHEMBL296682	=	IC50	nM	1500.0	CHEMBL3045	Homo sapiens	IC50	uM	1.5
	953098	CHEMBL762481	Inhibition of Protein kinase C beta	B	Nc1nccc(-c2c[nH]c3c(Br)ccc(O)c23)n1		CHEMBL296682	=	IC50	nM	2000.0	CHEMBL3045	Homo sapiens	IC50	uM	2.0
	990890	CHEMBL759473	Inhibition of protein kinase C beta 1	B	O=C(N[C@@H]1c2ccccc2CC1OC(=O)c1cc(O)c(C(=O)c2c(O)cccc2C(=O)O)c(O)c1)c1ccc(O)cc1		CHEMBL177308	=	IC50	nM	200.0	CHEMBL3045	Homo sapiens	IC50	uM	0.2
	990891	CHEMBL759474	Inhibition of protein kinase C beta II	B	O=C(N[C@@H]1c2ccccc2CC1OC(=O)c1cc(O)c(C(=O)c2c(O)cccc2C(=O)O)c(O)c1)c1ccc(O)cc1		CHEMBL177308	=	IC50	nM	170.0	CHEMBL3045	Homo sapiens	IC50	uM	0.17
	993183	CHEMBL759473	Inhibition of protein kinase C beta 1	B	O=C(N[C@@H]1CNCC1OC(=O)c1cc(O)c(C(=O)c2c(O)cccc2C(=O)O)c(O)c1)c1ccc(O)cc1		CHEMBL177635	=	IC50	nM	10.0	CHEMBL3045	Homo sapiens	IC50	uM	0.01
	993184	CHEMBL759474	Inhibition of protein kinase C beta II	B	O=C(N[C@@H]1CNCC1OC(=O)c1cc(O)c(C(=O)c2c(O)cccc2C(=O)O)c(O)c1)c1ccc(O)cc1		CHEMBL177635	=	IC50	nM	33.0	CHEMBL3045	Homo sapiens	IC50	uM	0.033
	995775	CHEMBL759473	Inhibition of protein kinase C beta 1	B	O=C(N[C@@H]1Cc2ccccc2C1OC(=O)c1cc(O)c(C(=O)c2c(O)cccc2C(=O)O)c(O)c1)c1ccc(O)cc1		CHEMBL367162	<	IC50	nM	29.0	CHEMBL3045	Homo sapiens	IC50	uM	0.029
	995776	CHEMBL759474	Inhibition of protein kinase C beta II	B	O=C(N[C@@H]1Cc2ccccc2C1OC(=O)c1cc(O)c(C(=O)c2c(O)cccc2C(=O)O)c(O)c1)c1ccc(O)cc1		CHEMBL367162	<	IC50	nM	25.0	CHEMBL3045	Homo sapiens	IC50	uM	0.025
	1001892	CHEMBL871969	Inhibition of Protein kinase C beta 1	B	O=C(NC1CNCCCC1OC(=O)c1cc(O)c(C(=O)c2c(O)cccc2C(=O)O)c(O)c1)c1ccc(O)cc1		CHEMBL49354	=	IC50	nM	80.0	CHEMBL3045	Homo sapiens	IC50	uM	0.08
	1001893	CHEMBL764581	Inhibition of Protein kinase C beta 2	B	O=C(NC1CNCCCC1OC(=O)c1cc(O)c(C(=O)c2c(O)cccc2C(=O)O)c(O)c1)c1ccc(O)cc1		CHEMBL49354	=	IC50	nM	260.0	CHEMBL3045	Homo sapiens	IC50	uM	0.26
	1004349	CHEMBL759473	Inhibition of protein kinase C beta 1	B	O=C(N[C@@H]1CCCC1OC(=O)c1cc(O)c(C(=O)c2c(O)cccc2C(=O)O)c(O)c1)c1ccc(O)cc1		CHEMBL427118	=	IC50	nM	40.0	CHEMBL3045	Homo sapiens	IC50	uM	0.04
	1004350	CHEMBL759474	Inhibition of protein kinase C beta II	B	O=C(N[C@@H]1CCCC1OC(=O)c1cc(O)c(C(=O)c2c(O)cccc2C(=O)O)c(O)c1)c1ccc(O)cc1		CHEMBL427118	=	IC50	nM	50.0	CHEMBL3045	Homo sapiens	IC50	uM	0.05
	1004357	CHEMBL759473	Inhibition of protein kinase C beta 1	B	O=C(N[C@H]1c2ccccc2CC1OC(=O)c1cc(O)c(C(=O)c2c(O)cccc2C(=O)O)c(O)c1)c1ccc(O)cc1		CHEMBL367457	=	IC50	nM	37000.0	CHEMBL3045	Homo sapiens	IC50	uM	37.0
	1004358	CHEMBL759474	Inhibition of protein kinase C beta II	B	O=C(N[C@H]1c2ccccc2CC1OC(=O)c1cc(O)c(C(=O)c2c(O)cccc2C(=O)O)c(O)c1)c1ccc(O)cc1		CHEMBL367457	=	IC50	nM	37000.0	CHEMBL3045	Homo sapiens	IC50	uM	37.0
	1004487	CHEMBL871969	Inhibition of Protein kinase C beta 1	B	O=C(N[C@H]1CNCCCC1OC(=O)c1cc(O)c(C(=O)c2c(O)cccc2C(=O)O)c(O)c1)c1ccc(O)cc1		CHEMBL367488	=	IC50	nM	500.0	CHEMBL3045	Homo sapiens	IC50	uM	0.5
	1004488	CHEMBL764581	Inhibition of Protein kinase C beta 2	B	O=C(N[C@H]1CNCCCC1OC(=O)c1cc(O)c(C(=O)c2c(O)cccc2C(=O)O)c(O)c1)c1ccc(O)cc1		CHEMBL367488	=	IC50	nM	880.0	CHEMBL3045	Homo sapiens	IC50	uM	0.88
	1005821	CHEMBL759473	Inhibition of protein kinase C beta 1	B	O=C(N[C@@H]1c2ccccc2C[C@H]1OC(=O)c1cc(O)c(C(=O)c2c(O)cccc2C(=O)O)c(O)c1)c1ccc(O)cc1		CHEMBL444877	>	IC50	nM	50000.0	CHEMBL3045	Homo sapiens	IC50	uM	50.0
	1005822	CHEMBL759474	Inhibition of protein kinase C beta II	B	O=C(N[C@@H]1c2ccccc2C[C@H]1OC(=O)c1cc(O)c(C(=O)c2c(O)cccc2C(=O)O)c(O)c1)c1ccc(O)cc1		CHEMBL444877	=	IC50	nM	39000.0	CHEMBL3045	Homo sapiens	IC50	uM	39.0
	1014350	CHEMBL759473	Inhibition of protein kinase C beta 1	B	O=C(N[C@@H]1c2ccccc2C[C@@H]1OC(=O)c1cc(O)c(C(=O)c2c(O)cccc2C(=O)O)c(O)c1)c1ccc(O)cc1		CHEMBL367127	=	IC50	nM	60.0	CHEMBL3045	Homo sapiens	IC50	uM	0.06
	1014351	CHEMBL759474	Inhibition of protein kinase C beta II	B	O=C(N[C@@H]1c2ccccc2C[C@@H]1OC(=O)c1cc(O)c(C(=O)c2c(O)cccc2C(=O)O)c(O)c1)c1ccc(O)cc1		CHEMBL367127	=	IC50	nM	50.0	CHEMBL3045	Homo sapiens	IC50	uM	0.05
	1017309	CHEMBL871969	Inhibition of Protein kinase C beta 1	B	O=C(N[C@@H]1CNCCCC1OC(=O)c1cc(O)c(C(=O)c2c(O)cccc2C(=O)O)c(O)c1)c1ccc(O)cc1		CHEMBL311399	=	IC50	nM	10.0	CHEMBL3045	Homo sapiens	IC50	uM	0.01
	1017310	CHEMBL764581	Inhibition of Protein kinase C beta 2	B	O=C(N[C@@H]1CNCCCC1OC(=O)c1cc(O)c(C(=O)c2c(O)cccc2C(=O)O)c(O)c1)c1ccc(O)cc1		CHEMBL311399	=	IC50	nM	10.0	CHEMBL3045	Homo sapiens	IC50	uM	0.01
	1027347	CHEMBL770295	Inhibitory activity against Protein kinase C beta isoform (PKC) from pig spleen.	B	N=C(N)NCCC[C@@H](NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@@H](CCCNC(=N)N)NC(=O)CCNC(=O)[C@H]1OC(n2cnc3c(N)ncnc32)[C@H](O)[C@@H]1O)C(=O)O		CHEMBL611122	=	IC50	nM	3000.0	CHEMBL3045	Homo sapiens	IC50	uM	3.0
	1027352	CHEMBL770295	Inhibitory activity against Protein kinase C beta isoform (PKC) from pig spleen.	B	N=C(N)NCCC[C@@H](NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@@H](CCCNC(=N)N)NC(=O)CCCNC(=O)[C@H]1OC(n2cnc3c(N)ncnc32)[C@H](O)[C@@H]1O)C(=O)O		CHEMBL611125	=	IC50	nM	1500.0	CHEMBL3045	Homo sapiens	IC50	uM	1.5
	1033508	CHEMBL770295	Inhibitory activity against Protein kinase C beta isoform (PKC) from pig spleen.	B	N=C(N)NCCC[C@@H](NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@@H](CCCNC(=N)N)NC(=O)CCCCCCCCCCNC(=O)[C@H]1OC(n2cnc3c(N)ncnc32)[C@H](O)[C@@H]1O)C(=O)O		CHEMBL611121	=	IC50	nM	320.0	CHEMBL3045	Homo sapiens	IC50	uM	0.32
	1033525	CHEMBL770295	Inhibitory activity against Protein kinase C beta isoform (PKC) from pig spleen.	B	C[C@H](C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@H](CCCNC(=N)N)C(=O)O)N1CCC[C@H]1C(=O)N1CCC[C@@H]1C(=O)[C@H]1OC(n2cnc3c(N)ncnc32)[C@H](O)[C@@H]1O		CHEMBL611120	=	IC50	nM	1200.0	CHEMBL3045	Homo sapiens	IC50	uM	1.2
	1034801	CHEMBL770295	Inhibitory activity against Protein kinase C beta isoform (PKC) from pig spleen.	B	N=C(N)NCCC[C@@H](NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@@H](CCCNC(=N)N)NC(=O)CCCCCCCNC(=O)[C@H]1OC(n2cnc3c(N)ncnc32)[C@H](O)[C@@H]1O)C(=O)O		CHEMBL610876	=	IC50	nM	140.0	CHEMBL3045	Homo sapiens	IC50	uM	0.14
	1037271	CHEMBL770295	Inhibitory activity against Protein kinase C beta isoform (PKC) from pig spleen.	B	NC(N)=NCCC[C@@H](N)C(=O)N[C@H](CCCN=C(N)N)C(=O)N[C@H](CCCN=C(N)N)C(=O)N[C@H](CCCN=C(N)N)C(=O)N[C@H](CCCN=C(N)N)C(=O)N[C@H](CCCN=C(N)N)C(=O)O		CHEMBL32709	~	IC50	nM	100000.0	CHEMBL3045	Homo sapiens	IC50	uM	100.0
	1039537	CHEMBL770295	Inhibitory activity against Protein kinase C beta isoform (PKC) from pig spleen.	B	CC(=O)NCCCCCC(=O)N[C@H](CCCN=C(N)N)C(=O)N[C@H](CCCN=C(N)N)C(=O)N[C@H](CCCN=C(N)N)C(=O)N[C@H](CCCN=C(N)N)C(=O)N[C@H](CCCN=C(N)N)C(=O)N[C@H](CCCN=C(N)N)C(=O)O		CHEMBL414907	>	IC50	nM	100000.0	CHEMBL3045	Homo sapiens	IC50	uM	100.0
	1043063	CHEMBL770295	Inhibitory activity against Protein kinase C beta isoform (PKC) from pig spleen.	B	Nc1ncnc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O	Outside typical range	CHEMBL477	=	IC50	nM	278000.0	CHEMBL3045	Homo sapiens	IC50	uM	278.0
	1043070	CHEMBL770295	Inhibitory activity against Protein kinase C beta isoform (PKC) from pig spleen.	B	N=C(N)NCCC[C@@H](NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@@H](CCCNC(=N)N)NC(=O)CCCCCNC(=O)[C@H]1OC(n2cnc3c(N)ncnc32)[C@H](O)[C@@H]1O)C(=O)O		CHEMBL610874	=	IC50	nM	270.0	CHEMBL3045	Homo sapiens	IC50	uM	0.27
	1045862	CHEMBL770295	Inhibitory activity against Protein kinase C beta isoform (PKC) from pig spleen.	B	N=C(N)NCCC[C@@H](NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@@H](CCCNC(=N)N)NC(=O)CNC(=O)[C@H]1OC(n2cnc3c(N)ncnc32)[C@H](O)[C@@H]1O)C(=O)O		CHEMBL611123	=	IC50	nM	10000.0	CHEMBL3045	Homo sapiens	IC50	uM	10.0
	1049374	CHEMBL770295	Inhibitory activity against Protein kinase C beta isoform (PKC) from pig spleen.	B	C[C@@H](NC(=O)C(CNC(=O)C(CNC(=O)[C@H]1OC(n2cnc3c(N)ncnc32)[C@H](O)[C@@H]1O)C(=O)O)C(=O)O)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@H](CCCNC(=N)N)C(=O)O		CHEMBL611127	=	IC50	nM	27000.0	CHEMBL3045	Homo sapiens	IC50	uM	27.0
	1054235	CHEMBL770295	Inhibitory activity against Protein kinase C beta isoform (PKC) from pig spleen.	B	C[C@@H](NC(=O)CCNC(=O)CCNC(=O)[C@H]1OC(n2cnc3c(N)ncnc32)[C@H](O)[C@@H]1O)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@H](CCCNC(=N)N)C(=O)O		CHEMBL610875	=	IC50	nM	2800.0	CHEMBL3045	Homo sapiens	IC50	uM	2.8
	1064386	CHEMBL770295	Inhibitory activity against Protein kinase C beta isoform (PKC) from pig spleen.	B	N=C(N)NCCC[C@@H](NC(=O)[C@@H](CCCNC(=N)N)NC(=O)CCCCCNC(=O)[C@H]1OC(n2cnc3c(N)ncnc32)[C@H](O)[C@@H]1O)C(=O)O		CHEMBL605688	=	IC50	nM	6900.0	CHEMBL3045	Homo sapiens	IC50	uM	6.9
	1146409	CHEMBL761757	Inhibition of Protein kinase C beta 1	B	O=C1NC(=O)C2=C1c1cn(c3ccccc13)CCO[C@H](CN1CCCC1)CCn1cc2c2ccccc21		CHEMBL419866	=	IC50	nM	120.0	CHEMBL3045	Homo sapiens	IC50	uM	0.12
	1146410	CHEMBL764575	Inhibition of Protein kinase C beta 2	B	O=C1NC(=O)C2=C1c1cn(c3ccccc13)CCO[C@H](CN1CCCC1)CCn1cc2c2ccccc21		CHEMBL419866	=	IC50	nM	44.0	CHEMBL3045	Homo sapiens	IC50	uM	0.044
	1148918	CHEMBL761757	Inhibition of Protein kinase C beta 1	B	CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL388978	=	IC50	nM	23.0	CHEMBL3045	Homo sapiens	IC50	uM	0.023
	1148919	CHEMBL764575	Inhibition of Protein kinase C beta 2	B	CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL388978	=	IC50	nM	19.0	CHEMBL3045	Homo sapiens	IC50	uM	0.019
	1151423	CHEMBL761757	Inhibition of Protein kinase C beta 1	B	CNC[C@@H]1CCn2cc(c3ccccc32)C2=C(C(=O)NC2=O)c2cn(c3ccccc23)CCO1		CHEMBL311543	=	IC50	nM	5.0	CHEMBL3045	Homo sapiens	IC50	uM	0.005
	1151424	CHEMBL764575	Inhibition of Protein kinase C beta 2	B	CNC[C@@H]1CCn2cc(c3ccccc32)C2=C(C(=O)NC2=O)c2cn(c3ccccc23)CCO1		CHEMBL311543	=	IC50	nM	5.0	CHEMBL3045	Homo sapiens	IC50	uM	0.005
	1153524	CHEMBL761751	Inhibition of protein kinase C beta	B	N=C(N)SCCCn1c(-c2cc3ccccc3s2)c(C2=CC(=O)NC2=O)c2ccccc21		CHEMBL350335	=	IC50	nM	3.0	CHEMBL3045	Homo sapiens	IC50	nM	3.0
	1153805	CHEMBL761757	Inhibition of Protein kinase C beta 1	B	CN(C)C[C@@H]1CCn2cc(c3ccccc32)C2=C(C(=O)NC2=O)c2cn(c3ccccc23)CCO1		CHEMBL91829	=	IC50	nM	4.7	CHEMBL3045	Homo sapiens	IC50	uM	0.0047
	1153806	CHEMBL764575	Inhibition of Protein kinase C beta 2	B	CN(C)C[C@@H]1CCn2cc(c3ccccc32)C2=C(C(=O)NC2=O)c2cn(c3ccccc23)CCO1		CHEMBL91829	=	IC50	nM	5.9	CHEMBL3045	Homo sapiens	IC50	uM	0.0059
	1161779	CHEMBL761757	Inhibition of Protein kinase C beta 1	B	CN1CCN(C[C@@H]2CCn3cc(c4ccccc43)C3=C(C(=O)NC3=O)c3cn(c4ccccc34)CCO2)CC1		CHEMBL91959	=	IC50	nM	30.0	CHEMBL3045	Homo sapiens	IC50	uM	0.03
	1161780	CHEMBL764575	Inhibition of Protein kinase C beta 2	B	CN1CCN(C[C@@H]2CCn3cc(c4ccccc43)C3=C(C(=O)NC3=O)c3cn(c4ccccc34)CCO2)CC1		CHEMBL91959	=	IC50	nM	24.0	CHEMBL3045	Homo sapiens	IC50	uM	0.024
	1161790	CHEMBL761757	Inhibition of Protein kinase C beta 1	B	O=C1NC(=O)C2=C1c1cn(c3ccccc13)CCO[C@H](CN1CCOCC1)CCn1cc2c2ccccc21		CHEMBL315357	=	IC50	nM	49.0	CHEMBL3045	Homo sapiens	IC50	uM	0.049
	1161791	CHEMBL764575	Inhibition of Protein kinase C beta 2	B	O=C1NC(=O)C2=C1c1cn(c3ccccc13)CCO[C@H](CN1CCOCC1)CCn1cc2c2ccccc21		CHEMBL315357	=	IC50	nM	38.0	CHEMBL3045	Homo sapiens	IC50	uM	0.038
	1163292	CHEMBL761757	Inhibition of Protein kinase C beta 1	B	O=C1NC(=O)C2=C1c1cn(c3ccccc13)CCO[C@H](CNCc1ccccc1)CCn1cc2c2ccccc21		CHEMBL328229	=	IC50	nM	330.0	CHEMBL3045	Homo sapiens	IC50	uM	0.33
	1163293	CHEMBL764575	Inhibition of Protein kinase C beta 2	B	O=C1NC(=O)C2=C1c1cn(c3ccccc13)CCO[C@H](CNCc1ccccc1)CCn1cc2c2ccccc21		CHEMBL328229	=	IC50	nM	310.0	CHEMBL3045	Homo sapiens	IC50	uM	0.31
	1168632	CHEMBL761757	Inhibition of Protein kinase C beta 1	B	O=C1NC(=O)C2=C1c1cn(c3ccccc13)CCO[C@H](CNS(=O)(=O)c1ccccc1)CCn1cc2c2ccccc21		CHEMBL315389	=	IC50	nM	170.0	CHEMBL3045	Homo sapiens	IC50	uM	0.17
	1168633	CHEMBL764575	Inhibition of Protein kinase C beta 2	B	O=C1NC(=O)C2=C1c1cn(c3ccccc13)CCO[C@H](CNS(=O)(=O)c1ccccc1)CCn1cc2c2ccccc21		CHEMBL315389	=	IC50	nM	44.0	CHEMBL3045	Homo sapiens	IC50	uM	0.044
	1169944	CHEMBL761757	Inhibition of Protein kinase C beta 1	B	O=C1NC(=O)C2=C1c1cn(c3ccccc13)CCO[C@H](CO)CCn1cc2c2ccccc21		CHEMBL292495	=	IC50	nM	73.0	CHEMBL3045	Homo sapiens	IC50	uM	0.073
	1169945	CHEMBL764575	Inhibition of Protein kinase C beta 2	B	O=C1NC(=O)C2=C1c1cn(c3ccccc13)CCO[C@H](CO)CCn1cc2c2ccccc21		CHEMBL292495	=	IC50	nM	28.0	CHEMBL3045	Homo sapiens	IC50	uM	0.028
	1180281	CHEMBL761757	Inhibition of Protein kinase C beta 1	B	NC[C@@H]1CCn2cc(c3ccccc32)C2=C(C(=O)NC2=O)c2cn(c3ccccc23)CCO1		CHEMBL316239	=	IC50	nM	48.0	CHEMBL3045	Homo sapiens	IC50	uM	0.048
	1180282	CHEMBL764575	Inhibition of Protein kinase C beta 2	B	NC[C@@H]1CCn2cc(c3ccccc32)C2=C(C(=O)NC2=O)c2cn(c3ccccc23)CCO1		CHEMBL316239	=	IC50	nM	33.0	CHEMBL3045	Homo sapiens	IC50	uM	0.033
	1189627	CHEMBL768242	Displacement of [3H]PDBu from protein kinase C beta C1b domain	B	CCCCCCCC(=O)O[C@H]1/C(=C/C(=O)OC)CC2C[C@H]([C@@H](C)O)OC(=O)C[C@H](O)C[C@@H]3CCC[C@H](C[C@@H]4CCO[C@H](/C=C/C(C)(C)[C@]1(O)O2)O4)O3		CHEMBL46252	=	Ki	nM	13.4	CHEMBL3045	Homo sapiens	Ki	nM	13.4
	1192003	CHEMBL768242	Displacement of [3H]PDBu from protein kinase C beta C1b domain	B	CCCCCCCC(=O)O[C@H]1/C(=C/C(=O)OC)CC2C[C@H]([C@@H](C)O)OC(=O)C[C@@H](O)C[C@@H]3CCC[C@H](C[C@@H]4CCO[C@H](/C=C/C(C)(C)[C@]1(O)O2)O4)O3		CHEMBL46053	=	Ki	nM	280.0	CHEMBL3045	Homo sapiens	Ki	nM	280.0
	1197025	CHEMBL768242	Displacement of [3H]PDBu from protein kinase C beta C1b domain	B	CCCCCCCC(=O)O[C@H]1/C(=C/C(=O)OC)CC2C[C@H]([C@@H](C)O)OC(=O)C[C@H](O)CCO[C@H](C(C)(C)C)C[C@@H]3CCO[C@H](/C=C/C(C)(C)[C@]1(O)O2)O3		CHEMBL45053	=	Ki	nM	36.4	CHEMBL3045	Homo sapiens	Ki	nM	36.4
	1214206	CHEMBL768241	Displacement of [3H]PDBu from protein kinase C beta C1b domain	B	CCCC(=O)O[C@@H]1[C@@H](C)[C@@]2(O)[C@@H](C=C(CO)C[C@]3(O)C(=O)C(C)=C[C@@H]23)[C@@H]2C(C)(C)[C@]12OC(=O)CCC		CHEMBL27768	=	Kd	nM	1.3	CHEMBL3045	Homo sapiens	Kd	nM	1.3
	1228424	CHEMBL759070	Inhibition of protein kinase C beta I	B	O=C(NC1CCCC1OC(=O)c1cc(O)c(C(=O)c2c(O)cccc2C(=O)O)c(O)c1)c1ccc(O)cc1		CHEMBL48636	=	IC50	nM	40.0	CHEMBL3045	Homo sapiens	IC50	uM	0.04
	1228425	CHEMBL759071	Inhibition of protein kinase C beta II	B	O=C(NC1CCCC1OC(=O)c1cc(O)c(C(=O)c2c(O)cccc2C(=O)O)c(O)c1)c1ccc(O)cc1		CHEMBL48636	=	IC50	nM	50.0	CHEMBL3045	Homo sapiens	IC50	uM	0.05
	1233140	CHEMBL759070	Inhibition of protein kinase C beta I	B	O=C(NC1CNCCCC1OC(=O)c1cc(O)c(C(=O)c2c(O)cccc2C(=O)O)c(O)c1)c1ccc(O)cc1		CHEMBL49354	=	IC50	nM	30.0	CHEMBL3045	Homo sapiens	IC50	uM	0.03
	1233141	CHEMBL759071	Inhibition of protein kinase C beta II	B	O=C(NC1CNCCCC1OC(=O)c1cc(O)c(C(=O)c2c(O)cccc2C(=O)O)c(O)c1)c1ccc(O)cc1		CHEMBL49354	=	IC50	nM	30.0	CHEMBL3045	Homo sapiens	IC50	uM	0.03
	1245251	CHEMBL759070	Inhibition of protein kinase C beta I	B	O=C(OC1CNCC1Cc1ccc(O)cc1)c1cc(O)c(C(=O)c2c(O)cccc2C(=O)O)c(O)c1		CHEMBL300422	=	IC50	nM	10.0	CHEMBL3045	Homo sapiens	IC50	uM	0.01
	1245252	CHEMBL759071	Inhibition of protein kinase C beta II	B	O=C(OC1CNCC1Cc1ccc(O)cc1)c1cc(O)c(C(=O)c2c(O)cccc2C(=O)O)c(O)c1		CHEMBL300422	=	IC50	nM	30.0	CHEMBL3045	Homo sapiens	IC50	uM	0.03
	1245260	CHEMBL759070	Inhibition of protein kinase C beta I	B	O=C(OC1CCCC1Cc1ccc(O)cc1)c1cc(O)c(C(=O)c2c(O)cccc2C(=O)O)c(O)c1		CHEMBL295806	=	IC50	nM	4.0	CHEMBL3045	Homo sapiens	IC50	uM	0.004
	1245261	CHEMBL759071	Inhibition of protein kinase C beta II	B	O=C(OC1CCCC1Cc1ccc(O)cc1)c1cc(O)c(C(=O)c2c(O)cccc2C(=O)O)c(O)c1		CHEMBL295806	=	IC50	nM	3.0	CHEMBL3045	Homo sapiens	IC50	uM	0.003
	1250292	CHEMBL759070	Inhibition of protein kinase C beta I	B	O=C(NC1CNCC1OC(=O)c1cc(O)c(C(=O)c2c(O)cccc2C(=O)O)c(O)c1)c1ccc(O)cc1		CHEMBL265559	=	IC50	nM	10.0	CHEMBL3045	Homo sapiens	IC50	uM	0.01
	1250293	CHEMBL759071	Inhibition of protein kinase C beta II	B	O=C(NC1CNCC1OC(=O)c1cc(O)c(C(=O)c2c(O)cccc2C(=O)O)c(O)c1)c1ccc(O)cc1		CHEMBL265559	=	IC50	nM	33.0	CHEMBL3045	Homo sapiens	IC50	uM	0.033
	1255029	CHEMBL759070	Inhibition of protein kinase C beta I	B	O=C(NC1CNCCCC1OC(=O)c1cc(O)c(C(=O)c2c(O)cccc2C(=O)O)c(O)c1)c1ccc(O)cc1		CHEMBL49354	=	IC50	nM	10.0	CHEMBL3045	Homo sapiens	IC50	uM	0.01
	1255030	CHEMBL759071	Inhibition of protein kinase C beta II	B	O=C(NC1CNCCCC1OC(=O)c1cc(O)c(C(=O)c2c(O)cccc2C(=O)O)c(O)c1)c1ccc(O)cc1		CHEMBL49354	=	IC50	nM	10.0	CHEMBL3045	Homo sapiens	IC50	uM	0.01
	1256470	CHEMBL759070	Inhibition of protein kinase C beta I	B	O=C(OC1CCCC1Oc1ccc(O)cc1)c1cc(O)c(C(=O)c2c(O)cccc2C(=O)O)c(O)c1		CHEMBL48988	=	IC50	nM	20.0	CHEMBL3045	Homo sapiens	IC50	uM	0.02
	1256471	CHEMBL759071	Inhibition of protein kinase C beta II	B	O=C(OC1CCCC1Oc1ccc(O)cc1)c1cc(O)c(C(=O)c2c(O)cccc2C(=O)O)c(O)c1		CHEMBL48988	=	IC50	nM	20.0	CHEMBL3045	Homo sapiens	IC50	uM	0.02
	1259045	CHEMBL759070	Inhibition of protein kinase C beta I	B	COC(=O)c1cccc(O)c1C(=O)c1c(O)cc(C(=O)OC2CNCC2Cc2ccc(O)cc2)cc1O		CHEMBL48546	=	IC50	nM	110.0	CHEMBL3045	Homo sapiens	IC50	uM	0.11
	1259046	CHEMBL759071	Inhibition of protein kinase C beta II	B	COC(=O)c1cccc(O)c1C(=O)c1c(O)cc(C(=O)OC2CNCC2Cc2ccc(O)cc2)cc1O		CHEMBL48546	=	IC50	nM	250.0	CHEMBL3045	Homo sapiens	IC50	uM	0.25
	1259054	CHEMBL759070	Inhibition of protein kinase C beta I	B	O=C(OC1CCCC1Cc1ccc(O)cc1)c1cc(O)c(C(=O)c2c(O)cccc2C(=O)O)c(O)c1		CHEMBL295806	=	IC50	nM	20.0	CHEMBL3045	Homo sapiens	IC50	uM	0.02
	1259055	CHEMBL759071	Inhibition of protein kinase C beta II	B	O=C(OC1CCCC1Cc1ccc(O)cc1)c1cc(O)c(C(=O)c2c(O)cccc2C(=O)O)c(O)c1		CHEMBL295806	=	IC50	nM	20.0	CHEMBL3045	Homo sapiens	IC50	uM	0.02
	1265100	CHEMBL759070	Inhibition of protein kinase C beta I	B	COC(=O)c1cccc(O)c1C(=O)c1c(O)cc(C(=O)OC2CCCC2Cc2ccc(O)cc2)cc1O		CHEMBL48665	=	IC50	nM	100.0	CHEMBL3045	Homo sapiens	IC50	uM	0.1
	1265101	CHEMBL759071	Inhibition of protein kinase C beta II	B	COC(=O)c1cccc(O)c1C(=O)c1c(O)cc(C(=O)OC2CCCC2Cc2ccc(O)cc2)cc1O		CHEMBL48665	=	IC50	nM	90.0	CHEMBL3045	Homo sapiens	IC50	uM	0.09
	1269307	CHEMBL761763	Inhibition of human Protein kinase C beta 1	B	O=C(N[C@@H]1CNCCC[C@H]1OC(=O)c1cc(O)c(C(=O)c2c(O)cccc2C(=O)O)c(O)c1)c1ccc(O)cc1		CHEMBL60254	=	IC50	nM	30.0	CHEMBL3045	Homo sapiens	IC50	uM	0.03
	1269308	CHEMBL768104	Inhibition of human Protein kinase C beta 2	B	O=C(N[C@@H]1CNCCC[C@H]1OC(=O)c1cc(O)c(C(=O)c2c(O)cccc2C(=O)O)c(O)c1)c1ccc(O)cc1		CHEMBL60254	=	IC50	nM	40.0	CHEMBL3045	Homo sapiens	IC50	uM	0.04
	1269315	CHEMBL761763	Inhibition of human Protein kinase C beta 1	B	O=C(N[C@@H]1CCC[C@H]1OC(=O)c1cc(O)c(C(=O)c2c(O)cccc2C(=O)O)c(O)c1)c1ccc(O)cc1		CHEMBL52529	=	IC50	nM	40.0	CHEMBL3045	Homo sapiens	IC50	uM	0.04
	1269316	CHEMBL768104	Inhibition of human Protein kinase C beta 2	B	O=C(N[C@@H]1CCC[C@H]1OC(=O)c1cc(O)c(C(=O)c2c(O)cccc2C(=O)O)c(O)c1)c1ccc(O)cc1		CHEMBL52529	=	IC50	nM	50.0	CHEMBL3045	Homo sapiens	IC50	uM	0.05
	1269323	CHEMBL761763	Inhibition of human Protein kinase C beta 1	B	NC[C@@H]1C[C@H](NC(=O)c2ccc(O)cc2)[C@H](OC(=O)c2cc(O)c(C(=O)c3c(O)cccc3C(=O)O)c(O)c2)C1		CHEMBL67290	=	IC50	nM	5.0	CHEMBL3045	Homo sapiens	IC50	uM	0.005
	1269324	CHEMBL768102	Inhibition of human Protein kinase C beta 2	B	NC[C@@H]1C[C@H](NC(=O)c2ccc(O)cc2)[C@H](OC(=O)c2cc(O)c(C(=O)c3c(O)cccc3C(=O)O)c(O)c2)C1		CHEMBL67290	=	IC50	nM	5.0	CHEMBL3045	Homo sapiens	IC50	uM	0.005
	1275866	CHEMBL761763	Inhibition of human Protein kinase C beta 1	B	O=C(N[C@H]1C[C@@H](CO)C[C@H]1OC(=O)c1cc(O)c(C(=O)c2c(O)cccc2C(=O)O)c(O)c1)c1ccc(O)cc1		CHEMBL431955	=	IC50	nM	60.0	CHEMBL3045	Homo sapiens	IC50	uM	0.06
	1275867	CHEMBL768102	Inhibition of human Protein kinase C beta 2	B	O=C(N[C@H]1C[C@@H](CO)C[C@H]1OC(=O)c1cc(O)c(C(=O)c2c(O)cccc2C(=O)O)c(O)c1)c1ccc(O)cc1		CHEMBL431955	=	IC50	nM	20.0	CHEMBL3045	Homo sapiens	IC50	uM	0.02
	1278518	CHEMBL761763	Inhibition of human Protein kinase C beta 1	B	O=C(N[C@@H]1CNC[C@H]1OC(=O)c1cc(O)c(C(=O)c2c(O)cccc2C(=O)O)c(O)c1)c1ccc(O)cc1		CHEMBL59828	=	IC50	nM	17.0	CHEMBL3045	Homo sapiens	IC50	uM	0.017
	1278519	CHEMBL768104	Inhibition of human Protein kinase C beta 2	B	O=C(N[C@@H]1CNC[C@H]1OC(=O)c1cc(O)c(C(=O)c2c(O)cccc2C(=O)O)c(O)c1)c1ccc(O)cc1		CHEMBL59828	=	IC50	nM	33.0	CHEMBL3045	Homo sapiens	IC50	uM	0.033
	1279711	CHEMBL761763	Inhibition of human Protein kinase C beta 1	B	O=C(N[C@H]1C[C@H](CO)C[C@H]1OC(=O)c1cc(O)c(C(=O)c2c(O)cccc2C(=O)O)c(O)c1)c1ccc(O)cc1		CHEMBL306427	=	IC50	nM	4.0	CHEMBL3045	Homo sapiens	IC50	uM	0.004
	1279712	CHEMBL768102	Inhibition of human Protein kinase C beta 2	B	O=C(N[C@H]1C[C@H](CO)C[C@H]1OC(=O)c1cc(O)c(C(=O)c2c(O)cccc2C(=O)O)c(O)c1)c1ccc(O)cc1		CHEMBL306427	=	IC50	nM	3.0	CHEMBL3045	Homo sapiens	IC50	uM	0.003
	1285811	CHEMBL761763	Inhibition of human Protein kinase C beta 1	B	N[C@@H]1C[C@H](NC(=O)c2ccc(O)cc2)[C@H](OC(=O)c2cc(O)c(C(=O)c3c(O)cccc3C(=O)O)c(O)c2)C1		CHEMBL417051	=	IC50	nM	4.0	CHEMBL3045	Homo sapiens	IC50	uM	0.004
	1285812	CHEMBL768104	Inhibition of human Protein kinase C beta 2	B	N[C@@H]1C[C@H](NC(=O)c2ccc(O)cc2)[C@H](OC(=O)c2cc(O)c(C(=O)c3c(O)cccc3C(=O)O)c(O)c2)C1		CHEMBL417051	=	IC50	nM	2.0	CHEMBL3045	Homo sapiens	IC50	uM	0.002
	1300777	CHEMBL761763	Inhibition of human Protein kinase C beta 1	B	O=C(N[C@H]1C[C@H](O)C[C@H]1OC(=O)c1cc(O)c(C(=O)c2c(O)cccc2C(=O)O)c(O)c1)c1ccc(O)cc1		CHEMBL67716	=	IC50	nM	20.0	CHEMBL3045	Homo sapiens	IC50	uM	0.02
	1300778	CHEMBL768102	Inhibition of human Protein kinase C beta 2	B	O=C(N[C@H]1C[C@H](O)C[C@H]1OC(=O)c1cc(O)c(C(=O)c2c(O)cccc2C(=O)O)c(O)c1)c1ccc(O)cc1		CHEMBL67716	=	IC50	nM	20.0	CHEMBL3045	Homo sapiens	IC50	uM	0.02
	1300785	CHEMBL761763	Inhibition of human Protein kinase C beta 1	B	O=C(N[C@H]1C[C@@H](O)C[C@H]1OC(=O)c1cc(O)c(C(=O)c2c(O)cccc2C(=O)O)c(O)c1)c1ccc(O)cc1.O=C(N[C@H]1C[C@H](O)C[C@H]1OC(=O)c1cc(O)c(C(=O)c2c(O)cccc2C(=O)O)c(O)c1)c1ccc(O)cc1		CHEMBL1794808	=	IC50	nM	20.0	CHEMBL3045	Homo sapiens	IC50	uM	0.02
	1300786	CHEMBL768102	Inhibition of human Protein kinase C beta 2	B	O=C(N[C@H]1C[C@@H](O)C[C@H]1OC(=O)c1cc(O)c(C(=O)c2c(O)cccc2C(=O)O)c(O)c1)c1ccc(O)cc1.O=C(N[C@H]1C[C@H](O)C[C@H]1OC(=O)c1cc(O)c(C(=O)c2c(O)cccc2C(=O)O)c(O)c1)c1ccc(O)cc1		CHEMBL1794808	=	IC50	nM	10.0	CHEMBL3045	Homo sapiens	IC50	uM	0.01
	1305092	CHEMBL761763	Inhibition of human Protein kinase C beta 1	B	NC[C@H]1C[C@H](NC(=O)c2ccc(O)cc2)[C@H](OC(=O)c2cc(O)c(C(=O)c3c(O)cccc3C(=O)O)c(O)c2)C1		CHEMBL421866	=	IC50	nM	4.0	CHEMBL3045	Homo sapiens	IC50	uM	0.004
	1305093	CHEMBL768102	Inhibition of human Protein kinase C beta 2	B	NC[C@H]1C[C@H](NC(=O)c2ccc(O)cc2)[C@H](OC(=O)c2cc(O)c(C(=O)c3c(O)cccc3C(=O)O)c(O)c2)C1		CHEMBL421866	=	IC50	nM	4.0	CHEMBL3045	Homo sapiens	IC50	uM	0.004
	1400115	CHEMBL827837	Inhibition of protein kinase C beta 2	B	OCCCNc1cncc(-c2cncc(Nc3cccc(Cl)c3)n2)c1		CHEMBL177688	>	IC50	nM	10000.0	CHEMBL3045	Homo sapiens	IC50	uM	10.0
Not Determined	1403555	CHEMBL828669	Inhibition of human Protein kinase C beta 1 using [gamma-33P]ATP; nd= not determined	B	C=Cn1cc(C2=C(c3nn(CCCN(C)C)c4ccccc34)C(=O)NC2=O)c2ccccc21		CHEMBL368193		IC50	nM		CHEMBL3045	Homo sapiens	IC50	uM	
	1403556	CHEMBL829571	Inhibition of human Protein kinase C beta 2 using [gamma-33P]-ATP	B	C=Cn1cc(C2=C(c3nn(CCCN(C)C)c4ccccc34)C(=O)NC2=O)c2ccccc21		CHEMBL368193	=	IC50	nM	23.0	CHEMBL3045	Homo sapiens	IC50	uM	0.023
	1403560	CHEMBL829570	Inhibition of human Protein kinase C beta 1 using [gamma-33P]-ATP	B	CN(C)CCCn1nc(C2=C(c3cn(-c4ccccc4)c4ccccc34)C(=O)NC2=O)c2ccccc21		CHEMBL366668	=	IC50	nM	46.0	CHEMBL3045	Homo sapiens	IC50	uM	0.046
	1403561	CHEMBL829571	Inhibition of human Protein kinase C beta 2 using [gamma-33P]-ATP	B	CN(C)CCCn1nc(C2=C(c3cn(-c4ccccc4)c4ccccc34)C(=O)NC2=O)c2ccccc21		CHEMBL366668	=	IC50	nM	13.0	CHEMBL3045	Homo sapiens	IC50	uM	0.013
	1403573	CHEMBL834104	Inhibition of IL-8 release by HEK293 cells expressing PKC-beta2	F	CN(C)CCCn1nc(C2=C(c3cn(-c4cccs4)c4ccccc34)C(=O)NC2=O)c2ccccc21		CHEMBL178945	=	IC50	nM	75.0	CHEMBL3045	Homo sapiens	IC50	uM	0.075
	1403576	CHEMBL829570	Inhibition of human Protein kinase C beta 1 using [gamma-33P]-ATP	B	CN(C)CCCn1nc(C2=C(c3cn(-c4cccs4)c4ccccc34)C(=O)NC2=O)c2ccccc21		CHEMBL178945	=	IC50	nM	15.0	CHEMBL3045	Homo sapiens	IC50	uM	0.015
	1403577	CHEMBL829571	Inhibition of human Protein kinase C beta 2 using [gamma-33P]-ATP	B	CN(C)CCCn1nc(C2=C(c3cn(-c4cccs4)c4ccccc34)C(=O)NC2=O)c2ccccc21		CHEMBL178945	=	IC50	nM	10.0	CHEMBL3045	Homo sapiens	IC50	uM	0.01
	1403593	CHEMBL834104	Inhibition of IL-8 release by HEK293 cells expressing PKC-beta2	F	CN(C)CCCn1nc(C2=C(c3cn(-c4cccnc4)c4ccccc34)C(=O)NC2=O)c2ccccc21		CHEMBL368416	=	IC50	nM	82.0	CHEMBL3045	Homo sapiens	IC50	uM	0.082
	1403596	CHEMBL829570	Inhibition of human Protein kinase C beta 1 using [gamma-33P]-ATP	B	CN(C)CCCn1nc(C2=C(c3cn(-c4cccnc4)c4ccccc34)C(=O)NC2=O)c2ccccc21		CHEMBL368416	=	IC50	nM	19.0	CHEMBL3045	Homo sapiens	IC50	uM	0.019
	1403597	CHEMBL829571	Inhibition of human Protein kinase C beta 2 using [gamma-33P]-ATP	B	CN(C)CCCn1nc(C2=C(c3cn(-c4cccnc4)c4ccccc34)C(=O)NC2=O)c2ccccc21		CHEMBL368416	=	IC50	nM	7.0	CHEMBL3045	Homo sapiens	IC50	uM	0.007
	1403605	CHEMBL829570	Inhibition of human Protein kinase C beta 1 using [gamma-33P]-ATP	B	O=C1NC(=O)C(c2cn(-c3cccnc3)c3ccccc23)=C1c1[nH]nc2ccccc12		CHEMBL175956	=	IC50	nM	460.0	CHEMBL3045	Homo sapiens	IC50	uM	0.46
	1403606	CHEMBL829571	Inhibition of human Protein kinase C beta 2 using [gamma-33P]-ATP	B	O=C1NC(=O)C(c2cn(-c3cccnc3)c3ccccc23)=C1c1[nH]nc2ccccc12		CHEMBL175956	=	IC50	nM	220.0	CHEMBL3045	Homo sapiens	IC50	uM	0.22
	1403618	CHEMBL834104	Inhibition of IL-8 release by HEK293 cells expressing PKC-beta2	F	CN(C)CCCn1nc(C2=C(c3cn(-c4ccc5ccccc5c4)c4ccccc34)C(=O)NC2=O)c2ccccc21		CHEMBL368895	=	IC50	nM	24.0	CHEMBL3045	Homo sapiens	IC50	uM	0.024
	1403622	CHEMBL829570	Inhibition of human Protein kinase C beta 1 using [gamma-33P]-ATP	B	CN(C)CCCn1nc(C2=C(c3cn(-c4ccc5ccccc5c4)c4ccccc34)C(=O)NC2=O)c2ccccc21		CHEMBL368895	=	IC50	nM	33.0	CHEMBL3045	Homo sapiens	IC50	uM	0.033
	1403623	CHEMBL829571	Inhibition of human Protein kinase C beta 2 using [gamma-33P]-ATP	B	CN(C)CCCn1nc(C2=C(c3cn(-c4ccc5ccccc5c4)c4ccccc34)C(=O)NC2=O)c2ccccc21		CHEMBL368895	=	IC50	nM	5.0	CHEMBL3045	Homo sapiens	IC50	uM	0.005
	1403639	CHEMBL834104	Inhibition of IL-8 release by HEK293 cells expressing PKC-beta2	F	CN(C)CCCn1nc(C2=C(c3cn(-c4cccc5ccccc45)c4ccccc34)C(=O)NC2=O)c2ccccc21		CHEMBL360304	=	IC50	nM	600.0	CHEMBL3045	Homo sapiens	IC50	uM	0.6
	1403642	CHEMBL829570	Inhibition of human Protein kinase C beta 1 using [gamma-33P]-ATP	B	CN(C)CCCn1nc(C2=C(c3cn(-c4cccc5ccccc45)c4ccccc34)C(=O)NC2=O)c2ccccc21		CHEMBL360304	=	IC50	nM	87.0	CHEMBL3045	Homo sapiens	IC50	uM	0.087
	1403643	CHEMBL829571	Inhibition of human Protein kinase C beta 2 using [gamma-33P]-ATP	B	CN(C)CCCn1nc(C2=C(c3cn(-c4cccc5ccccc45)c4ccccc34)C(=O)NC2=O)c2ccccc21		CHEMBL360304	=	IC50	nM	29.0	CHEMBL3045	Homo sapiens	IC50	uM	0.029
	1403655	CHEMBL829570	Inhibition of human Protein kinase C beta 1 using [gamma-33P]-ATP	B	CN(C)CCCn1nc(C2=C(c3cn(-c4cncc5ccccc45)c4ccccc34)C(=O)NC2=O)c2ccccc21		CHEMBL359808	=	IC50	nM	92.0	CHEMBL3045	Homo sapiens	IC50	uM	0.092
	1403656	CHEMBL829571	Inhibition of human Protein kinase C beta 2 using [gamma-33P]-ATP	B	CN(C)CCCn1nc(C2=C(c3cn(-c4cncc5ccccc45)c4ccccc34)C(=O)NC2=O)c2ccccc21		CHEMBL359808	=	IC50	nM	15.0	CHEMBL3045	Homo sapiens	IC50	uM	0.015
	1403658	CHEMBL834104	Inhibition of IL-8 release by HEK293 cells expressing PKC-beta2	F	CN(C)CCCn1nc(C2=C(c3cn(-c4cncc5ccccc45)c4ccccc34)C(=O)NC2=O)c2ccccc21		CHEMBL359808	=	IC50	nM	86.0	CHEMBL3045	Homo sapiens	IC50	uM	0.086
	1403670	CHEMBL834104	Inhibition of IL-8 release by HEK293 cells expressing PKC-beta2	F	CN(C)CCCn1nc(C2=C(c3cn(-c4cnc5ccccc5c4)c4ccccc34)C(=O)NC2=O)c2ccccc21		CHEMBL359486	=	IC50	nM	20.0	CHEMBL3045	Homo sapiens	IC50	uM	0.02
	1403673	CHEMBL829570	Inhibition of human Protein kinase C beta 1 using [gamma-33P]-ATP	B	CN(C)CCCn1nc(C2=C(c3cn(-c4cnc5ccccc5c4)c4ccccc34)C(=O)NC2=O)c2ccccc21		CHEMBL359486	=	IC50	nM	7.0	CHEMBL3045	Homo sapiens	IC50	uM	0.007
	1403674	CHEMBL829571	Inhibition of human Protein kinase C beta 2 using [gamma-33P]-ATP	B	CN(C)CCCn1nc(C2=C(c3cn(-c4cnc5ccccc5c4)c4ccccc34)C(=O)NC2=O)c2ccccc21		CHEMBL359486	=	IC50	nM	4.0	CHEMBL3045	Homo sapiens	IC50	uM	0.004
	1404538	CHEMBL834104	Inhibition of IL-8 release by HEK293 cells expressing PKC-beta2	F	CN(C)CCCn1nc(C2=C(c3cn(-c4csc5ccccc45)c4ccccc34)C(=O)NC2=O)c2ccccc21		CHEMBL426587	=	IC50	nM	630.0	CHEMBL3045	Homo sapiens	IC50	uM	0.63
	1404541	CHEMBL829570	Inhibition of human Protein kinase C beta 1 using [gamma-33P]-ATP	B	CN(C)CCCn1nc(C2=C(c3cn(-c4csc5ccccc45)c4ccccc34)C(=O)NC2=O)c2ccccc21		CHEMBL426587	=	IC50	nM	86.0	CHEMBL3045	Homo sapiens	IC50	uM	0.086
	1404542	CHEMBL829571	Inhibition of human Protein kinase C beta 2 using [gamma-33P]-ATP	B	CN(C)CCCn1nc(C2=C(c3cn(-c4csc5ccccc45)c4ccccc34)C(=O)NC2=O)c2ccccc21		CHEMBL426587	=	IC50	nM	37.0	CHEMBL3045	Homo sapiens	IC50	uM	0.037
	1404550	CHEMBL829570	Inhibition of human Protein kinase C beta 1 using [gamma-33P]-ATP	B	O=C1NC(=O)C(c2nn(CCCN3CCOCC3)c3ccccc23)=C1c1cn(-c2ccc3ccccc3c2)c2ccccc12		CHEMBL367106	=	IC50	nM	190.0	CHEMBL3045	Homo sapiens	IC50	uM	0.19
	1404551	CHEMBL829571	Inhibition of human Protein kinase C beta 2 using [gamma-33P]-ATP	B	O=C1NC(=O)C(c2nn(CCCN3CCOCC3)c3ccccc23)=C1c1cn(-c2ccc3ccccc3c2)c2ccccc12		CHEMBL367106	=	IC50	nM	18.0	CHEMBL3045	Homo sapiens	IC50	uM	0.018
	1404553	CHEMBL834104	Inhibition of IL-8 release by HEK293 cells expressing PKC-beta2	F	O=C1NC(=O)C(c2nn(CCCN3CCOCC3)c3ccccc23)=C1c1cn(-c2ccc3ccccc3c2)c2ccccc12		CHEMBL367106	=	IC50	nM	72.0	CHEMBL3045	Homo sapiens	IC50	uM	0.072
	1404557	CHEMBL829570	Inhibition of human Protein kinase C beta 1 using [gamma-33P]-ATP	B	O=C1NC(=O)C(c2nn(CCCN3CCCC3)c3ccccc23)=C1c1cn(-c2ccc3ccccc3c2)c2ccccc12		CHEMBL367107	=	IC50	nM	120.0	CHEMBL3045	Homo sapiens	IC50	uM	0.12
	1404558	CHEMBL829571	Inhibition of human Protein kinase C beta 2 using [gamma-33P]-ATP	B	O=C1NC(=O)C(c2nn(CCCN3CCCC3)c3ccccc23)=C1c1cn(-c2ccc3ccccc3c2)c2ccccc12		CHEMBL367107	=	IC50	nM	44.0	CHEMBL3045	Homo sapiens	IC50	uM	0.044
	1404560	CHEMBL834104	Inhibition of IL-8 release by HEK293 cells expressing PKC-beta2	F	O=C1NC(=O)C(c2nn(CCCN3CCCC3)c3ccccc23)=C1c1cn(-c2ccc3ccccc3c2)c2ccccc12		CHEMBL367107	=	IC50	nM	170.0	CHEMBL3045	Homo sapiens	IC50	uM	0.17
	1404564	CHEMBL829570	Inhibition of human Protein kinase C beta 1 using [gamma-33P]-ATP	B	CN1CCN(CCCn2nc(C3=C(c4cn(-c5ccc6ccccc6c5)c5ccccc45)C(=O)NC3=O)c3ccccc32)CC1		CHEMBL175845	=	IC50	nM	62.0	CHEMBL3045	Homo sapiens	IC50	uM	0.062
	1404565	CHEMBL829571	Inhibition of human Protein kinase C beta 2 using [gamma-33P]-ATP	B	CN1CCN(CCCn2nc(C3=C(c4cn(-c5ccc6ccccc6c5)c5ccccc45)C(=O)NC3=O)c3ccccc32)CC1		CHEMBL175845	=	IC50	nM	92.0	CHEMBL3045	Homo sapiens	IC50	uM	0.092
Not Determined	1404674	CHEMBL874937	Inhibition of IL-8 release by HEK293 cells expressing PKC-beta2; Not determined	F	CN1CCN(CCCn2nc(C3=C(c4cn(-c5ccc6ccccc6c5)c5ccccc45)C(=O)NC3=O)c3ccccc32)CC1		CHEMBL175845		IC50	nM		CHEMBL3045	Homo sapiens	IC50	uM	
	1404685	CHEMBL834104	Inhibition of IL-8 release by HEK293 cells expressing PKC-beta2	F	CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL388978	=	IC50	nM	77.0	CHEMBL3045	Homo sapiens	IC50	uM	0.077
	1404688	CHEMBL829570	Inhibition of human Protein kinase C beta 1 using [gamma-33P]-ATP	B	CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL388978	=	IC50	nM	63.0	CHEMBL3045	Homo sapiens	IC50	uM	0.063
	1404689	CHEMBL829571	Inhibition of human Protein kinase C beta 2 using [gamma-33P]-ATP	B	CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL388978	=	IC50	nM	10.0	CHEMBL3045	Homo sapiens	IC50	uM	0.01
	1442937	CHEMBL828239	In vitro inhibitory concentration against human protein kinase C beta-2 (PKCbetaII) by using [gamma-33P]-ATP] as radioligand	B	Nc1nc(C2=C3C(=Nc4ccccc43)C(=O)NCC2)c(O)[nH]1		CHEMBL332551	=	IC50	nM	3381.0	CHEMBL3045	Homo sapiens	IC50	nM	3381.0
	1443236	CHEMBL828239	In vitro inhibitory concentration against human protein kinase C beta-2 (PKCbetaII) by using [gamma-33P]-ATP] as radioligand	B	NC1=NC(=O)/C(=C2\CCNC(=O)c3[nH]c(Br)cc32)N1		CHEMBL361708	=	IC50	nM	1200.0	CHEMBL3045	Homo sapiens	IC50	nM	1200.0
Not Determined	1443243	CHEMBL832328	In vitro inhibitory concentration against human protein kinase C beta-2 (PKCbetaII) by using [gamma-33P]-ATP] as radioligand; NA is value not available	B	NC1=N/C(=C2/CCNC(=O)c3[nH]ccc32)C(=O)N1		CHEMBL255465		IC50	nM		CHEMBL3045	Homo sapiens	IC50	nM	
	1451058	CHEMBL828576	Inhibitory concentration against recombinant human Protein kinase C beta 2	B	CN(C)CCCn1cc(C2=C(Nc3cccc(Cl)c3)C(=O)NC2=O)c2ccccc21		CHEMBL364337	=	IC50	nM	10.0	CHEMBL3045	Homo sapiens	IC50	nM	10.0
	1451061	CHEMBL828576	Inhibitory concentration against recombinant human Protein kinase C beta 2	B	O=C1NC(=O)C(c2cn(CCCN3CCCC3)c3ccccc23)=C1Nc1ccccc1		CHEMBL184042	=	IC50	nM	18.0	CHEMBL3045	Homo sapiens	IC50	nM	18.0
	1451064	CHEMBL828576	Inhibitory concentration against recombinant human Protein kinase C beta 2	B	O=C1NC(=O)C(c2cn(CCCN3CCCCC3)c3ccccc23)=C1Nc1ccccc1		CHEMBL187235	=	IC50	nM	17.0	CHEMBL3045	Homo sapiens	IC50	nM	17.0
	1451067	CHEMBL828576	Inhibitory concentration against recombinant human Protein kinase C beta 2	B	CN1CCN(CCCn2cc(C3=C(Nc4ccccc4)C(=O)NC3=O)c3ccccc32)CC1		CHEMBL184146	=	IC50	nM	23.0	CHEMBL3045	Homo sapiens	IC50	nM	23.0
	1451070	CHEMBL828576	Inhibitory concentration against recombinant human Protein kinase C beta 2	B	Br.N=C(N)SCCCn1cc(C2=C(Nc3ccccc3)C(=O)NC2=O)c2ccccc21		CHEMBL540357	=	IC50	nM	2.0	CHEMBL3045	Homo sapiens	IC50	nM	2.0
	1451073	CHEMBL828575	Inhibitory concentration against recombinant human Protein kinase C beta 1	B	O=C1NC(=O)C(c2cn(CCCn3ccnc3)c3ccccc23)=C1Nc1ccccc1		CHEMBL366266	=	IC50	nM	21.0	CHEMBL3045	Homo sapiens	IC50	nM	21.0
	1451074	CHEMBL828576	Inhibitory concentration against recombinant human Protein kinase C beta 2	B	O=C1NC(=O)C(c2cn(CCCn3ccnc3)c3ccccc23)=C1Nc1ccccc1		CHEMBL366266	=	IC50	nM	5.0	CHEMBL3045	Homo sapiens	IC50	nM	5.0
	1451452	CHEMBL828575	Inhibitory concentration against recombinant human Protein kinase C beta 1	B	CN(C)C[C@@H]1CCn2cc(c3ccccc32)C2=C(C(=O)NC2=O)c2cn(c3ccccc23)CCO1		CHEMBL91829	=	IC50	nM	4.7	CHEMBL3045	Homo sapiens	IC50	nM	4.7
	1451453	CHEMBL828576	Inhibitory concentration against recombinant human Protein kinase C beta 2	B	CN(C)C[C@@H]1CCn2cc(c3ccccc32)C2=C(C(=O)NC2=O)c2cn(c3ccccc23)CCO1		CHEMBL91829	=	IC50	nM	5.9	CHEMBL3045	Homo sapiens	IC50	nM	5.9
	1452423	CHEMBL828576	Inhibitory concentration against recombinant human Protein kinase C beta 2	B	O=C1NC(=O)C(c2c[nH]c3ccccc23)=C1NCc1ccccc1		CHEMBL364374	>	IC50	nM	10000.0	CHEMBL3045	Homo sapiens	IC50	nM	10000.0
	1452424	CHEMBL828576	Inhibitory concentration against recombinant human Protein kinase C beta 2	B	O=C1NC(=O)C(c2c[nH]c3ccccc23)=C1NC1CCCCC1		CHEMBL184826	=	IC50	nM	2448.0	CHEMBL3045	Homo sapiens	IC50	nM	2448.0
	1452425	CHEMBL828575	Inhibitory concentration against recombinant human Protein kinase C beta 1	B	O=C1NC(=O)C(c2c[nH]c3ccccc23)=C1Nc1ccccc1		CHEMBL183310	=	IC50	nM	395.0	CHEMBL3045	Homo sapiens	IC50	nM	395.0
	1452426	CHEMBL828576	Inhibitory concentration against recombinant human Protein kinase C beta 2	B	O=C1NC(=O)C(c2c[nH]c3ccccc23)=C1Nc1ccccc1		CHEMBL183310	=	IC50	nM	223.0	CHEMBL3045	Homo sapiens	IC50	nM	223.0
	1452429	CHEMBL828576	Inhibitory concentration against recombinant human Protein kinase C beta 2	B	CN(C1=C(c2c[nH]c3ccccc23)C(=O)NC1=O)c1ccccc1		CHEMBL187024	=	IC50	nM	939.0	CHEMBL3045	Homo sapiens	IC50	nM	939.0
	1452430	CHEMBL828576	Inhibitory concentration against recombinant human Protein kinase C beta 2	B	Cc1ccccc1NC1=C(c2c[nH]c3ccccc23)C(=O)NC1=O		CHEMBL435104	=	IC50	nM	2146.0	CHEMBL3045	Homo sapiens	IC50	nM	2146.0
	1452431	CHEMBL828576	Inhibitory concentration against recombinant human Protein kinase C beta 2	B	Cc1cccc(NC2=C(c3c[nH]c4ccccc34)C(=O)NC2=O)c1		CHEMBL185573	=	IC50	nM	151.0	CHEMBL3045	Homo sapiens	IC50	nM	151.0
	1452432	CHEMBL828576	Inhibitory concentration against recombinant human Protein kinase C beta 2	B	Cc1ccc(NC2=C(c3c[nH]c4ccccc34)C(=O)NC2=O)cc1		CHEMBL186980	=	IC50	nM	480.0	CHEMBL3045	Homo sapiens	IC50	nM	480.0
	1452433	CHEMBL828576	Inhibitory concentration against recombinant human Protein kinase C beta 2	B	O=C1NC(=O)C(c2c[nH]c3ccccc23)=C1Nc1cccc(F)c1		CHEMBL186981	=	IC50	nM	249.0	CHEMBL3045	Homo sapiens	IC50	nM	249.0
	1452434	CHEMBL828576	Inhibitory concentration against recombinant human Protein kinase C beta 2	B	O=C1NC(=O)C(c2c[nH]c3ccccc23)=C1Nc1cccc(Cl)c1		CHEMBL187325	=	IC50	nM	198.0	CHEMBL3045	Homo sapiens	IC50	nM	198.0
	1452435	CHEMBL828576	Inhibitory concentration against recombinant human Protein kinase C beta 2	B	COc1cccc(NC2=C(c3c[nH]c4ccccc34)C(=O)NC2=O)c1		CHEMBL186901	=	IC50	nM	747.0	CHEMBL3045	Homo sapiens	IC50	nM	747.0
	1452436	CHEMBL828576	Inhibitory concentration against recombinant human Protein kinase C beta 2	B	O=C1NC(=O)C(c2c[nH]c3ccccc23)=C1Nc1cccc(C(F)(F)F)c1		CHEMBL424809	=	IC50	nM	1450.0	CHEMBL3045	Homo sapiens	IC50	nM	1450.0
	1452437	CHEMBL828576	Inhibitory concentration against recombinant human Protein kinase C beta 2	B	CC(C)c1cccc(NC2=C(c3c[nH]c4ccccc34)C(=O)NC2=O)c1		CHEMBL184269	=	IC50	nM	2863.0	CHEMBL3045	Homo sapiens	IC50	nM	2863.0
	1452438	CHEMBL828575	Inhibitory concentration against recombinant human Protein kinase C beta 1	B	O=C1NC(=O)C(c2c[nH]c3ccccc23)=C1c1c[nH]c2ccccc12		CHEMBL266487	=	IC50	nM	304.0	CHEMBL3045	Homo sapiens	IC50	nM	304.0
	1452439	CHEMBL828576	Inhibitory concentration against recombinant human Protein kinase C beta 2	B	O=C1NC(=O)C(c2c[nH]c3ccccc23)=C1c1c[nH]c2ccccc12		CHEMBL266487	=	IC50	nM	212.0	CHEMBL3045	Homo sapiens	IC50	nM	212.0
	1452442	CHEMBL828576	Inhibitory concentration against recombinant human Protein kinase C beta 2	B	CN(C)CCn1cc(C2=C(Nc3ccccc3)C(=O)NC2=O)c2ccccc21		CHEMBL184649	=	IC50	nM	28.0	CHEMBL3045	Homo sapiens	IC50	nM	28.0
	1452819	CHEMBL828576	Inhibitory concentration against recombinant human Protein kinase C beta 2	B	CN(C)CCCn1cc(C2=C(Nc3ccccc3)C(=O)NC2=O)c2ccccc21		CHEMBL365656	=	IC50	nM	12.0	CHEMBL3045	Homo sapiens	IC50	nM	12.0
	1452822	CHEMBL828576	Inhibitory concentration against recombinant human Protein kinase C beta 2	B	CN(C)CCCCn1cc(C2=C(Nc3ccccc3)C(=O)NC2=O)c2ccccc21		CHEMBL184548	=	IC50	nM	15.0	CHEMBL3045	Homo sapiens	IC50	nM	15.0
	1452825	CHEMBL828576	Inhibitory concentration against recombinant human Protein kinase C beta 2	B	CN(C)CCCCCn1cc(C2=C(Nc3ccccc3)C(=O)NC2=O)c2ccccc21		CHEMBL184647	=	IC50	nM	41.0	CHEMBL3045	Homo sapiens	IC50	nM	41.0
	1452828	CHEMBL828576	Inhibitory concentration against recombinant human Protein kinase C beta 2	B	O=C1NC(=O)C(c2cn(CCCO)c3ccccc23)=C1Nc1ccccc1		CHEMBL185221	=	IC50	nM	30.0	CHEMBL3045	Homo sapiens	IC50	nM	30.0
	1452831	CHEMBL828576	Inhibitory concentration against recombinant human Protein kinase C beta 2	B	Cc1cccc(NC2=C(c3cn(CCCN(C)C)c4ccccc34)C(=O)NC2=O)c1		CHEMBL369114	=	IC50	nM	15.0	CHEMBL3045	Homo sapiens	IC50	nM	15.0
	1462033	CHEMBL829308	Inhibition of human Protein kinase C beta 2	B	CC(C)OC(=O)N1CCn2cc(C3=C(c4cnc5ccccn45)C(=O)NC3=O)c3cccc(c32)C1		CHEMBL363058	=	IC50	nM	800.0	CHEMBL3045	Homo sapiens	IC50	uM	0.8
	1462149	CHEMBL829308	Inhibition of human Protein kinase C beta 2	B	O=C1NC(=O)C(c2cnc3ccccn23)=C1c1cn2c3c(cccc13)CN(C(=O)N1CCCCC1)CC2		CHEMBL362588	=	IC50	nM	560.0	CHEMBL3045	Homo sapiens	IC50	uM	0.56
	1462171	CHEMBL829308	Inhibition of human Protein kinase C beta 2	B	Cc1cc2c3c(c1)c(C1=C(c4cnc5ccccn45)C(=O)NC1=O)cn3CCN(C(=O)N1CCCCC1)C2		CHEMBL186290	=	IC50	nM	370.0	CHEMBL3045	Homo sapiens	IC50	uM	0.37
	1462284	CHEMBL829308	Inhibition of human Protein kinase C beta 2	B	O=C1NC(=O)C(c2cnc3ccccn23)=C1c1cn2c3c(cccc13)CN(C(=O)N1CCOCC1)CC2		CHEMBL178737	=	IC50	nM	1100.0	CHEMBL3045	Homo sapiens	IC50	uM	1.1
	1462300	CHEMBL829308	Inhibition of human Protein kinase C beta 2	B	CN(C)C(=O)N1CCn2cc(C3=C(c4cnc5ccccn45)C(=O)NC3=O)c3cccc(c32)C1		CHEMBL362814	=	IC50	nM	1000.0	CHEMBL3045	Homo sapiens	IC50	uM	1.0
	1462426	CHEMBL829308	Inhibition of human Protein kinase C beta 2	B	O=C1NC(=O)C(c2cnc3ccccn23)=C1c1cn2c3c(cc(F)cc13)CN(C(=O)N1CCCCC1)CC2		CHEMBL362558	=	IC50	nM	420.0	CHEMBL3045	Homo sapiens	IC50	uM	0.42
Not Determined	1481548	CHEMBL830114	Inhibition of protein kinase C beta; not determined	B	Clc1cccc(Nc2cncc(-c3cncc(NCCCn4cccn4)c3)n2)c1		CHEMBL371169		IC50	nM		CHEMBL3045	Homo sapiens	IC50	uM	
Not Determined	1481572	CHEMBL833050	Concentration inhibiting protein kinase C beta activity, not determined	B	Clc1cccc(Nc2cncc(-c3cncc(NCCCn4cncn4)c3)n2)c1		CHEMBL372657		IC50	nM		CHEMBL3045	Homo sapiens	IC50	uM	
	1482752	CHEMBL877330	Inhibition of protein kinase C beta activity	B	OCCCNc1cncc(-c2cncc(Nc3cccc(Cl)c3)n2)c1		CHEMBL177688	>	IC50	nM	10000.0	CHEMBL3045	Homo sapiens	IC50	uM	10.0
	1483020	CHEMBL877330	Inhibition of protein kinase C beta activity	B	OCCCCNc1cncc(-c2cncc(Nc3cccc(Cl)c3)n2)c1		CHEMBL188386	>	IC50	nM	10000.0	CHEMBL3045	Homo sapiens	IC50	uM	10.0
	1483091	CHEMBL835541	Percentage inhibition of Protein kinase C beta 1 at 50 uM	B	CN1C(=O)C(c2c[nH]c3ccccc23)=C(c2cn(CCCN)c3ccccc23)C1=O		CHEMBL188282	=	Activity	%	78.0	CHEMBL3045	Homo sapiens	Activity	%	78.0
	1483092	CHEMBL835542	Percentage inhibition of Protein kinase C beta 2 at 50 uM	B	CN1C(=O)C(c2c[nH]c3ccccc23)=C(c2cn(CCCN)c3ccccc23)C1=O		CHEMBL188282	=	Activity	%	84.0	CHEMBL3045	Homo sapiens	Activity	%	84.0
	1483103	CHEMBL835541	Percentage inhibition of Protein kinase C beta 1 at 50 uM	B	CCCCCNC1=C(c2cn(C)c3ccccc23)C(=O)N(C)C1=O		CHEMBL365337	=	Activity	%	84.0	CHEMBL3045	Homo sapiens	Activity	%	84.0
	1483104	CHEMBL835542	Percentage inhibition of Protein kinase C beta 2 at 50 uM	B	CCCCCNC1=C(c2cn(C)c3ccccc23)C(=O)N(C)C1=O		CHEMBL365337	=	Activity	%	106.0	CHEMBL3045	Homo sapiens	Activity	%	106.0
	1483155	CHEMBL877330	Inhibition of protein kinase C beta activity	B	CN(C)CCNc1cncc(-c2cncc(Nc3cccc(Cl)c3)n2)c1		CHEMBL190984	>	IC50	nM	10000.0	CHEMBL3045	Homo sapiens	IC50	uM	10.0
Not Determined	1483423	CHEMBL830114	Inhibition of protein kinase C beta; not determined	B	Clc1cccc(Nc2cncc(-c3cncc(NCCCc4cccnc4)c3)n2)c1		CHEMBL188502		IC50	nM		CHEMBL3045	Homo sapiens	IC50	uM	
	1487650	CHEMBL827896	Inhibition of Protein kinase C- beta 2	B	Cc1ccsc1C(=O)n1nc(Nc2ccc(S(N)(=O)=O)cc2)nc1N		CHEMBL363130	>	IC50	nM	100000.0	CHEMBL3045	Homo sapiens	IC50	uM	100.0
Not Determined	1487786	CHEMBL832834	Inhibition of Protein kinase C- beta 2 activity; Not determined	B	Nc1nc(Nc2ccc(S(N)(=O)=O)cc2)nn1C(=S)Nc1c(F)cccc1F		CHEMBL261720		IC50			CHEMBL3045	Homo sapiens	IC50		
	1489537	CHEMBL827896	Inhibition of Protein kinase C- beta 2	B	Nc1nc(Nc2ccc(S(N)(=O)=O)cc2)nn1C(=O)c1c(F)cccc1F		CHEMBL191003	>	IC50	nM	100000.0	CHEMBL3045	Homo sapiens	IC50	uM	100.0
	1489565	CHEMBL827896	Inhibition of Protein kinase C- beta 2	B	Cc1ccc(F)c(C(=O)n2nc(Nc3ccc(S(N)(=O)=O)cc3)nc2C)c1F		CHEMBL363607	>	IC50	nM	100000.0	CHEMBL3045	Homo sapiens	IC50	uM	100.0
	1711414	CHEMBL867850	Displacement of [3H]phorbol 12,13-dibutyrate from PKC beta-C1A	B	CCCCCCCCc1cccc2c1CC[C@@H](CO)NC(=O)[C@H](C(C)C)N2C		CHEMBL206866	>	Ki	nM	10000.0	CHEMBL3045	Homo sapiens	Ki	nM	10000.0
	1711415	CHEMBL867851	Displacement of [3H]phorbol 12,13-dibutyrate from PKC beta-C1B	B	CCCCCCCCc1cccc2c1CC[C@@H](CO)NC(=O)[C@H](C(C)C)N2C		CHEMBL206866	>	Ki	nM	10000.0	CHEMBL3045	Homo sapiens	Ki	nM	10000.0
	1711427	CHEMBL859937	Induction of GFP-tagged PKC beta translocation in HeLa cells measured as ratio of fluorescence intensity in plasma membrane to cytosol at 10 uM	B	CCCCCCN1C[C@H]2C[C@@H](CO)NC(=O)[C@H](C(C)C)N(C)c3cccc1c32		CHEMBL207363	=	Ratio		2.38	CHEMBL3045	Homo sapiens	Ratio		2.38
	1711433	CHEMBL857896	Induction of GFP-tagged PKC beta translocation in HeLa cells measured as ratio of fluorescence intensity in plasma membrane to cytosol at 1 uM	B	CCCCCCN1C[C@H]2C[C@@H](CO)NC(=O)[C@H](C(C)C)N(C)c3cccc1c32		CHEMBL207363	=	Ratio		2.39	CHEMBL3045	Homo sapiens	Ratio		2.39
	1711439	CHEMBL858890	Induction of GFP-tagged PKC beta translocation in HeLa cells measured as ratio of fluorescence intensity in plasma membrane to cytosol at 0.5 uM	B	CCCCCCN1C[C@H]2C[C@@H](CO)NC(=O)[C@H](C(C)C)N(C)c3cccc1c32		CHEMBL207363	=	Ratio		0.95	CHEMBL3045	Homo sapiens	Ratio		0.95
	1711445	CHEMBL859935	Induction of GFP-tagged PKC beta translocation in HeLa cells measured as ratio of fluorescence intensity in plasma membrane to cytosol at 30 uM	B	CCCCCCCCc1cccc2c1CC[C@@H](CO)NC(=O)[C@H](C(C)C)N2C		CHEMBL206866	=	Ratio		2.4	CHEMBL3045	Homo sapiens	Ratio		2.4
	1711451	CHEMBL859936	Induction of GFP-tagged PKC beta translocation in HeLa cells measured as ratio of fluorescence intensity in plasma membrane to cytosol at 20 uM	B	CCCCCCCCc1cccc2c1CC[C@@H](CO)NC(=O)[C@H](C(C)C)N2C		CHEMBL206866	=	Ratio		0.97	CHEMBL3045	Homo sapiens	Ratio		0.97
	1711457	CHEMBL859937	Induction of GFP-tagged PKC beta translocation in HeLa cells measured as ratio of fluorescence intensity in plasma membrane to cytosol at 10 uM	B	CCCCCCCCc1cccc2c1CC[C@@H](CO)NC(=O)[C@H](C(C)C)N2C		CHEMBL206866	=	Ratio		0.97	CHEMBL3045	Homo sapiens	Ratio		0.97
Not Determined	1711463	CHEMBL857895	Induction of GFP-tagged PKC beta translocation in HeLa cells measured as ratio of fluorescence intensity in plasma membrane to cytosol at 5 uM	B	CCCCCCCCc1cccc2c1CC[C@@H](CO)NC(=O)[C@H](C(C)C)N2C		CHEMBL206866		Ratio			CHEMBL3045	Homo sapiens	Ratio		
Not Determined	1711469	CHEMBL857896	Induction of GFP-tagged PKC beta translocation in HeLa cells measured as ratio of fluorescence intensity in plasma membrane to cytosol at 1 uM	B	CCCCCCCCc1cccc2c1CC[C@@H](CO)NC(=O)[C@H](C(C)C)N2C		CHEMBL206866		Ratio			CHEMBL3045	Homo sapiens	Ratio		
Not Determined	1711473	CHEMBL858890	Induction of GFP-tagged PKC beta translocation in HeLa cells measured as ratio of fluorescence intensity in plasma membrane to cytosol at 0.5 uM	B	CCCCCCCCc1cccc2c1CC[C@@H](CO)NC(=O)[C@H](C(C)C)N2C		CHEMBL206866		Ratio			CHEMBL3045	Homo sapiens	Ratio		
	1734133	CHEMBL854411	Residual activity at human PKCbeta2 at 10 uM in presence of 10 uM ATP relative to control	B	O=C1NC(=O)/C(=C/c2ccc(-c3ccc(F)cc3O)o2)S1		CHEMBL379156	=	Activity	%	98.0	CHEMBL3045	Homo sapiens	Activity	%	98.0
	1769422	CHEMBL910937	Inhibition of PKCbeta2	B	C[C@@H]1C[C@H]2CN1CCn1nc3c(cccc3c1O)-c1nc3c(cccc3nc1O)O2		CHEMBL215803	>	IC50	nM	1000.0	CHEMBL3045	Homo sapiens	IC50	uM	1.0
	1777529	CHEMBL908835	Inhibition of PKC beta	B	COc1ccc(F)c(F)c1C(=O)c1cnc(NC2CCN(S(C)(=O)=O)CC2)nc1N		CHEMBL384304	>	Ki	nM	5000.0	CHEMBL3045	Homo sapiens	Ki	uM	5.0
	1782053	CHEMBL913515	Inhibition of PKCbeta	B	CO[C@@H](C(=O)N1Cc2n[nH]c(NC(=O)c3ccc(N4CCN(C)CC4)cc3)c2C1)c1ccccc1		CHEMBL402548	>	IC50	nM	10000.0	CHEMBL3045	Homo sapiens	IC50	uM	10.0
	1790037	CHEMBL854705	Percentage activity of human PKC betaII -His in the presence of 10 uM of compound and 10 uM of ATP in comparison with control	B	O=C(NCc1ccc(S(=O)(=O)N2CCC(n3nnc4ccccc43)CC2)s1)c1ccc(Cl)cc1		CHEMBL383955	=	Activity	%	88.0	CHEMBL3045	Homo sapiens	Activity	%	88.0
	1856211	CHEMBL919736	Inhibition of PKCbeta2	B	Cc1cccc(C)c1Nc1ncc(-c2ccc(OCC3CCCN(C)C3)cc2)n2cncc12.Cl		CHEMBL534948	>	IC50	nM	10000.0	CHEMBL3045	Homo sapiens	IC50	uM	10.0
	1968072	CHEMBL896388	Inhibition of PKCbeta at 10 uM	B	CN(C(=O)C1CCCCC1)c1ccc2c(c1)nc(NC(=O)c1cccs1)n2CCCN		CHEMBL233338	=	Inhibition	%	21.0	CHEMBL3045	Homo sapiens	Inhibition	%	21.0
	1975568	CHEMBL898648	Inhibition of PKCbeta at 1 uM	B	O=C1NC(=O)c2c1c1c3cc(Cl)ccc3[nH]c1c1cccn21		CHEMBL392052	=	Inhibition	%	79.0	CHEMBL3045	Homo sapiens	Inhibition	%	79.0
	1975575	CHEMBL898648	Inhibition of PKCbeta at 1 uM	B	O=C1NC(=O)c2c1c1c3cc(Br)ccc3[nH]c1c1cccn21		CHEMBL238625	=	Inhibition	%	98.0	CHEMBL3045	Homo sapiens	Inhibition	%	98.0
	1986217	CHEMBL899837	Inhibition of PKCbeta1	B	COc1ccc2cc(-c3c(-c4ccncc4)nc(-c4ccc([S+](C)[O-])cc4C)n3C)ccc2c1		CHEMBL237570	>	IC50	nM	30000.0	CHEMBL3045	Homo sapiens	IC50	nM	30000.0
	1989375	CHEMBL898057	Inhibition of PKCbeta at 1 uM	B	CC(C)NCc1ccc(Nc2cc(-c3ccc(-c4ccc(O)cc4O)cc3)[nH]n2)cc1		CHEMBL398606	=	Inhibition	%	16.0	CHEMBL3045	Homo sapiens	Inhibition	%	16.0
	2025107	CHEMBL886932	Inhibition of human recombinant PKCbeta2	B	CN(C)c1cc2cc(n1)CCCn1cc(c3ccccc31)C1=C(C(=O)NC1=O)c1cn(c3ccccc13)CCC2		CHEMBL247067	=	IC50	nM	2400.0	CHEMBL3045	Homo sapiens	IC50	uM	2.4
	2025179	CHEMBL887006	Inhibition of human PKCbeta2 at 1 uM relative to control	B	CN(C)c1cc2cc(n1)CCCn1cc(c3ccccc31)C1=C(C(=O)NC1=O)c1cn(c3ccccc13)CCC2		CHEMBL247067	=	Inhibition	%	68.0	CHEMBL3045	Homo sapiens	Inhibition	%	68.0
	2025212	CHEMBL886932	Inhibition of human recombinant PKCbeta2	B	CN(C)c1nc2ccc1CCCn1cc(c3ccccc31)C1=C(C(=O)NC1=O)c1cn(c3ccccc13)CC2		CHEMBL1162963	=	IC50	nM	1400.0	CHEMBL3045	Homo sapiens	IC50	uM	1.4
Not Determined	2025213	CHEMBL886932	Inhibition of human recombinant PKCbeta2	B	CN(C)c1nc2ccc1CCCn1cc(c3ccccc31)C1=C(C(=O)NC1=O)c1cn(c3ccccc13)CCC2		CHEMBL392167		Activity			CHEMBL3045	Homo sapiens	Activity		
	2025214	CHEMBL886932	Inhibition of human recombinant PKCbeta2	B	O=C1NC(=O)C2=C1c1cn(c3ccccc13)CCCc1ccc(c(N3CCCC3)n1)CCCn1cc2c2ccccc21		CHEMBL396327	=	IC50	nM	2200.0	CHEMBL3045	Homo sapiens	IC50	uM	2.2
	2025215	CHEMBL886932	Inhibition of human recombinant PKCbeta2	B	O=C1NC(=O)C2=C1c1cn(c3ccccc13)CCCc1cc(nc(N3CCCC3)c1)CCCn1cc2c2ccccc21		CHEMBL397771	=	IC50	nM	1200.0	CHEMBL3045	Homo sapiens	IC50	uM	1.2
	2025429	CHEMBL887006	Inhibition of human PKCbeta2 at 1 uM relative to control	B	CN(C)c1nc2ccc1CCCn1cc(c3ccccc31)C1=C(C(=O)NC1=O)c1cn(c3ccccc13)CC2		CHEMBL1162963	=	Inhibition	%	64.0	CHEMBL3045	Homo sapiens	Inhibition	%	64.0
	2025430	CHEMBL887006	Inhibition of human PKCbeta2 at 1 uM relative to control	B	O=C1NC(=O)C2=C1c1cn(c3ccccc13)CCCc1ccc(c(N3CCCC3)n1)CCCn1cc2c2ccccc21		CHEMBL396327	=	Inhibition	%	77.0	CHEMBL3045	Homo sapiens	Inhibition	%	77.0
	2025431	CHEMBL887006	Inhibition of human PKCbeta2 at 1 uM relative to control	B	O=C1NC(=O)C2=C1c1cn(c3ccccc13)CCCc1cc(nc(N3CCCC3)c1)CCCn1cc2c2ccccc21		CHEMBL397771	=	Inhibition	%	74.0	CHEMBL3045	Homo sapiens	Inhibition	%	74.0
Not Determined	2025523	CHEMBL886932	Inhibition of human recombinant PKCbeta2	B	O=C1NC(=O)C2=C1c1cn(c3ccccc13)CCCCc1ccc(c(N3CCCC3)n1)CCCCn1cc2c2ccccc21		CHEMBL247271		IC50			CHEMBL3045	Homo sapiens	IC50		
	2064407	CHEMBL927259	Displacement of [3H]PDBu from PKCbeta C1A domain	B	CC(C)[C@H]1C(=O)N[C@H](CO)Cc2c[nH]c3cccc(c23)N1C		CHEMBL27266	=	Ki	nM	19.0	CHEMBL3045	Homo sapiens	Ki	nM	19.0
	2064408	CHEMBL927260	Displacement of [3H]PDBu from PKCbeta C1B domain	B	CC(C)[C@H]1C(=O)N[C@H](CO)Cc2c[nH]c3cccc(c23)N1C		CHEMBL27266	=	Ki	nM	140.0	CHEMBL3045	Homo sapiens	Ki	nM	140.0
	2064416	CHEMBL927259	Displacement of [3H]PDBu from PKCbeta C1A domain	B	CCCCCCCCc1cccc2c1CC[C@@H](CO)NC(=O)[C@H](C(C)C)N2C		CHEMBL206866	>	Ki	nM	10000.0	CHEMBL3045	Homo sapiens	Ki	nM	10000.0
	2064418	CHEMBL927260	Displacement of [3H]PDBu from PKCbeta C1B domain	B	CCCCCCCCc1cccc2c1CC[C@@H](CO)NC(=O)[C@H](C(C)C)N2C		CHEMBL206866	>	Ki	nM	10000.0	CHEMBL3045	Homo sapiens	Ki	nM	10000.0
	2064427	CHEMBL927259	Displacement of [3H]PDBu from PKCbeta C1A domain	B	CCCCCCn1cc2c3c(cccc31)N(C)[C@@H](C(C)C)C(=O)N[C@H](CO)C2		CHEMBL399981	=	Ki	nM	9.8	CHEMBL3045	Homo sapiens	Ki	nM	9.8
	2064428	CHEMBL927260	Displacement of [3H]PDBu from PKCbeta C1B domain	B	CCCCCCn1cc2c3c(cccc31)N(C)[C@@H](C(C)C)C(=O)N[C@H](CO)C2		CHEMBL399981	=	Ki	nM	11.0	CHEMBL3045	Homo sapiens	Ki	nM	11.0
	2064437	CHEMBL927259	Displacement of [3H]PDBu from PKCbeta C1A domain	B	CCCCCCn1cc2c3c(cccc31)N(C)[C@@H](C(C)C)C(=O)N[C@H](CO)CC2		CHEMBL401369	=	Ki	nM	9200.0	CHEMBL3045	Homo sapiens	Ki	nM	9200.0
	2064438	CHEMBL927260	Displacement of [3H]PDBu from PKCbeta C1B domain	B	CCCCCCn1cc2c3c(cccc31)N(C)[C@@H](C(C)C)C(=O)N[C@H](CO)CC2		CHEMBL401369	=	Ki	nM	440.0	CHEMBL3045	Homo sapiens	Ki	nM	440.0
Not Determined	2064465	CHEMBL927275	Induction of GFP-tagged PKC-beta-1 translocation in HeLa cells assessed as ratio of protein level in plasma membrane to cytosol at 10 uM	B	CCCCCCn1cc2c3c(cccc31)N(C)[C@@H](C(C)C)C(=O)N[C@H](CO)CC2		CHEMBL401369		Ratio			CHEMBL3045	Homo sapiens	Ratio		
	2064466	CHEMBL927276	Induction of GFP-tagged PKC-beta-1 translocation in HeLa cells assessed as ratio of protein level in plasma membrane to cytosol at 1 uM	B	CCCCCCn1cc2c3c(cccc31)N(C)[C@@H](C(C)C)C(=O)N[C@H](CO)CC2		CHEMBL401369	=	Ratio		1.4	CHEMBL3045	Homo sapiens	Ratio		1.4
	2064467	CHEMBL927277	Induction of GFP-tagged PKC-beta-1 translocation in HeLa cells assessed as ratio of protein level in plasma membrane to cytosol at 500 nM	B	CCCCCCn1cc2c3c(cccc31)N(C)[C@@H](C(C)C)C(=O)N[C@H](CO)CC2		CHEMBL401369	=	Ratio		1.18	CHEMBL3045	Homo sapiens	Ratio		1.18
	2064468	CHEMBL927278	Induction of GFP-tagged PKC-beta-1 translocation in HeLa cells assessed as ratio of protein level in plasma membrane to cytosol at 100 nM	B	CCCCCCn1cc2c3c(cccc31)N(C)[C@@H](C(C)C)C(=O)N[C@H](CO)CC2		CHEMBL401369	=	Ratio		1.03	CHEMBL3045	Homo sapiens	Ratio		1.03
	2064486	CHEMBL927276	Induction of GFP-tagged PKC-beta-1 translocation in HeLa cells assessed as ratio of protein level in plasma membrane to cytosol at 1 uM	B	CC(C)[C@H]1C(=O)N[C@H](CO)Cc2c[nH]c3cccc(c23)N1C		CHEMBL27266	=	Ratio		3.71	CHEMBL3045	Homo sapiens	Ratio		3.71
Not Active	2064493	CHEMBL926302	Displacement of [3H]PDBu from PKCbeta C1A domain at 10 uM	B	CCCCCCn1cc2c3c(c(Cl)ccc31)N(C)[C@@H](C(C)C)C(=O)N[C@H](CO)CC2		CHEMBL400487		Activity			CHEMBL3045	Homo sapiens	Activity		
Not Active	2064494	CHEMBL926303	Displacement of [3H]PDBu from PKCbeta C1B domain at 10 uM	B	CCCCCCn1cc2c3c(c(Cl)ccc31)N(C)[C@@H](C(C)C)C(=O)N[C@H](CO)CC2		CHEMBL400487		Activity			CHEMBL3045	Homo sapiens	Activity		
Not Active	2064495	CHEMBL926302	Displacement of [3H]PDBu from PKCbeta C1A domain at 10 uM	B	CCCCCCn1c(Br)c2c3c(cccc31)N(C)[C@@H](C(C)C)C(=O)N[C@H](CO)CC2		CHEMBL255043		Activity			CHEMBL3045	Homo sapiens	Activity		
Not Active	2064496	CHEMBL926303	Displacement of [3H]PDBu from PKCbeta C1B domain at 10 uM	B	CCCCCCn1c(Br)c2c3c(cccc31)N(C)[C@@H](C(C)C)C(=O)N[C@H](CO)CC2		CHEMBL255043		Activity			CHEMBL3045	Homo sapiens	Activity		
	2081810	CHEMBL928834	Inhibition of PKCbeta1 at 10 uM	B	CC[C@@H](C)Nc1nc2ccc(-c3c(-c4ccccc4F)n[nH]c3N)cc2s1		CHEMBL404115	<=	Inhibition	%	20.0	CHEMBL3045	Homo sapiens	Inhibition	%	20.0
	2081811	CHEMBL928835	Inhibition of PKC-beta-2 at 10 uM	B	CC[C@@H](C)Nc1nc2ccc(-c3c(-c4ccccc4F)n[nH]c3N)cc2s1		CHEMBL404115	<=	Inhibition	%	20.0	CHEMBL3045	Homo sapiens	Inhibition	%	20.0
	2085331	CHEMBL930943	Displacement of [3H]PDBu from PKCbeta C1B domain	B	CC(C)[C@H]1C(=O)N[C@H](CO)Cc2cn3nc(C(F)(F)F)c4ccc(c2c43)N1C		CHEMBL261387	=	Ki	nM	9380.0	CHEMBL3045	Homo sapiens	Ki	nM	9380.0
	2085332	CHEMBL930943	Displacement of [3H]PDBu from PKCbeta C1B domain	B	Cc1nn2cc3c4c(ccc1c42)N(C)[C@@H](C(C)C)C(=O)N[C@H](CO)C3		CHEMBL441897	>	Ki	nM	10000.0	CHEMBL3045	Homo sapiens	Ki	nM	10000.0
	2085333	CHEMBL930943	Displacement of [3H]PDBu from PKCbeta C1B domain	B	CC(C)[C@H]1C(=O)N[C@H](CO)Cc2cn3ncc4ccc(c2c43)N1C		CHEMBL271403	=	Ki	nM	5960.0	CHEMBL3045	Homo sapiens	Ki	nM	5960.0
	2085334	CHEMBL930944	Displacement of [3H]PDBu from PKCbeta C1A domain	B	CC(C)[C@H]1C(=O)N[C@H](CO)Cc2cn3nc(C(F)(F)F)c4ccc(c2c43)N1C		CHEMBL261387	=	Ki	nM	127.0	CHEMBL3045	Homo sapiens	Ki	nM	127.0
	2085335	CHEMBL930944	Displacement of [3H]PDBu from PKCbeta C1A domain	B	Cc1nn2cc3c4c(ccc1c42)N(C)[C@@H](C(C)C)C(=O)N[C@H](CO)C3		CHEMBL441897	=	Ki	nM	1100.0	CHEMBL3045	Homo sapiens	Ki	nM	1100.0
	2085336	CHEMBL930944	Displacement of [3H]PDBu from PKCbeta C1A domain	B	CC(C)[C@H]1C(=O)N[C@H](CO)Cc2cn3ncc4ccc(c2c43)N1C		CHEMBL271403	=	Ki	nM	88.0	CHEMBL3045	Homo sapiens	Ki	nM	88.0
	2085359	CHEMBL930943	Displacement of [3H]PDBu from PKCbeta C1B domain	B	CC(C)[C@H]1C(=O)N[C@H](CO)Cc2c[nH]c3cccc(c23)N1C		CHEMBL27266	=	Ki	nM	4000.0	CHEMBL3045	Homo sapiens	Ki	nM	4000.0
	2085360	CHEMBL930944	Displacement of [3H]PDBu from PKCbeta C1A domain	B	CC(C)[C@H]1C(=O)N[C@H](CO)Cc2c[nH]c3cccc(c23)N1C		CHEMBL27266	=	Ki	nM	19.0	CHEMBL3045	Homo sapiens	Ki	nM	19.0
	2133122	CHEMBL938477	Inhibition of PKCbeta	B	COc1cc(Nc2nn3c(N[C@H](CO)Cc4ccccc4)cc(C4CC4)nc3c2C(N)=O)cc(OC)c1		CHEMBL260861	>	IC50	nM	10000.0	CHEMBL3045	Homo sapiens	IC50	uM	10.0
	2136970	CHEMBL939360	Inhibition of PKCbeta	B	Cn1c2ccccc2c2c3c(c4c5ccccc5n(CCC#N)c4c21)CNC3=O		CHEMBL302449	=	IC50	nM	2.0	CHEMBL3045	Homo sapiens	IC50	nM	2.0
	2137078	CHEMBL921711	Inhibition of PKCbeta	B	O=C1NC(=O)C(c2cn(CCCn3ccnc3)c3ccccc23)=C1Nc1ccccc1		CHEMBL366266	=	IC50	nM	5.0	CHEMBL3045	Homo sapiens	IC50	nM	5.0
	2147353	CHEMBL922039	Activity of human PKC-beta-1 kinase at 1 uM	B	O=C(O)c1ccc(Nc2ncc3c(n2)-c2ccc(Cl)cc2C(c2c(F)cccc2F)=NC3)cc1		CHEMBL259084	=	Activity	%	98.0	CHEMBL3045	Homo sapiens	Activity	%	98.0
	2147354	CHEMBL922139	Activity of human PKC-beta-2 kinase at 1 uM	B	O=C(O)c1ccc(Nc2ncc3c(n2)-c2ccc(Cl)cc2C(c2c(F)cccc2F)=NC3)cc1		CHEMBL259084	=	Activity	%	100.0	CHEMBL3045	Homo sapiens	Activity	%	100.0
	2153724	CHEMBL935761	Inhibition of PKC-beta-2 at 20 uM	B	CN(C)CCOc1ccc2c(-c3c(-c4ccccn4)nn4c3CCC4)ccnc2c1		CHEMBL409525	<	Inhibition	%	50.0	CHEMBL3045	Homo sapiens	Inhibition	%	50.0
	2153759	CHEMBL935761	Inhibition of PKC-beta-2 at 20 uM	B	c1ccc(-c2nn3c(c2-c2ccnc4cc(OCCN5CCOCC5)ccc24)CCC3)nc1		CHEMBL260015	<	Inhibition	%	50.0	CHEMBL3045	Homo sapiens	Inhibition	%	50.0
	2168112	CHEMBL927982	Inhibition of PKCbeta	B	Cc1c(Nc2c(C#N)cnc3sc(-c4cccc(CN(C)C)c4)cc23)ccc2[nH]ccc12		CHEMBL402818	=	IC50	nM	1600.0	CHEMBL3045	Homo sapiens	IC50	uM	1.6
	2182370	CHEMBL950791	Inhibition of PKCbeta1	B	Cn1c2ccccc2c2c3c(c4c5ccccc5n(CCC#N)c4c21)CNC3=O		CHEMBL302449	=	IC50	nM	6.2	CHEMBL3045	Homo sapiens	IC50	nM	6.2
	2182830	CHEMBL941456	Inhibition of PRKCB1 at 5 uM	B	O=c1cc(N2CCOCC2)nc2c3ccccc3ccn12		CHEMBL179242	=	Inhibition	%	8.0	CHEMBL3045	Homo sapiens	INH	%	8.0
	2204092	CHEMBL991515	Agonist activity at protein kinase C beta-1 at 50 pg/mL	F	CC(CCCCCCCCc1ccccc1)C[C@]1(C)C[C@]2(C)OC(=O)C[C@@H]2OO1		CHEMBL460022	=	Activity	%	13.0	CHEMBL3045	Homo sapiens	Activity	%	13.0
	2204093	CHEMBL991516	Agonist activity at protein kinase C beta2 at 50 pg/mL	F	CC(CCCCCCCCc1ccccc1)C[C@]1(C)C[C@]2(C)OC(=O)C[C@@H]2OO1		CHEMBL460022	=	Activity	%	27.0	CHEMBL3045	Homo sapiens	Activity	%	27.0
	2204098	CHEMBL991521	Antagonist activity at protein kinase C beta-1	F	CCCCCCCCCCCCCCCC[C@@]1(OC)C=C[C@@H](CC(=O)OC)OO1		CHEMBL163015	=	IC50	ug.mL-1	49.0	CHEMBL3045	Homo sapiens	IC50	ug ml-1	49.0
	2204099	CHEMBL991522	Antagonist activity at protein kinase C beta2	F	CCCCCCCCCCCCCCCC[C@@]1(OC)C=C[C@@H](CC(=O)OC)OO1		CHEMBL163015	=	IC50	ug.mL-1	49.0	CHEMBL3045	Homo sapiens	IC50	ug ml-1	49.0
	2248279	CHEMBL1012714	Inhibition of PKCbeta2 at 5 uM	B	O=C1NC(=O)/C(=C/c2cccc(C(F)(F)F)c2)S1		CHEMBL183906	=	Inhibition	%	-2.0	CHEMBL3045	Homo sapiens	INH	%	-2.0
	2248280	CHEMBL1012714	Inhibition of PKCbeta2 at 5 uM	B	CCCOc1ccc(/C=C2\SC(=O)NC2=O)cc1		CHEMBL84558	=	Inhibition	%	-1.0	CHEMBL3045	Homo sapiens	INH	%	-1.0
	2250926	CHEMBL1022470	Inhibition of PKCbeta	B	Nc1nccc(-c2cc3c([nH]2)[C@@H](CCF)CNC3=O)n1		CHEMBL524266	=	IC50	nM	1149.0	CHEMBL3045	Homo sapiens	IC50	uM	1.149
	2251058	CHEMBL1011933	Inhibition of PKCbeta1 at 100 nM relative to control	B	N=C(N)NCCC[C@@H](NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@@H](CCCNC(=N)N)NC(=O)CCCCCNC(=O)[C@@H](CCCCN)NC(=O)CCCCCNC(=O)[C@H]1O[C@@H](n2cnc3c(N)ncnc32)[C@H](O)[C@@H]1O)C(N)=O		CHEMBL525385	=	Inhibition	%	97.0	CHEMBL3045	Homo sapiens	INH	%	97.0
	2251059	CHEMBL1011934	Inhibition of PKCbeta2 at 100 nM relative to control	B	N=C(N)NCCC[C@@H](NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@@H](CCCNC(=N)N)NC(=O)CCCCCNC(=O)[C@@H](CCCCN)NC(=O)CCCCCNC(=O)[C@H]1O[C@@H](n2cnc3c(N)ncnc32)[C@H](O)[C@@H]1O)C(N)=O		CHEMBL525385	=	Inhibition	%	94.0	CHEMBL3045	Homo sapiens	INH	%	94.0
	2264765	CHEMBL963877	Binding affinity to PKC beta2	B	CS(=O)(=O)c1ccc(CNCc2cc(C(=O)O)c(Nc3ccc(I)cc3F)c(F)c2F)cc1		CHEMBL465465	>	IC50	nM	30000.0	CHEMBL3045	Homo sapiens	IC50	uM	30.0
	2264766	CHEMBL963877	Binding affinity to PKC beta2	B	NC(=O)C[C@H](N)C(=O)NCc1cc(C(=O)O)c(Nc2ccc(I)cc2F)c(F)c1F		CHEMBL517647	=	IC50	nM	2000.0	CHEMBL3045	Homo sapiens	IC50	uM	2.0
	2264767	CHEMBL963877	Binding affinity to PKC beta2	B	O=C(N/N=C/c1cc(C(=O)O)c(Nc2ccc(I)cc2F)c(F)c1F)c1ccc(CO)o1		CHEMBL481968	>	IC50	nM	30000.0	CHEMBL3045	Homo sapiens	IC50	uM	30.0
	2264768	CHEMBL963877	Binding affinity to PKC beta2	B	O=C(CS(=O)(=O)c1ccc(Cl)cc1)N/N=C/c1cc(C(=O)O)c(Nc2ccc(I)cc2F)c(F)c1F		CHEMBL481969	>	IC50	nM	30000.0	CHEMBL3045	Homo sapiens	IC50	uM	30.0
	2356968	CHEMBL958265	Inhibition of PKCbeta at 1 uM relative to control	B	Cc1ccn(-c2cccc(C(F)(F)F)c2)c(=O)c1-c1ccc2nc(N)ncc2c1		CHEMBL504805	>	Inhibition	%	50.0	CHEMBL3045	Homo sapiens	INH	%	50.0
	2356978	CHEMBL958274	Inhibition of PKCbeta2 at 1 uM relative to control	B	Cc1ccn(-c2ccc(-c3ncco3)cc2)c(=O)c1-c1ccc2nc(N)ncc2c1		CHEMBL525893	>	Inhibition	%	50.0	CHEMBL3045	Homo sapiens	INH	%	50.0
	2362669	CHEMBL1034874	Inhibition of PKCbeta by fluorescence polarization assay	B	COc1ccc(-c2cncc(C#N)c2Nc2ccc3[nH]ccc3c2)cc1OC		CHEMBL492251	>	IC50	nM	50000.0	CHEMBL3045	Homo sapiens	IC50	uM	50.0
	2367321	CHEMBL1028107	Inhibition of human PKCbeta1	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OC[C@H]3CCCNC3)c21		CHEMBL494089	=	IC50	nM	19.0	CHEMBL3045	Homo sapiens	IC50	uM	0.019
	2420222	CHEMBL994313	Inhibition of human PKCbeta1	B	CC(C)[C@H](CO)Nc1nc(Nc2cccc(Cl)c2)c2ncn(C(C)C)c2n1		CHEMBL23327	>	IC50	nM	10000.0	CHEMBL3045	Homo sapiens	IC50	nM	10000.0
	2420223	CHEMBL994314	Inhibition of human PKCbeta2	B	CC(C)[C@H](CO)Nc1nc(Nc2cccc(Cl)c2)c2ncn(C(C)C)c2n1		CHEMBL23327	>	IC50	nM	10000.0	CHEMBL3045	Homo sapiens	IC50	nM	10000.0
	2420239	CHEMBL994313	Inhibition of human PKCbeta1	B	CC(C)[C@H](CO)Nc1nc(Nc2ccc(C(=O)O)c(Cl)c2)c2ncn(C(C)C)c2n1		CHEMBL23254	>	IC50	nM	100000.0	CHEMBL3045	Homo sapiens	IC50	nM	100000.0
	2420240	CHEMBL994314	Inhibition of human PKCbeta2	B	CC(C)[C@H](CO)Nc1nc(Nc2ccc(C(=O)O)c(Cl)c2)c2ncn(C(C)C)c2n1		CHEMBL23254	>	IC50	nM	100000.0	CHEMBL3045	Homo sapiens	IC50	nM	100000.0
	2430672	CHEMBL1018245	Agonist activity at PKCbeta1 at 50 ug/ml	F	CC(CCCCCCCCc1ccccc1)C[C@]1(C)C[C@]2(C)OC(=O)C[C@@H]2OO1		CHEMBL460022	=	Activity	%	-13.0	CHEMBL3045	Homo sapiens	Activity	%	-13.0
	2430673	CHEMBL1018246	Agonist activity at PKCbeta2 at 50 ug/ml	F	CC(CCCCCCCCc1ccccc1)C[C@]1(C)C[C@]2(C)OC(=O)C[C@@H]2OO1		CHEMBL460022	=	Activity	%	-27.0	CHEMBL3045	Homo sapiens	Activity	%	-27.0
	2430680	CHEMBL1018251	Inhibition of PKCbeta1	B	CCCCCCCCCCCCCCCC[C@@]1(OC)C=C[C@@H](CC(=O)OC)OO1		CHEMBL163015	=	IC50	ug.mL-1	49.0	CHEMBL3045	Homo sapiens	IC50	ug ml-1	49.0
Not Determined	2430681	CHEMBL1018251	Inhibition of PKCbeta1	B	CC(CCCCCCc1ccccc1)CC(C)C[C@]1(C)C[C@]2(C)OC(=O)C[C@@H]2OO1		CHEMBL462106		Activity			CHEMBL3045	Homo sapiens	Activity		
Not Determined	2430682	CHEMBL1018251	Inhibition of PKCbeta1	B	COC(=O)C[C@@]1(C)C[C@](C)(CC(C)CCCCCCc2ccccc2)OO1		CHEMBL462107		Activity			CHEMBL3045	Homo sapiens	Activity		
	2430683	CHEMBL1018252	Inhibition of PKCbeta2	B	CCCCCCCCCCCCCCCC[C@@]1(OC)C=C[C@@H](CC(=O)OC)OO1		CHEMBL163015	=	IC50	ug.mL-1	49.0	CHEMBL3045	Homo sapiens	IC50	ug ml-1	49.0
Not Determined	2430684	CHEMBL1018252	Inhibition of PKCbeta2	B	CC(CCCCCCc1ccccc1)CC(C)C[C@]1(C)C[C@]2(C)OC(=O)C[C@@H]2OO1		CHEMBL462106		Activity			CHEMBL3045	Homo sapiens	Activity		
Not Determined	2430685	CHEMBL1018252	Inhibition of PKCbeta2	B	COC(=O)C[C@@]1(C)C[C@](C)(CC(C)CCCCCCc2ccccc2)OO1		CHEMBL462107		Activity			CHEMBL3045	Homo sapiens	Activity		
	2440361	CHEMBL997493	Inhibition of PKC beta2	B	C=C(C)[C@@H]1CC[C@]2(C(=O)O)CC[C@]3(C)[C@H](CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@]43C)[C@@H]12	Outside typical range	CHEMBL269277	>	IC50	nM	150000.0	CHEMBL3045	Homo sapiens	IC50	uM	150.0
	2440362	CHEMBL997493	Inhibition of PKC beta2	B	CC(=O)[C@@H]1CC[C@]2(C(=O)O)CC[C@]3(C)[C@H](CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@]43C)[C@@H]12	Outside typical range	CHEMBL80460	>	IC50	nM	150000.0	CHEMBL3045	Homo sapiens	IC50	uM	150.0
	2440363	CHEMBL997493	Inhibition of PKC beta2	B	CC(C)[C@@H]1CC[C@]2(C(=O)O)CC[C@]3(C)C(CCC4[C@@]5(C)CC[C@H](O)C(C)(C)C5CC[C@]43C)C12	Outside typical range	CHEMBL108505	>	IC50	nM	150000.0	CHEMBL3045	Homo sapiens	IC50	uM	150.0
	2440364	CHEMBL997493	Inhibition of PKC beta2	B	C=C(C)[C@@H]1CC[C@]2(CO)CC[C@]3(C)[C@H](CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@]43C)[C@@H]12	Outside typical range	CHEMBL23236	>	IC50	nM	150000.0	CHEMBL3045	Homo sapiens	IC50	uM	150.0
	2440365	CHEMBL997493	Inhibition of PKC beta2	B	C=C(C)[C@@H]1CC[C@]2(C(=O)OCC(=O)OC)CC[C@]3(C)[C@H](CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@]43C)[C@@H]12	Outside typical range	CHEMBL509422	>	IC50	nM	150000.0	CHEMBL3045	Homo sapiens	IC50	uM	150.0
	2440366	CHEMBL997493	Inhibition of PKC beta2	B	C=C(C)[C@@H]1CC[C@]2(C(=O)O)CC[C@]3(C)[C@H](CC[C@@H]4[C@@]5(C)CC[C@H](OC(C)=O)C(C)(C)[C@@H]5CC[C@]43C)[C@@H]12	Outside typical range	CHEMBL312687	>	IC50	nM	150000.0	CHEMBL3045	Homo sapiens	IC50	uM	150.0
	2440367	CHEMBL997493	Inhibition of PKC beta2	B	C=C(C)[C@@H]1CC[C@]2(C(=O)O)CC[C@]3(C)[C@H](CC[C@@H]4[C@@]5(C)CC[C@H](OC(=O)c6ccccc6)C(C)(C)[C@@H]5CC[C@]43C)[C@@H]12	Outside typical range	CHEMBL509553	>	IC50	nM	150000.0	CHEMBL3045	Homo sapiens	IC50	uM	150.0
	2440368	CHEMBL997493	Inhibition of PKC beta2	B	C=C(C)[C@@H]1CC[C@]2(C(=O)O)CC[C@]3(C)[C@H](CC[C@@H]4[C@@]5(C)CC[C@H](OC(=O)/C=C/C)C(C)(C)[C@@H]5CC[C@]43C)[C@@H]12	Outside typical range	CHEMBL448637	>	IC50	nM	150000.0	CHEMBL3045	Homo sapiens	IC50	uM	150.0
	2440369	CHEMBL997493	Inhibition of PKC beta2	B	C=C(C)[C@@H]1CC[C@]2(C(=O)O)CC[C@]3(C)[C@H](CC[C@@H]4[C@@]5(C)CC[C@H](OS(=O)(=O)[O-])C(C)(C)[C@@H]5CC[C@]43C)[C@@H]12.[K+]	Outside typical range	CHEMBL502585	>	IC50	nM	150000.0	CHEMBL3045	Homo sapiens	IC50	uM	150.0
	2440370	CHEMBL997493	Inhibition of PKC beta2	B	C=C(C)[C@@H]1CC[C@]2(C(=O)O)CC[C@]3(C)[C@H](CC[C@@H]4[C@@]5(C)CC[C@H](OC(=O)CCC(=O)O)C(C)(C)[C@@H]5CC[C@]43C)[C@@H]12	Outside typical range	CHEMBL446317	>	IC50	nM	150000.0	CHEMBL3045	Homo sapiens	IC50	uM	150.0
	2440371	CHEMBL997493	Inhibition of PKC beta2	B	Cc1cn([C@H]2C[C@H](N=[N+]=[N-])[C@@H](CO)O2)c(=O)[nH]c1=O	Outside typical range	CHEMBL129	>	IC50	nM	150000.0	CHEMBL3045	Homo sapiens	IC50	uM	150.0
	2476701	CHEMBL982729	Binding affinity to human PKACB at 10 uM relative to control	B	NC(=O)c1ccc(-c2cc(C(N)=O)c(N)c(-c3ccc(S(N)(=O)=O)cc3)c2)cc1		CHEMBL514582	=	Activity	%	16.15	CHEMBL3045	Homo sapiens	Activity	%	16.15
Not Evaluated	2476904	CHEMBL982729	Binding affinity to human PKACB at 10 uM relative to control	B	N#Cc1c(NC(=O)c2ccccc2)sc2c1CCCC2		CHEMBL233000		Activity			CHEMBL3045	Homo sapiens	Activity		
Not Evaluated	2478743	CHEMBL982729	Binding affinity to human PKACB at 10 uM relative to control	B	O=C1Nc2ccccc2/C1=C/c1ccc[nH]1		CHEMBL86755		Activity			CHEMBL3045	Homo sapiens	Activity		
Not Evaluated	2479598	CHEMBL982729	Binding affinity to human PKACB at 10 uM relative to control	B	N#Cc1ccc(-c2cnc3[nH]cc(NC(=O)c4cccnc4)c3c2)cc1		CHEMBL516312		Activity			CHEMBL3045	Homo sapiens	Activity		
Not Evaluated	2479801	CHEMBL982729	Binding affinity to human PKACB at 10 uM relative to control	B	NC(=O)Nc1sc(-c2ccc(F)cc2)cc1C(N)=O		CHEMBL257167		Activity			CHEMBL3045	Homo sapiens	Activity		
	2480598	CHEMBL982729	Binding affinity to human PKACB at 10 uM relative to control	B	CCS(=O)(=O)Nc1ccc2c(c1)/C(=C(/Nc1ccc(CN3CCCCC3)cc1)c1ccccc1)C(=O)N2		CHEMBL514409	=	Activity	%	7.0	CHEMBL3045	Homo sapiens	Activity	%	7.0
Not Evaluated	2480800	CHEMBL982729	Binding affinity to human PKACB at 10 uM relative to control	B	Cc1cc(Nc2cc(N3CCN(C)CC3)nc(Sc3ccc(NC(=O)C4CC4)cc3)n2)n[nH]1		CHEMBL572878		Activity			CHEMBL3045	Homo sapiens	Activity		
	2488592	CHEMBL938981	Inhibition of human PKCbeta by scintillation proximity assay	B	CC(=O)C1=C(O)C=C2Oc3c(C(N)=O)c(O)cc(O)c3[C@]2(C)C1=O		CHEMBL475816	=	IC50	nM	350.0	CHEMBL3045	Homo sapiens	IC50	uM	0.35
Not Active	2488628	CHEMBL1024658	Inhibition of PKCbeta1 at 1 uM	B	CC(=O)C1=C(O)C=C2Oc3c4c(cc(O)c3[C@]2(C)C1=O)OC(C)(C)NC4=O		CHEMBL474846		Activity			CHEMBL3045	Homo sapiens	Activity		
Not Active	2488645	CHEMBL1024666	Inhibition of PKCbeta2 at 1 uM	B	CC(=O)C1=C(O)C=C2Oc3c4c(cc(O)c3[C@]2(C)C1=O)OC(C)(C)NC4=O		CHEMBL474846		Activity			CHEMBL3045	Homo sapiens	Activity		
	2489301	CHEMBL991251	Inhibition of human full length PKCbeta	B	COc1ccc(CN(C)C)c(-c2cc3c(Nc4ccc5[nH]ccc5c4C)c(C#N)cnc3s2)c1		CHEMBL479835	=	IC50	nM	22000.0	CHEMBL3045	Homo sapiens	IC50	uM	22.0
	2509793	CHEMBL1000237	Displacement of [3H]PDBu form human PKCbeta in presence of phosphatidylserine	B	CC(C)=C1CC(CO)(COC(=O)COc2ccc(C#Cc3ccc(C)cc3)cc2)OC1=O		CHEMBL523155	=	Ki	nM	76.0	CHEMBL3045	Homo sapiens	Ki	nM	76.0
	2509798	CHEMBL1000242	Displacement of [3H]PDBu form human PKCbeta in presence of plasma membrane lipid mimetic mixture	B	CC(C)=C1CC(CO)(COC(=O)COc2ccc(C#Cc3ccc(C)cc3)cc2)OC1=O		CHEMBL523155	=	Ki	nM	100.3	CHEMBL3045	Homo sapiens	Ki	nM	100.3
	2509803	CHEMBL1000237	Displacement of [3H]PDBu form human PKCbeta in presence of phosphatidylserine	B	CC(C)=C1CC(CO)(COC(=O)CCOc2ccc(C#Cc3ccc(C)cc3)cc2)OC1=O		CHEMBL492118	=	Ki	nM	57.0	CHEMBL3045	Homo sapiens	Ki	nM	57.0
	2509808	CHEMBL1000242	Displacement of [3H]PDBu form human PKCbeta in presence of plasma membrane lipid mimetic mixture	B	CC(C)=C1CC(CO)(COC(=O)CCOc2ccc(C#Cc3ccc(C)cc3)cc2)OC1=O		CHEMBL492118	=	Ki	nM	66.0	CHEMBL3045	Homo sapiens	Ki	nM	66.0
	2509813	CHEMBL1000237	Displacement of [3H]PDBu form human PKCbeta in presence of phosphatidylserine	B	CC(C)=C1CC(CO)(COC(=O)CCCOc2ccc(C#Cc3ccc(C)cc3)cc2)OC1=O		CHEMBL489520	=	Ki	nM	15.2	CHEMBL3045	Homo sapiens	Ki	nM	15.2
	2509818	CHEMBL1000242	Displacement of [3H]PDBu form human PKCbeta in presence of plasma membrane lipid mimetic mixture	B	CC(C)=C1CC(CO)(COC(=O)CCCOc2ccc(C#Cc3ccc(C)cc3)cc2)OC1=O		CHEMBL489520	=	Ki	nM	43.8	CHEMBL3045	Homo sapiens	Ki	nM	43.8
	2509823	CHEMBL1000237	Displacement of [3H]PDBu form human PKCbeta in presence of phosphatidylserine	B	CC(C)=C1CC(CO)(COC(=O)c2ccc(C#Cc3ccc(C)cc3)cc2)OC1=O		CHEMBL522428	=	Ki	nM	4.1	CHEMBL3045	Homo sapiens	Ki	nM	4.1
	2509828	CHEMBL1000242	Displacement of [3H]PDBu form human PKCbeta in presence of plasma membrane lipid mimetic mixture	B	CC(C)=C1CC(CO)(COC(=O)c2ccc(C#Cc3ccc(C)cc3)cc2)OC1=O		CHEMBL522428	=	Ki	nM	12.6	CHEMBL3045	Homo sapiens	Ki	nM	12.6
	2559667	CHEMBL986470	Inhibition of PKCbeta	B	Cc1c(Nc2c(C#N)cnc3sc(/C=C/C(=O)N4CCCC4)cc23)ccc2[nH]ccc12		CHEMBL477817	>	IC50	nM	100000.0	CHEMBL3045	Homo sapiens	IC50	nM	100000.0
	2575707	CHEMBL981182	Inhibition of PKCbeta2	B	CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL388978	=	IC50	nM	4.0	CHEMBL3045	Homo sapiens	IC50	uM	0.004
	2575710	CHEMBL981182	Inhibition of PKCbeta2	B	COc1cc(Nc2nc(N[C@H]3CCCC[C@H]3N)n3ncnc3c2C(N)=O)cc(OC)c1		CHEMBL475575	=	IC50	nM	2660.0	CHEMBL3045	Homo sapiens	IC50	uM	2.66
	2575711	CHEMBL981182	Inhibition of PKCbeta2	B	COc1cc(Nc2nc(N[C@H]3CCCC[C@H]3N)n3cnnc3c2C(N)=O)cc(OC)c1		CHEMBL475609	=	IC50	nM	680.0	CHEMBL3045	Homo sapiens	IC50	uM	0.68
Not Evaluated	2577219	CHEMBL982729	Binding affinity to human PKACB at 10 uM relative to control	B	CC(=O)c1c(-c2ccncc2)[nH]c(-c2ccncc2)c1C		CHEMBL526901		Activity			CHEMBL3045	Homo sapiens	Activity		
Not Evaluated	2577422	CHEMBL982729	Binding affinity to human PKACB at 10 uM relative to control	B	NC(=O)c1ccc(Nc2cc(-c3ccc(F)cc3)[nH]n2)cc1		CHEMBL511337		Activity			CHEMBL3045	Homo sapiens	Activity		
Not Determined	2592631	CHEMBL1020477	Inhibition of PKC beta2	B	COc1cc(Nc2nc(NCc3ccccc3)n3ccnc3c2C(N)=O)cc(OC)c1		CHEMBL520608		IC50			CHEMBL3045	Homo sapiens	IC50		
	2592638	CHEMBL1020477	Inhibition of PKC beta2	B	CCOC(=O)/C=C/c1ccc(CNc2nc(Nc3cc(OC)cc(OC)c3)c(C(N)=O)c3nccn23)cc1		CHEMBL480014	>	IC50	nM	10000.0	CHEMBL3045	Homo sapiens	IC50	uM	10.0
	2592645	CHEMBL1020477	Inhibition of PKC beta2	B	COc1cc(Nc2nc(NCc3ccc(/C=C/C(=O)O)cc3)n3ccnc3c2C(N)=O)cc(OC)c1		CHEMBL511829	>	IC50	nM	10000.0	CHEMBL3045	Homo sapiens	IC50	uM	10.0
Not Evaluated	2593627	CHEMBL982729	Binding affinity to human PKACB at 10 uM relative to control	B	Cc1ccc(O)cc1Nc1ccnc(Nc2cccc(C(N)=O)c2)n1		CHEMBL249097		Activity			CHEMBL3045	Homo sapiens	Activity		
	2593893	CHEMBL982729	Binding affinity to human PKACB at 10 uM relative to control	B	Nc1ncnc2c1c(-c1cccc(O)c1)cn2C1CCNCC1		CHEMBL450519	=	Activity	%	32.2	CHEMBL3045	Homo sapiens	Activity	%	32.2
Not Evaluated	2594096	CHEMBL982729	Binding affinity to human PKACB at 10 uM relative to control	B	Cc1ccc(C(=O)Nc2cccc(C(C)(C)C)c2)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL515466		Activity			CHEMBL3045	Homo sapiens	Activity		
Not Evaluated	2594836	CHEMBL982729	Binding affinity to human PKACB at 10 uM relative to control	B	Cc1ccc(C(=O)NC2CC2)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL478649		Activity			CHEMBL3045	Homo sapiens	Activity		
Not Evaluated	2595039	CHEMBL982729	Binding affinity to human PKACB at 10 uM relative to control	B	Cc1ccc(NC(=O)c2cccc(N3CCCCC3)c2)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL1964275		Activity			CHEMBL3045	Homo sapiens	Activity		
Not Evaluated	2596236	CHEMBL982729	Binding affinity to human PKACB at 10 uM relative to control	B	CN(C)c1ccc(-c2cc3ncccc3c(NCCCCN)n2)cc1		CHEMBL282342		Activity			CHEMBL3045	Homo sapiens	Activity		
Not Evaluated	2596439	CHEMBL982729	Binding affinity to human PKACB at 10 uM relative to control	B	O=C(Nc1n[nH]c2nc(-c3cccc(O)c3)ccc12)C1CC1		CHEMBL408019		Activity			CHEMBL3045	Homo sapiens	Activity		
Not Evaluated	2597708	CHEMBL982729	Binding affinity to human PKACB at 10 uM relative to control	B	c1ccc(-c2n[nH]cc2-c2ccnc3ccccc23)nc1		CHEMBL261454		Activity			CHEMBL3045	Homo sapiens	Activity		
	2624351	CHEMBL1007478	Inhibition of human PKCbeta by IMAP assay	B	Cc1c(Nc2c(C#N)cncc2-c2ccc(OCCN3CCN(C)CC3)cc2)ccc2[nH]ccc12		CHEMBL467069	=	IC50	nM	22000.0	CHEMBL3045	Homo sapiens	IC50	uM	22.0
	2636772	CHEMBL978885	Inhibition of PKCbeta	B	CN1CCN(CCOc2cccc(-c3cncc(C#N)c3Nc3cccc4[nH]ccc34)c2)CC1		CHEMBL467321	=	IC50	nM	2000.0	CHEMBL3045	Homo sapiens	IC50	uM	2.0
	2661424	CHEMBL1058630	Inhibition of PKCbeta	B	CNC(=O)c1nn(C)c2c1C(C)(C)Cc1cnc(Nc3ccc(N4CCN(C)CC4)cc3)nc1-2		CHEMBL564829	>	IC50	nM	10000.0	CHEMBL3045	Homo sapiens	IC50	uM	10.0
	2661600	CHEMBL1061351	Inhibition of PKCbeta after 1 hr by mobility shift electrophoresis assay	B	COC(=O)Nc1ccc(-c2nc(N3CCOCC3)c3cnn(C4CCN(C(=O)OC)CC4)c3n2)cc1		CHEMBL561708	>	IC50	nM	50000.0	CHEMBL3045	Homo sapiens	IC50	uM	50.0
	2721693	CHEMBL1054320	Inhibition of PKCbeta1 at 1 uM	B	C[C@@H](Oc1cc(-c2cnc3ccccn23)sc1C(N)=O)c1ccc(CNC(C)(C)C)cc1OC(F)F		CHEMBL551079	<	Inhibition	%	50.0	CHEMBL3045	Homo sapiens	INH	%	50.0
	2721694	CHEMBL1054321	Inhibition of PKCbeta2 at 1 uM	B	C[C@@H](Oc1cc(-c2cnc3ccccn23)sc1C(N)=O)c1ccc(CNC(C)(C)C)cc1OC(F)F		CHEMBL551079	<	Inhibition	%	50.0	CHEMBL3045	Homo sapiens	INH	%	50.0
	2892473	CHEMBL1051358	Selectivity for PRKCB1 as proportion of 290 kinases in screen with similar potency; non-selective = 1 highly selective = 0	B	CN(C)C[C@@H]1CCn2cc(c3ccccc32)C2=C(C(=O)NC2=O)c2cn(c3ccccc23)CCO1		CHEMBL91829	=	Selectivity		0.0138	CHEMBL3045	Homo sapiens	Selectivity		0.0138
	2938457	CHEMBL1041408	Inhibition of PKCbeta2 at 2 uM	B	Cc1cnc(Nc2ccc(F)cc2Cl)nc1-c1c[nH]c(C(=O)N[C@H](CO)c2cccc(Cl)c2)c1		CHEMBL583042	=	Inhibition	%	4.0	CHEMBL3045	Homo sapiens	INH	%	4.0
	2938460	CHEMBL1041405	Inhibition of PKCbeta1 at 1 uM	B	Cc1cnc(Nc2ccc(F)cc2Cl)nc1-c1c[nH]c(C(=O)N[C@H](CO)c2cccc(Cl)c2)c1		CHEMBL583042	=	Inhibition	%	4.0	CHEMBL3045	Homo sapiens	INH	%	4.0
Not Active	2938621	CHEMBL1041491	Inhibition of PKCbeta2 at 10 uM	B	O=C1OC(/C=C/c2ccccc2)=N/C1=C\c1cccnc1		CHEMBL565286		Inhibition	%		CHEMBL3045	Homo sapiens	INH		
	2983223	CHEMBL1046254	Inhibition of PKCbeta1	B	CC1(C)CC(NC(=O)c2cccc(-c3cc4nccc(Nc5cccc(O)c5)n4n3)c2)CC(C)(C)N1[O]		CHEMBL1163016	>	IC50	nM	60000.0	CHEMBL3045	Homo sapiens	IC50	uM	60.0
	2992237	CHEMBL1044540	Inhibition of human PKCbeta1 at 20 uM by FRET assay	B	C#Cn1c(C#CCCO)nc(-c2ccc(F)cc2)c1-c1ccncc1		CHEMBL576620	=	Inhibition	%	80.0	CHEMBL3045	Homo sapiens	INH	%	80.0
	2992420	CHEMBL1040087	Inhibition of PKCbeta1 by SPA	B	CN(C)CCCn1cc(C2=C(c3c[nH]c4ccccc34)C(=O)NC2=O)c2ccccc21		CHEMBL7463	=	IC50	nM	1.6	CHEMBL3045	Homo sapiens	IC50	nM	1.6
	2992421	CHEMBL1040087	Inhibition of PKCbeta1 by SPA	B	CN(C)CCOc1cc(C2=C(c3c[nH]c4ccccc34)C(=O)NC2=O)c2ccccc2c1		CHEMBL565632	=	IC50	nM	2.1	CHEMBL3045	Homo sapiens	IC50	nM	2.1
	2992423	CHEMBL1040087	Inhibition of PKCbeta1 by SPA	B	CN1CCN(c2nc(C3=C(c4c[nH]c5ccccc45)C(=O)NC3=O)c3ccccc3n2)CC1		CHEMBL565612	=	IC50	nM	2.0	CHEMBL3045	Homo sapiens	IC50	nM	2.0
	2992426	CHEMBL1040087	Inhibition of PKCbeta1 by SPA	B	CN1CCN(c2cc(C3=C(c4c[nH]c5ccccc45)C(=O)NC3=O)c3ccccc3c2)CC1		CHEMBL568580	=	IC50	nM	1.8	CHEMBL3045	Homo sapiens	IC50	nM	1.8
	2992438	CHEMBL1040087	Inhibition of PKCbeta1 by SPA	B	CN(C)CCOc1cccc(C2=C(c3c[nH]c4ccccc34)C(=O)NC2=O)c1		CHEMBL566853	=	IC50	nM	58.0	CHEMBL3045	Homo sapiens	IC50	nM	58.0
	2992451	CHEMBL1040087	Inhibition of PKCbeta1 by SPA	B	CN(C)CCCn1cc(C2=C(c3csc4ccccc34)C(=O)NC2=O)c2ccccc21		CHEMBL566424	=	IC50	nM	47.0	CHEMBL3045	Homo sapiens	IC50	nM	47.0
	2992455	CHEMBL1040087	Inhibition of PKCbeta1 by SPA	B	CN(C)CCCn1cc(C2=C(c3cccc4ccccc34)C(=O)NC2=O)c2ccccc21		CHEMBL584483	=	IC50	nM	60.0	CHEMBL3045	Homo sapiens	IC50	nM	60.0
	2992457	CHEMBL1040087	Inhibition of PKCbeta1 by SPA	B	CN1CCN(c2cccc(C3=C(c4c[nH]c5ccccc45)C(=O)NC3=O)c2)CC1		CHEMBL585500	=	IC50	nM	36.0	CHEMBL3045	Homo sapiens	IC50	nM	36.0
	2992473	CHEMBL1040087	Inhibition of PKCbeta1 by SPA	B	O=C1NC(=O)C(c2c[nH]c3ccccc23)=C1c1nc(N2CCOCC2)nc2ccccc12		CHEMBL584817	=	IC50	nM	1268.0	CHEMBL3045	Homo sapiens	IC50	nM	1268.0
	2992480	CHEMBL1040087	Inhibition of PKCbeta1 by SPA	B	CN(C)CCCn1cc(C2=C(c3n[nH]c4ccccc34)C(=O)NC2=O)c2ccccc21		CHEMBL585281	>	IC50	nM	315.0	CHEMBL3045	Homo sapiens	IC50	nM	315.0
	3001929	CHEMBL1047193	Inhibition of PKCbeta by IMAP fluorescence polarization technology	B	Cc1c(Nc2c(C#N)cncc2-c2cc3cc(CN4CCN(C)CC4)ccc3o2)ccc2[nH]ccc12		CHEMBL571581	=	IC50	nM	800.0	CHEMBL3045	Homo sapiens	IC50	uM	0.8
	3011615	CHEMBL1037489	Inhibition of PKCbeta by IMAP kinase assay	B	C#Cc1cccc(-c2ccc(CN3CCN(C)CC3)o2)c1Cc1ccc2c(c1C)C=CC2		CHEMBL570865	=	IC50	nM	2500.0	CHEMBL3045	Homo sapiens	IC50	uM	2.5
	3017858	CHEMBL1039939	Inhibition of PKCbeta by IMAP kinase assay	B	Cc1c(Nc2c(C#N)cncc2/C=C/c2cccc(OCCN3CCN(C)CC3)c2)ccc2[nH]ccc12		CHEMBL567124	=	IC50	nM	1300.0	CHEMBL3045	Homo sapiens	IC50	uM	1.3
	3052444	CHEMBL1070479	Residual activity of PKCbeta1 at 0.1 uM by microplate scintillation counting	B	COc1cc2c(Oc3ccc(-c4nc5ccccc5s4)cc3F)ncnc2cc1OCCCN1CCN(C)CC1		CHEMBL604483	=	Residual activity	%	109.0	CHEMBL3045	Homo sapiens	Residual activity	%	109.0
	3052445	CHEMBL1070480	Residual activity of PKCbeta2 at 0.1 uM by microplate scintillation counting	B	COc1cc2c(Oc3ccc(-c4nc5ccccc5s4)cc3F)ncnc2cc1OCCCN1CCN(C)CC1		CHEMBL604483	=	Residual activity	%	87.0	CHEMBL3045	Homo sapiens	Residual activity	%	87.0
	3052696	CHEMBL1040273	Residual activity of PKCbeta1 at 1 uM by microplate scintillation counting	B	COc1cc2c(Oc3ccc(-c4nc5ccccc5s4)cc3F)ncnc2cc1OCCCN1CCN(C)CC1		CHEMBL604483	=	Residual activity	%	103.0	CHEMBL3045	Homo sapiens	Residual activity	%	103.0
	3052697	CHEMBL1040274	Residual activity of PKCbeta2 at 1 uM by microplate scintillation counting	B	COc1cc2c(Oc3ccc(-c4nc5ccccc5s4)cc3F)ncnc2cc1OCCCN1CCN(C)CC1		CHEMBL604483	=	Residual activity	%	132.0	CHEMBL3045	Homo sapiens	Residual activity	%	132.0
	3054005	CHEMBL1050336	Residual activity of PKCbeta1 at 10 uM by microplate scintillation counting	B	COc1cc2c(Oc3ccc(-c4nc5ccccc5s4)cc3F)ncnc2cc1OCCCN1CCN(C)CC1		CHEMBL604483	=	Residual activity	%	57.0	CHEMBL3045	Homo sapiens	Residual activity	%	57.0
	3054006	CHEMBL1050337	Residual activity of PKCbeta2 at 10 uM by microplate scintillation counting	B	COc1cc2c(Oc3ccc(-c4nc5ccccc5s4)cc3F)ncnc2cc1OCCCN1CCN(C)CC1		CHEMBL604483	=	Residual activity	%	53.0	CHEMBL3045	Homo sapiens	Residual activity	%	53.0
	3054257	CHEMBL1070479	Residual activity of PKCbeta1 at 0.1 uM by microplate scintillation counting	B	COc1cc2c(Oc3ccc(-c4nc5ccccc5s4)cc3)ncnc2cc1OCCCN1CCN(C)CC1		CHEMBL595143	=	Residual activity	%	100.0	CHEMBL3045	Homo sapiens	Residual activity	%	100.0
	3054258	CHEMBL1070480	Residual activity of PKCbeta2 at 0.1 uM by microplate scintillation counting	B	COc1cc2c(Oc3ccc(-c4nc5ccccc5s4)cc3)ncnc2cc1OCCCN1CCN(C)CC1		CHEMBL595143	=	Residual activity	%	101.0	CHEMBL3045	Homo sapiens	Residual activity	%	101.0
	3055544	CHEMBL1040273	Residual activity of PKCbeta1 at 1 uM by microplate scintillation counting	B	COc1cc2c(Oc3ccc(-c4nc5ccccc5s4)cc3)ncnc2cc1OCCCN1CCN(C)CC1		CHEMBL595143	=	Residual activity	%	108.0	CHEMBL3045	Homo sapiens	Residual activity	%	108.0
	3055545	CHEMBL1040274	Residual activity of PKCbeta2 at 1 uM by microplate scintillation counting	B	COc1cc2c(Oc3ccc(-c4nc5ccccc5s4)cc3)ncnc2cc1OCCCN1CCN(C)CC1		CHEMBL595143	=	Residual activity	%	104.0	CHEMBL3045	Homo sapiens	Residual activity	%	104.0
	3056849	CHEMBL1050336	Residual activity of PKCbeta1 at 10 uM by microplate scintillation counting	B	COc1cc2c(Oc3ccc(-c4nc5ccccc5s4)cc3)ncnc2cc1OCCCN1CCN(C)CC1		CHEMBL595143	=	Residual activity	%	81.0	CHEMBL3045	Homo sapiens	Residual activity	%	81.0
	3056850	CHEMBL1050337	Residual activity of PKCbeta2 at 10 uM by microplate scintillation counting	B	COc1cc2c(Oc3ccc(-c4nc5ccccc5s4)cc3)ncnc2cc1OCCCN1CCN(C)CC1		CHEMBL595143	=	Residual activity	%	77.0	CHEMBL3045	Homo sapiens	Residual activity	%	77.0
	3057101	CHEMBL1070479	Residual activity of PKCbeta1 at 0.1 uM by microplate scintillation counting	B	COc1cc2c(Oc3ccc(-c4nc5ccccc5s4)cc3)ncnc2cc1OCCCN1CCCC1		CHEMBL595373	=	Residual activity	%	102.0	CHEMBL3045	Homo sapiens	Residual activity	%	102.0
	3057102	CHEMBL1070480	Residual activity of PKCbeta2 at 0.1 uM by microplate scintillation counting	B	COc1cc2c(Oc3ccc(-c4nc5ccccc5s4)cc3)ncnc2cc1OCCCN1CCCC1		CHEMBL595373	=	Residual activity	%	99.0	CHEMBL3045	Homo sapiens	Residual activity	%	99.0
	3058421	CHEMBL1040273	Residual activity of PKCbeta1 at 1 uM by microplate scintillation counting	B	COc1cc2c(Oc3ccc(-c4nc5ccccc5s4)cc3)ncnc2cc1OCCCN1CCCC1		CHEMBL595373	=	Residual activity	%	105.0	CHEMBL3045	Homo sapiens	Residual activity	%	105.0
	3058422	CHEMBL1040274	Residual activity of PKCbeta2 at 1 uM by microplate scintillation counting	B	COc1cc2c(Oc3ccc(-c4nc5ccccc5s4)cc3)ncnc2cc1OCCCN1CCCC1		CHEMBL595373	=	Residual activity	%	111.0	CHEMBL3045	Homo sapiens	Residual activity	%	111.0
	3059705	CHEMBL1050336	Residual activity of PKCbeta1 at 10 uM by microplate scintillation counting	B	COc1cc2c(Oc3ccc(-c4nc5ccccc5s4)cc3)ncnc2cc1OCCCN1CCCC1		CHEMBL595373	=	Residual activity	%	73.0	CHEMBL3045	Homo sapiens	Residual activity	%	73.0
	3059706	CHEMBL1050337	Residual activity of PKCbeta2 at 10 uM by microplate scintillation counting	B	COc1cc2c(Oc3ccc(-c4nc5ccccc5s4)cc3)ncnc2cc1OCCCN1CCCC1		CHEMBL595373	=	Residual activity	%	69.0	CHEMBL3045	Homo sapiens	Residual activity	%	69.0
	3089517	CHEMBL1070551	Inhibition of PKCbeta by fluorescence polarization assay	B	Cc1c(Nc2c(C#N)cncc2/C=C/CCN2CCNCC2)ccc2[nH]ccc12		CHEMBL603418	=	IC50	nM	2500.0	CHEMBL3045	Homo sapiens	IC50	nM	2500.0
	3089519	CHEMBL1070551	Inhibition of PKCbeta by fluorescence polarization assay	B	Cc1c(Nc2c(C#N)cncc2/C=C/CCN2CCC(N)CC2)ccc2[nH]ccc12		CHEMBL593883	=	IC50	nM	2300.0	CHEMBL3045	Homo sapiens	IC50	nM	2300.0
	3089525	CHEMBL1070551	Inhibition of PKCbeta by fluorescence polarization assay	B	Cc1c(Nc2c(C#N)cncc2/C=C/CCN2CCC(NS(C)(=O)=O)CC2)ccc2[nH]ccc12		CHEMBL595048	=	IC50	nM	1400.0	CHEMBL3045	Homo sapiens	IC50	nM	1400.0
	3089588	CHEMBL1070551	Inhibition of PKCbeta by fluorescence polarization assay	B	Cc1c(Nc2c(C#N)cncc2/C=C/CN2CCNCC2)ccc2[nH]ccc12		CHEMBL593619	>	IC50	nM	100.0	CHEMBL3045	Homo sapiens	IC50	nM	100.0
	3090492	CHEMBL1070551	Inhibition of PKCbeta by fluorescence polarization assay	B	Cc1c(Nc2c(C#N)cncc2/C=C/CCN2CCC[C@@H](N)C2)ccc2[nH]ccc12		CHEMBL606245	>	IC50	nM	100000.0	CHEMBL3045	Homo sapiens	IC50	nM	100000.0
	3104130	CHEMBL1068970	Inhibition of recombinant PKCbeta2 by IMAP assay	B	C[C@@H](Oc1ccc2ncccc2c1)c1c(Cl)ccc(F)c1Cl		CHEMBL600795	>	IC50	nM	50000.0	CHEMBL3045	Homo sapiens	IC50	uM	50.0
	3104131	CHEMBL1066419	Inhibition of recombinant PKCbeta1 by IMAP assay	B	C[C@@H](Oc1ccc2ncccc2c1)c1c(Cl)ccc(F)c1Cl		CHEMBL600795	>	IC50	nM	50000.0	CHEMBL3045	Homo sapiens	IC50	uM	50.0
	3104177	CHEMBL1068970	Inhibition of recombinant PKCbeta2 by IMAP assay	B	C[C@@H](Oc1ccc2ncc(C3CC3C(N)=O)cc2c1)c1c(Cl)ccc(F)c1Cl		CHEMBL602472	>	IC50	nM	50000.0	CHEMBL3045	Homo sapiens	IC50	uM	50.0
	3104178	CHEMBL1066419	Inhibition of recombinant PKCbeta1 by IMAP assay	B	C[C@@H](Oc1ccc2ncc(C3CC3C(N)=O)cc2c1)c1c(Cl)ccc(F)c1Cl		CHEMBL602472	>	IC50	nM	50000.0	CHEMBL3045	Homo sapiens	IC50	uM	50.0
	3104233	CHEMBL1066419	Inhibition of recombinant PKCbeta1 by IMAP assay	B	C[C@@H](Oc1ccc2ncc(/C=C/C(N)=O)cc2c1)c1c(Cl)ccc(F)c1Cl		CHEMBL602471	>	IC50	nM	50000.0	CHEMBL3045	Homo sapiens	IC50	uM	50.0
	3104234	CHEMBL1068970	Inhibition of recombinant PKCbeta2 by IMAP assay	B	C[C@@H](Oc1ccc2ncc(/C=C/C(N)=O)cc2c1)c1c(Cl)ccc(F)c1Cl		CHEMBL602471	>	IC50	nM	50000.0	CHEMBL3045	Homo sapiens	IC50	uM	50.0
	3117948	CHEMBL1072224	Inhibition of PKCbeta1	B	CC(=O)N1CCC(Nc2ncc3c(n2)-c2c(c(C(N)=O)nn2C)CC3)CC1		CHEMBL599224	>	IC50	nM	10000.0	CHEMBL3045	Homo sapiens	IC50	uM	10.0
	3118001	CHEMBL1072224	Inhibition of PKCbeta1	B	Cn1nc(C(N)=O)c2c1-c1nc(NC3CCN(C(=O)c4ccccc4)CC3)ncc1CC2		CHEMBL599428	>	IC50	nM	10000.0	CHEMBL3045	Homo sapiens	IC50	uM	10.0
	3118054	CHEMBL1072224	Inhibition of PKCbeta1	B	CNC(=O)c1nn(C)c2c1CCc1cnc(NC3CCN(C(=O)C4CCN(S(C)(=O)=O)CC4)CC3)nc1-2		CHEMBL597754	>	IC50	nM	10000.0	CHEMBL3045	Homo sapiens	IC50	uM	10.0
	3185708	CHEMBL1105157	Inhibition of PKCbeta	B	Cc1c(Nc2c(C#N)cncc2/C=C/c2cccc(CN3CCN(C)CC3)n2)ccc2[nH]ccc12		CHEMBL1084411	=	IC50	nM	700.0	CHEMBL3045	Homo sapiens	IC50	nM	700.0
	3210388	CHEMBL1109437	Inhibition of PKCbeta2 after 1 hr	B	O=C(Nc1cccc(-c2cn3ccnc3c(NCc3ccncc3)n2)c1)Nc1cccc(C(F)(F)F)c1		CHEMBL1081198	=	IC50	nM	50000.0	CHEMBL3045	Homo sapiens	IC50	uM	50.0
	3214014	CHEMBL1116762	Inhibition of PKCbeta1 at 5 uM	B	O=C(Nc1ccccc1Cl)c1cnc2ccc(C3CCNCC3)cn12.O=C(O)C(=O)O		CHEMBL1077739	=	Inhibition	%	-5.0	CHEMBL3045	Homo sapiens	INH	%	-5.0
	3214015	CHEMBL1116763	Inhibition of PKCbeta2 at 5 uM	B	O=C(Nc1ccccc1Cl)c1cnc2ccc(C3CCNCC3)cn12.O=C(O)C(=O)O		CHEMBL1077739	=	Inhibition	%	-7.0	CHEMBL3045	Homo sapiens	INH	%	-7.0
	3219690	CHEMBL1110441	Inhibition of PKCbeta1 at 100 nM relative to control	B	N=C(N)NCCC[C@@H](NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@@H](CCCNC(=N)N)NC(=O)CCCCCNC(=O)[C@@H](CCCCN)NC(=O)CCCCCNC(=O)c1ccc(-c2ccnc(N)n2)s1)C(N)=O		CHEMBL1077375	=	Inhibition	%	100.0	CHEMBL3045	Homo sapiens	INH	%	100.0
	3219691	CHEMBL1110442	Inhibition of PKCbeta2 at 100 nM relative to control	B	N=C(N)NCCC[C@@H](NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@@H](CCCNC(=N)N)NC(=O)CCCCCNC(=O)[C@@H](CCCCN)NC(=O)CCCCCNC(=O)c1ccc(-c2ccnc(N)n2)s1)C(N)=O		CHEMBL1077375	=	Inhibition	%	104.0	CHEMBL3045	Homo sapiens	INH	%	104.0
	3219842	CHEMBL1114002	Inhibition of PKCbeta	B	Cc1c(Nc2c(C#N)cncc2/C=C/c2cccc(S(=O)(=O)N3CCN(C)CC3)c2)ccc2[nH]ccc12		CHEMBL1080994	=	IC50	nM	41000.0	CHEMBL3045	Homo sapiens	IC50	nM	41000.0
	3219843	CHEMBL1114002	Inhibition of PKCbeta	B	Cc1ncc(C#N)c(Nc2ccc3[nH]ccc3c2C)c1/C=C/c1cccc(S(=O)(=O)N2CCN(C)CC2)c1		CHEMBL1080995	>	IC50	nM	50000.0	CHEMBL3045	Homo sapiens	IC50	nM	50000.0
	3220014	CHEMBL1115863	Inhibition of PKCbeta	B	CN1C[C@@H]2C[C@H]1CN2c1ccc(-c2ccnc3c(-c4cccc(O)c4)c(-c4ccncc4)nn23)cc1		CHEMBL1087650	=	IC50	nM	119.0	CHEMBL3045	Homo sapiens	IC50	uM	0.119
	3224927	CHEMBL1101005	Inhibition of PKCbeta1 at 10 uM	B	Cc1cc(OCc2ccc(F)cc2F)c(Br)c(=O)n1-c1cnc(CO)cn1		CHEMBL1081678	<	Inhibition	%	50.0	CHEMBL3045	Homo sapiens	INH	%	50.0
	3224928	CHEMBL1101006	Inhibition of PKCbeta2 at 10 uM	B	Cc1cc(OCc2ccc(F)cc2F)c(Br)c(=O)n1-c1cnc(CO)cn1		CHEMBL1081678	<	Inhibition	%	50.0	CHEMBL3045	Homo sapiens	INH	%	50.0
	3226306	CHEMBL1101005	Inhibition of PKCbeta1 at 10 uM	B	Cc1cc(OCc2ccc(F)cc2F)c(Br)c(=O)n1Cc1ccc(CN(C)C)cc1		CHEMBL1078665	<	Inhibition	%	50.0	CHEMBL3045	Homo sapiens	INH	%	50.0
	3226307	CHEMBL1101006	Inhibition of PKCbeta2 at 10 uM	B	Cc1cc(OCc2ccc(F)cc2F)c(Br)c(=O)n1Cc1ccc(CN(C)C)cc1		CHEMBL1078665	<	Inhibition	%	50.0	CHEMBL3045	Homo sapiens	INH	%	50.0
	3242227	CHEMBL1111613	Inhibition of PKCbeta	B	CC(C)N1CCN(C(=O)c2ccc(NC(=O)Nc3ccc(-c4nc(C5CCOCC5)nc(N5C6CCC5COC6)n4)cc3)cc2)CC1		CHEMBL1091356	<	IC50	nM	50000.0	CHEMBL3045	Homo sapiens	IC50	uM	50.0
	3260506	CHEMBL1109841	Inhibition of PKCbeta	B	O=C(Nc1cccc(-c2ccnc3cc(-c4ccncc4)nn23)c1)c1cccc(C(F)(F)F)c1		CHEMBL1089082	>	IC50	nM	50000.0	CHEMBL3045	Homo sapiens	IC50	uM	50.0
Not Active	3272476	CHEMBL1108315	Inhibition of PKCbeta2	B	COc1cc(OC)c(C=C2C(=O)Nc3ccccc32)c(OC)c1		CHEMBL576349		Inhibition	%		CHEMBL3045	Homo sapiens	INH		
Not Active	3272477	CHEMBL1108315	Inhibition of PKCbeta2	B	COc1ccccc1/C=C1/C(=O)Nc2ccccc21		CHEMBL444673		Inhibition	%		CHEMBL3045	Homo sapiens	INH		
Not Active	3272478	CHEMBL1108315	Inhibition of PKCbeta2	B	O=C1Nc2ccc(Cl)cc2/C1=C\c1ccccc1F		CHEMBL1088391		Inhibition	%		CHEMBL3045	Homo sapiens	INH		
Not Active	3272479	CHEMBL1108315	Inhibition of PKCbeta2	B	O=C1Nc2ccc(Cl)cc2/C1=C\c1ccccc1[N+](=O)[O-]		CHEMBL1088392		Inhibition	%		CHEMBL3045	Homo sapiens	INH		
Not Active	3272480	CHEMBL1108315	Inhibition of PKCbeta2	B	O=C1Nc2ccc(Cl)cc2/C1=C\c1ccccc1S(=O)(=O)O		CHEMBL1088529		Inhibition	%		CHEMBL3045	Homo sapiens	INH		
Not Active	3272481	CHEMBL1108315	Inhibition of PKCbeta2	B	O=C1Nc2ccc(Cl)cc2/C1=C\c1ccc2c(c1)OCO2		CHEMBL1086669		Inhibition	%		CHEMBL3045	Homo sapiens	INH		
Not Active	3272482	CHEMBL1108315	Inhibition of PKCbeta2	B	O=C1Nc2ccc(Cl)cc2/C1=C\c1cc(F)cc(F)c1		CHEMBL1086670		Inhibition	%		CHEMBL3045	Homo sapiens	INH		
Not Active	3272483	CHEMBL1108315	Inhibition of PKCbeta2	B	NC(=O)Cc1ccc(/C=C2/C(=O)Nc3ccc(Cl)cc32)cc1		CHEMBL1086795		Inhibition	%		CHEMBL3045	Homo sapiens	INH		
Not Active	3272484	CHEMBL1108315	Inhibition of PKCbeta2	B	COc1ccc(/C=C2/C(=O)Nc3ccc(Cl)cc32)c(OC)c1OC		CHEMBL1086796		Inhibition	%		CHEMBL3045	Homo sapiens	INH		
Not Active	3272485	CHEMBL1108315	Inhibition of PKCbeta2	B	COc1cc(/C=C2/C(=O)Nc3ccc(Cl)cc32)cc(OC)c1OC		CHEMBL383871		Inhibition	%		CHEMBL3045	Homo sapiens	INH		
	3272486	CHEMBL1108315	Inhibition of PKCbeta2	B	COc1cc(OC)c(/C=C2/C(=O)Nc3ccc(Cl)cc32)c(OC)c1		CHEMBL1086939	<	Inhibition	%	20.0	CHEMBL3045	Homo sapiens	INH	%	20.0
Not Active	3272487	CHEMBL1108315	Inhibition of PKCbeta2	B	CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C		CHEMBL535		Inhibition	%		CHEMBL3045	Homo sapiens	INH		
	3291467	CHEMBL1111966	Inhibition of PKC-beta assessed as [33P]gamma-ATP incorporation into substrate after 60 mins by gamma counting	B	COc1ccc(N2CCN(C)CC2)cc1Nc1ncc2c(n1)-c1c(c(C(N)=O)nn1C)CC2		CHEMBL1094408	>	IC50	nM	10000.0	CHEMBL3045	Homo sapiens	IC50	uM	10.0
Not Active	3367508	CHEMBL1176376	Inhibition of PKCbeta up to 8 uM	B	Cc1cc2nc(NCCCO)n(CC(=O)c3cc(C(C)(C)C)c(O)c(C(C)(C)C)c3)c2cc1C		CHEMBL374350		Inhibition	%		CHEMBL3045	Homo sapiens	INH		
	3419133	CHEMBL1228801	Inhibition of PKCbeta2 at 100 uM relative to control	B	NC(=O)c1sc2c([N+](=O)[O-])cc(C(F)(F)F)cc2[n+]1[O-]		CHEMBL476124	=	Inhibition	%	82.0	CHEMBL3045	Homo sapiens	INH	%	82.0
	3420248	CHEMBL1226944	Inhibition of PKCbeta	B	O=C1NCCc2[nH]c(-c3ccncc3)cc21		CHEMBL225519	>	IC50	nM	10000.0	CHEMBL3045	Homo sapiens	IC50	nM	10000.0
	3443491	CHEMBL1244257	Inhibition of PRKCbeta1 at 1 uM after 60 mins by FRET assay in presence of 10 uM ATP	B	CC(C)n1nc(-c2ccc(Br)c(O)c2)c2c(N)ncnc21		CHEMBL1241578	=	Inhibition	%	48.0	CHEMBL3045	Homo sapiens	INH	%	48.0
	3443492	CHEMBL1244258	Inhibition of PRKCbeta2 at 1 uM after 60 mins by FRET assay in presence of 10 uM ATP	B	CC(C)n1nc(-c2ccc(Br)c(O)c2)c2c(N)ncnc21		CHEMBL1241578	=	Inhibition	%	29.0	CHEMBL3045	Homo sapiens	INH	%	29.0
	3443708	CHEMBL1244257	Inhibition of PRKCbeta1 at 1 uM after 60 mins by FRET assay in presence of 10 uM ATP	B	Nc1ncnc2c1c(-c1cnc3[nH]ccc3c1)nn2C1CCCC1		CHEMBL1081312	=	Inhibition	%	40.0	CHEMBL3045	Homo sapiens	INH	%	40.0
	3443709	CHEMBL1244258	Inhibition of PRKCbeta2 at 1 uM after 60 mins by FRET assay in presence of 10 uM ATP	B	Nc1ncnc2c1c(-c1cnc3[nH]ccc3c1)nn2C1CCCC1		CHEMBL1081312	=	Inhibition	%	36.0	CHEMBL3045	Homo sapiens	INH	%	36.0
	3444863	CHEMBL1244257	Inhibition of PRKCbeta1 at 1 uM after 60 mins by FRET assay in presence of 10 uM ATP	B	CC(C)n1nc(-c2ccc3ncccc3c2)c2c(N)ncnc21		CHEMBL1233882	=	Inhibition	%	25.0	CHEMBL3045	Homo sapiens	INH	%	25.0
	3444864	CHEMBL1244258	Inhibition of PRKCbeta2 at 1 uM after 60 mins by FRET assay in presence of 10 uM ATP	B	CC(C)n1nc(-c2ccc3ncccc3c2)c2c(N)ncnc21		CHEMBL1233882	=	Inhibition	%	13.0	CHEMBL3045	Homo sapiens	INH	%	13.0
	3445487	CHEMBL1244257	Inhibition of PRKCbeta1 at 1 uM after 60 mins by FRET assay in presence of 10 uM ATP	B	COc1ccc(-c2nn(C3CCC3)c3ncnc(N)c23)cc1OC		CHEMBL1233881	=	Inhibition	%	12.0	CHEMBL3045	Homo sapiens	INH	%	12.0
	3445488	CHEMBL1244258	Inhibition of PRKCbeta2 at 1 uM after 60 mins by FRET assay in presence of 10 uM ATP	B	COc1ccc(-c2nn(C3CCC3)c3ncnc(N)c23)cc1OC		CHEMBL1233881	=	Inhibition	%	8.0	CHEMBL3045	Homo sapiens	INH	%	8.0
	3445704	CHEMBL1244257	Inhibition of PRKCbeta1 at 1 uM after 60 mins by FRET assay in presence of 10 uM ATP	B	CC(C)n1nc(-c2cc3cc(O)ccc3[nH]2)c2c(N)ncnc21		CHEMBL1241674	=	Inhibition	%	66.0	CHEMBL3045	Homo sapiens	INH	%	66.0
	3445705	CHEMBL1244258	Inhibition of PRKCbeta2 at 1 uM after 60 mins by FRET assay in presence of 10 uM ATP	B	CC(C)n1nc(-c2cc3cc(O)ccc3[nH]2)c2c(N)ncnc21		CHEMBL1241674	=	Inhibition	%	81.0	CHEMBL3045	Homo sapiens	INH	%	81.0
	3445899	CHEMBL1244257	Inhibition of PRKCbeta1 at 1 uM after 60 mins by FRET assay in presence of 10 uM ATP	B	CC(C)n1nc(-c2cccc(O)c2)c2c(N)ncnc21		CHEMBL1230790	=	Inhibition	%	23.0	CHEMBL3045	Homo sapiens	INH	%	23.0
	3445900	CHEMBL1244258	Inhibition of PRKCbeta2 at 1 uM after 60 mins by FRET assay in presence of 10 uM ATP	B	CC(C)n1nc(-c2cccc(O)c2)c2c(N)ncnc21		CHEMBL1230790	=	Inhibition	%	21.0	CHEMBL3045	Homo sapiens	INH	%	21.0
	3446089	CHEMBL1244257	Inhibition of PRKCbeta1 at 1 uM after 60 mins by FRET assay in presence of 10 uM ATP	B	Cn1nc(-c2ccc3ccccc3c2)c2c(N)ncnc21		CHEMBL1234815	=	Inhibition	%	15.0	CHEMBL3045	Homo sapiens	INH	%	15.0
	3446090	CHEMBL1244258	Inhibition of PRKCbeta2 at 1 uM after 60 mins by FRET assay in presence of 10 uM ATP	B	Cn1nc(-c2ccc3ccccc3c2)c2c(N)ncnc21		CHEMBL1234815	=	Inhibition	%	15.0	CHEMBL3045	Homo sapiens	INH	%	15.0
	3463324	CHEMBL1252626	Inhibition of PRKCB1 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	B	Cc1n[nH]c2ccc(-c3cncc(OC[C@@H](N)Cc4c[nH]c5ccccc45)c3)cc12		CHEMBL379300	=	Inhibition	%	97.0	CHEMBL3045	Homo sapiens	INH	%	97.0
	3463325	CHEMBL1252627	Inhibition of PRKCB2 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	B	Cc1n[nH]c2ccc(-c3cncc(OC[C@@H](N)Cc4c[nH]c5ccccc45)c3)cc12		CHEMBL379300	=	Inhibition	%	68.0	CHEMBL3045	Homo sapiens	INH	%	68.0
	3463868	CHEMBL1252626	Inhibition of PRKCB1 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	B	COc1ccccc1N1CCN(c2ncnc3[nH]nc(Br)c23)CC1		CHEMBL1254209	=	Inhibition	%	35.0	CHEMBL3045	Homo sapiens	INH	%	35.0
	3463869	CHEMBL1252627	Inhibition of PRKCB2 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	B	COc1ccccc1N1CCN(c2ncnc3[nH]nc(Br)c23)CC1		CHEMBL1254209	=	Inhibition	%	32.0	CHEMBL3045	Homo sapiens	INH	%	32.0
	3464087	CHEMBL1252626	Inhibition of PRKCB1 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	B	O=C(NCCCNc1nc(Nc2cccc(NC(=O)N3CCCC3)c2)ncc1I)c1cccs1		CHEMBL577784	=	Inhibition	%	28.0	CHEMBL3045	Homo sapiens	INH	%	28.0
	3464088	CHEMBL1252627	Inhibition of PRKCB2 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	B	O=C(NCCCNc1nc(Nc2cccc(NC(=O)N3CCCC3)c2)ncc1I)c1cccs1		CHEMBL577784	=	Inhibition	%	35.0	CHEMBL3045	Homo sapiens	INH	%	35.0
	3502331	CHEMBL1259593	Inhibition of PKCbeta1 at 1 uM	B	Cc1c[nH]c2ncnc(N3CCN(C(=O)[C@H](N)Cc4ccc(F)cc4)CC3)c12		CHEMBL1257282	>	Inhibition	%	90.0	CHEMBL3045	Homo sapiens	INH	%	90.0
	3504212	CHEMBL1260173	Inhibition of PKCbeta	B	O=C(Nc1n[nH]c2cc(C(=O)N[C@H](CN3CCCC3)c3ccccc3)sc12)c1ccc(N2CCOCC2)cc1		CHEMBL1258913	=	IC50	nM	1212.0	CHEMBL3045	Homo sapiens	IC50	uM	1.212
	3504866	CHEMBL1260394	Inhibition of [3H]PDBu binding to PKC beta C1A peptide	B	CO[C@@H](CC[C@H](C)[C@H]1O[C@@]23C[C@H](OC(=O)C[C@H]([C@@H](C)O)OC(=O)C[C@](O)(O2)[C@H](C)CC3(C)C)[C@@H]1C)c1cc(O)ccc1Br		CHEMBL1256416	=	Ki	nM	0.45	CHEMBL3045	Homo sapiens	Ki	nM	0.45
	3504874	CHEMBL1260394	Inhibition of [3H]PDBu binding to PKC beta C1A peptide	B	CCCC(=O)O[C@@H]1[C@@H](C)[C@@]2(O)[C@@H](C=C(CO)C[C@]3(O)C(=O)C(C)=C[C@@H]23)[C@@H]2C(C)(C)[C@]12OC(=O)CCC		CHEMBL27768	=	Kd	nM	1.3	CHEMBL3045	Homo sapiens	Kd	nM	1.3
	3504882	CHEMBL1260394	Inhibition of [3H]PDBu binding to PKC beta C1A peptide	B	CC1(C)CC[C@@H]2CC(=O)O[C@@H](CO)CC(=O)O[C@@H]3C[C@@H](CCCCc4ccccc4)O[C@@]1(C3)O2		CHEMBL1258117	=	Ki	nM	140.0	CHEMBL3045	Homo sapiens	Ki	nM	140.0
	3504889	CHEMBL1260394	Inhibition of [3H]PDBu binding to PKC beta C1A peptide	B	CC1(C)CC[C@@H]2CC(=O)O[C@@H](CO)CC(=O)O[C@@H]3C[C@@H](CCCCc4cccc(O)c4)O[C@@]1(C3)O2		CHEMBL1258348	=	Ki	nM	89.0	CHEMBL3045	Homo sapiens	Ki	nM	89.0
	3504897	CHEMBL1260394	Inhibition of [3H]PDBu binding to PKC beta C1A peptide	B	O=C1C[C@H]2CCC[C@]3(C[C@@H](C[C@@H](CCCCc4ccccc4)O3)OC(=O)C[C@H](CO)O1)O2		CHEMBL1258349	=	Ki	nM	3500.0	CHEMBL3045	Homo sapiens	Ki	nM	3500.0
	3527001	CHEMBL1274132	Inhibition of PKCbeta	B	NC(=O)c1cc(-c2ccnc(N)n2)[nH]c1-c1ccccc1		CHEMBL1270230	=	IC50	nM	3700.0	CHEMBL3045	Homo sapiens	IC50	uM	3.7
	3556503	CHEMBL1285613	Inhibition of PRKCB2 at 1 uM	B	CN1C[C@@H]2C[C@H]1CN2c1cc(F)c(-c2ccnc3c(-c4cccc5[nH]ncc45)c(-c4ccncc4)nn23)c(F)c1		CHEMBL1276179	=	Inhibition	%	51.0	CHEMBL3045	Homo sapiens	INH	%	51.0
	3556506	CHEMBL1285612	Inhibition of PRKCB1 at 1 uM	B	CN1C[C@@H]2C[C@H]1CN2c1cc(F)c(-c2ccnc3c(-c4cccc5[nH]ncc45)c(-c4ccncc4)nn23)c(F)c1		CHEMBL1276179	=	Inhibition	%	39.0	CHEMBL3045	Homo sapiens	INH	%	39.0
	3561322	CHEMBL1287078	Inhibition of human PKCbeta at 10 uM	B	Cc1c2c(=O)n(-c3ccccc3Cl)[nH]c2cc(=O)n1Cc1ccccn1		CHEMBL1276946	=	Inhibition	%	0.0	CHEMBL3045	Homo sapiens	INH	%	0.0
	3590880	CHEMBL1292178	Inhibition of PKAbeta	B	Cc1ccc(C(=O)Nc2ccon2)cc1NC(=O)c1cnn(-c2ccccc2F)c1N		CHEMBL1290746	>	IC50	nM	40000.0	CHEMBL3045	Homo sapiens	IC50	uM	40.0
	3601441	CHEMBL1292415	Inhibition of PKC-beta1	B	COc1ccc2cc(-c3n[nH]c4cccnc34)[nH]c2c1		CHEMBL1288582	>	IC50	nM	30000.0	CHEMBL3045	Homo sapiens	IC50	uM	30.0
	3603122	CHEMBL1291219	Inhibition of PRKCB1 at 10 uM	B	O=C(Cc1cccc2cnccc12)Nc1scnc1-c1cscn1		CHEMBL1288160	=	Inihibition	%	18.0	CHEMBL3045	Homo sapiens	Inihibition	%	18.0
Not Active	4988696	CHEMBL1614099	PUBCHEM_BIOASSAY: In Vitro Kinase Assay Using Purified Enzyme PKC-beta. (Class of assay: confirmatory) [Related pubchem assays: 1299, 1270, 1295, 1375, 1287, 1281, 1293, 1291, 1289, 465, 1364, 1282, 1372, 1365, 1370, 1367, 1366, 1266, 1269, 1373, 1292, 1290, 1302, 1371, 1283, 1271, 1294, 1374, 1368, 1369 ]	B	Br.Cc1cc2nc(NCCCO)n(CC(=O)c3cc(C(C)(C)C)c(O)c(C(C)(C)C)c3)c2cc1C		CHEMBL1427791	>	EC50	nM	4000.0	CHEMBL3045	Homo sapiens	EC50	um	4.0
	5120073	CHEMBL1648816	Inhibition of PRKCB1 at 10 uM after 60 mins by TR-FRET assay	B	O=c1[nH]nc(-c2ccnc(NC3CCCCC3)c2)n1-c1ccc2ccccc2c1		CHEMBL1644618	=	Inhibition	%	2.0	CHEMBL3045	Homo sapiens	INH	%	2.0
	5120138	CHEMBL1648816	Inhibition of PRKCB1 at 10 uM after 60 mins by TR-FRET assay	B	O=c1n(C2CCOCC2)nc(-c2ccnc(NC3CCCCC3)c2)n1-c1ccc2ccccc2c1		CHEMBL1644639	=	Inhibition	%	7.0	CHEMBL3045	Homo sapiens	INH	%	7.0
	5120139	CHEMBL1648816	Inhibition of PRKCB1 at 10 uM after 60 mins by TR-FRET assay	B	O=c1n(Cc2ccccn2)nc(-c2ccnc(NC3CCOCC3)c2)n1-c1ccc2ccccc2c1		CHEMBL1644615	=	Inhibition	%	7.0	CHEMBL3045	Homo sapiens	INH	%	7.0
	5120157	CHEMBL1648816	Inhibition of PRKCB1 at 10 uM after 60 mins by TR-FRET assay	B	O=c1[nH]nc(-c2ccnc(NC3CCCOC3)c2)n1-c1ccc2ccccc2c1		CHEMBL1644619	=	Inhibition	%	10.0	CHEMBL3045	Homo sapiens	INH	%	10.0
	5120167	CHEMBL1648816	Inhibition of PRKCB1 at 10 uM after 60 mins by TR-FRET assay	B	O=c1[nH]nc(-c2ccnc(NC3CCOCC3)c2)n1-c1ccc2ccccc2c1		CHEMBL1644620	=	Inhibition	%	11.0	CHEMBL3045	Homo sapiens	INH	%	11.0
	5120196	CHEMBL1648816	Inhibition of PRKCB1 at 10 uM after 60 mins by TR-FRET assay	B	O=c1n(Cc2ccncc2)nc(-c2ccnc(NC3CCCCC3)c2)n1-c1ccc2ccccc2c1		CHEMBL1644642	=	Inhibition	%	19.0	CHEMBL3045	Homo sapiens	INH	%	19.0
	5120372	CHEMBL1648679	Inhibition of human PKCbeta2 at 10 uM after 60 mins by TR-FRET assay	B	S=c1[nH]nc(-c2ccncc2)n1-c1ccc2ccccc2c1		CHEMBL1644616	=	Inhibition	%	105.0	CHEMBL3045	Homo sapiens	INH	%	105.0
	5120420	CHEMBL1648678	Inhibition of human PKCbeta1 at 10 uM after 60 mins by TR-FRET assay	B	S=c1[nH]nc(-c2ccncc2)n1-c1ccc2ccccc2c1		CHEMBL1644616	=	Inhibition	%	109.0	CHEMBL3045	Homo sapiens	INH	%	109.0
	5120856	CHEMBL1646942	Inhibition of PRKCB at 10 uM	B	CC(C)(C)c1cc(C(=O)O)c(NC(=O)Nc2ccc3[nH]ncc3c2)s1		CHEMBL1641799	=	Inhibition	%	10.0	CHEMBL3045	Homo sapiens	INH	%	10.0
	5140490	CHEMBL1646797	Inhibition of PRKCB at 1 uM	B	CC(C)(C)c1cc(C(=O)O)c(NC(=O)Nc2ccc3[nH]ncc3c2)s1		CHEMBL1641799	=	Inhibition	%	10.0	CHEMBL3045	Homo sapiens	INH	%	10.0
Not Active	5220339	CHEMBL1681595	Inhibition of human recombinant PKCbeta1 at < 10 uM after 10 mins by radiometric assay	B	O=C1NCCCc2c1oc1ccc(O)cc21		CHEMBL1450770		Inhibition	%		CHEMBL3045	Homo sapiens	INH		
Not Active	5220340	CHEMBL1681595	Inhibition of human recombinant PKCbeta1 at < 10 uM after 10 mins by radiometric assay	B	O=C1NCCCc2c1[nH]c1ccc(O)cc21		CHEMBL1672570		Inhibition	%		CHEMBL3045	Homo sapiens	INH		
Not Active	5220341	CHEMBL1681595	Inhibition of human recombinant PKCbeta1 at < 10 uM after 10 mins by radiometric assay	B	O=C1NCCSc2c1sc1ccc(O)cc21		CHEMBL1672571		Inhibition	%		CHEMBL3045	Homo sapiens	INH		
Not Active	5220342	CHEMBL1681595	Inhibition of human recombinant PKCbeta1 at < 10 uM after 10 mins by radiometric assay	B	COc1ccc2sc3c(c2c1)SCCNC3=O		CHEMBL319170		Inhibition	%		CHEMBL3045	Homo sapiens	INH		
Not Active	5220343	CHEMBL1681595	Inhibition of human recombinant PKCbeta1 at < 10 uM after 10 mins by radiometric assay	B	[N-]=[N+]=Nc1ccc2sc3c(c2c1)SCCNC3=O		CHEMBL1672572		Inhibition	%		CHEMBL3045	Homo sapiens	INH		
Not Active	5220344	CHEMBL1681595	Inhibition of human recombinant PKCbeta1 at < 10 uM after 10 mins by radiometric assay	B	O=C1NCCCSc2c1sc1ccc(O)cc21		CHEMBL1672573		Inhibition	%		CHEMBL3045	Homo sapiens	INH		
Not Active	5220345	CHEMBL1681595	Inhibition of human recombinant PKCbeta1 at < 10 uM after 10 mins by radiometric assay	B	COc1ccc2sc3c(c2c1)SCCCNC3=O		CHEMBL1672574		Inhibition	%		CHEMBL3045	Homo sapiens	INH		
Not Active	5220346	CHEMBL1681595	Inhibition of human recombinant PKCbeta1 at < 10 uM after 10 mins by radiometric assay	B	COc1ncc2sc3c(c2n1)SCCNC3=O		CHEMBL1672575		Inhibition	%		CHEMBL3045	Homo sapiens	INH		
	5249446	CHEMBL1686797	Inhibition of PRKCB1 at 10 uM	B	O=C(Cc1cccc2cnccc12)Nc1scc(Cl)c1-c1ncn[nH]1		CHEMBL1682017	=	Inhibition	%	3.0	CHEMBL3045	Homo sapiens	INH	%	3.0
	6167668	CHEMBL1769209	Inhibition of PKCbeta	B	CNc1cncc(-c2c[nH]c(=O)c(NC(=O)c3ccc(N4CCC[C@H]4CN4CCCC4)cc3)c2)n1		CHEMBL1765781	>	Ki	nM	1000.0	CHEMBL3045	Homo sapiens	Ki	uM	1.0
	6198145	CHEMBL1776307	Inhibition of PKCbeta assessed as [33P]gamma-ATP incorporation into substrate after 60 mins by gamma counting	B	CN1CCN(c2ccc(OC(F)(F)F)c(Nc3ncc4c(n3)-c3c(c(C(N)=O)nn3CCO)CC4)c2)CC1		CHEMBL1738758	>	IC50	nM	10000.0	CHEMBL3045	Homo sapiens	IC50	uM	10.0
	6201882	CHEMBL1781781	Inhibition of PKCbeta1 assessed as FLC-SIYRRGSRRWRKL peptide phosphorylation by fluorescence polarization assay	B	CC1(C)c2cc(C3CCN(C4COC4)CC3)ccc2C(=O)c2c1[nH]c1cc(C#N)ccc21		CHEMBL1779202	>	IC50	nM	50000.0	CHEMBL3045	Homo sapiens	IC50	uM	50.0
	6201883	CHEMBL1781782	Inhibition of PKCbeta2 assessed as FLC-SIYRRGSRRWRKL peptide phosphorylation by fluorescence polarization assay	B	CC1(C)c2cc(C3CCN(C4COC4)CC3)ccc2C(=O)c2c1[nH]c1cc(C#N)ccc21		CHEMBL1779202	>	IC50	nM	50000.0	CHEMBL3045	Homo sapiens	IC50	uM	50.0
	6221251	CHEMBL1787676	Inhibition of PRKCB1 at 10 uM	B	S=c1[nH]nc(-c2ccncc2)n1-c1ccc2ccccc2c1		CHEMBL1644616	=	Inhibition	%	25.0	CHEMBL3045	Homo sapiens	INH	%	25.0
	6297263	CHEMBL1809445	Inhibition of [3H]PDBu binding to PKCbeta-C1A domain peptide	B	C=C[C@@]1(C)CC[C@](C)(C(C)C)c2cc3c4c(c[nH]c4c21)CC(=O)NC(=O)[C@H](C(C)C)N3C		CHEMBL1807163	=	Ki	nM	730.0	CHEMBL3045	Homo sapiens	Ki	nM	730.0
	6297269	CHEMBL1809451	Binding affinity to PKCbeta-C1A domain peptide using [3H]-labeled compound	B	CCCC(=O)O[C@@H]1[C@@H](C)[C@@]2(O)[C@@H](C=C(CO)C[C@]3(O)C(=O)C(C)=C[C@@H]23)[C@@H]2C(C)(C)[C@]12OC(=O)CCC		CHEMBL27768	=	Kd	nM	1.3	CHEMBL3045	Homo sapiens	Kd	nM	1.3
	6335510	CHEMBL1821106	Inhibition of N-terminal GST-fused PKCbeta2 (1-673) expressed in baculovirus expression system at 30 uM after 1 hr by off-chip mobility shift assay relative to control	B	CCCCCCCCCCCCCC[C@@H]1OC[C@H](N)[C@@H]1O		CHEMBL447577	=	Inhibition	%	27.9	CHEMBL3045	Homo sapiens	INH	%	27.9
	6335511	CHEMBL1821105	Inhibition of N-terminal GST-fused PKCbeta1 (1-671) expressed in baculovirus expression system at 30 uM after 1 hr by off-chip mobility shift assay relative to control	B	CCCCCCCCCCCCCC[C@@H]1OC[C@H](N)[C@@H]1O		CHEMBL447577	=	Inhibition	%	48.5	CHEMBL3045	Homo sapiens	INH	%	48.5
	6335522	CHEMBL1821106	Inhibition of N-terminal GST-fused PKCbeta2 (1-673) expressed in baculovirus expression system at 30 uM after 1 hr by off-chip mobility shift assay relative to control	B	CCCCCCCCCCCCC/C=C/[C@@H](O)[C@H](CO)N(C)C		CHEMBL322333	=	Inhibition	%	44.3	CHEMBL3045	Homo sapiens	INH	%	44.3
	6335523	CHEMBL1821105	Inhibition of N-terminal GST-fused PKCbeta1 (1-671) expressed in baculovirus expression system at 30 uM after 1 hr by off-chip mobility shift assay relative to control	B	CCCCCCCCCCCCC/C=C/[C@@H](O)[C@H](CO)N(C)C		CHEMBL322333	=	Inhibition	%	68.5	CHEMBL3045	Homo sapiens	INH	%	68.5
	6335536	CHEMBL1821106	Inhibition of N-terminal GST-fused PKCbeta2 (1-673) expressed in baculovirus expression system at 30 uM after 1 hr by off-chip mobility shift assay relative to control	B	CCCCCCCCCCCCCC[C@@H]1OC[C@@H](N)[C@@H]1O		CHEMBL1819205	=	Inhibition	%	22.9	CHEMBL3045	Homo sapiens	INH	%	22.9
	6335537	CHEMBL1821105	Inhibition of N-terminal GST-fused PKCbeta1 (1-671) expressed in baculovirus expression system at 30 uM after 1 hr by off-chip mobility shift assay relative to control	B	CCCCCCCCCCCCCC[C@@H]1OC[C@@H](N)[C@@H]1O		CHEMBL1819205	=	Inhibition	%	45.1	CHEMBL3045	Homo sapiens	INH	%	45.1
	6335550	CHEMBL1821106	Inhibition of N-terminal GST-fused PKCbeta2 (1-673) expressed in baculovirus expression system at 30 uM after 1 hr by off-chip mobility shift assay relative to control	B	CCCCCCCCCCCCCC[C@H]1OC[C@@H](N)[C@@H]1O		CHEMBL1819204	=	Inhibition	%	43.9	CHEMBL3045	Homo sapiens	INH	%	43.9
	6335551	CHEMBL1821105	Inhibition of N-terminal GST-fused PKCbeta1 (1-671) expressed in baculovirus expression system at 30 uM after 1 hr by off-chip mobility shift assay relative to control	B	CCCCCCCCCCCCCC[C@H]1OC[C@@H](N)[C@@H]1O		CHEMBL1819204	=	Inhibition	%	79.2	CHEMBL3045	Homo sapiens	INH	%	79.2
	6339231	CHEMBL1828181	Inhibition of PKCb2 activity by fluorescence polarization assay	B	CCc1cc2c(cc1N1CCN(C3COC3)CC1)C(C)(C)c1[nH]c3cc(C#N)ccc3c1C2=O		CHEMBL1823221	>	IC50	nM	50000.0	CHEMBL3045	Homo sapiens	IC50	uM	50.0
	6339232	CHEMBL1828181	Inhibition of PKCb2 activity by fluorescence polarization assay	B	CC1(C)c2cc(C3CCN(C4COC4)CC3)ccc2C(=O)c2c1[nH]c1cc(C#N)ccc21		CHEMBL1779202	>	IC50	nM	50000.0	CHEMBL3045	Homo sapiens	IC50	uM	50.0
	6339233	CHEMBL1828182	Inhibition of PKCb1 activity by fluorescence polarization assay	B	CCc1cc2c(cc1N1CCN(C3COC3)CC1)C(C)(C)c1[nH]c3cc(C#N)ccc3c1C2=O		CHEMBL1823221	>	IC50	nM	50000.0	CHEMBL3045	Homo sapiens	IC50	uM	50.0
	6339234	CHEMBL1828182	Inhibition of PKCb1 activity by fluorescence polarization assay	B	CC1(C)c2cc(C3CCN(C4COC4)CC3)ccc2C(=O)c2c1[nH]c1cc(C#N)ccc21		CHEMBL1779202	>	IC50	nM	50000.0	CHEMBL3045	Homo sapiens	IC50	uM	50.0
	6353475	CHEMBL1825787	Inhibition of PRKCB1 at 10 uM	B	O=C(Cn1c(=O)ccc2cc(C(F)(F)F)ccc21)Nc1scc(Br)c1-c1ncn[nH]1		CHEMBL1822146	=	Inhibition	%	4.0	CHEMBL3045	Homo sapiens	INH	%	4.0
	6384619	CHEMBL1837772	Inhibition of human PKCbeta in HL60 cells lysate at 10 uM using post probe-labeling by LC-MS/MS analysis relative to control	B	Nc1c(F)c(NCCCc2ccccc2)c(F)c2c1c(=O)c(C(=O)O)cn2C1CC1		CHEMBL1834114	<	Inhibition	%	35.0	CHEMBL3045	Homo sapiens	INH	%	35.0
	6384620	CHEMBL1837772	Inhibition of human PKCbeta in HL60 cells lysate at 10 uM using post probe-labeling by LC-MS/MS analysis relative to control	B	Nc1c(F)c(NCCNc2ccccn2)c(F)c2c1c(=O)c(C(=O)O)cn2C1CCCC1		CHEMBL1834318	<	Inhibition	%	35.0	CHEMBL3045	Homo sapiens	INH	%	35.0
	6384621	CHEMBL1837772	Inhibition of human PKCbeta in HL60 cells lysate at 10 uM using post probe-labeling by LC-MS/MS analysis relative to control	B	C[C@H]1COc2c(NCCNc3ccccn3)c(F)c(N)c3c(=O)c(C(=O)O)cn1c23		CHEMBL1834323	<	Inhibition	%	35.0	CHEMBL3045	Homo sapiens	INH	%	35.0
	6384622	CHEMBL1837772	Inhibition of human PKCbeta in HL60 cells lysate at 10 uM using post probe-labeling by LC-MS/MS analysis relative to control	B	CC(C)[C@@H]1COc2c(NCCNc3ccccn3)c(F)c(N)c3c(=O)c(C(=O)O)cn1c23		CHEMBL1834324	<	Inhibition	%	35.0	CHEMBL3045	Homo sapiens	INH	%	35.0
	6384623	CHEMBL1837772	Inhibition of human PKCbeta in HL60 cells lysate at 10 uM using post probe-labeling by LC-MS/MS analysis relative to control	B	Nc1c(F)c(NCCNc2ccccn2)c2c3c1c(=O)c(C(=O)O)cn3C1(CCCC1)CO2		CHEMBL1834330	<	Inhibition	%	35.0	CHEMBL3045	Homo sapiens	INH	%	35.0
	7961113	CHEMBL1931538	Inhibition of PKCbeta1	B	CN(C)CCN1CCN(C(=O)c2cc(C(C)(C)C)sc2NC(=O)Nc2cccc(Cl)c2Cl)CCC1=O		CHEMBL1929238	>	IC50	nM	30000.0	CHEMBL3045	Homo sapiens	IC50	uM	30.0
	7961114	CHEMBL1931538	Inhibition of PKCbeta1	B	Cc1ccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2ccc(OCCN3CCOCC3)c3ccccc23)cc1		CHEMBL103667	=	IC50	nM	40000.0	CHEMBL3045	Homo sapiens	IC50	uM	40.0
	7961115	CHEMBL1931539	Inhibition of PKCbeta2	B	CN(C)CCN1CCN(C(=O)c2cc(C(C)(C)C)sc2NC(=O)Nc2cccc(Cl)c2Cl)CCC1=O		CHEMBL1929238	=	IC50	nM	32000.0	CHEMBL3045	Homo sapiens	IC50	uM	32.0
	7961116	CHEMBL1931539	Inhibition of PKCbeta2	B	Cc1ccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2ccc(OCCN3CCOCC3)c3ccccc23)cc1		CHEMBL103667	=	IC50	nM	6900.0	CHEMBL3045	Homo sapiens	IC50	uM	6.9
	7971375	CHEMBL1929909	Inhibition of PKCbeta2 at 10 uM	B	NCCN1C(=O)S/C(=C\CCC2CCCCC2)C1=O		CHEMBL1929247	=	Inhibition	%	16.0	CHEMBL3045	Homo sapiens	INH	%	16.0
	7984705	CHEMBL1936627	Inhibition of PKCbeta	B	CN1CCN(c2ccc(OC(F)(F)F)c(Nc3nccc(-c4cc(C(N)=O)cn4C)n3)c2)CC1		CHEMBL1933576	>	IC50	nM	10000.0	CHEMBL3045	Homo sapiens	IC50	uM	10.0
	7984706	CHEMBL1936627	Inhibition of PKCbeta	B	CN1CCN(c2ccc(OC(F)(F)F)c(Nc3nccc(-c4cc5c(n4C)CCNC5=O)n3)c2)CC1		CHEMBL1933582	>	IC50	nM	10000.0	CHEMBL3045	Homo sapiens	IC50	uM	10.0
	7992215	CHEMBL1936087	Inhibition of PKC beta 1 at 1 uM	B	CN(c1ccccc1-c1cc(Cl)c2cnc(Nc3ccc(C4CCN(CC(N)=O)CC4)cc3)nn12)S(C)(=O)=O		CHEMBL1934353	=	Inhibition	%	71.0	CHEMBL3045	Homo sapiens	INH	%	71.0
	8045866	CHEMBL1959345	Inhibition of human PKCb1 catalytic domain after by scintillation counting	B	COc1ccc(COc2ccc(Cc3cnc(N)nc3N)cc2OC)cc1		CHEMBL261849	>	IC50	nM	13000.0	CHEMBL3045	Homo sapiens	IC50	uM	13.0
	8061231	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	Cl.NCc1ccc(-c2nc(-c3ccc(Cl)c(O)c3)c(-c3ccncc3)[nH]2)cc1		CHEMBL1909412	=	Inhibition	%	5.37	CHEMBL3045	Homo sapiens	Inhibition	%	5.37
	8061236	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	Cl.NCc1ccc(-c2nc(-c3ccc(Cl)c(O)c3)c(-c3ccncc3)[nH]2)cc1		CHEMBL1909412	=	Inhibition	%	0.76	CHEMBL3045	Homo sapiens	Inhibition	%	0.76
	8061408	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	COc1cc(C=NNc2ncnc3c2cnn3Cc2ccccc2)ccc1O		CHEMBL1789962	=	Inhibition	%	3.19	CHEMBL3045	Homo sapiens	Inhibition	%	3.19
	8061413	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	COc1cc(C=NNc2ncnc3c2cnn3Cc2ccccc2)ccc1O		CHEMBL1789962	=	Inhibition	%	1.44	CHEMBL3045	Homo sapiens	Inhibition	%	1.44
	8061632	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccc(Cl)c(C(F)(F)F)c3)n2)cc1		CHEMBL188794	=	Inhibition	%	0.17	CHEMBL3045	Homo sapiens	Inhibition	%	0.17
	8061637	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccc(Cl)c(C(F)(F)F)c3)n2)cc1		CHEMBL188794	=	Inhibition	%	0.91	CHEMBL3045	Homo sapiens	Inhibition	%	0.91
	8061739	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	CN1CCC(n2cnc(-c3ccc(F)cc3)c2-c2ccnc(Nc3ccccc3)n2)CC1		CHEMBL318892	=	Inhibition	%	50.97	CHEMBL3045	Homo sapiens	Inhibition	%	50.97
	8061744	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	CN1CCC(n2cnc(-c3ccc(F)cc3)c2-c2ccnc(Nc3ccccc3)n2)CC1		CHEMBL318892	=	Inhibition	%	66.5	CHEMBL3045	Homo sapiens	Inhibition	%	66.5
	8061930	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	Cn1cc(C=C2C(=O)Nc3cccnc32)c2ccccc21		CHEMBL1516890	=	Inhibition	%	-0.06	CHEMBL3045	Homo sapiens	Inhibition	%	-0.06
	8061935	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	Cn1cc(C=C2C(=O)Nc3cccnc32)c2ccccc21		CHEMBL1516890	=	Inhibition	%	0.8	CHEMBL3045	Homo sapiens	Inhibition	%	0.8
	8062154	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	Cn1cc(C=C2C(=O)Nc3cccnc32)c2ccccc21		CHEMBL1516890	=	Inhibition	%	-1.44	CHEMBL3045	Homo sapiens	Inhibition	%	-1.44
	8062159	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	Cn1cc(C=C2C(=O)Nc3cccnc32)c2ccccc21		CHEMBL1516890	=	Inhibition	%	0.8	CHEMBL3045	Homo sapiens	Inhibition	%	0.8
	8062270	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	Cn1c(-c2nonc2N)nc2cnccc21		CHEMBL188048	=	Inhibition	%	7.33	CHEMBL3045	Homo sapiens	Inhibition	%	7.33
	8062275	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	Cn1c(-c2nonc2N)nc2cnccc21		CHEMBL188048	=	Inhibition	%	1.16	CHEMBL3045	Homo sapiens	Inhibition	%	1.16
	8062656	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	O=C1Nc2ccccc2/C1=C/Nc1ccc(-n2cncn2)cc1		CHEMBL1794056	=	Inhibition	%	0.83	CHEMBL3045	Homo sapiens	Inhibition	%	0.83
	8062661	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	O=C1Nc2ccccc2/C1=C/Nc1ccc(-n2cncn2)cc1		CHEMBL1794056	=	Inhibition	%	1.94	CHEMBL3045	Homo sapiens	Inhibition	%	1.94
	8062759	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2ccncc21		CHEMBL185710	=	Inhibition	%	0.57	CHEMBL3045	Homo sapiens	Inhibition	%	0.57
	8062978	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	CN(C)C(=O)O[C@@H]1CN[C@@H](C#Cc2cc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3s2)C1		CHEMBL466412	=	Inhibition	%	-1.27	CHEMBL3045	Homo sapiens	Inhibition	%	-1.27
	8062983	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	CN(C)C(=O)O[C@@H]1CN[C@@H](C#Cc2cc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3s2)C1		CHEMBL466412	=	Inhibition	%	0.88	CHEMBL3045	Homo sapiens	Inhibition	%	0.88
	8063110	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	Cl.NCc1ccc(-c2nc(-c3ccc(Cl)c(O)c3)c(-c3ccncc3)[nH]2)cc1		CHEMBL1909412	=	Inhibition	%	27.87	CHEMBL3045	Homo sapiens	Inhibition	%	27.87
	8063115	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	Cl.NCc1ccc(-c2nc(-c3ccc(Cl)c(O)c3)c(-c3ccncc3)[nH]2)cc1		CHEMBL1909412	=	Inhibition	%	10.83	CHEMBL3045	Homo sapiens	Inhibition	%	10.83
	8063501	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	COc1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccc(Cl)c(C(F)(F)F)c3)n2)cc1		CHEMBL188794	=	Inhibition	%	3.13	CHEMBL3045	Homo sapiens	Inhibition	%	3.13
	8063506	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	COc1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccc(Cl)c(C(F)(F)F)c3)n2)cc1		CHEMBL188794	=	Inhibition	%	0.81	CHEMBL3045	Homo sapiens	Inhibition	%	0.81
	8063609	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	Cl.NC(=O)c1ccc(-c2nc(-c3ccccn3)c(-c3ccc4c(c3)OCO4)[nH]2)cc1		CHEMBL1909378	=	Inhibition	%	-0.16	CHEMBL3045	Homo sapiens	Inhibition	%	-0.16
	8063614	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	Cl.NC(=O)c1ccc(-c2nc(-c3ccccn3)c(-c3ccc4c(c3)OCO4)[nH]2)cc1		CHEMBL1909378	=	Inhibition	%	1.96	CHEMBL3045	Homo sapiens	Inhibition	%	1.96
	8063833	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	Cl.NC(=O)c1ccc(-c2nc(-c3ccccn3)c(-c3ccc4c(c3)OCO4)[nH]2)cc1		CHEMBL1909378	=	Inhibition	%	2.78	CHEMBL3045	Homo sapiens	Inhibition	%	2.78
	8063838	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	Cl.NC(=O)c1ccc(-c2nc(-c3ccccn3)c(-c3ccc4c(c3)OCO4)[nH]2)cc1		CHEMBL1909378	=	Inhibition	%	5.1	CHEMBL3045	Homo sapiens	Inhibition	%	5.1
	8064015	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	FC(F)(F)c1cccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccc4c(c3)OCCO4)n2)c1		CHEMBL362155	=	Inhibition	%	0.07	CHEMBL3045	Homo sapiens	Inhibition	%	0.07
	8064020	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	FC(F)(F)c1cccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccc4c(c3)OCCO4)n2)c1		CHEMBL362155	=	Inhibition	%	0.37	CHEMBL3045	Homo sapiens	Inhibition	%	0.37
	8064130	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	Cn1c(-c2nonc2N)nc2cnccc21		CHEMBL188048	=	Inhibition	%	36.25	CHEMBL3045	Homo sapiens	Inhibition	%	36.25
	8064135	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	Cn1c(-c2nonc2N)nc2cnccc21		CHEMBL188048	=	Inhibition	%	5.62	CHEMBL3045	Homo sapiens	Inhibition	%	5.62
	8064354	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2cnc(Oc3cccc(NC(=O)c4ccc(N(C)C)cc4)c3)cc21		CHEMBL220465	=	Inhibition	%	16.7	CHEMBL3045	Homo sapiens	Inhibition	%	16.7
	8064359	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2cnc(Oc3cccc(NC(=O)c4ccc(N(C)C)cc4)c3)cc21		CHEMBL220465	=	Inhibition	%	4.27	CHEMBL3045	Homo sapiens	Inhibition	%	4.27
	8064564	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	CN(C)C(=O)O[C@@H]1CN[C@@H](C#Cc2cc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3s2)C1		CHEMBL466412	=	Inhibition	%	2.12	CHEMBL3045	Homo sapiens	Inhibition	%	2.12
	8064569	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	CN(C)C(=O)O[C@@H]1CN[C@@H](C#Cc2cc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3s2)C1		CHEMBL466412	=	Inhibition	%	0.87	CHEMBL3045	Homo sapiens	Inhibition	%	0.87
	8064702	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc(Nc2ncc(-c3ccccc3)o2)cc1OC.Cl		CHEMBL1794060	=	Inhibition	%	-0.02	CHEMBL3045	Homo sapiens	Inhibition	%	-0.02
	8064707	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc(Nc2ncc(-c3ccccc3)o2)cc1OC.Cl		CHEMBL1794060	=	Inhibition	%	-0.24	CHEMBL3045	Homo sapiens	Inhibition	%	-0.24
	8064926	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	COc1ccc(Nc2ncc(-c3ccccc3)o2)cc1OC.Cl		CHEMBL1794060	=	Inhibition	%	3.24	CHEMBL3045	Homo sapiens	Inhibition	%	3.24
	8064931	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	COc1ccc(Nc2ncc(-c3ccccc3)o2)cc1OC.Cl		CHEMBL1794060	=	Inhibition	%	1.4	CHEMBL3045	Homo sapiens	Inhibition	%	1.4
	8065092	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc(-c2ccc3c(NC(=O)C4CC4)n[nH]c3n2)cc1		CHEMBL408732	=	Inhibition	%	-0.58	CHEMBL3045	Homo sapiens	Inhibition	%	-0.58
	8065097	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc(-c2ccc3c(NC(=O)C4CC4)n[nH]c3n2)cc1		CHEMBL408732	=	Inhibition	%	0.8	CHEMBL3045	Homo sapiens	Inhibition	%	0.8
	8065432	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	COC(=O)Nc1nc2cc(Oc3ccc(NC(=O)Nc4cccc(Br)c4)cc3)ccc2[nH]1.Cl		CHEMBL1909370	=	Inhibition	%	-0.97	CHEMBL3045	Homo sapiens	Inhibition	%	-0.97
	8065437	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	COC(=O)Nc1nc2cc(Oc3ccc(NC(=O)Nc4cccc(Br)c4)cc3)ccc2[nH]1.Cl		CHEMBL1909370	=	Inhibition	%	0.71	CHEMBL3045	Homo sapiens	Inhibition	%	0.71
	8065607	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	FC(F)(F)c1cccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccc4c(c3)OCCO4)n2)c1		CHEMBL362155	=	Inhibition	%	-2.34	CHEMBL3045	Homo sapiens	Inhibition	%	-2.34
	8065612	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	FC(F)(F)c1cccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccc4c(c3)OCCO4)n2)c1		CHEMBL362155	=	Inhibition	%	0.77	CHEMBL3045	Homo sapiens	Inhibition	%	0.77
	8065946	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2cnc(Oc3cccc(NC(=O)c4ccc(N(C)C)cc4)c3)cc21		CHEMBL220465	=	Inhibition	%	53.56	CHEMBL3045	Homo sapiens	Inhibition	%	53.56
	8065951	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2cnc(Oc3cccc(NC(=O)c4ccc(N(C)C)cc4)c3)cc21		CHEMBL220465	=	Inhibition	%	21.83	CHEMBL3045	Homo sapiens	Inhibition	%	21.83
	8066156	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	CCc1nccc2c1nc(-c1nonc1N)n2CC		CHEMBL365072	=	Inhibition	%	2.42	CHEMBL3045	Homo sapiens	Inhibition	%	2.42
	8066161	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	CCc1nccc2c1nc(-c1nonc1N)n2CC		CHEMBL365072	=	Inhibition	%	0.5	CHEMBL3045	Homo sapiens	Inhibition	%	0.5
	8066516	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc(Nc2nccc(-c3cnn4ncccc34)n2)cc(OC)c1		CHEMBL359999	=	Inhibition	%	0.12	CHEMBL3045	Homo sapiens	Inhibition	%	0.12
	8066521	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc(Nc2nccc(-c3cnn4ncccc34)n2)cc(OC)c1		CHEMBL359999	=	Inhibition	%	1.8	CHEMBL3045	Homo sapiens	Inhibition	%	1.8
	8066682	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	COc1ccc(-c2ccc3c(NC(=O)C4CC4)n[nH]c3n2)cc1		CHEMBL408732	=	Inhibition	%	1.54	CHEMBL3045	Homo sapiens	Inhibition	%	1.54
	8066687	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	COc1ccc(-c2ccc3c(NC(=O)C4CC4)n[nH]c3n2)cc1		CHEMBL408732	=	Inhibition	%	0.48	CHEMBL3045	Homo sapiens	Inhibition	%	0.48
	8067030	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	COC(=O)Nc1nc2cc(Oc3ccc(NC(=O)Nc4cccc(Br)c4)cc3)ccc2[nH]1.Cl		CHEMBL1909370	=	Inhibition	%	2.4	CHEMBL3045	Homo sapiens	Inhibition	%	2.4
	8067035	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	COC(=O)Nc1nc2cc(Oc3ccc(NC(=O)Nc4cccc(Br)c4)cc3)ccc2[nH]1.Cl		CHEMBL1909370	=	Inhibition	%	2.06	CHEMBL3045	Homo sapiens	Inhibition	%	2.06
	8067205	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	COC(=O)Nc1nc2ccc(S(=O)(=O)c3ccc(NC(=O)Nc4cc(C(F)(F)F)ccc4F)cc3)cc2[nH]1.Cl		CHEMBL1909367	=	Inhibition	%	0.31	CHEMBL3045	Homo sapiens	Inhibition	%	0.31
	8067210	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	COC(=O)Nc1nc2ccc(S(=O)(=O)c3ccc(NC(=O)Nc4cc(C(F)(F)F)ccc4F)cc3)cc2[nH]1.Cl		CHEMBL1909367	=	Inhibition	%	0.33	CHEMBL3045	Homo sapiens	Inhibition	%	0.33
	8067550	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	Fc1ccc(-c2nn3ccccc3c2-c2ccncc2)cc1		CHEMBL485745	=	Inhibition	%	8.61	CHEMBL3045	Homo sapiens	Inhibition	%	8.61
	8067555	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	Fc1ccc(-c2nn3ccccc3c2-c2ccncc2)cc1		CHEMBL485745	=	Inhibition	%	1.95	CHEMBL3045	Homo sapiens	Inhibition	%	1.95
	8067760	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	CCc1nccc2c1nc(-c1nonc1N)n2CC		CHEMBL365072	=	Inhibition	%	20.03	CHEMBL3045	Homo sapiens	Inhibition	%	20.03
	8067765	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	CCc1nccc2c1nc(-c1nonc1N)n2CC		CHEMBL365072	=	Inhibition	%	1.81	CHEMBL3045	Homo sapiens	Inhibition	%	1.81
	8068119	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	COc1cc(Nc2nccc(-c3cnn4ncccc34)n2)cc(OC)c1		CHEMBL359999	=	Inhibition	%	8.95	CHEMBL3045	Homo sapiens	Inhibition	%	8.95
	8068124	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	COc1cc(Nc2nccc(-c3cnn4ncccc34)n2)cc(OC)c1		CHEMBL359999	=	Inhibition	%	16.93	CHEMBL3045	Homo sapiens	Inhibition	%	16.93
	8068283	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	Cl.N#Cc1cccc(Nc2ncc(-c3ccccc3)o2)c1		CHEMBL1794061	=	Inhibition	%	0.7	CHEMBL3045	Homo sapiens	Inhibition	%	0.7
	8068288	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	Cl.N#Cc1cccc(Nc2ncc(-c3ccccc3)o2)c1		CHEMBL1794061	=	Inhibition	%	0.6	CHEMBL3045	Homo sapiens	Inhibition	%	0.6
	8068507	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	Cl.N#Cc1cccc(Nc2ncc(-c3ccccc3)o2)c1		CHEMBL1794061	=	Inhibition	%	2.96	CHEMBL3045	Homo sapiens	Inhibition	%	2.96
	8068632	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	N#Cc1c(NC(=O)c2ccc(F)cc2)sc2c1CCCC2		CHEMBL397570	=	Inhibition	%	-1.4	CHEMBL3045	Homo sapiens	Inhibition	%	-1.4
	8068637	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	N#Cc1c(NC(=O)c2ccc(F)cc2)sc2c1CCCC2		CHEMBL397570	=	Inhibition	%	1.04	CHEMBL3045	Homo sapiens	Inhibition	%	1.04
	8068806	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	COC(=O)Nc1nc2ccc(S(=O)(=O)c3ccc(NC(=O)Nc4cc(C(F)(F)F)ccc4F)cc3)cc2[nH]1.Cl		CHEMBL1909367	=	Inhibition	%	0.32	CHEMBL3045	Homo sapiens	Inhibition	%	0.32
	8068811	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	COC(=O)Nc1nc2ccc(S(=O)(=O)c3ccc(NC(=O)Nc4cc(C(F)(F)F)ccc4F)cc3)cc2[nH]1.Cl		CHEMBL1909367	=	Inhibition	%	0.07	CHEMBL3045	Homo sapiens	Inhibition	%	0.07
	8069030	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc2cc(-c3c(-c4ccncc4)nc(-c4ccc([S+](C)[O-])cc4)n3C)ccc2c1		CHEMBL399410	=	Inhibition	%	0.88	CHEMBL3045	Homo sapiens	Inhibition	%	0.88
	8069035	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc2cc(-c3c(-c4ccncc4)nc(-c4ccc([S+](C)[O-])cc4)n3C)ccc2c1		CHEMBL399410	=	Inhibition	%	0.67	CHEMBL3045	Homo sapiens	Inhibition	%	0.67
	8069155	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	Fc1ccc(-c2nn3ccccc3c2-c2ccncc2)cc1		CHEMBL485745	=	Inhibition	%	37.79	CHEMBL3045	Homo sapiens	Inhibition	%	37.79
	8069160	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	Fc1ccc(-c2nn3ccccc3c2-c2ccncc2)cc1		CHEMBL485745	=	Inhibition	%	10.91	CHEMBL3045	Homo sapiens	Inhibition	%	10.91
	8069450	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	CN1CCN(c2ccc(Nc3nccc(-c4cnn5ncccc45)n3)cc2C(F)(F)F)CC1		CHEMBL468963	=	Inhibition	%	3.89	CHEMBL3045	Homo sapiens	Inhibition	%	3.89
	8069455	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	CN1CCN(c2ccc(Nc3nccc(-c4cnn5ncccc45)n3)cc2C(F)(F)F)CC1		CHEMBL468963	=	Inhibition	%	6.74	CHEMBL3045	Homo sapiens	Inhibition	%	6.74
	8069616	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	Cl.N#Cc1cccc(Nc2ncc(-c3ccccc3)o2)c1		CHEMBL1794061	=	Inhibition	%	1.2	CHEMBL3045	Homo sapiens	Inhibition	%	1.2
	8069835	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	Cc1cc(Cl)cc2c1NC(=O)C2=NNc1ccc(S(N)(=O)=O)cc1		CHEMBL1909397	=	Inhibition	%	0.78	CHEMBL3045	Homo sapiens	Inhibition	%	0.78
	8069840	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	Cc1cc(Cl)cc2c1NC(=O)C2=NNc1ccc(S(N)(=O)=O)cc1		CHEMBL1909397	=	Inhibition	%	0.04	CHEMBL3045	Homo sapiens	Inhibition	%	0.04
	8069961	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	N#Cc1c(NC(=O)c2ccc(F)cc2)sc2c1CCCC2		CHEMBL397570	=	Inhibition	%	2.12	CHEMBL3045	Homo sapiens	Inhibition	%	2.12
	8069966	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	N#Cc1c(NC(=O)c2ccc(F)cc2)sc2c1CCCC2		CHEMBL397570	=	Inhibition	%	0.69	CHEMBL3045	Homo sapiens	Inhibition	%	0.69
	8070357	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	COc1ccc2cc(-c3c(-c4ccncc4)nc(-c4ccc([S+](C)[O-])cc4)n3C)ccc2c1		CHEMBL399410	=	Inhibition	%	7.1	CHEMBL3045	Homo sapiens	Inhibition	%	7.1
	8070362	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	COc1ccc2cc(-c3c(-c4ccncc4)nc(-c4ccc([S+](C)[O-])cc4)n3C)ccc2c1		CHEMBL399410	=	Inhibition	%	3.79	CHEMBL3045	Homo sapiens	Inhibition	%	3.79
	8070482	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	CC(C)c1ccc(-c2cc(-c3c[nH]nc3-c3ccccn3)ccn2)cc1		CHEMBL206544	=	Inhibition	%	2.16	CHEMBL3045	Homo sapiens	Inhibition	%	2.16
	8070487	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	CC(C)c1ccc(-c2cc(-c3c[nH]nc3-c3ccccn3)ccn2)cc1		CHEMBL206544	=	Inhibition	%	0.43	CHEMBL3045	Homo sapiens	Inhibition	%	0.43
	8070706	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	CC(C)c1ccc(-c2cc(-c3c[nH]nc3-c3ccccn3)ccn2)cc1		CHEMBL206544	=	Inhibition	%	3.68	CHEMBL3045	Homo sapiens	Inhibition	%	3.68
	8070711	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	CC(C)c1ccc(-c2cc(-c3c[nH]nc3-c3ccccn3)ccn2)cc1		CHEMBL206544	=	Inhibition	%	1.4	CHEMBL3045	Homo sapiens	Inhibition	%	1.4
	8070780	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	CN1CCN(c2ccc(Nc3nccc(-c4cnn5ncccc45)n3)cc2C(F)(F)F)CC1		CHEMBL468963	=	Inhibition	%	25.89	CHEMBL3045	Homo sapiens	Inhibition	%	25.89
	8070785	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	CN1CCN(c2ccc(Nc3nccc(-c4cnn5ncccc45)n3)cc2C(F)(F)F)CC1		CHEMBL468963	=	Inhibition	%	36.33	CHEMBL3045	Homo sapiens	Inhibition	%	36.33
	8071161	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	Cc1cc(Cl)cc2c1NC(=O)C2=NNc1ccc(S(N)(=O)=O)cc1		CHEMBL1909397	=	Inhibition	%	2.56	CHEMBL3045	Homo sapiens	Inhibition	%	2.56
	8071166	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	Cc1cc(Cl)cc2c1NC(=O)C2=NNc1ccc(S(N)(=O)=O)cc1		CHEMBL1909397	=	Inhibition	%	1.07	CHEMBL3045	Homo sapiens	Inhibition	%	1.07
	8071287	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	Cc1cccc(-c2n[nH]cc2-c2ccc3ncccc3n2)n1		CHEMBL185238	=	Inhibition	%	0.17	CHEMBL3045	Homo sapiens	Inhibition	%	0.17
	8071292	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	Cc1cccc(-c2n[nH]cc2-c2ccc3ncccc3n2)n1		CHEMBL185238	=	Inhibition	%	0.52	CHEMBL3045	Homo sapiens	Inhibition	%	0.52
	8071511	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	Cc1cccc(-c2n[nH]cc2-c2ccc3ncccc3n2)n1		CHEMBL185238	=	Inhibition	%	0.39	CHEMBL3045	Homo sapiens	Inhibition	%	0.39
	8071516	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	Cc1cccc(-c2n[nH]cc2-c2ccc3ncccc3n2)n1		CHEMBL185238	=	Inhibition	%	0.49	CHEMBL3045	Homo sapiens	Inhibition	%	0.49
	8071684	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	O=C(Nc1n[nH]c2nc(-c3ccco3)c(Br)cc12)C1CC1		CHEMBL408564	=	Inhibition	%	1.29	CHEMBL3045	Homo sapiens	Inhibition	%	1.29
	8071689	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	O=C(Nc1n[nH]c2nc(-c3ccco3)c(Br)cc12)C1CC1		CHEMBL408564	=	Inhibition	%	0.69	CHEMBL3045	Homo sapiens	Inhibition	%	0.69
	8072033	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	COC(=O)Nc1nc2ccc(Oc3ccc(NC(=O)Nc4cc(C(F)(F)F)ccc4F)cc3)cc2s1.Cl		CHEMBL1909369	=	Inhibition	%	1.64	CHEMBL3045	Homo sapiens	Inhibition	%	1.64
	8072038	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	COC(=O)Nc1nc2ccc(Oc3ccc(NC(=O)Nc4cc(C(F)(F)F)ccc4F)cc3)cc2s1.Cl		CHEMBL1909369	=	Inhibition	%	-0.19	CHEMBL3045	Homo sapiens	Inhibition	%	-0.19
	8072123	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	COC(=O)Nc1nc2cc(Oc3cccc(NC(=O)Nc4cc(C(F)(F)F)ccc4F)c3)ccc2[nH]1.Cl		CHEMBL1909366	=	Inhibition	%	0.04	CHEMBL3045	Homo sapiens	Inhibition	%	0.04
	8072128	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	COC(=O)Nc1nc2cc(Oc3cccc(NC(=O)Nc4cc(C(F)(F)F)ccc4F)c3)ccc2[nH]1.Cl		CHEMBL1909366	=	Inhibition	%	3.01	CHEMBL3045	Homo sapiens	Inhibition	%	3.01
	8072347	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	COC(=O)Nc1nc2cc(Oc3cccc(NC(=O)Nc4cc(C(F)(F)F)ccc4F)c3)ccc2[nH]1.Cl		CHEMBL1909366	=	Inhibition	%	2.71	CHEMBL3045	Homo sapiens	Inhibition	%	2.71
	8072352	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	COC(=O)Nc1nc2cc(Oc3cccc(NC(=O)Nc4cc(C(F)(F)F)ccc4F)c3)ccc2[nH]1.Cl		CHEMBL1909366	=	Inhibition	%	1.79	CHEMBL3045	Homo sapiens	Inhibition	%	1.79
	8072504	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	COC(=O)Nc1nc2cc(Oc3ccc(NC(=O)Nc4ccccc4)cc3)ccc2[nH]1.Cl		CHEMBL1909371	=	Inhibition	%	1.53	CHEMBL3045	Homo sapiens	Inhibition	%	1.53
	8072509	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	COC(=O)Nc1nc2cc(Oc3ccc(NC(=O)Nc4ccccc4)cc3)ccc2[nH]1.Cl		CHEMBL1909371	=	Inhibition	%	0.28	CHEMBL3045	Homo sapiens	Inhibition	%	0.28
	8072853	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(OCc4ccccc4C(F)(F)F)c(C(=O)N(C)C)s3)c2cc1OC		CHEMBL482326	=	Inhibition	%	0.35	CHEMBL3045	Homo sapiens	Inhibition	%	0.35
	8072858	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(OCc4ccccc4C(F)(F)F)c(C(=O)N(C)C)s3)c2cc1OC		CHEMBL482326	=	Inhibition	%	0.03	CHEMBL3045	Homo sapiens	Inhibition	%	0.03
	8073020	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	O=C(Nc1n[nH]c2nc(-c3ccco3)c(Br)cc12)C1CC1		CHEMBL408564	=	Inhibition	%	-0.77	CHEMBL3045	Homo sapiens	Inhibition	%	-0.77
	8073025	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	O=C(Nc1n[nH]c2nc(-c3ccco3)c(Br)cc12)C1CC1		CHEMBL408564	=	Inhibition	%	1.19	CHEMBL3045	Homo sapiens	Inhibition	%	1.19
	8073369	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	COC(=O)Nc1nc2ccc(Oc3ccc(NC(=O)Nc4cc(C(F)(F)F)ccc4F)cc3)cc2s1.Cl		CHEMBL1909369	=	Inhibition	%	2.17	CHEMBL3045	Homo sapiens	Inhibition	%	2.17
	8073374	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	COC(=O)Nc1nc2ccc(Oc3ccc(NC(=O)Nc4cc(C(F)(F)F)ccc4F)cc3)cc2s1.Cl		CHEMBL1909369	=	Inhibition	%	-0.04	CHEMBL3045	Homo sapiens	Inhibition	%	-0.04
	8073488	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	Cc1ccc2c(c1)/C(=N/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2		CHEMBL271843	=	Inhibition	%	-0.92	CHEMBL3045	Homo sapiens	Inhibition	%	-0.92
	8073493	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	Cc1ccc2c(c1)/C(=N/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2		CHEMBL271843	=	Inhibition	%	0.19	CHEMBL3045	Homo sapiens	Inhibition	%	0.19
	8073712	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	Cc1ccc2c(c1)/C(=N/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2		CHEMBL271843	=	Inhibition	%	0.39	CHEMBL3045	Homo sapiens	Inhibition	%	0.39
	8073717	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	Cc1ccc2c(c1)/C(=N/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2		CHEMBL271843	=	Inhibition	%	0.09	CHEMBL3045	Homo sapiens	Inhibition	%	0.09
	8073945	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)nc(CN3CCCC3)cc21		CHEMBL1096290	=	Inhibition	%	3.02	CHEMBL3045	Homo sapiens	Inhibition	%	3.02
	8073950	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)nc(CN3CCCC3)cc21		CHEMBL1096290	=	Inhibition	%	3.25	CHEMBL3045	Homo sapiens	Inhibition	%	3.25
	8074097	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	COC(=O)Nc1nc2cc(Oc3ccc(NC(=O)Nc4ccccc4)cc3)ccc2[nH]1.Cl		CHEMBL1909371	=	Inhibition	%	2.12	CHEMBL3045	Homo sapiens	Inhibition	%	2.12
	8074102	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	COC(=O)Nc1nc2cc(Oc3ccc(NC(=O)Nc4ccccc4)cc3)ccc2[nH]1.Cl		CHEMBL1909371	=	Inhibition	%	0.72	CHEMBL3045	Homo sapiens	Inhibition	%	0.72
	8074451	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(OCc4ccccc4C(F)(F)F)c(C(=O)N(C)C)s3)c2cc1OC		CHEMBL482326	=	Inhibition	%	-0.32	CHEMBL3045	Homo sapiens	Inhibition	%	-0.32
	8074456	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(OCc4ccccc4C(F)(F)F)c(C(=O)N(C)C)s3)c2cc1OC		CHEMBL482326	=	Inhibition	%	0.09	CHEMBL3045	Homo sapiens	Inhibition	%	0.09
	8074608	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	NC(=O)Cc1ccccc1Oc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCNCC2)n1		CHEMBL1785002	=	Inhibition	%	-0.44	CHEMBL3045	Homo sapiens	Inhibition	%	-0.44
	8074613	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	NC(=O)Cc1ccccc1Oc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCNCC2)n1		CHEMBL1785002	=	Inhibition	%	1.22	CHEMBL3045	Homo sapiens	Inhibition	%	1.22
	8074832	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	NC(=O)Cc1ccccc1Oc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCNCC2)n1		CHEMBL1785002	=	Inhibition	%	3.18	CHEMBL3045	Homo sapiens	Inhibition	%	3.18
	8074837	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	NC(=O)Cc1ccccc1Oc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCNCC2)n1		CHEMBL1785002	=	Inhibition	%	3.91	CHEMBL3045	Homo sapiens	Inhibition	%	3.91
	8074959	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc(N2CCN(C(C)C)CC2)ccc1Nc1nc(Nc2cccc3ncccc23)c2cc[nH]c2n1		CHEMBL458438	=	Inhibition	%	-0.38	CHEMBL3045	Homo sapiens	Inhibition	%	-0.38
	8074964	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc(N2CCN(C(C)C)CC2)ccc1Nc1nc(Nc2cccc3ncccc23)c2cc[nH]c2n1		CHEMBL458438	=	Inhibition	%	-0.21	CHEMBL3045	Homo sapiens	Inhibition	%	-0.21
	8075294	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	Fc1ccc(-c2ncn(CCCN3CCOCC3)c2-c2ccncc2)cc1		CHEMBL14112	=	Inhibition	%	-0.46	CHEMBL3045	Homo sapiens	Inhibition	%	-0.46
	8075299	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	Fc1ccc(-c2ncn(CCCN3CCOCC3)c2-c2ccncc2)cc1		CHEMBL14112	=	Inhibition	%	0.1	CHEMBL3045	Homo sapiens	Inhibition	%	0.1
	8075531	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)nc(CN3CCCC3)cc21		CHEMBL1096290	=	Inhibition	%	14.17	CHEMBL3045	Homo sapiens	Inhibition	%	14.17
	8075536	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)nc(CN3CCCC3)cc21		CHEMBL1096290	=	Inhibition	%	6.65	CHEMBL3045	Homo sapiens	Inhibition	%	6.65
	8075672	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	O=C1NC(=O)C(c2cccc(Cl)c2)=C1Nc1ccc(Cl)c(C(=O)O)c1		CHEMBL156987	=	Inhibition	%	0.61	CHEMBL3045	Homo sapiens	Inhibition	%	0.61
	8075677	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	O=C1NC(=O)C(c2cccc(Cl)c2)=C1Nc1ccc(Cl)c(C(=O)O)c1		CHEMBL156987	=	Inhibition	%	1.0	CHEMBL3045	Homo sapiens	Inhibition	%	1.0
	8075896	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	O=C1NC(=O)C(c2cccc(Cl)c2)=C1Nc1ccc(Cl)c(C(=O)O)c1		CHEMBL156987	=	Inhibition	%	1.11	CHEMBL3045	Homo sapiens	Inhibition	%	1.11
	8075901	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	O=C1NC(=O)C(c2cccc(Cl)c2)=C1Nc1ccc(Cl)c(C(=O)O)c1		CHEMBL156987	=	Inhibition	%	1.2	CHEMBL3045	Homo sapiens	Inhibition	%	1.2
	8076038	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc2ncn(-c3cc(O[C@H](C)c4ccccc4C(F)(F)F)c(C(N)=O)s3)c2c1		CHEMBL522709	=	Inhibition	%	0.44	CHEMBL3045	Homo sapiens	Inhibition	%	0.44
	8076043	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc2ncn(-c3cc(O[C@H](C)c4ccccc4C(F)(F)F)c(C(N)=O)s3)c2c1		CHEMBL522709	=	Inhibition	%	-0.24	CHEMBL3045	Homo sapiens	Inhibition	%	-0.24
	8076410	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(OCCc4ccccc4)c(C(N)=O)s3)c2cc1OC		CHEMBL473629	=	Inhibition	%	0.05	CHEMBL3045	Homo sapiens	Inhibition	%	0.05
	8076415	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(OCCc4ccccc4)c(C(N)=O)s3)c2cc1OC		CHEMBL473629	=	Inhibition	%	0.9	CHEMBL3045	Homo sapiens	Inhibition	%	0.9
	8076544	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	COc1cc(N2CCN(C(C)C)CC2)ccc1Nc1nc(Nc2cccc3ncccc23)c2cc[nH]c2n1		CHEMBL458438	=	Inhibition	%	2.34	CHEMBL3045	Homo sapiens	Inhibition	%	2.34
	8076549	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	COc1cc(N2CCN(C(C)C)CC2)ccc1Nc1nc(Nc2cccc3ncccc23)c2cc[nH]c2n1		CHEMBL458438	=	Inhibition	%	0.45	CHEMBL3045	Homo sapiens	Inhibition	%	0.45
	8076870	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	Fc1ccc(-c2ncn(CCCN3CCOCC3)c2-c2ccncc2)cc1		CHEMBL14112	=	Inhibition	%	-0.8	CHEMBL3045	Homo sapiens	Inhibition	%	-0.8
	8076875	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	Fc1ccc(-c2ncn(CCCN3CCOCC3)c2-c2ccncc2)cc1		CHEMBL14112	=	Inhibition	%	0.17	CHEMBL3045	Homo sapiens	Inhibition	%	0.17
	8077117	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)nc(O[C@@H](CN)c3ccccc3)cc21.O=C(O)C(F)(F)F		CHEMBL1909349	=	Inhibition	%	44.84	CHEMBL3045	Homo sapiens	Inhibition	%	44.84
	8077122	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)nc(O[C@@H](CN)c3ccccc3)cc21.O=C(O)C(F)(F)F		CHEMBL1909349	=	Inhibition	%	49.25	CHEMBL3045	Homo sapiens	Inhibition	%	49.25
	8077469	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	Cc1nnc(-c2ccc(C)c(-c3ccc(C(=O)Nc4cccc(C#N)c4)cc3)c2)o1		CHEMBL270164	=	Inhibition	%	-0.92	CHEMBL3045	Homo sapiens	Inhibition	%	-0.92
	8077474	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	Cc1nnc(-c2ccc(C)c(-c3ccc(C(=O)Nc4cccc(C#N)c4)cc3)c2)o1		CHEMBL270164	=	Inhibition	%	1.09	CHEMBL3045	Homo sapiens	Inhibition	%	1.09
	8077620	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	COc1ccc2ncn(-c3cc(O[C@H](C)c4ccccc4C(F)(F)F)c(C(N)=O)s3)c2c1		CHEMBL522709	=	Inhibition	%	1.04	CHEMBL3045	Homo sapiens	Inhibition	%	1.04
	8077625	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	COc1ccc2ncn(-c3cc(O[C@H](C)c4ccccc4C(F)(F)F)c(C(N)=O)s3)c2c1		CHEMBL522709	=	Inhibition	%	0.08	CHEMBL3045	Homo sapiens	Inhibition	%	0.08
	8077987	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(OCCc4ccccc4)c(C(N)=O)s3)c2cc1OC		CHEMBL473629	=	Inhibition	%	-0.8	CHEMBL3045	Homo sapiens	Inhibition	%	-0.8
	8077992	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(OCCc4ccccc4)c(C(N)=O)s3)c2cc1OC		CHEMBL473629	=	Inhibition	%	1.22	CHEMBL3045	Homo sapiens	Inhibition	%	1.22
	8078126	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(Nc2cc(-c3ccc(O)c(F)c3)n[nH]2)cc1		CHEMBL103115	=	Inhibition	%	-0.01	CHEMBL3045	Homo sapiens	Inhibition	%	-0.01
	8078131	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(Nc2cc(-c3ccc(O)c(F)c3)n[nH]2)cc1		CHEMBL103115	=	Inhibition	%	-0.96	CHEMBL3045	Homo sapiens	Inhibition	%	-0.96
	8078350	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(Nc2cc(-c3ccc(O)c(F)c3)n[nH]2)cc1		CHEMBL103115	=	Inhibition	%	0.79	CHEMBL3045	Homo sapiens	Inhibition	%	0.79
	8078355	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(Nc2cc(-c3ccc(O)c(F)c3)n[nH]2)cc1		CHEMBL103115	=	Inhibition	%	0.72	CHEMBL3045	Homo sapiens	Inhibition	%	0.72
	8078452	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	Cl.ON=C1CCc2cc(-c3nc(C4CCNCC4)[nH]c3-c3ccncc3)ccc21		CHEMBL1794071	=	Inhibition	%	-0.12	CHEMBL3045	Homo sapiens	Inhibition	%	-0.12
	8078457	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	Cl.ON=C1CCc2cc(-c3nc(C4CCNCC4)[nH]c3-c3ccncc3)ccc21		CHEMBL1794071	=	Inhibition	%	0.45	CHEMBL3045	Homo sapiens	Inhibition	%	0.45
	8078702	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)nc(O[C@@H](CN)c3ccccc3)cc21.O=C(O)C(F)(F)F		CHEMBL1909349	=	Inhibition	%	71.44	CHEMBL3045	Homo sapiens	Inhibition	%	71.44
	8078707	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)nc(O[C@@H](CN)c3ccccc3)cc21.O=C(O)C(F)(F)F		CHEMBL1909349	=	Inhibition	%	80.54	CHEMBL3045	Homo sapiens	Inhibition	%	80.54
	8079042	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	Cc1nnc(-c2ccc(C)c(-c3ccc(C(=O)Nc4cccc(C#N)c4)cc3)c2)o1		CHEMBL270164	=	Inhibition	%	2.05	CHEMBL3045	Homo sapiens	Inhibition	%	2.05
	8079047	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	Cc1nnc(-c2ccc(C)c(-c3ccc(C(=O)Nc4cccc(C#N)c4)cc3)c2)o1		CHEMBL270164	=	Inhibition	%	1.38	CHEMBL3045	Homo sapiens	Inhibition	%	1.38
	8079200	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	C[C@@H](Oc1cc(-n2cnc3ccc(OC[C@@H](O)CO)cc32)sc1C(N)=O)c1ccccc1Cl		CHEMBL1794067	=	Inhibition	%	-0.38	CHEMBL3045	Homo sapiens	Inhibition	%	-0.38
	8079205	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	C[C@@H](Oc1cc(-n2cnc3ccc(OC[C@@H](O)CO)cc32)sc1C(N)=O)c1ccccc1Cl		CHEMBL1794067	=	Inhibition	%	-1.05	CHEMBL3045	Homo sapiens	Inhibition	%	-1.05
	8079424	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	C[C@@H](Oc1cc(-n2cnc3ccc(OC[C@@H](O)CO)cc32)sc1C(N)=O)c1ccccc1Cl		CHEMBL1794067	=	Inhibition	%	1.7	CHEMBL3045	Homo sapiens	Inhibition	%	1.7
	8079429	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	C[C@@H](Oc1cc(-n2cnc3ccc(OC[C@@H](O)CO)cc32)sc1C(N)=O)c1ccccc1Cl		CHEMBL1794067	=	Inhibition	%	2.03	CHEMBL3045	Homo sapiens	Inhibition	%	2.03
	8079566	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	Cl.[O-][S+]1CCN(Cc2ccc(-c3ccc4ncnc(Nc5ccc(OCc6ccccc6)c(F)c5)c4c3)o2)CC1		CHEMBL1909391	=	Inhibition	%	-0.89	CHEMBL3045	Homo sapiens	Inhibition	%	-0.89
	8079571	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	Cl.[O-][S+]1CCN(Cc2ccc(-c3ccc4ncnc(Nc5ccc(OCc6ccccc6)c(F)c5)c4c3)o2)CC1		CHEMBL1909391	=	Inhibition	%	0.35	CHEMBL3045	Homo sapiens	Inhibition	%	0.35
	8079929	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	CCCN1CCC(c2ccc(Nc3nc(Nc4cc(F)ccc4C(N)=O)c4cc[nH]c4n3)c(OC)c2)CC1		CHEMBL476259	=	Inhibition	%	0.19	CHEMBL3045	Homo sapiens	Inhibition	%	0.19
	8079934	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	CCCN1CCC(c2ccc(Nc3nc(Nc4cc(F)ccc4C(N)=O)c4cc[nH]c4n3)c(OC)c2)CC1		CHEMBL476259	=	Inhibition	%	1.54	CHEMBL3045	Homo sapiens	Inhibition	%	1.54
	8080034	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	Cl.ON=C1CCc2cc(-c3nc(C4CCNCC4)[nH]c3-c3ccncc3)ccc21		CHEMBL1794071	=	Inhibition	%	11.1	CHEMBL3045	Homo sapiens	Inhibition	%	11.1
	8080039	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	Cl.ON=C1CCc2cc(-c3nc(C4CCNCC4)[nH]c3-c3ccncc3)ccc21		CHEMBL1794071	=	Inhibition	%	7.96	CHEMBL3045	Homo sapiens	Inhibition	%	7.96
	8080258	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	O=C1NC(=O)C(c2cccc(Cl)c2)=C1Nc1ccc(O)c(Cl)c1		CHEMBL160333	=	Inhibition	%	0.44	CHEMBL3045	Homo sapiens	Inhibition	%	0.44
	8080263	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	O=C1NC(=O)C(c2cccc(Cl)c2)=C1Nc1ccc(O)c(Cl)c1		CHEMBL160333	=	Inhibition	%	0.56	CHEMBL3045	Homo sapiens	Inhibition	%	0.56
	8080286	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	CC(C)COC(=O)c1ccc2c(c1)/C(=C/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2		CHEMBL269883	=	Inhibition	%	3.19	CHEMBL3045	Homo sapiens	Inhibition	%	3.19
	8080291	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	CC(C)COC(=O)c1ccc2c(c1)/C(=C/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2		CHEMBL269883	=	Inhibition	%	3.37	CHEMBL3045	Homo sapiens	Inhibition	%	3.37
	8080510	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	CC(C)COC(=O)c1ccc2c(c1)/C(=C/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2		CHEMBL269883	=	Inhibition	%	5.57	CHEMBL3045	Homo sapiens	Inhibition	%	5.57
	8080515	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	CC(C)COC(=O)c1ccc2c(c1)/C(=C/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2		CHEMBL269883	=	Inhibition	%	6.47	CHEMBL3045	Homo sapiens	Inhibition	%	6.47
	8080625	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc2ncnc(Nc3ccc(OCc4ccccc4)cc3)c2c1.Cl		CHEMBL1909411	=	Inhibition	%	0.57	CHEMBL3045	Homo sapiens	Inhibition	%	0.57
	8080630	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc2ncnc(Nc3ccc(OCc4ccccc4)cc3)c2c1.Cl		CHEMBL1909411	=	Inhibition	%	0.9	CHEMBL3045	Homo sapiens	Inhibition	%	0.9
	8081013	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	Cl.Nc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCNCC2)n1		CHEMBL1909407	=	Inhibition	%	1.41	CHEMBL3045	Homo sapiens	Inhibition	%	1.41
	8081018	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	Cl.Nc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCNCC2)n1		CHEMBL1909407	=	Inhibition	%	3.39	CHEMBL3045	Homo sapiens	Inhibition	%	3.39
	8081148	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	Cl.[O-][S+]1CCN(Cc2ccc(-c3ccc4ncnc(Nc5ccc(OCc6ccccc6)c(F)c5)c4c3)o2)CC1		CHEMBL1909391	=	Inhibition	%	-0.42	CHEMBL3045	Homo sapiens	Inhibition	%	-0.42
	8081153	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	Cl.[O-][S+]1CCN(Cc2ccc(-c3ccc4ncnc(Nc5ccc(OCc6ccccc6)c(F)c5)c4c3)o2)CC1		CHEMBL1909391	=	Inhibition	%	0.5	CHEMBL3045	Homo sapiens	Inhibition	%	0.5
	8081516	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	CCCN1CCC(c2ccc(Nc3nc(Nc4cc(F)ccc4C(N)=O)c4cc[nH]c4n3)c(OC)c2)CC1		CHEMBL476259	=	Inhibition	%	4.9	CHEMBL3045	Homo sapiens	Inhibition	%	4.9
	8081521	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	CCCN1CCC(c2ccc(Nc3nc(Nc4cc(F)ccc4C(N)=O)c4cc[nH]c4n3)c(OC)c2)CC1		CHEMBL476259	=	Inhibition	%	6.05	CHEMBL3045	Homo sapiens	Inhibition	%	6.05
	8081843	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	O=C1NC(=O)C(c2cccc(Cl)c2)=C1Nc1ccc(O)c(Cl)c1		CHEMBL160333	=	Inhibition	%	4.94	CHEMBL3045	Homo sapiens	Inhibition	%	4.94
	8081848	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	O=C1NC(=O)C(c2cccc(Cl)c2)=C1Nc1ccc(O)c(Cl)c1		CHEMBL160333	=	Inhibition	%	8.45	CHEMBL3045	Homo sapiens	Inhibition	%	8.45
	8082095	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	Nc1nonc1-c1nc2cnccc2n1C1CCCCC1		CHEMBL189231	=	Inhibition	%	30.98	CHEMBL3045	Homo sapiens	Inhibition	%	30.98
	8082100	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	Nc1nonc1-c1nc2cnccc2n1C1CCCCC1		CHEMBL189231	=	Inhibition	%	6.66	CHEMBL3045	Homo sapiens	Inhibition	%	6.66
	8082208	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	COc1ccc2ncnc(Nc3ccc(OCc4ccccc4)cc3)c2c1.Cl		CHEMBL1909411	=	Inhibition	%	2.16	CHEMBL3045	Homo sapiens	Inhibition	%	2.16
	8082213	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	COc1ccc2ncnc(Nc3ccc(OCc4ccccc4)cc3)c2c1.Cl		CHEMBL1909411	=	Inhibition	%	1.9	CHEMBL3045	Homo sapiens	Inhibition	%	1.9
	8082432	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	CN1CCC(n2cnc(-c3ccc(F)cc3)c2-c2ccnc(N)n2)CC1		CHEMBL95207	=	Inhibition	%	0.83	CHEMBL3045	Homo sapiens	Inhibition	%	0.83
	8082437	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	CN1CCC(n2cnc(-c3ccc(F)cc3)c2-c2ccnc(N)n2)CC1		CHEMBL95207	=	Inhibition	%	2.83	CHEMBL3045	Homo sapiens	Inhibition	%	2.83
	8082605	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	Cl.Nc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCNCC2)n1		CHEMBL1909407	=	Inhibition	%	17.89	CHEMBL3045	Homo sapiens	Inhibition	%	17.89
	8082610	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	Cl.Nc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCNCC2)n1		CHEMBL1909407	=	Inhibition	%	28.41	CHEMBL3045	Homo sapiens	Inhibition	%	28.41
	8082728	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	Cc1ccc(C(=O)NC2CCC2)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL517507	=	Inhibition	%	0.31	CHEMBL3045	Homo sapiens	Inhibition	%	0.31
	8082733	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	Cc1ccc(C(=O)NC2CCC2)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL517507	=	Inhibition	%	0.24	CHEMBL3045	Homo sapiens	Inhibition	%	0.24
	8082952	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	Cc1ccc(C(=O)NC2CCC2)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL517507	=	Inhibition	%	1.48	CHEMBL3045	Homo sapiens	Inhibition	%	1.48
	8082957	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	Cc1ccc(C(=O)NC2CCC2)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL517507	=	Inhibition	%	0.53	CHEMBL3045	Homo sapiens	Inhibition	%	0.53
	8083108	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc(C(=O)NCCCn4ccnc4)cc32)cc1		CHEMBL272026	=	Inhibition	%	0.75	CHEMBL3045	Homo sapiens	Inhibition	%	0.75
	8083113	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc(C(=O)NCCCn4ccnc4)cc32)cc1		CHEMBL272026	=	Inhibition	%	2.11	CHEMBL3045	Homo sapiens	Inhibition	%	2.11
	8083431	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)Nc1cccc(-c2ccc3c(NC(=O)C4CC4)n[nH]c3c2)c1		CHEMBL103080	=	Inhibition	%	-1.18	CHEMBL3045	Homo sapiens	Inhibition	%	-1.18
	8083436	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)Nc1cccc(-c2ccc3c(NC(=O)C4CC4)n[nH]c3c2)c1		CHEMBL103080	=	Inhibition	%	-0.25	CHEMBL3045	Homo sapiens	Inhibition	%	-0.25
	8083685	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	Nc1nonc1-c1nc2cnccc2n1C1CCCCC1		CHEMBL189231	=	Inhibition	%	65.26	CHEMBL3045	Homo sapiens	Inhibition	%	65.26
	8083690	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	Nc1nonc1-c1nc2cnccc2n1C1CCCCC1		CHEMBL189231	=	Inhibition	%	33.69	CHEMBL3045	Homo sapiens	Inhibition	%	33.69
	8084019	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	CN1CCC(n2cnc(-c3ccc(F)cc3)c2-c2ccnc(N)n2)CC1		CHEMBL95207	=	Inhibition	%	7.02	CHEMBL3045	Homo sapiens	Inhibition	%	7.02
	8084024	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	CN1CCC(n2cnc(-c3ccc(F)cc3)c2-c2ccnc(N)n2)CC1		CHEMBL95207	=	Inhibition	%	12.35	CHEMBL3045	Homo sapiens	Inhibition	%	12.35
	8084204	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc4ncccc4c32)cc1		CHEMBL409892	=	Inhibition	%	-0.44	CHEMBL3045	Homo sapiens	Inhibition	%	-0.44
	8084209	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc4ncccc4c32)cc1		CHEMBL409892	=	Inhibition	%	1.28	CHEMBL3045	Homo sapiens	Inhibition	%	1.28
	8084546	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	CN(C)c1cc2c(Nc3ccc4c(cnn4Cc4ccccc4)c3)ncnc2cn1		CHEMBL30432	=	Inhibition	%	0.49	CHEMBL3045	Homo sapiens	Inhibition	%	0.49
	8084551	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	CN(C)c1cc2c(Nc3ccc4c(cnn4Cc4ccccc4)c3)ncnc2cn1		CHEMBL30432	=	Inhibition	%	0.51	CHEMBL3045	Homo sapiens	Inhibition	%	0.51
	8084707	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc(C(=O)NCCCn4ccnc4)cc32)cc1		CHEMBL272026	=	Inhibition	%	3.15	CHEMBL3045	Homo sapiens	Inhibition	%	3.15
	8084712	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc(C(=O)NCCCn4ccnc4)cc32)cc1		CHEMBL272026	=	Inhibition	%	4.2	CHEMBL3045	Homo sapiens	Inhibition	%	4.2
	8085029	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)Nc1cccc(-c2ccc3c(NC(=O)C4CC4)n[nH]c3c2)c1		CHEMBL103080	=	Inhibition	%	-0.16	CHEMBL3045	Homo sapiens	Inhibition	%	-0.16
	8085034	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)Nc1cccc(-c2ccc3c(NC(=O)C4CC4)n[nH]c3c2)c1		CHEMBL103080	=	Inhibition	%	0.61	CHEMBL3045	Homo sapiens	Inhibition	%	0.61
	8085285	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc(C=NNc2ncnc3c2cnn3Cc2ccccc2)ccc1O		CHEMBL1789962	=	Inhibition	%	0.36	CHEMBL3045	Homo sapiens	Inhibition	%	0.36
	8085290	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc(C=NNc2ncnc3c2cnn3Cc2ccccc2)ccc1O		CHEMBL1789962	=	Inhibition	%	-1.09	CHEMBL3045	Homo sapiens	Inhibition	%	-1.09
	8085617	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	CN1CCC(n2cnc(-c3ccc(F)cc3)c2-c2ccnc(Nc3ccccc3)n2)CC1		CHEMBL318892	=	Inhibition	%	16.14	CHEMBL3045	Homo sapiens	Inhibition	%	16.14
	8085622	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	CN1CCC(n2cnc(-c3ccc(F)cc3)c2-c2ccnc(Nc3ccccc3)n2)CC1		CHEMBL318892	=	Inhibition	%	27.36	CHEMBL3045	Homo sapiens	Inhibition	%	27.36
	8085806	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc4ncccc4c32)cc1		CHEMBL409892	=	Inhibition	%	-0.03	CHEMBL3045	Homo sapiens	Inhibition	%	-0.03
	8085811	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc4ncccc4c32)cc1		CHEMBL409892	=	Inhibition	%	3.78	CHEMBL3045	Homo sapiens	Inhibition	%	3.78
	8086145	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	CN(C)c1cc2c(Nc3ccc4c(cnn4Cc4ccccc4)c3)ncnc2cn1		CHEMBL30432	=	Inhibition	%	1.62	CHEMBL3045	Homo sapiens	Inhibition	%	1.62
	8086150	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	CN(C)c1cc2c(Nc3ccc4c(cnn4Cc4ccccc4)c3)ncnc2cn1		CHEMBL30432	=	Inhibition	%	0.93	CHEMBL3045	Homo sapiens	Inhibition	%	0.93
	8086307	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	CN1CCC(C(=O)Nc2n[nH]c3nc(-c4ccc(O)cc4)c(Br)cc23)CC1		CHEMBL261129	=	Inhibition	%	2.04	CHEMBL3045	Homo sapiens	Inhibition	%	2.04
	8086312	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	CN1CCC(C(=O)Nc2n[nH]c3nc(-c4ccc(O)cc4)c(Br)cc23)CC1		CHEMBL261129	=	Inhibition	%	6.51	CHEMBL3045	Homo sapiens	Inhibition	%	6.51
	8086531	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	CN1CCC(C(=O)Nc2n[nH]c3nc(-c4ccc(O)cc4)c(Br)cc23)CC1		CHEMBL261129	=	Inhibition	%	13.92	CHEMBL3045	Homo sapiens	Inhibition	%	13.92
	8086536	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	CN1CCC(C(=O)Nc2n[nH]c3nc(-c4ccc(O)cc4)c(Br)cc23)CC1		CHEMBL261129	=	Inhibition	%	30.54	CHEMBL3045	Homo sapiens	Inhibition	%	30.54
	8086630	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2ccncc21		CHEMBL185710	=	Inhibition	%	-0.82	CHEMBL3045	Homo sapiens	Inhibition	%	-0.82
	8086635	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2ccncc21		CHEMBL185710	=	Inhibition	%	-0.19	CHEMBL3045	Homo sapiens	Inhibition	%	-0.19
	8086854	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2ccncc21		CHEMBL185710	=	Inhibition	%	1.95	CHEMBL3045	Homo sapiens	Inhibition	%	1.95
	8087065	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	CNC(=O)c1cncc(/C=C/c2c(Cl)cccc2Cl)c1		CHEMBL263796	=	Inhibition	%	0.23	CHEMBL3045	Homo sapiens	Inhibition	%	0.23
	8087070	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	CNC(=O)c1cncc(/C=C/c2c(Cl)cccc2Cl)c1		CHEMBL263796	=	Inhibition	%	1.27	CHEMBL3045	Homo sapiens	Inhibition	%	1.27
	8087223	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	CCC(=O)Nc1ccc(C)c(-c2ccc(C(=O)NCC3CC3)cc2)c1		CHEMBL517666	=	Inhibition	%	0.07	CHEMBL3045	Homo sapiens	Inhibition	%	0.07
	8087228	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	CCC(=O)Nc1ccc(C)c(-c2ccc(C(=O)NCC3CC3)cc2)c1		CHEMBL517666	=	Inhibition	%	0.61	CHEMBL3045	Homo sapiens	Inhibition	%	0.61
	8087561	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccccc1Nc1ncc(-c2ccccc2)o1.Cl		CHEMBL1794062	=	Inhibition	%	1.34	CHEMBL3045	Homo sapiens	Inhibition	%	1.34
	8087566	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccccc1Nc1ncc(-c2ccccc2)o1.Cl		CHEMBL1794062	=	Inhibition	%	1.12	CHEMBL3045	Homo sapiens	Inhibition	%	1.12
	8087699	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	CN1CCN(Cc2ccc(-c3cc4ncnc(Nc5ccc(OCc6cccc(F)c6)c(Cl)c5)c4s3)o2)CC1		CHEMBL475761	=	Inhibition	%	0.12	CHEMBL3045	Homo sapiens	Inhibition	%	0.12
	8087704	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	CN1CCN(Cc2ccc(-c3cc4ncnc(Nc5ccc(OCc6cccc(F)c6)c(Cl)c5)c4s3)o2)CC1		CHEMBL475761	=	Inhibition	%	2.27	CHEMBL3045	Homo sapiens	Inhibition	%	2.27
	8087923	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	Fc1ccc(-c2ncn(C3CCNCC3)c2-c2ccnc(Oc3ccccc3)n2)cc1		CHEMBL275798	=	Inhibition	%	0.95	CHEMBL3045	Homo sapiens	Inhibition	%	0.95
	8087928	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	Fc1ccc(-c2ncn(C3CCNCC3)c2-c2ccnc(Oc3ccccc3)n2)cc1		CHEMBL275798	=	Inhibition	%	1.22	CHEMBL3045	Homo sapiens	Inhibition	%	1.22
	8088065	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2cncc(C(=O)N3CCNCC3)c21.Cl		CHEMBL1909376	=	Inhibition	%	4.3	CHEMBL3045	Homo sapiens	Inhibition	%	4.3
	8088070	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2cncc(C(=O)N3CCNCC3)c21.Cl		CHEMBL1909376	=	Inhibition	%	3.67	CHEMBL3045	Homo sapiens	Inhibition	%	3.67
	8088437	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)Nc1ccc(-c2cc(-c3ccccc3)cc(C(N)=O)c2N)cc1		CHEMBL230597	=	Inhibition	%	-0.92	CHEMBL3045	Homo sapiens	Inhibition	%	-0.92
	8088442	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)Nc1ccc(-c2cc(-c3ccccc3)cc(C(N)=O)c2N)cc1		CHEMBL230597	=	Inhibition	%	1.98	CHEMBL3045	Homo sapiens	Inhibition	%	1.98
	8088565	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(O[C@@H](C)c4ccccc4Cl)c(C(N)=O)s3)c2cc1OC		CHEMBL521806	=	Inhibition	%	3.42	CHEMBL3045	Homo sapiens	Inhibition	%	3.42
	8088570	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(O[C@@H](C)c4ccccc4Cl)c(C(N)=O)s3)c2cc1OC		CHEMBL521806	=	Inhibition	%	1.99	CHEMBL3045	Homo sapiens	Inhibition	%	1.99
	8088882	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2ccccc21		CHEMBL365286	=	Inhibition	%	46.48	CHEMBL3045	Homo sapiens	Inhibition	%	46.48
	8088887	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2ccccc21		CHEMBL365286	=	Inhibition	%	7.2	CHEMBL3045	Homo sapiens	Inhibition	%	7.2
	8089234	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	CCCN1CCC(Oc2cc(Nc3nc(Nc4cccc(F)c4C(N)=O)c4cc[nH]c4n3)c(OC)cc2Cl)CC1		CHEMBL517171	=	Inhibition	%	1.21	CHEMBL3045	Homo sapiens	Inhibition	%	1.21
	8089239	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	CCCN1CCC(Oc2cc(Nc3nc(Nc4cccc(F)c4C(N)=O)c4cc[nH]c4n3)c(OC)cc2Cl)CC1		CHEMBL517171	=	Inhibition	%	4.52	CHEMBL3045	Homo sapiens	Inhibition	%	4.52
	8089382	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	CC(C)=Cc1cccc2c1/C(=N/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2		CHEMBL270544	=	Inhibition	%	0.26	CHEMBL3045	Homo sapiens	Inhibition	%	0.26
	8089387	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	CC(C)=Cc1cccc2c1/C(=N/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2		CHEMBL270544	=	Inhibition	%	0.32	CHEMBL3045	Homo sapiens	Inhibition	%	0.32
	8089726	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	CCS(=O)(=O)c1ccc(OC)c(Nc2ncc(-c3ccccc3Cl)o2)c1		CHEMBL179453	=	Inhibition	%	0.67	CHEMBL3045	Homo sapiens	Inhibition	%	0.67
	8089731	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	CCS(=O)(=O)c1ccc(OC)c(Nc2ncc(-c3ccccc3Cl)o2)c1		CHEMBL179453	=	Inhibition	%	-0.13	CHEMBL3045	Homo sapiens	Inhibition	%	-0.13
	8089906	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	Nc1nccc(-c2c(-c3ccc(F)cc3)nn3cc(C(F)(F)F)ccc23)n1		CHEMBL1909402	=	Inhibition	%	0.52	CHEMBL3045	Homo sapiens	Inhibition	%	0.52
	8089911	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	Nc1nccc(-c2c(-c3ccc(F)cc3)nn3cc(C(F)(F)F)ccc23)n1		CHEMBL1909402	=	Inhibition	%	2.07	CHEMBL3045	Homo sapiens	Inhibition	%	2.07
	8090130	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	Cc1cc(-c2ccco2)cc(C)c1/C=C/c1cncc(-c2nn[nH]n2)c1.Cl		CHEMBL1909353	=	Inhibition	%	-0.49	CHEMBL3045	Homo sapiens	Inhibition	%	-0.49
	8090135	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	Cc1cc(-c2ccco2)cc(C)c1/C=C/c1cncc(-c2nn[nH]n2)c1.Cl		CHEMBL1909353	=	Inhibition	%	-0.04	CHEMBL3045	Homo sapiens	Inhibition	%	-0.04
	8090295	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	COc1cc2c(cc1Nc1nc(Nc3cccc(F)c3C(N)=O)c3cc[nH]c3n1)N(C(=O)CN1CCN(C(C)C)CC1)CC2		CHEMBL505915	=	Inhibition	%	3.47	CHEMBL3045	Homo sapiens	Inhibition	%	3.47
	8090300	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	COc1cc2c(cc1Nc1nc(Nc3cccc(F)c3C(N)=O)c3cc[nH]c3n1)N(C(=O)CN1CCN(C(C)C)CC1)CC2		CHEMBL505915	=	Inhibition	%	2.64	CHEMBL3045	Homo sapiens	Inhibition	%	2.64
	8090462	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	Cc1nc(-c2ccccc2)n2nc(NCCCN3CCOCC3)ncc12		CHEMBL486124	=	Inhibition	%	-0.19	CHEMBL3045	Homo sapiens	Inhibition	%	-0.19
	8090467	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	Cc1nc(-c2ccccc2)n2nc(NCCCN3CCOCC3)ncc12		CHEMBL486124	=	Inhibition	%	1.18	CHEMBL3045	Homo sapiens	Inhibition	%	1.18
	8090825	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	CN(c1ccc(NC(=O)Nc2ccc(OC(F)(F)F)cc2)cc1)c1ccnc(Nc2cccc(S(N)(=O)=O)c2)n1		CHEMBL188381	=	Inhibition	%	0.45	CHEMBL3045	Homo sapiens	Inhibition	%	0.45
	8090830	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	CN(c1ccc(NC(=O)Nc2ccc(OC(F)(F)F)cc2)cc1)c1ccnc(Nc2cccc(S(N)(=O)=O)c2)n1		CHEMBL188381	=	Inhibition	%	-0.08	CHEMBL3045	Homo sapiens	Inhibition	%	-0.08
	8091030	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5ccccc5)cc4)c3c2)o1.Cl		CHEMBL1909385	=	Inhibition	%	1.41	CHEMBL3045	Homo sapiens	Inhibition	%	1.41
	8091035	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5ccccc5)cc4)c3c2)o1.Cl		CHEMBL1909385	=	Inhibition	%	0.51	CHEMBL3045	Homo sapiens	Inhibition	%	0.51
	8091391	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	CCCN1CCC=C(c2ccc(Nc3nc(Nc4ccccc4C(N)=O)c4cc[nH]c4n3)c(C)c2)C1		CHEMBL513897	=	Inhibition	%	-0.14	CHEMBL3045	Homo sapiens	Inhibition	%	-0.14
	8091396	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	CCCN1CCC=C(c2ccc(Nc3nc(Nc4ccccc4C(N)=O)c4cc[nH]c4n3)c(C)c2)C1		CHEMBL513897	=	Inhibition	%	1.44	CHEMBL3045	Homo sapiens	Inhibition	%	1.44
	8091546	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	CCC(=O)Nc1ccc(C)c(-c2ccc(C(=O)NCC3CC3)cc2)c1		CHEMBL517666	=	Inhibition	%	-0.89	CHEMBL3045	Homo sapiens	Inhibition	%	-0.89
	8091551	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	CCC(=O)Nc1ccc(C)c(-c2ccc(C(=O)NCC3CC3)cc2)c1		CHEMBL517666	=	Inhibition	%	1.48	CHEMBL3045	Homo sapiens	Inhibition	%	1.48
	8091770	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc2ncnc(Nc3ccc4c(cnn4Cc4ccccc4)c3)c2cc1OC.Cl		CHEMBL1909380	=	Inhibition	%	0.81	CHEMBL3045	Homo sapiens	Inhibition	%	0.81
	8091775	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc2ncnc(Nc3ccc4c(cnn4Cc4ccccc4)c3)c2cc1OC.Cl		CHEMBL1909380	=	Inhibition	%	0.94	CHEMBL3045	Homo sapiens	Inhibition	%	0.94
	8091886	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	COc1ccccc1Nc1ncc(-c2ccccc2)o1.Cl		CHEMBL1794062	=	Inhibition	%	-6.48	CHEMBL3045	Homo sapiens	Inhibition	%	-6.48
	8091891	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	COc1ccccc1Nc1ncc(-c2ccccc2)o1.Cl		CHEMBL1794062	=	Inhibition	%	1.8	CHEMBL3045	Homo sapiens	Inhibition	%	1.8
	8092247	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	Fc1ccc(-c2ncn(C3CCNCC3)c2-c2ccnc(Oc3ccccc3)n2)cc1		CHEMBL275798	=	Inhibition	%	8.43	CHEMBL3045	Homo sapiens	Inhibition	%	8.43
	8092252	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	Fc1ccc(-c2ncn(C3CCNCC3)c2-c2ccnc(Oc3ccccc3)n2)cc1		CHEMBL275798	=	Inhibition	%	5.65	CHEMBL3045	Homo sapiens	Inhibition	%	5.65
	8092398	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1cc(-c2cc3c(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)ncnc3s2)cs1		CHEMBL475599	=	Inhibition	%	0.43	CHEMBL3045	Homo sapiens	Inhibition	%	0.43
	8092403	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1cc(-c2cc3c(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)ncnc3s2)cs1		CHEMBL475599	=	Inhibition	%	0.62	CHEMBL3045	Homo sapiens	Inhibition	%	0.62
	8092770	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	Fc1cccc(COc2ccc(Nc3ncnc4sc(-c5cccs5)cc34)cc2Cl)c1		CHEMBL506414	=	Inhibition	%	-0.52	CHEMBL3045	Homo sapiens	Inhibition	%	-0.52
	8092775	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	Fc1cccc(COc2ccc(Nc3ncnc4sc(-c5cccs5)cc34)cc2Cl)c1		CHEMBL506414	=	Inhibition	%	-0.19	CHEMBL3045	Homo sapiens	Inhibition	%	-0.19
	8092899	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(O[C@@H](C)c4ccccc4Cl)c(C(N)=O)s3)c2cc1OC		CHEMBL521806	=	Inhibition	%	4.55	CHEMBL3045	Homo sapiens	Inhibition	%	4.55
	8092904	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(O[C@@H](C)c4ccccc4Cl)c(C(N)=O)s3)c2cc1OC		CHEMBL521806	=	Inhibition	%	5.36	CHEMBL3045	Homo sapiens	Inhibition	%	5.36
	8093123	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc2ncn(-c3cc(O[C@H](C)c4ccccc4Cl)c(C(N)=O)s3)c2c1		CHEMBL493326	=	Inhibition	%	1.09	CHEMBL3045	Homo sapiens	Inhibition	%	1.09
	8093128	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc2ncn(-c3cc(O[C@H](C)c4ccccc4Cl)c(C(N)=O)s3)c2c1		CHEMBL493326	=	Inhibition	%	1.24	CHEMBL3045	Homo sapiens	Inhibition	%	1.24
	8093211	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	O=C(O)/C=C/C(=O)O.OCCCNc1nccc(-c2c(-c3ccc(F)cc3)nn3cc(C(F)(F)F)ccc23)n1		CHEMBL1909403	=	Inhibition	%	3.23	CHEMBL3045	Homo sapiens	Inhibition	%	3.23
	8093216	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	O=C(O)/C=C/C(=O)O.OCCCNc1nccc(-c2c(-c3ccc(F)cc3)nn3cc(C(F)(F)F)ccc23)n1		CHEMBL1909403	=	Inhibition	%	1.5	CHEMBL3045	Homo sapiens	Inhibition	%	1.5
	8093575	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)nc(OC[C@@H](N)c3ccccc3)cc21		CHEMBL1096626	=	Inhibition	%	6.21	CHEMBL3045	Homo sapiens	Inhibition	%	6.21
	8093580	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)nc(OC[C@@H](N)c3ccccc3)cc21		CHEMBL1096626	=	Inhibition	%	3.74	CHEMBL3045	Homo sapiens	Inhibition	%	3.74
	8093714	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	CC(C)=Cc1cccc2c1/C(=N/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2		CHEMBL270544	=	Inhibition	%	1.55	CHEMBL3045	Homo sapiens	Inhibition	%	1.55
	8093719	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	CC(C)=Cc1cccc2c1/C(=N/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2		CHEMBL270544	=	Inhibition	%	1.68	CHEMBL3045	Homo sapiens	Inhibition	%	1.68
	8093938	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	COC(=O)Nc1nc2cc(Oc3ccc(NC(=O)Nc4cccc(C(=O)O)c4)cc3)ccc2[nH]1.Cl		CHEMBL1909373	=	Inhibition	%	0.02	CHEMBL3045	Homo sapiens	Inhibition	%	0.02
	8093943	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	COC(=O)Nc1nc2cc(Oc3ccc(NC(=O)Nc4cccc(C(=O)O)c4)cc3)ccc2[nH]1.Cl		CHEMBL1909373	=	Inhibition	%	-0.5	CHEMBL3045	Homo sapiens	Inhibition	%	-0.5
	8094058	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	CCS(=O)(=O)c1ccc(OC)c(Nc2ncc(-c3ccccc3Cl)o2)c1		CHEMBL179453	=	Inhibition	%	0.07	CHEMBL3045	Homo sapiens	Inhibition	%	0.07
	8094063	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	CCS(=O)(=O)c1ccc(OC)c(Nc2ncc(-c3ccccc3Cl)o2)c1		CHEMBL179453	=	Inhibition	%	2.01	CHEMBL3045	Homo sapiens	Inhibition	%	2.01
	8094462	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	Cc1cc(-c2ccco2)cc(C)c1/C=C/c1cncc(-c2nn[nH]n2)c1.Cl		CHEMBL1909353	=	Inhibition	%	0.6	CHEMBL3045	Homo sapiens	Inhibition	%	0.6
	8094467	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	Cc1cc(-c2ccco2)cc(C)c1/C=C/c1cncc(-c2nn[nH]n2)c1.Cl		CHEMBL1909353	=	Inhibition	%	-0.06	CHEMBL3045	Homo sapiens	Inhibition	%	-0.06
	8094637	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc(N2CCN(C(C)C)CC2)ccc1Nc1nc(Nc2ccc(F)cc2C(N)=O)c2cc[nH]c2n1		CHEMBL458865	=	Inhibition	%	1.83	CHEMBL3045	Homo sapiens	Inhibition	%	1.83
	8094642	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc(N2CCN(C(C)C)CC2)ccc1Nc1nc(Nc2ccc(F)cc2C(N)=O)c2cc[nH]c2n1		CHEMBL458865	=	Inhibition	%	1.59	CHEMBL3045	Homo sapiens	Inhibition	%	1.59
	8094793	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	Cc1nc(-c2ccccc2)n2nc(NCCCN3CCOCC3)ncc12		CHEMBL486124	=	Inhibition	%	0.04	CHEMBL3045	Homo sapiens	Inhibition	%	0.04
	8094798	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	Cc1nc(-c2ccccc2)n2nc(NCCCN3CCOCC3)ncc12		CHEMBL486124	=	Inhibition	%	2.05	CHEMBL3045	Homo sapiens	Inhibition	%	2.05
	8095017	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1coc(-c2ccc3ncnc(Nc4ccc(OCc5ccccc5)cc4)c3c2)c1.Cl		CHEMBL1909386	=	Inhibition	%	0.47	CHEMBL3045	Homo sapiens	Inhibition	%	0.47
	8095022	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1coc(-c2ccc3ncnc(Nc4ccc(OCc5ccccc5)cc4)c3c2)c1.Cl		CHEMBL1909386	=	Inhibition	%	-0.17	CHEMBL3045	Homo sapiens	Inhibition	%	-0.17
	8095157	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	CN(c1ccc(NC(=O)Nc2ccc(OC(F)(F)F)cc2)cc1)c1ccnc(Nc2cccc(S(N)(=O)=O)c2)n1		CHEMBL188381	=	Inhibition	%	0.52	CHEMBL3045	Homo sapiens	Inhibition	%	0.52
	8095162	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	CN(c1ccc(NC(=O)Nc2ccc(OC(F)(F)F)cc2)cc1)c1ccnc(Nc2cccc(S(N)(=O)=O)c2)n1		CHEMBL188381	=	Inhibition	%	0.69	CHEMBL3045	Homo sapiens	Inhibition	%	0.69
	8095360	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5ccccc5)cc4)c3c2)o1.Cl		CHEMBL1909385	=	Inhibition	%	0.21	CHEMBL3045	Homo sapiens	Inhibition	%	0.21
	8095365	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5ccccc5)cc4)c3c2)o1.Cl		CHEMBL1909385	=	Inhibition	%	0.86	CHEMBL3045	Homo sapiens	Inhibition	%	0.86
	8095584	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	N#Cc1ccc2c(-c3ccnc(NC4CC4)n3)c(-c3ccc(F)cc3)nn2c1		CHEMBL1885746	=	Inhibition	%	-1.19	CHEMBL3045	Homo sapiens	Inhibition	%	-1.19
	8095589	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	N#Cc1ccc2c(-c3ccnc(NC4CC4)n3)c(-c3ccc(F)cc3)nn2c1		CHEMBL1885746	=	Inhibition	%	1.33	CHEMBL3045	Homo sapiens	Inhibition	%	1.33
	8095725	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	CCCN1CCC=C(c2ccc(Nc3nc(Nc4ccccc4C(N)=O)c4cc[nH]c4n3)c(C)c2)C1		CHEMBL513897	=	Inhibition	%	-0.64	CHEMBL3045	Homo sapiens	Inhibition	%	-0.64
	8095730	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	CCCN1CCC=C(c2ccc(Nc3nc(Nc4ccccc4C(N)=O)c4cc[nH]c4n3)c(C)c2)C1		CHEMBL513897	=	Inhibition	%	3.5	CHEMBL3045	Homo sapiens	Inhibition	%	3.5
	8096097	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	COc1cc2ncnc(Nc3ccc4c(cnn4Cc4ccccc4)c3)c2cc1OC.Cl		CHEMBL1909380	=	Inhibition	%	-2.42	CHEMBL3045	Homo sapiens	Inhibition	%	-2.42
	8096102	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	COc1cc2ncnc(Nc3ccc4c(cnn4Cc4ccccc4)c3)c2cc1OC.Cl		CHEMBL1909380	=	Inhibition	%	0.88	CHEMBL3045	Homo sapiens	Inhibition	%	0.88
	8096214	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	Fc1ccc(-c2ncn(C3CCNCC3)c2-c2ccnc(Oc3cccc(C(F)(F)F)c3)n2)cc1		CHEMBL275666	=	Inhibition	%	0.77	CHEMBL3045	Homo sapiens	Inhibition	%	0.77
	8096219	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	Fc1ccc(-c2ncn(C3CCNCC3)c2-c2ccnc(Oc3cccc(C(F)(F)F)c3)n2)cc1		CHEMBL275666	=	Inhibition	%	2.34	CHEMBL3045	Homo sapiens	Inhibition	%	2.34
	8096438	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	Fc1ccc(-c2ncn(C3CCNCC3)c2-c2ccnc(Oc3cccc(C(F)(F)F)c3)n2)cc1		CHEMBL275666	=	Inhibition	%	3.8	CHEMBL3045	Homo sapiens	Inhibition	%	3.8
	8096577	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	Cl.[O-][S+]1CCN(Cc2ccc(-c3ccc4ncnc(Nc5ccc(OCc6ccccc6)c(Cl)c5)c4c3)o2)CC1		CHEMBL1909393	=	Inhibition	%	0.56	CHEMBL3045	Homo sapiens	Inhibition	%	0.56
	8096582	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	Cl.[O-][S+]1CCN(Cc2ccc(-c3ccc4ncnc(Nc5ccc(OCc6ccccc6)c(Cl)c5)c4c3)o2)CC1		CHEMBL1909393	=	Inhibition	%	0.97	CHEMBL3045	Homo sapiens	Inhibition	%	0.97
	8096733	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1cc(-c2cc3c(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)ncnc3s2)cs1		CHEMBL475599	=	Inhibition	%	1.19	CHEMBL3045	Homo sapiens	Inhibition	%	1.19
	8096738	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1cc(-c2cc3c(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)ncnc3s2)cs1		CHEMBL475599	=	Inhibition	%	2.0	CHEMBL3045	Homo sapiens	Inhibition	%	2.0
	8096957	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc(-c2ccncc2)cc1C(N)=O		CHEMBL231013	=	Inhibition	%	-0.74	CHEMBL3045	Homo sapiens	Inhibition	%	-0.74
	8096962	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc(-c2ccncc2)cc1C(N)=O		CHEMBL231013	=	Inhibition	%	0.88	CHEMBL3045	Homo sapiens	Inhibition	%	0.88
	8097104	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	Fc1cccc(COc2ccc(Nc3ncnc4sc(-c5cccs5)cc34)cc2Cl)c1		CHEMBL506414	=	Inhibition	%	-0.08	CHEMBL3045	Homo sapiens	Inhibition	%	-0.08
	8097109	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	Fc1cccc(COc2ccc(Nc3ncnc4sc(-c5cccs5)cc34)cc2Cl)c1		CHEMBL506414	=	Inhibition	%	0.44	CHEMBL3045	Homo sapiens	Inhibition	%	0.44
	8097411	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	O=C(O)/C=C/C(=O)O.OCCCNc1nccc(-c2c(-c3ccc(F)cc3)nn3cc(C(F)(F)F)ccc23)n1		CHEMBL1909403	=	Inhibition	%	5.54	CHEMBL3045	Homo sapiens	Inhibition	%	5.54
	8097416	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	O=C(O)/C=C/C(=O)O.OCCCNc1nccc(-c2c(-c3ccc(F)cc3)nn3cc(C(F)(F)F)ccc23)n1		CHEMBL1909403	=	Inhibition	%	7.52	CHEMBL3045	Homo sapiens	Inhibition	%	7.52
	8097635	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	COc1cccc(-c2c[nH]c3c(N/N=C/c4ccncc4)ncnc23)c1		CHEMBL206010	=	Inhibition	%	2.33	CHEMBL3045	Homo sapiens	Inhibition	%	2.33
	8097640	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	COc1cccc(-c2c[nH]c3c(N/N=C/c4ccncc4)ncnc23)c1		CHEMBL206010	=	Inhibition	%	1.66	CHEMBL3045	Homo sapiens	Inhibition	%	1.66
	8097785	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)nc(OC[C@@H](N)c3ccccc3)cc21		CHEMBL1096626	=	Inhibition	%	35.97	CHEMBL3045	Homo sapiens	Inhibition	%	35.97
	8097790	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)nc(OC[C@@H](N)c3ccccc3)cc21		CHEMBL1096626	=	Inhibition	%	23.05	CHEMBL3045	Homo sapiens	Inhibition	%	23.05
	8098142	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	COC(=O)Nc1nc2cc(Oc3ccc(NC(=O)Nc4cccc(C(=O)O)c4)cc3)ccc2[nH]1.Cl		CHEMBL1909373	=	Inhibition	%	1.6	CHEMBL3045	Homo sapiens	Inhibition	%	1.6
	8098147	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	COC(=O)Nc1nc2cc(Oc3ccc(NC(=O)Nc4cccc(C(=O)O)c4)cc3)ccc2[nH]1.Cl		CHEMBL1909373	=	Inhibition	%	0.44	CHEMBL3045	Homo sapiens	Inhibition	%	0.44
	8098262	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	COc1cccc(COc2cc(-n3cnc4ccccc43)sc2C(N)=O)c1		CHEMBL516248	=	Inhibition	%	-0.69	CHEMBL3045	Homo sapiens	Inhibition	%	-0.69
	8098267	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	COc1cccc(COc2cc(-n3cnc4ccccc43)sc2C(N)=O)c1		CHEMBL516248	=	Inhibition	%	0.72	CHEMBL3045	Homo sapiens	Inhibition	%	0.72
	8098486	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	COc1cccc(COc2cc(-n3cnc4ccccc43)sc2C(N)=O)c1		CHEMBL516248	=	Inhibition	%	0.94	CHEMBL3045	Homo sapiens	Inhibition	%	0.94
	8098491	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	COc1cccc(COc2cc(-n3cnc4ccccc43)sc2C(N)=O)c1		CHEMBL516248	=	Inhibition	%	1.77	CHEMBL3045	Homo sapiens	Inhibition	%	1.77
	8098666	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	c1ccc(COc2ccc(Nc3ncnc4ccc(-c5ccco5)cc34)cc2)cc1		CHEMBL215993	=	Inhibition	%	-0.86	CHEMBL3045	Homo sapiens	Inhibition	%	-0.86
	8098671	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	c1ccc(COc2ccc(Nc3ncnc4ccc(-c5ccco5)cc34)cc2)cc1		CHEMBL215993	=	Inhibition	%	0.49	CHEMBL3045	Homo sapiens	Inhibition	%	0.49
	8098851	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	COc1cc(N2CCN(C(C)C)CC2)ccc1Nc1nc(Nc2ccc(F)cc2C(N)=O)c2cc[nH]c2n1		CHEMBL458865	=	Inhibition	%	4.58	CHEMBL3045	Homo sapiens	Inhibition	%	4.58
	8098856	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	COc1cc(N2CCN(C(C)C)CC2)ccc1Nc1nc(Nc2ccc(F)cc2C(N)=O)c2cc[nH]c2n1		CHEMBL458865	=	Inhibition	%	5.72	CHEMBL3045	Homo sapiens	Inhibition	%	5.72
	8099219	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1coc(-c2ccc3ncnc(Nc4ccc(OCc5ccccc5)cc4)c3c2)c1.Cl		CHEMBL1909386	=	Inhibition	%	-1.0	CHEMBL3045	Homo sapiens	Inhibition	%	-1.0
	8099224	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1coc(-c2ccc3ncnc(Nc4ccc(OCc5ccccc5)cc4)c3c2)c1.Cl		CHEMBL1909386	=	Inhibition	%	1.35	CHEMBL3045	Homo sapiens	Inhibition	%	1.35
	8099361	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(OCc4ccccc4C(F)(F)F)c(C(C)=O)s3)c2cc1OC		CHEMBL471789	=	Inhibition	%	1.02	CHEMBL3045	Homo sapiens	Inhibition	%	1.02
	8099366	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(OCc4ccccc4C(F)(F)F)c(C(C)=O)s3)c2cc1OC		CHEMBL471789	=	Inhibition	%	0.72	CHEMBL3045	Homo sapiens	Inhibition	%	0.72
	8099585	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(OCc4ccccc4C(F)(F)F)c(C(C)=O)s3)c2cc1OC		CHEMBL471789	=	Inhibition	%	0.44	CHEMBL3045	Homo sapiens	Inhibition	%	0.44
	8099779	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	N#Cc1ccc2c(-c3ccnc(NC4CC4)n3)c(-c3ccc(F)cc3)nn2c1		CHEMBL1885746	=	Inhibition	%	-0.72	CHEMBL3045	Homo sapiens	Inhibition	%	-0.72
	8099784	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	N#Cc1ccc2c(-c3ccnc(NC4CC4)n3)c(-c3ccc(F)cc3)nn2c1		CHEMBL1885746	=	Inhibition	%	4.8	CHEMBL3045	Homo sapiens	Inhibition	%	4.8
	8099926	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	COc1cccc(-n2ncc3c(N/N=C/c4ccc(C)cc4)ncnc32)c1		CHEMBL303687	=	Inhibition	%	0.67	CHEMBL3045	Homo sapiens	Inhibition	%	0.67
	8099931	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	COc1cccc(-n2ncc3c(N/N=C/c4ccc(C)cc4)ncnc32)c1		CHEMBL303687	=	Inhibition	%	1.4	CHEMBL3045	Homo sapiens	Inhibition	%	1.4
	8100296	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc(-c4cnco4)cc32)cc1		CHEMBL269827	=	Inhibition	%	1.26	CHEMBL3045	Homo sapiens	Inhibition	%	1.26
	8100301	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc(-c4cnco4)cc32)cc1		CHEMBL269827	=	Inhibition	%	0.38	CHEMBL3045	Homo sapiens	Inhibition	%	0.38
	8100417	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	Fc1ccc(-c2ncn(C3CCNCC3)c2-c2ccnc(Oc3cccc(C(F)(F)F)c3)n2)cc1		CHEMBL275666	=	Inhibition	%	4.66	CHEMBL3045	Homo sapiens	Inhibition	%	4.66
	8100636	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	N#Cc1ccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)cc1		CHEMBL13972	=	Inhibition	%	1.45	CHEMBL3045	Homo sapiens	Inhibition	%	1.45
	8100641	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	N#Cc1ccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)cc1		CHEMBL13972	=	Inhibition	%	0.99	CHEMBL3045	Homo sapiens	Inhibition	%	0.99
	8100776	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	Cl.[O-][S+]1CCN(Cc2ccc(-c3ccc4ncnc(Nc5ccc(OCc6ccccc6)c(Cl)c5)c4c3)o2)CC1		CHEMBL1909393	=	Inhibition	%	0.65	CHEMBL3045	Homo sapiens	Inhibition	%	0.65
	8100781	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	Cl.[O-][S+]1CCN(Cc2ccc(-c3ccc4ncnc(Nc5ccc(OCc6ccccc6)c(Cl)c5)c4c3)o2)CC1		CHEMBL1909393	=	Inhibition	%	2.88	CHEMBL3045	Homo sapiens	Inhibition	%	2.88
	8101160	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	COc1ccc(-c2ccncc2)cc1C(N)=O		CHEMBL231013	=	Inhibition	%	0.96	CHEMBL3045	Homo sapiens	Inhibition	%	0.96
	8101165	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	COc1ccc(-c2ccncc2)cc1C(N)=O		CHEMBL231013	=	Inhibition	%	2.35	CHEMBL3045	Homo sapiens	Inhibition	%	2.35
	8101302	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc(Nc2ncc(-c3ccccc3)o2)cc(OC)c1OC		CHEMBL443563	=	Inhibition	%	-1.34	CHEMBL3045	Homo sapiens	Inhibition	%	-1.34
	8101307	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc(Nc2ncc(-c3ccccc3)o2)cc(OC)c1OC		CHEMBL443563	=	Inhibition	%	0.3	CHEMBL3045	Homo sapiens	Inhibition	%	0.3
	8101711	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	COc1ccc2ncn(-c3cc(O[C@H](C)c4ccccc4Cl)c(C(N)=O)s3)c2c1		CHEMBL493326	=	Inhibition	%	2.58	CHEMBL3045	Homo sapiens	Inhibition	%	2.58
	8101716	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	COc1ccc2ncn(-c3cc(O[C@H](C)c4ccccc4Cl)c(C(N)=O)s3)c2c1		CHEMBL493326	=	Inhibition	%	2.97	CHEMBL3045	Homo sapiens	Inhibition	%	2.97
	8101964	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	COc1cccc(-c2c[nH]c3c(N/N=C/c4ccncc4)ncnc23)c1		CHEMBL206010	=	Inhibition	%	4.29	CHEMBL3045	Homo sapiens	Inhibition	%	4.29
	8101969	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	COc1cccc(-c2c[nH]c3c(N/N=C/c4ccncc4)ncnc23)c1		CHEMBL206010	=	Inhibition	%	5.79	CHEMBL3045	Homo sapiens	Inhibition	%	5.79
	8102119	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	NC(=O)c1cccc(Nc2nccc(Nc3cccc4[nH]ncc34)n2)c1		CHEMBL251549	=	Inhibition	%	0.67	CHEMBL3045	Homo sapiens	Inhibition	%	0.67
	8102124	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	NC(=O)c1cccc(Nc2nccc(Nc3cccc4[nH]ncc34)n2)c1		CHEMBL251549	=	Inhibition	%	-1.01	CHEMBL3045	Homo sapiens	Inhibition	%	-1.01
	8102474	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	CCN(CC)S(=O)(=O)c1ccc(OC)c(Nc2ncc(-c3ccccc3)o2)c1		CHEMBL275473	=	Inhibition	%	1.38	CHEMBL3045	Homo sapiens	Inhibition	%	1.38
	8102479	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	CCN(CC)S(=O)(=O)c1ccc(OC)c(Nc2ncc(-c3ccccc3)o2)c1		CHEMBL275473	=	Inhibition	%	0.23	CHEMBL3045	Homo sapiens	Inhibition	%	0.23
	8102818	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	CCn1cc(-c2ccnc3[nH]ccc23)c(-c2cccc(NC(=O)Nc3ccc(OCc4ccccc4)cc3)c2)n1		CHEMBL505187	=	Inhibition	%	0.5	CHEMBL3045	Homo sapiens	Inhibition	%	0.5
	8102823	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	CCn1cc(-c2ccnc3[nH]ccc23)c(-c2cccc(NC(=O)Nc3ccc(OCc4ccccc4)cc3)c2)n1		CHEMBL505187	=	Inhibition	%	0.47	CHEMBL3045	Homo sapiens	Inhibition	%	0.47
	8102996	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	c1ccc(COc2ccc(Nc3ncnc4ccc(-c5ccco5)cc34)cc2)cc1		CHEMBL215993	=	Inhibition	%	-0.3	CHEMBL3045	Homo sapiens	Inhibition	%	-0.3
	8103001	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	c1ccc(COc2ccc(Nc3ncnc4ccc(-c5ccco5)cc34)cc2)cc1		CHEMBL215993	=	Inhibition	%	0.58	CHEMBL3045	Homo sapiens	Inhibition	%	0.58
	8103192	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)nc(OC[C@H](N)c3ccccc3)cc21		CHEMBL1096634	=	Inhibition	%	32.71	CHEMBL3045	Homo sapiens	Inhibition	%	32.71
	8103197	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)nc(OC[C@H](N)c3ccccc3)cc21		CHEMBL1096634	=	Inhibition	%	16.28	CHEMBL3045	Homo sapiens	Inhibition	%	16.28
	8103416	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)nc(OC[C@H](N)c3ccccc3)cc21		CHEMBL1096634	=	Inhibition	%	67.29	CHEMBL3045	Homo sapiens	Inhibition	%	67.29
	8103421	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)nc(OC[C@H](N)c3ccccc3)cc21		CHEMBL1096634	=	Inhibition	%	59.35	CHEMBL3045	Homo sapiens	Inhibition	%	59.35
	8103554	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	Cl.NC(=O)c1cccc(Nc2nccc(Nc3cccc(F)c3)n2)c1		CHEMBL1909382	=	Inhibition	%	-2.22	CHEMBL3045	Homo sapiens	Inhibition	%	-2.22
	8103559	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	Cl.NC(=O)c1cccc(Nc2nccc(Nc3cccc(F)c3)n2)c1		CHEMBL1909382	=	Inhibition	%	2.1	CHEMBL3045	Homo sapiens	Inhibition	%	2.1
	8103709	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(OCc4ccccc4C(F)(F)F)c(C(C)=O)s3)c2cc1OC		CHEMBL471789	=	Inhibition	%	0.23	CHEMBL3045	Homo sapiens	Inhibition	%	0.23
	8103928	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	CNC(=O)c1sc(-n2cnc3cc(OC)c(OC)cc32)cc1OCc1ccccc1C(F)(F)F		CHEMBL518968	=	Inhibition	%	1.29	CHEMBL3045	Homo sapiens	Inhibition	%	1.29
	8103933	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	CNC(=O)c1sc(-n2cnc3cc(OC)c(OC)cc32)cc1OCc1ccccc1C(F)(F)F		CHEMBL518968	=	Inhibition	%	1.04	CHEMBL3045	Homo sapiens	Inhibition	%	1.04
	8104113	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	COC(=O)Nc1nc2ccc(Oc3ccc(NC(=O)Nc4cccc(Cl)c4)cc3)cc2[nH]1.Cl		CHEMBL1909364	=	Inhibition	%	-1.37	CHEMBL3045	Homo sapiens	Inhibition	%	-1.37
	8104118	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	COC(=O)Nc1nc2ccc(Oc3ccc(NC(=O)Nc4cccc(Cl)c4)cc3)cc2[nH]1.Cl		CHEMBL1909364	=	Inhibition	%	0.5	CHEMBL3045	Homo sapiens	Inhibition	%	0.5
	8104261	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	COc1cccc(-n2ncc3c(N/N=C/c4ccc(C)cc4)ncnc32)c1		CHEMBL303687	=	Inhibition	%	1.01	CHEMBL3045	Homo sapiens	Inhibition	%	1.01
	8104266	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	COc1cccc(-n2ncc3c(N/N=C/c4ccc(C)cc4)ncnc32)c1		CHEMBL303687	=	Inhibition	%	2.79	CHEMBL3045	Homo sapiens	Inhibition	%	2.79
	8104485	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	C[C@@H](Oc1cc(-n2cnc3ccc(OCC4CCN(C)CC4)cc32)sc1C(N)=O)c1ccccc1Cl		CHEMBL1794069	=	Inhibition	%	1.4	CHEMBL3045	Homo sapiens	Inhibition	%	1.4
	8104490	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	C[C@@H](Oc1cc(-n2cnc3ccc(OCC4CCN(C)CC4)cc32)sc1C(N)=O)c1ccccc1Cl		CHEMBL1794069	=	Inhibition	%	3.47	CHEMBL3045	Homo sapiens	Inhibition	%	3.47
	8104631	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc(-c4cnco4)cc32)cc1		CHEMBL269827	=	Inhibition	%	0.36	CHEMBL3045	Homo sapiens	Inhibition	%	0.36
	8104636	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc(-c4cnco4)cc32)cc1		CHEMBL269827	=	Inhibition	%	1.12	CHEMBL3045	Homo sapiens	Inhibition	%	1.12
	8104969	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	N#Cc1ccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)cc1		CHEMBL13972	=	Inhibition	%	2.93	CHEMBL3045	Homo sapiens	Inhibition	%	2.93
	8104974	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	N#Cc1ccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)cc1		CHEMBL13972	=	Inhibition	%	3.08	CHEMBL3045	Homo sapiens	Inhibition	%	3.08
	8105109	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	Fc1ccc(-c2ncn(C3CCNCC3)c2-c2ccnc(Oc3ccc(Cl)cc3)n2)cc1		CHEMBL275168	=	Inhibition	%	1.12	CHEMBL3045	Homo sapiens	Inhibition	%	1.12
	8105114	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	Fc1ccc(-c2ncn(C3CCNCC3)c2-c2ccnc(Oc3ccc(Cl)cc3)n2)cc1		CHEMBL275168	=	Inhibition	%	0.33	CHEMBL3045	Homo sapiens	Inhibition	%	0.33
	8105333	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	Fc1ccc(-c2ncn(C3CCNCC3)c2-c2ccnc(Oc3ccc(Cl)cc3)n2)cc1		CHEMBL275168	=	Inhibition	%	8.1	CHEMBL3045	Homo sapiens	Inhibition	%	8.1
	8105338	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	Fc1ccc(-c2ncn(C3CCNCC3)c2-c2ccnc(Oc3ccc(Cl)cc3)n2)cc1		CHEMBL275168	=	Inhibition	%	5.01	CHEMBL3045	Homo sapiens	Inhibition	%	5.01
	8105499	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	C[C@@H](Oc1cc(-n2cnc3ccc(OC4CCN(C)CC4)cc32)sc1C(N)=O)c1ccccc1Cl		CHEMBL1794070	=	Inhibition	%	0.95	CHEMBL3045	Homo sapiens	Inhibition	%	0.95
	8105504	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	C[C@@H](Oc1cc(-n2cnc3ccc(OC4CCN(C)CC4)cc32)sc1C(N)=O)c1ccccc1Cl		CHEMBL1794070	=	Inhibition	%	1.56	CHEMBL3045	Homo sapiens	Inhibition	%	1.56
	8105637	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	COc1cc(Nc2ncc(-c3ccccc3)o2)cc(OC)c1OC		CHEMBL443563	=	Inhibition	%	2.43	CHEMBL3045	Homo sapiens	Inhibition	%	2.43
	8105642	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	COc1cc(Nc2ncc(-c3ccccc3)o2)cc(OC)c1OC		CHEMBL443563	=	Inhibition	%	2.2	CHEMBL3045	Homo sapiens	Inhibition	%	2.2
	8105861	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc(Nc2ncc(-c3ccccc3)o2)cc(OC)c1		CHEMBL176553	=	Inhibition	%	0.24	CHEMBL3045	Homo sapiens	Inhibition	%	0.24
	8105866	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc(Nc2ncc(-c3ccccc3)o2)cc(OC)c1		CHEMBL176553	=	Inhibition	%	0.78	CHEMBL3045	Homo sapiens	Inhibition	%	0.78
	8105917	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	CC(=O)Nc1cccc(C#Cc2cncnc2Nc2ccc(OCc3cccc(F)c3)c(Cl)c2)c1		CHEMBL205798	=	Inhibition	%	0.65	CHEMBL3045	Homo sapiens	Inhibition	%	0.65
	8105922	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	CC(=O)Nc1cccc(C#Cc2cncnc2Nc2ccc(OCc3cccc(F)c3)c(Cl)c2)c1		CHEMBL205798	=	Inhibition	%	1.6	CHEMBL3045	Homo sapiens	Inhibition	%	1.6
	8106141	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	CC(=O)Nc1cccc(C#Cc2cncnc2Nc2ccc(OCc3cccc(F)c3)c(Cl)c2)c1		CHEMBL205798	=	Inhibition	%	0.21	CHEMBL3045	Homo sapiens	Inhibition	%	0.21
	8106146	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	CC(=O)Nc1cccc(C#Cc2cncnc2Nc2ccc(OCc3cccc(F)c3)c(Cl)c2)c1		CHEMBL205798	=	Inhibition	%	0.79	CHEMBL3045	Homo sapiens	Inhibition	%	0.79
	8106306	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	CN(C)CCCNc1nccc(-c2c(-c3ccc(F)cc3)nn3cc(C(F)(F)F)ccc23)n1.CS(=O)(=O)O		CHEMBL1909405	=	Inhibition	%	2.22	CHEMBL3045	Homo sapiens	Inhibition	%	2.22
	8106311	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	CN(C)CCCNc1nccc(-c2c(-c3ccc(F)cc3)nn3cc(C(F)(F)F)ccc23)n1.CS(=O)(=O)O		CHEMBL1909405	=	Inhibition	%	0.57	CHEMBL3045	Homo sapiens	Inhibition	%	0.57
	8106462	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	NC(=O)c1cccc(Nc2nccc(Nc3cccc4[nH]ncc34)n2)c1		CHEMBL251549	=	Inhibition	%	2.07	CHEMBL3045	Homo sapiens	Inhibition	%	2.07
	8106467	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	NC(=O)c1cccc(Nc2nccc(Nc3cccc4[nH]ncc34)n2)c1		CHEMBL251549	=	Inhibition	%	7.52	CHEMBL3045	Homo sapiens	Inhibition	%	7.52
	8106686	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CCN)ncc(OCCCN)c21.O=C(O)C(F)(F)F		CHEMBL1794064	=	Inhibition	%	14.69	CHEMBL3045	Homo sapiens	Inhibition	%	14.69
	8106691	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CCN)ncc(OCCCN)c21.O=C(O)C(F)(F)F		CHEMBL1794064	=	Inhibition	%	4.07	CHEMBL3045	Homo sapiens	Inhibition	%	4.07
	8106815	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	CCN(CC)S(=O)(=O)c1ccc(OC)c(Nc2ncc(-c3ccccc3)o2)c1		CHEMBL275473	=	Inhibition	%	1.74	CHEMBL3045	Homo sapiens	Inhibition	%	1.74
	8106820	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	CCN(CC)S(=O)(=O)c1ccc(OC)c(Nc2ncc(-c3ccccc3)o2)c1		CHEMBL275473	=	Inhibition	%	1.41	CHEMBL3045	Homo sapiens	Inhibition	%	1.41
	8107160	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	CCn1cc(-c2ccnc3[nH]ccc23)c(-c2cccc(NC(=O)Nc3ccc(OCc4ccccc4)cc3)c2)n1		CHEMBL505187	=	Inhibition	%	1.43	CHEMBL3045	Homo sapiens	Inhibition	%	1.43
	8107165	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	CCn1cc(-c2ccnc3[nH]ccc23)c(-c2cccc(NC(=O)Nc3ccc(OCc4ccccc4)cc3)c2)n1		CHEMBL505187	=	Inhibition	%	1.93	CHEMBL3045	Homo sapiens	Inhibition	%	1.93
	8107332	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	NC(=O)c1sc(-n2cnc3cc(C(F)(F)F)ccc32)cc1OCc1ccccc1Br		CHEMBL480371	=	Inhibition	%	0.86	CHEMBL3045	Homo sapiens	Inhibition	%	0.86
	8107337	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	NC(=O)c1sc(-n2cnc3cc(C(F)(F)F)ccc32)cc1OCc1ccccc1Br		CHEMBL480371	=	Inhibition	%	0.4	CHEMBL3045	Homo sapiens	Inhibition	%	0.4
	8107757	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	Cc1cccc(Nc2ncc(-c3ccccc3)o2)c1		CHEMBL192417	=	Inhibition	%	3.52	CHEMBL3045	Homo sapiens	Inhibition	%	3.52
	8107762	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	Cc1cccc(Nc2ncc(-c3ccccc3)o2)c1		CHEMBL192417	=	Inhibition	%	2.39	CHEMBL3045	Homo sapiens	Inhibition	%	2.39
	8107892	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	Cl.NC(=O)c1cccc(Nc2nccc(Nc3cccc(F)c3)n2)c1		CHEMBL1909382	=	Inhibition	%	-5.72	CHEMBL3045	Homo sapiens	Inhibition	%	-5.72
	8107897	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	Cl.NC(=O)c1cccc(Nc2nccc(Nc3cccc(F)c3)n2)c1		CHEMBL1909382	=	Inhibition	%	4.84	CHEMBL3045	Homo sapiens	Inhibition	%	4.84
	8108274	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	CNC(=O)c1sc(-n2cnc3cc(OC)c(OC)cc32)cc1OCc1ccccc1C(F)(F)F		CHEMBL518968	=	Inhibition	%	-0.63	CHEMBL3045	Homo sapiens	Inhibition	%	-0.63
	8108279	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	CNC(=O)c1sc(-n2cnc3cc(OC)c(OC)cc32)cc1OCc1ccccc1C(F)(F)F		CHEMBL518968	=	Inhibition	%	1.38	CHEMBL3045	Homo sapiens	Inhibition	%	1.38
	8108449	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	COC(=O)Nc1nc2ccc(Oc3ccc(NC(=O)Nc4cccc(Cl)c4)cc3)cc2[nH]1.Cl		CHEMBL1909364	=	Inhibition	%	-5.17	CHEMBL3045	Homo sapiens	Inhibition	%	-5.17
	8108454	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	COC(=O)Nc1nc2ccc(Oc3ccc(NC(=O)Nc4cccc(Cl)c4)cc3)cc2[nH]1.Cl		CHEMBL1909364	=	Inhibition	%	0.57	CHEMBL3045	Homo sapiens	Inhibition	%	0.57
	8108820	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	C[C@@H](Oc1cc(-n2cnc3ccc(OCC4CCN(C)CC4)cc32)sc1C(N)=O)c1ccccc1Cl		CHEMBL1794069	=	Inhibition	%	3.67	CHEMBL3045	Homo sapiens	Inhibition	%	3.67
	8108825	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	C[C@@H](Oc1cc(-n2cnc3ccc(OCC4CCN(C)CC4)cc32)sc1C(N)=O)c1ccccc1Cl		CHEMBL1794069	=	Inhibition	%	11.62	CHEMBL3045	Homo sapiens	Inhibition	%	11.62
	8108962	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	O=S(=O)(CCOCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1)c1ccccc1		CHEMBL212250	=	Inhibition	%	-0.21	CHEMBL3045	Homo sapiens	Inhibition	%	-0.21
	8108967	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	O=S(=O)(CCOCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1)c1ccccc1		CHEMBL212250	=	Inhibition	%	0.96	CHEMBL3045	Homo sapiens	Inhibition	%	0.96
	8109300	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	Cc1cccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)c1C.O=C(O)C(F)(F)F		CHEMBL1909400	=	Inhibition	%	-0.74	CHEMBL3045	Homo sapiens	Inhibition	%	-0.74
	8109305	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	Cc1cccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)c1C.O=C(O)C(F)(F)F		CHEMBL1909400	=	Inhibition	%	1.25	CHEMBL3045	Homo sapiens	Inhibition	%	1.25
	8109654	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	NC(=O)CCc1ccccc1Oc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCNCC2)n1		CHEMBL1785003	=	Inhibition	%	-1.55	CHEMBL3045	Homo sapiens	Inhibition	%	-1.55
	8109659	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	NC(=O)CCc1ccccc1Oc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCNCC2)n1		CHEMBL1785003	=	Inhibition	%	0.09	CHEMBL3045	Homo sapiens	Inhibition	%	0.09
	8109825	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	C[C@@H](Oc1cc(-n2cnc3ccc(OC4CCN(C)CC4)cc32)sc1C(N)=O)c1ccccc1Cl		CHEMBL1794070	=	Inhibition	%	3.55	CHEMBL3045	Homo sapiens	Inhibition	%	3.55
	8109830	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	C[C@@H](Oc1cc(-n2cnc3ccc(OC4CCN(C)CC4)cc32)sc1C(N)=O)c1ccccc1Cl		CHEMBL1794070	=	Inhibition	%	8.48	CHEMBL3045	Homo sapiens	Inhibition	%	8.48
	8110181	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	COc1cc(Nc2ncc(-c3ccccc3)o2)cc(OC)c1		CHEMBL176553	=	Inhibition	%	2.31	CHEMBL3045	Homo sapiens	Inhibition	%	2.31
	8110186	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	COc1cc(Nc2ncc(-c3ccccc3)o2)cc(OC)c1		CHEMBL176553	=	Inhibition	%	2.17	CHEMBL3045	Homo sapiens	Inhibition	%	2.17
	8110460	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	Cc1ccc(C(=O)NC2CCCCC2)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL477978	=	Inhibition	%	1.17	CHEMBL3045	Homo sapiens	Inhibition	%	1.17
	8110465	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	Cc1ccc(C(=O)NC2CCCCC2)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL477978	=	Inhibition	%	1.11	CHEMBL3045	Homo sapiens	Inhibition	%	1.11
	8110626	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	CN(C)CCCNc1nccc(-c2c(-c3ccc(F)cc3)nn3cc(C(F)(F)F)ccc23)n1.CS(=O)(=O)O		CHEMBL1909405	=	Inhibition	%	0.97	CHEMBL3045	Homo sapiens	Inhibition	%	0.97
	8110631	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	CN(C)CCCNc1nccc(-c2c(-c3ccc(F)cc3)nn3cc(C(F)(F)F)ccc23)n1.CS(=O)(=O)O		CHEMBL1909405	=	Inhibition	%	3.33	CHEMBL3045	Homo sapiens	Inhibition	%	3.33
	8111008	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CCN)ncc(OCCCN)c21.O=C(O)C(F)(F)F		CHEMBL1794064	=	Inhibition	%	47.78	CHEMBL3045	Homo sapiens	Inhibition	%	47.78
	8111013	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CCN)ncc(OCCCN)c21.O=C(O)C(F)(F)F		CHEMBL1794064	=	Inhibition	%	11.96	CHEMBL3045	Homo sapiens	Inhibition	%	11.96
	8111131	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	CCc1cccc(NC(=O)Nc2ccc(Oc3ccc4nc(NC(=O)OC)[nH]c4c3)cc2)c1		CHEMBL243907	=	Inhibition	%	0.28	CHEMBL3045	Homo sapiens	Inhibition	%	0.28
	8111136	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	CCc1cccc(NC(=O)Nc2ccc(Oc3ccc4nc(NC(=O)OC)[nH]c4c3)cc2)c1		CHEMBL243907	=	Inhibition	%	-0.27	CHEMBL3045	Homo sapiens	Inhibition	%	-0.27
	8111355	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	CCc1cccc(NC(=O)Nc2ccc(Oc3ccc4nc(NC(=O)OC)[nH]c4c3)cc2)c1		CHEMBL243907	=	Inhibition	%	1.12	CHEMBL3045	Homo sapiens	Inhibition	%	1.12
	8111360	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	CCc1cccc(NC(=O)Nc2ccc(Oc3ccc4nc(NC(=O)OC)[nH]c4c3)cc2)c1		CHEMBL243907	=	Inhibition	%	-1.17	CHEMBL3045	Homo sapiens	Inhibition	%	-1.17
	8111482	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OC[C@@H]3CCCN3)c21.O=C(O)C(F)(F)F		CHEMBL1909375	=	Inhibition	%	30.15	CHEMBL3045	Homo sapiens	Inhibition	%	30.15
	8111487	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OC[C@@H]3CCCN3)c21.O=C(O)C(F)(F)F		CHEMBL1909375	=	Inhibition	%	7.63	CHEMBL3045	Homo sapiens	Inhibition	%	7.63
	8111648	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	NC(=O)c1sc(-n2cnc3cc(C(F)(F)F)ccc32)cc1OCc1ccccc1Br		CHEMBL480371	=	Inhibition	%	-1.32	CHEMBL3045	Homo sapiens	Inhibition	%	-1.32
	8111653	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	NC(=O)c1sc(-n2cnc3cc(C(F)(F)F)ccc32)cc1OCc1ccccc1Br		CHEMBL480371	=	Inhibition	%	0.57	CHEMBL3045	Homo sapiens	Inhibition	%	0.57
	8111872	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	CC(C)(CO)CNC(=O)c1ccc2c(c1)/C(=N/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2		CHEMBL410072	=	Inhibition	%	-0.69	CHEMBL3045	Homo sapiens	Inhibition	%	-0.69
	8111877	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	CC(C)(CO)CNC(=O)c1ccc2c(c1)/C(=N/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2		CHEMBL410072	=	Inhibition	%	0.36	CHEMBL3045	Homo sapiens	Inhibition	%	0.36
	8112077	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	Cc1cccc(Nc2ncc(-c3ccccc3)o2)c1		CHEMBL192417	=	Inhibition	%	5.79	CHEMBL3045	Homo sapiens	Inhibition	%	5.79
	8112082	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	Cc1cccc(Nc2ncc(-c3ccccc3)o2)c1		CHEMBL192417	=	Inhibition	%	7.38	CHEMBL3045	Homo sapiens	Inhibition	%	7.38
	8112214	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	COc1cccc(-n2nc(C)c3c(N/N=C(\C)c4ccncc4)ncnc32)c1		CHEMBL442363	=	Inhibition	%	0.03	CHEMBL3045	Homo sapiens	Inhibition	%	0.03
	8112219	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	COc1cccc(-n2nc(C)c3c(N/N=C(\C)c4ccncc4)ncnc32)c1		CHEMBL442363	=	Inhibition	%	0.75	CHEMBL3045	Homo sapiens	Inhibition	%	0.75
	8112438	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	COc1cccc(-n2nc(C)c3c(N/N=C(\C)c4ccncc4)ncnc32)c1		CHEMBL442363	=	Inhibition	%	-2.45	CHEMBL3045	Homo sapiens	Inhibition	%	-2.45
	8112443	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	COc1cccc(-n2nc(C)c3c(N/N=C(\C)c4ccncc4)ncnc32)c1		CHEMBL442363	=	Inhibition	%	0.46	CHEMBL3045	Homo sapiens	Inhibition	%	0.46
	8112606	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	Nc1ncc(-c2cccc(S(N)(=O)=O)c2)c2scc(-c3ccc(F)c(Cl)c3)c12		CHEMBL241517	=	Inhibition	%	-0.08	CHEMBL3045	Homo sapiens	Inhibition	%	-0.08
	8112611	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	Nc1ncc(-c2cccc(S(N)(=O)=O)c2)c2scc(-c3ccc(F)c(Cl)c3)c12		CHEMBL241517	=	Inhibition	%	0.92	CHEMBL3045	Homo sapiens	Inhibition	%	0.92
	8112778	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1ccoc1-c1ccc2ncnc(Nc3ccc(OCc4ccccc4)cc3)c2c1.Cl		CHEMBL1909388	=	Inhibition	%	-0.13	CHEMBL3045	Homo sapiens	Inhibition	%	-0.13
	8112783	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1ccoc1-c1ccc2ncnc(Nc3ccc(OCc4ccccc4)cc3)c2c1.Cl		CHEMBL1909388	=	Inhibition	%	-0.23	CHEMBL3045	Homo sapiens	Inhibition	%	-0.23
	8113002	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1ccoc1-c1ccc2ncnc(Nc3ccc(OCc4ccccc4)cc3)c2c1.Cl		CHEMBL1909388	=	Inhibition	%	-4.5	CHEMBL3045	Homo sapiens	Inhibition	%	-4.5
	8113007	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1ccoc1-c1ccc2ncnc(Nc3ccc(OCc4ccccc4)cc3)c2c1.Cl		CHEMBL1909388	=	Inhibition	%	0.72	CHEMBL3045	Homo sapiens	Inhibition	%	0.72
	8113154	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)nc(OCCNC)cc21.Cl		CHEMBL1909350	=	Inhibition	%	4.85	CHEMBL3045	Homo sapiens	Inhibition	%	4.85
	8113159	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)nc(OCCNC)cc21.Cl		CHEMBL1909350	=	Inhibition	%	1.53	CHEMBL3045	Homo sapiens	Inhibition	%	1.53
	8113290	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	O=S(=O)(CCOCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1)c1ccccc1		CHEMBL212250	=	Inhibition	%	-0.92	CHEMBL3045	Homo sapiens	Inhibition	%	-0.92
	8113295	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	O=S(=O)(CCOCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1)c1ccccc1		CHEMBL212250	=	Inhibition	%	1.53	CHEMBL3045	Homo sapiens	Inhibition	%	1.53
	8113514	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5ccccc5)c(Cl)c4)c3c2)o1.Cl		CHEMBL529066	=	Inhibition	%	-1.09	CHEMBL3045	Homo sapiens	Inhibition	%	-1.09
	8113519	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5ccccc5)c(Cl)c4)c3c2)o1.Cl		CHEMBL529066	=	Inhibition	%	-0.28	CHEMBL3045	Homo sapiens	Inhibition	%	-0.28
	8113638	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	Cc1cccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)c1C.O=C(O)C(F)(F)F		CHEMBL1909400	=	Inhibition	%	6.3	CHEMBL3045	Homo sapiens	Inhibition	%	6.3
	8113643	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	Cc1cccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)c1C.O=C(O)C(F)(F)F		CHEMBL1909400	=	Inhibition	%	5.33	CHEMBL3045	Homo sapiens	Inhibition	%	5.33
	8113978	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	NC(=O)CCc1ccccc1Oc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCNCC2)n1		CHEMBL1785003	=	Inhibition	%	1.67	CHEMBL3045	Homo sapiens	Inhibition	%	1.67
	8113983	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	NC(=O)CCc1ccccc1Oc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCNCC2)n1		CHEMBL1785003	=	Inhibition	%	3.24	CHEMBL3045	Homo sapiens	Inhibition	%	3.24
	8114154	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(C(F)(F)F)c5)cc4)c3c2)o1.Cl		CHEMBL1909387	=	Inhibition	%	1.32	CHEMBL3045	Homo sapiens	Inhibition	%	1.32
	8114159	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(C(F)(F)F)c5)cc4)c3c2)o1.Cl		CHEMBL1909387	=	Inhibition	%	1.56	CHEMBL3045	Homo sapiens	Inhibition	%	1.56
	8114510	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	Fc1cccc(COc2ccc(Nc3ncnc4sc(-c5ccco5)cc34)cc2Cl)c1		CHEMBL514938	=	Inhibition	%	0.29	CHEMBL3045	Homo sapiens	Inhibition	%	0.29
	8114515	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	Fc1cccc(COc2ccc(Nc3ncnc4sc(-c5ccco5)cc34)cc2Cl)c1		CHEMBL514938	=	Inhibition	%	1.0	CHEMBL3045	Homo sapiens	Inhibition	%	1.0
	8114786	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	Cc1ccc(C(=O)NC2CCCCC2)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL477978	=	Inhibition	%	1.93	CHEMBL3045	Homo sapiens	Inhibition	%	1.93
	8114791	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	Cc1ccc(C(=O)NC2CCCCC2)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL477978	=	Inhibition	%	3.12	CHEMBL3045	Homo sapiens	Inhibition	%	3.12
	8114952	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	Cl.Nc1ncnc2occ(-c3ccc(NC(=O)Nc4cc(C(F)(F)F)ccc4F)cc3)c12		CHEMBL588025	=	Inhibition	%	1.05	CHEMBL3045	Homo sapiens	Inhibition	%	1.05
	8114957	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	Cl.Nc1ncnc2occ(-c3ccc(NC(=O)Nc4cc(C(F)(F)F)ccc4F)cc3)c12		CHEMBL588025	=	Inhibition	%	0.86	CHEMBL3045	Homo sapiens	Inhibition	%	0.86
	8115176	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	Cl.Nc1ncnc2occ(-c3ccc(NC(=O)Nc4cc(C(F)(F)F)ccc4F)cc3)c12		CHEMBL588025	=	Inhibition	%	1.13	CHEMBL3045	Homo sapiens	Inhibition	%	1.13
	8115181	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	Cl.Nc1ncnc2occ(-c3ccc(NC(=O)Nc4cc(C(F)(F)F)ccc4F)cc3)c12		CHEMBL588025	=	Inhibition	%	1.67	CHEMBL3045	Homo sapiens	Inhibition	%	1.67
	8115341	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	CC(=O)Nc1cccc(C#Cc2cncnc2Nc2ccc(OCc3cccc(F)c3)c(Cl)c2)n1		CHEMBL205765	=	Inhibition	%	5.03	CHEMBL3045	Homo sapiens	Inhibition	%	5.03
	8115346	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	CC(=O)Nc1cccc(C#Cc2cncnc2Nc2ccc(OCc3cccc(F)c3)c(Cl)c2)n1		CHEMBL205765	=	Inhibition	%	2.66	CHEMBL3045	Homo sapiens	Inhibition	%	2.66
	8115685	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1nc(-c2ccc3ncnc(Nc4ccc(F)c(Cl)c4)c3c2)cs1.Cl		CHEMBL1909355	=	Inhibition	%	1.56	CHEMBL3045	Homo sapiens	Inhibition	%	1.56
	8115690	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1nc(-c2ccc3ncnc(Nc4ccc(F)c(Cl)c4)c3c2)cs1.Cl		CHEMBL1909355	=	Inhibition	%	-0.23	CHEMBL3045	Homo sapiens	Inhibition	%	-0.23
	8115818	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OC[C@@H]3CCCN3)c21.O=C(O)C(F)(F)F		CHEMBL1909375	=	Inhibition	%	61.32	CHEMBL3045	Homo sapiens	Inhibition	%	61.32
	8115823	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OC[C@@H]3CCCN3)c21.O=C(O)C(F)(F)F		CHEMBL1909375	=	Inhibition	%	37.14	CHEMBL3045	Homo sapiens	Inhibition	%	37.14
	8116201	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	CC(C)(CO)CNC(=O)c1ccc2c(c1)/C(=N/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2		CHEMBL410072	=	Inhibition	%	0.02	CHEMBL3045	Homo sapiens	Inhibition	%	0.02
	8116206	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	CC(C)(CO)CNC(=O)c1ccc2c(c1)/C(=N/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2		CHEMBL410072	=	Inhibition	%	1.12	CHEMBL3045	Homo sapiens	Inhibition	%	1.12
	8116404	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OC3CCNCC3)c21.O=C(O)C(F)(F)F		CHEMBL1794066	=	Inhibition	%	41.75	CHEMBL3045	Homo sapiens	Inhibition	%	41.75
	8116409	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OC3CCNCC3)c21.O=C(O)C(F)(F)F		CHEMBL1794066	=	Inhibition	%	19.73	CHEMBL3045	Homo sapiens	Inhibition	%	19.73
	8116762	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	CC(C)c1ccc2c(c1)NC(=O)/C2=N/Nc1ccc(S(N)(=O)=O)cc1		CHEMBL271594	=	Inhibition	%	-0.04	CHEMBL3045	Homo sapiens	Inhibition	%	-0.04
	8116767	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	CC(C)c1ccc2c(c1)NC(=O)/C2=N/Nc1ccc(S(N)(=O)=O)cc1		CHEMBL271594	=	Inhibition	%	-0.24	CHEMBL3045	Homo sapiens	Inhibition	%	-0.24
	8116934	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	Nc1ncc(-c2cccc(S(N)(=O)=O)c2)c2scc(-c3ccc(F)c(Cl)c3)c12		CHEMBL241517	=	Inhibition	%	0.9	CHEMBL3045	Homo sapiens	Inhibition	%	0.9
	8116939	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	Nc1ncc(-c2cccc(S(N)(=O)=O)c2)c2scc(-c3ccc(F)c(Cl)c3)c12		CHEMBL241517	=	Inhibition	%	1.52	CHEMBL3045	Homo sapiens	Inhibition	%	1.52
	8117329	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	Cl.NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3cccc(CCc4ccncc4)c32)cc1		CHEMBL1909399	=	Inhibition	%	-0.59	CHEMBL3045	Homo sapiens	Inhibition	%	-0.59
	8117334	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	Cl.NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3cccc(CCc4ccncc4)c32)cc1		CHEMBL1909399	=	Inhibition	%	-0.03	CHEMBL3045	Homo sapiens	Inhibition	%	-0.03
	8117487	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)nc(OCCNC)cc21.Cl		CHEMBL1909350	=	Inhibition	%	29.9	CHEMBL3045	Homo sapiens	Inhibition	%	29.9
	8117492	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)nc(OCCNC)cc21.Cl		CHEMBL1909350	=	Inhibition	%	10.76	CHEMBL3045	Homo sapiens	Inhibition	%	10.76
	8117841	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5ccccc5)c(Cl)c4)c3c2)o1.Cl		CHEMBL529066	=	Inhibition	%	-2.64	CHEMBL3045	Homo sapiens	Inhibition	%	-2.64
	8117846	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5ccccc5)c(Cl)c4)c3c2)o1.Cl		CHEMBL529066	=	Inhibition	%	0.08	CHEMBL3045	Homo sapiens	Inhibition	%	0.08
	8117979	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	Fc1ccc(-c2ncn(C3CCNCC3)c2-c2ccnc(Oc3ccc(F)c(F)c3)n2)cc1		CHEMBL1785004	=	Inhibition	%	-0.22	CHEMBL3045	Homo sapiens	Inhibition	%	-0.22
	8117984	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	Fc1ccc(-c2ncn(C3CCNCC3)c2-c2ccnc(Oc3ccc(F)c(F)c3)n2)cc1		CHEMBL1785004	=	Inhibition	%	0.97	CHEMBL3045	Homo sapiens	Inhibition	%	0.97
	8118203	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	Fc1ccc(-c2ncn(C3CCNCC3)c2-c2ccnc(Oc3ccc(F)c(F)c3)n2)cc1		CHEMBL1785004	=	Inhibition	%	3.21	CHEMBL3045	Homo sapiens	Inhibition	%	3.21
	8118208	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	Fc1ccc(-c2ncn(C3CCNCC3)c2-c2ccnc(Oc3ccc(F)c(F)c3)n2)cc1		CHEMBL1785004	=	Inhibition	%	3.85	CHEMBL3045	Homo sapiens	Inhibition	%	3.85
	8118319	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	COc1c(C(N)=O)cc(-c2ccc(Cl)cc2)cc1-c1ccc(S(N)(=O)=O)cc1		CHEMBL268885	=	Inhibition	%	0.62	CHEMBL3045	Homo sapiens	Inhibition	%	0.62
	8118324	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	COc1c(C(N)=O)cc(-c2ccc(Cl)cc2)cc1-c1ccc(S(N)(=O)=O)cc1		CHEMBL268885	=	Inhibition	%	1.11	CHEMBL3045	Homo sapiens	Inhibition	%	1.11
	8118491	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(C(F)(F)F)c5)cc4)c3c2)o1.Cl		CHEMBL1909387	=	Inhibition	%	0.08	CHEMBL3045	Homo sapiens	Inhibition	%	0.08
	8118496	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(C(F)(F)F)c5)cc4)c3c2)o1.Cl		CHEMBL1909387	=	Inhibition	%	3.15	CHEMBL3045	Homo sapiens	Inhibition	%	3.15
	8118715	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	Fc1ccc(-c2ncn(C3CCNCC3)c2-c2ccnc(Oc3cccc(F)c3)n2)cc1		CHEMBL14014	=	Inhibition	%	2.31	CHEMBL3045	Homo sapiens	Inhibition	%	2.31
	8118720	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	Fc1ccc(-c2ncn(C3CCNCC3)c2-c2ccnc(Oc3cccc(F)c3)n2)cc1		CHEMBL14014	=	Inhibition	%	1.84	CHEMBL3045	Homo sapiens	Inhibition	%	1.84
	8118851	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	Fc1cccc(COc2ccc(Nc3ncnc4sc(-c5ccco5)cc34)cc2Cl)c1		CHEMBL514938	=	Inhibition	%	-3.68	CHEMBL3045	Homo sapiens	Inhibition	%	-3.68
	8118856	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	Fc1cccc(COc2ccc(Nc3ncnc4sc(-c5ccco5)cc34)cc2Cl)c1		CHEMBL514938	=	Inhibition	%	1.15	CHEMBL3045	Homo sapiens	Inhibition	%	1.15
	8119122	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc(C)c(NC(=O)CN(C)C)cc1Nc1nc(Nc2cccc(F)c2C(N)=O)c2cc[nH]c2n1		CHEMBL511765	=	Inhibition	%	-0.18	CHEMBL3045	Homo sapiens	Inhibition	%	-0.18
	8119127	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc(C)c(NC(=O)CN(C)C)cc1Nc1nc(Nc2cccc(F)c2C(N)=O)c2cc[nH]c2n1		CHEMBL511765	=	Inhibition	%	0.38	CHEMBL3045	Homo sapiens	Inhibition	%	0.38
	8119505	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc(C=NNc2ncnc3c2cnn3-c2ccccc2)ccc1O		CHEMBL1789961	=	Inhibition	%	1.19	CHEMBL3045	Homo sapiens	Inhibition	%	1.19
	8119510	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc(C=NNc2ncnc3c2cnn3-c2ccccc2)ccc1O		CHEMBL1789961	=	Inhibition	%	1.72	CHEMBL3045	Homo sapiens	Inhibition	%	1.72
	8119672	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	CC(=O)Nc1cccc(C#Cc2cncnc2Nc2ccc(OCc3cccc(F)c3)c(Cl)c2)n1		CHEMBL205765	=	Inhibition	%	8.84	CHEMBL3045	Homo sapiens	Inhibition	%	8.84
	8119677	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	CC(=O)Nc1cccc(C#Cc2cncnc2Nc2ccc(OCc3cccc(F)c3)c(Cl)c2)n1		CHEMBL205765	=	Inhibition	%	2.15	CHEMBL3045	Homo sapiens	Inhibition	%	2.15
	8120015	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1nc(-c2ccc3ncnc(Nc4ccc(F)c(Cl)c4)c3c2)cs1.Cl		CHEMBL1909355	=	Inhibition	%	2.07	CHEMBL3045	Homo sapiens	Inhibition	%	2.07
	8120020	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1nc(-c2ccc3ncnc(Nc4ccc(F)c(Cl)c4)c3c2)cs1.Cl		CHEMBL1909355	=	Inhibition	%	2.18	CHEMBL3045	Homo sapiens	Inhibition	%	2.18
	8120154	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	Cc1ccc2c(-c3ccnc(Nc4ccc5c(c4)OCCO5)n3)c(-c3ccc(C(F)(F)F)cc3)nn2n1		CHEMBL188247	=	Inhibition	%	2.2	CHEMBL3045	Homo sapiens	Inhibition	%	2.2
	8120159	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	Cc1ccc2c(-c3ccnc(Nc4ccc5c(c4)OCCO5)n3)c(-c3ccc(C(F)(F)F)cc3)nn2n1		CHEMBL188247	=	Inhibition	%	0.24	CHEMBL3045	Homo sapiens	Inhibition	%	0.24
	8120378	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	Cc1ccc2c(-c3ccnc(Nc4ccc5c(c4)OCCO5)n3)c(-c3ccc(C(F)(F)F)cc3)nn2n1		CHEMBL188247	=	Inhibition	%	2.03	CHEMBL3045	Homo sapiens	Inhibition	%	2.03
	8120383	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	Cc1ccc2c(-c3ccnc(Nc4ccc5c(c4)OCCO5)n3)c(-c3ccc(C(F)(F)F)cc3)nn2n1		CHEMBL188247	=	Inhibition	%	2.06	CHEMBL3045	Homo sapiens	Inhibition	%	2.06
	8120538	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	Cl.O=C(O[C@H]1CN[C@H](C#Cc2cc3ncnc(Nc4ccc5c(cnn5Cc5ccccc5)c4)c3s2)C1)N1CCOCC1		CHEMBL1909408	=	Inhibition	%	-0.18	CHEMBL3045	Homo sapiens	Inhibition	%	-0.18
	8120543	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	Cl.O=C(O[C@H]1CN[C@H](C#Cc2cc3ncnc(Nc4ccc5c(cnn5Cc5ccccc5)c4)c3s2)C1)N1CCOCC1		CHEMBL1909408	=	Inhibition	%	-0.16	CHEMBL3045	Homo sapiens	Inhibition	%	-0.16
	8120739	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OC3CCNCC3)c21.O=C(O)C(F)(F)F		CHEMBL1794066	=	Inhibition	%	73.17	CHEMBL3045	Homo sapiens	Inhibition	%	73.17
	8120744	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OC3CCNCC3)c21.O=C(O)C(F)(F)F		CHEMBL1794066	=	Inhibition	%	61.68	CHEMBL3045	Homo sapiens	Inhibition	%	61.68
	8121091	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	CC(C)c1ccc2c(c1)NC(=O)/C2=N/Nc1ccc(S(N)(=O)=O)cc1		CHEMBL271594	=	Inhibition	%	-5.38	CHEMBL3045	Homo sapiens	Inhibition	%	-5.38
	8121096	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	CC(C)c1ccc2c(c1)NC(=O)/C2=N/Nc1ccc(S(N)(=O)=O)cc1		CHEMBL271594	=	Inhibition	%	0.73	CHEMBL3045	Homo sapiens	Inhibition	%	0.73
	8121263	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	O=C(O)C(F)(F)F.O=C(O[C@H]1CN[C@H](C#Cc2cc3ncnc(Nc4ccc(Cc5ccccc5)cc4)c3s2)C1)N1CCOCC1		CHEMBL1909409	=	Inhibition	%	2.02	CHEMBL3045	Homo sapiens	Inhibition	%	2.02
	8121268	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	O=C(O)C(F)(F)F.O=C(O[C@H]1CN[C@H](C#Cc2cc3ncnc(Nc4ccc(Cc5ccccc5)cc4)c3s2)C1)N1CCOCC1		CHEMBL1909409	=	Inhibition	%	2.68	CHEMBL3045	Homo sapiens	Inhibition	%	2.68
	8121487	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	O=C(O)C(F)(F)F.O=C(O[C@H]1CN[C@H](C#Cc2cc3ncnc(Nc4ccc(Cc5ccccc5)cc4)c3s2)C1)N1CCOCC1		CHEMBL1909409	=	Inhibition	%	4.66	CHEMBL3045	Homo sapiens	Inhibition	%	4.66
	8121492	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	O=C(O)C(F)(F)F.O=C(O[C@H]1CN[C@H](C#Cc2cc3ncnc(Nc4ccc(Cc5ccccc5)cc4)c3s2)C1)N1CCOCC1		CHEMBL1909409	=	Inhibition	%	4.05	CHEMBL3045	Homo sapiens	Inhibition	%	4.05
	8121654	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	Cl.NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3cccc(CCc4ccncc4)c32)cc1		CHEMBL1909399	=	Inhibition	%	-0.96	CHEMBL3045	Homo sapiens	Inhibition	%	-0.96
	8121659	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	Cl.NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3cccc(CCc4ccncc4)c32)cc1		CHEMBL1909399	=	Inhibition	%	0.05	CHEMBL3045	Homo sapiens	Inhibition	%	0.05
	8121817	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	NC(=O)c1sc(-n2cnc3ccccc32)cc1OCc1ccccc1Br		CHEMBL518953	=	Inhibition	%	-0.55	CHEMBL3045	Homo sapiens	Inhibition	%	-0.55
	8121822	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	NC(=O)c1sc(-n2cnc3ccccc32)cc1OCc1ccccc1Br		CHEMBL518953	=	Inhibition	%	1.02	CHEMBL3045	Homo sapiens	Inhibition	%	1.02
	8122162	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	Nc1ncnc2occ(-c3ccc(NC(=O)Nc4cc(C(F)(F)F)ccc4F)cc3)c12		CHEMBL247228	=	Inhibition	%	-0.26	CHEMBL3045	Homo sapiens	Inhibition	%	-0.26
	8122167	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	Nc1ncnc2occ(-c3ccc(NC(=O)Nc4cc(C(F)(F)F)ccc4F)cc3)c12		CHEMBL247228	=	Inhibition	%	-0.64	CHEMBL3045	Homo sapiens	Inhibition	%	-0.64
	8122524	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(N/C=C2\C(=O)Nc3ccc4ncsc4c32)cc1		CHEMBL271595	=	Inhibition	%	-0.49	CHEMBL3045	Homo sapiens	Inhibition	%	-0.49
	8122529	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(N/C=C2\C(=O)Nc3ccc4ncsc4c32)cc1		CHEMBL271595	=	Inhibition	%	1.34	CHEMBL3045	Homo sapiens	Inhibition	%	1.34
	8122644	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	COc1c(C(N)=O)cc(-c2ccc(Cl)cc2)cc1-c1ccc(S(N)(=O)=O)cc1		CHEMBL268885	=	Inhibition	%	3.84	CHEMBL3045	Homo sapiens	Inhibition	%	3.84
	8122649	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	COc1c(C(N)=O)cc(-c2ccc(Cl)cc2)cc1-c1ccc(S(N)(=O)=O)cc1		CHEMBL268885	=	Inhibition	%	3.56	CHEMBL3045	Homo sapiens	Inhibition	%	3.56
	8123035	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	Fc1ccc(-c2ncn(C3CCNCC3)c2-c2ccnc(Oc3cccc(F)c3)n2)cc1		CHEMBL14014	=	Inhibition	%	8.71	CHEMBL3045	Homo sapiens	Inhibition	%	8.71
	8123040	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	Fc1ccc(-c2ncn(C3CCNCC3)c2-c2ccnc(Oc3cccc(F)c3)n2)cc1		CHEMBL14014	=	Inhibition	%	6.85	CHEMBL3045	Homo sapiens	Inhibition	%	6.85
	8123177	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(OCc4ccccc4C(F)(F)F)c(C(N)=O)s3)c2cc1OC		CHEMBL514499	=	Inhibition	%	0.23	CHEMBL3045	Homo sapiens	Inhibition	%	0.23
	8123182	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(OCc4ccccc4C(F)(F)F)c(C(N)=O)s3)c2cc1OC		CHEMBL514499	=	Inhibition	%	1.23	CHEMBL3045	Homo sapiens	Inhibition	%	1.23
	8123401	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(OCc4ccccc4C(F)(F)F)c(C(N)=O)s3)c2cc1OC		CHEMBL514499	=	Inhibition	%	0.89	CHEMBL3045	Homo sapiens	Inhibition	%	0.89
	8123406	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(OCc4ccccc4C(F)(F)F)c(C(N)=O)s3)c2cc1OC		CHEMBL514499	=	Inhibition	%	2.0	CHEMBL3045	Homo sapiens	Inhibition	%	2.0
	8123455	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	COc1cc(C)c(NC(=O)CN(C)C)cc1Nc1nc(Nc2cccc(F)c2C(N)=O)c2cc[nH]c2n1		CHEMBL511765	=	Inhibition	%	-0.1	CHEMBL3045	Homo sapiens	Inhibition	%	-0.1
	8123460	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	COc1cc(C)c(NC(=O)CN(C)C)cc1Nc1nc(Nc2cccc(F)c2C(N)=O)c2cc[nH]c2n1		CHEMBL511765	=	Inhibition	%	0.55	CHEMBL3045	Homo sapiens	Inhibition	%	0.55
	8123679	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc(Nc2ncc3c(C)nc(-c4cccc(Oc5ccccc5)c4)n3n2)cc(OC)c1OC		CHEMBL519881	=	Inhibition	%	-0.46	CHEMBL3045	Homo sapiens	Inhibition	%	-0.46
	8123829	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	COc1cc(C=NNc2ncnc3c2cnn3-c2ccccc2)ccc1O		CHEMBL1789961	=	Inhibition	%	4.02	CHEMBL3045	Homo sapiens	Inhibition	%	4.02
	8123834	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	COc1cc(C=NNc2ncnc3c2cnn3-c2ccccc2)ccc1O		CHEMBL1789961	=	Inhibition	%	5.98	CHEMBL3045	Homo sapiens	Inhibition	%	5.98
	8123996	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	COc1cccc(-n2cnc3c(N/N=C/c4ccncc4)ncnc32)c1		CHEMBL204934	=	Inhibition	%	3.24	CHEMBL3045	Homo sapiens	Inhibition	%	3.24
	8124001	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	COc1cccc(-n2cnc3c(N/N=C/c4ccncc4)ncnc32)c1		CHEMBL204934	=	Inhibition	%	2.34	CHEMBL3045	Homo sapiens	Inhibition	%	2.34
	8124220	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	COc1cccc(-n2cnc3c(N/N=C/c4ccncc4)ncnc32)c1		CHEMBL204934	=	Inhibition	%	5.82	CHEMBL3045	Homo sapiens	Inhibition	%	5.82
	8124225	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	COc1cccc(-n2cnc3c(N/N=C/c4ccncc4)ncnc32)c1		CHEMBL204934	=	Inhibition	%	2.1	CHEMBL3045	Homo sapiens	Inhibition	%	2.1
	8124339	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	COc1cccc(Nc2nccc(-c3cnn4ncccc34)n2)c1		CHEMBL187081	=	Inhibition	%	0.55	CHEMBL3045	Homo sapiens	Inhibition	%	0.55
	8124344	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	COc1cccc(Nc2nccc(-c3cnn4ncccc34)n2)c1		CHEMBL187081	=	Inhibition	%	0.37	CHEMBL3045	Homo sapiens	Inhibition	%	0.37
	8124702	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	O=C1NC(=O)C(c2cccc([N+](=O)[O-])c2)=C1Nc1cc(Cl)c(O)c(Cl)c1		CHEMBL352222	=	Inhibition	%	-0.53	CHEMBL3045	Homo sapiens	Inhibition	%	-0.53
	8124707	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	O=C1NC(=O)C(c2cccc([N+](=O)[O-])c2)=C1Nc1cc(Cl)c(O)c(Cl)c1		CHEMBL352222	=	Inhibition	%	0.87	CHEMBL3045	Homo sapiens	Inhibition	%	0.87
	8124867	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	Cl.O=C(O[C@H]1CN[C@H](C#Cc2cc3ncnc(Nc4ccc5c(cnn5Cc5ccccc5)c4)c3s2)C1)N1CCOCC1		CHEMBL1909408	=	Inhibition	%	-6.28	CHEMBL3045	Homo sapiens	Inhibition	%	-6.28
	8124872	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	Cl.O=C(O[C@H]1CN[C@H](C#Cc2cc3ncnc(Nc4ccc5c(cnn5Cc5ccccc5)c4)c3s2)C1)N1CCOCC1		CHEMBL1909408	=	Inhibition	%	-0.06	CHEMBL3045	Homo sapiens	Inhibition	%	-0.06
	8125068	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	CCc1ccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)cc1		CHEMBL428877	=	Inhibition	%	3.94	CHEMBL3045	Homo sapiens	Inhibition	%	3.94
	8125073	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	CCc1ccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)cc1		CHEMBL428877	=	Inhibition	%	2.37	CHEMBL3045	Homo sapiens	Inhibition	%	2.37
	8125292	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	CCc1ccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)cc1		CHEMBL428877	=	Inhibition	%	14.86	CHEMBL3045	Homo sapiens	Inhibition	%	14.86
	8125297	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	CCc1ccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)cc1		CHEMBL428877	=	Inhibition	%	9.56	CHEMBL3045	Homo sapiens	Inhibition	%	9.56
	8125422	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	O=C(Nc1n[nH]c2nnc(-c3cccnc3)cc12)C1CC1.O=C(O)C(F)(F)F		CHEMBL1909343	=	Inhibition	%	-0.7	CHEMBL3045	Homo sapiens	Inhibition	%	-0.7
	8125427	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	O=C(Nc1n[nH]c2nnc(-c3cccnc3)cc12)C1CC1.O=C(O)C(F)(F)F		CHEMBL1909343	=	Inhibition	%	0.49	CHEMBL3045	Homo sapiens	Inhibition	%	0.49
	8125814	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	FC(F)(F)CNc1nccc(-c2cnn3ncccc23)n1		CHEMBL446024	=	Inhibition	%	1.27	CHEMBL3045	Homo sapiens	Inhibition	%	1.27
	8125819	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	FC(F)(F)CNc1nccc(-c2cnn3ncccc23)n1		CHEMBL446024	=	Inhibition	%	0.94	CHEMBL3045	Homo sapiens	Inhibition	%	0.94
	8125978	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	CCN1CCC(C(=O)Nc2n[nH]c3nnc(-c4cccc(F)c4F)cc23)CC1.Cl		CHEMBL1909345	=	Inhibition	%	-0.34	CHEMBL3045	Homo sapiens	Inhibition	%	-0.34
	8125983	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	CCN1CCC(C(=O)Nc2n[nH]c3nnc(-c4cccc(F)c4F)cc23)CC1.Cl		CHEMBL1909345	=	Inhibition	%	0.39	CHEMBL3045	Homo sapiens	Inhibition	%	0.39
	8126142	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	NC(=O)c1sc(-n2cnc3ccccc32)cc1OCc1ccccc1Br		CHEMBL518953	=	Inhibition	%	0.73	CHEMBL3045	Homo sapiens	Inhibition	%	0.73
	8126147	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	NC(=O)c1sc(-n2cnc3ccccc32)cc1OCc1ccccc1Br		CHEMBL518953	=	Inhibition	%	2.96	CHEMBL3045	Homo sapiens	Inhibition	%	2.96
	8126366	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	CCN(CC)Cc1ccc(Nc2nccc(-c3cnn4ncccc34)n2)cc1		CHEMBL1882194	=	Inhibition	%	0.22	CHEMBL3045	Homo sapiens	Inhibition	%	0.22
	8126371	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	CCN(CC)Cc1ccc(Nc2nccc(-c3cnn4ncccc34)n2)cc1		CHEMBL1882194	=	Inhibition	%	1.0	CHEMBL3045	Homo sapiens	Inhibition	%	1.0
	8126481	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	Nc1ncnc2occ(-c3ccc(NC(=O)Nc4cc(C(F)(F)F)ccc4F)cc3)c12		CHEMBL247228	=	Inhibition	%	0.29	CHEMBL3045	Homo sapiens	Inhibition	%	0.29
	8126486	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	Nc1ncnc2occ(-c3ccc(NC(=O)Nc4cc(C(F)(F)F)ccc4F)cc3)c12		CHEMBL247228	=	Inhibition	%	0.08	CHEMBL3045	Homo sapiens	Inhibition	%	0.08
	8126841	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(N/C=C2\C(=O)Nc3ccc4ncsc4c32)cc1	Outside typical range	CHEMBL271595	=	Inhibition	%	-12.46	CHEMBL3045	Homo sapiens	Inhibition	%	-12.46
	8126846	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(N/C=C2\C(=O)Nc3ccc4ncsc4c32)cc1		CHEMBL271595	=	Inhibition	%	3.28	CHEMBL3045	Homo sapiens	Inhibition	%	3.28
	8126963	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	Fc1ccc(-c2ncn(C3CCNCC3)c2-c2ccnc(Oc3ccc(Oc4ccccc4)cc3)n2)cc1		CHEMBL13868	=	Inhibition	%	1.48	CHEMBL3045	Homo sapiens	Inhibition	%	1.48
	8126968	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	Fc1ccc(-c2ncn(C3CCNCC3)c2-c2ccnc(Oc3ccc(Oc4ccccc4)cc3)n2)cc1		CHEMBL13868	=	Inhibition	%	2.63	CHEMBL3045	Homo sapiens	Inhibition	%	2.63
	8127187	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	Fc1ccc(-c2ncn(C3CCNCC3)c2-c2ccnc(Oc3ccc(Oc4ccccc4)cc3)n2)cc1		CHEMBL13868	=	Inhibition	%	11.23	CHEMBL3045	Homo sapiens	Inhibition	%	11.23
	8127192	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	Fc1ccc(-c2ncn(C3CCNCC3)c2-c2ccnc(Oc3ccc(Oc4ccccc4)cc3)n2)cc1		CHEMBL13868	=	Inhibition	%	12.41	CHEMBL3045	Homo sapiens	Inhibition	%	12.41
	8127354	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	CCS(=O)(=O)c1ccc(OC)c(Nc2ncc(-c3cccc(F)c3)o2)c1		CHEMBL179465	=	Inhibition	%	-1.13	CHEMBL3045	Homo sapiens	Inhibition	%	-1.13
	8127359	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	CCS(=O)(=O)c1ccc(OC)c(Nc2ncc(-c3cccc(F)c3)o2)c1		CHEMBL179465	=	Inhibition	%	1.9	CHEMBL3045	Homo sapiens	Inhibition	%	1.9
	8127720	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	Nc1ncnc2occ(-c3ccc(NC(=O)Nc4cccc(C(F)(F)F)c4)cc3)c12		CHEMBL273564	=	Inhibition	%	0.7	CHEMBL3045	Homo sapiens	Inhibition	%	0.7
	8127725	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	Nc1ncnc2occ(-c3ccc(NC(=O)Nc4cccc(C(F)(F)F)c4)cc3)c12		CHEMBL273564	=	Inhibition	%	1.71	CHEMBL3045	Homo sapiens	Inhibition	%	1.71
	8127789	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc(Nc2ncc3c(C)nc(-c4cccc(Oc5ccccc5)c4)n3n2)cc(OC)c1OC		CHEMBL519881	=	Inhibition	%	0.53	CHEMBL3045	Homo sapiens	Inhibition	%	0.53
	8128008	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	COc1cc(Nc2ncc3c(C)nc(-c4cccc(Oc5ccccc5)c4)n3n2)cc(OC)c1OC		CHEMBL519881	=	Inhibition	%	-0.16	CHEMBL3045	Homo sapiens	Inhibition	%	-0.16
	8128013	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	COc1cc(Nc2ncc3c(C)nc(-c4cccc(Oc5ccccc5)c4)n3n2)cc(OC)c1OC		CHEMBL519881	=	Inhibition	%	0.55	CHEMBL3045	Homo sapiens	Inhibition	%	0.55
	8128160	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	Cc1cc(O)cc(C)c1/C=C/c1cncc(C(=O)N(C)C)c1		CHEMBL220244	=	Inhibition	%	0.67	CHEMBL3045	Homo sapiens	Inhibition	%	0.67
	8128165	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	Cc1cc(O)cc(C)c1/C=C/c1cncc(C(=O)N(C)C)c1		CHEMBL220244	=	Inhibition	%	0.19	CHEMBL3045	Homo sapiens	Inhibition	%	0.19
	8128551	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	CNC(=O)c1cncc(/C=C/c2ccccc2Cl)c1		CHEMBL218970	=	Inhibition	%	2.7	CHEMBL3045	Homo sapiens	Inhibition	%	2.7
	8128556	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	CNC(=O)c1cncc(/C=C/c2ccccc2Cl)c1		CHEMBL218970	=	Inhibition	%	2.46	CHEMBL3045	Homo sapiens	Inhibition	%	2.46
	8128670	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	COc1cccc(Nc2nccc(-c3cnn4ncccc34)n2)c1		CHEMBL187081	=	Inhibition	%	5.61	CHEMBL3045	Homo sapiens	Inhibition	%	5.61
	8128675	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	COc1cccc(Nc2nccc(-c3cnn4ncccc34)n2)c1		CHEMBL187081	=	Inhibition	%	7.43	CHEMBL3045	Homo sapiens	Inhibition	%	7.43
	8129031	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	O=C1NC(=O)C(c2cccc([N+](=O)[O-])c2)=C1Nc1cc(Cl)c(O)c(Cl)c1		CHEMBL352222	=	Inhibition	%	1.87	CHEMBL3045	Homo sapiens	Inhibition	%	1.87
	8129036	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	O=C1NC(=O)C(c2cccc([N+](=O)[O-])c2)=C1Nc1cc(Cl)c(O)c(Cl)c1		CHEMBL352222	=	Inhibition	%	3.52	CHEMBL3045	Homo sapiens	Inhibition	%	3.52
	8129202	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	CN(C)CCOc1ccc(-c2cc(-c3ccc4c(c3)CCC4=NO)c(-c3ccncc3)o2)cc1.Cl		CHEMBL1794072	=	Inhibition	%	-1.02	CHEMBL3045	Homo sapiens	Inhibition	%	-1.02
	8129207	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	CN(C)CCOc1ccc(-c2cc(-c3ccc4c(c3)CCC4=NO)c(-c3ccncc3)o2)cc1.Cl		CHEMBL1794072	=	Inhibition	%	-0.72	CHEMBL3045	Homo sapiens	Inhibition	%	-0.72
	8129426	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	CN(C)CCOc1ccc(-c2cc(-c3ccc4c(c3)CCC4=NO)c(-c3ccncc3)o2)cc1.Cl		CHEMBL1794072	=	Inhibition	%	4.4	CHEMBL3045	Homo sapiens	Inhibition	%	4.4
	8129615	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	CN1CCN(C(=O)c2ccc(NC(=O)Nc3ccc(N(C)c4ccnc(Nc5ccc(CS(C)(=O)=O)cc5)n4)cc3)cc2)CC1.Cl		CHEMBL1909360	=	Inhibition	%	0.01	CHEMBL3045	Homo sapiens	Inhibition	%	0.01
	8129620	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	CN1CCN(C(=O)c2ccc(NC(=O)Nc3ccc(N(C)c4ccnc(Nc5ccc(CS(C)(=O)=O)cc5)n4)cc3)cc2)CC1.Cl		CHEMBL1909360	=	Inhibition	%	1.51	CHEMBL3045	Homo sapiens	Inhibition	%	1.51
	8129754	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	O=C(Nc1n[nH]c2nnc(-c3cccnc3)cc12)C1CC1.O=C(O)C(F)(F)F		CHEMBL1909343	=	Inhibition	%	0.6	CHEMBL3045	Homo sapiens	Inhibition	%	0.6
	8129759	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	O=C(Nc1n[nH]c2nnc(-c3cccnc3)cc12)C1CC1.O=C(O)C(F)(F)F		CHEMBL1909343	=	Inhibition	%	3.21	CHEMBL3045	Homo sapiens	Inhibition	%	3.21
	8130139	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	FC(F)(F)CNc1nccc(-c2cnn3ncccc23)n1		CHEMBL446024	=	Inhibition	%	1.54	CHEMBL3045	Homo sapiens	Inhibition	%	1.54
	8130144	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	FC(F)(F)CNc1nccc(-c2cnn3ncccc23)n1		CHEMBL446024	=	Inhibition	%	1.72	CHEMBL3045	Homo sapiens	Inhibition	%	1.72
	8130311	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	CCN1CCC(C(=O)Nc2n[nH]c3nnc(-c4cccc(F)c4F)cc23)CC1.Cl		CHEMBL1909345	=	Inhibition	%	-0.14	CHEMBL3045	Homo sapiens	Inhibition	%	-0.14
	8130316	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	CCN1CCC(C(=O)Nc2n[nH]c3nnc(-c4cccc(F)c4F)cc23)CC1.Cl		CHEMBL1909345	=	Inhibition	%	0.87	CHEMBL3045	Homo sapiens	Inhibition	%	0.87
	8130695	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	CCN(CC)Cc1ccc(Nc2nccc(-c3cnn4ncccc34)n2)cc1		CHEMBL1882194	=	Inhibition	%	-5.55	CHEMBL3045	Homo sapiens	Inhibition	%	-5.55
	8130700	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	CCN(CC)Cc1ccc(Nc2nccc(-c3cnn4ncccc34)n2)cc1		CHEMBL1882194	=	Inhibition	%	6.38	CHEMBL3045	Homo sapiens	Inhibition	%	6.38
	8130811	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)c1ccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)cc1		CHEMBL418348	=	Inhibition	%	2.26	CHEMBL3045	Homo sapiens	Inhibition	%	2.26
	8130816	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)c1ccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)cc1		CHEMBL418348	=	Inhibition	%	0.91	CHEMBL3045	Homo sapiens	Inhibition	%	0.91
	8131035	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)c1ccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)cc1		CHEMBL418348	=	Inhibition	%	2.31	CHEMBL3045	Homo sapiens	Inhibition	%	2.31
	8131040	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)c1ccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)cc1		CHEMBL418348	=	Inhibition	%	3.5	CHEMBL3045	Homo sapiens	Inhibition	%	3.5
	8131174	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccccc1Oc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCNCC2)n1		CHEMBL417804	=	Inhibition	%	1.79	CHEMBL3045	Homo sapiens	Inhibition	%	1.79
	8131179	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccccc1Oc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCNCC2)n1		CHEMBL417804	=	Inhibition	%	1.35	CHEMBL3045	Homo sapiens	Inhibition	%	1.35
	8131518	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	Fc1ccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)cc1		CHEMBL269450	=	Inhibition	%	1.77	CHEMBL3045	Homo sapiens	Inhibition	%	1.77
	8131523	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	Fc1ccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)cc1		CHEMBL269450	=	Inhibition	%	2.0	CHEMBL3045	Homo sapiens	Inhibition	%	2.0
	8131685	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	CCS(=O)(=O)c1ccc(OC)c(Nc2ncc(-c3cccc(F)c3)o2)c1		CHEMBL179465	=	Inhibition	%	2.28	CHEMBL3045	Homo sapiens	Inhibition	%	2.28
	8131690	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	CCS(=O)(=O)c1ccc(OC)c(Nc2ncc(-c3cccc(F)c3)o2)c1		CHEMBL179465	=	Inhibition	%	4.01	CHEMBL3045	Homo sapiens	Inhibition	%	4.01
	8132050	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	Nc1ncnc2occ(-c3ccc(NC(=O)Nc4cccc(C(F)(F)F)c4)cc3)c12		CHEMBL273564	=	Inhibition	%	12.59	CHEMBL3045	Homo sapiens	Inhibition	%	12.59
	8132055	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	Nc1ncnc2occ(-c3ccc(NC(=O)Nc4cccc(C(F)(F)F)c4)cc3)c12		CHEMBL273564	=	Inhibition	%	2.2	CHEMBL3045	Homo sapiens	Inhibition	%	2.2
	8132336	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc(C)c(N(C)C(=O)CN(C)C)cc1Nc1nc(Nc2cccc(F)c2C(N)=O)c2cc[nH]c2n1		CHEMBL467581	=	Inhibition	%	1.6	CHEMBL3045	Homo sapiens	Inhibition	%	1.6
	8132341	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc(C)c(N(C)C(=O)CN(C)C)cc1Nc1nc(Nc2cccc(F)c2C(N)=O)c2cc[nH]c2n1		CHEMBL467581	=	Inhibition	%	0.9	CHEMBL3045	Homo sapiens	Inhibition	%	0.9
	8132483	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	Cc1cc(O)cc(C)c1/C=C/c1cncc(C(=O)N(C)C)c1		CHEMBL220244	=	Inhibition	%	1.26	CHEMBL3045	Homo sapiens	Inhibition	%	1.26
	8132488	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	Cc1cc(O)cc(C)c1/C=C/c1cncc(C(=O)N(C)C)c1		CHEMBL220244	=	Inhibition	%	3.0	CHEMBL3045	Homo sapiens	Inhibition	%	3.0
	8132707	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	CC1=C(C(=O)Nc2ccc3[nH]ncc3c2)C(c2ccc(Cl)c(Cl)c2)CC(=O)N1		CHEMBL374453	=	Inhibition	%	-1.01	CHEMBL3045	Homo sapiens	Inhibition	%	-1.01
	8132712	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	CC1=C(C(=O)Nc2ccc3[nH]ncc3c2)C(c2ccc(Cl)c(Cl)c2)CC(=O)N1		CHEMBL374453	=	Inhibition	%	0.17	CHEMBL3045	Homo sapiens	Inhibition	%	0.17
	8132875	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	CNC(=O)c1cncc(/C=C/c2ccccc2Cl)c1		CHEMBL218970	=	Inhibition	%	5.12	CHEMBL3045	Homo sapiens	Inhibition	%	5.12
	8132880	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	CNC(=O)c1cncc(/C=C/c2ccccc2Cl)c1		CHEMBL218970	=	Inhibition	%	1.4	CHEMBL3045	Homo sapiens	Inhibition	%	1.4
	8132996	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	Clc1ccc(CNc2nccc(-c3cnn4ncccc34)n2)cc1		CHEMBL513330	=	Inhibition	%	0.26	CHEMBL3045	Homo sapiens	Inhibition	%	0.26
	8133001	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	Clc1ccc(CNc2nccc(-c3cnn4ncccc34)n2)cc1		CHEMBL513330	=	Inhibition	%	0.21	CHEMBL3045	Homo sapiens	Inhibition	%	0.21
	8133220	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	Clc1ccc(CNc2nccc(-c3cnn4ncccc34)n2)cc1		CHEMBL513330	=	Inhibition	%	1.03	CHEMBL3045	Homo sapiens	Inhibition	%	1.03
	8133225	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	Clc1ccc(CNc2nccc(-c3cnn4ncccc34)n2)cc1		CHEMBL513330	=	Inhibition	%	0.83	CHEMBL3045	Homo sapiens	Inhibition	%	0.83
	8133358	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	CCN1CCC(CC(=O)Nc2n[nH]c3nnc(-c4cccc(F)c4F)cc23)CC1.O=C(O)C(O)C(O)C(=O)O		CHEMBL2062289	=	Inhibition	%	2.14	CHEMBL3045	Homo sapiens	Inhibition	%	2.14
	8133363	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	CCN1CCC(CC(=O)Nc2n[nH]c3nnc(-c4cccc(F)c4F)cc23)CC1.O=C(O)C(O)C(O)C(=O)O		CHEMBL2062289	=	Inhibition	%	0.16	CHEMBL3045	Homo sapiens	Inhibition	%	0.16
	8133535	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	CN(C)CCOc1ccc(-c2cc(-c3ccc4c(c3)CCC4=NO)c(-c3ccncc3)o2)cc1.Cl		CHEMBL1794072	=	Inhibition	%	2.28	CHEMBL3045	Homo sapiens	Inhibition	%	2.28
	8133754	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	N#Cc1c(NC(=O)c2ccccc2F)sc2c1CCCC2		CHEMBL234838	=	Inhibition	%	0.38	CHEMBL3045	Homo sapiens	Inhibition	%	0.38
	8133759	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	N#Cc1c(NC(=O)c2ccccc2F)sc2c1CCCC2		CHEMBL234838	=	Inhibition	%	-0.47	CHEMBL3045	Homo sapiens	Inhibition	%	-0.47
	8133934	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	CN1CCN(C(=O)c2ccc(NC(=O)Nc3ccc(N(C)c4ccnc(Nc5ccc(CS(C)(=O)=O)cc5)n4)cc3)cc2)CC1.Cl		CHEMBL1909360	=	Inhibition	%	2.15	CHEMBL3045	Homo sapiens	Inhibition	%	2.15
	8133939	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	CN1CCN(C(=O)c2ccc(NC(=O)Nc3ccc(N(C)c4ccnc(Nc5ccc(CS(C)(=O)=O)cc5)n4)cc3)cc2)CC1.Cl		CHEMBL1909360	=	Inhibition	%	2.4	CHEMBL3045	Homo sapiens	Inhibition	%	2.4
	8134082	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc(-c2cc3c(N)ncnc3o2)cc1		CHEMBL373073	=	Inhibition	%	-0.74	CHEMBL3045	Homo sapiens	Inhibition	%	-0.74
	8134087	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc(-c2cc3c(N)ncnc3o2)cc1		CHEMBL373073	=	Inhibition	%	0.45	CHEMBL3045	Homo sapiens	Inhibition	%	0.45
	8134306	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	COc1ccc(-c2cc3c(N)ncnc3o2)cc1		CHEMBL373073	=	Inhibition	%	-2.12	CHEMBL3045	Homo sapiens	Inhibition	%	-2.12
	8134311	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	COc1ccc(-c2cc3c(N)ncnc3o2)cc1		CHEMBL373073	=	Inhibition	%	1.65	CHEMBL3045	Homo sapiens	Inhibition	%	1.65
	8134466	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	Cc1ccc(NC(=O)c2ccoc2)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL477583	=	Inhibition	%	1.84	CHEMBL3045	Homo sapiens	Inhibition	%	1.84
	8134471	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	Cc1ccc(NC(=O)c2ccoc2)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL477583	=	Inhibition	%	-0.21	CHEMBL3045	Homo sapiens	Inhibition	%	-0.21
	8134650	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)Nc1ccc(N/C=C2\C(=O)Nc3ccccc32)cc1		CHEMBL1794058	=	Inhibition	%	-0.94	CHEMBL3045	Homo sapiens	Inhibition	%	-0.94
	8134655	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)Nc1ccc(N/C=C2\C(=O)Nc3ccccc32)cc1		CHEMBL1794058	=	Inhibition	%	-1.02	CHEMBL3045	Homo sapiens	Inhibition	%	-1.02
	8134874	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)Nc1ccc(N/C=C2\C(=O)Nc3ccccc32)cc1		CHEMBL1794058	=	Inhibition	%	-1.13	CHEMBL3045	Homo sapiens	Inhibition	%	-1.13
	8134879	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)Nc1ccc(N/C=C2\C(=O)Nc3ccccc32)cc1		CHEMBL1794058	=	Inhibition	%	-0.85	CHEMBL3045	Homo sapiens	Inhibition	%	-0.85
	8135034	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	Cc1cc(-c2ccccn2)cc(C)c1/C=C/c1cncc(-c2nn[nH]n2)c1.Cl		CHEMBL1909354	=	Inhibition	%	0.54	CHEMBL3045	Homo sapiens	Inhibition	%	0.54
	8135039	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	Cc1cc(-c2ccccn2)cc(C)c1/C=C/c1cncc(-c2nn[nH]n2)c1.Cl		CHEMBL1909354	=	Inhibition	%	1.2	CHEMBL3045	Homo sapiens	Inhibition	%	1.2
	8135373	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5ccccc5)c(C(F)(F)F)c4)c3c2)o1.Cl		CHEMBL1909389	=	Inhibition	%	0.21	CHEMBL3045	Homo sapiens	Inhibition	%	0.21
	8135378	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5ccccc5)c(C(F)(F)F)c4)c3c2)o1.Cl		CHEMBL1909389	=	Inhibition	%	1.11	CHEMBL3045	Homo sapiens	Inhibition	%	1.11
	8135514	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	COc1ccccc1Oc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCNCC2)n1		CHEMBL417804	=	Inhibition	%	3.03	CHEMBL3045	Homo sapiens	Inhibition	%	3.03
	8135519	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	COc1ccccc1Oc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCNCC2)n1		CHEMBL417804	=	Inhibition	%	3.22	CHEMBL3045	Homo sapiens	Inhibition	%	3.22
	8135859	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	Fc1ccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)cc1		CHEMBL269450	=	Inhibition	%	4.96	CHEMBL3045	Homo sapiens	Inhibition	%	4.96
	8135864	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	Fc1ccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)cc1		CHEMBL269450	=	Inhibition	%	3.88	CHEMBL3045	Homo sapiens	Inhibition	%	3.88
	8136027	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	COc1cccc(/C=N/Nc2ncnc3c2cnn3-c2cccc(OC)c2)c1		CHEMBL305477	=	Inhibition	%	-0.96	CHEMBL3045	Homo sapiens	Inhibition	%	-0.96
	8136032	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	COc1cccc(/C=N/Nc2ncnc3c2cnn3-c2cccc(OC)c2)c1		CHEMBL305477	=	Inhibition	%	0.47	CHEMBL3045	Homo sapiens	Inhibition	%	0.47
	8136251	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	COc1cccc(/C=N/Nc2ncnc3c2cnn3-c2cccc(OC)c2)c1		CHEMBL305477	=	Inhibition	%	0.85	CHEMBL3045	Homo sapiens	Inhibition	%	0.85
	8136256	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	COc1cccc(/C=N/Nc2ncnc3c2cnn3-c2cccc(OC)c2)c1		CHEMBL305477	=	Inhibition	%	1.93	CHEMBL3045	Homo sapiens	Inhibition	%	1.93
	8136395	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	Fc1ccc(-c2ncn(C3CCNCC3)c2-c2ccnc(Oc3ccc4c(c3)OCO4)n2)cc1		CHEMBL273611	=	Inhibition	%	1.12	CHEMBL3045	Homo sapiens	Inhibition	%	1.12
	8136400	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	Fc1ccc(-c2ncn(C3CCNCC3)c2-c2ccnc(Oc3ccc4c(c3)OCO4)n2)cc1		CHEMBL273611	=	Inhibition	%	1.38	CHEMBL3045	Homo sapiens	Inhibition	%	1.38
	8136685	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	COc1cc(C)c(N(C)C(=O)CN(C)C)cc1Nc1nc(Nc2cccc(F)c2C(N)=O)c2cc[nH]c2n1		CHEMBL467581	=	Inhibition	%	-0.89	CHEMBL3045	Homo sapiens	Inhibition	%	-0.89
	8136690	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	COc1cc(C)c(N(C)C(=O)CN(C)C)cc1Nc1nc(Nc2cccc(F)c2C(N)=O)c2cc[nH]c2n1		CHEMBL467581	=	Inhibition	%	0.92	CHEMBL3045	Homo sapiens	Inhibition	%	0.92
	8137044	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	CC1=C(C(=O)Nc2ccc3[nH]ncc3c2)C(c2ccc(Cl)c(Cl)c2)CC(=O)N1		CHEMBL374453	=	Inhibition	%	-0.1	CHEMBL3045	Homo sapiens	Inhibition	%	-0.1
	8137049	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	CC1=C(C(=O)Nc2ccc3[nH]ncc3c2)C(c2ccc(Cl)c(Cl)c2)CC(=O)N1		CHEMBL374453	=	Inhibition	%	0.61	CHEMBL3045	Homo sapiens	Inhibition	%	0.61
	8137207	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	CCCNc1cccc(-n2ncc3c(N/N=C/c4ccncc4)ncnc32)c1		CHEMBL67241	=	Inhibition	%	1.35	CHEMBL3045	Homo sapiens	Inhibition	%	1.35
	8137212	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	CCCNc1cccc(-n2ncc3c(N/N=C/c4ccncc4)ncnc32)c1		CHEMBL67241	=	Inhibition	%	3.39	CHEMBL3045	Homo sapiens	Inhibition	%	3.39
	8137551	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	CNC(=O)c1cncc(/C=C/c2c(C)cccc2C)c1		CHEMBL218859	=	Inhibition	%	1.56	CHEMBL3045	Homo sapiens	Inhibition	%	1.56
	8137556	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	CNC(=O)c1cncc(/C=C/c2c(C)cccc2C)c1		CHEMBL218859	=	Inhibition	%	-0.12	CHEMBL3045	Homo sapiens	Inhibition	%	-0.12
	8137699	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	CCN1CCC(CC(=O)Nc2n[nH]c3nnc(-c4cccc(F)c4F)cc23)CC1.O=C(O)C(O)C(O)C(=O)O		CHEMBL2062289	=	Inhibition	%	0.03	CHEMBL3045	Homo sapiens	Inhibition	%	0.03
	8137704	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	CCN1CCC(CC(=O)Nc2n[nH]c3nnc(-c4cccc(F)c4F)cc23)CC1.O=C(O)C(O)C(O)C(=O)O		CHEMBL2062289	=	Inhibition	%	0.85	CHEMBL3045	Homo sapiens	Inhibition	%	0.85
	8138089	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	N#Cc1c(NC(=O)c2ccccc2F)sc2c1CCCC2		CHEMBL234838	=	Inhibition	%	1.07	CHEMBL3045	Homo sapiens	Inhibition	%	1.07
	8138094	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	N#Cc1c(NC(=O)c2ccccc2F)sc2c1CCCC2		CHEMBL234838	=	Inhibition	%	0.43	CHEMBL3045	Homo sapiens	Inhibition	%	0.43
	8138268	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1nc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(C(F)(F)F)c5)cc4)c3c2)cs1.Cl		CHEMBL1909356	=	Inhibition	%	0.26	CHEMBL3045	Homo sapiens	Inhibition	%	0.26
	8138273	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1nc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(C(F)(F)F)c5)cc4)c3c2)cs1.Cl		CHEMBL1909356	=	Inhibition	%	0.86	CHEMBL3045	Homo sapiens	Inhibition	%	0.86
	8138640	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	Cc1ccc(C(=O)NC(C)C)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL477979	=	Inhibition	%	-0.62	CHEMBL3045	Homo sapiens	Inhibition	%	-0.62
	8138645	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	Cc1ccc(C(=O)NC(C)C)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL477979	=	Inhibition	%	-0.65	CHEMBL3045	Homo sapiens	Inhibition	%	-0.65
	8138798	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	Cc1ccc(NC(=O)c2ccoc2)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL477583	=	Inhibition	%	1.76	CHEMBL3045	Homo sapiens	Inhibition	%	1.76
	8138803	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	Cc1ccc(NC(=O)c2ccoc2)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL477583	=	Inhibition	%	0.92	CHEMBL3045	Homo sapiens	Inhibition	%	0.92
	8139207	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	O=C1Nc2ccc(I)cc2C1=Cc1cc(Br)c(O)c(Br)c1		CHEMBL1880739	=	Inhibition	%	0.25	CHEMBL3045	Homo sapiens	Inhibition	%	0.25
	8139212	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	O=C1Nc2ccc(I)cc2C1=Cc1cc(Br)c(O)c(Br)c1		CHEMBL1880739	=	Inhibition	%	0.99	CHEMBL3045	Homo sapiens	Inhibition	%	0.99
	8139366	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	Cc1cc(-c2ccccn2)cc(C)c1/C=C/c1cncc(-c2nn[nH]n2)c1.Cl		CHEMBL1909354	=	Inhibition	%	0.37	CHEMBL3045	Homo sapiens	Inhibition	%	0.37
	8139371	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	Cc1cc(-c2ccccn2)cc(C)c1/C=C/c1cncc(-c2nn[nH]n2)c1.Cl		CHEMBL1909354	=	Inhibition	%	2.79	CHEMBL3045	Homo sapiens	Inhibition	%	2.79
	8139704	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5ccccc5)c(C(F)(F)F)c4)c3c2)o1.Cl		CHEMBL1909389	=	Inhibition	%	1.23	CHEMBL3045	Homo sapiens	Inhibition	%	1.23
	8139709	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5ccccc5)c(C(F)(F)F)c4)c3c2)o1.Cl		CHEMBL1909389	=	Inhibition	%	1.5	CHEMBL3045	Homo sapiens	Inhibition	%	1.5
	8139845	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	O=C(O)C(F)(F)F.[O-][S+]1CCN(Cc2ccc(-c3ccc4ncnc(Nc5ccc(OCc6cccc(F)c6)c(Cl)c5)c4c3)o2)CC1		CHEMBL1909390	=	Inhibition	%	-0.91	CHEMBL3045	Homo sapiens	Inhibition	%	-0.91
	8139850	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	O=C(O)C(F)(F)F.[O-][S+]1CCN(Cc2ccc(-c3ccc4ncnc(Nc5ccc(OCc6cccc(F)c6)c(Cl)c5)c4c3)o2)CC1		CHEMBL1909390	=	Inhibition	%	2.05	CHEMBL3045	Homo sapiens	Inhibition	%	2.05
	8140069	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	O=C(O)C(F)(F)F.[O-][S+]1CCN(Cc2ccc(-c3ccc4ncnc(Nc5ccc(OCc6cccc(F)c6)c(Cl)c5)c4c3)o2)CC1		CHEMBL1909390	=	Inhibition	%	1.67	CHEMBL3045	Homo sapiens	Inhibition	%	1.67
	8140074	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	O=C(O)C(F)(F)F.[O-][S+]1CCN(Cc2ccc(-c3ccc4ncnc(Nc5ccc(OCc6cccc(F)c6)c(Cl)c5)c4c3)o2)CC1		CHEMBL1909390	=	Inhibition	%	2.51	CHEMBL3045	Homo sapiens	Inhibition	%	2.51
	8140192	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	O=C([O-])c1ccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)cc1.[Li+]		CHEMBL1909401	=	Inhibition	%	1.67	CHEMBL3045	Homo sapiens	Inhibition	%	1.67
	8140197	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	O=C([O-])c1ccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)cc1.[Li+]		CHEMBL1909401	=	Inhibition	%	2.77	CHEMBL3045	Homo sapiens	Inhibition	%	2.77
	8140575	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	CNC(=O)c1cc(-c2ccc(F)cc2)cc(-c2ccc(S(=O)(=O)N3CCCC3)cc2)c1N		CHEMBL230592	=	Inhibition	%	-0.39	CHEMBL3045	Homo sapiens	Inhibition	%	-0.39
	8140580	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	CNC(=O)c1cc(-c2ccc(F)cc2)cc(-c2ccc(S(=O)(=O)N3CCCC3)cc2)c1N		CHEMBL230592	=	Inhibition	%	-0.56	CHEMBL3045	Homo sapiens	Inhibition	%	-0.56
	8140718	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	Fc1ccc(-c2ncn(C3CCNCC3)c2-c2ccnc(Oc3ccc4c(c3)OCO4)n2)cc1		CHEMBL273611	=	Inhibition	%	8.79	CHEMBL3045	Homo sapiens	Inhibition	%	8.79
	8140723	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	Fc1ccc(-c2ncn(C3CCNCC3)c2-c2ccnc(Oc3ccc4c(c3)OCO4)n2)cc1		CHEMBL273611	=	Inhibition	%	5.69	CHEMBL3045	Homo sapiens	Inhibition	%	5.69
	8141020	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc2c(cc1Nc1nc(N3CCc4ccccc43)c3cc[nH]c3n1)N(C(=O)CN(C)C)CC2		CHEMBL458415	=	Inhibition	%	1.5	CHEMBL3045	Homo sapiens	Inhibition	%	1.5
	8141025	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc2c(cc1Nc1nc(N3CCc4ccccc43)c3cc[nH]c3n1)N(C(=O)CN(C)C)CC2		CHEMBL458415	=	Inhibition	%	1.14	CHEMBL3045	Homo sapiens	Inhibition	%	1.14
	8141374	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	O=C(Nc1n[nH]c2nc(-c3ccco3)ccc12)C1CC1		CHEMBL101804	=	Inhibition	%	-0.22	CHEMBL3045	Homo sapiens	Inhibition	%	-0.22
	8141379	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	O=C(Nc1n[nH]c2nc(-c3ccco3)ccc12)C1CC1		CHEMBL101804	=	Inhibition	%	0.74	CHEMBL3045	Homo sapiens	Inhibition	%	0.74
	8141534	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	CCCNc1cccc(-n2ncc3c(N/N=C/c4ccncc4)ncnc32)c1		CHEMBL67241	=	Inhibition	%	5.99	CHEMBL3045	Homo sapiens	Inhibition	%	5.99
	8141539	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	CCCNc1cccc(-n2ncc3c(N/N=C/c4ccncc4)ncnc32)c1		CHEMBL67241	=	Inhibition	%	3.89	CHEMBL3045	Homo sapiens	Inhibition	%	3.89
	8141877	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	CNC(=O)c1cncc(/C=C/c2c(C)cccc2C)c1		CHEMBL218859	=	Inhibition	%	-0.29	CHEMBL3045	Homo sapiens	Inhibition	%	-0.29
	8141882	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	CNC(=O)c1cncc(/C=C/c2c(C)cccc2C)c1		CHEMBL218859	=	Inhibition	%	1.01	CHEMBL3045	Homo sapiens	Inhibition	%	1.01
	8142038	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccc4c(c3)OCCO4)n2)cc1		CHEMBL188257	=	Inhibition	%	-1.85	CHEMBL3045	Homo sapiens	Inhibition	%	-1.85
	8142043	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccc4c(c3)OCCO4)n2)cc1		CHEMBL188257	=	Inhibition	%	1.22	CHEMBL3045	Homo sapiens	Inhibition	%	1.22
	8142262	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	COc1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccc4c(c3)OCCO4)n2)cc1		CHEMBL188257	=	Inhibition	%	3.69	CHEMBL3045	Homo sapiens	Inhibition	%	3.69
	8142267	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	COc1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccc4c(c3)OCCO4)n2)cc1		CHEMBL188257	=	Inhibition	%	7.32	CHEMBL3045	Homo sapiens	Inhibition	%	7.32
	8142430	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	C[C@@H](Oc1cc(-n2cnc3ccc(OCC4CCN(C)CC4)cc32)sc1C(N)=O)c1ccccc1C(F)(F)F		CHEMBL1794068	=	Inhibition	%	0.2	CHEMBL3045	Homo sapiens	Inhibition	%	0.2
	8142435	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	C[C@@H](Oc1cc(-n2cnc3ccc(OCC4CCN(C)CC4)cc32)sc1C(N)=O)c1ccccc1C(F)(F)F		CHEMBL1794068	=	Inhibition	%	2.07	CHEMBL3045	Homo sapiens	Inhibition	%	2.07
	8142606	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1nc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(C(F)(F)F)c5)cc4)c3c2)cs1.Cl		CHEMBL1909356	=	Inhibition	%	1.43	CHEMBL3045	Homo sapiens	Inhibition	%	1.43
	8142611	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1nc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(C(F)(F)F)c5)cc4)c3c2)cs1.Cl		CHEMBL1909356	=	Inhibition	%	1.98	CHEMBL3045	Homo sapiens	Inhibition	%	1.98
	8142830	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	CN1CCC(C(=O)Nc2n[nH]c3nc(-c4ccc(O)cc4)c(Br)cc23)CC1.O=C(O)/C=C\C(=O)O		CHEMBL1909347	=	Inhibition	%	0.96	CHEMBL3045	Homo sapiens	Inhibition	%	0.96
	8142835	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	CN1CCC(C(=O)Nc2n[nH]c3nc(-c4ccc(O)cc4)c(Br)cc23)CC1.O=C(O)/C=C\C(=O)O		CHEMBL1909347	=	Inhibition	%	5.4	CHEMBL3045	Homo sapiens	Inhibition	%	5.4
	8142979	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	Cc1ccc(C(=O)NC(C)C)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL477979	=	Inhibition	%	-0.82	CHEMBL3045	Homo sapiens	Inhibition	%	-0.82
	8142984	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	Cc1ccc(C(=O)NC(C)C)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL477979	=	Inhibition	%	-0.9	CHEMBL3045	Homo sapiens	Inhibition	%	-0.9
	8143134	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	Nc1ccc(C#Cc2cncnc2Nc2ccc(OCc3cccc(F)c3)c(Cl)c2)cc1		CHEMBL205966	=	Inhibition	%	1.2	CHEMBL3045	Homo sapiens	Inhibition	%	1.2
	8143139	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	Nc1ccc(C#Cc2cncnc2Nc2ccc(OCc3cccc(F)c3)c(Cl)c2)cc1		CHEMBL205966	=	Inhibition	%	0.84	CHEMBL3045	Homo sapiens	Inhibition	%	0.84
	8143358	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	Nc1ccc(C#Cc2cncnc2Nc2ccc(OCc3cccc(F)c3)c(Cl)c2)cc1		CHEMBL205966	=	Inhibition	%	2.03	CHEMBL3045	Homo sapiens	Inhibition	%	2.03
	8143363	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	Nc1ccc(C#Cc2cncnc2Nc2ccc(OCc3cccc(F)c3)c(Cl)c2)cc1		CHEMBL205966	=	Inhibition	%	0.6	CHEMBL3045	Homo sapiens	Inhibition	%	0.6
	8143545	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	O=C1Nc2ccc(I)cc2C1=Cc1cc(Br)c(O)c(Br)c1		CHEMBL1880739	=	Inhibition	%	1.41	CHEMBL3045	Homo sapiens	Inhibition	%	1.41
	8143550	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	O=C1Nc2ccc(I)cc2C1=Cc1cc(Br)c(O)c(Br)c1		CHEMBL1880739	=	Inhibition	%	1.87	CHEMBL3045	Homo sapiens	Inhibition	%	1.87
	8143704	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	Cc1ccc2c(-c3ccnc(Nc4cccc(C(F)(F)F)c4)n3)c(-c3ccccc3)nn2n1		CHEMBL434729	=	Inhibition	%	0.54	CHEMBL3045	Homo sapiens	Inhibition	%	0.54
	8143709	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	Cc1ccc2c(-c3ccnc(Nc4cccc(C(F)(F)F)c4)n3)c(-c3ccccc3)nn2n1		CHEMBL434729	=	Inhibition	%	1.37	CHEMBL3045	Homo sapiens	Inhibition	%	1.37
	8143928	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	Cc1ccc2c(-c3ccnc(Nc4cccc(C(F)(F)F)c4)n3)c(-c3ccccc3)nn2n1		CHEMBL434729	=	Inhibition	%	3.6	CHEMBL3045	Homo sapiens	Inhibition	%	3.6
	8143933	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	Cc1ccc2c(-c3ccnc(Nc4cccc(C(F)(F)F)c4)n3)c(-c3ccccc3)nn2n1		CHEMBL434729	=	Inhibition	%	5.0	CHEMBL3045	Homo sapiens	Inhibition	%	5.0
	8144042	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5ccccc5)c(Br)c4)c3c2)o1.Cl		CHEMBL1909392	=	Inhibition	%	0.95	CHEMBL3045	Homo sapiens	Inhibition	%	0.95
	8144047	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5ccccc5)c(Br)c4)c3c2)o1.Cl		CHEMBL1909392	=	Inhibition	%	0.97	CHEMBL3045	Homo sapiens	Inhibition	%	0.97
	8144405	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	CC(C)(C)c1ccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)cc1		CHEMBL275200	=	Inhibition	%	0.73	CHEMBL3045	Homo sapiens	Inhibition	%	0.73
	8144410	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	CC(C)(C)c1ccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)cc1		CHEMBL275200	=	Inhibition	%	0.95	CHEMBL3045	Homo sapiens	Inhibition	%	0.95
	8144535	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	O=C([O-])c1ccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)cc1.[Li+]		CHEMBL1909401	=	Inhibition	%	2.29	CHEMBL3045	Homo sapiens	Inhibition	%	2.29
	8144540	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	O=C([O-])c1ccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)cc1.[Li+]		CHEMBL1909401	=	Inhibition	%	3.57	CHEMBL3045	Homo sapiens	Inhibition	%	3.57
	8144759	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	NC(=O)c1ccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)cc1		CHEMBL275724	=	Inhibition	%	1.04	CHEMBL3045	Homo sapiens	Inhibition	%	1.04
	8144764	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	NC(=O)c1ccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)cc1		CHEMBL275724	=	Inhibition	%	1.9	CHEMBL3045	Homo sapiens	Inhibition	%	1.9
	8144912	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	CNC(=O)c1cc(-c2ccc(F)cc2)cc(-c2ccc(S(=O)(=O)N3CCCC3)cc2)c1N		CHEMBL230592	=	Inhibition	%	0.24	CHEMBL3045	Homo sapiens	Inhibition	%	0.24
	8144917	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	CNC(=O)c1cc(-c2ccc(F)cc2)cc(-c2ccc(S(=O)(=O)N3CCCC3)cc2)c1N		CHEMBL230592	=	Inhibition	%	1.04	CHEMBL3045	Homo sapiens	Inhibition	%	1.04
	8145049	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	Cl.O=S(=O)(CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1)c1ccccc1		CHEMBL1909395	=	Inhibition	%	0.95	CHEMBL3045	Homo sapiens	Inhibition	%	0.95
	8145054	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	Cl.O=S(=O)(CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1)c1ccccc1		CHEMBL1909395	=	Inhibition	%	2.03	CHEMBL3045	Homo sapiens	Inhibition	%	2.03
	8145273	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	Cl.O=S(=O)(CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1)c1ccccc1		CHEMBL1909395	=	Inhibition	%	2.13	CHEMBL3045	Homo sapiens	Inhibition	%	2.13
	8145278	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	Cl.O=S(=O)(CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1)c1ccccc1		CHEMBL1909395	=	Inhibition	%	2.6	CHEMBL3045	Homo sapiens	Inhibition	%	2.6
	8145362	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	COc1cc2c(cc1Nc1nc(N3CCc4ccccc43)c3cc[nH]c3n1)N(C(=O)CN(C)C)CC2		CHEMBL458415	=	Inhibition	%	0.59	CHEMBL3045	Homo sapiens	Inhibition	%	0.59
	8145367	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	COc1cc2c(cc1Nc1nc(N3CCc4ccccc43)c3cc[nH]c3n1)N(C(=O)CN(C)C)CC2		CHEMBL458415	=	Inhibition	%	1.29	CHEMBL3045	Homo sapiens	Inhibition	%	1.29
	8145586	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	CNC(=O)Oc1cc(C)c(/C=C/c2cncc(C(=O)NC)c2)c(C)c1		CHEMBL218932	=	Inhibition	%	-0.06	CHEMBL3045	Homo sapiens	Inhibition	%	-0.06
	8145710	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	O=C(Nc1n[nH]c2nc(-c3ccco3)ccc12)C1CC1		CHEMBL101804	=	Inhibition	%	-1.09	CHEMBL3045	Homo sapiens	Inhibition	%	-1.09
	8145715	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	O=C(Nc1n[nH]c2nc(-c3ccco3)ccc12)C1CC1		CHEMBL101804	=	Inhibition	%	1.21	CHEMBL3045	Homo sapiens	Inhibition	%	1.21
	8145871	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	CN(c1ccc(NC(=O)Nc2c(Cl)cccc2Cl)cc1)c1ccnc(Nc2cccc(CS(C)(=O)=O)c2)n1		CHEMBL189353	=	Inhibition	%	0.67	CHEMBL3045	Homo sapiens	Inhibition	%	0.67
	8145876	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	CN(c1ccc(NC(=O)Nc2c(Cl)cccc2Cl)cc1)c1ccnc(Nc2cccc(CS(C)(=O)=O)c2)n1		CHEMBL189353	=	Inhibition	%	0.41	CHEMBL3045	Homo sapiens	Inhibition	%	0.41
	8146095	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	CN(c1ccc(NC(=O)Nc2c(Cl)cccc2Cl)cc1)c1ccnc(Nc2cccc(CS(C)(=O)=O)c2)n1		CHEMBL189353	=	Inhibition	%	1.35	CHEMBL3045	Homo sapiens	Inhibition	%	1.35
	8146100	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	CN(c1ccc(NC(=O)Nc2c(Cl)cccc2Cl)cc1)c1ccnc(Nc2cccc(CS(C)(=O)=O)c2)n1		CHEMBL189353	=	Inhibition	%	3.24	CHEMBL3045	Homo sapiens	Inhibition	%	3.24
	8146215	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	COC(=O)Nc1nc2ccc(Sc3ccc(NC(=O)Nc4cc(C(F)(F)F)ccc4F)cc3)cc2[nH]1.O=S(=O)(O)O		CHEMBL1909365	=	Inhibition	%	0.84	CHEMBL3045	Homo sapiens	Inhibition	%	0.84
	8146220	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	COC(=O)Nc1nc2ccc(Sc3ccc(NC(=O)Nc4cc(C(F)(F)F)ccc4F)cc3)cc2[nH]1.O=S(=O)(O)O		CHEMBL1909365	=	Inhibition	%	0.31	CHEMBL3045	Homo sapiens	Inhibition	%	0.31
	8146599	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc2c(cc1Nc1nc(Nc3ccsc3C(N)=O)c3cc[nH]c3n1)N(C(=O)CN(C)C)CCC2		CHEMBL456252	=	Inhibition	%	-0.18	CHEMBL3045	Homo sapiens	Inhibition	%	-0.18
	8146604	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc2c(cc1Nc1nc(Nc3ccsc3C(N)=O)c3cc[nH]c3n1)N(C(=O)CN(C)C)CCC2		CHEMBL456252	=	Inhibition	%	-1.27	CHEMBL3045	Homo sapiens	Inhibition	%	-1.27
	8146766	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	C[C@@H](Oc1cc(-n2cnc3ccc(OCC4CCN(C)CC4)cc32)sc1C(N)=O)c1ccccc1C(F)(F)F		CHEMBL1794068	=	Inhibition	%	5.91	CHEMBL3045	Homo sapiens	Inhibition	%	5.91
	8146771	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	C[C@@H](Oc1cc(-n2cnc3ccc(OCC4CCN(C)CC4)cc32)sc1C(N)=O)c1ccccc1C(F)(F)F		CHEMBL1794068	=	Inhibition	%	18.84	CHEMBL3045	Homo sapiens	Inhibition	%	18.84
	8147159	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	CN1CCC(C(=O)Nc2n[nH]c3nc(-c4ccc(O)cc4)c(Br)cc23)CC1.O=C(O)/C=C\C(=O)O		CHEMBL1909347	=	Inhibition	%	10.23	CHEMBL3045	Homo sapiens	Inhibition	%	10.23
	8147164	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	CN1CCC(C(=O)Nc2n[nH]c3nc(-c4ccc(O)cc4)c(Br)cc23)CC1.O=C(O)/C=C\C(=O)O		CHEMBL1909347	=	Inhibition	%	31.2	CHEMBL3045	Homo sapiens	Inhibition	%	31.2
	8147301	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	FC(F)(F)c1cccc(Nc2nccc(-c3cnn4nc(-c5ccccc5)ccc34)n2)c1		CHEMBL189415	=	Inhibition	%	-0.86	CHEMBL3045	Homo sapiens	Inhibition	%	-0.86
	8147306	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	FC(F)(F)c1cccc(Nc2nccc(-c3cnn4nc(-c5ccccc5)ccc34)n2)c1		CHEMBL189415	=	Inhibition	%	1.28	CHEMBL3045	Homo sapiens	Inhibition	%	1.28
	8147678	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3cccc(C(F)(F)F)c3)n2)cc1		CHEMBL186213	=	Inhibition	%	1.46	CHEMBL3045	Homo sapiens	Inhibition	%	1.46
	8147683	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3cccc(C(F)(F)F)c3)n2)cc1		CHEMBL186213	=	Inhibition	%	1.35	CHEMBL3045	Homo sapiens	Inhibition	%	1.35
	8147865	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	COC(=O)c1ccc2c(c1)C(=Cc1cc(Br)c(O)c(Br)c1)C(=O)N2		CHEMBL1794052	=	Inhibition	%	-0.23	CHEMBL3045	Homo sapiens	Inhibition	%	-0.23
	8147870	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	COC(=O)c1ccc2c(c1)C(=Cc1cc(Br)c(O)c(Br)c1)C(=O)N2		CHEMBL1794052	=	Inhibition	%	1.12	CHEMBL3045	Homo sapiens	Inhibition	%	1.12
	8148247	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	c1ccc(Nc2ncc(-c3ccccc3)o2)cc1		CHEMBL318728	=	Inhibition	%	-0.26	CHEMBL3045	Homo sapiens	Inhibition	%	-0.26
	8148252	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	c1ccc(Nc2ncc(-c3ccccc3)o2)cc1		CHEMBL318728	=	Inhibition	%	1.46	CHEMBL3045	Homo sapiens	Inhibition	%	1.46
	8148361	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5ccccc5)c(Br)c4)c3c2)o1.Cl		CHEMBL1909392	=	Inhibition	%	-0.59	CHEMBL3045	Homo sapiens	Inhibition	%	-0.59
	8148366	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5ccccc5)c(Br)c4)c3c2)o1.Cl		CHEMBL1909392	=	Inhibition	%	1.27	CHEMBL3045	Homo sapiens	Inhibition	%	1.27
	8148585	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	CCS(=O)(=O)c1ccc(OC)c(Nc2nccc(N(C)c3ccc4c(C)n[nH]c4c3)n2)c1.Cl		CHEMBL1909358	=	Inhibition	%	0.4	CHEMBL3045	Homo sapiens	Inhibition	%	0.4
	8148590	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	CCS(=O)(=O)c1ccc(OC)c(Nc2nccc(N(C)c3ccc4c(C)n[nH]c4c3)n2)c1.Cl		CHEMBL1909358	=	Inhibition	%	1.61	CHEMBL3045	Homo sapiens	Inhibition	%	1.61
	8148724	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	CC(C)(C)c1ccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)cc1		CHEMBL275200	=	Inhibition	%	3.55	CHEMBL3045	Homo sapiens	Inhibition	%	3.55
	8148729	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	CC(C)(C)c1ccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)cc1		CHEMBL275200	=	Inhibition	%	5.68	CHEMBL3045	Homo sapiens	Inhibition	%	5.68
	8149086	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	NC(=O)c1ccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)cc1		CHEMBL275724	=	Inhibition	%	5.96	CHEMBL3045	Homo sapiens	Inhibition	%	5.96
	8149091	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	NC(=O)c1ccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)cc1		CHEMBL275724	=	Inhibition	%	5.22	CHEMBL3045	Homo sapiens	Inhibition	%	5.22
	8149245	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)CCN(CC#N)Cc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1		CHEMBL384407	=	Inhibition	%	-0.34	CHEMBL3045	Homo sapiens	Inhibition	%	-0.34
	8149250	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)CCN(CC#N)Cc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1		CHEMBL384407	=	Inhibition	%	0.59	CHEMBL3045	Homo sapiens	Inhibition	%	0.59
	8149603	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2cncc(C(=O)NCCNC)c21		CHEMBL506153	=	Inhibition	%	61.12	CHEMBL3045	Homo sapiens	Inhibition	%	61.12
	8149608	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2cncc(C(=O)NCCNC)c21		CHEMBL506153	=	Inhibition	%	21.07	CHEMBL3045	Homo sapiens	Inhibition	%	21.07
	8149706	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	CNC(=O)Oc1cc(C)c(/C=C/c2cncc(C(=O)NC)c2)c(C)c1		CHEMBL218932	=	Inhibition	%	1.05	CHEMBL3045	Homo sapiens	Inhibition	%	1.05
	8149925	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	CNC(=O)Oc1cc(C)c(/C=C/c2cncc(C(=O)NC)c2)c(C)c1		CHEMBL218932	=	Inhibition	%	0.33	CHEMBL3045	Homo sapiens	Inhibition	%	0.33
	8149930	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	CNC(=O)Oc1cc(C)c(/C=C/c2cncc(C(=O)NC)c2)c(C)c1		CHEMBL218932	=	Inhibition	%	0.33	CHEMBL3045	Homo sapiens	Inhibition	%	0.33
	8150050	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	Cl.O=C(Nc1ccc(Oc2ccc3[nH]c(NC(=O)c4ccco4)nc3c2)cc1)Nc1cc(C(F)(F)F)ccc1F		CHEMBL1909368	=	Inhibition	%	-0.09	CHEMBL3045	Homo sapiens	Inhibition	%	-0.09
	8150055	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	Cl.O=C(Nc1ccc(Oc2ccc3[nH]c(NC(=O)c4ccco4)nc3c2)cc1)Nc1cc(C(F)(F)F)ccc1F		CHEMBL1909368	=	Inhibition	%	0.05	CHEMBL3045	Homo sapiens	Inhibition	%	0.05
	8150434	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	CNC(=O)c1cccc(C#Cc2cncnc2Nc2ccc(OCc3cccc(F)c3)c(Cl)c2)c1		CHEMBL207410	=	Inhibition	%	0.07	CHEMBL3045	Homo sapiens	Inhibition	%	0.07
	8150439	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	CNC(=O)c1cccc(C#Cc2cncnc2Nc2ccc(OCc3cccc(F)c3)c(Cl)c2)c1		CHEMBL207410	=	Inhibition	%	-3.35	CHEMBL3045	Homo sapiens	Inhibition	%	-3.35
	8150554	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	COC(=O)Nc1nc2ccc(Sc3ccc(NC(=O)Nc4cc(C(F)(F)F)ccc4F)cc3)cc2[nH]1.O=S(=O)(O)O		CHEMBL1909365	=	Inhibition	%	0.31	CHEMBL3045	Homo sapiens	Inhibition	%	0.31
	8150559	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	COC(=O)Nc1nc2ccc(Sc3ccc(NC(=O)Nc4cc(C(F)(F)F)ccc4F)cc3)cc2[nH]1.O=S(=O)(O)O		CHEMBL1909365	=	Inhibition	%	0.4	CHEMBL3045	Homo sapiens	Inhibition	%	0.4
	8150778	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	Cc1ccc(NC(=O)c2ccnc(N3CCOCC3)c2)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL476351	=	Inhibition	%	0.97	CHEMBL3045	Homo sapiens	Inhibition	%	0.97
	8150783	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	Cc1ccc(NC(=O)c2ccnc(N3CCOCC3)c2)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL476351	=	Inhibition	%	0.09	CHEMBL3045	Homo sapiens	Inhibition	%	0.09
	8150943	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	COc1cc2c(cc1Nc1nc(Nc3ccsc3C(N)=O)c3cc[nH]c3n1)N(C(=O)CN(C)C)CCC2		CHEMBL456252	=	Inhibition	%	1.94	CHEMBL3045	Homo sapiens	Inhibition	%	1.94
	8150948	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	COc1cc2c(cc1Nc1nc(Nc3ccsc3C(N)=O)c3cc[nH]c3n1)N(C(=O)CN(C)C)CCC2		CHEMBL456252	=	Inhibition	%	2.49	CHEMBL3045	Homo sapiens	Inhibition	%	2.49
	8151106	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	Cc1ccc(C(=O)NC2CC2)cc1-c1ccc2[nH]ncc2c1		CHEMBL495902	=	Inhibition	%	-0.41	CHEMBL3045	Homo sapiens	Inhibition	%	-0.41
	8151111	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	Cc1ccc(C(=O)NC2CC2)cc1-c1ccc2[nH]ncc2c1		CHEMBL495902	=	Inhibition	%	-0.94	CHEMBL3045	Homo sapiens	Inhibition	%	-0.94
	8151330	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	Cc1ccc(C(=O)NC2CC2)cc1-c1ccc2[nH]ncc2c1		CHEMBL495902	=	Inhibition	%	-0.31	CHEMBL3045	Homo sapiens	Inhibition	%	-0.31
	8151335	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	Cc1ccc(C(=O)NC2CC2)cc1-c1ccc2[nH]ncc2c1		CHEMBL495902	=	Inhibition	%	-0.69	CHEMBL3045	Homo sapiens	Inhibition	%	-0.69
	8151507	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	CCc1nn2ncccc2c1-c1ccnc(NC2CC2)n1		CHEMBL524057	=	Inhibition	%	1.02	CHEMBL3045	Homo sapiens	Inhibition	%	1.02
	8151512	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	CCc1nn2ncccc2c1-c1ccnc(NC2CC2)n1		CHEMBL524057	=	Inhibition	%	1.1	CHEMBL3045	Homo sapiens	Inhibition	%	1.1
	8151645	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	FC(F)(F)c1cccc(Nc2nccc(-c3cnn4nc(-c5ccccc5)ccc34)n2)c1		CHEMBL189415	=	Inhibition	%	2.15	CHEMBL3045	Homo sapiens	Inhibition	%	2.15
	8151650	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	FC(F)(F)c1cccc(Nc2nccc(-c3cnn4nc(-c5ccccc5)ccc34)n2)c1		CHEMBL189415	=	Inhibition	%	1.35	CHEMBL3045	Homo sapiens	Inhibition	%	1.35
	8151869	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	CCOc1ccc2c(-c3ccnc(Nc4cccc(C(F)(F)F)c4)n3)cnn2n1		CHEMBL183993	=	Inhibition	%	0.58	CHEMBL3045	Homo sapiens	Inhibition	%	0.58
	8151874	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	CCOc1ccc2c(-c3ccnc(Nc4cccc(C(F)(F)F)c4)n3)cnn2n1		CHEMBL183993	=	Inhibition	%	0.45	CHEMBL3045	Homo sapiens	Inhibition	%	0.45
	8152023	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	COc1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3cccc(C(F)(F)F)c3)n2)cc1		CHEMBL186213	=	Inhibition	%	2.39	CHEMBL3045	Homo sapiens	Inhibition	%	2.39
	8152028	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	COc1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3cccc(C(F)(F)F)c3)n2)cc1		CHEMBL186213	=	Inhibition	%	2.07	CHEMBL3045	Homo sapiens	Inhibition	%	2.07
	8152211	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	COC(=O)c1ccc2c(c1)C(=Cc1cc(Br)c(O)c(Br)c1)C(=O)N2		CHEMBL1794052	=	Inhibition	%	-0.51	CHEMBL3045	Homo sapiens	Inhibition	%	-0.51
	8152216	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	COC(=O)c1ccc2c(c1)C(=Cc1cc(Br)c(O)c(Br)c1)C(=O)N2		CHEMBL1794052	=	Inhibition	%	1.9	CHEMBL3045	Homo sapiens	Inhibition	%	1.9
	8152435	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	CNC(=O)c1cncc(/C=C/c2c(Cl)cccc2Cl)c1		CHEMBL263796	=	Inhibition	%	0.07	CHEMBL3045	Homo sapiens	Inhibition	%	0.07
	8152440	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	CNC(=O)c1cncc(/C=C/c2c(Cl)cccc2Cl)c1		CHEMBL263796	=	Inhibition	%	0.86	CHEMBL3045	Homo sapiens	Inhibition	%	0.86
	8152593	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	c1ccc(Nc2ncc(-c3ccccc3)o2)cc1		CHEMBL318728	=	Inhibition	%	-0.49	CHEMBL3045	Homo sapiens	Inhibition	%	-0.49
	8152598	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	c1ccc(Nc2ncc(-c3ccccc3)o2)cc1		CHEMBL318728	=	Inhibition	%	2.63	CHEMBL3045	Homo sapiens	Inhibition	%	2.63
	8152931	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	CCS(=O)(=O)c1ccc(OC)c(Nc2nccc(N(C)c3ccc4c(C)n[nH]c4c3)n2)c1.Cl		CHEMBL1909358	=	Inhibition	%	-2.93	CHEMBL3045	Homo sapiens	Inhibition	%	-2.93
	8152936	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	CCS(=O)(=O)c1ccc(OC)c(Nc2nccc(N(C)c3ccc4c(C)n[nH]c4c3)n2)c1.Cl		CHEMBL1909358	=	Inhibition	%	2.71	CHEMBL3045	Homo sapiens	Inhibition	%	2.71
	8153070	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	CN1CCN(Cc2ccc(-c3cc4ncnc(Nc5ccc(OCc6cccc(F)c6)c(Cl)c5)c4s3)o2)CC1		CHEMBL475761	=	Inhibition	%	-1.25	CHEMBL3045	Homo sapiens	Inhibition	%	-1.25
	8153075	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	CN1CCN(Cc2ccc(-c3cc4ncnc(Nc5ccc(OCc6cccc(F)c6)c(Cl)c5)c4s3)o2)CC1		CHEMBL475761	=	Inhibition	%	0.98	CHEMBL3045	Homo sapiens	Inhibition	%	0.98
	8153431	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2cncc(C(=O)N3CCNCC3)c21.Cl		CHEMBL1909376	=	Inhibition	%	2.12	CHEMBL3045	Homo sapiens	Inhibition	%	2.12
	8153436	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2cncc(C(=O)N3CCNCC3)c21.Cl		CHEMBL1909376	=	Inhibition	%	1.85	CHEMBL3045	Homo sapiens	Inhibition	%	1.85
	8153588	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)CCN(CC#N)Cc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1		CHEMBL384407	=	Inhibition	%	-1.95	CHEMBL3045	Homo sapiens	Inhibition	%	-1.95
	8153593	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)CCN(CC#N)Cc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1		CHEMBL384407	=	Inhibition	%	0.66	CHEMBL3045	Homo sapiens	Inhibition	%	0.66
	8153812	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)Nc1ccc(-c2cc(-c3ccccc3)cc(C(N)=O)c2N)cc1		CHEMBL230597	=	Inhibition	%	-0.05	CHEMBL3045	Homo sapiens	Inhibition	%	-0.05
	8153817	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)Nc1ccc(-c2cc(-c3ccccc3)cc(C(N)=O)c2N)cc1		CHEMBL230597	=	Inhibition	%	0.99	CHEMBL3045	Homo sapiens	Inhibition	%	0.99
	8153945	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2cncc(C(=O)NCCNC)c21		CHEMBL506153	=	Inhibition	%	74.38	CHEMBL3045	Homo sapiens	Inhibition	%	74.38
	8153950	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2cncc(C(=O)NCCNC)c21		CHEMBL506153	=	Inhibition	%	61.04	CHEMBL3045	Homo sapiens	Inhibition	%	61.04
	8154266	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2ccccc21		CHEMBL365286	=	Inhibition	%	12.7	CHEMBL3045	Homo sapiens	Inhibition	%	12.7
	8154271	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2ccccc21		CHEMBL365286	=	Inhibition	%	0.96	CHEMBL3045	Homo sapiens	Inhibition	%	0.96
	8154392	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	Cl.O=C(Nc1ccc(Oc2ccc3[nH]c(NC(=O)c4ccco4)nc3c2)cc1)Nc1cc(C(F)(F)F)ccc1F		CHEMBL1909368	=	Inhibition	%	-1.32	CHEMBL3045	Homo sapiens	Inhibition	%	-1.32
	8154397	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	Cl.O=C(Nc1ccc(Oc2ccc3[nH]c(NC(=O)c4ccco4)nc3c2)cc1)Nc1cc(C(F)(F)F)ccc1F		CHEMBL1909368	=	Inhibition	%	1.61	CHEMBL3045	Homo sapiens	Inhibition	%	1.61
	8154616	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	CCCN1CCC(Oc2cc(Nc3nc(Nc4cccc(F)c4C(N)=O)c4cc[nH]c4n3)c(OC)cc2Cl)CC1		CHEMBL517171	=	Inhibition	%	0.29	CHEMBL3045	Homo sapiens	Inhibition	%	0.29
	8154621	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	CCCN1CCC(Oc2cc(Nc3nc(Nc4cccc(F)c4C(N)=O)c4cc[nH]c4n3)c(OC)cc2Cl)CC1		CHEMBL517171	=	Inhibition	%	1.2	CHEMBL3045	Homo sapiens	Inhibition	%	1.2
	8154775	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	CNC(=O)c1cccc(C#Cc2cncnc2Nc2ccc(OCc3cccc(F)c3)c(Cl)c2)c1		CHEMBL207410	=	Inhibition	%	1.77	CHEMBL3045	Homo sapiens	Inhibition	%	1.77
	8154780	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	CNC(=O)c1cccc(C#Cc2cncnc2Nc2ccc(OCc3cccc(F)c3)c(Cl)c2)c1		CHEMBL207410	=	Inhibition	%	-0.69	CHEMBL3045	Homo sapiens	Inhibition	%	-0.69
	8155119	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	Cc1ccc(NC(=O)c2ccnc(N3CCOCC3)c2)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL476351	=	Inhibition	%	0.01	CHEMBL3045	Homo sapiens	Inhibition	%	0.01
	8155124	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	Cc1ccc(NC(=O)c2ccnc(N3CCOCC3)c2)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL476351	=	Inhibition	%	-0.35	CHEMBL3045	Homo sapiens	Inhibition	%	-0.35
	8155295	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	Nc1nccc(-c2c(-c3ccc(F)cc3)nn3cc(C(F)(F)F)ccc23)n1		CHEMBL1909402	=	Inhibition	%	-1.02	CHEMBL3045	Homo sapiens	Inhibition	%	-1.02
	8155300	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	Nc1nccc(-c2c(-c3ccc(F)cc3)nn3cc(C(F)(F)F)ccc23)n1		CHEMBL1909402	=	Inhibition	%	-0.91	CHEMBL3045	Homo sapiens	Inhibition	%	-0.91
	8155680	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc2c(cc1Nc1nc(Nc3cccc(F)c3C(N)=O)c3cc[nH]c3n1)N(C(=O)CN1CCN(C(C)C)CC1)CC2		CHEMBL505915	=	Inhibition	%	0.6	CHEMBL3045	Homo sapiens	Inhibition	%	0.6
	8155685	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc2c(cc1Nc1nc(Nc3cccc(F)c3C(N)=O)c3cc[nH]c3n1)N(C(=O)CN1CCN(C(C)C)CC1)CC2		CHEMBL505915	=	Inhibition	%	1.31	CHEMBL3045	Homo sapiens	Inhibition	%	1.31
	8155858	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	CCc1nn2ncccc2c1-c1ccnc(NC2CC2)n1		CHEMBL524057	=	Inhibition	%	2.65	CHEMBL3045	Homo sapiens	Inhibition	%	2.65
	8155863	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	CCc1nn2ncccc2c1-c1ccnc(NC2CC2)n1		CHEMBL524057	=	Inhibition	%	3.32	CHEMBL3045	Homo sapiens	Inhibition	%	3.32
	8156220	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	CCOc1ccc2c(-c3ccnc(Nc4cccc(C(F)(F)F)c4)n3)cnn2n1		CHEMBL183993	=	Inhibition	%	0.67	CHEMBL3045	Homo sapiens	Inhibition	%	0.67
	8156225	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	CCOc1ccc2c(-c3ccnc(Nc4cccc(C(F)(F)F)c4)n3)cnn2n1		CHEMBL183993	=	Inhibition	%	0.29	CHEMBL3045	Homo sapiens	Inhibition	%	0.29
	8156432	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	Cc1ccc(-c2cc3c(NC(=O)C4CC4)ncnc3o2)cc1		CHEMBL182283	=	Inhibition	%	2.14	CHEMBL3045	Homo sapiens	Inhibition	%	2.14
	8156437	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	Cc1ccc(-c2cc3c(NC(=O)C4CC4)ncnc3o2)cc1		CHEMBL182283	=	Inhibition	%	5.24	CHEMBL3045	Homo sapiens	Inhibition	%	5.24
	8156582	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	CCS(=O)(=O)c1ccc(OC)c(Nc2ncc(-c3cccc(C(C)=O)c3)o2)c1		CHEMBL191705	=	Inhibition	%	3.77	CHEMBL3045	Homo sapiens	Inhibition	%	3.77
	8156587	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	CCS(=O)(=O)c1ccc(OC)c(Nc2ncc(-c3cccc(C(C)=O)c3)o2)c1		CHEMBL191705	=	Inhibition	%	1.89	CHEMBL3045	Homo sapiens	Inhibition	%	1.89
	8156806	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	CN(c1ccc(NC(=O)NCCN2CCOCC2)cc1)c1ccnc(Nc2ccc(CS(C)(=O)=O)cc2)n1.Cl		CHEMBL1909361	=	Inhibition	%	0.46	CHEMBL3045	Homo sapiens	Inhibition	%	0.46
	8156811	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	CN(c1ccc(NC(=O)NCCN2CCOCC2)cc1)c1ccnc(Nc2ccc(CS(C)(=O)=O)cc2)n1.Cl		CHEMBL1909361	=	Inhibition	%	0.67	CHEMBL3045	Homo sapiens	Inhibition	%	0.67
	8156949	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(Nc2ncc(-c3ccccc3)o2)cc1		CHEMBL194062	=	Inhibition	%	1.54	CHEMBL3045	Homo sapiens	Inhibition	%	1.54
	8156954	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(Nc2ncc(-c3ccccc3)o2)cc1		CHEMBL194062	=	Inhibition	%	2.07	CHEMBL3045	Homo sapiens	Inhibition	%	2.07
	8157293	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	CC1=C(C(=O)Nc2ccc3[nH]nc(C)c3c2)C(c2ccc(C(F)(F)F)cc2)CC(=O)N1		CHEMBL218720	=	Inhibition	%	-0.53	CHEMBL3045	Homo sapiens	Inhibition	%	-0.53
	8157298	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	CC1=C(C(=O)Nc2ccc3[nH]nc(C)c3c2)C(c2ccc(C(F)(F)F)cc2)CC(=O)N1		CHEMBL218720	=	Inhibition	%	1.95	CHEMBL3045	Homo sapiens	Inhibition	%	1.95
	8157434	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc(Nc2ncc3c(C)nc(-c4cccc(C(F)(F)F)c4)n3n2)cc(OC)c1OC		CHEMBL520037	=	Inhibition	%	0.93	CHEMBL3045	Homo sapiens	Inhibition	%	0.93
	8157439	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc(Nc2ncc3c(C)nc(-c4cccc(C(F)(F)F)c4)n3n2)cc(OC)c1OC		CHEMBL520037	=	Inhibition	%	1.35	CHEMBL3045	Homo sapiens	Inhibition	%	1.35
	8157658	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	COc1cc(Nc2ncc3c(C)nc(-c4cccc(C(F)(F)F)c4)n3n2)cc(OC)c1OC		CHEMBL520037	=	Inhibition	%	5.54	CHEMBL3045	Homo sapiens	Inhibition	%	5.54
	8157663	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	COc1cc(Nc2ncc3c(C)nc(-c4cccc(C(F)(F)F)c4)n3n2)cc(OC)c1OC		CHEMBL520037	=	Inhibition	%	2.31	CHEMBL3045	Homo sapiens	Inhibition	%	2.31
	8157788	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccccc1C1=C(Nc2ccccc2)C(=O)NC1=O		CHEMBL156263	=	Inhibition	%	2.3	CHEMBL3045	Homo sapiens	Inhibition	%	2.3
	8157793	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccccc1C1=C(Nc2ccccc2)C(=O)NC1=O		CHEMBL156263	=	Inhibition	%	5.42	CHEMBL3045	Homo sapiens	Inhibition	%	5.42
	8157954	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	COc1ccc(COc2ccc(Cc3cnc(N)nc3N)cc2OC)cc1		CHEMBL261849	=	Inhibition	%	1.96	CHEMBL3045	Homo sapiens	Inhibition	%	1.96
	8158173	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	CN1CCN(CCCNc2nc3ccc(Oc4ccc(NC(=O)Nc5cc(C(F)(F)F)ccc5F)cc4)cc3[nH]2)CC1.Cl		CHEMBL1909372	=	Inhibition	%	2.13	CHEMBL3045	Homo sapiens	Inhibition	%	2.13
	8158178	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	CN1CCN(CCCNc2nc3ccc(Oc4ccc(NC(=O)Nc5cc(C(F)(F)F)ccc5F)cc4)cc3[nH]2)CC1.Cl		CHEMBL1909372	=	Inhibition	%	2.09	CHEMBL3045	Homo sapiens	Inhibition	%	2.09
	8158423	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2cncc(C(=O)N3CC[C@H](N)C3)c21.Cl		CHEMBL1909384	=	Inhibition	%	43.87	CHEMBL3045	Homo sapiens	Inhibition	%	43.87
	8158428	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2cncc(C(=O)N3CC[C@H](N)C3)c21.Cl		CHEMBL1909384	=	Inhibition	%	11.43	CHEMBL3045	Homo sapiens	Inhibition	%	11.43
	8158581	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	Cc1ccc(NC(=O)c2ccnc(N3CCCC3)c2)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL477182	=	Inhibition	%	-1.68	CHEMBL3045	Homo sapiens	Inhibition	%	-1.68
	8158586	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	Cc1ccc(NC(=O)c2ccnc(N3CCCC3)c2)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL477182	=	Inhibition	%	2.94	CHEMBL3045	Homo sapiens	Inhibition	%	2.94
	8158974	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	O=C(Nc1n[nH]c2cc(-c3cc(F)ccc3F)ccc12)C1CC1		CHEMBL261440	=	Inhibition	%	2.04	CHEMBL3045	Homo sapiens	Inhibition	%	2.04
	8158979	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	O=C(Nc1n[nH]c2cc(-c3cc(F)ccc3F)ccc12)C1CC1		CHEMBL261440	=	Inhibition	%	4.18	CHEMBL3045	Homo sapiens	Inhibition	%	4.18
	8159109	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	O=C(O[C@H]1CN[C@H](C#Cc2cc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3s2)C1)N1CCOCC1		CHEMBL507329	=	Inhibition	%	1.43	CHEMBL3045	Homo sapiens	Inhibition	%	1.43
	8159114	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	O=C(O[C@H]1CN[C@H](C#Cc2cc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3s2)C1)N1CCOCC1		CHEMBL507329	=	Inhibition	%	2.11	CHEMBL3045	Homo sapiens	Inhibition	%	2.11
	8159453	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	Fc1ccc(-c2c(-c3ccncc3)nc3n2CCS3)cc1		CHEMBL266707	=	Inhibition	%	2.56	CHEMBL3045	Homo sapiens	Inhibition	%	2.56
	8159458	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	Fc1ccc(-c2c(-c3ccncc3)nc3n2CCS3)cc1		CHEMBL266707	=	Inhibition	%	1.11	CHEMBL3045	Homo sapiens	Inhibition	%	1.11
	8159808	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	CCCN1CCCC(c2ccc(Nc3nc(Nc4cc(F)ccc4C(N)=O)c4cc[nH]c4n3)c(OC)c2)C1		CHEMBL477069	=	Inhibition	%	-0.31	CHEMBL3045	Homo sapiens	Inhibition	%	-0.31
	8159813	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	CCCN1CCCC(c2ccc(Nc3nc(Nc4cc(F)ccc4C(N)=O)c4cc[nH]c4n3)c(OC)c2)C1		CHEMBL477069	=	Inhibition	%	1.85	CHEMBL3045	Homo sapiens	Inhibition	%	1.85
	8159949	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	Cl.c1ccc(-c2nc3n(c2-c2ccc4c(c2)OCO4)CCC3)nc1		CHEMBL1909377	=	Inhibition	%	5.04	CHEMBL3045	Homo sapiens	Inhibition	%	5.04
	8159954	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	Cl.c1ccc(-c2nc3n(c2-c2ccc4c(c2)OCO4)CCC3)nc1		CHEMBL1909377	=	Inhibition	%	4.57	CHEMBL3045	Homo sapiens	Inhibition	%	4.57
	8160310	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	N#Cc1c(NC(=O)CN2CCOCC2)sc2c1CCCC2.O=C(O)C(=O)O		CHEMBL1909342	=	Inhibition	%	2.05	CHEMBL3045	Homo sapiens	Inhibition	%	2.05
	8160315	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	N#Cc1c(NC(=O)CN2CCOCC2)sc2c1CCCC2.O=C(O)C(=O)O		CHEMBL1909342	=	Inhibition	%	2.84	CHEMBL3045	Homo sapiens	Inhibition	%	2.84
	8160460	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	Nc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCC(O)CC2)n1		CHEMBL1888586	=	Inhibition	%	3.05	CHEMBL3045	Homo sapiens	Inhibition	%	3.05
	8160465	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	Nc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCC(O)CC2)n1		CHEMBL1888586	=	Inhibition	%	1.56	CHEMBL3045	Homo sapiens	Inhibition	%	1.56
	8160754	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	Cc1ccc(-c2cc3c(NC(=O)C4CC4)ncnc3o2)cc1		CHEMBL182283	=	Inhibition	%	2.41	CHEMBL3045	Homo sapiens	Inhibition	%	2.41
	8160759	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	Cc1ccc(-c2cc3c(NC(=O)C4CC4)ncnc3o2)cc1		CHEMBL182283	=	Inhibition	%	0.65	CHEMBL3045	Homo sapiens	Inhibition	%	0.65
	8161128	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	CN(c1ccc(NC(=O)NCCN2CCOCC2)cc1)c1ccnc(Nc2ccc(CS(C)(=O)=O)cc2)n1.Cl		CHEMBL1909361	=	Inhibition	%	1.54	CHEMBL3045	Homo sapiens	Inhibition	%	1.54
	8161133	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	CN(c1ccc(NC(=O)NCCN2CCOCC2)cc1)c1ccnc(Nc2ccc(CS(C)(=O)=O)cc2)n1.Cl		CHEMBL1909361	=	Inhibition	%	-0.33	CHEMBL3045	Homo sapiens	Inhibition	%	-0.33
	8161271	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	c1cnn2ncc(-c3ccnc(Nc4ccc5c(c4)OCCO5)n3)c2c1		CHEMBL361894	=	Inhibition	%	1.95	CHEMBL3045	Homo sapiens	Inhibition	%	1.95
	8161276	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	c1cnn2ncc(-c3ccnc(Nc4ccc5c(c4)OCCO5)n3)c2c1		CHEMBL361894	=	Inhibition	%	0.79	CHEMBL3045	Homo sapiens	Inhibition	%	0.79
	8161495	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	c1cnn2ncc(-c3ccnc(Nc4ccc5c(c4)OCCO5)n3)c2c1		CHEMBL361894	=	Inhibition	%	4.36	CHEMBL3045	Homo sapiens	Inhibition	%	4.36
	8161500	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	c1cnn2ncc(-c3ccnc(Nc4ccc5c(c4)OCCO5)n3)c2c1		CHEMBL361894	=	Inhibition	%	5.22	CHEMBL3045	Homo sapiens	Inhibition	%	5.22
	8161620	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	O=C1NC(=O)C(c2ccccc2Cl)=C1Nc1cccc(O)c1		CHEMBL160937	=	Inhibition	%	0.31	CHEMBL3045	Homo sapiens	Inhibition	%	0.31
	8161625	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	O=C1NC(=O)C(c2ccccc2Cl)=C1Nc1cccc(O)c1		CHEMBL160937	=	Inhibition	%	2.15	CHEMBL3045	Homo sapiens	Inhibition	%	2.15
	8161982	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	Cl.NS(=O)(=O)c1cccc(Nc2cc(-c3ccc(F)cc3)n[nH]2)c1		CHEMBL1909351	=	Inhibition	%	2.83	CHEMBL3045	Homo sapiens	Inhibition	%	2.83
	8161987	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	Cl.NS(=O)(=O)c1cccc(Nc2cc(-c3ccc(F)cc3)n[nH]2)c1		CHEMBL1909351	=	Inhibition	%	1.7	CHEMBL3045	Homo sapiens	Inhibition	%	1.7
	8162112	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	COc1ccccc1C1=C(Nc2ccccc2)C(=O)NC1=O		CHEMBL156263	=	Inhibition	%	16.94	CHEMBL3045	Homo sapiens	Inhibition	%	16.94
	8162117	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	COc1ccccc1C1=C(Nc2ccccc2)C(=O)NC1=O		CHEMBL156263	=	Inhibition	%	24.71	CHEMBL3045	Homo sapiens	Inhibition	%	24.71
	8162496	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	CN1CCN(CCCNc2nc3ccc(Oc4ccc(NC(=O)Nc5cc(C(F)(F)F)ccc5F)cc4)cc3[nH]2)CC1.Cl		CHEMBL1909372	=	Inhibition	%	1.42	CHEMBL3045	Homo sapiens	Inhibition	%	1.42
	8162501	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	CN1CCN(CCCNc2nc3ccc(Oc4ccc(NC(=O)Nc5cc(C(F)(F)F)ccc5F)cc4)cc3[nH]2)CC1.Cl		CHEMBL1909372	=	Inhibition	%	2.68	CHEMBL3045	Homo sapiens	Inhibition	%	2.68
	8162749	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2cncc(C(=O)N3CC[C@H](N)C3)c21.Cl		CHEMBL1909384	=	Inhibition	%	74.45	CHEMBL3045	Homo sapiens	Inhibition	%	74.45
	8162754	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2cncc(C(=O)N3CC[C@H](N)C3)c21.Cl		CHEMBL1909384	=	Inhibition	%	45.56	CHEMBL3045	Homo sapiens	Inhibition	%	45.56
	8162897	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(NC=C2C(=O)Nc3ccc4ncsc4c32)cc1		CHEMBL1794055	=	Inhibition	%	0.12	CHEMBL3045	Homo sapiens	Inhibition	%	0.12
	8162902	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(NC=C2C(=O)Nc3ccc4ncsc4c32)cc1		CHEMBL1794055	=	Inhibition	%	2.28	CHEMBL3045	Homo sapiens	Inhibition	%	2.28
	8163121	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(NC=C2C(=O)Nc3ccc4ncsc4c32)cc1		CHEMBL1794055	=	Inhibition	%	2.75	CHEMBL3045	Homo sapiens	Inhibition	%	2.75
	8163126	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(NC=C2C(=O)Nc3ccc4ncsc4c32)cc1		CHEMBL1794055	=	Inhibition	%	6.13	CHEMBL3045	Homo sapiens	Inhibition	%	6.13
	8163290	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	N#Cc1c(NC(=O)c2cccc3ccccc23)sc2c1CCCC2		CHEMBL233001	=	Inhibition	%	1.24	CHEMBL3045	Homo sapiens	Inhibition	%	1.24
	8163295	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	N#Cc1c(NC(=O)c2cccc3ccccc23)sc2c1CCCC2		CHEMBL233001	=	Inhibition	%	2.18	CHEMBL3045	Homo sapiens	Inhibition	%	2.18
	8163424	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	O=C(O[C@H]1CN[C@H](C#Cc2cc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3s2)C1)N1CCOCC1		CHEMBL507329	=	Inhibition	%	2.48	CHEMBL3045	Homo sapiens	Inhibition	%	2.48
	8163429	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	O=C(O[C@H]1CN[C@H](C#Cc2cc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3s2)C1)N1CCOCC1		CHEMBL507329	=	Inhibition	%	1.21	CHEMBL3045	Homo sapiens	Inhibition	%	1.21
	8163648	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2ccc(F)cc21		CHEMBL426800	=	Inhibition	%	2.61	CHEMBL3045	Homo sapiens	Inhibition	%	2.61
	8163653	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2ccc(F)cc21		CHEMBL426800	=	Inhibition	%	1.15	CHEMBL3045	Homo sapiens	Inhibition	%	1.15
	8163771	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	Fc1ccc(-c2c(-c3ccncc3)nc3n2CCS3)cc1		CHEMBL266707	=	Inhibition	%	15.87	CHEMBL3045	Homo sapiens	Inhibition	%	15.87
	8163776	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	Fc1ccc(-c2c(-c3ccncc3)nc3n2CCS3)cc1		CHEMBL266707	=	Inhibition	%	3.63	CHEMBL3045	Homo sapiens	Inhibition	%	3.63
	8164129	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	CCCN1CCCC(c2ccc(Nc3nc(Nc4cc(F)ccc4C(N)=O)c4cc[nH]c4n3)c(OC)c2)C1		CHEMBL477069	=	Inhibition	%	3.2	CHEMBL3045	Homo sapiens	Inhibition	%	3.2
	8164134	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	CCCN1CCCC(c2ccc(Nc3nc(Nc4cc(F)ccc4C(N)=O)c4cc[nH]c4n3)c(OC)c2)C1		CHEMBL477069	=	Inhibition	%	5.27	CHEMBL3045	Homo sapiens	Inhibition	%	5.27
	8164269	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	CC1(C)CC(n2cnc(-c3ccc(F)cc3)c2-c2ccnc(N)n2)CC(C)(C)N1		CHEMBL95502	=	Inhibition	%	1.89	CHEMBL3045	Homo sapiens	Inhibition	%	1.89
	8164274	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	CC1(C)CC(n2cnc(-c3ccc(F)cc3)c2-c2ccnc(N)n2)CC(C)(C)N1		CHEMBL95502	=	Inhibition	%	1.08	CHEMBL3045	Homo sapiens	Inhibition	%	1.08
	8164493	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	CC1(C)CC(n2cnc(-c3ccc(F)cc3)c2-c2ccnc(N)n2)CC(C)(C)N1		CHEMBL95502	=	Inhibition	%	3.35	CHEMBL3045	Homo sapiens	Inhibition	%	3.35
	8164498	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	CC1(C)CC(n2cnc(-c3ccc(F)cc3)c2-c2ccnc(N)n2)CC(C)(C)N1		CHEMBL95502	=	Inhibition	%	4.59	CHEMBL3045	Homo sapiens	Inhibition	%	4.59
	8164648	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	N#Cc1cccc(Nc2nccc(-c3cnn4ncccc34)n2)c1		CHEMBL495696	=	Inhibition	%	2.69	CHEMBL3045	Homo sapiens	Inhibition	%	2.69
	8164653	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	N#Cc1cccc(Nc2nccc(-c3cnn4ncccc34)n2)c1		CHEMBL495696	=	Inhibition	%	6.33	CHEMBL3045	Homo sapiens	Inhibition	%	6.33
	8164792	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	Nc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCC(O)CC2)n1		CHEMBL1888586	=	Inhibition	%	20.26	CHEMBL3045	Homo sapiens	Inhibition	%	20.26
	8164797	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	Nc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCC(O)CC2)n1		CHEMBL1888586	=	Inhibition	%	16.31	CHEMBL3045	Homo sapiens	Inhibition	%	16.31
	8165016	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)Nc1ccc(-c2ccc3c(NC(=O)C4CC4)n[nH]c3c2)cc1		CHEMBL102936	=	Inhibition	%	-0.7	CHEMBL3045	Homo sapiens	Inhibition	%	-0.7
	8165021	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)Nc1ccc(-c2ccc3c(NC(=O)C4CC4)n[nH]c3c2)cc1		CHEMBL102936	=	Inhibition	%	1.18	CHEMBL3045	Homo sapiens	Inhibition	%	1.18
	8165086	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	CNC(=O)c1ncccc1Nc1nc(Nc2cc3c(cc2OC)CCCN3C(=O)CN(C)C)nc2[nH]ccc12		CHEMBL1895450	=	Inhibition	%	1.41	CHEMBL3045	Homo sapiens	Inhibition	%	1.41
	8165091	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	CNC(=O)c1ncccc1Nc1nc(Nc2cc3c(cc2OC)CCCN3C(=O)CN(C)C)nc2[nH]ccc12		CHEMBL1895450	=	Inhibition	%	1.44	CHEMBL3045	Homo sapiens	Inhibition	%	1.44
	8165310	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	CNC(=O)c1ncccc1Nc1nc(Nc2cc3c(cc2OC)CCCN3C(=O)CN(C)C)nc2[nH]ccc12		CHEMBL1895450	=	Inhibition	%	1.37	CHEMBL3045	Homo sapiens	Inhibition	%	1.37
	8165315	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	CNC(=O)c1ncccc1Nc1nc(Nc2cc3c(cc2OC)CCCN3C(=O)CN(C)C)nc2[nH]ccc12		CHEMBL1895450	=	Inhibition	%	7.12	CHEMBL3045	Homo sapiens	Inhibition	%	7.12
	8165451	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	O=C1NC(=O)C(c2ccccc2Cl)=C1Nc1cc(Cl)c(O)c(Cl)c1		CHEMBL157258	=	Inhibition	%	0.56	CHEMBL3045	Homo sapiens	Inhibition	%	0.56
	8165456	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	O=C1NC(=O)C(c2ccccc2Cl)=C1Nc1cc(Cl)c(O)c(Cl)c1		CHEMBL157258	=	Inhibition	%	3.48	CHEMBL3045	Homo sapiens	Inhibition	%	3.48
	8165818	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	Nc1ncnc2occ(-c3ccc(NC(=O)Nc4cc(C(F)(F)F)cc(C(F)(F)F)c4)cc3)c12		CHEMBL396107	=	Inhibition	%	-0.8	CHEMBL3045	Homo sapiens	Inhibition	%	-0.8
	8165823	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	Nc1ncnc2occ(-c3ccc(NC(=O)Nc4cc(C(F)(F)F)cc(C(F)(F)F)c4)cc3)c12		CHEMBL396107	=	Inhibition	%	0.68	CHEMBL3045	Homo sapiens	Inhibition	%	0.68
	8165944	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	O=C1NC(=O)C(c2ccccc2Cl)=C1Nc1cccc(O)c1		CHEMBL160937	=	Inhibition	%	5.5	CHEMBL3045	Homo sapiens	Inhibition	%	5.5
	8165949	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	O=C1NC(=O)C(c2ccccc2Cl)=C1Nc1cccc(O)c1		CHEMBL160937	=	Inhibition	%	14.46	CHEMBL3045	Homo sapiens	Inhibition	%	14.46
	8166306	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	Cl.NS(=O)(=O)c1cccc(Nc2cc(-c3ccc(F)cc3)n[nH]2)c1		CHEMBL1909351	=	Inhibition	%	6.0	CHEMBL3045	Homo sapiens	Inhibition	%	6.0
	8166311	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	Cl.NS(=O)(=O)c1cccc(Nc2cc(-c3ccc(F)cc3)n[nH]2)c1		CHEMBL1909351	=	Inhibition	%	3.53	CHEMBL3045	Homo sapiens	Inhibition	%	3.53
	8166436	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	Cl.Oc1cccc(-c2nc(-c3ccccc3)[nH]c2-c2ccncc2)c1		CHEMBL1909413	=	Inhibition	%	2.07	CHEMBL3045	Homo sapiens	Inhibition	%	2.07
	8166441	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	Cl.Oc1cccc(-c2nc(-c3ccccc3)[nH]c2-c2ccncc2)c1		CHEMBL1909413	=	Inhibition	%	0.99	CHEMBL3045	Homo sapiens	Inhibition	%	0.99
	8166660	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	Cl.Oc1cccc(-c2nc(-c3ccccc3)[nH]c2-c2ccncc2)c1		CHEMBL1909413	=	Inhibition	%	8.23	CHEMBL3045	Homo sapiens	Inhibition	%	8.23
	8166665	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	Cl.Oc1cccc(-c2nc(-c3ccccc3)[nH]c2-c2ccncc2)c1		CHEMBL1909413	=	Inhibition	%	7.1	CHEMBL3045	Homo sapiens	Inhibition	%	7.1
	8166761	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	COc1cc(Nc2nccc(Nc3ccc4c(C)n[nH]c4c3)n2)cc(OC)c1OC		CHEMBL479079	=	Inhibition	%	1.99	CHEMBL3045	Homo sapiens	Inhibition	%	1.99
	8166766	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	COc1cc(Nc2nccc(Nc3ccc4c(C)n[nH]c4c3)n2)cc(OC)c1OC		CHEMBL479079	=	Inhibition	%	6.67	CHEMBL3045	Homo sapiens	Inhibition	%	6.67
	8167073	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2cnc(Oc3cccc(NC(=O)c4ccc(OCCN5CCOCC5)cc4)c3)cc21.Cl		CHEMBL1909363	=	Inhibition	%	37.33	CHEMBL3045	Homo sapiens	Inhibition	%	37.33
	8167078	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2cnc(Oc3cccc(NC(=O)c4ccc(OCCN5CCOCC5)cc4)c3)cc21.Cl		CHEMBL1909363	=	Inhibition	%	11.55	CHEMBL3045	Homo sapiens	Inhibition	%	11.55
	8167438	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc2c(cc1Nc1nc(Nc3ccsc3C(N)=O)c3cc[nH]c3n1)N(C(=O)CN(C)C)CCC2(C)C		CHEMBL463931	=	Inhibition	%	2.16	CHEMBL3045	Homo sapiens	Inhibition	%	2.16
	8167443	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc2c(cc1Nc1nc(Nc3ccsc3C(N)=O)c3cc[nH]c3n1)N(C(=O)CN(C)C)CCC2(C)C		CHEMBL463931	=	Inhibition	%	3.45	CHEMBL3045	Homo sapiens	Inhibition	%	3.45
	8167602	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	N#Cc1c(NC(=O)c2cccc3ccccc23)sc2c1CCCC2		CHEMBL233001	=	Inhibition	%	-1.28	CHEMBL3045	Homo sapiens	Inhibition	%	-1.28
	8167607	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	N#Cc1c(NC(=O)c2cccc3ccccc23)sc2c1CCCC2		CHEMBL233001	=	Inhibition	%	2.04	CHEMBL3045	Homo sapiens	Inhibition	%	2.04
	8167959	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2ccc(F)cc21		CHEMBL426800	=	Inhibition	%	15.62	CHEMBL3045	Homo sapiens	Inhibition	%	15.62
	8167964	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2ccc(F)cc21		CHEMBL426800	=	Inhibition	%	4.26	CHEMBL3045	Homo sapiens	Inhibition	%	4.26
	8168083	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	CC1=C(C(=O)Nc2ccc3[nH]ncc3c2)C(c2ccc(F)cc2)NC(=O)N1		CHEMBL384073	=	Inhibition	%	-0.65	CHEMBL3045	Homo sapiens	Inhibition	%	-0.65
	8168088	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	CC1=C(C(=O)Nc2ccc3[nH]ncc3c2)C(c2ccc(F)cc2)NC(=O)N1		CHEMBL384073	=	Inhibition	%	1.62	CHEMBL3045	Homo sapiens	Inhibition	%	1.62
	8168307	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	CC1=C(C(=O)Nc2ccc3[nH]ncc3c2)C(c2ccc(F)cc2)NC(=O)N1		CHEMBL384073	=	Inhibition	%	1.36	CHEMBL3045	Homo sapiens	Inhibition	%	1.36
	8168312	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	CC1=C(C(=O)Nc2ccc3[nH]ncc3c2)C(c2ccc(F)cc2)NC(=O)N1		CHEMBL384073	=	Inhibition	%	1.76	CHEMBL3045	Homo sapiens	Inhibition	%	1.76
	8168448	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	NC(=O)c1ccc2c(-c3ccnc(NCCCO)n3)c(-c3ccc(F)cc3)nn2c1		CHEMBL1909404	=	Inhibition	%	2.42	CHEMBL3045	Homo sapiens	Inhibition	%	2.42
	8168453	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	NC(=O)c1ccc2c(-c3ccnc(NCCCO)n3)c(-c3ccc(F)cc3)nn2c1		CHEMBL1909404	=	Inhibition	%	4.8	CHEMBL3045	Homo sapiens	Inhibition	%	4.8
	8168808	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	NS(=O)(=O)c1cccc(-c2ccc3c(NC(=O)C4CC4)n[nH]c3c2)c1		CHEMBL407113	=	Inhibition	%	-0.11	CHEMBL3045	Homo sapiens	Inhibition	%	-0.11
	8168813	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	NS(=O)(=O)c1cccc(-c2ccc3c(NC(=O)C4CC4)n[nH]c3c2)c1		CHEMBL407113	=	Inhibition	%	-0.62	CHEMBL3045	Homo sapiens	Inhibition	%	-0.62
	8168972	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	N#Cc1cccc(Nc2nccc(-c3cnn4ncccc34)n2)c1		CHEMBL495696	=	Inhibition	%	19.97	CHEMBL3045	Homo sapiens	Inhibition	%	19.97
	8168977	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	N#Cc1cccc(Nc2nccc(-c3cnn4ncccc34)n2)c1		CHEMBL495696	=	Inhibition	%	30.19	CHEMBL3045	Homo sapiens	Inhibition	%	30.19
	8169338	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)Nc1ccc(-c2ccc3c(NC(=O)C4CC4)n[nH]c3c2)cc1		CHEMBL102936	=	Inhibition	%	0.21	CHEMBL3045	Homo sapiens	Inhibition	%	0.21
	8169343	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)Nc1ccc(-c2ccc3c(NC(=O)C4CC4)n[nH]c3c2)cc1		CHEMBL102936	=	Inhibition	%	1.78	CHEMBL3045	Homo sapiens	Inhibition	%	1.78
	8169642	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc(C(=O)NCCc4c[nH]cn4)cc32)cc1		CHEMBL272028	=	Inhibition	%	1.16	CHEMBL3045	Homo sapiens	Inhibition	%	1.16
	8169647	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc(C(=O)NCCc4c[nH]cn4)cc32)cc1		CHEMBL272028	=	Inhibition	%	1.05	CHEMBL3045	Homo sapiens	Inhibition	%	1.05
	8169776	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	O=C1NC(=O)C(c2ccccc2Cl)=C1Nc1cc(Cl)c(O)c(Cl)c1		CHEMBL157258	=	Inhibition	%	2.96	CHEMBL3045	Homo sapiens	Inhibition	%	2.96
	8169781	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	O=C1NC(=O)C(c2ccccc2Cl)=C1Nc1cc(Cl)c(O)c(Cl)c1		CHEMBL157258	=	Inhibition	%	3.15	CHEMBL3045	Homo sapiens	Inhibition	%	3.15
	8170145	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	Nc1ncnc2occ(-c3ccc(NC(=O)Nc4cc(C(F)(F)F)cc(C(F)(F)F)c4)cc3)c12		CHEMBL396107	=	Inhibition	%	-1.24	CHEMBL3045	Homo sapiens	Inhibition	%	-1.24
	8170150	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	Nc1ncnc2occ(-c3ccc(NC(=O)Nc4cc(C(F)(F)F)cc(C(F)(F)F)c4)cc3)c12		CHEMBL396107	=	Inhibition	%	0.44	CHEMBL3045	Homo sapiens	Inhibition	%	0.44
	8170270	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	Cc1cccc2c1NC(=O)/C2=N\Nc1ccc(S(N)(=O)=O)cc1		CHEMBL1909398	=	Inhibition	%	0.49	CHEMBL3045	Homo sapiens	Inhibition	%	0.49
	8170275	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	Cc1cccc2c1NC(=O)/C2=N\Nc1ccc(S(N)(=O)=O)cc1		CHEMBL1909398	=	Inhibition	%	2.86	CHEMBL3045	Homo sapiens	Inhibition	%	2.86
	8170494	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	Cc1cccc2c1NC(=O)/C2=N\Nc1ccc(S(N)(=O)=O)cc1		CHEMBL1909398	=	Inhibition	%	-1.37	CHEMBL3045	Homo sapiens	Inhibition	%	-1.37
	8170499	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	Cc1cccc2c1NC(=O)/C2=N\Nc1ccc(S(N)(=O)=O)cc1		CHEMBL1909398	=	Inhibition	%	0.46	CHEMBL3045	Homo sapiens	Inhibition	%	0.46
	8170634	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OCC3CCNCC3)c21.O=C(O)C(F)(F)F		CHEMBL1794065	=	Inhibition	%	29.94	CHEMBL3045	Homo sapiens	Inhibition	%	29.94
	8170639	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OCC3CCNCC3)c21.O=C(O)C(F)(F)F		CHEMBL1794065	=	Inhibition	%	8.97	CHEMBL3045	Homo sapiens	Inhibition	%	8.97
	8170993	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	CC(C)c1ccc(Nc2nccc(-c3cnn4ncccc34)n2)cc1		CHEMBL359963	=	Inhibition	%	0.55	CHEMBL3045	Homo sapiens	Inhibition	%	0.55
	8170998	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	CC(C)c1ccc(Nc2nccc(-c3cnn4ncccc34)n2)cc1		CHEMBL359963	=	Inhibition	%	0.59	CHEMBL3045	Homo sapiens	Inhibition	%	0.59
	8171190	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc(Nc2nccc(Nc3ccc4c(C)n[nH]c4c3)n2)cc(OC)c1OC		CHEMBL479079	=	Inhibition	%	1.4	CHEMBL3045	Homo sapiens	Inhibition	%	1.4
	8171195	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc(Nc2nccc(Nc3ccc4c(C)n[nH]c4c3)n2)cc(OC)c1OC		CHEMBL479079	=	Inhibition	%	2.72	CHEMBL3045	Homo sapiens	Inhibition	%	2.72
	8171407	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2cnc(Oc3cccc(NC(=O)c4ccc(OCCN5CCOCC5)cc4)c3)cc21.Cl		CHEMBL1909363	=	Inhibition	%	64.24	CHEMBL3045	Homo sapiens	Inhibition	%	64.24
	8171412	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2cnc(Oc3cccc(NC(=O)c4ccc(OCCN5CCOCC5)cc4)c3)cc21.Cl		CHEMBL1909363	=	Inhibition	%	42.4	CHEMBL3045	Homo sapiens	Inhibition	%	42.4
	8171772	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	COc1cc2c(cc1Nc1nc(Nc3ccsc3C(N)=O)c3cc[nH]c3n1)N(C(=O)CN(C)C)CCC2(C)C		CHEMBL463931	=	Inhibition	%	3.73	CHEMBL3045	Homo sapiens	Inhibition	%	3.73
	8171777	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	COc1cc2c(cc1Nc1nc(Nc3ccsc3C(N)=O)c3cc[nH]c3n1)N(C(=O)CN(C)C)CCC2(C)C		CHEMBL463931	=	Inhibition	%	15.04	CHEMBL3045	Homo sapiens	Inhibition	%	15.04
	8171925	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	COc1cccc(-n2ncc3c(N/N=C/c4cccc(F)c4)ncnc32)c1		CHEMBL69757	=	Inhibition	%	0.85	CHEMBL3045	Homo sapiens	Inhibition	%	0.85
	8171930	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	COc1cccc(-n2ncc3c(N/N=C/c4cccc(F)c4)ncnc32)c1		CHEMBL69757	=	Inhibition	%	1.7	CHEMBL3045	Homo sapiens	Inhibition	%	1.7
	8172149	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	COc1cccc(-n2ncc3c(N/N=C/c4cccc(F)c4)ncnc32)c1		CHEMBL69757	=	Inhibition	%	1.36	CHEMBL3045	Homo sapiens	Inhibition	%	1.36
	8172154	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	COc1cccc(-n2ncc3c(N/N=C/c4cccc(F)c4)ncnc32)c1		CHEMBL69757	=	Inhibition	%	3.14	CHEMBL3045	Homo sapiens	Inhibition	%	3.14
	8172281	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	O=C1Nc2ccccc2/C1=C/Nc1ccc2[nH]c(=O)[nH]c2c1		CHEMBL1794057	=	Inhibition	%	0.19	CHEMBL3045	Homo sapiens	Inhibition	%	0.19
	8172286	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	O=C1Nc2ccccc2/C1=C/Nc1ccc2[nH]c(=O)[nH]c2c1		CHEMBL1794057	=	Inhibition	%	1.79	CHEMBL3045	Homo sapiens	Inhibition	%	1.79
	8172633	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	c1ccc(-c2n[nH]cc2-c2ccnc(-c3ccc(OCCn4ccnc4)cc3)c2)nc1		CHEMBL208437	=	Inhibition	%	0.31	CHEMBL3045	Homo sapiens	Inhibition	%	0.31
	8172638	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	c1ccc(-c2n[nH]cc2-c2ccnc(-c3ccc(OCCn4ccnc4)cc3)c2)nc1		CHEMBL208437	=	Inhibition	%	0.85	CHEMBL3045	Homo sapiens	Inhibition	%	0.85
	8172775	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	NC(=O)c1ccc2c(-c3ccnc(NCCCO)n3)c(-c3ccc(F)cc3)nn2c1		CHEMBL1909404	=	Inhibition	%	17.52	CHEMBL3045	Homo sapiens	Inhibition	%	17.52
	8172780	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	NC(=O)c1ccc2c(-c3ccnc(NCCCO)n3)c(-c3ccc(F)cc3)nn2c1		CHEMBL1909404	=	Inhibition	%	24.33	CHEMBL3045	Homo sapiens	Inhibition	%	24.33
	8173135	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	NS(=O)(=O)c1cccc(-c2ccc3c(NC(=O)C4CC4)n[nH]c3c2)c1		CHEMBL407113	=	Inhibition	%	2.66	CHEMBL3045	Homo sapiens	Inhibition	%	2.66
	8173140	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	NS(=O)(=O)c1cccc(-c2ccc3c(NC(=O)C4CC4)n[nH]c3c2)c1		CHEMBL407113	=	Inhibition	%	2.57	CHEMBL3045	Homo sapiens	Inhibition	%	2.57
	8173300	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	COc1cccc(-n2ncc3c(N/N=C/c4ccncc4)ncnc32)c1		CHEMBL306865	=	Inhibition	%	1.63	CHEMBL3045	Homo sapiens	Inhibition	%	1.63
	8173305	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	COc1cccc(-n2ncc3c(N/N=C/c4ccncc4)ncnc32)c1		CHEMBL306865	=	Inhibition	%	2.37	CHEMBL3045	Homo sapiens	Inhibition	%	2.37
	8173524	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	COc1cccc(-n2ncc3c(N/N=C/c4ccncc4)ncnc32)c1		CHEMBL306865	=	Inhibition	%	7.79	CHEMBL3045	Homo sapiens	Inhibition	%	7.79
	8173529	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	COc1cccc(-n2ncc3c(N/N=C/c4ccncc4)ncnc32)c1		CHEMBL306865	=	Inhibition	%	9.57	CHEMBL3045	Homo sapiens	Inhibition	%	9.57
	8173665	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	Cl.O=C1Nc2ccc(-c3cccnc3)cc2C1=Cc1cc(Br)c(O)c(Br)c1		CHEMBL1794050	=	Inhibition	%	0.24	CHEMBL3045	Homo sapiens	Inhibition	%	0.24
	8173670	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	Cl.O=C1Nc2ccc(-c3cccnc3)cc2C1=Cc1cc(Br)c(O)c(Br)c1		CHEMBL1794050	=	Inhibition	%	0.86	CHEMBL3045	Homo sapiens	Inhibition	%	0.86
	8173976	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc(C(=O)NCCc4c[nH]cn4)cc32)cc1		CHEMBL272028	=	Inhibition	%	-0.4	CHEMBL3045	Homo sapiens	Inhibition	%	-0.4
	8173981	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc(C(=O)NCCc4c[nH]cn4)cc32)cc1		CHEMBL272028	=	Inhibition	%	2.48	CHEMBL3045	Homo sapiens	Inhibition	%	2.48
	8174108	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	COC(=O)c1cncc(/C=C/c2c(C)cc(O)cc2C)c1		CHEMBL220243	=	Inhibition	%	0.78	CHEMBL3045	Homo sapiens	Inhibition	%	0.78
	8174113	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	COC(=O)c1cncc(/C=C/c2c(C)cc(O)cc2C)c1		CHEMBL220243	=	Inhibition	%	-1.36	CHEMBL3045	Homo sapiens	Inhibition	%	-1.36
	8174332	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	COC(=O)c1cncc(/C=C/c2c(C)cc(O)cc2C)c1		CHEMBL220243	=	Inhibition	%	2.09	CHEMBL3045	Homo sapiens	Inhibition	%	2.09
	8174337	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	COC(=O)c1cncc(/C=C/c2c(C)cc(O)cc2C)c1		CHEMBL220243	=	Inhibition	%	2.82	CHEMBL3045	Homo sapiens	Inhibition	%	2.82
	8174480	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	O=C(NCC1CC1)c1ccc(-c2cccc(C(=O)NC3CC3)c2)cc1		CHEMBL479038	=	Inhibition	%	-0.06	CHEMBL3045	Homo sapiens	Inhibition	%	-0.06
	8174485	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	O=C(NCC1CC1)c1ccc(-c2cccc(C(=O)NC3CC3)c2)cc1		CHEMBL479038	=	Inhibition	%	0.69	CHEMBL3045	Homo sapiens	Inhibition	%	0.69
	8174826	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	CCNC(=O)O[C@H]1CN[C@H](C#Cc2cc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3s2)C1		CHEMBL512076	=	Inhibition	%	0.61	CHEMBL3045	Homo sapiens	Inhibition	%	0.61
	8174831	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	CCNC(=O)O[C@H]1CN[C@H](C#Cc2cc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3s2)C1		CHEMBL512076	=	Inhibition	%	-0.74	CHEMBL3045	Homo sapiens	Inhibition	%	-0.74
	8174969	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OCC3CCNCC3)c21.O=C(O)C(F)(F)F		CHEMBL1794065	=	Inhibition	%	64.42	CHEMBL3045	Homo sapiens	Inhibition	%	64.42
	8174974	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OCC3CCNCC3)c21.O=C(O)C(F)(F)F		CHEMBL1794065	=	Inhibition	%	37.64	CHEMBL3045	Homo sapiens	Inhibition	%	37.64
	8175329	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	CC(C)c1ccc(Nc2nccc(-c3cnn4ncccc34)n2)cc1		CHEMBL359963	=	Inhibition	%	1.57	CHEMBL3045	Homo sapiens	Inhibition	%	1.57
	8175334	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	CC(C)c1ccc(Nc2nccc(-c3cnn4ncccc34)n2)cc1		CHEMBL359963	=	Inhibition	%	1.47	CHEMBL3045	Homo sapiens	Inhibition	%	1.47
	8175585	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	O=C1Nc2ccccc2/C1=C/Nc1ccc(-n2cncn2)cc1		CHEMBL1794056	=	Inhibition	%	2.25	CHEMBL3045	Homo sapiens	Inhibition	%	2.25
	8175590	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	O=C1Nc2ccccc2/C1=C/Nc1ccc(-n2cncn2)cc1		CHEMBL1794056	=	Inhibition	%	4.54	CHEMBL3045	Homo sapiens	Inhibition	%	4.54
	8175748	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	Cc1nn(C)c2cc(N(C)c3ccnc(Nc4cccc(S(N)(=O)=O)c4)n3)ccc12.Cl		CHEMBL1794073	=	Inhibition	%	1.44	CHEMBL3045	Homo sapiens	Inhibition	%	1.44
	8175753	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	Cc1nn(C)c2cc(N(C)c3ccnc(Nc4cccc(S(N)(=O)=O)c4)n3)ccc12.Cl		CHEMBL1794073	=	Inhibition	%	2.72	CHEMBL3045	Homo sapiens	Inhibition	%	2.72
	8175972	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	Cc1nn(C)c2cc(N(C)c3ccnc(Nc4cccc(S(N)(=O)=O)c4)n3)ccc12.Cl		CHEMBL1794073	=	Inhibition	%	6.0	CHEMBL3045	Homo sapiens	Inhibition	%	6.0
	8175977	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	Cc1nn(C)c2cc(N(C)c3ccnc(Nc4cccc(S(N)(=O)=O)c4)n3)ccc12.Cl		CHEMBL1794073	=	Inhibition	%	6.99	CHEMBL3045	Homo sapiens	Inhibition	%	6.99
	8176125	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	NCc1ccc(-n2c(-c3nonc3N)nc3cnccc32)cc1		CHEMBL188268	=	Inhibition	%	29.09	CHEMBL3045	Homo sapiens	Inhibition	%	29.09
	8176130	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	NCc1ccc(-n2c(-c3nonc3N)nc3cnccc32)cc1		CHEMBL188268	=	Inhibition	%	7.63	CHEMBL3045	Homo sapiens	Inhibition	%	7.63
	8176498	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	CN(C)c1ccc2c(c1)/C(=C/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2		CHEMBL272414	=	Inhibition	%	0.94	CHEMBL3045	Homo sapiens	Inhibition	%	0.94
	8176503	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	CN(C)c1ccc2c(c1)/C(=C/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2		CHEMBL272414	=	Inhibition	%	1.61	CHEMBL3045	Homo sapiens	Inhibition	%	1.61
	8176630	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	O=C1Nc2ccccc2/C1=C/Nc1ccc2[nH]c(=O)[nH]c2c1		CHEMBL1794057	=	Inhibition	%	4.33	CHEMBL3045	Homo sapiens	Inhibition	%	4.33
	8176635	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	O=C1Nc2ccccc2/C1=C/Nc1ccc2[nH]c(=O)[nH]c2c1		CHEMBL1794057	=	Inhibition	%	2.19	CHEMBL3045	Homo sapiens	Inhibition	%	2.19
	8176984	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	c1ccc(-c2n[nH]cc2-c2ccnc(-c3ccc(OCCn4ccnc4)cc3)c2)nc1		CHEMBL208437	=	Inhibition	%	0.68	CHEMBL3045	Homo sapiens	Inhibition	%	0.68
	8176989	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	c1ccc(-c2n[nH]cc2-c2ccnc(-c3ccc(OCCn4ccnc4)cc3)c2)nc1		CHEMBL208437	=	Inhibition	%	-0.29	CHEMBL3045	Homo sapiens	Inhibition	%	-0.29
	8177126	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	Cc1cc(O)cc(C)c1/C=C/c1cncc(-c2nn[nH]n2)c1.Cl		CHEMBL1909352	=	Inhibition	%	0.1	CHEMBL3045	Homo sapiens	Inhibition	%	0.1
	8177131	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	Cc1cc(O)cc(C)c1/C=C/c1cncc(-c2nn[nH]n2)c1.Cl		CHEMBL1909352	=	Inhibition	%	1.15	CHEMBL3045	Homo sapiens	Inhibition	%	1.15
	8177350	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	Cc1cc(O)cc(C)c1/C=C/c1cncc(-c2nn[nH]n2)c1.Cl		CHEMBL1909352	=	Inhibition	%	2.35	CHEMBL3045	Homo sapiens	Inhibition	%	2.35
	8177355	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	Cc1cc(O)cc(C)c1/C=C/c1cncc(-c2nn[nH]n2)c1.Cl		CHEMBL1909352	=	Inhibition	%	4.04	CHEMBL3045	Homo sapiens	Inhibition	%	4.04
	8177488	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc2[nH]c3c4[nH]c5ccc(OC)cc5c4c4c(c3c2c1)C(=O)NC4=O		CHEMBL1956068	=	Inhibition	%	1.55	CHEMBL3045	Homo sapiens	Inhibition	%	1.55
	8177493	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc2[nH]c3c4[nH]c5ccc(OC)cc5c4c4c(c3c2c1)C(=O)NC4=O		CHEMBL1956068	=	Inhibition	%	3.68	CHEMBL3045	Homo sapiens	Inhibition	%	3.68
	8177876	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	Nc1nc(-c2ccc(F)cc2)c(-c2ccc3ncccc3n2)s1		CHEMBL361237	=	Inhibition	%	0.21	CHEMBL3045	Homo sapiens	Inhibition	%	0.21
	8177881	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	Nc1nc(-c2ccc(F)cc2)c(-c2ccc3ncccc3n2)s1		CHEMBL361237	=	Inhibition	%	1.11	CHEMBL3045	Homo sapiens	Inhibition	%	1.11
	8178016	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	Cl.O=C1Nc2ccc(-c3cccnc3)cc2C1=Cc1cc(Br)c(O)c(Br)c1		CHEMBL1794050	=	Inhibition	%	-1.03	CHEMBL3045	Homo sapiens	Inhibition	%	-1.03
	8178021	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	Cl.O=C1Nc2ccc(-c3cccnc3)cc2C1=Cc1cc(Br)c(O)c(Br)c1		CHEMBL1794050	=	Inhibition	%	1.44	CHEMBL3045	Homo sapiens	Inhibition	%	1.44
	8178328	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	CN(C)C(=O)O[C@H]1CN[C@H](C#Cc2cc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3s2)C1		CHEMBL517123	=	Inhibition	%	-1.06	CHEMBL3045	Homo sapiens	Inhibition	%	-1.06
	8178333	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	CN(C)C(=O)O[C@H]1CN[C@H](C#Cc2cc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3s2)C1		CHEMBL517123	=	Inhibition	%	1.29	CHEMBL3045	Homo sapiens	Inhibition	%	1.29
	8178679	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	COc1cccc(-n2ncc3c(N/N=C/c4ccc(F)cc4)ncnc32)c1		CHEMBL65884	=	Inhibition	%	1.01	CHEMBL3045	Homo sapiens	Inhibition	%	1.01
	8178684	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	COc1cccc(-n2ncc3c(N/N=C/c4ccc(F)cc4)ncnc32)c1		CHEMBL65884	=	Inhibition	%	2.56	CHEMBL3045	Homo sapiens	Inhibition	%	2.56
	8178828	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	O=C(NCC1CC1)c1ccc(-c2cccc(C(=O)NC3CC3)c2)cc1		CHEMBL479038	=	Inhibition	%	-2.0	CHEMBL3045	Homo sapiens	Inhibition	%	-2.0
	8178833	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	O=C(NCC1CC1)c1ccc(-c2cccc(C(=O)NC3CC3)c2)cc1		CHEMBL479038	=	Inhibition	%	-1.18	CHEMBL3045	Homo sapiens	Inhibition	%	-1.18
	8179175	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	CCNC(=O)O[C@H]1CN[C@H](C#Cc2cc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3s2)C1		CHEMBL512076	=	Inhibition	%	-2.05	CHEMBL3045	Homo sapiens	Inhibition	%	-2.05
	8179180	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	CCNC(=O)O[C@H]1CN[C@H](C#Cc2cc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3s2)C1		CHEMBL512076	=	Inhibition	%	0.7	CHEMBL3045	Homo sapiens	Inhibition	%	0.7
	8179319	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc(C(=O)NCc4ccncc4)cc32)cc1		CHEMBL272165	=	Inhibition	%	-0.39	CHEMBL3045	Homo sapiens	Inhibition	%	-0.39
	8179324	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc(C(=O)NCc4ccncc4)cc32)cc1		CHEMBL272165	=	Inhibition	%	1.7	CHEMBL3045	Homo sapiens	Inhibition	%	1.7
	8179543	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc(C(=O)NCc4ccncc4)cc32)cc1		CHEMBL272165	=	Inhibition	%	5.08	CHEMBL3045	Homo sapiens	Inhibition	%	5.08
	8179548	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc(C(=O)NCc4ccncc4)cc32)cc1		CHEMBL272165	=	Inhibition	%	4.09	CHEMBL3045	Homo sapiens	Inhibition	%	4.09
	8179680	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	CCCN(CCS(C)(=O)=O)Cc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1.Cl		CHEMBL1909394	=	Inhibition	%	0.26	CHEMBL3045	Homo sapiens	Inhibition	%	0.26
	8179685	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	CCCN(CCS(C)(=O)=O)Cc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1.Cl		CHEMBL1909394	=	Inhibition	%	1.13	CHEMBL3045	Homo sapiens	Inhibition	%	1.13
	8179937	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	CN1CCC(C(=O)Nc2n[nH]c3nnc(-c4ccccc4)cc23)CC1.Cl		CHEMBL1909344	=	Inhibition	%	1.03	CHEMBL3045	Homo sapiens	Inhibition	%	1.03
	8179942	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	CN1CCC(C(=O)Nc2n[nH]c3nnc(-c4ccccc4)cc23)CC1.Cl		CHEMBL1909344	=	Inhibition	%	1.32	CHEMBL3045	Homo sapiens	Inhibition	%	1.32
	8180315	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	Cl.Fc1cccc(COc2ccc(Nc3ncnc4cc(-c5ccc[nH]5)sc34)cc2Cl)c1		CHEMBL1909415	=	Inhibition	%	1.37	CHEMBL3045	Homo sapiens	Inhibition	%	1.37
	8180320	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	Cl.Fc1cccc(COc2ccc(Nc3ncnc4cc(-c5ccc[nH]5)sc34)cc2Cl)c1		CHEMBL1909415	=	Inhibition	%	0.99	CHEMBL3045	Homo sapiens	Inhibition	%	0.99
	8180471	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	NCc1ccc(-n2c(-c3nonc3N)nc3cnccc32)cc1		CHEMBL188268	=	Inhibition	%	64.47	CHEMBL3045	Homo sapiens	Inhibition	%	64.47
	8180476	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	NCc1ccc(-n2c(-c3nonc3N)nc3cnccc32)cc1		CHEMBL188268	=	Inhibition	%	37.74	CHEMBL3045	Homo sapiens	Inhibition	%	37.74
	8180843	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	CN(C)c1ccc2c(c1)/C(=C/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2		CHEMBL272414	=	Inhibition	%	0.89	CHEMBL3045	Homo sapiens	Inhibition	%	0.89
	8180848	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	CN(C)c1ccc2c(c1)/C(=C/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2		CHEMBL272414	=	Inhibition	%	1.98	CHEMBL3045	Homo sapiens	Inhibition	%	1.98
	8180976	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	Cc1ccc(O)cc1Nc1ccnc2ccc(S(C)(=O)=O)cc12		CHEMBL237347	=	Inhibition	%	1.93	CHEMBL3045	Homo sapiens	Inhibition	%	1.93
	8180981	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	Cc1ccc(O)cc1Nc1ccnc2ccc(S(C)(=O)=O)cc12		CHEMBL237347	=	Inhibition	%	2.21	CHEMBL3045	Homo sapiens	Inhibition	%	2.21
	8181200	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	Cc1ccc(O)cc1Nc1ccnc2ccc(S(C)(=O)=O)cc12		CHEMBL237347	=	Inhibition	%	4.87	CHEMBL3045	Homo sapiens	Inhibition	%	4.87
	8181205	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	Cc1ccc(O)cc1Nc1ccnc2ccc(S(C)(=O)=O)cc12		CHEMBL237347	=	Inhibition	%	4.59	CHEMBL3045	Homo sapiens	Inhibition	%	4.59
	8181331	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	C/C(Nc1ccc(S(N)(=O)=O)cc1)=C1/C(=O)Nc2ccccc21		CHEMBL405042	=	Inhibition	%	-0.26	CHEMBL3045	Homo sapiens	Inhibition	%	-0.26
	8181336	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	C/C(Nc1ccc(S(N)(=O)=O)cc1)=C1/C(=O)Nc2ccccc21		CHEMBL405042	=	Inhibition	%	-0.77	CHEMBL3045	Homo sapiens	Inhibition	%	-0.77
	8181695	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	O=C(Nc1n[nH]c2cc(-c3ccccc3)ccc12)C1CC1		CHEMBL405021	=	Inhibition	%	-0.78	CHEMBL3045	Homo sapiens	Inhibition	%	-0.78
	8181700	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	O=C(Nc1n[nH]c2cc(-c3ccccc3)ccc12)C1CC1		CHEMBL405021	=	Inhibition	%	1.8	CHEMBL3045	Homo sapiens	Inhibition	%	1.8
	8181834	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	COc1ccc2[nH]c3c4[nH]c5ccc(OC)cc5c4c4c(c3c2c1)C(=O)NC4=O		CHEMBL1956068	=	Inhibition	%	8.91	CHEMBL3045	Homo sapiens	Inhibition	%	8.91
	8181839	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	COc1ccc2[nH]c3c4[nH]c5ccc(OC)cc5c4c4c(c3c2c1)C(=O)NC4=O		CHEMBL1956068	=	Inhibition	%	12.87	CHEMBL3045	Homo sapiens	Inhibition	%	12.87
	8182058	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccc(F)c(F)c3)n2)cc1		CHEMBL427159	=	Inhibition	%	1.53	CHEMBL3045	Homo sapiens	Inhibition	%	1.53
	8182221	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	Nc1nc(-c2ccc(F)cc2)c(-c2ccc3ncccc3n2)s1		CHEMBL361237	=	Inhibition	%	3.92	CHEMBL3045	Homo sapiens	Inhibition	%	3.92
	8182226	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	Nc1nc(-c2ccc(F)cc2)c(-c2ccc3ncccc3n2)s1		CHEMBL361237	=	Inhibition	%	3.48	CHEMBL3045	Homo sapiens	Inhibition	%	3.48
	8182361	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	Fc1ccc(Nc2nccc(-c3c(-c4ccc(C(F)(F)F)cc4)nn4ncccc34)n2)cc1F		CHEMBL188784	=	Inhibition	%	-0.08	CHEMBL3045	Homo sapiens	Inhibition	%	-0.08
	8182366	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	Fc1ccc(Nc2nccc(-c3c(-c4ccc(C(F)(F)F)cc4)nn4ncccc34)n2)cc1F		CHEMBL188784	=	Inhibition	%	0.7	CHEMBL3045	Homo sapiens	Inhibition	%	0.7
	8182585	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	Fc1ccc(Nc2nccc(-c3c(-c4ccc(C(F)(F)F)cc4)nn4ncccc34)n2)cc1F		CHEMBL188784	=	Inhibition	%	-1.29	CHEMBL3045	Homo sapiens	Inhibition	%	-1.29
	8182590	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	Fc1ccc(Nc2nccc(-c3c(-c4ccc(C(F)(F)F)cc4)nn4ncccc34)n2)cc1F		CHEMBL188784	=	Inhibition	%	0.3	CHEMBL3045	Homo sapiens	Inhibition	%	0.3
	8182677	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	CN(C)C(=O)O[C@H]1CN[C@H](C#Cc2cc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3s2)C1		CHEMBL517123	=	Inhibition	%	0.39	CHEMBL3045	Homo sapiens	Inhibition	%	0.39
	8182682	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	CN(C)C(=O)O[C@H]1CN[C@H](C#Cc2cc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3s2)C1		CHEMBL517123	=	Inhibition	%	1.12	CHEMBL3045	Homo sapiens	Inhibition	%	1.12
	8183023	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	COc1cccc(-n2ncc3c(N/N=C/c4ccc(F)cc4)ncnc32)c1		CHEMBL65884	=	Inhibition	%	0.97	CHEMBL3045	Homo sapiens	Inhibition	%	0.97
	8183028	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	COc1cccc(-n2ncc3c(N/N=C/c4ccc(F)cc4)ncnc32)c1		CHEMBL65884	=	Inhibition	%	0.22	CHEMBL3045	Homo sapiens	Inhibition	%	0.22
	8183172	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	CCS(=O)(=O)c1ccc(OC)c(Nc2ncc(-c3cccc(OC)c3)o2)c1		CHEMBL179311	=	Inhibition	%	0.07	CHEMBL3045	Homo sapiens	Inhibition	%	0.07
	8183177	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	CCS(=O)(=O)c1ccc(OC)c(Nc2ncc(-c3cccc(OC)c3)o2)c1		CHEMBL179311	=	Inhibition	%	0.6	CHEMBL3045	Homo sapiens	Inhibition	%	0.6
	8183396	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	CCS(=O)(=O)c1ccc(OC)c(Nc2ncc(-c3cccc(OC)c3)o2)c1		CHEMBL179311	=	Inhibition	%	-1.05	CHEMBL3045	Homo sapiens	Inhibition	%	-1.05
	8183401	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	CCS(=O)(=O)c1ccc(OC)c(Nc2ncc(-c3cccc(OC)c3)o2)c1		CHEMBL179311	=	Inhibition	%	2.93	CHEMBL3045	Homo sapiens	Inhibition	%	2.93
	8183525	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	FC(F)(F)c1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccc4c(c3)OCCO4)n2)cc1		CHEMBL185939	=	Inhibition	%	8.14	CHEMBL3045	Homo sapiens	Inhibition	%	8.14
	8183530	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	FC(F)(F)c1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccc4c(c3)OCCO4)n2)cc1		CHEMBL185939	=	Inhibition	%	5.29	CHEMBL3045	Homo sapiens	Inhibition	%	5.29
	8183891	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc(Cl)cc32)cc1		CHEMBL270054	=	Inhibition	%	1.35	CHEMBL3045	Homo sapiens	Inhibition	%	1.35
	8183896	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc(Cl)cc32)cc1		CHEMBL270054	=	Inhibition	%	0.92	CHEMBL3045	Homo sapiens	Inhibition	%	0.92
	8184027	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	CCCN(CCS(C)(=O)=O)Cc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1.Cl		CHEMBL1909394	=	Inhibition	%	0.52	CHEMBL3045	Homo sapiens	Inhibition	%	0.52
	8184032	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	CCCN(CCS(C)(=O)=O)Cc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1.Cl		CHEMBL1909394	=	Inhibition	%	2.02	CHEMBL3045	Homo sapiens	Inhibition	%	2.02
	8184251	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	COc1cccc(-n2ncc3c(N/N=C/c4ccc(S(C)(=O)=O)cc4)ncnc32)c1		CHEMBL66292	=	Inhibition	%	2.22	CHEMBL3045	Homo sapiens	Inhibition	%	2.22
	8184256	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	COc1cccc(-n2ncc3c(N/N=C/c4ccc(S(C)(=O)=O)cc4)ncnc32)c1		CHEMBL66292	=	Inhibition	%	2.19	CHEMBL3045	Homo sapiens	Inhibition	%	2.19
	8184293	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	CN1CCC(C(=O)Nc2n[nH]c3nnc(-c4ccccc4)cc23)CC1.Cl		CHEMBL1909344	=	Inhibition	%	1.27	CHEMBL3045	Homo sapiens	Inhibition	%	1.27
	8184298	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	CN1CCC(C(=O)Nc2n[nH]c3nnc(-c4ccccc4)cc23)CC1.Cl		CHEMBL1909344	=	Inhibition	%	1.6	CHEMBL3045	Homo sapiens	Inhibition	%	1.6
	8184517	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	CN1CCN(Cc2ccc(-c3cc4ncnc(Nc5ccc(OCc6cccc(F)c6)c(Cl)c5)c4s3)o2)CC1		CHEMBL475761	=	Inhibition	%	0.04	CHEMBL3045	Homo sapiens	Inhibition	%	0.04
	8184522	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	CN1CCN(Cc2ccc(-c3cc4ncnc(Nc5ccc(OCc6cccc(F)c6)c(Cl)c5)c4s3)o2)CC1		CHEMBL475761	=	Inhibition	%	1.08	CHEMBL3045	Homo sapiens	Inhibition	%	1.08
	8184664	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	Cl.Fc1cccc(COc2ccc(Nc3ncnc4cc(-c5ccc[nH]5)sc34)cc2Cl)c1		CHEMBL1909415	=	Inhibition	%	0.9	CHEMBL3045	Homo sapiens	Inhibition	%	0.9
	8184669	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	Cl.Fc1cccc(COc2ccc(Nc3ncnc4cc(-c5ccc[nH]5)sc34)cc2Cl)c1		CHEMBL1909415	=	Inhibition	%	2.94	CHEMBL3045	Homo sapiens	Inhibition	%	2.94
	8184821	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	Fc1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccc4c(c3)OCCO4)n2)cc1		CHEMBL365297	=	Inhibition	%	1.43	CHEMBL3045	Homo sapiens	Inhibition	%	1.43
	8184826	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	Fc1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccc4c(c3)OCCO4)n2)cc1		CHEMBL365297	=	Inhibition	%	3.86	CHEMBL3045	Homo sapiens	Inhibition	%	3.86
	8185045	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	Fc1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccc4c(c3)OCCO4)n2)cc1		CHEMBL365297	=	Inhibition	%	13.32	CHEMBL3045	Homo sapiens	Inhibition	%	13.32
	8185050	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	Fc1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccc4c(c3)OCCO4)n2)cc1		CHEMBL365297	=	Inhibition	%	20.09	CHEMBL3045	Homo sapiens	Inhibition	%	20.09
	8185194	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	CC(=O)NCc1cccc(C#Cc2cncnc2Nc2ccc(OCc3cccc(F)c3)c(Cl)c2)c1		CHEMBL207247	=	Inhibition	%	-0.24	CHEMBL3045	Homo sapiens	Inhibition	%	-0.24
	8185199	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	CC(=O)NCc1cccc(C#Cc2cncnc2Nc2ccc(OCc3cccc(F)c3)c(Cl)c2)c1		CHEMBL207247	=	Inhibition	%	0.7	CHEMBL3045	Homo sapiens	Inhibition	%	0.7
	8185549	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	C#Cc1cccc(Nc2ncnc3ccc(OCCCCNCCS(C)(=O)=O)cc23)c1		CHEMBL517907	=	Inhibition	%	1.6	CHEMBL3045	Homo sapiens	Inhibition	%	1.6
	8185554	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	C#Cc1cccc(Nc2ncnc3ccc(OCCCCNCCS(C)(=O)=O)cc23)c1		CHEMBL517907	=	Inhibition	%	1.93	CHEMBL3045	Homo sapiens	Inhibition	%	1.93
	8185680	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	C/C(Nc1ccc(S(N)(=O)=O)cc1)=C1/C(=O)Nc2ccccc21		CHEMBL405042	=	Inhibition	%	1.85	CHEMBL3045	Homo sapiens	Inhibition	%	1.85
	8185685	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	C/C(Nc1ccc(S(N)(=O)=O)cc1)=C1/C(=O)Nc2ccccc21		CHEMBL405042	=	Inhibition	%	1.28	CHEMBL3045	Homo sapiens	Inhibition	%	1.28
	8185904	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccccc1-c1cc(/C=C2\C(=O)Nc3ncc(Br)cc32)cc(Br)c1O		CHEMBL176857	=	Inhibition	%	-0.31	CHEMBL3045	Homo sapiens	Inhibition	%	-0.31
	8186043	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	O=C(Nc1n[nH]c2cc(-c3ccccc3)ccc12)C1CC1		CHEMBL405021	=	Inhibition	%	4.47	CHEMBL3045	Homo sapiens	Inhibition	%	4.47
	8186048	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	O=C(Nc1n[nH]c2cc(-c3ccccc3)ccc12)C1CC1		CHEMBL405021	=	Inhibition	%	3.32	CHEMBL3045	Homo sapiens	Inhibition	%	3.32
	8186189	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccc(F)c(F)c3)n2)cc1		CHEMBL427159	=	Inhibition	%	1.81	CHEMBL3045	Homo sapiens	Inhibition	%	1.81
	8186408	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	COc1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccc(F)c(F)c3)n2)cc1		CHEMBL427159	=	Inhibition	%	5.16	CHEMBL3045	Homo sapiens	Inhibition	%	5.16
	8186413	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	COc1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccc(F)c(F)c3)n2)cc1		CHEMBL427159	=	Inhibition	%	3.24	CHEMBL3045	Homo sapiens	Inhibition	%	3.24
	8186572	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc(C2=C(N3CCc4ccccc43)C(=O)NC2=O)cc1		CHEMBL347580	=	Inhibition	%	1.02	CHEMBL3045	Homo sapiens	Inhibition	%	1.02
	8186577	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc(C2=C(N3CCc4ccccc43)C(=O)NC2=O)cc1		CHEMBL347580	=	Inhibition	%	1.22	CHEMBL3045	Homo sapiens	Inhibition	%	1.22
	8186935	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	CN(C)CCNC(=O)Nc1ccc(N(C)c2ccnc(Nc3ccc(CS(C)(=O)=O)cc3)n2)cc1.Cl		CHEMBL1909362	=	Inhibition	%	-0.61	CHEMBL3045	Homo sapiens	Inhibition	%	-0.61
	8186940	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	CN(C)CCNC(=O)Nc1ccc(N(C)c2ccnc(Nc3ccc(CS(C)(=O)=O)cc3)n2)cc1.Cl		CHEMBL1909362	=	Inhibition	%	0.79	CHEMBL3045	Homo sapiens	Inhibition	%	0.79
	8187033	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	Cc1cc(O)cc(C)c1/C=C/c1cncc(C(N)=O)c1		CHEMBL218088	=	Inhibition	%	-0.18	CHEMBL3045	Homo sapiens	Inhibition	%	-0.18
	8187038	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	Cc1cc(O)cc(C)c1/C=C/c1cncc(C(N)=O)c1		CHEMBL218088	=	Inhibition	%	1.28	CHEMBL3045	Homo sapiens	Inhibition	%	1.28
	8187257	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	Cc1cc(O)cc(C)c1/C=C/c1cncc(C(N)=O)c1		CHEMBL218088	=	Inhibition	%	-2.09	CHEMBL3045	Homo sapiens	Inhibition	%	-2.09
	8187262	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	Cc1cc(O)cc(C)c1/C=C/c1cncc(C(N)=O)c1		CHEMBL218088	=	Inhibition	%	1.05	CHEMBL3045	Homo sapiens	Inhibition	%	1.05
	8187381	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc2c(-c3ccnc(Nc4cccc(OC(F)(F)F)c4)n3)cnn2n1		CHEMBL365248	=	Inhibition	%	0.08	CHEMBL3045	Homo sapiens	Inhibition	%	0.08
	8187386	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc2c(-c3ccnc(Nc4cccc(OC(F)(F)F)c4)n3)cnn2n1		CHEMBL365248	=	Inhibition	%	1.08	CHEMBL3045	Homo sapiens	Inhibition	%	1.08
	8187753	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	CCc1cccc(CC)c1/C=C/c1cncc(C(=O)NC)c1		CHEMBL385426	=	Inhibition	%	0.31	CHEMBL3045	Homo sapiens	Inhibition	%	0.31
	8187758	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	CCc1cccc(CC)c1/C=C/c1cncc(C(=O)NC)c1		CHEMBL385426	=	Inhibition	%	0.14	CHEMBL3045	Homo sapiens	Inhibition	%	0.14
	8187882	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	FC(F)(F)c1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccc4c(c3)OCCO4)n2)cc1		CHEMBL185939	=	Inhibition	%	11.88	CHEMBL3045	Homo sapiens	Inhibition	%	11.88
	8187887	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	FC(F)(F)c1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccc4c(c3)OCCO4)n2)cc1		CHEMBL185939	=	Inhibition	%	6.33	CHEMBL3045	Homo sapiens	Inhibition	%	6.33
	8188106	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc(CNC(=O)c2ccc(-c3cc(-c4nnc(C)o4)ccc3C)cc2)cc1		CHEMBL269985	=	Inhibition	%	6.66	CHEMBL3045	Homo sapiens	Inhibition	%	6.66
	8188111	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc(CNC(=O)c2ccc(-c3cc(-c4nnc(C)o4)ccc3C)cc2)cc1		CHEMBL269985	=	Inhibition	%	2.73	CHEMBL3045	Homo sapiens	Inhibition	%	2.73
	8188249	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc(Cl)cc32)cc1		CHEMBL270054	=	Inhibition	%	2.75	CHEMBL3045	Homo sapiens	Inhibition	%	2.75
	8188254	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc(Cl)cc32)cc1		CHEMBL270054	=	Inhibition	%	1.29	CHEMBL3045	Homo sapiens	Inhibition	%	1.29
	8188608	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	COc1cccc(-n2ncc3c(N/N=C/c4ccc(S(C)(=O)=O)cc4)ncnc32)c1		CHEMBL66292	=	Inhibition	%	7.27	CHEMBL3045	Homo sapiens	Inhibition	%	7.27
	8188613	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	COc1cccc(-n2ncc3c(N/N=C/c4ccc(S(C)(=O)=O)cc4)ncnc32)c1		CHEMBL66292	=	Inhibition	%	13.31	CHEMBL3045	Homo sapiens	Inhibition	%	13.31
	8188882	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	CN1CCN(Cc2ccc(-c3cc4ncnc(Nc5ccc(OCc6cccc(F)c6)c(Cl)c5)c4s3)o2)CC1		CHEMBL475761	=	Inhibition	%	3.28	CHEMBL3045	Homo sapiens	Inhibition	%	3.28
	8188887	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	CN1CCN(Cc2ccc(-c3cc4ncnc(Nc5ccc(OCc6cccc(F)c6)c(Cl)c5)c4s3)o2)CC1		CHEMBL475761	=	Inhibition	%	3.9	CHEMBL3045	Homo sapiens	Inhibition	%	3.9
	8189030	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc(/C=N/Nc2ncnc3c2cnn3C(C)C)ccc1O		CHEMBL63728	=	Inhibition	%	0.72	CHEMBL3045	Homo sapiens	Inhibition	%	0.72
	8189035	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc(/C=N/Nc2ncnc3c2cnn3C(C)C)ccc1O		CHEMBL63728	=	Inhibition	%	1.47	CHEMBL3045	Homo sapiens	Inhibition	%	1.47
	8189410	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	NS(=O)(=O)c1cccc(N/C=C2\C(=O)Nc3ccccc32)c1		CHEMBL1794059	=	Inhibition	%	-0.22	CHEMBL3045	Homo sapiens	Inhibition	%	-0.22
	8189415	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	NS(=O)(=O)c1cccc(N/C=C2\C(=O)Nc3ccccc32)c1		CHEMBL1794059	=	Inhibition	%	1.9	CHEMBL3045	Homo sapiens	Inhibition	%	1.9
	8189559	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	CC(=O)NCc1cccc(C#Cc2cncnc2Nc2ccc(OCc3cccc(F)c3)c(Cl)c2)c1		CHEMBL207247	=	Inhibition	%	3.27	CHEMBL3045	Homo sapiens	Inhibition	%	3.27
	8189564	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	CC(=O)NCc1cccc(C#Cc2cncnc2Nc2ccc(OCc3cccc(F)c3)c(Cl)c2)c1		CHEMBL207247	=	Inhibition	%	0.37	CHEMBL3045	Homo sapiens	Inhibition	%	0.37
	8189915	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	C#Cc1cccc(Nc2ncnc3ccc(OCCCCNCCS(C)(=O)=O)cc23)c1		CHEMBL517907	=	Inhibition	%	4.77	CHEMBL3045	Homo sapiens	Inhibition	%	4.77
	8189920	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	C#Cc1cccc(Nc2ncnc3ccc(OCCCCNCCS(C)(=O)=O)cc23)c1		CHEMBL517907	=	Inhibition	%	6.61	CHEMBL3045	Homo sapiens	Inhibition	%	6.61
	8190052	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccccc1-c1cc(/C=C2\C(=O)Nc3ncc(Br)cc32)cc(Br)c1O		CHEMBL176857	=	Inhibition	%	2.24	CHEMBL3045	Homo sapiens	Inhibition	%	2.24
	8190271	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	COc1ccccc1-c1cc(/C=C2\C(=O)Nc3ncc(Br)cc32)cc(Br)c1O		CHEMBL176857	=	Inhibition	%	0.26	CHEMBL3045	Homo sapiens	Inhibition	%	0.26
	8190276	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	COc1ccccc1-c1cc(/C=C2\C(=O)Nc3ncc(Br)cc32)cc(Br)c1O		CHEMBL176857	=	Inhibition	%	0.81	CHEMBL3045	Homo sapiens	Inhibition	%	0.81
	8190411	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	NC(=O)c1cc(-c2ccncc2)cc(-c2ccccc2)c1N		CHEMBL230911	=	Inhibition	%	1.43	CHEMBL3045	Homo sapiens	Inhibition	%	1.43
	8190416	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	NC(=O)c1cc(-c2ccncc2)cc(-c2ccccc2)c1N		CHEMBL230911	=	Inhibition	%	1.9	CHEMBL3045	Homo sapiens	Inhibition	%	1.9
	8190772	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	CN1CCC(n2cnc(-c3ccc(F)cc3)c2-c2ccnc(NCCO)n2)CC1		CHEMBL330422	=	Inhibition	%	0.78	CHEMBL3045	Homo sapiens	Inhibition	%	0.78
	8190777	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	CN1CCC(n2cnc(-c3ccc(F)cc3)c2-c2ccnc(NCCO)n2)CC1		CHEMBL330422	=	Inhibition	%	1.17	CHEMBL3045	Homo sapiens	Inhibition	%	1.17
	8190936	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	COc1ccc(C2=C(N3CCc4ccccc43)C(=O)NC2=O)cc1		CHEMBL347580	=	Inhibition	%	2.88	CHEMBL3045	Homo sapiens	Inhibition	%	2.88
	8190941	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	COc1ccc(C2=C(N3CCc4ccccc43)C(=O)NC2=O)cc1		CHEMBL347580	=	Inhibition	%	3.96	CHEMBL3045	Homo sapiens	Inhibition	%	3.96
	8191298	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	CN(C)CCNC(=O)Nc1ccc(N(C)c2ccnc(Nc3ccc(CS(C)(=O)=O)cc3)n2)cc1.Cl		CHEMBL1909362	=	Inhibition	%	0.12	CHEMBL3045	Homo sapiens	Inhibition	%	0.12
	8191303	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	CN(C)CCNC(=O)Nc1ccc(N(C)c2ccnc(Nc3ccc(CS(C)(=O)=O)cc3)n2)cc1.Cl		CHEMBL1909362	=	Inhibition	%	0.59	CHEMBL3045	Homo sapiens	Inhibition	%	0.59
	8191618	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	CC1=C(C(=O)Nc2ccc3[nH]ncc3c2)C(c2ccc(F)cc2)N=C(c2ccc(C(F)(F)F)nc2)N1		CHEMBL485598	=	Inhibition	%	0.07	CHEMBL3045	Homo sapiens	Inhibition	%	0.07
	8191623	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	CC1=C(C(=O)Nc2ccc3[nH]ncc3c2)C(c2ccc(F)cc2)N=C(c2ccc(C(F)(F)F)nc2)N1		CHEMBL485598	=	Inhibition	%	4.27	CHEMBL3045	Homo sapiens	Inhibition	%	4.27
	8191740	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	COc1ccc2c(-c3ccnc(Nc4cccc(OC(F)(F)F)c4)n3)cnn2n1		CHEMBL365248	=	Inhibition	%	3.07	CHEMBL3045	Homo sapiens	Inhibition	%	3.07
	8191745	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	COc1ccc2c(-c3ccnc(Nc4cccc(OC(F)(F)F)c4)n3)cnn2n1		CHEMBL365248	=	Inhibition	%	5.19	CHEMBL3045	Homo sapiens	Inhibition	%	5.19
	8191964	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	Cl.c1ccc(Cc2nc3ccc(Nc4ncnc5ccccc45)cc3[nH]2)cc1		CHEMBL1909379	=	Inhibition	%	1.26	CHEMBL3045	Homo sapiens	Inhibition	%	1.26
	8191969	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	Cl.c1ccc(Cc2nc3ccc(Nc4ncnc5ccccc45)cc3[nH]2)cc1		CHEMBL1909379	=	Inhibition	%	0.1	CHEMBL3045	Homo sapiens	Inhibition	%	0.1
	8192113	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	CCc1cccc(CC)c1/C=C/c1cncc(C(=O)NC)c1		CHEMBL385426	=	Inhibition	%	0.32	CHEMBL3045	Homo sapiens	Inhibition	%	0.32
	8192118	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	CCc1cccc(CC)c1/C=C/c1cncc(C(=O)NC)c1		CHEMBL385426	=	Inhibition	%	-0.35	CHEMBL3045	Homo sapiens	Inhibition	%	-0.35
	8192466	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	COc1ccc(CNC(=O)c2ccc(-c3cc(-c4nnc(C)o4)ccc3C)cc2)cc1		CHEMBL269985	=	Inhibition	%	9.43	CHEMBL3045	Homo sapiens	Inhibition	%	9.43
	8192471	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	COc1ccc(CNC(=O)c2ccc(-c3cc(-c4nnc(C)o4)ccc3C)cc2)cc1		CHEMBL269985	=	Inhibition	%	3.61	CHEMBL3045	Homo sapiens	Inhibition	%	3.61
	8192610	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	CNC(=O)c1cncc(/C=C/c2ccccc2C)c1		CHEMBL218969	=	Inhibition	%	1.31	CHEMBL3045	Homo sapiens	Inhibition	%	1.31
	8192615	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	CNC(=O)c1cncc(/C=C/c2ccccc2C)c1		CHEMBL218969	=	Inhibition	%	0.51	CHEMBL3045	Homo sapiens	Inhibition	%	0.51
	8192970	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	CCOc1ccc2c(-c3ccnc(Nc4cc(OC)cc(C(F)(F)F)c4)n3)cnn2n1		CHEMBL188426	=	Inhibition	%	5.55	CHEMBL3045	Homo sapiens	Inhibition	%	5.55
	8192975	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	CCOc1ccc2c(-c3ccnc(Nc4cc(OC)cc(C(F)(F)F)c4)n3)cnn2n1		CHEMBL188426	=	Inhibition	%	1.09	CHEMBL3045	Homo sapiens	Inhibition	%	1.09
	8193242	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	NC(=O)c1cc(-c2ccc(F)cc2)cc(-c2ccncc2)c1N		CHEMBL231623	=	Inhibition	%	-1.29	CHEMBL3045	Homo sapiens	Inhibition	%	-1.29
	8193247	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	NC(=O)c1cc(-c2ccc(F)cc2)cc(-c2ccncc2)c1N		CHEMBL231623	=	Inhibition	%	1.46	CHEMBL3045	Homo sapiens	Inhibition	%	1.46
	8193387	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	COc1cc(/C=N/Nc2ncnc3c2cnn3C(C)C)ccc1O		CHEMBL63728	=	Inhibition	%	3.01	CHEMBL3045	Homo sapiens	Inhibition	%	3.01
	8193392	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	COc1cc(/C=N/Nc2ncnc3c2cnn3C(C)C)ccc1O		CHEMBL63728	=	Inhibition	%	4.67	CHEMBL3045	Homo sapiens	Inhibition	%	4.67
	8193611	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(OCc4ccccc4Cl)c(C(N)=O)s3)c2cc1OC		CHEMBL514162	=	Inhibition	%	0.65	CHEMBL3045	Homo sapiens	Inhibition	%	0.65
	8193616	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(OCc4ccccc4Cl)c(C(N)=O)s3)c2cc1OC		CHEMBL514162	=	Inhibition	%	0.93	CHEMBL3045	Homo sapiens	Inhibition	%	0.93
	8193768	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	NS(=O)(=O)c1cccc(N/C=C2\C(=O)Nc3ccccc32)c1		CHEMBL1794059	=	Inhibition	%	2.02	CHEMBL3045	Homo sapiens	Inhibition	%	2.02
	8193773	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	NS(=O)(=O)c1cccc(N/C=C2\C(=O)Nc3ccccc32)c1		CHEMBL1794059	=	Inhibition	%	3.11	CHEMBL3045	Homo sapiens	Inhibition	%	3.11
	8193917	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(N3CCCC3)nccc21		CHEMBL187985	=	Inhibition	%	0.38	CHEMBL3045	Homo sapiens	Inhibition	%	0.38
	8193922	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(N3CCCC3)nccc21		CHEMBL187985	=	Inhibition	%	-1.87	CHEMBL3045	Homo sapiens	Inhibition	%	-1.87
	8194141	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(N3CCCC3)nccc21		CHEMBL187985	=	Inhibition	%	13.37	CHEMBL3045	Homo sapiens	Inhibition	%	13.37
	8194146	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(N3CCCC3)nccc21		CHEMBL187985	=	Inhibition	%	2.46	CHEMBL3045	Homo sapiens	Inhibition	%	2.46
	8194272	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc2ncnc(Nc3ccc(C)c(O)c3)c2cc1OC.Cl		CHEMBL1909357	=	Inhibition	%	1.28	CHEMBL3045	Homo sapiens	Inhibition	%	1.28
	8194277	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc2ncnc(Nc3ccc(C)c(O)c3)c2cc1OC.Cl		CHEMBL1909357	=	Inhibition	%	2.8	CHEMBL3045	Homo sapiens	Inhibition	%	2.8
	8194627	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	O=C1NC(=O)C(N2CCc3ccccc32)=C1c1ccc(Cl)cc1		CHEMBL156524	=	Inhibition	%	-0.46	CHEMBL3045	Homo sapiens	Inhibition	%	-0.46
	8194632	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	O=C1NC(=O)C(N2CCc3ccccc32)=C1c1ccc(Cl)cc1		CHEMBL156524	=	Inhibition	%	1.71	CHEMBL3045	Homo sapiens	Inhibition	%	1.71
	8194770	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	NC(=O)c1cc(-c2ccncc2)cc(-c2ccccc2)c1N		CHEMBL230911	=	Inhibition	%	1.87	CHEMBL3045	Homo sapiens	Inhibition	%	1.87
	8194775	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	NC(=O)c1cc(-c2ccncc2)cc(-c2ccccc2)c1N		CHEMBL230911	=	Inhibition	%	2.02	CHEMBL3045	Homo sapiens	Inhibition	%	2.02
	8194994	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	CN(C)c1cc2c(Nc3ccc4nc(Cc5ccccc5)[nH]c4c3)ncnc2cn1		CHEMBL531804	=	Inhibition	%	-1.06	CHEMBL3045	Homo sapiens	Inhibition	%	-1.06
	8194999	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	CN(C)c1cc2c(Nc3ccc4nc(Cc5ccccc5)[nH]c4c3)ncnc2cn1		CHEMBL531804	=	Inhibition	%	1.18	CHEMBL3045	Homo sapiens	Inhibition	%	1.18
	8195127	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	CN1CCC(n2cnc(-c3ccc(F)cc3)c2-c2ccnc(NCCO)n2)CC1		CHEMBL330422	=	Inhibition	%	5.76	CHEMBL3045	Homo sapiens	Inhibition	%	5.76
	8195132	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	CN1CCC(n2cnc(-c3ccc(F)cc3)c2-c2ccnc(NCCO)n2)CC1		CHEMBL330422	=	Inhibition	%	7.68	CHEMBL3045	Homo sapiens	Inhibition	%	7.68
	8195291	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	O=C1Nc2ccc(C(=O)c3ccco3)cc2C1=Cc1cc(Cl)c(O)c(Cl)c1		CHEMBL1789963	=	Inhibition	%	-0.57	CHEMBL3045	Homo sapiens	Inhibition	%	-0.57
	8195296	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	O=C1Nc2ccc(C(=O)c3ccco3)cc2C1=Cc1cc(Cl)c(O)c(Cl)c1		CHEMBL1789963	=	Inhibition	%	1.83	CHEMBL3045	Homo sapiens	Inhibition	%	1.83
	8195515	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	O=C1Nc2ccc(C(=O)c3ccco3)cc2C1=Cc1cc(Cl)c(O)c(Cl)c1		CHEMBL1789963	=	Inhibition	%	1.37	CHEMBL3045	Homo sapiens	Inhibition	%	1.37
	8195520	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	O=C1Nc2ccc(C(=O)c3ccco3)cc2C1=Cc1cc(Cl)c(O)c(Cl)c1		CHEMBL1789963	=	Inhibition	%	3.01	CHEMBL3045	Homo sapiens	Inhibition	%	3.01
	8195654	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	OCc1ccc(-c2nc(-c3ccccn3)c(-c3ccc4c(c3)OCO4)[nH]2)cc1		CHEMBL267228	=	Inhibition	%	0.21	CHEMBL3045	Homo sapiens	Inhibition	%	0.21
	8195659	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	OCc1ccc(-c2nc(-c3ccccn3)c(-c3ccc4c(c3)OCO4)[nH]2)cc1		CHEMBL267228	=	Inhibition	%	0.63	CHEMBL3045	Homo sapiens	Inhibition	%	0.63
	8195976	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	CC1=C(C(=O)Nc2ccc3[nH]ncc3c2)C(c2ccc(F)cc2)N=C(c2ccc(C(F)(F)F)nc2)N1		CHEMBL485598	=	Inhibition	%	-0.53	CHEMBL3045	Homo sapiens	Inhibition	%	-0.53
	8195981	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	CC1=C(C(=O)Nc2ccc3[nH]ncc3c2)C(c2ccc(F)cc2)N=C(c2ccc(C(F)(F)F)nc2)N1		CHEMBL485598	=	Inhibition	%	0.68	CHEMBL3045	Homo sapiens	Inhibition	%	0.68
	8196317	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	Cl.c1ccc(Cc2nc3ccc(Nc4ncnc5ccccc45)cc3[nH]2)cc1		CHEMBL1909379	=	Inhibition	%	1.59	CHEMBL3045	Homo sapiens	Inhibition	%	1.59
	8196322	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	Cl.c1ccc(Cc2nc3ccc(Nc4ncnc5ccccc45)cc3[nH]2)cc1		CHEMBL1909379	=	Inhibition	%	0.12	CHEMBL3045	Homo sapiens	Inhibition	%	0.12
	8196467	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	Cc1ccc2c(-c3ccnc(Nc4ccccc4)n3)c(-c3ccc(F)cc3)nn2n1		CHEMBL189459	=	Inhibition	%	1.13	CHEMBL3045	Homo sapiens	Inhibition	%	1.13
	8196472	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	Cc1ccc2c(-c3ccnc(Nc4ccccc4)n3)c(-c3ccc(F)cc3)nn2n1		CHEMBL189459	=	Inhibition	%	1.79	CHEMBL3045	Homo sapiens	Inhibition	%	1.79
	8196819	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(OCc4cccs4)c(C(N)=O)s3)c2cc1OC		CHEMBL480382	=	Inhibition	%	5.39	CHEMBL3045	Homo sapiens	Inhibition	%	5.39
	8196824	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(OCc4cccs4)c(C(N)=O)s3)c2cc1OC		CHEMBL480382	=	Inhibition	%	2.61	CHEMBL3045	Homo sapiens	Inhibition	%	2.61
	8196960	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	CNC(=O)c1cncc(/C=C/c2ccccc2C)c1		CHEMBL218969	=	Inhibition	%	5.47	CHEMBL3045	Homo sapiens	Inhibition	%	5.47
	8196965	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	CNC(=O)c1cncc(/C=C/c2ccccc2C)c1		CHEMBL218969	=	Inhibition	%	3.14	CHEMBL3045	Homo sapiens	Inhibition	%	3.14
	8197184	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(-c2cc3ccncc3cc2OCc2ccccc2)cc1		CHEMBL483748	=	Inhibition	%	0.43	CHEMBL3045	Homo sapiens	Inhibition	%	0.43
	8197189	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(-c2cc3ccncc3cc2OCc2ccccc2)cc1		CHEMBL483748	=	Inhibition	%	0.66	CHEMBL3045	Homo sapiens	Inhibition	%	0.66
	8197321	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	CCOc1ccc2c(-c3ccnc(Nc4cc(OC)cc(C(F)(F)F)c4)n3)cnn2n1		CHEMBL188426	=	Inhibition	%	2.13	CHEMBL3045	Homo sapiens	Inhibition	%	2.13
	8197326	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	CCOc1ccc2c(-c3ccnc(Nc4cc(OC)cc(C(F)(F)F)c4)n3)cnn2n1		CHEMBL188426	=	Inhibition	%	3.36	CHEMBL3045	Homo sapiens	Inhibition	%	3.36
	8197596	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	NC(=O)c1cc(-c2ccc(F)cc2)cc(-c2ccncc2)c1N		CHEMBL231623	=	Inhibition	%	3.15	CHEMBL3045	Homo sapiens	Inhibition	%	3.15
	8197601	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	NC(=O)c1cc(-c2ccc(F)cc2)cc(-c2ccncc2)c1N		CHEMBL231623	=	Inhibition	%	1.35	CHEMBL3045	Homo sapiens	Inhibition	%	1.35
	8197960	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(OCc4ccccc4Cl)c(C(N)=O)s3)c2cc1OC		CHEMBL514162	=	Inhibition	%	0.68	CHEMBL3045	Homo sapiens	Inhibition	%	0.68
	8197965	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(OCc4ccccc4Cl)c(C(N)=O)s3)c2cc1OC		CHEMBL514162	=	Inhibition	%	0.76	CHEMBL3045	Homo sapiens	Inhibition	%	0.76
	8198117	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	Cl.Fc1ccc(-c2nc3n(c2-c2ccncc2)CCS3)cc1		CHEMBL1909406	=	Inhibition	%	0.64	CHEMBL3045	Homo sapiens	Inhibition	%	0.64
	8198122	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	Cl.Fc1ccc(-c2nc3n(c2-c2ccncc2)CCS3)cc1		CHEMBL1909406	=	Inhibition	%	1.53	CHEMBL3045	Homo sapiens	Inhibition	%	1.53
	8198479	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	Fc1ccc(-c2cc(-c3c[nH]nc3-c3ccccn3)ccn2)cc1		CHEMBL381948	=	Inhibition	%	1.93	CHEMBL3045	Homo sapiens	Inhibition	%	1.93
	8198484	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	Fc1ccc(-c2cc(-c3c[nH]nc3-c3ccccn3)ccn2)cc1		CHEMBL381948	=	Inhibition	%	1.48	CHEMBL3045	Homo sapiens	Inhibition	%	1.48
	8198609	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	COc1cc2ncnc(Nc3ccc(C)c(O)c3)c2cc1OC.Cl		CHEMBL1909357	=	Inhibition	%	5.43	CHEMBL3045	Homo sapiens	Inhibition	%	5.43
	8198614	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	COc1cc2ncnc(Nc3ccc(C)c(O)c3)c2cc1OC.Cl		CHEMBL1909357	=	Inhibition	%	5.81	CHEMBL3045	Homo sapiens	Inhibition	%	5.81
	8198833	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	O=C1NC(=O)C(c2ccccc2)=C1Nc1ccccc1		CHEMBL346551	=	Inhibition	%	2.0	CHEMBL3045	Homo sapiens	Inhibition	%	2.0
	8198838	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	O=C1NC(=O)C(c2ccccc2)=C1Nc1ccccc1		CHEMBL346551	=	Inhibition	%	4.21	CHEMBL3045	Homo sapiens	Inhibition	%	4.21
	8198964	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	O=C1NC(=O)C(N2CCc3ccccc32)=C1c1ccc(Cl)cc1		CHEMBL156524	=	Inhibition	%	0.52	CHEMBL3045	Homo sapiens	Inhibition	%	0.52
	8198969	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	O=C1NC(=O)C(N2CCc3ccccc32)=C1c1ccc(Cl)cc1		CHEMBL156524	=	Inhibition	%	1.65	CHEMBL3045	Homo sapiens	Inhibition	%	1.65
	8199336	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	CN(C)c1cc2c(Nc3ccc4nc(Cc5ccccc5)[nH]c4c3)ncnc2cn1		CHEMBL531804	=	Inhibition	%	2.6	CHEMBL3045	Homo sapiens	Inhibition	%	2.6
	8199341	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	CN(C)c1cc2c(Nc3ccc4nc(Cc5ccccc5)[nH]c4c3)ncnc2cn1		CHEMBL531804	=	Inhibition	%	3.96	CHEMBL3045	Homo sapiens	Inhibition	%	3.96
	8199470	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	Fc1cccc(COc2ccc(Nc3ncncc3C#Cc3ccccc3)cc2Cl)c1		CHEMBL379093	=	Inhibition	%	1.01	CHEMBL3045	Homo sapiens	Inhibition	%	1.01
	8199475	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	Fc1cccc(COc2ccc(Nc3ncncc3C#Cc3ccccc3)cc2Cl)c1		CHEMBL379093	=	Inhibition	%	0.66	CHEMBL3045	Homo sapiens	Inhibition	%	0.66
	8199857	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	Cc1cc(O)cc(C)c1/C=C/c1cncc(C(=O)OC(C)(C)C)c1		CHEMBL374060	=	Inhibition	%	0.46	CHEMBL3045	Homo sapiens	Inhibition	%	0.46
	8199862	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	Cc1cc(O)cc(C)c1/C=C/c1cncc(C(=O)OC(C)(C)C)c1		CHEMBL374060	=	Inhibition	%	1.37	CHEMBL3045	Homo sapiens	Inhibition	%	1.37
	8199995	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	OCc1ccc(-c2nc(-c3ccccn3)c(-c3ccc4c(c3)OCO4)[nH]2)cc1		CHEMBL267228	=	Inhibition	%	0.2	CHEMBL3045	Homo sapiens	Inhibition	%	0.2
	8200000	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	OCc1ccc(-c2nc(-c3ccccn3)c(-c3ccc4c(c3)OCO4)[nH]2)cc1		CHEMBL267228	=	Inhibition	%	0.97	CHEMBL3045	Homo sapiens	Inhibition	%	0.97
	8200219	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	Cc1ccc(O)cc1Nc1ccnc2cc(-c3ccccn3)ccc12.Cl		CHEMBL581096	=	Inhibition	%	-0.22	CHEMBL3045	Homo sapiens	Inhibition	%	-0.22
	8200224	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	Cc1ccc(O)cc1Nc1ccnc2cc(-c3ccccn3)ccc12.Cl		CHEMBL581096	=	Inhibition	%	1.13	CHEMBL3045	Homo sapiens	Inhibition	%	1.13
	8200323	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	Clc1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccccc3)n2)cc1		CHEMBL189148	=	Inhibition	%	0.65	CHEMBL3045	Homo sapiens	Inhibition	%	0.65
	8200328	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	Clc1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccccc3)n2)cc1		CHEMBL189148	=	Inhibition	%	-0.06	CHEMBL3045	Homo sapiens	Inhibition	%	-0.06
	8200662	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc(/C=N/Nc2ncnc3[nH]ncc23)ccc1O		CHEMBL66004	=	Inhibition	%	-0.06	CHEMBL3045	Homo sapiens	Inhibition	%	-0.06
	8200667	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc(/C=N/Nc2ncnc3[nH]ncc23)ccc1O		CHEMBL66004	=	Inhibition	%	0.58	CHEMBL3045	Homo sapiens	Inhibition	%	0.58
	8200812	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	Cc1ccc2c(-c3ccnc(Nc4ccccc4)n3)c(-c3ccc(F)cc3)nn2n1		CHEMBL189459	=	Inhibition	%	6.49	CHEMBL3045	Homo sapiens	Inhibition	%	6.49
	8200817	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	Cc1ccc2c(-c3ccnc(Nc4ccccc4)n3)c(-c3ccc(F)cc3)nn2n1		CHEMBL189459	=	Inhibition	%	12.32	CHEMBL3045	Homo sapiens	Inhibition	%	12.32
	8201036	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	c1cc(-c2cnn3nc(N4CCOCC4)ccc23)nc(NC2CC2)n1		CHEMBL495771	=	Inhibition	%	-0.45	CHEMBL3045	Homo sapiens	Inhibition	%	-0.45
	8201041	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	c1cc(-c2cnn3nc(N4CCOCC4)ccc23)nc(NC2CC2)n1		CHEMBL495771	=	Inhibition	%	0.87	CHEMBL3045	Homo sapiens	Inhibition	%	0.87
	8201166	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(OCc4cccs4)c(C(N)=O)s3)c2cc1OC		CHEMBL480382	=	Inhibition	%	8.77	CHEMBL3045	Homo sapiens	Inhibition	%	8.77
	8201171	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(OCc4cccs4)c(C(N)=O)s3)c2cc1OC		CHEMBL480382	=	Inhibition	%	4.99	CHEMBL3045	Homo sapiens	Inhibition	%	4.99
	8201525	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(-c2cc3ccncc3cc2OCc2ccccc2)cc1		CHEMBL483748	=	Inhibition	%	3.25	CHEMBL3045	Homo sapiens	Inhibition	%	3.25
	8201530	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(-c2cc3ccncc3cc2OCc2ccccc2)cc1		CHEMBL483748	=	Inhibition	%	1.74	CHEMBL3045	Homo sapiens	Inhibition	%	1.74
	8201658	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc2cc(-c3c(-c4ccncc4)nc(-c4ccc([S+](C)[O-])cc4C)n3C)ccc2c1		CHEMBL237570	=	Inhibition	%	2.04	CHEMBL3045	Homo sapiens	Inhibition	%	2.04
	8201663	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc2cc(-c3c(-c4ccncc4)nc(-c4ccc([S+](C)[O-])cc4C)n3C)ccc2c1		CHEMBL237570	=	Inhibition	%	0.04	CHEMBL3045	Homo sapiens	Inhibition	%	0.04
	8201937	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(C(F)(F)F)c4)c3c2)o1		CHEMBL215814	=	Inhibition	%	0.59	CHEMBL3045	Homo sapiens	Inhibition	%	0.59
	8201942	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(C(F)(F)F)c4)c3c2)o1		CHEMBL215814	=	Inhibition	%	1.67	CHEMBL3045	Homo sapiens	Inhibition	%	1.67
	8202301	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	Cl.Nc1nc(-c2ccc3c(c2)C(=Cc2cc(Br)c(O)c(Br)c2)C(=O)N3)cs1		CHEMBL1794053	=	Inhibition	%	0.67	CHEMBL3045	Homo sapiens	Inhibition	%	0.67
	8202306	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	Cl.Nc1nc(-c2ccc3c(c2)C(=Cc2cc(Br)c(O)c(Br)c2)C(=O)N3)cs1		CHEMBL1794053	=	Inhibition	%	-0.52	CHEMBL3045	Homo sapiens	Inhibition	%	-0.52
	8202468	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	Cl.Fc1ccc(-c2nc3n(c2-c2ccncc2)CCS3)cc1		CHEMBL1909406	=	Inhibition	%	9.28	CHEMBL3045	Homo sapiens	Inhibition	%	9.28
	8202473	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	Cl.Fc1ccc(-c2nc3n(c2-c2ccncc2)CCS3)cc1		CHEMBL1909406	=	Inhibition	%	4.27	CHEMBL3045	Homo sapiens	Inhibition	%	4.27
	8202817	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	Fc1ccc(-c2cc(-c3c[nH]nc3-c3ccccn3)ccn2)cc1		CHEMBL381948	=	Inhibition	%	3.1	CHEMBL3045	Homo sapiens	Inhibition	%	3.1
	8202822	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	Fc1ccc(-c2cc(-c3c[nH]nc3-c3ccccn3)ccn2)cc1		CHEMBL381948	=	Inhibition	%	1.07	CHEMBL3045	Homo sapiens	Inhibition	%	1.07
	8203171	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	O=C1NC(=O)C(c2ccccc2)=C1Nc1ccccc1		CHEMBL346551	=	Inhibition	%	6.45	CHEMBL3045	Homo sapiens	Inhibition	%	6.45
	8203176	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	O=C1NC(=O)C(c2ccccc2)=C1Nc1ccccc1		CHEMBL346551	=	Inhibition	%	11.61	CHEMBL3045	Homo sapiens	Inhibition	%	11.61
	8203302	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	Cc1c2ccc(N(C)c3ccnc(Nc4cccc(S(N)(=O)=O)c4)n3)cc2nn1C.Cl		CHEMBL1909359	=	Inhibition	%	0.1	CHEMBL3045	Homo sapiens	Inhibition	%	0.1
	8203307	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	Cc1c2ccc(N(C)c3ccnc(Nc4cccc(S(N)(=O)=O)c4)n3)cc2nn1C.Cl		CHEMBL1909359	=	Inhibition	%	1.36	CHEMBL3045	Homo sapiens	Inhibition	%	1.36
	8203672	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	c1cnn2ncc(-c3ccnc(NCCCN4CCOCC4)n3)c2c1		CHEMBL524901	=	Inhibition	%	2.73	CHEMBL3045	Homo sapiens	Inhibition	%	2.73
	8203677	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	c1cnn2ncc(-c3ccnc(NCCCN4CCOCC4)n3)c2c1		CHEMBL524901	=	Inhibition	%	1.96	CHEMBL3045	Homo sapiens	Inhibition	%	1.96
	8203806	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	Fc1cccc(COc2ccc(Nc3ncncc3C#Cc3ccccc3)cc2Cl)c1		CHEMBL379093	=	Inhibition	%	4.8	CHEMBL3045	Homo sapiens	Inhibition	%	4.8
	8203811	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	Fc1cccc(COc2ccc(Nc3ncncc3C#Cc3ccccc3)cc2Cl)c1		CHEMBL379093	=	Inhibition	%	1.48	CHEMBL3045	Homo sapiens	Inhibition	%	1.48
	8204030	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc(-c2cc(-c3c[nH]nc3-c3ccccn3)ccn2)cc1		CHEMBL202891	=	Inhibition	%	1.41	CHEMBL3045	Homo sapiens	Inhibition	%	1.41
	8204035	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc(-c2cc(-c3c[nH]nc3-c3ccccn3)ccn2)cc1		CHEMBL202891	=	Inhibition	%	0.62	CHEMBL3045	Homo sapiens	Inhibition	%	0.62
	8204196	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	Cc1cc(O)cc(C)c1/C=C/c1cncc(C(=O)OC(C)(C)C)c1		CHEMBL374060	=	Inhibition	%	-1.03	CHEMBL3045	Homo sapiens	Inhibition	%	-1.03
	8204201	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	Cc1cc(O)cc(C)c1/C=C/c1cncc(C(=O)OC(C)(C)C)c1		CHEMBL374060	=	Inhibition	%	1.05	CHEMBL3045	Homo sapiens	Inhibition	%	1.05
	8204557	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	Cc1ccc(O)cc1Nc1ccnc2cc(-c3ccccn3)ccc12.Cl		CHEMBL581096	=	Inhibition	%	0.21	CHEMBL3045	Homo sapiens	Inhibition	%	0.21
	8204562	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	Cc1ccc(O)cc1Nc1ccnc2cc(-c3ccccn3)ccc12.Cl		CHEMBL581096	=	Inhibition	%	1.55	CHEMBL3045	Homo sapiens	Inhibition	%	1.55
	8204662	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	Clc1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccccc3)n2)cc1		CHEMBL189148	=	Inhibition	%	1.93	CHEMBL3045	Homo sapiens	Inhibition	%	1.93
	8204667	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	Clc1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccccc3)n2)cc1		CHEMBL189148	=	Inhibition	%	3.99	CHEMBL3045	Homo sapiens	Inhibition	%	3.99
	8204886	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	CCS(=O)(=O)c1ccc(OC)c(Nc2ncc(-c3cccc(-c4ccccc4F)c3)o2)c1		CHEMBL372474	=	Inhibition	%	0.49	CHEMBL3045	Homo sapiens	Inhibition	%	0.49
	8204891	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	CCS(=O)(=O)c1ccc(OC)c(Nc2ncc(-c3cccc(-c4ccccc4F)c3)o2)c1		CHEMBL372474	=	Inhibition	%	-0.13	CHEMBL3045	Homo sapiens	Inhibition	%	-0.13
	8205001	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	COc1cc(/C=N/Nc2ncnc3[nH]ncc23)ccc1O		CHEMBL66004	=	Inhibition	%	4.56	CHEMBL3045	Homo sapiens	Inhibition	%	4.56
	8205006	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	COc1cc(/C=N/Nc2ncnc3[nH]ncc23)ccc1O		CHEMBL66004	=	Inhibition	%	4.16	CHEMBL3045	Homo sapiens	Inhibition	%	4.16
	8205374	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	c1cc(-c2cnn3nc(N4CCOCC4)ccc23)nc(NC2CC2)n1		CHEMBL495771	=	Inhibition	%	-0.77	CHEMBL3045	Homo sapiens	Inhibition	%	-0.77
	8205379	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	c1cc(-c2cnn3nc(N4CCOCC4)ccc23)nc(NC2CC2)n1		CHEMBL495771	=	Inhibition	%	1.89	CHEMBL3045	Homo sapiens	Inhibition	%	1.89
	8205510	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	CCOc1nccc2c1nc(-c1nonc1N)n2CC		CHEMBL188240	=	Inhibition	%	11.63	CHEMBL3045	Homo sapiens	Inhibition	%	11.63
	8205515	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	CCOc1nccc2c1nc(-c1nonc1N)n2CC		CHEMBL188240	=	Inhibition	%	3.06	CHEMBL3045	Homo sapiens	Inhibition	%	3.06
	8205873	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	Cc1ccc(NC(=O)CC2CC2)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL516908	=	Inhibition	%	-0.34	CHEMBL3045	Homo sapiens	Inhibition	%	-0.34
	8205878	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	Cc1ccc(NC(=O)CC2CC2)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL516908	=	Inhibition	%	1.0	CHEMBL3045	Homo sapiens	Inhibition	%	1.0
	8206005	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	COc1ccc2cc(-c3c(-c4ccncc4)nc(-c4ccc([S+](C)[O-])cc4C)n3C)ccc2c1		CHEMBL237570	=	Inhibition	%	12.97	CHEMBL3045	Homo sapiens	Inhibition	%	12.97
	8206010	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	COc1ccc2cc(-c3c(-c4ccncc4)nc(-c4ccc([S+](C)[O-])cc4C)n3C)ccc2c1		CHEMBL237570	=	Inhibition	%	5.01	CHEMBL3045	Homo sapiens	Inhibition	%	5.01
	8206229	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	CCN1CCC(CC(=O)Nc2n[nH]c3nc(-c4cccs4)c(Br)cc23)CC1.O=C(O)C(O)C(O)C(=O)O		CHEMBL2062290	=	Inhibition	%	2.07	CHEMBL3045	Homo sapiens	Inhibition	%	2.07
	8206234	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	CCN1CCC(CC(=O)Nc2n[nH]c3nc(-c4cccs4)c(Br)cc23)CC1.O=C(O)C(O)C(O)C(=O)O		CHEMBL2062290	=	Inhibition	%	-1.4	CHEMBL3045	Homo sapiens	Inhibition	%	-1.4
	8206281	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(C(F)(F)F)c4)c3c2)o1		CHEMBL215814	=	Inhibition	%	1.62	CHEMBL3045	Homo sapiens	Inhibition	%	1.62
	8206286	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(C(F)(F)F)c4)c3c2)o1		CHEMBL215814	=	Inhibition	%	2.44	CHEMBL3045	Homo sapiens	Inhibition	%	2.44
	8206505	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	Cc1nnc(-c2ccc(C)c(-c3ccc(C(=O)NCc4ccc(Cl)cc4)cc3)c2)o1		CHEMBL402108	=	Inhibition	%	0.85	CHEMBL3045	Homo sapiens	Inhibition	%	0.85
	8206510	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	Cc1nnc(-c2ccc(C)c(-c3ccc(C(=O)NCc4ccc(Cl)cc4)cc3)c2)o1		CHEMBL402108	=	Inhibition	%	1.36	CHEMBL3045	Homo sapiens	Inhibition	%	1.36
	8206648	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	Cl.Nc1nc(-c2ccc3c(c2)C(=Cc2cc(Br)c(O)c(Br)c2)C(=O)N3)cs1		CHEMBL1794053	=	Inhibition	%	0.52	CHEMBL3045	Homo sapiens	Inhibition	%	0.52
	8206653	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	Cl.Nc1nc(-c2ccc3c(c2)C(=Cc2cc(Br)c(O)c(Br)c2)C(=O)N3)cs1		CHEMBL1794053	=	Inhibition	%	1.78	CHEMBL3045	Homo sapiens	Inhibition	%	1.78
	8206828	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	CN(C)CCCn1c(-c2nonc2N)nc2cnccc21		CHEMBL191105	=	Inhibition	%	1.86	CHEMBL3045	Homo sapiens	Inhibition	%	1.86
	8206833	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	CN(C)CCCn1c(-c2nonc2N)nc2cnccc21		CHEMBL191105	=	Inhibition	%	2.32	CHEMBL3045	Homo sapiens	Inhibition	%	2.32
	8207052	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	CN(C)CCCn1c(-c2nonc2N)nc2cnccc21		CHEMBL191105	=	Inhibition	%	14.47	CHEMBL3045	Homo sapiens	Inhibition	%	14.47
	8207057	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	CN(C)CCCn1c(-c2nonc2N)nc2cnccc21		CHEMBL191105	=	Inhibition	%	4.48	CHEMBL3045	Homo sapiens	Inhibition	%	4.48
	8207178	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	Nc1nc(-c2cccc(Cl)c2)c(-c2ccc3ncccc3n2)s1		CHEMBL365663	=	Inhibition	%	2.33	CHEMBL3045	Homo sapiens	Inhibition	%	2.33
	8207183	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	Nc1nc(-c2cccc(Cl)c2)c(-c2ccc3ncccc3n2)s1		CHEMBL365663	=	Inhibition	%	2.82	CHEMBL3045	Homo sapiens	Inhibition	%	2.82
	8207532	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	O=C(Nc1n[nH]c2nc(-c3ccc(O)cc3)c(Br)cc12)C1CC1		CHEMBL260417	=	Inhibition	%	6.11	CHEMBL3045	Homo sapiens	Inhibition	%	6.11
	8207537	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	O=C(Nc1n[nH]c2nc(-c3ccc(O)cc3)c(Br)cc12)C1CC1		CHEMBL260417	=	Inhibition	%	18.99	CHEMBL3045	Homo sapiens	Inhibition	%	18.99
	8207664	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	Cc1c2ccc(N(C)c3ccnc(Nc4cccc(S(N)(=O)=O)c4)n3)cc2nn1C.Cl		CHEMBL1909359	=	Inhibition	%	-0.52	CHEMBL3045	Homo sapiens	Inhibition	%	-0.52
	8207669	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	Cc1c2ccc(N(C)c3ccnc(Nc4cccc(S(N)(=O)=O)c4)n3)cc2nn1C.Cl		CHEMBL1909359	=	Inhibition	%	2.7	CHEMBL3045	Homo sapiens	Inhibition	%	2.7
	8207888	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	NS(=O)(=O)c1cccc(-c2cc3ccncc3cc2OCc2ccccc2)c1		CHEMBL483747	=	Inhibition	%	-0.33	CHEMBL3045	Homo sapiens	Inhibition	%	-0.33
	8207893	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	NS(=O)(=O)c1cccc(-c2cc3ccncc3cc2OCc2ccccc2)c1		CHEMBL483747	=	Inhibition	%	2.02	CHEMBL3045	Homo sapiens	Inhibition	%	2.02
	8208033	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	c1cnn2ncc(-c3ccnc(NCCCN4CCOCC4)n3)c2c1		CHEMBL524901	=	Inhibition	%	5.57	CHEMBL3045	Homo sapiens	Inhibition	%	5.57
	8208038	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	c1cnn2ncc(-c3ccnc(NCCCN4CCOCC4)n3)c2c1		CHEMBL524901	=	Inhibition	%	3.47	CHEMBL3045	Homo sapiens	Inhibition	%	3.47
	8208389	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	COc1ccc(-c2cc(-c3c[nH]nc3-c3ccccn3)ccn2)cc1		CHEMBL202891	=	Inhibition	%	3.92	CHEMBL3045	Homo sapiens	Inhibition	%	3.92
	8208394	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	COc1ccc(-c2cc(-c3c[nH]nc3-c3ccccn3)ccn2)cc1		CHEMBL202891	=	Inhibition	%	1.96	CHEMBL3045	Homo sapiens	Inhibition	%	1.96
	8208555	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	CC1=C(C(=O)Nc2ccc3[nH]ncc3c2)C(c2ccc3ccccc3c2)CC(=O)N1		CHEMBL441702	=	Inhibition	%	1.81	CHEMBL3045	Homo sapiens	Inhibition	%	1.81
	8208560	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	CC1=C(C(=O)Nc2ccc3[nH]ncc3c2)C(c2ccc3ccccc3c2)CC(=O)N1		CHEMBL441702	=	Inhibition	%	0.83	CHEMBL3045	Homo sapiens	Inhibition	%	0.83
	8208912	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	Nc1nonc1-c1nc2cnccc2n1C1CC1		CHEMBL185962	=	Inhibition	%	44.97	CHEMBL3045	Homo sapiens	Inhibition	%	44.97
	8208917	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	Nc1nonc1-c1nc2cnccc2n1C1CC1		CHEMBL185962	=	Inhibition	%	7.25	CHEMBL3045	Homo sapiens	Inhibition	%	7.25
	8209241	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	CCS(=O)(=O)c1ccc(OC)c(Nc2ncc(-c3cccc(-c4ccccc4F)c3)o2)c1		CHEMBL372474	=	Inhibition	%	0.3	CHEMBL3045	Homo sapiens	Inhibition	%	0.3
	8209246	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	CCS(=O)(=O)c1ccc(OC)c(Nc2ncc(-c3cccc(-c4ccccc4F)c3)o2)c1		CHEMBL372474	=	Inhibition	%	1.06	CHEMBL3045	Homo sapiens	Inhibition	%	1.06
	8209357	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	Nc1nc(-c2ccccn2)c(-c2ccc3ncccc3n2)s1		CHEMBL181361	=	Inhibition	%	0.07	CHEMBL3045	Homo sapiens	Inhibition	%	0.07
	8209362	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	Nc1nc(-c2ccccn2)c(-c2ccc3ncccc3n2)s1		CHEMBL181361	=	Inhibition	%	-0.19	CHEMBL3045	Homo sapiens	Inhibition	%	-0.19
	8209581	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	Nc1nc(-c2ccccn2)c(-c2ccc3ncccc3n2)s1		CHEMBL181361	=	Inhibition	%	1.26	CHEMBL3045	Homo sapiens	Inhibition	%	1.26
	8209731	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(-c2ccc3c(NC(=O)C4CC4)n[nH]c3c2)cc1		CHEMBL103098	=	Inhibition	%	-1.4	CHEMBL3045	Homo sapiens	Inhibition	%	-1.4
	8209736	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(-c2ccc3c(NC(=O)C4CC4)n[nH]c3c2)cc1		CHEMBL103098	=	Inhibition	%	0.67	CHEMBL3045	Homo sapiens	Inhibition	%	0.67
	8209867	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	CCOc1nccc2c1nc(-c1nonc1N)n2CC		CHEMBL188240	=	Inhibition	%	39.67	CHEMBL3045	Homo sapiens	Inhibition	%	39.67
	8209872	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	CCOc1nccc2c1nc(-c1nonc1N)n2CC		CHEMBL188240	=	Inhibition	%	5.23	CHEMBL3045	Homo sapiens	Inhibition	%	5.23
	8210091	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(O[C@H](C)c4ccccc4Cl)c(C(N)=O)s3)c2cc1OC		CHEMBL222419	=	Inhibition	%	3.14	CHEMBL3045	Homo sapiens	Inhibition	%	3.14
	8210096	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(O[C@H](C)c4ccccc4Cl)c(C(N)=O)s3)c2cc1OC		CHEMBL222419	=	Inhibition	%	2.75	CHEMBL3045	Homo sapiens	Inhibition	%	2.75
	8210232	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	Cc1ccc(NC(=O)CC2CC2)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL516908	=	Inhibition	%	2.08	CHEMBL3045	Homo sapiens	Inhibition	%	2.08
	8210237	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	Cc1ccc(NC(=O)CC2CC2)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL516908	=	Inhibition	%	2.35	CHEMBL3045	Homo sapiens	Inhibition	%	2.35
	8210592	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	CCN1CCC(CC(=O)Nc2n[nH]c3nc(-c4cccs4)c(Br)cc23)CC1.O=C(O)C(O)C(O)C(=O)O		CHEMBL2062290	=	Inhibition	%	1.35	CHEMBL3045	Homo sapiens	Inhibition	%	1.35
	8210597	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	CCN1CCC(CC(=O)Nc2n[nH]c3nc(-c4cccs4)c(Br)cc23)CC1.O=C(O)C(O)C(O)C(=O)O		CHEMBL2062290	=	Inhibition	%	2.84	CHEMBL3045	Homo sapiens	Inhibition	%	2.84
	8210851	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	Cc1nnc(-c2ccc(C)c(-c3ccc(C(=O)NCc4ccc(Cl)cc4)cc3)c2)o1		CHEMBL402108	=	Inhibition	%	0.84	CHEMBL3045	Homo sapiens	Inhibition	%	0.84
	8210856	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	Cc1nnc(-c2ccc(C)c(-c3ccc(C(=O)NCc4ccc(Cl)cc4)cc3)c2)o1		CHEMBL402108	=	Inhibition	%	3.21	CHEMBL3045	Homo sapiens	Inhibition	%	3.21
	8210995	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	COC(=O)c1sc(-n2cnc3cc(OC)c(OC)cc32)cc1OCc1ccccc1C(F)(F)F		CHEMBL473420	=	Inhibition	%	-0.94	CHEMBL3045	Homo sapiens	Inhibition	%	-0.94
	8211000	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	COC(=O)c1sc(-n2cnc3cc(OC)c(OC)cc32)cc1OCc1ccccc1C(F)(F)F		CHEMBL473420	=	Inhibition	%	0.96	CHEMBL3045	Homo sapiens	Inhibition	%	0.96
	8211389	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	O=C(O)C(F)(F)F.O=C(O[C@H]1CN[C@H](C#Cc2cc3ncnc(Nc4ccc5c(ccn5Cc5cc(F)ccc5F)c4)c3s2)C1)N1CCOCC1		CHEMBL1909410	=	Inhibition	%	1.59	CHEMBL3045	Homo sapiens	Inhibition	%	1.59
	8211394	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	O=C(O)C(F)(F)F.O=C(O[C@H]1CN[C@H](C#Cc2cc3ncnc(Nc4ccc5c(ccn5Cc5cc(F)ccc5F)c4)c3s2)C1)N1CCOCC1		CHEMBL1909410	=	Inhibition	%	1.75	CHEMBL3045	Homo sapiens	Inhibition	%	1.75
	8211512	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	Nc1nc(-c2cccc(Cl)c2)c(-c2ccc3ncccc3n2)s1		CHEMBL365663	=	Inhibition	%	4.87	CHEMBL3045	Homo sapiens	Inhibition	%	4.87
	8211517	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	Nc1nc(-c2cccc(Cl)c2)c(-c2ccc3ncccc3n2)s1		CHEMBL365663	=	Inhibition	%	2.11	CHEMBL3045	Homo sapiens	Inhibition	%	2.11
	8211736	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc(N2CCN(C(C)C)CC2)ccc1Nc1nc(Nc2ccc(F)cc2C(=O)NC[C@@H](O)CO)c2cc[nH]c2n1		CHEMBL450071	=	Inhibition	%	1.6	CHEMBL3045	Homo sapiens	Inhibition	%	1.6
	8211741	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc(N2CCN(C(C)C)CC2)ccc1Nc1nc(Nc2ccc(F)cc2C(=O)NC[C@@H](O)CO)c2cc[nH]c2n1		CHEMBL450071	=	Inhibition	%	1.04	CHEMBL3045	Homo sapiens	Inhibition	%	1.04
	8211865	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	O=C(Nc1n[nH]c2nc(-c3ccc(O)cc3)c(Br)cc12)C1CC1		CHEMBL260417	=	Inhibition	%	36.48	CHEMBL3045	Homo sapiens	Inhibition	%	36.48
	8211870	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	O=C(Nc1n[nH]c2nc(-c3ccc(O)cc3)c(Br)cc12)C1CC1		CHEMBL260417	=	Inhibition	%	57.65	CHEMBL3045	Homo sapiens	Inhibition	%	57.65
	8212221	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	NS(=O)(=O)c1cccc(-c2cc3ccncc3cc2OCc2ccccc2)c1		CHEMBL483747	=	Inhibition	%	0.71	CHEMBL3045	Homo sapiens	Inhibition	%	0.71
	8212226	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	NS(=O)(=O)c1cccc(-c2cc3ccncc3cc2OCc2ccccc2)c1		CHEMBL483747	=	Inhibition	%	2.23	CHEMBL3045	Homo sapiens	Inhibition	%	2.23
	8212362	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	O=C(Nc1n[nH]c2cc(-c3ccc(F)cc3)ccc12)C1CC1		CHEMBL419903	=	Inhibition	%	2.92	CHEMBL3045	Homo sapiens	Inhibition	%	2.92
	8212367	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	O=C(Nc1n[nH]c2cc(-c3ccc(F)cc3)ccc12)C1CC1		CHEMBL419903	=	Inhibition	%	2.1	CHEMBL3045	Homo sapiens	Inhibition	%	2.1
	8212586	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	O=C(Nc1n[nH]c2cc(-c3ccc(F)cc3)ccc12)C1CC1		CHEMBL419903	=	Inhibition	%	6.56	CHEMBL3045	Homo sapiens	Inhibition	%	6.56
	8212719	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	Cc1nnc(-c2cccc(-c3ccc(C(=O)NCC4CC4)cc3)c2)o1		CHEMBL257113	=	Inhibition	%	2.27	CHEMBL3045	Homo sapiens	Inhibition	%	2.27
	8212724	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	Cc1nnc(-c2cccc(-c3ccc(C(=O)NCC4CC4)cc3)c2)o1		CHEMBL257113	=	Inhibition	%	1.13	CHEMBL3045	Homo sapiens	Inhibition	%	1.13
	8212889	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	CC1=C(C(=O)Nc2ccc3[nH]ncc3c2)C(c2ccc3ccccc3c2)CC(=O)N1		CHEMBL441702	=	Inhibition	%	0.44	CHEMBL3045	Homo sapiens	Inhibition	%	0.44
	8212894	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	CC1=C(C(=O)Nc2ccc3[nH]ncc3c2)C(c2ccc3ccccc3c2)CC(=O)N1		CHEMBL441702	=	Inhibition	%	1.67	CHEMBL3045	Homo sapiens	Inhibition	%	1.67
	8213113	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	Cl.c1ccc(Oc2ccc(Nc3ncc(-c4ccccc4)o3)cc2)cc1		CHEMBL1909341	=	Inhibition	%	1.14	CHEMBL3045	Homo sapiens	Inhibition	%	1.14
	8213118	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	Cl.c1ccc(Oc2ccc(Nc3ncc(-c4ccccc4)o3)cc2)cc1		CHEMBL1909341	=	Inhibition	%	0.45	CHEMBL3045	Homo sapiens	Inhibition	%	0.45
	8213242	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	Nc1nonc1-c1nc2cnccc2n1C1CC1		CHEMBL185962	=	Inhibition	%	68.29	CHEMBL3045	Homo sapiens	Inhibition	%	68.29
	8213247	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	Nc1nonc1-c1nc2cnccc2n1C1CC1		CHEMBL185962	=	Inhibition	%	31.2	CHEMBL3045	Homo sapiens	Inhibition	%	31.2
	8213570	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	O=C1NC(=O)C(c2ccc(Cl)cc2)=C1Nc1ccc(Cl)c(C(=O)O)c1		CHEMBL160876	=	Inhibition	%	-1.13	CHEMBL3045	Homo sapiens	Inhibition	%	-1.13
	8213575	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	O=C1NC(=O)C(c2ccc(Cl)cc2)=C1Nc1ccc(Cl)c(C(=O)O)c1		CHEMBL160876	=	Inhibition	%	-0.73	CHEMBL3045	Homo sapiens	Inhibition	%	-0.73
	8213688	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	Nc1nc(-c2ccccn2)c(-c2ccc3ncccc3n2)s1		CHEMBL181361	=	Inhibition	%	0.88	CHEMBL3045	Homo sapiens	Inhibition	%	0.88
	8213907	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	CN(C)CCOc1ccc(-c2nc(-c3ccncc3)c(-c3ccc4c(c3)CC/C4=N\O)[nH]2)cc1.Cl.O		CHEMBL1909414	=	Inhibition	%	1.27	CHEMBL3045	Homo sapiens	Inhibition	%	1.27
	8213912	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	CN(C)CCOc1ccc(-c2nc(-c3ccncc3)c(-c3ccc4c(c3)CC/C4=N\O)[nH]2)cc1.Cl.O		CHEMBL1909414	=	Inhibition	%	0.36	CHEMBL3045	Homo sapiens	Inhibition	%	0.36
	8214054	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(-c2ccc3c(NC(=O)C4CC4)n[nH]c3c2)cc1		CHEMBL103098	=	Inhibition	%	-0.63	CHEMBL3045	Homo sapiens	Inhibition	%	-0.63
	8214059	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(-c2ccc3c(NC(=O)C4CC4)n[nH]c3c2)cc1		CHEMBL103098	=	Inhibition	%	1.78	CHEMBL3045	Homo sapiens	Inhibition	%	1.78
	8214415	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(O[C@H](C)c4ccccc4Cl)c(C(N)=O)s3)c2cc1OC		CHEMBL222419	=	Inhibition	%	5.95	CHEMBL3045	Homo sapiens	Inhibition	%	5.95
	8214420	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(O[C@H](C)c4ccccc4Cl)c(C(N)=O)s3)c2cc1OC		CHEMBL222419	=	Inhibition	%	3.52	CHEMBL3045	Homo sapiens	Inhibition	%	3.52
	8214549	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	Cc1ccc(Nc2ccnc(Nc3cccc(C(N)=O)c3)n2)cc1O.Cl		CHEMBL1909381	=	Inhibition	%	0.32	CHEMBL3045	Homo sapiens	Inhibition	%	0.32
	8214554	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	Cc1ccc(Nc2ccnc(Nc3cccc(C(N)=O)c3)n2)cc1O.Cl		CHEMBL1909381	=	Inhibition	%	1.81	CHEMBL3045	Homo sapiens	Inhibition	%	1.81
	8214773	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	Cc1ccc(Nc2ccnc(Nc3cccc(C(N)=O)c3)n2)cc1O.Cl		CHEMBL1909381	=	Inhibition	%	4.35	CHEMBL3045	Homo sapiens	Inhibition	%	4.35
	8214778	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	Cc1ccc(Nc2ccnc(Nc3cccc(C(N)=O)c3)n2)cc1O.Cl		CHEMBL1909381	=	Inhibition	%	8.28	CHEMBL3045	Homo sapiens	Inhibition	%	8.28
	8214925	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	c1ccc(-c2n[nH]cc2-c2ccnc(-c3ccc(OCCN4CCOCC4)cc3)c2)nc1		CHEMBL205158	=	Inhibition	%	5.36	CHEMBL3045	Homo sapiens	Inhibition	%	5.36
	8214930	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	c1ccc(-c2n[nH]cc2-c2ccnc(-c3ccc(OCCN4CCOCC4)cc3)c2)nc1		CHEMBL205158	=	Inhibition	%	3.96	CHEMBL3045	Homo sapiens	Inhibition	%	3.96
	8215176	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	Nc1nccc(-c2c(-c3ccc(F)cc3)ncn2CCCN2CCOCC2)n1		CHEMBL274863	=	Inhibition	%	1.5	CHEMBL3045	Homo sapiens	Inhibition	%	1.5
	8215181	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	Nc1nccc(-c2c(-c3ccc(F)cc3)ncn2CCCN2CCOCC2)n1		CHEMBL274863	=	Inhibition	%	3.01	CHEMBL3045	Homo sapiens	Inhibition	%	3.01
	8215329	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	COC(=O)c1sc(-n2cnc3cc(OC)c(OC)cc32)cc1OCc1ccccc1C(F)(F)F		CHEMBL473420	=	Inhibition	%	0.17	CHEMBL3045	Homo sapiens	Inhibition	%	0.17
	8215334	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	COC(=O)c1sc(-n2cnc3cc(OC)c(OC)cc32)cc1OCc1ccccc1C(F)(F)F		CHEMBL473420	=	Inhibition	%	1.08	CHEMBL3045	Homo sapiens	Inhibition	%	1.08
	8215553	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc(-c2coc3ncnc(N)c23)cc1		CHEMBL196022	=	Inhibition	%	-0.46	CHEMBL3045	Homo sapiens	Inhibition	%	-0.46
	8215558	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc(-c2coc3ncnc(N)c23)cc1		CHEMBL196022	=	Inhibition	%	1.62	CHEMBL3045	Homo sapiens	Inhibition	%	1.62
	8215717	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	O=C(O)C(F)(F)F.O=C(O[C@H]1CN[C@H](C#Cc2cc3ncnc(Nc4ccc5c(ccn5Cc5cc(F)ccc5F)c4)c3s2)C1)N1CCOCC1		CHEMBL1909410	=	Inhibition	%	1.27	CHEMBL3045	Homo sapiens	Inhibition	%	1.27
	8215722	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	O=C(O)C(F)(F)F.O=C(O[C@H]1CN[C@H](C#Cc2cc3ncnc(Nc4ccc5c(ccn5Cc5cc(F)ccc5F)c4)c3s2)C1)N1CCOCC1		CHEMBL1909410	=	Inhibition	%	0.99	CHEMBL3045	Homo sapiens	Inhibition	%	0.99
	8216060	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	COc1cc(N2CCN(C(C)C)CC2)ccc1Nc1nc(Nc2ccc(F)cc2C(=O)NC[C@@H](O)CO)c2cc[nH]c2n1		CHEMBL450071	=	Inhibition	%	4.35	CHEMBL3045	Homo sapiens	Inhibition	%	4.35
	8216065	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	COc1cc(N2CCN(C(C)C)CC2)ccc1Nc1nc(Nc2ccc(F)cc2C(=O)NC[C@@H](O)CO)c2cc[nH]c2n1		CHEMBL450071	=	Inhibition	%	2.5	CHEMBL3045	Homo sapiens	Inhibition	%	2.5
	8216179	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	NC(=O)c1sc(-n2cnc3ccc(C(F)(F)F)cc32)cc1OCc1ccccc1Br		CHEMBL481510	=	Inhibition	%	-0.05	CHEMBL3045	Homo sapiens	Inhibition	%	-0.05
	8216184	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	NC(=O)c1sc(-n2cnc3ccc(C(F)(F)F)cc32)cc1OCc1ccccc1Br		CHEMBL481510	=	Inhibition	%	1.28	CHEMBL3045	Homo sapiens	Inhibition	%	1.28
	8216403	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	NC(=O)c1sc(-n2cnc3ccc(C(F)(F)F)cc32)cc1OCc1ccccc1Br		CHEMBL481510	=	Inhibition	%	1.5	CHEMBL3045	Homo sapiens	Inhibition	%	1.5
	8216539	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	O=C1Nc2ccccc2/C1=C1\CCc2cc(O)ccc21		CHEMBL175321	=	Inhibition	%	0.69	CHEMBL3045	Homo sapiens	Inhibition	%	0.69
	8216544	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	O=C1Nc2ccccc2/C1=C1\CCc2cc(O)ccc21		CHEMBL175321	=	Inhibition	%	1.94	CHEMBL3045	Homo sapiens	Inhibition	%	1.94
	8216682	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	O=C(Nc1n[nH]c2cc(-c3ccc(F)cc3)ccc12)C1CC1		CHEMBL419903	=	Inhibition	%	4.04	CHEMBL3045	Homo sapiens	Inhibition	%	4.04
	8216901	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	Nc1nonc1-c1nc2cnccc2n1C1CC1		CHEMBL185962	=	Inhibition	%	47.94	CHEMBL3045	Homo sapiens	Inhibition	%	47.94
	8216906	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	Nc1nonc1-c1nc2cnccc2n1C1CC1		CHEMBL185962	=	Inhibition	%	6.7	CHEMBL3045	Homo sapiens	Inhibition	%	6.7
	8217035	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	Cc1nnc(-c2cccc(-c3ccc(C(=O)NCC4CC4)cc3)c2)o1		CHEMBL257113	=	Inhibition	%	3.52	CHEMBL3045	Homo sapiens	Inhibition	%	3.52
	8217040	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	Cc1nnc(-c2cccc(-c3ccc(C(=O)NCC4CC4)cc3)c2)o1		CHEMBL257113	=	Inhibition	%	2.65	CHEMBL3045	Homo sapiens	Inhibition	%	2.65
	8217433	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	Cl.c1ccc(Oc2ccc(Nc3ncc(-c4ccccc4)o3)cc2)cc1		CHEMBL1909341	=	Inhibition	%	0.76	CHEMBL3045	Homo sapiens	Inhibition	%	0.76
	8217438	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	Cl.c1ccc(Oc2ccc(Nc3ncc(-c4ccccc4)o3)cc2)cc1		CHEMBL1909341	=	Inhibition	%	1.67	CHEMBL3045	Homo sapiens	Inhibition	%	1.67
	8217564	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(OCc4ccccc4S(C)(=O)=O)c(C#N)s3)c2cc1OC		CHEMBL373751	=	Inhibition	%	2.71	CHEMBL3045	Homo sapiens	Inhibition	%	2.71
	8217569	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(OCc4ccccc4S(C)(=O)=O)c(C#N)s3)c2cc1OC		CHEMBL373751	=	Inhibition	%	1.55	CHEMBL3045	Homo sapiens	Inhibition	%	1.55
	8217889	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	O=C1NC(=O)C(c2ccc(Cl)cc2)=C1Nc1ccc(Cl)c(C(=O)O)c1		CHEMBL160876	=	Inhibition	%	-0.89	CHEMBL3045	Homo sapiens	Inhibition	%	-0.89
	8217894	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	O=C1NC(=O)C(c2ccc(Cl)cc2)=C1Nc1ccc(Cl)c(C(=O)O)c1		CHEMBL160876	=	Inhibition	%	3.47	CHEMBL3045	Homo sapiens	Inhibition	%	3.47
	8218228	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	CN(C)CCOc1ccc(-c2nc(-c3ccncc3)c(-c3ccc4c(c3)CC/C4=N\O)[nH]2)cc1.Cl.O		CHEMBL1909414	=	Inhibition	%	11.9	CHEMBL3045	Homo sapiens	Inhibition	%	11.9
	8218233	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	CN(C)CCOc1ccc(-c2nc(-c3ccncc3)c(-c3ccc4c(c3)CC/C4=N\O)[nH]2)cc1.Cl.O		CHEMBL1909414	=	Inhibition	%	3.35	CHEMBL3045	Homo sapiens	Inhibition	%	3.35
	8218355	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	COc1cccc(-n2ncc3c(N/N=C/c4ccc(C(=O)NCCN(C)C)cc4)ncnc32)c1.Cl		CHEMBL1909383	=	Inhibition	%	1.2	CHEMBL3045	Homo sapiens	Inhibition	%	1.2
	8218360	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	COc1cccc(-n2ncc3c(N/N=C/c4ccc(C(=O)NCCN(C)C)cc4)ncnc32)c1.Cl		CHEMBL1909383	=	Inhibition	%	1.88	CHEMBL3045	Homo sapiens	Inhibition	%	1.88
	8218579	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	COc1cccc(-n2ncc3c(N/N=C/c4ccc(C(=O)NCCN(C)C)cc4)ncnc32)c1.Cl		CHEMBL1909383	=	Inhibition	%	6.99	CHEMBL3045	Homo sapiens	Inhibition	%	6.99
	8218584	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	COc1cccc(-n2ncc3c(N/N=C/c4ccc(C(=O)NCCN(C)C)cc4)ncnc32)c1.Cl		CHEMBL1909383	=	Inhibition	%	17.73	CHEMBL3045	Homo sapiens	Inhibition	%	17.73
	8218722	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc(-c2oc3ncnc(N)c3c2-c2ccc(NC(=O)Nc3cc(C(F)(F)F)ccc3F)cc2)cc1.Cl		CHEMBL1909396	=	Inhibition	%	3.38	CHEMBL3045	Homo sapiens	Inhibition	%	3.38
	8218727	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc(-c2oc3ncnc(N)c3c2-c2ccc(NC(=O)Nc3cc(C(F)(F)F)ccc3F)cc2)cc1.Cl		CHEMBL1909396	=	Inhibition	%	1.71	CHEMBL3045	Homo sapiens	Inhibition	%	1.71
	8219077	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	Cl.O=C(Nc1ccc(Oc2ccc3[nH]c(NC(=O)c4ccccc4)nc3c2)cc1)Nc1cc(C(F)(F)F)ccc1F		CHEMBL1909374	=	Inhibition	%	0.29	CHEMBL3045	Homo sapiens	Inhibition	%	0.29
	8219082	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	Cl.O=C(Nc1ccc(Oc2ccc3[nH]c(NC(=O)c4ccccc4)nc3c2)cc1)Nc1cc(C(F)(F)F)ccc1F		CHEMBL1909374	=	Inhibition	%	1.51	CHEMBL3045	Homo sapiens	Inhibition	%	1.51
	8219237	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	c1ccc(-c2n[nH]cc2-c2ccnc(-c3ccc(OCCN4CCOCC4)cc3)c2)nc1		CHEMBL205158	=	Inhibition	%	3.85	CHEMBL3045	Homo sapiens	Inhibition	%	3.85
	8219242	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	c1ccc(-c2n[nH]cc2-c2ccnc(-c3ccc(OCCN4CCOCC4)cc3)c2)nc1		CHEMBL205158	=	Inhibition	%	3.92	CHEMBL3045	Homo sapiens	Inhibition	%	3.92
	8219487	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	Nc1nccc(-c2c(-c3ccc(F)cc3)ncn2CCCN2CCOCC2)n1		CHEMBL274863	=	Inhibition	%	7.05	CHEMBL3045	Homo sapiens	Inhibition	%	7.05
	8219492	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	Nc1nccc(-c2c(-c3ccc(F)cc3)ncn2CCCN2CCOCC2)n1		CHEMBL274863	=	Inhibition	%	7.42	CHEMBL3045	Homo sapiens	Inhibition	%	7.42
	8219872	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	COc1ccc(-c2coc3ncnc(N)c23)cc1		CHEMBL196022	=	Inhibition	%	-0.25	CHEMBL3045	Homo sapiens	Inhibition	%	-0.25
	8219877	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	COc1ccc(-c2coc3ncnc(N)c23)cc1		CHEMBL196022	=	Inhibition	%	2.4	CHEMBL3045	Homo sapiens	Inhibition	%	2.4
	8220041	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	N#Cc1c(NC(=O)c2ccc(F)c3ccccc23)sc2c1CCCC2		CHEMBL233002	=	Inhibition	%	0.53	CHEMBL3045	Homo sapiens	Inhibition	%	0.53
	8220046	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	N#Cc1c(NC(=O)c2ccc(F)c3ccccc23)sc2c1CCCC2		CHEMBL233002	=	Inhibition	%	1.06	CHEMBL3045	Homo sapiens	Inhibition	%	1.06
	8220394	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	N#Cc1c(NC(=O)c2cccc3ccccc23)sc2c1CCCN2C(=O)C1CC1		CHEMBL232601	=	Inhibition	%	0.71	CHEMBL3045	Homo sapiens	Inhibition	%	0.71
	8220399	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	N#Cc1c(NC(=O)c2cccc3ccccc23)sc2c1CCCN2C(=O)C1CC1		CHEMBL232601	=	Inhibition	%	1.7	CHEMBL3045	Homo sapiens	Inhibition	%	1.7
	8220513	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	NC(=O)c1sc(-n2cnc3ccc(C(F)(F)F)cc32)cc1OCc1ccccc1Br		CHEMBL481510	=	Inhibition	%	1.31	CHEMBL3045	Homo sapiens	Inhibition	%	1.31
	8220732	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	CC1=C(C(=O)Nc2cc(Cl)c3[nH]ncc3c2)C(c2ccc(C(F)(F)F)cc2)CC(=O)N1		CHEMBL427058	=	Inhibition	%	0.15	CHEMBL3045	Homo sapiens	Inhibition	%	0.15
	8220737	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	CC1=C(C(=O)Nc2cc(Cl)c3[nH]ncc3c2)C(c2ccc(C(F)(F)F)cc2)CC(=O)N1		CHEMBL427058	=	Inhibition	%	1.98	CHEMBL3045	Homo sapiens	Inhibition	%	1.98
	8220870	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	O=C1Nc2ccccc2/C1=C1\CCc2cc(O)ccc21		CHEMBL175321	=	Inhibition	%	1.16	CHEMBL3045	Homo sapiens	Inhibition	%	1.16
	8220875	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	O=C1Nc2ccccc2/C1=C1\CCc2cc(O)ccc21		CHEMBL175321	=	Inhibition	%	1.69	CHEMBL3045	Homo sapiens	Inhibition	%	1.69
	8221230	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	Nc1nonc1-c1nc2cnccc2n1C1CC1		CHEMBL185962	=	Inhibition	%	74.8	CHEMBL3045	Homo sapiens	Inhibition	%	74.8
	8221235	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	Nc1nonc1-c1nc2cnccc2n1C1CC1		CHEMBL185962	=	Inhibition	%	31.33	CHEMBL3045	Homo sapiens	Inhibition	%	31.33
	8221363	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc(N2CCN(C(C)C)CC2)ccc1Nc1nc(Nc2cccc(F)c2C(=O)O)c2cc[nH]c2n1		CHEMBL514261	=	Inhibition	%	-0.07	CHEMBL3045	Homo sapiens	Inhibition	%	-0.07
	8221368	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc(N2CCN(C(C)C)CC2)ccc1Nc1nc(Nc2cccc(F)c2C(=O)O)c2cc[nH]c2n1		CHEMBL514261	=	Inhibition	%	1.66	CHEMBL3045	Homo sapiens	Inhibition	%	1.66
	8221587	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	COc1cc(N2CCN(C(C)C)CC2)ccc1Nc1nc(Nc2cccc(F)c2C(=O)O)c2cc[nH]c2n1		CHEMBL514261	=	Inhibition	%	3.07	CHEMBL3045	Homo sapiens	Inhibition	%	3.07
	8221592	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	COc1cc(N2CCN(C(C)C)CC2)ccc1Nc1nc(Nc2cccc(F)c2C(=O)O)c2cc[nH]c2n1		CHEMBL514261	=	Inhibition	%	2.08	CHEMBL3045	Homo sapiens	Inhibition	%	2.08
	8221752	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	Cl.Nc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCNCC2)n1		CHEMBL1909407	=	Inhibition	%	3.25	CHEMBL3045	Homo sapiens	Inhibition	%	3.25
	8221757	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	Cl.Nc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCNCC2)n1		CHEMBL1909407	=	Inhibition	%	5.75	CHEMBL3045	Homo sapiens	Inhibition	%	5.75
	8221883	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(OCc4ccccc4S(C)(=O)=O)c(C#N)s3)c2cc1OC		CHEMBL373751	=	Inhibition	%	5.16	CHEMBL3045	Homo sapiens	Inhibition	%	5.16
	8221888	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(OCc4ccccc4S(C)(=O)=O)c(C#N)s3)c2cc1OC		CHEMBL373751	=	Inhibition	%	4.05	CHEMBL3045	Homo sapiens	Inhibition	%	4.05
	8222107	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	Nc1nccc(C#Cc2cncnc2Nc2ccc(OCc3cccc(F)c3)c(Cl)c2)n1		CHEMBL381604	=	Inhibition	%	2.69	CHEMBL3045	Homo sapiens	Inhibition	%	2.69
	8222112	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	Nc1nccc(C#Cc2cncnc2Nc2ccc(OCc3cccc(F)c3)c(Cl)c2)n1		CHEMBL381604	=	Inhibition	%	0.73	CHEMBL3045	Homo sapiens	Inhibition	%	0.73
	8222205	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	CCS(=O)(=O)c1ccc(OC)c(Nc2ncc(-c3cccc(C(C)=O)c3)o2)c1		CHEMBL191705	=	Inhibition	%	-0.44	CHEMBL3045	Homo sapiens	Inhibition	%	-0.44
	8222210	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	CCS(=O)(=O)c1ccc(OC)c(Nc2ncc(-c3cccc(C(C)=O)c3)o2)c1		CHEMBL191705	=	Inhibition	%	1.16	CHEMBL3045	Homo sapiens	Inhibition	%	1.16
	8222563	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(Nc2ncc(-c3ccccc3)o2)cc1		CHEMBL194062	=	Inhibition	%	-0.16	CHEMBL3045	Homo sapiens	Inhibition	%	-0.16
	8222568	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(Nc2ncc(-c3ccccc3)o2)cc1		CHEMBL194062	=	Inhibition	%	0.96	CHEMBL3045	Homo sapiens	Inhibition	%	0.96
	8222905	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	CC1=C(C(=O)Nc2ccc3[nH]nc(C)c3c2)C(c2ccc(C(F)(F)F)cc2)CC(=O)N1		CHEMBL218720	=	Inhibition	%	-0.41	CHEMBL3045	Homo sapiens	Inhibition	%	-0.41
	8222910	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	CC1=C(C(=O)Nc2ccc3[nH]nc(C)c3c2)C(c2ccc(C(F)(F)F)cc2)CC(=O)N1		CHEMBL218720	=	Inhibition	%	0.62	CHEMBL3045	Homo sapiens	Inhibition	%	0.62
	8223049	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	COc1ccc(-c2oc3ncnc(N)c3c2-c2ccc(NC(=O)Nc3cc(C(F)(F)F)ccc3F)cc2)cc1.Cl		CHEMBL1909396	=	Inhibition	%	6.16	CHEMBL3045	Homo sapiens	Inhibition	%	6.16
	8223054	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	COc1ccc(-c2oc3ncnc(N)c3c2-c2ccc(NC(=O)Nc3cc(C(F)(F)F)ccc3F)cc2)cc1.Cl		CHEMBL1909396	=	Inhibition	%	4.49	CHEMBL3045	Homo sapiens	Inhibition	%	4.49
	8223402	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	Cl.O=C(Nc1ccc(Oc2ccc3[nH]c(NC(=O)c4ccccc4)nc3c2)cc1)Nc1cc(C(F)(F)F)ccc1F		CHEMBL1909374	=	Inhibition	%	3.18	CHEMBL3045	Homo sapiens	Inhibition	%	3.18
	8223407	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	Cl.O=C(Nc1ccc(Oc2ccc3[nH]c(NC(=O)c4ccccc4)nc3c2)cc1)Nc1cc(C(F)(F)F)ccc1F		CHEMBL1909374	=	Inhibition	%	4.95	CHEMBL3045	Homo sapiens	Inhibition	%	4.95
	8223563	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc(COc2ccc(Cc3cnc(N)nc3N)cc2OC)cc1		CHEMBL261849	=	Inhibition	%	3.26	CHEMBL3045	Homo sapiens	Inhibition	%	3.26
	8223568	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc(COc2ccc(Cc3cnc(N)nc3N)cc2OC)cc1		CHEMBL261849	=	Inhibition	%	2.0	CHEMBL3045	Homo sapiens	Inhibition	%	2.0
	8223787	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	COc1ccc(COc2ccc(Cc3cnc(N)nc3N)cc2OC)cc1		CHEMBL261849	=	Inhibition	%	2.56	CHEMBL3045	Homo sapiens	Inhibition	%	2.56
	8223813	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc2cc(-c3c(-c4ccncc4)nc(-c4ccc(S(C)(=O)=O)cc4C)n3C)ccc2c1		CHEMBL237571	=	Inhibition	%	2.3	CHEMBL3045	Homo sapiens	Inhibition	%	2.3
	8223818	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc2cc(-c3c(-c4ccncc4)nc(-c4ccc(S(C)(=O)=O)cc4C)n3C)ccc2c1		CHEMBL237571	=	Inhibition	%	3.45	CHEMBL3045	Homo sapiens	Inhibition	%	3.45
	8224037	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	COc1ccc2cc(-c3c(-c4ccncc4)nc(-c4ccc(S(C)(=O)=O)cc4C)n3C)ccc2c1		CHEMBL237571	=	Inhibition	%	14.48	CHEMBL3045	Homo sapiens	Inhibition	%	14.48
	8224042	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	COc1ccc2cc(-c3c(-c4ccncc4)nc(-c4ccc(S(C)(=O)=O)cc4C)n3C)ccc2c1		CHEMBL237571	=	Inhibition	%	9.63	CHEMBL3045	Homo sapiens	Inhibition	%	9.63
	8224199	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	Cc1ccc(NC(=O)c2ccnc(N3CCCC3)c2)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL477182	=	Inhibition	%	0.1	CHEMBL3045	Homo sapiens	Inhibition	%	0.1
	8224204	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	Cc1ccc(NC(=O)c2ccnc(N3CCCC3)c2)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL477182	=	Inhibition	%	1.24	CHEMBL3045	Homo sapiens	Inhibition	%	1.24
	8224369	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	N#Cc1c(NC(=O)c2ccc(F)c3ccccc23)sc2c1CCCC2		CHEMBL233002	=	Inhibition	%	1.1	CHEMBL3045	Homo sapiens	Inhibition	%	1.1
	8224374	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	N#Cc1c(NC(=O)c2ccc(F)c3ccccc23)sc2c1CCCC2		CHEMBL233002	=	Inhibition	%	3.38	CHEMBL3045	Homo sapiens	Inhibition	%	3.38
	8224593	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	O=C(Nc1n[nH]c2cc(-c3cc(F)ccc3F)ccc12)C1CC1		CHEMBL261440	=	Inhibition	%	0.43	CHEMBL3045	Homo sapiens	Inhibition	%	0.43
	8224598	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	O=C(Nc1n[nH]c2cc(-c3cc(F)ccc3F)ccc12)C1CC1		CHEMBL261440	=	Inhibition	%	1.71	CHEMBL3045	Homo sapiens	Inhibition	%	1.71
	8224728	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	N#Cc1c(NC(=O)c2cccc3ccccc23)sc2c1CCCN2C(=O)C1CC1		CHEMBL232601	=	Inhibition	%	5.43	CHEMBL3045	Homo sapiens	Inhibition	%	5.43
	8224733	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	N#Cc1c(NC(=O)c2cccc3ccccc23)sc2c1CCCN2C(=O)C1CC1		CHEMBL232601	=	Inhibition	%	2.41	CHEMBL3045	Homo sapiens	Inhibition	%	2.41
	8225066	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	CC1=C(C(=O)Nc2cc(Cl)c3[nH]ncc3c2)C(c2ccc(C(F)(F)F)cc2)CC(=O)N1		CHEMBL427058	=	Inhibition	%	2.02	CHEMBL3045	Homo sapiens	Inhibition	%	2.02
	8225071	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	CC1=C(C(=O)Nc2cc(Cl)c3[nH]ncc3c2)C(c2ccc(C(F)(F)F)cc2)CC(=O)N1		CHEMBL427058	=	Inhibition	%	2.19	CHEMBL3045	Homo sapiens	Inhibition	%	2.19
	8225200	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(Nc2cc(-c3cccc(O)c3)n[nH]2)cc1		CHEMBL103104	=	Inhibition	%	-3.34	CHEMBL3045	Homo sapiens	Inhibition	%	-3.34
	8225205	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(Nc2cc(-c3cccc(O)c3)n[nH]2)cc1		CHEMBL103104	=	Inhibition	%	1.35	CHEMBL3045	Homo sapiens	Inhibition	%	1.35
	8225424	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(Nc2cc(-c3cccc(O)c3)n[nH]2)cc1		CHEMBL103104	=	Inhibition	%	1.78	CHEMBL3045	Homo sapiens	Inhibition	%	1.78
	8225429	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(Nc2cc(-c3cccc(O)c3)n[nH]2)cc1		CHEMBL103104	=	Inhibition	%	3.75	CHEMBL3045	Homo sapiens	Inhibition	%	3.75
	8225562	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	Cl.c1ccc(-c2nc3n(c2-c2ccc4c(c2)OCO4)CCC3)nc1		CHEMBL1909377	=	Inhibition	%	3.53	CHEMBL3045	Homo sapiens	Inhibition	%	3.53
	8225567	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	Cl.c1ccc(-c2nc3n(c2-c2ccc4c(c2)OCO4)CCC3)nc1		CHEMBL1909377	=	Inhibition	%	1.96	CHEMBL3045	Homo sapiens	Inhibition	%	1.96
	8225921	CHEMBL1961900	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	N#Cc1c(NC(=O)CN2CCOCC2)sc2c1CCCC2.O=C(O)C(=O)O		CHEMBL1909342	=	Inhibition	%	0.89	CHEMBL3045	Homo sapiens	Inhibition	%	0.89
	8225926	CHEMBL1961910	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn]	B	N#Cc1c(NC(=O)CN2CCOCC2)sc2c1CCCC2.O=C(O)C(=O)O		CHEMBL1909342	=	Inhibition	%	1.49	CHEMBL3045	Homo sapiens	Inhibition	%	1.49
	8226079	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	Cl.Nc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCNCC2)n1		CHEMBL1909407	=	Inhibition	%	21.35	CHEMBL3045	Homo sapiens	Inhibition	%	21.35
	8226084	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	Cl.Nc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCNCC2)n1		CHEMBL1909407	=	Inhibition	%	33.65	CHEMBL3045	Homo sapiens	Inhibition	%	33.65
	8226428	CHEMBL1961901	GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	Nc1nccc(C#Cc2cncnc2Nc2ccc(OCc3cccc(F)c3)c(Cl)c2)n1		CHEMBL381604	=	Inhibition	%	2.19	CHEMBL3045	Homo sapiens	Inhibition	%	2.19
	8226433	CHEMBL1961911	GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn]	B	Nc1nccc(C#Cc2cncnc2Nc2ccc(OCc3cccc(F)c3)c(Cl)c2)n1		CHEMBL381604	=	Inhibition	%	1.49	CHEMBL3045	Homo sapiens	Inhibition	%	1.49
	10839455	CHEMBL2015486	Inhibition of PKCbeta1 at 10 uM	B	COc1ccc2c3ccnc(C(F)(F)F)c3n(CCCCN)c2c1		CHEMBL2012574	=	Inhibition	%	35.0	CHEMBL3045	Homo sapiens	INH	%	35.0
	10839456	CHEMBL2015487	Inhibition of PKCbeta2 at 10 uM	B	COc1ccc2c3ccnc(C(F)(F)F)c3n(CCCCN)c2c1		CHEMBL2012574	=	Inhibition	%	28.0	CHEMBL3045	Homo sapiens	INH	%	28.0
	10850662	CHEMBL2019782	Inhibition of human PKCbeta2 at 1 uM	B	Cn1cc(-c2cccc(-c3cnc(N)c(C(=O)N[C@H]4C5CC6CC4C[C@@](O)(C6)C5)n3)c2)cn1		CHEMBL2018022	<	Inhibition	%	50.0	CHEMBL3045	Homo sapiens	INH	%	50.0
	10867539	CHEMBL2027429	Inhibition of PKCb2 at 2 uM	B	O=c1ncn2nc(Sc3ccc(F)cc3F)ccc2c1-c1c(Cl)cccc1Cl		CHEMBL119385	=	Inhibition	%	5.0	CHEMBL3045	Homo sapiens	INH	%	5.0
Active	10896663	CHEMBL2034155	Modulation of PKCbeta in human K562 cells assessed as protein down-regulation after 24 hrs by Western blotting analysis	B	CCC/C=C/C=C/C(=O)O[C@H]1/C(=C/C(=O)OC)C[C@H]2C[C@H]([C@@H](C)O)OC(=O)C[C@H](O)C[C@@H]3C[C@H](OC(C)=O)C(C)(C)[C@](O)(C[C@@H]4C/C(=C/C(=O)OC)C[C@H](/C=C/C(C)(C)[C@]1(O)O2)O4)O3		CHEMBL449158		Activity			CHEMBL3045	Homo sapiens	Activity		
	10941288	CHEMBL2049856	Inhibition of PKCbeta	B	CC(C)C[C@H]1CN(c2ccc(C(F)(F)F)c(C(=O)c3cccnc3N)n2)CCN1		CHEMBL2046643	=	Ki	nM	260.0	CHEMBL3045	Homo sapiens	Ki	uM	0.26
	10984753	CHEMBL2072049	Inhibition of human PKCbeta2 at 1 uM	B	Nc1cc(Nc2cnccn2)nc(-c2ccnc(N3CCNCC3)c2)c1		CHEMBL2069349	<	Inhibition	%	50.0	CHEMBL3045	Homo sapiens	INH	%	50.0
	12035061	CHEMBL2150521	Inhibition of recombinant human PKCbeta1 assessed as [33P]-ATP incorporation into tridecapeptide substrate after 60 mins by scintillation proximity assay	B	NCCNc1nc(-c2ccncc2)cc2cnccc12		CHEMBL1214929	=	IC50	nM	859.0	CHEMBL3045	Homo sapiens	IC50	nM	859.0
	12035062	CHEMBL2150521	Inhibition of recombinant human PKCbeta1 assessed as [33P]-ATP incorporation into tridecapeptide substrate after 60 mins by scintillation proximity assay	B	NCCNc1nc(-c2ccncc2)cc2ccccc12		CHEMBL2147531	>	IC50	nM	1000.0	CHEMBL3045	Homo sapiens	IC50	nM	1000.0
	12035063	CHEMBL2150521	Inhibition of recombinant human PKCbeta1 assessed as [33P]-ATP incorporation into tridecapeptide substrate after 60 mins by scintillation proximity assay	B	NCCNc1nc(-c2ccncc2)cc2ncccc12		CHEMBL2147532	>	IC50	nM	1000.0	CHEMBL3045	Homo sapiens	IC50	nM	1000.0
	12035064	CHEMBL2150521	Inhibition of recombinant human PKCbeta1 assessed as [33P]-ATP incorporation into tridecapeptide substrate after 60 mins by scintillation proximity assay	B	NCCNc1nc(-c2ccncc2)cc2ccncc12		CHEMBL2147533	>	IC50	nM	1000.0	CHEMBL3045	Homo sapiens	IC50	nM	1000.0
	12035065	CHEMBL2150521	Inhibition of recombinant human PKCbeta1 assessed as [33P]-ATP incorporation into tridecapeptide substrate after 60 mins by scintillation proximity assay	B	NCCNc1cc(-c2ccncc2)cc2cnccc12		CHEMBL2147534	>	IC50	nM	1000.0	CHEMBL3045	Homo sapiens	IC50	nM	1000.0
	12035066	CHEMBL2150521	Inhibition of recombinant human PKCbeta1 assessed as [33P]-ATP incorporation into tridecapeptide substrate after 60 mins by scintillation proximity assay	B	NCCNc1nc(-c2ccncc2)nc2cnccc12		CHEMBL2147535	>	IC50	nM	1000.0	CHEMBL3045	Homo sapiens	IC50	nM	1000.0
	12035067	CHEMBL2150521	Inhibition of recombinant human PKCbeta1 assessed as [33P]-ATP incorporation into tridecapeptide substrate after 60 mins by scintillation proximity assay	B	NCCOc1nc(-c2ccncc2)cc2cnccc12		CHEMBL2147536	>	IC50	nM	1000.0	CHEMBL3045	Homo sapiens	IC50	nM	1000.0
	12035068	CHEMBL2150521	Inhibition of recombinant human PKCbeta1 assessed as [33P]-ATP incorporation into tridecapeptide substrate after 60 mins by scintillation proximity assay	B	C[C@H](N)CNc1nc(-c2ccncc2)cc2cnccc12		CHEMBL2147537	=	IC50	nM	378.0	CHEMBL3045	Homo sapiens	IC50	nM	378.0
	12035069	CHEMBL2150521	Inhibition of recombinant human PKCbeta1 assessed as [33P]-ATP incorporation into tridecapeptide substrate after 60 mins by scintillation proximity assay	B	CC(C)(N)CNc1nc(-c2ccncc2)cc2cnccc12		CHEMBL2147538	=	IC50	nM	942.0	CHEMBL3045	Homo sapiens	IC50	nM	942.0
	12035070	CHEMBL2150521	Inhibition of recombinant human PKCbeta1 assessed as [33P]-ATP incorporation into tridecapeptide substrate after 60 mins by scintillation proximity assay	B	NC(CNc1nc(-c2ccncc2)cc2cnccc12)Cc1ccccc1		CHEMBL2147539	>	IC50	nM	1000.0	CHEMBL3045	Homo sapiens	IC50	nM	1000.0
	12035071	CHEMBL2150521	Inhibition of recombinant human PKCbeta1 assessed as [33P]-ATP incorporation into tridecapeptide substrate after 60 mins by scintillation proximity assay	B	CN(CCN)c1nc(-c2ccncc2)cc2cnccc12		CHEMBL2147540	>	IC50	nM	1000.0	CHEMBL3045	Homo sapiens	IC50	nM	1000.0
	12035072	CHEMBL2150521	Inhibition of recombinant human PKCbeta1 assessed as [33P]-ATP incorporation into tridecapeptide substrate after 60 mins by scintillation proximity assay	B	CNCCNc1nc(-c2ccncc2)cc2cnccc12		CHEMBL2147541	>	IC50	nM	1000.0	CHEMBL3045	Homo sapiens	IC50	nM	1000.0
	12035073	CHEMBL2150521	Inhibition of recombinant human PKCbeta1 assessed as [33P]-ATP incorporation into tridecapeptide substrate after 60 mins by scintillation proximity assay	B	c1cc(-c2cc3cnccc3c(N3CCNCC3)n2)ccn1		CHEMBL1214932	=	IC50	nM	823.0	CHEMBL3045	Homo sapiens	IC50	nM	823.0
	12035074	CHEMBL2150521	Inhibition of recombinant human PKCbeta1 assessed as [33P]-ATP incorporation into tridecapeptide substrate after 60 mins by scintillation proximity assay	B	c1cc(-c2cc3cnccc3c(N3CCCNCC3)n2)ccn1		CHEMBL2147542	=	IC50	nM	661.0	CHEMBL3045	Homo sapiens	IC50	nM	661.0
	12035075	CHEMBL2150521	Inhibition of recombinant human PKCbeta1 assessed as [33P]-ATP incorporation into tridecapeptide substrate after 60 mins by scintillation proximity assay	B	NC1CCCN(c2nc(-c3ccncc3)cc3cnccc23)C1		CHEMBL2147543	=	IC50	nM	865.0	CHEMBL3045	Homo sapiens	IC50	nM	865.0
	12035076	CHEMBL2150521	Inhibition of recombinant human PKCbeta1 assessed as [33P]-ATP incorporation into tridecapeptide substrate after 60 mins by scintillation proximity assay	B	NCCCNc1nc(-c2ccncc2)cc2cnccc12		CHEMBL2147544	=	IC50	nM	779.0	CHEMBL3045	Homo sapiens	IC50	nM	779.0
	12035077	CHEMBL2150521	Inhibition of recombinant human PKCbeta1 assessed as [33P]-ATP incorporation into tridecapeptide substrate after 60 mins by scintillation proximity assay	B	OCCNc1nc(-c2ccncc2)cc2cnccc12		CHEMBL2147545	>	IC50	nM	1000.0	CHEMBL3045	Homo sapiens	IC50	nM	1000.0
	12035078	CHEMBL2150521	Inhibition of recombinant human PKCbeta1 assessed as [33P]-ATP incorporation into tridecapeptide substrate after 60 mins by scintillation proximity assay	B	O=C1CN(c2nc(-c3ccncc3)cc3cnccc23)CCN1		CHEMBL2147546	>	IC50	nM	1000.0	CHEMBL3045	Homo sapiens	IC50	nM	1000.0
	12035079	CHEMBL2150521	Inhibition of recombinant human PKCbeta1 assessed as [33P]-ATP incorporation into tridecapeptide substrate after 60 mins by scintillation proximity assay	B	CC(C)(N)CNc1nc(-c2cccnc2)cc2cnccc12		CHEMBL2147547	>	IC50	nM	1000.0	CHEMBL3045	Homo sapiens	IC50	nM	1000.0
	12035080	CHEMBL2150521	Inhibition of recombinant human PKCbeta1 assessed as [33P]-ATP incorporation into tridecapeptide substrate after 60 mins by scintillation proximity assay	B	CC(C)(N)CNc1nc(-c2ccnc(N)c2)cc2cnccc12		CHEMBL2147548	>	IC50	nM	1000.0	CHEMBL3045	Homo sapiens	IC50	nM	1000.0
	12035081	CHEMBL2150521	Inhibition of recombinant human PKCbeta1 assessed as [33P]-ATP incorporation into tridecapeptide substrate after 60 mins by scintillation proximity assay	B	CC(C)Nc1cc(-c2cc3cnccc3c(NCC(C)(C)N)n2)ccn1		CHEMBL2147549	>	IC50	nM	1000.0	CHEMBL3045	Homo sapiens	IC50	nM	1000.0
	12035082	CHEMBL2150521	Inhibition of recombinant human PKCbeta1 assessed as [33P]-ATP incorporation into tridecapeptide substrate after 60 mins by scintillation proximity assay	B	CC(C)(N)CNc1nc(-c2ccncc2F)cc2cnccc12		CHEMBL2147550	=	IC50	nM	961.0	CHEMBL3045	Homo sapiens	IC50	nM	961.0
	12035083	CHEMBL2150521	Inhibition of recombinant human PKCbeta1 assessed as [33P]-ATP incorporation into tridecapeptide substrate after 60 mins by scintillation proximity assay	B	CC(C)(N)CNc1nc(-c2ccncc2Cl)cc2cnccc12		CHEMBL2147551	>	IC50	nM	1000.0	CHEMBL3045	Homo sapiens	IC50	nM	1000.0
	12035084	CHEMBL2150521	Inhibition of recombinant human PKCbeta1 assessed as [33P]-ATP incorporation into tridecapeptide substrate after 60 mins by scintillation proximity assay	B	Cc1cnccc1-c1cc2cnccc2c(NCC(C)(C)N)n1		CHEMBL2147552	>	IC50	nM	1000.0	CHEMBL3045	Homo sapiens	IC50	nM	1000.0
	12035185	CHEMBL2150528	Inhibition of recombinant human PKCbeta1 at 1 uM	B	C[C@H](N)CNc1nc(-c2ccncc2)cc2cnccc12		CHEMBL2147537	>	Inhibition	%	80.0	CHEMBL3045	Homo sapiens	INH	%	80.0
	12039651	CHEMBL2148238	Inhibition of [3H]PDBu binding to PKCbeta C1A domain	B	CO[C@@H](CC[C@H](C)[C@H]1O[C@@]23C[C@H](OC(=O)C[C@H]([C@@H](C)O)OC(=O)C[C@](O)(O2)[C@H](C)CC3(C)C)[C@@H]1C)c1cccc(O)c1		CHEMBL2148106	=	Ki	nM	0.17	CHEMBL3045	Homo sapiens	Ki	nM	0.17
	12039673	CHEMBL2148238	Inhibition of [3H]PDBu binding to PKCbeta C1A domain	B	CC1(C)CC[C@@H]2CC(=O)O[C@@H](CO)CC(=O)O[C@@H]3C[C@@H](CCCCc4cccc(O)c4)O[C@@]1(C3)O2		CHEMBL1258348	=	Ki	nM	89.0	CHEMBL3045	Homo sapiens	Ki	nM	89.0
	12039690	CHEMBL2148238	Inhibition of [3H]PDBu binding to PKCbeta C1A domain	B	C[C@@H]1CC(C)(C)[C@@]23C[C@@H](C[C@@H](CCCCc4cccc(O)c4)O2)OC(=O)C[C@H](CO)OC(=O)C[C@@H]1O3		CHEMBL2148107	=	Ki	nM	15.0	CHEMBL3045	Homo sapiens	Ki	nM	15.0
	12039708	CHEMBL2148238	Inhibition of [3H]PDBu binding to PKCbeta C1A domain	B	C[C@H]1[C@@H]2C[C@@]3(O[C@H](CCC3(C)C)CC(=O)O[C@@H](CO)CC(=O)O2)O[C@@H]1CCCCc1cccc(O)c1		CHEMBL2148108	=	Ki	nM	12.0	CHEMBL3045	Homo sapiens	Ki	nM	12.0
	12047313	CHEMBL2157338	Inhibition of PKCbeta1 at 1 uM	B	CC(C)(O)C1CCN(Cc2ccc3nc(-c4c(F)ccc5[nH]ccc45)nc(N4CCOCC4)c3n2)CC1		CHEMBL2152768	=	Inhibition	%	3.6	CHEMBL3045	Homo sapiens	INH	%	3.6
	12047314	CHEMBL2157339	Inhibition of PKCbeta2 at 1 uM	B	CC(C)(O)C1CCN(Cc2ccc3nc(-c4c(F)ccc5[nH]ccc45)nc(N4CCOCC4)c3n2)CC1		CHEMBL2152768	=	Inhibition	%	13.3	CHEMBL3045	Homo sapiens	INH	%	13.3
	12049491	CHEMBL2156012	Inhibition of PKCbeta-1 by scintillation proximity assay	B	CN1CCN(c2nc(C3=C(c4c[nH]c5ccccc45)C(=O)NC3=O)c3ccccc3n2)CC1		CHEMBL565612	=	IC50	nM	2.0	CHEMBL3045	Homo sapiens	IC50	nM	2.0
	12049500	CHEMBL2156012	Inhibition of PKCbeta-1 by scintillation proximity assay	B	CN1CCN(c2cc(C3=C(c4c[nH]c5ccccc45)C(=O)NC3=O)c3ccccc3c2)CC1		CHEMBL568580	=	IC50	nM	1.8	CHEMBL3045	Homo sapiens	IC50	nM	1.8
	12049509	CHEMBL2156012	Inhibition of PKCbeta-1 by scintillation proximity assay	B	CN1CCN(c2cc(C3=C(c4c[nH]c5ccccc45)C(=O)NC3=O)c3ccccc3n2)CC1		CHEMBL2153747	=	IC50	nM	5.2	CHEMBL3045	Homo sapiens	IC50	nM	5.2
	12049518	CHEMBL2156012	Inhibition of PKCbeta-1 by scintillation proximity assay	B	CN1CCN(c2cc3ccccc3c(C3=C(c4c[nH]c5ccccc45)C(=O)NC3=O)n2)CC1		CHEMBL2153748	=	IC50	nM	2.0	CHEMBL3045	Homo sapiens	IC50	nM	2.0
	12049527	CHEMBL2156012	Inhibition of PKCbeta-1 by scintillation proximity assay	B	Cc1cccc2nc(N3CCN(C)CC3)nc(C3=C(c4c[nH]c5ccccc45)C(=O)NC3=O)c12		CHEMBL2153749	=	IC50	nM	3.8	CHEMBL3045	Homo sapiens	IC50	nM	3.8
	12049533	CHEMBL2156012	Inhibition of PKCbeta-1 by scintillation proximity assay	B	CN1CCN(c2nc(C3=C(c4c[nH]c5ccccc45)C(=O)NC3=O)c3cc(F)ccc3n2)CC1		CHEMBL2153750	=	IC50	nM	1.2	CHEMBL3045	Homo sapiens	IC50	nM	1.2
	12049539	CHEMBL2156012	Inhibition of PKCbeta-1 by scintillation proximity assay	B	CN1CCN(c2nc(C3=C(c4c[nH]c5ccccc45)C(=O)NC3=O)c3cc(Cl)ccc3n2)CC1		CHEMBL2153751	=	IC50	nM	23.0	CHEMBL3045	Homo sapiens	IC50	nM	23.0
	12049545	CHEMBL2156012	Inhibition of PKCbeta-1 by scintillation proximity assay	B	Cc1ccc2nc(N3CCN(C)CC3)nc(C3=C(c4c[nH]c5ccccc45)C(=O)NC3=O)c2c1		CHEMBL2153752	=	IC50	nM	140.0	CHEMBL3045	Homo sapiens	IC50	nM	140.0
	12049551	CHEMBL2156012	Inhibition of PKCbeta-1 by scintillation proximity assay	B	CC(C)c1ccc2nc(N3CCN(C)CC3)nc(C3=C(c4c[nH]c5ccccc45)C(=O)NC3=O)c2c1		CHEMBL2153753	>	IC50	nM	316.0	CHEMBL3045	Homo sapiens	IC50	nM	316.0
	12049557	CHEMBL2156012	Inhibition of PKCbeta-1 by scintillation proximity assay	B	CN1CCN(c2nc(C3=C(c4c[nH]c5ccccc45)C(=O)NC3=O)c3cc(C(C)(C)C)ccc3n2)CC1		CHEMBL2153754	>	IC50	nM	316.0	CHEMBL3045	Homo sapiens	IC50	nM	316.0
	12049563	CHEMBL2156012	Inhibition of PKCbeta-1 by scintillation proximity assay	B	CN1CCN(c2nc(C3=C(c4c[nH]c5ccccc45)C(=O)NC3=O)c3ccc(F)cc3n2)CC1		CHEMBL2153755	=	IC50	nM	5.0	CHEMBL3045	Homo sapiens	IC50	nM	5.0
	12049569	CHEMBL2156012	Inhibition of PKCbeta-1 by scintillation proximity assay	B	CN1CCN(c2nc(C3=C(c4c[nH]c5ccccc45)C(=O)NC3=O)c3ccc(Cl)cc3n2)CC1		CHEMBL2153756	=	IC50	nM	304.0	CHEMBL3045	Homo sapiens	IC50	nM	304.0
	12049575	CHEMBL2156012	Inhibition of PKCbeta-1 by scintillation proximity assay	B	Cc1cccc2c(C3=C(c4c[nH]c5ccccc45)C(=O)NC3=O)nc(N3CCN(C)CC3)nc12		CHEMBL2151406	>	IC50	nM	316.0	CHEMBL3045	Homo sapiens	IC50	nM	316.0
	12049581	CHEMBL2156012	Inhibition of PKCbeta-1 by scintillation proximity assay	B	CN1CCN(c2nc(C3=C(c4c[nH]c5cccc(Cl)c45)C(=O)NC3=O)c3ccccc3n2)CC1		CHEMBL2151407	=	IC50	nM	48.0	CHEMBL3045	Homo sapiens	IC50	nM	48.0
	12049587	CHEMBL2156012	Inhibition of PKCbeta-1 by scintillation proximity assay	B	CN1CCN(c2nc(C3=C(c4c[nH]c5ccc(Cl)cc45)C(=O)NC3=O)c3ccccc3n2)CC1		CHEMBL2151408	=	IC50	nM	6.5	CHEMBL3045	Homo sapiens	IC50	nM	6.5
	12049593	CHEMBL2156012	Inhibition of PKCbeta-1 by scintillation proximity assay	B	CN1CCN(c2nc(C3=C(c4c[nH]c5cc(Cl)ccc45)C(=O)NC3=O)c3ccccc3n2)CC1		CHEMBL2151409	=	IC50	nM	7.7	CHEMBL3045	Homo sapiens	IC50	nM	7.7
	12049599	CHEMBL2156012	Inhibition of PKCbeta-1 by scintillation proximity assay	B	CN1CCN(c2nc(C3=C(c4c[nH]c5c(Cl)cccc45)C(=O)NC3=O)c3ccccc3n2)CC1		CHEMBL2151410	=	IC50	nM	6.0	CHEMBL3045	Homo sapiens	IC50	nM	6.0
	12049605	CHEMBL2156012	Inhibition of PKCbeta-1 by scintillation proximity assay	B	Cc1cccc2c(C3=C(c4nc(N5CCN(C)CC5)nc5ccccc45)C(=O)NC3=O)c[nH]c12		CHEMBL2151411	=	IC50	nM	0.2	CHEMBL3045	Homo sapiens	IC50	nM	0.2
	12050501	CHEMBL2156012	Inhibition of PKCbeta-1 by scintillation proximity assay	B	CN1CCN(c2nc(C3=C(c4cn(C)c5ccccc45)C(=O)NC3=O)c3ccccc3n2)CC1		CHEMBL2151412	=	IC50	nM	5.1	CHEMBL3045	Homo sapiens	IC50	nM	5.1
	12050507	CHEMBL2156012	Inhibition of PKCbeta-1 by scintillation proximity assay	B	CC(C)n1cc(C2=C(c3nc(N4CCN(C)CC4)nc4ccccc34)C(=O)NC2=O)c2ccccc21		CHEMBL2151413	=	IC50	nM	7.8	CHEMBL3045	Homo sapiens	IC50	nM	7.8
	12050513	CHEMBL2156012	Inhibition of PKCbeta-1 by scintillation proximity assay	B	Cc1[nH]c2ccccc2c1C1=C(c2nc(N3CCN(C)CC3)nc3ccccc23)C(=O)NC1=O		CHEMBL2151414	=	IC50	nM	22.0	CHEMBL3045	Homo sapiens	IC50	nM	22.0
	12050521	CHEMBL2156012	Inhibition of PKCbeta-1 by scintillation proximity assay	B	O=C1NC(=O)C(c2c[nH]c3ccccc23)=C1c1nc(N2CCNCC2)nc2ccccc12		CHEMBL1996510	=	IC50	nM	0.6	CHEMBL3045	Homo sapiens	IC50	nM	0.6
	12050529	CHEMBL2156012	Inhibition of PKCbeta-1 by scintillation proximity assay	B	Cn1cc(C2=C(c3nc(N4CCNCC4)nc4ccccc34)C(=O)NC2=O)c2ccccc21		CHEMBL2151415	=	IC50	nM	1.4	CHEMBL3045	Homo sapiens	IC50	nM	1.4
	12074651	CHEMBL2161213	Inhibition of PKCbeta1 at 1 uM	B	CN(C)CC(=O)N1CCC(c2ccc(NC(=O)c3nc(C#N)c[nH]3)c(C3=CCCCC3)c2)CC1		CHEMBL1908842	<	Inhibition	%	50.0	CHEMBL3045	Homo sapiens	INH	%	50.0
	12074652	CHEMBL2161214	Inhibition of PKCbeta2 at 1 uM	B	CN(C)CC(=O)N1CCC(c2ccc(NC(=O)c3nc(C#N)c[nH]3)c(C3=CCCCC3)c2)CC1		CHEMBL1908842	<	Inhibition	%	50.0	CHEMBL3045	Homo sapiens	INH	%	50.0
	12145303	CHEMBL2186676	Inhibition of PKCbeta1 using fluorescent labelled substrate at 5 uM by caliper method	B	Nc1ncccc1-c1nc2cccnc2n1-c1ccc(CNC(=O)c2ccccc2)cc1		CHEMBL2177819	>	Inhibition	%	25.0	CHEMBL3045	Homo sapiens	INH	%	25.0
	12145304	CHEMBL2186676	Inhibition of PKCbeta1 using fluorescent labelled substrate at 5 uM by caliper method	B	Nc1ncccc1-c1nc2cccnc2n1-c1ccc(CC(=O)Nc2ccccc2)cc1		CHEMBL2177818	>	Inhibition	%	25.0	CHEMBL3045	Homo sapiens	INH	%	25.0
	12166106	CHEMBL2211135	Binding affinity to PKCbeta2 at 1 uM	B	Cc1nc(N)nc(-c2cc(Cl)cnc2Nc2cnc(Cl)c(NS(=O)(=O)N(C)C)c2)n1		CHEMBL2206921	<	Activity	%	50.0	CHEMBL3045	Homo sapiens	Activity	%	50.0
	12183828	CHEMBL2214432	Inhibition of PRKCB	B	CC(C)(C)NS(=O)(=O)c1cncc(-c2ccn3nc(N)nc3c2)c1		CHEMBL2205766	<	IC50	nM	10000.0	CHEMBL3045	Homo sapiens	pIC50		5.0
	12195590	CHEMBL2212369	Inhibition of human recombinant PKCbeta2 using CKRREILSRRPSYRK as substrate assessed as residual activity at 1 uM after 15 mins relative to staurosporine	B	CCN(CC)CCOc1ccc(/C=C2\C(=O)Nc3ccc(Cl)cc32)cc1		CHEMBL2206008	=	Activity	%	99.4	CHEMBL3045	Homo sapiens	Activity	%	99.4
	12264320	CHEMBL2219400	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	CC(C)(C)c1cc(C=C(C#N)C#N)cc(Br)c1O		CHEMBL2218926	=	Residual Activity	%	106.0	CHEMBL3045	Homo sapiens	Residual Activity	%	106.0
	12264321	CHEMBL2219400	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	O=C1NC(=O)C(c2c[nH]c3ccccc23)=C1c1c[nH]c2ccccc12		CHEMBL266487	=	Residual Activity	%	66.0	CHEMBL3045	Homo sapiens	Residual Activity	%	66.0
	12264322	CHEMBL2219400	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	O=C(Nc1cccc(Nc2cc(Nc3cccc(C(F)(F)F)c3)ncn2)c1)C1CC1		CHEMBL387187	=	Residual Activity	%	105.0	CHEMBL3045	Homo sapiens	Residual Activity	%	105.0
	12264323	CHEMBL2219400	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	COc1ccc(Cl)cc1NC(=O)Nc1cc(C)nc2ccccc12		CHEMBL439259	=	Residual Activity	%	106.0	CHEMBL3045	Homo sapiens	Residual Activity	%	106.0
	12264324	CHEMBL2219400	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	CNc1cc2c(Nc3cccc(Br)c3)ncnc2cn1		CHEMBL53753	=	Residual Activity	%	118.0	CHEMBL3045	Homo sapiens	Residual Activity	%	118.0
	12264325	CHEMBL2219400	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	Nc1ncnc2c1cnn2-c1ccccc1		CHEMBL65063	=	Residual Activity	%	111.0	CHEMBL3045	Homo sapiens	Residual Activity	%	111.0
	12264326	CHEMBL2219400	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	Cn1cc(/C=C2\C(=O)Nc3ccc(S(N)(=O)=O)cc32)c2ccccc21		CHEMBL104279	=	Residual Activity	%	111.0	CHEMBL3045	Homo sapiens	Residual Activity	%	111.0
	12264327	CHEMBL2219400	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	COc1cc2ncnc(Nc3cccc(Cl)c3)c2cc1OC		CHEMBL7917	=	Residual Activity	%	110.0	CHEMBL3045	Homo sapiens	Residual Activity	%	110.0
	12264328	CHEMBL2219400	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	Cc1nc2cc3nc(-c4cccs4)cnc3cc2n1C		CHEMBL2218927	=	Residual Activity	%	107.0	CHEMBL3045	Homo sapiens	Residual Activity	%	107.0
	12264329	CHEMBL2219400	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	Cn1cnc2cc3c(Nc4cccc(Br)c4)ncnc3cc21		CHEMBL174426	=	Residual Activity	%	109.0	CHEMBL3045	Homo sapiens	Residual Activity	%	109.0
	12264330	CHEMBL2219400	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	CC#CC(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cn1		CHEMBL203644	=	Residual Activity	%	113.0	CHEMBL3045	Homo sapiens	Residual Activity	%	113.0
	12264331	CHEMBL2219400	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	O=C(Nc1nc2ccccc2n1CCN1CCOCC1)c1cccc([N+](=O)[O-])c1		CHEMBL379787	=	Residual Activity	%	112.0	CHEMBL3045	Homo sapiens	Residual Activity	%	112.0
	12264332	CHEMBL2219400	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	CCC(=O)Nc1ccc2ncnc(Nc3cccc(Br)c3)c2c1		CHEMBL188762	=	Residual Activity	%	117.0	CHEMBL3045	Homo sapiens	Residual Activity	%	117.0
	12264333	CHEMBL2219400	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	CC(C)(C)n1nc(Cc2cccc3ccccc23)c2c(N)ncnc21		CHEMBL573578	=	Residual Activity	%	119.0	CHEMBL3045	Homo sapiens	Residual Activity	%	119.0
	12264334	CHEMBL2219400	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	NCCNc1ncc(C(N)=O)c(Nc2cccc(C(F)(F)F)c2)n1		CHEMBL471901	=	Residual Activity	%	106.0	CHEMBL3045	Homo sapiens	Residual Activity	%	106.0
	12264335	CHEMBL2219400	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	CCOC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccccc32)c1C		CHEMBL86943	=	Residual Activity	%	109.0	CHEMBL3045	Homo sapiens	Residual Activity	%	109.0
	12264336	CHEMBL2219400	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	CC[n+]1c(/C=C/N(C)c2ccccc2)n(-c2ccccc2)c2ccc(-c3nc4ccccc4s3)cc21		CHEMBL1186409	=	Residual Activity	%	103.0	CHEMBL3045	Homo sapiens	Residual Activity	%	103.0
	12264337	CHEMBL2219400	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	COc1ccc2c(c[n+](C)c3c4cc5c(cc4ccc23)OCO5)c1OC		CHEMBL13045	=	Residual Activity	%	110.0	CHEMBL3045	Homo sapiens	Residual Activity	%	110.0
	12264338	CHEMBL2219400	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	COc1ccc(C(=O)Nc2sc3c(c2C(N)=O)CCCC3)cc1OC		CHEMBL210833	=	Residual Activity	%	109.0	CHEMBL3045	Homo sapiens	Residual Activity	%	109.0
	12264339	CHEMBL2219400	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	CC(C)(C)c1nc2c3ccc(F)cc3c3c(=O)[nH]ccc3c2[nH]1		CHEMBL21156	=	Residual Activity	%	88.0	CHEMBL3045	Homo sapiens	Residual Activity	%	88.0
	12264340	CHEMBL2219400	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	CCCC(=O)Oc1ccc2[nH]c(C(=O)c3cc4ccccc4[nH]3)cc2c1		CHEMBL266325	=	Residual Activity	%	110.0	CHEMBL3045	Homo sapiens	Residual Activity	%	110.0
	12264341	CHEMBL2219400	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	O=C1NC(=O)c2cc(Nc3ccc(F)cc3)c(Nc3ccc(F)cc3)cc21		CHEMBL7939	=	Residual Activity	%	107.0	CHEMBL3045	Homo sapiens	Residual Activity	%	107.0
	12264342	CHEMBL2219400	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	O=[N+]([O-])/C=C/c1ccc2c(c1)OCO2		CHEMBL596380	=	Residual Activity	%	113.0	CHEMBL3045	Homo sapiens	Residual Activity	%	113.0
	12264343	CHEMBL2219400	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	O=C(Nc1ccc(Cl)cc1)c1ccccc1NCc1ccncc1		CHEMBL101683	=	Residual Activity	%	113.0	CHEMBL3045	Homo sapiens	Residual Activity	%	113.0
	12264344	CHEMBL2219400	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	CN1N=C(N)c2cn([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c3ncnc1c23		CHEMBL331237	=	Residual Activity	%	107.0	CHEMBL3045	Homo sapiens	Residual Activity	%	107.0
	12264345	CHEMBL2219400	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	CCOc1cc2ncnc(Nc3cccc(Br)c3)c2cc1OCC		CHEMBL35820	=	Residual Activity	%	87.0	CHEMBL3045	Homo sapiens	Residual Activity	%	87.0
	12264346	CHEMBL2219400	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	O=C(c1cc2cc(O)ccc2[nH]1)c1cc2cc(O)ccc2[nH]1		CHEMBL377193	=	Residual Activity	%	106.0	CHEMBL3045	Homo sapiens	Residual Activity	%	106.0
	12264347	CHEMBL2219400	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	COc1cc2ncnc(Nc3ccc(O)c(Br)c3)c2cc1OC		CHEMBL473773	=	Residual Activity	%	97.0	CHEMBL3045	Homo sapiens	Residual Activity	%	97.0
	12264348	CHEMBL2219400	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	COc1cc2ncnc(N3CCN(C(=O)Nc4ccc(Oc5ccccc5)cc4)CC3)c2cc1OC		CHEMBL102346	=	Residual Activity	%	106.0	CHEMBL3045	Homo sapiens	Residual Activity	%	106.0
	12264349	CHEMBL2219400	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	O=C1NC(=O)C(c2cn(CCCn3ccnc3)c3ccccc23)=C1Nc1ccccc1		CHEMBL366266	=	Residual Activity	%	19.0	CHEMBL3045	Homo sapiens	Residual Activity	%	19.0
	12264350	CHEMBL2219400	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	c1ccc(-c2n[nH]cc2-c2ccnc3ccccc23)nc1		CHEMBL261454	=	Residual Activity	%	105.0	CHEMBL3045	Homo sapiens	Residual Activity	%	105.0
	12264351	CHEMBL2219400	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC		CHEMBL1289494	=	Residual Activity	%	107.0	CHEMBL3045	Homo sapiens	Residual Activity	%	107.0
	12264352	CHEMBL2219400	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	O=c1[nH]c2ccccc2n1C1CCN(Cc2ccc(-c3nc4cc5[nH]cnc5cc4nc3-c3ccccc3)cc2)CC1		CHEMBL258844	=	Residual Activity	%	102.0	CHEMBL3045	Homo sapiens	Residual Activity	%	102.0
	12264353	CHEMBL2219400	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	O=c1cc(N2CCOCC2)oc2c1ccc1ccccc12		CHEMBL104468	=	Residual Activity	%	104.0	CHEMBL3045	Homo sapiens	Residual Activity	%	104.0
	12264354	CHEMBL2219400	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	COc1ccc(COc2ccc(Cc3cnc(N)nc3N)cc2OC)cc1		CHEMBL261849	=	Residual Activity	%	107.0	CHEMBL3045	Homo sapiens	Residual Activity	%	107.0
	12264355	CHEMBL2219400	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	CC(C)N(CCC(=O)c1ccc2ccccc2c1)Cc1ccccc1		CHEMBL596674	=	Residual Activity	%	97.0	CHEMBL3045	Homo sapiens	Residual Activity	%	97.0
	12264356	CHEMBL2219400	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	COc1cc2c(cc1OC)-c1n[nH]c(Nc3cccc(F)c3)c1C2		CHEMBL120077	=	Residual Activity	%	104.0	CHEMBL3045	Homo sapiens	Residual Activity	%	104.0
	12264357	CHEMBL2219400	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](O)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C		CHEMBL413	=	Residual Activity	%	107.0	CHEMBL3045	Homo sapiens	Residual Activity	%	107.0
	12264358	CHEMBL2219400	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	Cc1cccc(-c2[nH]c(C(C)(C)C)nc2-c2ccc3c(c2)OCO3)n1		CHEMBL226838	=	Residual Activity	%	103.0	CHEMBL3045	Homo sapiens	Residual Activity	%	103.0
	12264359	CHEMBL2219400	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	O=C1Nc2ccc(Br)cc2/C1=C\c1cc2c([nH]1)CCCC2		CHEMBL2218925	=	Residual Activity	%	96.0	CHEMBL3045	Homo sapiens	Residual Activity	%	96.0
	12264360	CHEMBL2219400	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	CCN(CC)CCCCN1c2ccccc2Oc2ccc(Cl)cc21		CHEMBL1398474	=	Residual Activity	%	105.0	CHEMBL3045	Homo sapiens	Residual Activity	%	105.0
	12264361	CHEMBL2219400	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	CC(=O)c1ccc(N2CCOCC2)cc1O		CHEMBL1317546	=	Residual Activity	%	107.0	CHEMBL3045	Homo sapiens	Residual Activity	%	107.0
	12264362	CHEMBL2219400	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	Cn1c2ccccc2c2c3c(c4c5ccccc5n(CCC#N)c4c21)CNC3=O		CHEMBL302449	=	Residual Activity	%	6.0	CHEMBL3045	Homo sapiens	Residual Activity	%	6.0
	12264363	CHEMBL2219400	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	O=C1Nc2ccc(-c3cccnc3)cc2/C1=C\c1ccc[nH]1		CHEMBL2218929	=	Residual Activity	%	93.0	CHEMBL3045	Homo sapiens	Residual Activity	%	93.0
	12264364	CHEMBL2219400	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	COc1cc2nccc(Oc3ccc(NC(=S)NC(=O)c4ccccc4C)cc3)c2cc1OC		CHEMBL2218930	=	Residual Activity	%	118.0	CHEMBL3045	Homo sapiens	Residual Activity	%	118.0
	12264365	CHEMBL2219400	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	c1ccc2c(-c3ccncc3)c[nH]c2c1		CHEMBL380071	=	Residual Activity	%	105.0	CHEMBL3045	Homo sapiens	Residual Activity	%	105.0
	12264366	CHEMBL2219400	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	COc1ccc(C=C(C#N)C#N)cc1		CHEMBL77456	=	Residual Activity	%	112.0	CHEMBL3045	Homo sapiens	Residual Activity	%	112.0
	12264367	CHEMBL2219400	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	Cc1cc(C)c(/C=C2\C(=O)Nc3ccccc32)[nH]1		CHEMBL276711	=	Residual Activity	%	111.0	CHEMBL3045	Homo sapiens	Residual Activity	%	111.0
	12264368	CHEMBL2219400	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	O=C1c2ccccc2-c2nc3nnnn3nc21		CHEMBL599894	=	Residual Activity	%	113.0	CHEMBL3045	Homo sapiens	Residual Activity	%	113.0
	12264369	CHEMBL2219400	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	Oc1cccc(-c2nc(N3CCOCC3)c3oc4ncccc4c3n2)c1		CHEMBL573339	=	Residual Activity	%	112.0	CHEMBL3045	Homo sapiens	Residual Activity	%	112.0
	12264370	CHEMBL2219400	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	COc1ccc2c(c1)c(C1=C(c3c[nH]c4ccccc34)C(=O)NC1=O)cn2CCCN(C)C		CHEMBL261491	=	Residual Activity	%	4.0	CHEMBL3045	Homo sapiens	Residual Activity	%	4.0
	12264371	CHEMBL2219400	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	Nc1ncnc2c1c(-c1ccc(Oc3ccccc3)cc1)cn2C1CCCC1		CHEMBL47940	=	Residual Activity	%	103.0	CHEMBL3045	Homo sapiens	Residual Activity	%	103.0
	12264372	CHEMBL2219400	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	O=C1Nc2ccc3ncsc3c2/C1=C/c1c[nH]cn1		CHEMBL235641	=	Residual Activity	%	55.0	CHEMBL3045	Homo sapiens	Residual Activity	%	55.0
	12264373	CHEMBL2219400	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	Cc1cncc2cccc(S(=O)(=O)N3CCCN(C(=O)CN)C[C@H]3C)c12		CHEMBL2218931	=	Residual Activity	%	82.0	CHEMBL3045	Homo sapiens	Residual Activity	%	82.0
	12264374	CHEMBL2219400	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	N#C/C(=C\c1ccc(O)c(O)c1)C(=O)NCc1ccccc1		CHEMBL56543	=	Residual Activity	%	114.0	CHEMBL3045	Homo sapiens	Residual Activity	%	114.0
	12264375	CHEMBL2219400	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	COc1ccc(-c2cnc3c(-c4ccsc4)cnn3c2)cc1		CHEMBL92461	=	Residual Activity	%	117.0	CHEMBL3045	Homo sapiens	Residual Activity	%	117.0
	12264376	CHEMBL2219400	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	COc1cc2ncnc(Nc3ccc(NC(=O)c4ccccc4)cc3)c2cc1OC		CHEMBL382590	=	Residual Activity	%	116.0	CHEMBL3045	Homo sapiens	Residual Activity	%	116.0
	12264377	CHEMBL2219400	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	O=c1c2ccccc2[nH]c(=S)n1CCN1CCC(=C(c2ccc(F)cc2)c2ccc(F)cc2)CC1		CHEMBL261131	=	Residual Activity	%	109.0	CHEMBL3045	Homo sapiens	Residual Activity	%	109.0
	12264378	CHEMBL2219400	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	c1ccc(-c2n[nH]c3c2oc2ccccc23)cc1		CHEMBL406375	=	Residual Activity	%	111.0	CHEMBL3045	Homo sapiens	Residual Activity	%	111.0
	12264379	CHEMBL2219400	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	O=c1cc(N2CCOCC2)oc2c(-c3ccccc3)cccc12		CHEMBL98350	=	Residual Activity	%	100.0	CHEMBL3045	Homo sapiens	Residual Activity	%	100.0
	12264380	CHEMBL2219400	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	O=C1Nc2ccc(Cl)cc2/C1=C/c1cc(Cl)c(O)c(Cl)c1		CHEMBL2218932	=	Residual Activity	%	106.0	CHEMBL3045	Homo sapiens	Residual Activity	%	106.0
	12264381	CHEMBL2219400	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL608533	=	Residual Activity	%	66.0	CHEMBL3045	Homo sapiens	Residual Activity	%	66.0
	12264382	CHEMBL2219400	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	N#CC(C#N)=C(N)/C(C#N)=C/c1ccc(O)cc1		CHEMBL76589	=	Residual Activity	%	120.0	CHEMBL3045	Homo sapiens	Residual Activity	%	120.0
	12264383	CHEMBL2219400	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	O=C(c1ccccc1)c1ccc(N2CCOCC2)cc1O		CHEMBL478980	=	Residual Activity	%	120.0	CHEMBL3045	Homo sapiens	Residual Activity	%	120.0
	12264384	CHEMBL2219400	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	NC(=O)c1cccc(-c2cc(Nc3ccc(OC(F)(F)F)cc3)ncn2)c1		CHEMBL483847	=	Residual Activity	%	114.0	CHEMBL3045	Homo sapiens	Residual Activity	%	114.0
	12264385	CHEMBL2219400	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	CN(C)c1ccc(/C=C2\C(=O)Nc3ccccc32)cc1		CHEMBL328710	=	Residual Activity	%	114.0	CHEMBL3045	Homo sapiens	Residual Activity	%	114.0
	12264386	CHEMBL2219400	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	CO[C@H]1/C=C/C=C(\C)C(=O)NC2=CC(=O)C=C(C2=O)[C@H](OC)[C@@H](C)C[C@H](OC)[C@H](OC)[C@@H](C)/C=C(\C)[C@@H]1OC(N)=O		CHEMBL479533	=	Residual Activity	%	106.0	CHEMBL3045	Homo sapiens	Residual Activity	%	106.0
	12264387	CHEMBL2219400	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	O=c1cc(N2CCNCC2)oc2c(-c3ccccc3)cccc12		CHEMBL1363184	=	Residual Activity	%	122.0	CHEMBL3045	Homo sapiens	Residual Activity	%	122.0
	12264388	CHEMBL2219400	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	O=C1NC(=O)/C(=C\c2ccc3nccnc3c2)S1		CHEMBL2218934	=	Residual Activity	%	124.0	CHEMBL3045	Homo sapiens	Residual Activity	%	124.0
	12264389	CHEMBL2219400	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	COc1cc2ncnc(Nc3ccc(Oc4ccccc4)cc3)c2cc1OC		CHEMBL97771	=	Residual Activity	%	120.0	CHEMBL3045	Homo sapiens	Residual Activity	%	120.0
	12264390	CHEMBL2219400	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	Cc1cc2ncc(-c3ccccc3)nc2cc1C		CHEMBL7724	=	Residual Activity	%	125.0	CHEMBL3045	Homo sapiens	Residual Activity	%	125.0
	12264391	CHEMBL2219400	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	O=C(Nc1cccc(Nc2nccc(Nc3cccc(C(F)(F)F)c3)n2)c1)C1CC1		CHEMBL383899	=	Residual Activity	%	110.0	CHEMBL3045	Homo sapiens	Residual Activity	%	110.0
	12264392	CHEMBL2219400	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	CN(C)CCCn1cc(C2=C(c3c[nH]c4ccccc34)C(=O)NC2=O)c2ccccc21		CHEMBL7463	=	Residual Activity	%	4.0	CHEMBL3045	Homo sapiens	Residual Activity	%	4.0
	12264393	CHEMBL2219400	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	COc1cc2ncnc(Nc3ccc(OCc4ccccc4)cc3)c2cc1OC		CHEMBL563845	=	Residual Activity	%	123.0	CHEMBL3045	Homo sapiens	Residual Activity	%	123.0
	12264394	CHEMBL2219400	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	c1ccc(-c2cnc(Nc3ccc(OCCN4CCCC4)cc3)s2)cc1		CHEMBL2218935	=	Residual Activity	%	121.0	CHEMBL3045	Homo sapiens	Residual Activity	%	121.0
	12264395	CHEMBL2219400	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	CC1=C(C(=O)N2CCN(C)CC2)C(C)=C(/C=C2\C(=O)Nc3ccc(S(=O)(=O)N(C)c4cccc(Cl)c4)cc32)C1		CHEMBL2218936	=	Residual Activity	%	129.0	CHEMBL3045	Homo sapiens	Residual Activity	%	129.0
	12264396	CHEMBL2219400	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	O=C1NC(=O)/C(=C/c2ccc3c(c2)OC(F)(F)O3)S1		CHEMBL1231533	=	Residual Activity	%	134.0	CHEMBL3045	Homo sapiens	Residual Activity	%	134.0
	12264397	CHEMBL2219400	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(Cl)cc32)c1C		CHEMBL13485	=	Residual Activity	%	125.0	CHEMBL3045	Homo sapiens	Residual Activity	%	125.0
	12264398	CHEMBL2219400	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	COc1cc2ncc(-c3ccccc3)nc2cc1OC		CHEMBL71191	=	Residual Activity	%	131.0	CHEMBL3045	Homo sapiens	Residual Activity	%	131.0
	12264399	CHEMBL2219400	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL388978	=	Residual Activity	%	1.0	CHEMBL3045	Homo sapiens	Residual Activity	%	1.0
	12264400	CHEMBL2219400	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	CN([C@@H](Cc1ccc(OS(=O)(=O)c2cccc3cnccc23)cc1)C(=O)N1CCN(c2ccccc2)CC1)S(=O)(=O)c1cccc2cnccc12		CHEMBL28324	=	Residual Activity	%	101.0	CHEMBL3045	Homo sapiens	Residual Activity	%	101.0
	12264401	CHEMBL2219400	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	Nc1nc(Nc2ccc(S(N)(=O)=O)cc2)nn1C(=O)c1c(F)cccc1F		CHEMBL191003	=	Residual Activity	%	83.0	CHEMBL3045	Homo sapiens	Residual Activity	%	83.0
	12264402	CHEMBL2219400	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	O=C1NC(=O)c2c1c1c3ccccc3[nH]c1c1[nH]c3cc(Br)ccc3c21		CHEMBL64758	=	Residual Activity	%	108.0	CHEMBL3045	Homo sapiens	Residual Activity	%	108.0
	12264403	CHEMBL2219400	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	C[C@@H](N)[C@H]1CC[C@H](C(=O)Nc2ccncc2)CC1		CHEMBL559147	=	Residual Activity	%	101.0	CHEMBL3045	Homo sapiens	Residual Activity	%	101.0
	12264404	CHEMBL2219400	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	CN(C)S(=O)(=O)c1ccc2c(c1)/C(=C/c1cc3c([nH]1)CCCC3)C(=O)N2		CHEMBL605003	=	Residual Activity	%	107.0	CHEMBL3045	Homo sapiens	Residual Activity	%	107.0
	12264405	CHEMBL2219400	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	O=C(CCCc1ccc(-c2ccccc2F)cc1)Nc1ccc(O)cc1		CHEMBL235658	=	Residual Activity	%	112.0	CHEMBL3045	Homo sapiens	Residual Activity	%	112.0
	12264406	CHEMBL2219400	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	CSc1nc(-c2ccc(F)cc2)c(-c2ccnc(NC(C)c3ccccc3)c2)[nH]1		CHEMBL111364	=	Residual Activity	%	105.0	CHEMBL3045	Homo sapiens	Residual Activity	%	105.0
	12264407	CHEMBL2219400	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	C[S+]([O-])c1ccc(-c2nc(-c3ccc(F)cc3)c(-c3ccncc3)[nH]2)cc1		CHEMBL10	=	Residual Activity	%	101.0	CHEMBL3045	Homo sapiens	Residual Activity	%	101.0
	12264408	CHEMBL2219400	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	O=c1cc(-c2cccc3c2Sc2ccccc2S3)oc(N2CCOCC2)c1		CHEMBL222102	=	Residual Activity	%	102.0	CHEMBL3045	Homo sapiens	Residual Activity	%	102.0
	12264409	CHEMBL2219400	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	O=Nc1c(-c2c(O)[nH]c3ccccc23)[nH]c2ccccc12		CHEMBL126077	=	Residual Activity	%	93.0	CHEMBL3045	Homo sapiens	Residual Activity	%	93.0
	12264410	CHEMBL2219400	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	COc1ccc(OC)c2c(=S)c3ccccc3[nH]c12		CHEMBL1331734	=	Residual Activity	%	89.0	CHEMBL3045	Homo sapiens	Residual Activity	%	89.0
	12264411	CHEMBL2219400	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	Nc1n[nH]c2nnc(-c3c(-c4ccccc4)nn4ccccc34)cc12		CHEMBL259551	=	Residual Activity	%	99.0	CHEMBL3045	Homo sapiens	Residual Activity	%	99.0
	12264412	CHEMBL2219400	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	Cc1cc(Nc2nc(-c3ccccc3)nc3ccccc23)n[nH]1		CHEMBL359482	=	Residual Activity	%	109.0	CHEMBL3045	Homo sapiens	Residual Activity	%	109.0
	12264413	CHEMBL2219400	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	CCOc1nc(NC(=O)Cc2cc(OC)ccc2OC)cc(N)c1C#N		CHEMBL210618	=	Residual Activity	%	109.0	CHEMBL3045	Homo sapiens	Residual Activity	%	109.0
	12264414	CHEMBL2219400	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	Oc1c(-c2ccc(F)cc2)c(-c2ccncc2)nn1-c1ccc(Cl)cc1		CHEMBL91730	=	Residual Activity	%	109.0	CHEMBL3045	Homo sapiens	Residual Activity	%	109.0
	12264415	CHEMBL2219400	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	O=S(=O)(c1cccc2cnccc12)N1CCCNCC1		CHEMBL38380	=	Residual Activity	%	75.0	CHEMBL3045	Homo sapiens	Residual Activity	%	75.0
	12264416	CHEMBL2219400	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	O=C(NC(NC(=S)Nc1ccc(F)c([N+](=O)[O-])c1)C(Cl)(Cl)Cl)C(c1ccccc1)c1ccccc1		CHEMBL1221601	=	Residual Activity	%	108.0	CHEMBL3045	Homo sapiens	Residual Activity	%	108.0
	12264417	CHEMBL2219400	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	Cc1ccc(S(=O)(=O)/C=C/C#N)cc1		CHEMBL403183	=	Residual Activity	%	98.0	CHEMBL3045	Homo sapiens	Residual Activity	%	98.0
	12264418	CHEMBL2219400	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	Cc1ccc(NC2=CC(=O)c3sc(C)nc3C2=O)cc1		CHEMBL290904	=	Residual Activity	%	98.0	CHEMBL3045	Homo sapiens	Residual Activity	%	98.0
	12264419	CHEMBL2219400	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	Oc1n[nH]c2nnc(-c3c(-c4ccccc4)nn4ccccc34)cc12		CHEMBL2218938	=	Residual Activity	%	94.0	CHEMBL3045	Homo sapiens	Residual Activity	%	94.0
	12264420	CHEMBL2219400	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	O=C1NC(=O)c2c1c1c3ccccc3[nH]c1n1cncc21		CHEMBL413188	=	Residual Activity	%	103.0	CHEMBL3045	Homo sapiens	Residual Activity	%	103.0
	12264421	CHEMBL2219400	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	COC(=O)[C@@]1(O)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL281948	=	Residual Activity	%	53.0	CHEMBL3045	Homo sapiens	Residual Activity	%	53.0
	12264422	CHEMBL2219400	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	COc1cccc(-c2cc(=O)c3ccccc3o2)c1N		CHEMBL35482	=	Residual Activity	%	106.0	CHEMBL3045	Homo sapiens	Residual Activity	%	106.0
	12264423	CHEMBL2219400	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	O=C1NC(=O)c2c1c1c3ccccc3n3c1c1c2c2ccccc2n1C1CCC3O1		CHEMBL304428	=	Residual Activity	%	95.0	CHEMBL3045	Homo sapiens	Residual Activity	%	95.0
	12264424	CHEMBL2219400	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	O=C1Cc2c([nH]c3ccc([N+](=O)[O-])cc23)-c2ccccc2N1		CHEMBL50894	=	Residual Activity	%	103.0	CHEMBL3045	Homo sapiens	Residual Activity	%	103.0
	12264425	CHEMBL2219400	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	CC(C)n1cnc2c(NCc3ccccc3)nc(NCCCO)nc21		CHEMBL83980	=	Residual Activity	%	106.0	CHEMBL3045	Homo sapiens	Residual Activity	%	106.0
	12264426	CHEMBL2219400	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	CCN1/C(=C/C(C)=O)Sc2ccc(OC)cc21		CHEMBL408982	=	Residual Activity	%	110.0	CHEMBL3045	Homo sapiens	Residual Activity	%	110.0
	12264427	CHEMBL2219400	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	O=C1c2ccccc2-[n+]2ccc3c([nH]c4ccccc43)c21		CHEMBL602937	=	Residual Activity	%	102.0	CHEMBL3045	Homo sapiens	Residual Activity	%	102.0
	12264428	CHEMBL2219400	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	COc1cc(OC)c(/C=C2\C(=O)Nc3ccccc32)c(OC)c1		CHEMBL404941	=	Residual Activity	%	105.0	CHEMBL3045	Homo sapiens	Residual Activity	%	105.0
	12264429	CHEMBL2219400	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	O=C1Cc2c([nH]c3ccc(Br)cc23)-c2ccccc2N1		CHEMBL296586	=	Residual Activity	%	114.0	CHEMBL3045	Homo sapiens	Residual Activity	%	114.0
	12264430	CHEMBL2219400	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	O=[N+]([O-])c1ccc(-c2nc(-c3ccc(F)cc3)c(-c3ccncc3)[nH]2)cc1		CHEMBL17331	=	Residual Activity	%	107.0	CHEMBL3045	Homo sapiens	Residual Activity	%	107.0
	12264431	CHEMBL2219400	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	Cc1nc(-c2ccccc2)c(-c2ccncc2)o1		CHEMBL36450	=	Residual Activity	%	109.0	CHEMBL3045	Homo sapiens	Residual Activity	%	109.0
	12264432	CHEMBL2219400	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	N#CCCc1ccc2c(c1)-c1[nH]c3ccc([N+](=O)[O-])cc3c1CC(=O)N2		CHEMBL260138	=	Residual Activity	%	99.0	CHEMBL3045	Homo sapiens	Residual Activity	%	99.0
	12264433	CHEMBL2219400	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	O=C1Nc2ccccc2/C1=C\c1c(Cl)[nH]c2ccccc12		CHEMBL261425	=	Residual Activity	%	103.0	CHEMBL3045	Homo sapiens	Residual Activity	%	103.0
	12264434	CHEMBL2219400	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	NC(=O)c1ccc2[nH]c(-c3ccc(Oc4ccc(Cl)cc4)cc3)nc2c1		CHEMBL179583	=	Residual Activity	%	111.0	CHEMBL3045	Homo sapiens	Residual Activity	%	111.0
	12264435	CHEMBL2219400	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	Cn1sc(=O)n(Cc2ccccc2)c1=O		CHEMBL284861	=	Residual Activity	%	94.0	CHEMBL3045	Homo sapiens	Residual Activity	%	94.0
	12264436	CHEMBL2219400	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	NC(=O)Nc1sc(-c2ccc(F)cc2)cc1C(N)=O		CHEMBL257167	=	Residual Activity	%	103.0	CHEMBL3045	Homo sapiens	Residual Activity	%	103.0
	12264437	CHEMBL2219400	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	COc1ccc(S(=O)(=O)N(CCO)c2ccccc2CN(C)C/C=C/c2ccc(Cl)cc2)cc1		CHEMBL155333	=	Residual Activity	%	106.0	CHEMBL3045	Homo sapiens	Residual Activity	%	106.0
	12264438	CHEMBL2219400	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	Nc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCNCC2)n1		CHEMBL274064	=	Residual Activity	%	115.0	CHEMBL3045	Homo sapiens	Residual Activity	%	115.0
	12264439	CHEMBL2219400	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	Fc1ccc(-c2nc3n(c2-c2ccncc2)CCS3)cc1		CHEMBL313417	=	Residual Activity	%	102.0	CHEMBL3045	Homo sapiens	Residual Activity	%	102.0
	12264440	CHEMBL2219400	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	CCCCc1c(-c2ccc(O)cc2)[nH]c2nccnc12		CHEMBL75680	=	Residual Activity	%	98.0	CHEMBL3045	Homo sapiens	Residual Activity	%	98.0
	12264441	CHEMBL2219400	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	CCn1cnc2c(Nc3cccc(Cl)c3)nc(N[C@@H]3CCCC[C@@H]3N)nc21		CHEMBL367625	=	Residual Activity	%	98.0	CHEMBL3045	Homo sapiens	Residual Activity	%	98.0
	12264442	CHEMBL2219400	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	CC(C)n1cnc2/c(=N/c3cccc(Cl)c3)nc(NCCO)[nH]c21		CHEMBL311228	=	Residual Activity	%	104.0	CHEMBL3045	Homo sapiens	Residual Activity	%	104.0
	12264443	CHEMBL2219400	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	Ic1cccc(CSc2nnc(-c3ccncc3)o2)c1		CHEMBL288064	=	Residual Activity	%	107.0	CHEMBL3045	Homo sapiens	Residual Activity	%	107.0
	12264444	CHEMBL2219400	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	O=C1Nc2ccccc2/C1=C1/Nc2ccccc2/C1=N\OCCC(O)CO		CHEMBL1802727	=	Residual Activity	%	108.0	CHEMBL3045	Homo sapiens	Residual Activity	%	108.0
	12264445	CHEMBL2219400	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	N#C/C(=C(/N)SC1C=CC=CC1)c1cccc(C(O)c2ccncc2)c1		CHEMBL2218939	=	Residual Activity	%	109.0	CHEMBL3045	Homo sapiens	Residual Activity	%	109.0
	12264446	CHEMBL2219400	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	CC(C)[C@H](CO)Nc1nc(Nc2cccc(Cl)c2)c2ncn(C(C)C)c2n1		CHEMBL23327	=	Residual Activity	%	108.0	CHEMBL3045	Homo sapiens	Residual Activity	%	108.0
	12264447	CHEMBL2219400	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	Oc1ccc(Nc2nc(-c3ccc(Cl)cc3)cs2)cc1		CHEMBL1076555	=	Residual Activity	%	105.0	CHEMBL3045	Homo sapiens	Residual Activity	%	105.0
	12264448	CHEMBL2219400	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	CCCCc1c(-c2ccc(OC)cc2)[nH]c2nccnc12		CHEMBL306498	=	Residual Activity	%	101.0	CHEMBL3045	Homo sapiens	Residual Activity	%	101.0
	12264449	CHEMBL2219400	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	Nc1nc(Nc2ccc(S(N)(=O)=O)cc2)nn1C(=S)Nc1c(F)cccc1F		CHEMBL261720	=	Residual Activity	%	84.0	CHEMBL3045	Homo sapiens	Residual Activity	%	84.0
	12264450	CHEMBL2219400	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	COc1ccc(CNc2nc(N(CCO)CCO)nc3c2ncn3C(C)C)cc1		CHEMBL80713	=	Residual Activity	%	87.0	CHEMBL3045	Homo sapiens	Residual Activity	%	87.0
	12264451	CHEMBL2219400	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	COc1ccc(CNC(=O)Nc2ncc([N+](=O)[O-])s2)cc1		CHEMBL259850	=	Residual Activity	%	94.0	CHEMBL3045	Homo sapiens	Residual Activity	%	94.0
	12264452	CHEMBL2219400	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	Oc1c2ccccc2c2c3c(cccc13)N=N2		CHEMBL1725279	=	Residual Activity	%	102.0	CHEMBL3045	Homo sapiens	Residual Activity	%	102.0
	12264453	CHEMBL2219400	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	O=C1C(Cl)=C(N2C(=O)CCC2=O)C(=O)c2ccccc21		CHEMBL404939	=	Residual Activity	%	110.0	CHEMBL3045	Homo sapiens	Residual Activity	%	110.0
	12264454	CHEMBL2219400	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	Nc1cccc(-c2cc3c(Oc4cccc(O)c4)ncnc3[nH]2)c1		CHEMBL405759	=	Residual Activity	%	96.0	CHEMBL3045	Homo sapiens	Residual Activity	%	96.0
	12264455	CHEMBL2219400	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	CC(C)[C@H](CO)Nc1nc(Nc2cc(N)cc(Cl)c2)c2ncn(C(C)C)c2n1		CHEMBL286721	=	Residual Activity	%	102.0	CHEMBL3045	Homo sapiens	Residual Activity	%	102.0
	12264456	CHEMBL2219400	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	Nc1n[nH]c2nc3ccccc3nc12		CHEMBL259389	=	Residual Activity	%	113.0	CHEMBL3045	Homo sapiens	Residual Activity	%	113.0
	12264457	CHEMBL2219400	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	CCN(CC)C(=O)c1ccc(Nc2nc(OCC3CCCCC3)c3nc[nH]c3n2)cc1		CHEMBL1802728	=	Residual Activity	%	109.0	CHEMBL3045	Homo sapiens	Residual Activity	%	109.0
	12264458	CHEMBL2219400	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	O=C1Nc2cc(Br)ccc2/C1=C1/Nc2ccccc2/C1=N\O		CHEMBL409450	=	Residual Activity	%	100.0	CHEMBL3045	Homo sapiens	Residual Activity	%	100.0
	12264459	CHEMBL2219400	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	Cn1nc2c3c(cccc31)C(=O)c1ccccc1-2		CHEMBL1802485	=	Residual Activity	%	107.0	CHEMBL3045	Homo sapiens	Residual Activity	%	107.0
	12264460	CHEMBL2219400	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	N#C/C(=C(\N)Sc1ccc(N)cc1)c1ccccc1C(F)(F)F		CHEMBL2218940	=	Residual Activity	%	114.0	CHEMBL3045	Homo sapiens	Residual Activity	%	114.0
	12264461	CHEMBL2219400	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	O=S(=O)(NCCNC/C=C/c1ccc(Br)cc1)c1cccc2cnccc12		CHEMBL104264	=	Residual Activity	%	104.0	CHEMBL3045	Homo sapiens	Residual Activity	%	104.0
	12264462	CHEMBL2219400	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	O=C(O)c1ccc2c3c1cccc3c(=O)n1c3ccccc3nc21		CHEMBL1182777	=	Residual Activity	%	125.0	CHEMBL3045	Homo sapiens	Residual Activity	%	125.0
	12264463	CHEMBL2219400	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	c1cc(-c2cnn3cc(-c4ccc(OCCN5CCCCC5)cc4)cnc23)ccn1		CHEMBL478629	=	Residual Activity	%	118.0	CHEMBL3045	Homo sapiens	Residual Activity	%	118.0
	12264464	CHEMBL2219400	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	NC(=O)c1ccc(-c2nc(-c3ccc4c(c3)OCCO4)c(-c3ccccn3)[nH]2)cc1		CHEMBL410456	=	Residual Activity	%	124.0	CHEMBL3045	Homo sapiens	Residual Activity	%	124.0
	12264465	CHEMBL2219400	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	CC(C)c1nn(-c2c(Cl)cccc2Cl)c2nc(Cc3ccc(OCCO)cc3)[nH]c(=O)c12		CHEMBL258721	=	Residual Activity	%	125.0	CHEMBL3045	Homo sapiens	Residual Activity	%	125.0
	12264466	CHEMBL2219400	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	CC(=O)O/N=C1C(=C2\C(=O)Nc3cc(Br)ccc32)\Nc2ccccc2\1		CHEMBL2218941	=	Residual Activity	%	122.0	CHEMBL3045	Homo sapiens	Residual Activity	%	122.0
	12264467	CHEMBL2219400	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	N#C/C(=C1/Nc2ccccc2S1)c1ccnc(NCCc2cccnc2)n1		CHEMBL191384	=	Residual Activity	%	125.0	CHEMBL3045	Homo sapiens	Residual Activity	%	125.0
	12264468	CHEMBL2219400	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	Nc1ncnc2[nH]nc(Nc3ccc(F)cc3)c12		CHEMBL1240885	=	Residual Activity	%	122.0	CHEMBL3045	Homo sapiens	Residual Activity	%	122.0
	12264469	CHEMBL2219400	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	CCc1nc(-c2ccc(OC)cc2)[nH]c1-c1ccncc1		CHEMBL278724	=	Residual Activity	%	127.0	CHEMBL3045	Homo sapiens	Residual Activity	%	127.0
	12264470	CHEMBL2219400	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	COc1ccc2c(c1)/C(=C/c1cnc[nH]1)C(=O)N2		CHEMBL258805	=	Residual Activity	%	120.0	CHEMBL3045	Homo sapiens	Residual Activity	%	120.0
	12264471	CHEMBL2219400	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	O=C(O)/C=C/c1cc(Br)c(Br)c(Br)c1Br		CHEMBL270724	=	Residual Activity	%	124.0	CHEMBL3045	Homo sapiens	Residual Activity	%	124.0
	12264472	CHEMBL2219400	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	N/C(=N\[N+](=O)[O-])N/N=C\c1ccc(-c2cccc([N+](=O)[O-])c2)o1		CHEMBL221271	=	Residual Activity	%	123.0	CHEMBL3045	Homo sapiens	Residual Activity	%	123.0
	12264473	CHEMBL2219400	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	O=C1NC(=O)C(c2cn(CCCO)c3ncccc23)=C1c1cnccn1		CHEMBL272629	=	Residual Activity	%	122.0	CHEMBL3045	Homo sapiens	Residual Activity	%	122.0
	12264474	CHEMBL2219400	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	N#Cc1c(NC(=O)c2cccc3ccccc23)sc2c1CCCC2		CHEMBL233001	=	Residual Activity	%	133.0	CHEMBL3045	Homo sapiens	Residual Activity	%	133.0
	12264475	CHEMBL2219400	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	Nc1ccc2ncnc(NCCc3ccc(Oc4ccccc4)cc3)c2c1		CHEMBL522502	=	Residual Activity	%	137.0	CHEMBL3045	Homo sapiens	Residual Activity	%	137.0
	12264476	CHEMBL2219400	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	Oc1ccc(-c2nc(-c3ccc(F)cc3)c(-c3ccncc3)[nH]2)cc1		CHEMBL278041	=	Residual Activity	%	124.0	CHEMBL3045	Homo sapiens	Residual Activity	%	124.0
	12264477	CHEMBL2219400	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	N#Cc1cnc2cnc(NCc3cccnc3)cc2c1Nc1ccc(F)c(Cl)c1		CHEMBL200381	=	Residual Activity	%	18.0	CHEMBL3045	Homo sapiens	Residual Activity	%	18.0
	12264478	CHEMBL2219401	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	CC(C)(C)c1cc(C=C(C#N)C#N)cc(Br)c1O		CHEMBL2218926	=	Residual Activity	%	97.0	CHEMBL3045	Homo sapiens	Residual Activity	%	97.0
	12264479	CHEMBL2219401	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	O=C1NC(=O)C(c2c[nH]c3ccccc23)=C1c1c[nH]c2ccccc12		CHEMBL266487	=	Residual Activity	%	23.0	CHEMBL3045	Homo sapiens	Residual Activity	%	23.0
	12264480	CHEMBL2219401	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	O=C(Nc1cccc(Nc2cc(Nc3cccc(C(F)(F)F)c3)ncn2)c1)C1CC1		CHEMBL387187	=	Residual Activity	%	104.0	CHEMBL3045	Homo sapiens	Residual Activity	%	104.0
	12264481	CHEMBL2219401	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	COc1ccc(Cl)cc1NC(=O)Nc1cc(C)nc2ccccc12		CHEMBL439259	=	Residual Activity	%	98.0	CHEMBL3045	Homo sapiens	Residual Activity	%	98.0
	12264482	CHEMBL2219401	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	CNc1cc2c(Nc3cccc(Br)c3)ncnc2cn1		CHEMBL53753	=	Residual Activity	%	105.0	CHEMBL3045	Homo sapiens	Residual Activity	%	105.0
	12264483	CHEMBL2219401	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	Nc1ncnc2c1cnn2-c1ccccc1		CHEMBL65063	=	Residual Activity	%	95.0	CHEMBL3045	Homo sapiens	Residual Activity	%	95.0
	12264484	CHEMBL2219401	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	Cn1cc(/C=C2\C(=O)Nc3ccc(S(N)(=O)=O)cc32)c2ccccc21		CHEMBL104279	=	Residual Activity	%	109.0	CHEMBL3045	Homo sapiens	Residual Activity	%	109.0
	12264485	CHEMBL2219401	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	COc1cc2ncnc(Nc3cccc(Cl)c3)c2cc1OC		CHEMBL7917	=	Residual Activity	%	106.0	CHEMBL3045	Homo sapiens	Residual Activity	%	106.0
	12264486	CHEMBL2219401	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	Cc1nc2cc3nc(-c4cccs4)cnc3cc2n1C		CHEMBL2218927	=	Residual Activity	%	105.0	CHEMBL3045	Homo sapiens	Residual Activity	%	105.0
	12264487	CHEMBL2219401	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	Cn1cnc2cc3c(Nc4cccc(Br)c4)ncnc3cc21		CHEMBL174426	=	Residual Activity	%	85.0	CHEMBL3045	Homo sapiens	Residual Activity	%	85.0
	12264488	CHEMBL2219401	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	CC#CC(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cn1		CHEMBL203644	=	Residual Activity	%	103.0	CHEMBL3045	Homo sapiens	Residual Activity	%	103.0
	12264489	CHEMBL2219401	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	O=C(Nc1nc2ccccc2n1CCN1CCOCC1)c1cccc([N+](=O)[O-])c1		CHEMBL379787	=	Residual Activity	%	98.0	CHEMBL3045	Homo sapiens	Residual Activity	%	98.0
	12264490	CHEMBL2219401	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	CCC(=O)Nc1ccc2ncnc(Nc3cccc(Br)c3)c2c1		CHEMBL188762	=	Residual Activity	%	99.0	CHEMBL3045	Homo sapiens	Residual Activity	%	99.0
	12264491	CHEMBL2219401	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	CC(C)(C)n1nc(Cc2cccc3ccccc23)c2c(N)ncnc21		CHEMBL573578	=	Residual Activity	%	97.0	CHEMBL3045	Homo sapiens	Residual Activity	%	97.0
	12264492	CHEMBL2219401	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	NCCNc1ncc(C(N)=O)c(Nc2cccc(C(F)(F)F)c2)n1		CHEMBL471901	=	Residual Activity	%	60.0	CHEMBL3045	Homo sapiens	Residual Activity	%	60.0
	12264493	CHEMBL2219401	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	CCOC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccccc32)c1C		CHEMBL86943	=	Residual Activity	%	97.0	CHEMBL3045	Homo sapiens	Residual Activity	%	97.0
	12264494	CHEMBL2219401	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	CC[n+]1c(/C=C/N(C)c2ccccc2)n(-c2ccccc2)c2ccc(-c3nc4ccccc4s3)cc21		CHEMBL1186409	=	Residual Activity	%	97.0	CHEMBL3045	Homo sapiens	Residual Activity	%	97.0
	12264495	CHEMBL2219401	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	COc1ccc2c(c[n+](C)c3c4cc5c(cc4ccc23)OCO5)c1OC		CHEMBL13045	=	Residual Activity	%	98.0	CHEMBL3045	Homo sapiens	Residual Activity	%	98.0
	12264496	CHEMBL2219401	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	COc1ccc(C(=O)Nc2sc3c(c2C(N)=O)CCCC3)cc1OC		CHEMBL210833	=	Residual Activity	%	94.0	CHEMBL3045	Homo sapiens	Residual Activity	%	94.0
	12264497	CHEMBL2219401	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	CC(C)(C)c1nc2c3ccc(F)cc3c3c(=O)[nH]ccc3c2[nH]1		CHEMBL21156	=	Residual Activity	%	32.0	CHEMBL3045	Homo sapiens	Residual Activity	%	32.0
	12264498	CHEMBL2219401	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	CCCC(=O)Oc1ccc2[nH]c(C(=O)c3cc4ccccc4[nH]3)cc2c1		CHEMBL266325	=	Residual Activity	%	93.0	CHEMBL3045	Homo sapiens	Residual Activity	%	93.0
	12264499	CHEMBL2219401	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	O=C1NC(=O)c2cc(Nc3ccc(F)cc3)c(Nc3ccc(F)cc3)cc21		CHEMBL7939	=	Residual Activity	%	86.0	CHEMBL3045	Homo sapiens	Residual Activity	%	86.0
	12264500	CHEMBL2219401	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	O=[N+]([O-])/C=C/c1ccc2c(c1)OCO2		CHEMBL596380	=	Residual Activity	%	102.0	CHEMBL3045	Homo sapiens	Residual Activity	%	102.0
	12264501	CHEMBL2219401	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	O=C(Nc1ccc(Cl)cc1)c1ccccc1NCc1ccncc1		CHEMBL101683	=	Residual Activity	%	89.0	CHEMBL3045	Homo sapiens	Residual Activity	%	89.0
	12264502	CHEMBL2219401	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	CN1N=C(N)c2cn([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c3ncnc1c23		CHEMBL331237	=	Residual Activity	%	94.0	CHEMBL3045	Homo sapiens	Residual Activity	%	94.0
	12264503	CHEMBL2219401	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	CCOc1cc2ncnc(Nc3cccc(Br)c3)c2cc1OCC		CHEMBL35820	=	Residual Activity	%	97.0	CHEMBL3045	Homo sapiens	Residual Activity	%	97.0
	12264504	CHEMBL2219401	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	O=C(c1cc2cc(O)ccc2[nH]1)c1cc2cc(O)ccc2[nH]1		CHEMBL377193	=	Residual Activity	%	91.0	CHEMBL3045	Homo sapiens	Residual Activity	%	91.0
	12264505	CHEMBL2219401	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	COc1cc2ncnc(Nc3ccc(O)c(Br)c3)c2cc1OC		CHEMBL473773	=	Residual Activity	%	83.0	CHEMBL3045	Homo sapiens	Residual Activity	%	83.0
	12264506	CHEMBL2219401	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	COc1cc2ncnc(N3CCN(C(=O)Nc4ccc(Oc5ccccc5)cc4)CC3)c2cc1OC		CHEMBL102346	=	Residual Activity	%	97.0	CHEMBL3045	Homo sapiens	Residual Activity	%	97.0
	12264507	CHEMBL2219401	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	O=C1NC(=O)C(c2cn(CCCn3ccnc3)c3ccccc23)=C1Nc1ccccc1		CHEMBL366266	=	Residual Activity	%	2.0	CHEMBL3045	Homo sapiens	Residual Activity	%	2.0
	12264508	CHEMBL2219401	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	c1ccc(-c2n[nH]cc2-c2ccnc3ccccc23)nc1		CHEMBL261454	=	Residual Activity	%	110.0	CHEMBL3045	Homo sapiens	Residual Activity	%	110.0
	12264509	CHEMBL2219401	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC		CHEMBL1289494	=	Residual Activity	%	97.0	CHEMBL3045	Homo sapiens	Residual Activity	%	97.0
	12264510	CHEMBL2219401	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	O=c1[nH]c2ccccc2n1C1CCN(Cc2ccc(-c3nc4cc5[nH]cnc5cc4nc3-c3ccccc3)cc2)CC1		CHEMBL258844	=	Residual Activity	%	93.0	CHEMBL3045	Homo sapiens	Residual Activity	%	93.0
	12264511	CHEMBL2219401	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	O=c1cc(N2CCOCC2)oc2c1ccc1ccccc12		CHEMBL104468	=	Residual Activity	%	95.0	CHEMBL3045	Homo sapiens	Residual Activity	%	95.0
	12264512	CHEMBL2219401	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	COc1ccc(COc2ccc(Cc3cnc(N)nc3N)cc2OC)cc1		CHEMBL261849	=	Residual Activity	%	109.0	CHEMBL3045	Homo sapiens	Residual Activity	%	109.0
	12264513	CHEMBL2219401	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	CC(C)N(CCC(=O)c1ccc2ccccc2c1)Cc1ccccc1		CHEMBL596674	=	Residual Activity	%	94.0	CHEMBL3045	Homo sapiens	Residual Activity	%	94.0
	12264514	CHEMBL2219401	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	COc1cc2c(cc1OC)-c1n[nH]c(Nc3cccc(F)c3)c1C2		CHEMBL120077	=	Residual Activity	%	108.0	CHEMBL3045	Homo sapiens	Residual Activity	%	108.0
	12264515	CHEMBL2219401	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](O)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C		CHEMBL413	=	Residual Activity	%	106.0	CHEMBL3045	Homo sapiens	Residual Activity	%	106.0
	12264516	CHEMBL2219401	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	Cc1cccc(-c2[nH]c(C(C)(C)C)nc2-c2ccc3c(c2)OCO3)n1		CHEMBL226838	=	Residual Activity	%	109.0	CHEMBL3045	Homo sapiens	Residual Activity	%	109.0
	12264517	CHEMBL2219401	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	O=C1Nc2ccc(Br)cc2/C1=C\c1cc2c([nH]1)CCCC2		CHEMBL2218925	=	Residual Activity	%	98.0	CHEMBL3045	Homo sapiens	Residual Activity	%	98.0
	12264518	CHEMBL2219401	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	CCN(CC)CCCCN1c2ccccc2Oc2ccc(Cl)cc21		CHEMBL1398474	=	Residual Activity	%	98.0	CHEMBL3045	Homo sapiens	Residual Activity	%	98.0
	12264519	CHEMBL2219401	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	CC(=O)c1ccc(N2CCOCC2)cc1O		CHEMBL1317546	=	Residual Activity	%	101.0	CHEMBL3045	Homo sapiens	Residual Activity	%	101.0
	12264520	CHEMBL2219401	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	Cn1c2ccccc2c2c3c(c4c5ccccc5n(CCC#N)c4c21)CNC3=O		CHEMBL302449	=	Residual Activity	%	6.0	CHEMBL3045	Homo sapiens	Residual Activity	%	6.0
	12264521	CHEMBL2219401	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	O=C1Nc2ccc(-c3cccnc3)cc2/C1=C\c1ccc[nH]1		CHEMBL2218929	=	Residual Activity	%	49.0	CHEMBL3045	Homo sapiens	Residual Activity	%	49.0
	12264522	CHEMBL2219401	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	COc1cc2nccc(Oc3ccc(NC(=S)NC(=O)c4ccccc4C)cc3)c2cc1OC		CHEMBL2218930	=	Residual Activity	%	113.0	CHEMBL3045	Homo sapiens	Residual Activity	%	113.0
	12264523	CHEMBL2219401	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	c1ccc2c(-c3ccncc3)c[nH]c2c1		CHEMBL380071	=	Residual Activity	%	64.0	CHEMBL3045	Homo sapiens	Residual Activity	%	64.0
	12264524	CHEMBL2219401	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	COc1ccc(C=C(C#N)C#N)cc1		CHEMBL77456	=	Residual Activity	%	114.0	CHEMBL3045	Homo sapiens	Residual Activity	%	114.0
	12264525	CHEMBL2219401	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	Cc1cc(C)c(/C=C2\C(=O)Nc3ccccc32)[nH]1		CHEMBL276711	=	Residual Activity	%	105.0	CHEMBL3045	Homo sapiens	Residual Activity	%	105.0
	12264526	CHEMBL2219401	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	O=C1c2ccccc2-c2nc3nnnn3nc21		CHEMBL599894	=	Residual Activity	%	93.0	CHEMBL3045	Homo sapiens	Residual Activity	%	93.0
	12264527	CHEMBL2219401	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	Oc1cccc(-c2nc(N3CCOCC3)c3oc4ncccc4c3n2)c1		CHEMBL573339	=	Residual Activity	%	107.0	CHEMBL3045	Homo sapiens	Residual Activity	%	107.0
	12264528	CHEMBL2219401	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	COc1ccc2c(c1)c(C1=C(c3c[nH]c4ccccc34)C(=O)NC1=O)cn2CCCN(C)C		CHEMBL261491	=	Residual Activity	%	-1.0	CHEMBL3045	Homo sapiens	Residual Activity	%	-1.0
	12264529	CHEMBL2219401	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	Nc1ncnc2c1c(-c1ccc(Oc3ccccc3)cc1)cn2C1CCCC1		CHEMBL47940	=	Residual Activity	%	103.0	CHEMBL3045	Homo sapiens	Residual Activity	%	103.0
	12264530	CHEMBL2219401	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	O=C1Nc2ccc3ncsc3c2/C1=C/c1c[nH]cn1		CHEMBL235641	=	Residual Activity	%	12.0	CHEMBL3045	Homo sapiens	Residual Activity	%	12.0
	12264531	CHEMBL2219401	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	Cc1cncc2cccc(S(=O)(=O)N3CCCN(C(=O)CN)C[C@H]3C)c12		CHEMBL2218931	=	Residual Activity	%	31.0	CHEMBL3045	Homo sapiens	Residual Activity	%	31.0
	12264532	CHEMBL2219401	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	N#C/C(=C\c1ccc(O)c(O)c1)C(=O)NCc1ccccc1		CHEMBL56543	=	Residual Activity	%	109.0	CHEMBL3045	Homo sapiens	Residual Activity	%	109.0
	12264533	CHEMBL2219401	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	COc1ccc(-c2cnc3c(-c4ccsc4)cnn3c2)cc1		CHEMBL92461	=	Residual Activity	%	112.0	CHEMBL3045	Homo sapiens	Residual Activity	%	112.0
	12266183	CHEMBL2219401	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	COc1cc2ncnc(Nc3ccc(NC(=O)c4ccccc4)cc3)c2cc1OC		CHEMBL382590	=	Residual Activity	%	106.0	CHEMBL3045	Homo sapiens	Residual Activity	%	106.0
	12266184	CHEMBL2219401	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	O=c1c2ccccc2[nH]c(=S)n1CCN1CCC(=C(c2ccc(F)cc2)c2ccc(F)cc2)CC1		CHEMBL261131	=	Residual Activity	%	109.0	CHEMBL3045	Homo sapiens	Residual Activity	%	109.0
	12266185	CHEMBL2219401	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	c1ccc(-c2n[nH]c3c2oc2ccccc23)cc1		CHEMBL406375	=	Residual Activity	%	90.0	CHEMBL3045	Homo sapiens	Residual Activity	%	90.0
	12266186	CHEMBL2219401	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	O=c1cc(N2CCOCC2)oc2c(-c3ccccc3)cccc12		CHEMBL98350	=	Residual Activity	%	88.0	CHEMBL3045	Homo sapiens	Residual Activity	%	88.0
	12266187	CHEMBL2219401	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	O=C1Nc2ccc(Cl)cc2/C1=C/c1cc(Cl)c(O)c(Cl)c1		CHEMBL2218932	=	Residual Activity	%	103.0	CHEMBL3045	Homo sapiens	Residual Activity	%	103.0
	12266188	CHEMBL2219401	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL608533	=	Residual Activity	%	14.0	CHEMBL3045	Homo sapiens	Residual Activity	%	14.0
	12266189	CHEMBL2219401	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	N#CC(C#N)=C(N)/C(C#N)=C/c1ccc(O)cc1		CHEMBL76589	=	Residual Activity	%	122.0	CHEMBL3045	Homo sapiens	Residual Activity	%	122.0
	12266190	CHEMBL2219401	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	O=C(c1ccccc1)c1ccc(N2CCOCC2)cc1O		CHEMBL478980	=	Residual Activity	%	113.0	CHEMBL3045	Homo sapiens	Residual Activity	%	113.0
	12266191	CHEMBL2219401	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	NC(=O)c1cccc(-c2cc(Nc3ccc(OC(F)(F)F)cc3)ncn2)c1		CHEMBL483847	=	Residual Activity	%	112.0	CHEMBL3045	Homo sapiens	Residual Activity	%	112.0
	12266192	CHEMBL2219401	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	CN(C)c1ccc(/C=C2\C(=O)Nc3ccccc32)cc1		CHEMBL328710	=	Residual Activity	%	112.0	CHEMBL3045	Homo sapiens	Residual Activity	%	112.0
	12266193	CHEMBL2219401	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	CO[C@H]1/C=C/C=C(\C)C(=O)NC2=CC(=O)C=C(C2=O)[C@H](OC)[C@@H](C)C[C@H](OC)[C@H](OC)[C@@H](C)/C=C(\C)[C@@H]1OC(N)=O		CHEMBL479533	=	Residual Activity	%	121.0	CHEMBL3045	Homo sapiens	Residual Activity	%	121.0
	12266194	CHEMBL2219401	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	O=c1cc(N2CCNCC2)oc2c(-c3ccccc3)cccc12		CHEMBL1363184	=	Residual Activity	%	109.0	CHEMBL3045	Homo sapiens	Residual Activity	%	109.0
	12266195	CHEMBL2219401	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	O=C1NC(=O)/C(=C\c2ccc3nccnc3c2)S1		CHEMBL2218934	=	Residual Activity	%	121.0	CHEMBL3045	Homo sapiens	Residual Activity	%	121.0
	12266196	CHEMBL2219401	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	COc1cc2ncnc(Nc3ccc(Oc4ccccc4)cc3)c2cc1OC		CHEMBL97771	=	Residual Activity	%	126.0	CHEMBL3045	Homo sapiens	Residual Activity	%	126.0
	12266197	CHEMBL2219401	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	Cc1cc2ncc(-c3ccccc3)nc2cc1C		CHEMBL7724	=	Residual Activity	%	131.0	CHEMBL3045	Homo sapiens	Residual Activity	%	131.0
	12266198	CHEMBL2219401	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	O=C(Nc1cccc(Nc2nccc(Nc3cccc(C(F)(F)F)c3)n2)c1)C1CC1		CHEMBL383899	=	Residual Activity	%	107.0	CHEMBL3045	Homo sapiens	Residual Activity	%	107.0
	12266199	CHEMBL2219401	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	CN(C)CCCn1cc(C2=C(c3c[nH]c4ccccc34)C(=O)NC2=O)c2ccccc21		CHEMBL7463	=	Residual Activity	%	1.0	CHEMBL3045	Homo sapiens	Residual Activity	%	1.0
	12266200	CHEMBL2219401	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	COc1cc2ncnc(Nc3ccc(OCc4ccccc4)cc3)c2cc1OC		CHEMBL563845	=	Residual Activity	%	106.0	CHEMBL3045	Homo sapiens	Residual Activity	%	106.0
	12266201	CHEMBL2219401	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	c1ccc(-c2cnc(Nc3ccc(OCCN4CCCC4)cc3)s2)cc1		CHEMBL2218935	=	Residual Activity	%	116.0	CHEMBL3045	Homo sapiens	Residual Activity	%	116.0
	12266202	CHEMBL2219401	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	CC1=C(C(=O)N2CCN(C)CC2)C(C)=C(/C=C2\C(=O)Nc3ccc(S(=O)(=O)N(C)c4cccc(Cl)c4)cc32)C1		CHEMBL2218936	=	Residual Activity	%	110.0	CHEMBL3045	Homo sapiens	Residual Activity	%	110.0
	12266203	CHEMBL2219401	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	O=C1NC(=O)/C(=C/c2ccc3c(c2)OC(F)(F)O3)S1		CHEMBL1231533	=	Residual Activity	%	126.0	CHEMBL3045	Homo sapiens	Residual Activity	%	126.0
	12266204	CHEMBL2219401	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(Cl)cc32)c1C		CHEMBL13485	=	Residual Activity	%	117.0	CHEMBL3045	Homo sapiens	Residual Activity	%	117.0
	12266205	CHEMBL2219401	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	COc1cc2ncc(-c3ccccc3)nc2cc1OC		CHEMBL71191	=	Residual Activity	%	124.0	CHEMBL3045	Homo sapiens	Residual Activity	%	124.0
	12266206	CHEMBL2219401	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL388978	=	Residual Activity	%	1.0	CHEMBL3045	Homo sapiens	Residual Activity	%	1.0
	12266207	CHEMBL2219401	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	CN([C@@H](Cc1ccc(OS(=O)(=O)c2cccc3cnccc23)cc1)C(=O)N1CCN(c2ccccc2)CC1)S(=O)(=O)c1cccc2cnccc12		CHEMBL28324	=	Residual Activity	%	98.0	CHEMBL3045	Homo sapiens	Residual Activity	%	98.0
	12266208	CHEMBL2219401	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	Nc1nc(Nc2ccc(S(N)(=O)=O)cc2)nn1C(=O)c1c(F)cccc1F		CHEMBL191003	=	Residual Activity	%	41.0	CHEMBL3045	Homo sapiens	Residual Activity	%	41.0
	12266209	CHEMBL2219401	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	O=C1NC(=O)c2c1c1c3ccccc3[nH]c1c1[nH]c3cc(Br)ccc3c21		CHEMBL64758	=	Residual Activity	%	95.0	CHEMBL3045	Homo sapiens	Residual Activity	%	95.0
	12266210	CHEMBL2219401	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	C[C@@H](N)[C@H]1CC[C@H](C(=O)Nc2ccncc2)CC1		CHEMBL559147	=	Residual Activity	%	87.0	CHEMBL3045	Homo sapiens	Residual Activity	%	87.0
	12266211	CHEMBL2219401	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	CN(C)S(=O)(=O)c1ccc2c(c1)/C(=C/c1cc3c([nH]1)CCCC3)C(=O)N2		CHEMBL605003	=	Residual Activity	%	103.0	CHEMBL3045	Homo sapiens	Residual Activity	%	103.0
	12266212	CHEMBL2219401	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	O=C(CCCc1ccc(-c2ccccc2F)cc1)Nc1ccc(O)cc1		CHEMBL235658	=	Residual Activity	%	108.0	CHEMBL3045	Homo sapiens	Residual Activity	%	108.0
	12266213	CHEMBL2219401	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	CSc1nc(-c2ccc(F)cc2)c(-c2ccnc(NC(C)c3ccccc3)c2)[nH]1		CHEMBL111364	=	Residual Activity	%	102.0	CHEMBL3045	Homo sapiens	Residual Activity	%	102.0
	12266214	CHEMBL2219401	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	C[S+]([O-])c1ccc(-c2nc(-c3ccc(F)cc3)c(-c3ccncc3)[nH]2)cc1		CHEMBL10	=	Residual Activity	%	70.0	CHEMBL3045	Homo sapiens	Residual Activity	%	70.0
	12266215	CHEMBL2219401	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	O=c1cc(-c2cccc3c2Sc2ccccc2S3)oc(N2CCOCC2)c1		CHEMBL222102	=	Residual Activity	%	100.0	CHEMBL3045	Homo sapiens	Residual Activity	%	100.0
	12266216	CHEMBL2219401	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	O=Nc1c(-c2c(O)[nH]c3ccccc23)[nH]c2ccccc12		CHEMBL126077	=	Residual Activity	%	94.0	CHEMBL3045	Homo sapiens	Residual Activity	%	94.0
	12266217	CHEMBL2219401	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	COc1ccc(OC)c2c(=S)c3ccccc3[nH]c12		CHEMBL1331734	=	Residual Activity	%	115.0	CHEMBL3045	Homo sapiens	Residual Activity	%	115.0
	12266218	CHEMBL2219401	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	Nc1n[nH]c2nnc(-c3c(-c4ccccc4)nn4ccccc34)cc12		CHEMBL259551	=	Residual Activity	%	96.0	CHEMBL3045	Homo sapiens	Residual Activity	%	96.0
	12266219	CHEMBL2219401	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	Cc1cc(Nc2nc(-c3ccccc3)nc3ccccc23)n[nH]1		CHEMBL359482	=	Residual Activity	%	88.0	CHEMBL3045	Homo sapiens	Residual Activity	%	88.0
	12266220	CHEMBL2219401	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	CCOc1nc(NC(=O)Cc2cc(OC)ccc2OC)cc(N)c1C#N		CHEMBL210618	=	Residual Activity	%	107.0	CHEMBL3045	Homo sapiens	Residual Activity	%	107.0
	12266221	CHEMBL2219401	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	Oc1c(-c2ccc(F)cc2)c(-c2ccncc2)nn1-c1ccc(Cl)cc1		CHEMBL91730	=	Residual Activity	%	92.0	CHEMBL3045	Homo sapiens	Residual Activity	%	92.0
	12266222	CHEMBL2219401	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	O=S(=O)(c1cccc2cnccc12)N1CCCNCC1		CHEMBL38380	=	Residual Activity	%	46.0	CHEMBL3045	Homo sapiens	Residual Activity	%	46.0
	12266223	CHEMBL2219401	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	O=C(NC(NC(=S)Nc1ccc(F)c([N+](=O)[O-])c1)C(Cl)(Cl)Cl)C(c1ccccc1)c1ccccc1		CHEMBL1221601	=	Residual Activity	%	105.0	CHEMBL3045	Homo sapiens	Residual Activity	%	105.0
	12266224	CHEMBL2219401	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	Cc1ccc(S(=O)(=O)/C=C/C#N)cc1		CHEMBL403183	=	Residual Activity	%	102.0	CHEMBL3045	Homo sapiens	Residual Activity	%	102.0
	12266225	CHEMBL2219401	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	Cc1ccc(NC2=CC(=O)c3sc(C)nc3C2=O)cc1		CHEMBL290904	=	Residual Activity	%	88.0	CHEMBL3045	Homo sapiens	Residual Activity	%	88.0
	12266226	CHEMBL2219401	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	Oc1n[nH]c2nnc(-c3c(-c4ccccc4)nn4ccccc34)cc12		CHEMBL2218938	=	Residual Activity	%	98.0	CHEMBL3045	Homo sapiens	Residual Activity	%	98.0
	12266227	CHEMBL2219401	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	O=C1NC(=O)c2c1c1c3ccccc3[nH]c1n1cncc21		CHEMBL413188	=	Residual Activity	%	100.0	CHEMBL3045	Homo sapiens	Residual Activity	%	100.0
	12266228	CHEMBL2219401	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	COC(=O)[C@@]1(O)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL281948	=	Residual Activity	%	13.0	CHEMBL3045	Homo sapiens	Residual Activity	%	13.0
	12266229	CHEMBL2219401	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	COc1cccc(-c2cc(=O)c3ccccc3o2)c1N		CHEMBL35482	=	Residual Activity	%	105.0	CHEMBL3045	Homo sapiens	Residual Activity	%	105.0
	12266230	CHEMBL2219401	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	O=C1NC(=O)c2c1c1c3ccccc3n3c1c1c2c2ccccc2n1C1CCC3O1		CHEMBL304428	=	Residual Activity	%	91.0	CHEMBL3045	Homo sapiens	Residual Activity	%	91.0
	12266231	CHEMBL2219401	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	O=C1Cc2c([nH]c3ccc([N+](=O)[O-])cc23)-c2ccccc2N1		CHEMBL50894	=	Residual Activity	%	90.0	CHEMBL3045	Homo sapiens	Residual Activity	%	90.0
	12266232	CHEMBL2219401	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	CC(C)n1cnc2c(NCc3ccccc3)nc(NCCCO)nc21		CHEMBL83980	=	Residual Activity	%	105.0	CHEMBL3045	Homo sapiens	Residual Activity	%	105.0
	12266233	CHEMBL2219401	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	CCN1/C(=C/C(C)=O)Sc2ccc(OC)cc21		CHEMBL408982	=	Residual Activity	%	100.0	CHEMBL3045	Homo sapiens	Residual Activity	%	100.0
	12266234	CHEMBL2219401	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	O=C1c2ccccc2-[n+]2ccc3c([nH]c4ccccc43)c21		CHEMBL602937	=	Residual Activity	%	97.0	CHEMBL3045	Homo sapiens	Residual Activity	%	97.0
	12266235	CHEMBL2219401	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	COc1cc(OC)c(/C=C2\C(=O)Nc3ccccc32)c(OC)c1		CHEMBL404941	=	Residual Activity	%	103.0	CHEMBL3045	Homo sapiens	Residual Activity	%	103.0
	12266236	CHEMBL2219401	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	O=C1Cc2c([nH]c3ccc(Br)cc23)-c2ccccc2N1		CHEMBL296586	=	Residual Activity	%	99.0	CHEMBL3045	Homo sapiens	Residual Activity	%	99.0
	12266237	CHEMBL2219401	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	O=[N+]([O-])c1ccc(-c2nc(-c3ccc(F)cc3)c(-c3ccncc3)[nH]2)cc1		CHEMBL17331	=	Residual Activity	%	97.0	CHEMBL3045	Homo sapiens	Residual Activity	%	97.0
	12266238	CHEMBL2219401	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	Cc1nc(-c2ccccc2)c(-c2ccncc2)o1		CHEMBL36450	=	Residual Activity	%	95.0	CHEMBL3045	Homo sapiens	Residual Activity	%	95.0
	12266239	CHEMBL2219401	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	N#CCCc1ccc2c(c1)-c1[nH]c3ccc([N+](=O)[O-])cc3c1CC(=O)N2		CHEMBL260138	=	Residual Activity	%	86.0	CHEMBL3045	Homo sapiens	Residual Activity	%	86.0
	12266240	CHEMBL2219401	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	O=C1Nc2ccccc2/C1=C\c1c(Cl)[nH]c2ccccc12		CHEMBL261425	=	Residual Activity	%	99.0	CHEMBL3045	Homo sapiens	Residual Activity	%	99.0
	12266241	CHEMBL2219401	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	NC(=O)c1ccc2[nH]c(-c3ccc(Oc4ccc(Cl)cc4)cc3)nc2c1		CHEMBL179583	=	Residual Activity	%	93.0	CHEMBL3045	Homo sapiens	Residual Activity	%	93.0
	12266242	CHEMBL2219401	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	Cn1sc(=O)n(Cc2ccccc2)c1=O		CHEMBL284861	=	Residual Activity	%	54.0	CHEMBL3045	Homo sapiens	Residual Activity	%	54.0
	12266243	CHEMBL2219401	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	NC(=O)Nc1sc(-c2ccc(F)cc2)cc1C(N)=O		CHEMBL257167	=	Residual Activity	%	77.0	CHEMBL3045	Homo sapiens	Residual Activity	%	77.0
	12266244	CHEMBL2219401	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	COc1ccc(S(=O)(=O)N(CCO)c2ccccc2CN(C)C/C=C/c2ccc(Cl)cc2)cc1		CHEMBL155333	=	Residual Activity	%	102.0	CHEMBL3045	Homo sapiens	Residual Activity	%	102.0
	12266245	CHEMBL2219401	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	Nc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCNCC2)n1		CHEMBL274064	=	Residual Activity	%	69.0	CHEMBL3045	Homo sapiens	Residual Activity	%	69.0
	12266246	CHEMBL2219401	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	Fc1ccc(-c2nc3n(c2-c2ccncc2)CCS3)cc1		CHEMBL313417	=	Residual Activity	%	82.0	CHEMBL3045	Homo sapiens	Residual Activity	%	82.0
	12266247	CHEMBL2219401	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	CCCCc1c(-c2ccc(O)cc2)[nH]c2nccnc12		CHEMBL75680	=	Residual Activity	%	94.0	CHEMBL3045	Homo sapiens	Residual Activity	%	94.0
	12266248	CHEMBL2219401	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	CCn1cnc2c(Nc3cccc(Cl)c3)nc(N[C@@H]3CCCC[C@@H]3N)nc21		CHEMBL367625	=	Residual Activity	%	85.0	CHEMBL3045	Homo sapiens	Residual Activity	%	85.0
	12266249	CHEMBL2219401	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	CC(C)n1cnc2/c(=N/c3cccc(Cl)c3)nc(NCCO)[nH]c21		CHEMBL311228	=	Residual Activity	%	89.0	CHEMBL3045	Homo sapiens	Residual Activity	%	89.0
	12266250	CHEMBL2219401	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	Ic1cccc(CSc2nnc(-c3ccncc3)o2)c1		CHEMBL288064	=	Residual Activity	%	102.0	CHEMBL3045	Homo sapiens	Residual Activity	%	102.0
	12266251	CHEMBL2219401	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	O=C1Nc2ccccc2/C1=C1/Nc2ccccc2/C1=N\OCCC(O)CO		CHEMBL1802727	=	Residual Activity	%	86.0	CHEMBL3045	Homo sapiens	Residual Activity	%	86.0
	12266252	CHEMBL2219401	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	N#C/C(=C(/N)SC1C=CC=CC1)c1cccc(C(O)c2ccncc2)c1		CHEMBL2218939	=	Residual Activity	%	109.0	CHEMBL3045	Homo sapiens	Residual Activity	%	109.0
	12266253	CHEMBL2219401	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	CC(C)[C@H](CO)Nc1nc(Nc2cccc(Cl)c2)c2ncn(C(C)C)c2n1		CHEMBL23327	=	Residual Activity	%	108.0	CHEMBL3045	Homo sapiens	Residual Activity	%	108.0
	12266254	CHEMBL2219401	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	Oc1ccc(Nc2nc(-c3ccc(Cl)cc3)cs2)cc1		CHEMBL1076555	=	Residual Activity	%	112.0	CHEMBL3045	Homo sapiens	Residual Activity	%	112.0
	12266255	CHEMBL2219401	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	CCCCc1c(-c2ccc(OC)cc2)[nH]c2nccnc12		CHEMBL306498	=	Residual Activity	%	90.0	CHEMBL3045	Homo sapiens	Residual Activity	%	90.0
	12266256	CHEMBL2219401	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	Nc1nc(Nc2ccc(S(N)(=O)=O)cc2)nn1C(=S)Nc1c(F)cccc1F		CHEMBL261720	=	Residual Activity	%	38.0	CHEMBL3045	Homo sapiens	Residual Activity	%	38.0
	12266257	CHEMBL2219401	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	COc1ccc(CNc2nc(N(CCO)CCO)nc3c2ncn3C(C)C)cc1		CHEMBL80713	=	Residual Activity	%	86.0	CHEMBL3045	Homo sapiens	Residual Activity	%	86.0
	12266258	CHEMBL2219401	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	COc1ccc(CNC(=O)Nc2ncc([N+](=O)[O-])s2)cc1		CHEMBL259850	=	Residual Activity	%	102.0	CHEMBL3045	Homo sapiens	Residual Activity	%	102.0
	12266259	CHEMBL2219401	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	Oc1c2ccccc2c2c3c(cccc13)N=N2		CHEMBL1725279	=	Residual Activity	%	104.0	CHEMBL3045	Homo sapiens	Residual Activity	%	104.0
	12266260	CHEMBL2219401	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	O=C1C(Cl)=C(N2C(=O)CCC2=O)C(=O)c2ccccc21		CHEMBL404939	=	Residual Activity	%	105.0	CHEMBL3045	Homo sapiens	Residual Activity	%	105.0
	12266261	CHEMBL2219401	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	Nc1cccc(-c2cc3c(Oc4cccc(O)c4)ncnc3[nH]2)c1		CHEMBL405759	=	Residual Activity	%	107.0	CHEMBL3045	Homo sapiens	Residual Activity	%	107.0
	12266262	CHEMBL2219401	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	CC(C)[C@H](CO)Nc1nc(Nc2cc(N)cc(Cl)c2)c2ncn(C(C)C)c2n1		CHEMBL286721	=	Residual Activity	%	99.0	CHEMBL3045	Homo sapiens	Residual Activity	%	99.0
	12266263	CHEMBL2219401	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	Nc1n[nH]c2nc3ccccc3nc12		CHEMBL259389	=	Residual Activity	%	93.0	CHEMBL3045	Homo sapiens	Residual Activity	%	93.0
	12266264	CHEMBL2219401	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	CCN(CC)C(=O)c1ccc(Nc2nc(OCC3CCCCC3)c3nc[nH]c3n2)cc1		CHEMBL1802728	=	Residual Activity	%	89.0	CHEMBL3045	Homo sapiens	Residual Activity	%	89.0
	12266265	CHEMBL2219401	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	O=C1Nc2cc(Br)ccc2/C1=C1/Nc2ccccc2/C1=N\O		CHEMBL409450	=	Residual Activity	%	101.0	CHEMBL3045	Homo sapiens	Residual Activity	%	101.0
	12266266	CHEMBL2219401	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	Cn1nc2c3c(cccc31)C(=O)c1ccccc1-2		CHEMBL1802485	=	Residual Activity	%	104.0	CHEMBL3045	Homo sapiens	Residual Activity	%	104.0
	12266267	CHEMBL2219401	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	N#C/C(=C(\N)Sc1ccc(N)cc1)c1ccccc1C(F)(F)F		CHEMBL2218940	=	Residual Activity	%	104.0	CHEMBL3045	Homo sapiens	Residual Activity	%	104.0
	12266268	CHEMBL2219401	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	O=S(=O)(NCCNC/C=C/c1ccc(Br)cc1)c1cccc2cnccc12		CHEMBL104264	=	Residual Activity	%	30.0	CHEMBL3045	Homo sapiens	Residual Activity	%	30.0
	12266269	CHEMBL2219401	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	O=C(O)c1ccc2c3c1cccc3c(=O)n1c3ccccc3nc21		CHEMBL1182777	=	Residual Activity	%	113.0	CHEMBL3045	Homo sapiens	Residual Activity	%	113.0
	12266270	CHEMBL2219401	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	c1cc(-c2cnn3cc(-c4ccc(OCCN5CCCCC5)cc4)cnc23)ccn1		CHEMBL478629	=	Residual Activity	%	104.0	CHEMBL3045	Homo sapiens	Residual Activity	%	104.0
	12266271	CHEMBL2219401	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	NC(=O)c1ccc(-c2nc(-c3ccc4c(c3)OCCO4)c(-c3ccccn3)[nH]2)cc1		CHEMBL410456	=	Residual Activity	%	121.0	CHEMBL3045	Homo sapiens	Residual Activity	%	121.0
	12266272	CHEMBL2219401	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	CC(C)c1nn(-c2c(Cl)cccc2Cl)c2nc(Cc3ccc(OCCO)cc3)[nH]c(=O)c12		CHEMBL258721	=	Residual Activity	%	106.0	CHEMBL3045	Homo sapiens	Residual Activity	%	106.0
	12266273	CHEMBL2219401	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	CC(=O)O/N=C1C(=C2\C(=O)Nc3cc(Br)ccc32)\Nc2ccccc2\1		CHEMBL2218941	=	Residual Activity	%	122.0	CHEMBL3045	Homo sapiens	Residual Activity	%	122.0
	12266274	CHEMBL2219401	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	N#C/C(=C1/Nc2ccccc2S1)c1ccnc(NCCc2cccnc2)n1		CHEMBL191384	=	Residual Activity	%	121.0	CHEMBL3045	Homo sapiens	Residual Activity	%	121.0
	12266275	CHEMBL2219401	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	Nc1ncnc2[nH]nc(Nc3ccc(F)cc3)c12		CHEMBL1240885	=	Residual Activity	%	110.0	CHEMBL3045	Homo sapiens	Residual Activity	%	110.0
	12266276	CHEMBL2219401	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	CCc1nc(-c2ccc(OC)cc2)[nH]c1-c1ccncc1		CHEMBL278724	=	Residual Activity	%	105.0	CHEMBL3045	Homo sapiens	Residual Activity	%	105.0
	12266277	CHEMBL2219401	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	COc1ccc2c(c1)/C(=C/c1cnc[nH]1)C(=O)N2		CHEMBL258805	=	Residual Activity	%	92.0	CHEMBL3045	Homo sapiens	Residual Activity	%	92.0
	12266278	CHEMBL2219401	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	O=C(O)/C=C/c1cc(Br)c(Br)c(Br)c1Br		CHEMBL270724	=	Residual Activity	%	114.0	CHEMBL3045	Homo sapiens	Residual Activity	%	114.0
	12266279	CHEMBL2219401	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	N/C(=N\[N+](=O)[O-])N/N=C\c1ccc(-c2cccc([N+](=O)[O-])c2)o1		CHEMBL221271	=	Residual Activity	%	110.0	CHEMBL3045	Homo sapiens	Residual Activity	%	110.0
	12266280	CHEMBL2219401	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	O=C1NC(=O)C(c2cn(CCCO)c3ncccc23)=C1c1cnccn1		CHEMBL272629	=	Residual Activity	%	117.0	CHEMBL3045	Homo sapiens	Residual Activity	%	117.0
	12266281	CHEMBL2219401	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	N#Cc1c(NC(=O)c2cccc3ccccc23)sc2c1CCCC2		CHEMBL233001	=	Residual Activity	%	122.0	CHEMBL3045	Homo sapiens	Residual Activity	%	122.0
	12266282	CHEMBL2219401	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	Nc1ccc2ncnc(NCCc3ccc(Oc4ccccc4)cc3)c2c1		CHEMBL522502	=	Residual Activity	%	113.0	CHEMBL3045	Homo sapiens	Residual Activity	%	113.0
	12266283	CHEMBL2219401	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	Oc1ccc(-c2nc(-c3ccc(F)cc3)c(-c3ccncc3)[nH]2)cc1		CHEMBL278041	=	Residual Activity	%	85.0	CHEMBL3045	Homo sapiens	Residual Activity	%	85.0
	12266284	CHEMBL2219401	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	N#Cc1cnc2cnc(NCc3cccnc3)cc2c1Nc1ccc(F)c(Cl)c1		CHEMBL200381	=	Residual Activity	%	18.0	CHEMBL3045	Homo sapiens	Residual Activity	%	18.0
	12266285	CHEMBL2219402	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	CC(C)(C)c1cc(C=C(C#N)C#N)cc(Br)c1O		CHEMBL2218926	=	Residual Activity	%	108.0	CHEMBL3045	Homo sapiens	Residual Activity	%	108.0
	12266286	CHEMBL2219402	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	O=C1NC(=O)C(c2c[nH]c3ccccc23)=C1c1c[nH]c2ccccc12		CHEMBL266487	=	Residual Activity	%	75.0	CHEMBL3045	Homo sapiens	Residual Activity	%	75.0
	12266287	CHEMBL2219402	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	O=C(Nc1cccc(Nc2cc(Nc3cccc(C(F)(F)F)c3)ncn2)c1)C1CC1		CHEMBL387187	=	Residual Activity	%	98.0	CHEMBL3045	Homo sapiens	Residual Activity	%	98.0
	12266288	CHEMBL2219402	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	COc1ccc(Cl)cc1NC(=O)Nc1cc(C)nc2ccccc12		CHEMBL439259	=	Residual Activity	%	104.0	CHEMBL3045	Homo sapiens	Residual Activity	%	104.0
	12266289	CHEMBL2219402	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	CNc1cc2c(Nc3cccc(Br)c3)ncnc2cn1		CHEMBL53753	=	Residual Activity	%	104.0	CHEMBL3045	Homo sapiens	Residual Activity	%	104.0
	12266290	CHEMBL2219402	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	Nc1ncnc2c1cnn2-c1ccccc1		CHEMBL65063	=	Residual Activity	%	112.0	CHEMBL3045	Homo sapiens	Residual Activity	%	112.0
	12266291	CHEMBL2219402	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	Cn1cc(/C=C2\C(=O)Nc3ccc(S(N)(=O)=O)cc32)c2ccccc21		CHEMBL104279	=	Residual Activity	%	103.0	CHEMBL3045	Homo sapiens	Residual Activity	%	103.0
	12266292	CHEMBL2219402	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	COc1cc2ncnc(Nc3cccc(Cl)c3)c2cc1OC		CHEMBL7917	=	Residual Activity	%	107.0	CHEMBL3045	Homo sapiens	Residual Activity	%	107.0
	12266293	CHEMBL2219402	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	Cc1nc2cc3nc(-c4cccs4)cnc3cc2n1C		CHEMBL2218927	=	Residual Activity	%	99.0	CHEMBL3045	Homo sapiens	Residual Activity	%	99.0
	12266294	CHEMBL2219402	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	Cn1cnc2cc3c(Nc4cccc(Br)c4)ncnc3cc21		CHEMBL174426	=	Residual Activity	%	100.0	CHEMBL3045	Homo sapiens	Residual Activity	%	100.0
	12266295	CHEMBL2219402	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	CC#CC(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cn1		CHEMBL203644	=	Residual Activity	%	101.0	CHEMBL3045	Homo sapiens	Residual Activity	%	101.0
	12266296	CHEMBL2219402	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	O=C(Nc1nc2ccccc2n1CCN1CCOCC1)c1cccc([N+](=O)[O-])c1		CHEMBL379787	=	Residual Activity	%	102.0	CHEMBL3045	Homo sapiens	Residual Activity	%	102.0
	12266297	CHEMBL2219402	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	CCC(=O)Nc1ccc2ncnc(Nc3cccc(Br)c3)c2c1		CHEMBL188762	=	Residual Activity	%	108.0	CHEMBL3045	Homo sapiens	Residual Activity	%	108.0
	12266298	CHEMBL2219402	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	CC(C)(C)n1nc(Cc2cccc3ccccc23)c2c(N)ncnc21		CHEMBL573578	=	Residual Activity	%	104.0	CHEMBL3045	Homo sapiens	Residual Activity	%	104.0
	12266299	CHEMBL2219402	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	NCCNc1ncc(C(N)=O)c(Nc2cccc(C(F)(F)F)c2)n1		CHEMBL471901	=	Residual Activity	%	92.0	CHEMBL3045	Homo sapiens	Residual Activity	%	92.0
	12266300	CHEMBL2219402	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	CCOC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccccc32)c1C		CHEMBL86943	=	Residual Activity	%	95.0	CHEMBL3045	Homo sapiens	Residual Activity	%	95.0
	12266301	CHEMBL2219402	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	CC[n+]1c(/C=C/N(C)c2ccccc2)n(-c2ccccc2)c2ccc(-c3nc4ccccc4s3)cc21		CHEMBL1186409	=	Residual Activity	%	96.0	CHEMBL3045	Homo sapiens	Residual Activity	%	96.0
	12266302	CHEMBL2219402	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	COc1ccc2c(c[n+](C)c3c4cc5c(cc4ccc23)OCO5)c1OC		CHEMBL13045	=	Residual Activity	%	87.0	CHEMBL3045	Homo sapiens	Residual Activity	%	87.0
	12266303	CHEMBL2219402	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	COc1ccc(C(=O)Nc2sc3c(c2C(N)=O)CCCC3)cc1OC		CHEMBL210833	=	Residual Activity	%	111.0	CHEMBL3045	Homo sapiens	Residual Activity	%	111.0
	12266304	CHEMBL2219402	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	CC(C)(C)c1nc2c3ccc(F)cc3c3c(=O)[nH]ccc3c2[nH]1		CHEMBL21156	=	Residual Activity	%	87.0	CHEMBL3045	Homo sapiens	Residual Activity	%	87.0
	12266305	CHEMBL2219402	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	CCCC(=O)Oc1ccc2[nH]c(C(=O)c3cc4ccccc4[nH]3)cc2c1		CHEMBL266325	=	Residual Activity	%	100.0	CHEMBL3045	Homo sapiens	Residual Activity	%	100.0
	12266306	CHEMBL2219402	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	O=C1NC(=O)c2cc(Nc3ccc(F)cc3)c(Nc3ccc(F)cc3)cc21		CHEMBL7939	=	Residual Activity	%	93.0	CHEMBL3045	Homo sapiens	Residual Activity	%	93.0
	12266307	CHEMBL2219402	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	O=[N+]([O-])/C=C/c1ccc2c(c1)OCO2		CHEMBL596380	=	Residual Activity	%	102.0	CHEMBL3045	Homo sapiens	Residual Activity	%	102.0
	12266308	CHEMBL2219402	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	O=C(Nc1ccc(Cl)cc1)c1ccccc1NCc1ccncc1		CHEMBL101683	=	Residual Activity	%	102.0	CHEMBL3045	Homo sapiens	Residual Activity	%	102.0
	12266309	CHEMBL2219402	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	CN1N=C(N)c2cn([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c3ncnc1c23		CHEMBL331237	=	Residual Activity	%	106.0	CHEMBL3045	Homo sapiens	Residual Activity	%	106.0
	12266310	CHEMBL2219402	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	CCOc1cc2ncnc(Nc3cccc(Br)c3)c2cc1OCC		CHEMBL35820	=	Residual Activity	%	100.0	CHEMBL3045	Homo sapiens	Residual Activity	%	100.0
	12266311	CHEMBL2219402	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	O=C(c1cc2cc(O)ccc2[nH]1)c1cc2cc(O)ccc2[nH]1		CHEMBL377193	=	Residual Activity	%	100.0	CHEMBL3045	Homo sapiens	Residual Activity	%	100.0
	12266312	CHEMBL2219402	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	COc1cc2ncnc(Nc3ccc(O)c(Br)c3)c2cc1OC		CHEMBL473773	=	Residual Activity	%	94.0	CHEMBL3045	Homo sapiens	Residual Activity	%	94.0
	12266313	CHEMBL2219402	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	COc1cc2ncnc(N3CCN(C(=O)Nc4ccc(Oc5ccccc5)cc4)CC3)c2cc1OC		CHEMBL102346	=	Residual Activity	%	101.0	CHEMBL3045	Homo sapiens	Residual Activity	%	101.0
	12266314	CHEMBL2219402	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	O=C1NC(=O)C(c2cn(CCCn3ccnc3)c3ccccc23)=C1Nc1ccccc1		CHEMBL366266	=	Residual Activity	%	27.0	CHEMBL3045	Homo sapiens	Residual Activity	%	27.0
	12266315	CHEMBL2219402	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	c1ccc(-c2n[nH]cc2-c2ccnc3ccccc23)nc1		CHEMBL261454	=	Residual Activity	%	101.0	CHEMBL3045	Homo sapiens	Residual Activity	%	101.0
	12266316	CHEMBL2219402	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC		CHEMBL1289494	=	Residual Activity	%	109.0	CHEMBL3045	Homo sapiens	Residual Activity	%	109.0
	12266317	CHEMBL2219402	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	O=c1[nH]c2ccccc2n1C1CCN(Cc2ccc(-c3nc4cc5[nH]cnc5cc4nc3-c3ccccc3)cc2)CC1		CHEMBL258844	=	Residual Activity	%	88.0	CHEMBL3045	Homo sapiens	Residual Activity	%	88.0
	12266318	CHEMBL2219402	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	O=c1cc(N2CCOCC2)oc2c1ccc1ccccc12		CHEMBL104468	=	Residual Activity	%	95.0	CHEMBL3045	Homo sapiens	Residual Activity	%	95.0
	12266319	CHEMBL2219402	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	COc1ccc(COc2ccc(Cc3cnc(N)nc3N)cc2OC)cc1		CHEMBL261849	=	Residual Activity	%	93.0	CHEMBL3045	Homo sapiens	Residual Activity	%	93.0
	12266320	CHEMBL2219402	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	CC(C)N(CCC(=O)c1ccc2ccccc2c1)Cc1ccccc1		CHEMBL596674	=	Residual Activity	%	92.0	CHEMBL3045	Homo sapiens	Residual Activity	%	92.0
	12266321	CHEMBL2219402	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	COc1cc2c(cc1OC)-c1n[nH]c(Nc3cccc(F)c3)c1C2		CHEMBL120077	=	Residual Activity	%	110.0	CHEMBL3045	Homo sapiens	Residual Activity	%	110.0
	12266322	CHEMBL2219402	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](O)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C		CHEMBL413	=	Residual Activity	%	105.0	CHEMBL3045	Homo sapiens	Residual Activity	%	105.0
	12266323	CHEMBL2219402	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	Cc1cccc(-c2[nH]c(C(C)(C)C)nc2-c2ccc3c(c2)OCO3)n1		CHEMBL226838	=	Residual Activity	%	101.0	CHEMBL3045	Homo sapiens	Residual Activity	%	101.0
	12266324	CHEMBL2219402	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	O=C1Nc2ccc(Br)cc2/C1=C\c1cc2c([nH]1)CCCC2		CHEMBL2218925	=	Residual Activity	%	97.0	CHEMBL3045	Homo sapiens	Residual Activity	%	97.0
	12266325	CHEMBL2219402	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	CCN(CC)CCCCN1c2ccccc2Oc2ccc(Cl)cc21		CHEMBL1398474	=	Residual Activity	%	103.0	CHEMBL3045	Homo sapiens	Residual Activity	%	103.0
	12266326	CHEMBL2219402	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	CC(=O)c1ccc(N2CCOCC2)cc1O		CHEMBL1317546	=	Residual Activity	%	100.0	CHEMBL3045	Homo sapiens	Residual Activity	%	100.0
	12266327	CHEMBL2219402	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	Cn1c2ccccc2c2c3c(c4c5ccccc5n(CCC#N)c4c21)CNC3=O		CHEMBL302449	=	Residual Activity	%	23.0	CHEMBL3045	Homo sapiens	Residual Activity	%	23.0
	12266328	CHEMBL2219402	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	O=C1Nc2ccc(-c3cccnc3)cc2/C1=C\c1ccc[nH]1		CHEMBL2218929	=	Residual Activity	%	83.0	CHEMBL3045	Homo sapiens	Residual Activity	%	83.0
	12266329	CHEMBL2219402	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	COc1cc2nccc(Oc3ccc(NC(=S)NC(=O)c4ccccc4C)cc3)c2cc1OC		CHEMBL2218930	=	Residual Activity	%	98.0	CHEMBL3045	Homo sapiens	Residual Activity	%	98.0
	12266330	CHEMBL2219402	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	c1ccc2c(-c3ccncc3)c[nH]c2c1		CHEMBL380071	=	Residual Activity	%	98.0	CHEMBL3045	Homo sapiens	Residual Activity	%	98.0
	12266331	CHEMBL2219402	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	COc1ccc(C=C(C#N)C#N)cc1		CHEMBL77456	=	Residual Activity	%	91.0	CHEMBL3045	Homo sapiens	Residual Activity	%	91.0
	12266332	CHEMBL2219402	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	Cc1cc(C)c(/C=C2\C(=O)Nc3ccccc32)[nH]1		CHEMBL276711	=	Residual Activity	%	108.0	CHEMBL3045	Homo sapiens	Residual Activity	%	108.0
	12266333	CHEMBL2219402	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	O=C1c2ccccc2-c2nc3nnnn3nc21		CHEMBL599894	=	Residual Activity	%	101.0	CHEMBL3045	Homo sapiens	Residual Activity	%	101.0
	12266334	CHEMBL2219402	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	Oc1cccc(-c2nc(N3CCOCC3)c3oc4ncccc4c3n2)c1		CHEMBL573339	=	Residual Activity	%	98.0	CHEMBL3045	Homo sapiens	Residual Activity	%	98.0
	12266335	CHEMBL2219402	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	COc1ccc2c(c1)c(C1=C(c3c[nH]c4ccccc34)C(=O)NC1=O)cn2CCCN(C)C		CHEMBL261491	=	Residual Activity	%	4.0	CHEMBL3045	Homo sapiens	Residual Activity	%	4.0
	12266336	CHEMBL2219402	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	Nc1ncnc2c1c(-c1ccc(Oc3ccccc3)cc1)cn2C1CCCC1		CHEMBL47940	=	Residual Activity	%	99.0	CHEMBL3045	Homo sapiens	Residual Activity	%	99.0
	12266337	CHEMBL2219402	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	O=C1Nc2ccc3ncsc3c2/C1=C/c1c[nH]cn1		CHEMBL235641	=	Residual Activity	%	67.0	CHEMBL3045	Homo sapiens	Residual Activity	%	67.0
	12266338	CHEMBL2219402	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	Cc1cncc2cccc(S(=O)(=O)N3CCCN(C(=O)CN)C[C@H]3C)c12		CHEMBL2218931	=	Residual Activity	%	95.0	CHEMBL3045	Homo sapiens	Residual Activity	%	95.0
	12266339	CHEMBL2219402	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	N#C/C(=C\c1ccc(O)c(O)c1)C(=O)NCc1ccccc1		CHEMBL56543	=	Residual Activity	%	96.0	CHEMBL3045	Homo sapiens	Residual Activity	%	96.0
	12266340	CHEMBL2219402	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	COc1ccc(-c2cnc3c(-c4ccsc4)cnn3c2)cc1		CHEMBL92461	=	Residual Activity	%	106.0	CHEMBL3045	Homo sapiens	Residual Activity	%	106.0
	12266341	CHEMBL2219402	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	COc1cc2ncnc(Nc3ccc(NC(=O)c4ccccc4)cc3)c2cc1OC		CHEMBL382590	=	Residual Activity	%	100.0	CHEMBL3045	Homo sapiens	Residual Activity	%	100.0
	12266342	CHEMBL2219402	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	O=c1c2ccccc2[nH]c(=S)n1CCN1CCC(=C(c2ccc(F)cc2)c2ccc(F)cc2)CC1		CHEMBL261131	=	Residual Activity	%	101.0	CHEMBL3045	Homo sapiens	Residual Activity	%	101.0
	12266343	CHEMBL2219402	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	c1ccc(-c2n[nH]c3c2oc2ccccc23)cc1		CHEMBL406375	=	Residual Activity	%	96.0	CHEMBL3045	Homo sapiens	Residual Activity	%	96.0
	12266344	CHEMBL2219402	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	O=c1cc(N2CCOCC2)oc2c(-c3ccccc3)cccc12		CHEMBL98350	=	Residual Activity	%	95.0	CHEMBL3045	Homo sapiens	Residual Activity	%	95.0
	12266345	CHEMBL2219402	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	O=C1Nc2ccc(Cl)cc2/C1=C/c1cc(Cl)c(O)c(Cl)c1		CHEMBL2218932	=	Residual Activity	%	97.0	CHEMBL3045	Homo sapiens	Residual Activity	%	97.0
	12266346	CHEMBL2219402	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL608533	=	Residual Activity	%	61.0	CHEMBL3045	Homo sapiens	Residual Activity	%	61.0
	12266347	CHEMBL2219402	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	N#CC(C#N)=C(N)/C(C#N)=C/c1ccc(O)cc1		CHEMBL76589	=	Residual Activity	%	96.0	CHEMBL3045	Homo sapiens	Residual Activity	%	96.0
	12266348	CHEMBL2219402	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	O=C(c1ccccc1)c1ccc(N2CCOCC2)cc1O		CHEMBL478980	=	Residual Activity	%	97.0	CHEMBL3045	Homo sapiens	Residual Activity	%	97.0
	12266349	CHEMBL2219402	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	NC(=O)c1cccc(-c2cc(Nc3ccc(OC(F)(F)F)cc3)ncn2)c1		CHEMBL483847	=	Residual Activity	%	92.0	CHEMBL3045	Homo sapiens	Residual Activity	%	92.0
	12266350	CHEMBL2219402	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	CN(C)c1ccc(/C=C2\C(=O)Nc3ccccc32)cc1		CHEMBL328710	=	Residual Activity	%	94.0	CHEMBL3045	Homo sapiens	Residual Activity	%	94.0
	12266351	CHEMBL2219402	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	CO[C@H]1/C=C/C=C(\C)C(=O)NC2=CC(=O)C=C(C2=O)[C@H](OC)[C@@H](C)C[C@H](OC)[C@H](OC)[C@@H](C)/C=C(\C)[C@@H]1OC(N)=O		CHEMBL479533	=	Residual Activity	%	92.0	CHEMBL3045	Homo sapiens	Residual Activity	%	92.0
	12266352	CHEMBL2219402	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	O=c1cc(N2CCNCC2)oc2c(-c3ccccc3)cccc12		CHEMBL1363184	=	Residual Activity	%	97.0	CHEMBL3045	Homo sapiens	Residual Activity	%	97.0
	12266353	CHEMBL2219402	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	O=C1NC(=O)/C(=C\c2ccc3nccnc3c2)S1		CHEMBL2218934	=	Residual Activity	%	101.0	CHEMBL3045	Homo sapiens	Residual Activity	%	101.0
	12266354	CHEMBL2219402	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	COc1cc2ncnc(Nc3ccc(Oc4ccccc4)cc3)c2cc1OC		CHEMBL97771	=	Residual Activity	%	104.0	CHEMBL3045	Homo sapiens	Residual Activity	%	104.0
	12266355	CHEMBL2219402	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	Cc1cc2ncc(-c3ccccc3)nc2cc1C		CHEMBL7724	=	Residual Activity	%	100.0	CHEMBL3045	Homo sapiens	Residual Activity	%	100.0
	12266356	CHEMBL2219402	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	O=C(Nc1cccc(Nc2nccc(Nc3cccc(C(F)(F)F)c3)n2)c1)C1CC1		CHEMBL383899	=	Residual Activity	%	99.0	CHEMBL3045	Homo sapiens	Residual Activity	%	99.0
	12266357	CHEMBL2219402	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	CN(C)CCCn1cc(C2=C(c3c[nH]c4ccccc34)C(=O)NC2=O)c2ccccc21		CHEMBL7463	=	Residual Activity	%	9.0	CHEMBL3045	Homo sapiens	Residual Activity	%	9.0
	12266358	CHEMBL2219402	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	COc1cc2ncnc(Nc3ccc(OCc4ccccc4)cc3)c2cc1OC		CHEMBL563845	=	Residual Activity	%	105.0	CHEMBL3045	Homo sapiens	Residual Activity	%	105.0
	12266359	CHEMBL2219402	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	c1ccc(-c2cnc(Nc3ccc(OCCN4CCCC4)cc3)s2)cc1		CHEMBL2218935	=	Residual Activity	%	97.0	CHEMBL3045	Homo sapiens	Residual Activity	%	97.0
	12266360	CHEMBL2219402	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	CC1=C(C(=O)N2CCN(C)CC2)C(C)=C(/C=C2\C(=O)Nc3ccc(S(=O)(=O)N(C)c4cccc(Cl)c4)cc32)C1		CHEMBL2218936	=	Residual Activity	%	99.0	CHEMBL3045	Homo sapiens	Residual Activity	%	99.0
	12266361	CHEMBL2219402	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	O=C1NC(=O)/C(=C/c2ccc3c(c2)OC(F)(F)O3)S1		CHEMBL1231533	=	Residual Activity	%	98.0	CHEMBL3045	Homo sapiens	Residual Activity	%	98.0
	12266362	CHEMBL2219402	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(Cl)cc32)c1C		CHEMBL13485	=	Residual Activity	%	105.0	CHEMBL3045	Homo sapiens	Residual Activity	%	105.0
	12266363	CHEMBL2219402	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	COc1cc2ncc(-c3ccccc3)nc2cc1OC		CHEMBL71191	=	Residual Activity	%	97.0	CHEMBL3045	Homo sapiens	Residual Activity	%	97.0
	12266364	CHEMBL2219402	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL388978	=	Residual Activity	%	2.0	CHEMBL3045	Homo sapiens	Residual Activity	%	2.0
	12266365	CHEMBL2219402	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	CN([C@@H](Cc1ccc(OS(=O)(=O)c2cccc3cnccc23)cc1)C(=O)N1CCN(c2ccccc2)CC1)S(=O)(=O)c1cccc2cnccc12		CHEMBL28324	=	Residual Activity	%	110.0	CHEMBL3045	Homo sapiens	Residual Activity	%	110.0
	12266366	CHEMBL2219402	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	Nc1nc(Nc2ccc(S(N)(=O)=O)cc2)nn1C(=O)c1c(F)cccc1F		CHEMBL191003	=	Residual Activity	%	90.0	CHEMBL3045	Homo sapiens	Residual Activity	%	90.0
	12266367	CHEMBL2219402	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	O=C1NC(=O)c2c1c1c3ccccc3[nH]c1c1[nH]c3cc(Br)ccc3c21		CHEMBL64758	=	Residual Activity	%	104.0	CHEMBL3045	Homo sapiens	Residual Activity	%	104.0
	12266368	CHEMBL2219402	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	C[C@@H](N)[C@H]1CC[C@H](C(=O)Nc2ccncc2)CC1		CHEMBL559147	=	Residual Activity	%	81.0	CHEMBL3045	Homo sapiens	Residual Activity	%	81.0
	12266369	CHEMBL2219402	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	CN(C)S(=O)(=O)c1ccc2c(c1)/C(=C/c1cc3c([nH]1)CCCC3)C(=O)N2		CHEMBL605003	=	Residual Activity	%	116.0	CHEMBL3045	Homo sapiens	Residual Activity	%	116.0
	12266370	CHEMBL2219402	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	O=C(CCCc1ccc(-c2ccccc2F)cc1)Nc1ccc(O)cc1		CHEMBL235658	=	Residual Activity	%	108.0	CHEMBL3045	Homo sapiens	Residual Activity	%	108.0
	12266371	CHEMBL2219402	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	CSc1nc(-c2ccc(F)cc2)c(-c2ccnc(NC(C)c3ccccc3)c2)[nH]1		CHEMBL111364	=	Residual Activity	%	108.0	CHEMBL3045	Homo sapiens	Residual Activity	%	108.0
	12266372	CHEMBL2219402	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	C[S+]([O-])c1ccc(-c2nc(-c3ccc(F)cc3)c(-c3ccncc3)[nH]2)cc1		CHEMBL10	=	Residual Activity	%	104.0	CHEMBL3045	Homo sapiens	Residual Activity	%	104.0
	12266373	CHEMBL2219402	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	O=c1cc(-c2cccc3c2Sc2ccccc2S3)oc(N2CCOCC2)c1		CHEMBL222102	=	Residual Activity	%	104.0	CHEMBL3045	Homo sapiens	Residual Activity	%	104.0
	12266374	CHEMBL2219402	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	O=Nc1c(-c2c(O)[nH]c3ccccc23)[nH]c2ccccc12		CHEMBL126077	=	Residual Activity	%	95.0	CHEMBL3045	Homo sapiens	Residual Activity	%	95.0
	12266375	CHEMBL2219402	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	COc1ccc(OC)c2c(=S)c3ccccc3[nH]c12		CHEMBL1331734	=	Residual Activity	%	106.0	CHEMBL3045	Homo sapiens	Residual Activity	%	106.0
	12266376	CHEMBL2219402	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	Nc1n[nH]c2nnc(-c3c(-c4ccccc4)nn4ccccc34)cc12		CHEMBL259551	=	Residual Activity	%	102.0	CHEMBL3045	Homo sapiens	Residual Activity	%	102.0
	12266377	CHEMBL2219402	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	Cc1cc(Nc2nc(-c3ccccc3)nc3ccccc23)n[nH]1		CHEMBL359482	=	Residual Activity	%	106.0	CHEMBL3045	Homo sapiens	Residual Activity	%	106.0
	12266378	CHEMBL2219402	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	CCOc1nc(NC(=O)Cc2cc(OC)ccc2OC)cc(N)c1C#N		CHEMBL210618	=	Residual Activity	%	113.0	CHEMBL3045	Homo sapiens	Residual Activity	%	113.0
	12266379	CHEMBL2219402	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	Oc1c(-c2ccc(F)cc2)c(-c2ccncc2)nn1-c1ccc(Cl)cc1		CHEMBL91730	=	Residual Activity	%	109.0	CHEMBL3045	Homo sapiens	Residual Activity	%	109.0
	12266380	CHEMBL2219402	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	O=S(=O)(c1cccc2cnccc12)N1CCCNCC1		CHEMBL38380	=	Residual Activity	%	87.0	CHEMBL3045	Homo sapiens	Residual Activity	%	87.0
	12266381	CHEMBL2219402	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	O=C(NC(NC(=S)Nc1ccc(F)c([N+](=O)[O-])c1)C(Cl)(Cl)Cl)C(c1ccccc1)c1ccccc1		CHEMBL1221601	=	Residual Activity	%	106.0	CHEMBL3045	Homo sapiens	Residual Activity	%	106.0
	12266382	CHEMBL2219402	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	Cc1ccc(S(=O)(=O)/C=C/C#N)cc1		CHEMBL403183	=	Residual Activity	%	104.0	CHEMBL3045	Homo sapiens	Residual Activity	%	104.0
	12266383	CHEMBL2219402	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	Cc1ccc(NC2=CC(=O)c3sc(C)nc3C2=O)cc1		CHEMBL290904	=	Residual Activity	%	112.0	CHEMBL3045	Homo sapiens	Residual Activity	%	112.0
	12266384	CHEMBL2219402	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	Oc1n[nH]c2nnc(-c3c(-c4ccccc4)nn4ccccc34)cc12		CHEMBL2218938	=	Residual Activity	%	103.0	CHEMBL3045	Homo sapiens	Residual Activity	%	103.0
	12266385	CHEMBL2219402	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	O=C1NC(=O)c2c1c1c3ccccc3[nH]c1n1cncc21		CHEMBL413188	=	Residual Activity	%	108.0	CHEMBL3045	Homo sapiens	Residual Activity	%	108.0
	12266386	CHEMBL2219402	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	COC(=O)[C@@]1(O)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL281948	=	Residual Activity	%	67.0	CHEMBL3045	Homo sapiens	Residual Activity	%	67.0
	12266387	CHEMBL2219402	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	COc1cccc(-c2cc(=O)c3ccccc3o2)c1N		CHEMBL35482	=	Residual Activity	%	121.0	CHEMBL3045	Homo sapiens	Residual Activity	%	121.0
	12266388	CHEMBL2219402	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	O=C1NC(=O)c2c1c1c3ccccc3n3c1c1c2c2ccccc2n1C1CCC3O1		CHEMBL304428	=	Residual Activity	%	112.0	CHEMBL3045	Homo sapiens	Residual Activity	%	112.0
	12266389	CHEMBL2219402	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	O=C1Cc2c([nH]c3ccc([N+](=O)[O-])cc23)-c2ccccc2N1		CHEMBL50894	=	Residual Activity	%	99.0	CHEMBL3045	Homo sapiens	Residual Activity	%	99.0
	12266390	CHEMBL2219402	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	CC(C)n1cnc2c(NCc3ccccc3)nc(NCCCO)nc21		CHEMBL83980	=	Residual Activity	%	105.0	CHEMBL3045	Homo sapiens	Residual Activity	%	105.0
	12266391	CHEMBL2219402	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	CCN1/C(=C/C(C)=O)Sc2ccc(OC)cc21		CHEMBL408982	=	Residual Activity	%	99.0	CHEMBL3045	Homo sapiens	Residual Activity	%	99.0
	12266392	CHEMBL2219402	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	O=C1c2ccccc2-[n+]2ccc3c([nH]c4ccccc43)c21		CHEMBL602937	=	Residual Activity	%	93.0	CHEMBL3045	Homo sapiens	Residual Activity	%	93.0
	12266393	CHEMBL2219402	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	COc1cc(OC)c(/C=C2\C(=O)Nc3ccccc32)c(OC)c1		CHEMBL404941	=	Residual Activity	%	103.0	CHEMBL3045	Homo sapiens	Residual Activity	%	103.0
	12266394	CHEMBL2219402	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	O=C1Cc2c([nH]c3ccc(Br)cc23)-c2ccccc2N1		CHEMBL296586	=	Residual Activity	%	117.0	CHEMBL3045	Homo sapiens	Residual Activity	%	117.0
	12266395	CHEMBL2219402	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	O=[N+]([O-])c1ccc(-c2nc(-c3ccc(F)cc3)c(-c3ccncc3)[nH]2)cc1		CHEMBL17331	=	Residual Activity	%	107.0	CHEMBL3045	Homo sapiens	Residual Activity	%	107.0
	12266396	CHEMBL2219402	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	Cc1nc(-c2ccccc2)c(-c2ccncc2)o1		CHEMBL36450	=	Residual Activity	%	106.0	CHEMBL3045	Homo sapiens	Residual Activity	%	106.0
	12266397	CHEMBL2219402	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	N#CCCc1ccc2c(c1)-c1[nH]c3ccc([N+](=O)[O-])cc3c1CC(=O)N2		CHEMBL260138	=	Residual Activity	%	105.0	CHEMBL3045	Homo sapiens	Residual Activity	%	105.0
	12266398	CHEMBL2219402	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	O=C1Nc2ccccc2/C1=C\c1c(Cl)[nH]c2ccccc12		CHEMBL261425	=	Residual Activity	%	97.0	CHEMBL3045	Homo sapiens	Residual Activity	%	97.0
	12266399	CHEMBL2219402	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	NC(=O)c1ccc2[nH]c(-c3ccc(Oc4ccc(Cl)cc4)cc3)nc2c1		CHEMBL179583	=	Residual Activity	%	95.0	CHEMBL3045	Homo sapiens	Residual Activity	%	95.0
	12266400	CHEMBL2219402	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	Cn1sc(=O)n(Cc2ccccc2)c1=O		CHEMBL284861	=	Residual Activity	%	89.0	CHEMBL3045	Homo sapiens	Residual Activity	%	89.0
	12266401	CHEMBL2219402	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	NC(=O)Nc1sc(-c2ccc(F)cc2)cc1C(N)=O		CHEMBL257167	=	Residual Activity	%	105.0	CHEMBL3045	Homo sapiens	Residual Activity	%	105.0
	12266402	CHEMBL2219402	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	COc1ccc(S(=O)(=O)N(CCO)c2ccccc2CN(C)C/C=C/c2ccc(Cl)cc2)cc1		CHEMBL155333	=	Residual Activity	%	115.0	CHEMBL3045	Homo sapiens	Residual Activity	%	115.0
	12266403	CHEMBL2219402	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	Nc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCNCC2)n1		CHEMBL274064	=	Residual Activity	%	98.0	CHEMBL3045	Homo sapiens	Residual Activity	%	98.0
	12266404	CHEMBL2219402	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	Fc1ccc(-c2nc3n(c2-c2ccncc2)CCS3)cc1		CHEMBL313417	=	Residual Activity	%	109.0	CHEMBL3045	Homo sapiens	Residual Activity	%	109.0
	12266405	CHEMBL2219402	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	CCCCc1c(-c2ccc(O)cc2)[nH]c2nccnc12		CHEMBL75680	=	Residual Activity	%	104.0	CHEMBL3045	Homo sapiens	Residual Activity	%	104.0
	12266406	CHEMBL2219402	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	CCn1cnc2c(Nc3cccc(Cl)c3)nc(N[C@@H]3CCCC[C@@H]3N)nc21		CHEMBL367625	=	Residual Activity	%	99.0	CHEMBL3045	Homo sapiens	Residual Activity	%	99.0
	12266407	CHEMBL2219402	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	CC(C)n1cnc2/c(=N/c3cccc(Cl)c3)nc(NCCO)[nH]c21		CHEMBL311228	=	Residual Activity	%	101.0	CHEMBL3045	Homo sapiens	Residual Activity	%	101.0
	12266408	CHEMBL2219402	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	Ic1cccc(CSc2nnc(-c3ccncc3)o2)c1		CHEMBL288064	=	Residual Activity	%	95.0	CHEMBL3045	Homo sapiens	Residual Activity	%	95.0
	12266409	CHEMBL2219402	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	O=C1Nc2ccccc2/C1=C1/Nc2ccccc2/C1=N\OCCC(O)CO		CHEMBL1802727	=	Residual Activity	%	97.0	CHEMBL3045	Homo sapiens	Residual Activity	%	97.0
	12266410	CHEMBL2219402	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	N#C/C(=C(/N)SC1C=CC=CC1)c1cccc(C(O)c2ccncc2)c1		CHEMBL2218939	=	Residual Activity	%	114.0	CHEMBL3045	Homo sapiens	Residual Activity	%	114.0
	12266411	CHEMBL2219402	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	CC(C)[C@H](CO)Nc1nc(Nc2cccc(Cl)c2)c2ncn(C(C)C)c2n1		CHEMBL23327	=	Residual Activity	%	120.0	CHEMBL3045	Homo sapiens	Residual Activity	%	120.0
	12266412	CHEMBL2219402	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	Oc1ccc(Nc2nc(-c3ccc(Cl)cc3)cs2)cc1		CHEMBL1076555	=	Residual Activity	%	121.0	CHEMBL3045	Homo sapiens	Residual Activity	%	121.0
	12266413	CHEMBL2219402	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	CCCCc1c(-c2ccc(OC)cc2)[nH]c2nccnc12		CHEMBL306498	=	Residual Activity	%	104.0	CHEMBL3045	Homo sapiens	Residual Activity	%	104.0
	12266414	CHEMBL2219402	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	Nc1nc(Nc2ccc(S(N)(=O)=O)cc2)nn1C(=S)Nc1c(F)cccc1F		CHEMBL261720	=	Residual Activity	%	88.0	CHEMBL3045	Homo sapiens	Residual Activity	%	88.0
	12266415	CHEMBL2219402	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	COc1ccc(CNc2nc(N(CCO)CCO)nc3c2ncn3C(C)C)cc1		CHEMBL80713	=	Residual Activity	%	87.0	CHEMBL3045	Homo sapiens	Residual Activity	%	87.0
	12266416	CHEMBL2219402	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	COc1ccc(CNC(=O)Nc2ncc([N+](=O)[O-])s2)cc1		CHEMBL259850	=	Residual Activity	%	99.0	CHEMBL3045	Homo sapiens	Residual Activity	%	99.0
	12266417	CHEMBL2219402	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	Oc1c2ccccc2c2c3c(cccc13)N=N2		CHEMBL1725279	=	Residual Activity	%	108.0	CHEMBL3045	Homo sapiens	Residual Activity	%	108.0
	12268060	CHEMBL2219402	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	O=C1C(Cl)=C(N2C(=O)CCC2=O)C(=O)c2ccccc21		CHEMBL404939	=	Residual Activity	%	114.0	CHEMBL3045	Homo sapiens	Residual Activity	%	114.0
	12268061	CHEMBL2219402	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	Nc1cccc(-c2cc3c(Oc4cccc(O)c4)ncnc3[nH]2)c1		CHEMBL405759	=	Residual Activity	%	104.0	CHEMBL3045	Homo sapiens	Residual Activity	%	104.0
	12268062	CHEMBL2219402	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	CC(C)[C@H](CO)Nc1nc(Nc2cc(N)cc(Cl)c2)c2ncn(C(C)C)c2n1		CHEMBL286721	=	Residual Activity	%	101.0	CHEMBL3045	Homo sapiens	Residual Activity	%	101.0
	12268063	CHEMBL2219402	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	Nc1n[nH]c2nc3ccccc3nc12		CHEMBL259389	=	Residual Activity	%	109.0	CHEMBL3045	Homo sapiens	Residual Activity	%	109.0
	12268064	CHEMBL2219402	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	CCN(CC)C(=O)c1ccc(Nc2nc(OCC3CCCCC3)c3nc[nH]c3n2)cc1		CHEMBL1802728	=	Residual Activity	%	105.0	CHEMBL3045	Homo sapiens	Residual Activity	%	105.0
	12268065	CHEMBL2219402	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	O=C1Nc2cc(Br)ccc2/C1=C1/Nc2ccccc2/C1=N\O		CHEMBL409450	=	Residual Activity	%	102.0	CHEMBL3045	Homo sapiens	Residual Activity	%	102.0
	12268066	CHEMBL2219402	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	Cn1nc2c3c(cccc31)C(=O)c1ccccc1-2		CHEMBL1802485	=	Residual Activity	%	109.0	CHEMBL3045	Homo sapiens	Residual Activity	%	109.0
	12268067	CHEMBL2219402	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	N#C/C(=C(\N)Sc1ccc(N)cc1)c1ccccc1C(F)(F)F		CHEMBL2218940	=	Residual Activity	%	114.0	CHEMBL3045	Homo sapiens	Residual Activity	%	114.0
	12268068	CHEMBL2219402	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	O=S(=O)(NCCNC/C=C/c1ccc(Br)cc1)c1cccc2cnccc12		CHEMBL104264	=	Residual Activity	%	86.0	CHEMBL3045	Homo sapiens	Residual Activity	%	86.0
	12268069	CHEMBL2219402	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	O=C(O)c1ccc2c3c1cccc3c(=O)n1c3ccccc3nc21		CHEMBL1182777	=	Residual Activity	%	115.0	CHEMBL3045	Homo sapiens	Residual Activity	%	115.0
	12268070	CHEMBL2219402	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	c1cc(-c2cnn3cc(-c4ccc(OCCN5CCCCC5)cc4)cnc23)ccn1		CHEMBL478629	=	Residual Activity	%	101.0	CHEMBL3045	Homo sapiens	Residual Activity	%	101.0
	12268071	CHEMBL2219402	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	NC(=O)c1ccc(-c2nc(-c3ccc4c(c3)OCCO4)c(-c3ccccn3)[nH]2)cc1		CHEMBL410456	=	Residual Activity	%	101.0	CHEMBL3045	Homo sapiens	Residual Activity	%	101.0
	12268072	CHEMBL2219402	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	CC(C)c1nn(-c2c(Cl)cccc2Cl)c2nc(Cc3ccc(OCCO)cc3)[nH]c(=O)c12		CHEMBL258721	=	Residual Activity	%	104.0	CHEMBL3045	Homo sapiens	Residual Activity	%	104.0
	12268073	CHEMBL2219402	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	CC(=O)O/N=C1C(=C2\C(=O)Nc3cc(Br)ccc32)\Nc2ccccc2\1		CHEMBL2218941	=	Residual Activity	%	105.0	CHEMBL3045	Homo sapiens	Residual Activity	%	105.0
	12268074	CHEMBL2219402	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	N#C/C(=C1/Nc2ccccc2S1)c1ccnc(NCCc2cccnc2)n1		CHEMBL191384	=	Residual Activity	%	104.0	CHEMBL3045	Homo sapiens	Residual Activity	%	104.0
	12268075	CHEMBL2219402	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	Nc1ncnc2[nH]nc(Nc3ccc(F)cc3)c12		CHEMBL1240885	=	Residual Activity	%	113.0	CHEMBL3045	Homo sapiens	Residual Activity	%	113.0
	12268076	CHEMBL2219402	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	CCc1nc(-c2ccc(OC)cc2)[nH]c1-c1ccncc1		CHEMBL278724	=	Residual Activity	%	114.0	CHEMBL3045	Homo sapiens	Residual Activity	%	114.0
	12268077	CHEMBL2219402	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	COc1ccc2c(c1)/C(=C/c1cnc[nH]1)C(=O)N2		CHEMBL258805	=	Residual Activity	%	133.0	CHEMBL3045	Homo sapiens	Residual Activity	%	133.0
	12268078	CHEMBL2219402	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	O=C(O)/C=C/c1cc(Br)c(Br)c(Br)c1Br		CHEMBL270724	=	Residual Activity	%	97.0	CHEMBL3045	Homo sapiens	Residual Activity	%	97.0
	12268079	CHEMBL2219402	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	N/C(=N\[N+](=O)[O-])N/N=C\c1ccc(-c2cccc([N+](=O)[O-])c2)o1		CHEMBL221271	=	Residual Activity	%	111.0	CHEMBL3045	Homo sapiens	Residual Activity	%	111.0
	12268080	CHEMBL2219402	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	O=C1NC(=O)C(c2cn(CCCO)c3ncccc23)=C1c1cnccn1		CHEMBL272629	=	Residual Activity	%	110.0	CHEMBL3045	Homo sapiens	Residual Activity	%	110.0
	12268081	CHEMBL2219402	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	N#Cc1c(NC(=O)c2cccc3ccccc23)sc2c1CCCC2		CHEMBL233001	=	Residual Activity	%	111.0	CHEMBL3045	Homo sapiens	Residual Activity	%	111.0
	12268082	CHEMBL2219402	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	Nc1ccc2ncnc(NCCc3ccc(Oc4ccccc4)cc3)c2c1		CHEMBL522502	=	Residual Activity	%	118.0	CHEMBL3045	Homo sapiens	Residual Activity	%	118.0
	12268083	CHEMBL2219402	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	Oc1ccc(-c2nc(-c3ccc(F)cc3)c(-c3ccncc3)[nH]2)cc1		CHEMBL278041	=	Residual Activity	%	110.0	CHEMBL3045	Homo sapiens	Residual Activity	%	110.0
	12268084	CHEMBL2219402	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	N#Cc1cnc2cnc(NCc3cccnc3)cc2c1Nc1ccc(F)c(Cl)c1		CHEMBL200381	=	Residual Activity	%	105.0	CHEMBL3045	Homo sapiens	Residual Activity	%	105.0
	12268085	CHEMBL2219403	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	CC(C)(C)c1cc(C=C(C#N)C#N)cc(Br)c1O		CHEMBL2218926	=	Residual Activity	%	108.0	CHEMBL3045	Homo sapiens	Residual Activity	%	108.0
	12268086	CHEMBL2219403	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	O=C1NC(=O)C(c2c[nH]c3ccccc23)=C1c1c[nH]c2ccccc12		CHEMBL266487	=	Residual Activity	%	27.0	CHEMBL3045	Homo sapiens	Residual Activity	%	27.0
	12268087	CHEMBL2219403	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	O=C(Nc1cccc(Nc2cc(Nc3cccc(C(F)(F)F)c3)ncn2)c1)C1CC1		CHEMBL387187	=	Residual Activity	%	97.0	CHEMBL3045	Homo sapiens	Residual Activity	%	97.0
	12268088	CHEMBL2219403	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	COc1ccc(Cl)cc1NC(=O)Nc1cc(C)nc2ccccc12		CHEMBL439259	=	Residual Activity	%	97.0	CHEMBL3045	Homo sapiens	Residual Activity	%	97.0
	12268089	CHEMBL2219403	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	CNc1cc2c(Nc3cccc(Br)c3)ncnc2cn1		CHEMBL53753	=	Residual Activity	%	103.0	CHEMBL3045	Homo sapiens	Residual Activity	%	103.0
	12268090	CHEMBL2219403	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	Nc1ncnc2c1cnn2-c1ccccc1		CHEMBL65063	=	Residual Activity	%	103.0	CHEMBL3045	Homo sapiens	Residual Activity	%	103.0
	12268091	CHEMBL2219403	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	Cn1cc(/C=C2\C(=O)Nc3ccc(S(N)(=O)=O)cc32)c2ccccc21		CHEMBL104279	=	Residual Activity	%	108.0	CHEMBL3045	Homo sapiens	Residual Activity	%	108.0
	12268092	CHEMBL2219403	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	COc1cc2ncnc(Nc3cccc(Cl)c3)c2cc1OC		CHEMBL7917	=	Residual Activity	%	108.0	CHEMBL3045	Homo sapiens	Residual Activity	%	108.0
	12268093	CHEMBL2219403	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	Cc1nc2cc3nc(-c4cccs4)cnc3cc2n1C		CHEMBL2218927	=	Residual Activity	%	99.0	CHEMBL3045	Homo sapiens	Residual Activity	%	99.0
	12268094	CHEMBL2219403	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	Cn1cnc2cc3c(Nc4cccc(Br)c4)ncnc3cc21		CHEMBL174426	=	Residual Activity	%	95.0	CHEMBL3045	Homo sapiens	Residual Activity	%	95.0
	12268095	CHEMBL2219403	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	CC#CC(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cn1		CHEMBL203644	=	Residual Activity	%	101.0	CHEMBL3045	Homo sapiens	Residual Activity	%	101.0
	12268096	CHEMBL2219403	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	O=C(Nc1nc2ccccc2n1CCN1CCOCC1)c1cccc([N+](=O)[O-])c1		CHEMBL379787	=	Residual Activity	%	108.0	CHEMBL3045	Homo sapiens	Residual Activity	%	108.0
	12268097	CHEMBL2219403	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	CCC(=O)Nc1ccc2ncnc(Nc3cccc(Br)c3)c2c1		CHEMBL188762	=	Residual Activity	%	104.0	CHEMBL3045	Homo sapiens	Residual Activity	%	104.0
	12268098	CHEMBL2219403	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	CC(C)(C)n1nc(Cc2cccc3ccccc23)c2c(N)ncnc21		CHEMBL573578	=	Residual Activity	%	105.0	CHEMBL3045	Homo sapiens	Residual Activity	%	105.0
	12268099	CHEMBL2219403	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	NCCNc1ncc(C(N)=O)c(Nc2cccc(C(F)(F)F)c2)n1		CHEMBL471901	=	Residual Activity	%	66.0	CHEMBL3045	Homo sapiens	Residual Activity	%	66.0
	12268100	CHEMBL2219403	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	CCOC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccccc32)c1C		CHEMBL86943	=	Residual Activity	%	101.0	CHEMBL3045	Homo sapiens	Residual Activity	%	101.0
	12268101	CHEMBL2219403	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	CC[n+]1c(/C=C/N(C)c2ccccc2)n(-c2ccccc2)c2ccc(-c3nc4ccccc4s3)cc21		CHEMBL1186409	=	Residual Activity	%	92.0	CHEMBL3045	Homo sapiens	Residual Activity	%	92.0
	12268102	CHEMBL2219403	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	COc1ccc2c(c[n+](C)c3c4cc5c(cc4ccc23)OCO5)c1OC		CHEMBL13045	=	Residual Activity	%	103.0	CHEMBL3045	Homo sapiens	Residual Activity	%	103.0
	12268103	CHEMBL2219403	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	COc1ccc(C(=O)Nc2sc3c(c2C(N)=O)CCCC3)cc1OC		CHEMBL210833	=	Residual Activity	%	101.0	CHEMBL3045	Homo sapiens	Residual Activity	%	101.0
	12268104	CHEMBL2219403	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	CC(C)(C)c1nc2c3ccc(F)cc3c3c(=O)[nH]ccc3c2[nH]1		CHEMBL21156	=	Residual Activity	%	94.0	CHEMBL3045	Homo sapiens	Residual Activity	%	94.0
	12268105	CHEMBL2219403	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	CCCC(=O)Oc1ccc2[nH]c(C(=O)c3cc4ccccc4[nH]3)cc2c1		CHEMBL266325	=	Residual Activity	%	106.0	CHEMBL3045	Homo sapiens	Residual Activity	%	106.0
	12268106	CHEMBL2219403	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	O=C1NC(=O)c2cc(Nc3ccc(F)cc3)c(Nc3ccc(F)cc3)cc21		CHEMBL7939	=	Residual Activity	%	103.0	CHEMBL3045	Homo sapiens	Residual Activity	%	103.0
	12268107	CHEMBL2219403	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	O=[N+]([O-])/C=C/c1ccc2c(c1)OCO2		CHEMBL596380	=	Residual Activity	%	106.0	CHEMBL3045	Homo sapiens	Residual Activity	%	106.0
	12268108	CHEMBL2219403	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	O=C(Nc1ccc(Cl)cc1)c1ccccc1NCc1ccncc1		CHEMBL101683	=	Residual Activity	%	107.0	CHEMBL3045	Homo sapiens	Residual Activity	%	107.0
	12268109	CHEMBL2219403	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	CN1N=C(N)c2cn([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c3ncnc1c23		CHEMBL331237	=	Residual Activity	%	106.0	CHEMBL3045	Homo sapiens	Residual Activity	%	106.0
	12268110	CHEMBL2219403	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	CCOc1cc2ncnc(Nc3cccc(Br)c3)c2cc1OCC		CHEMBL35820	=	Residual Activity	%	103.0	CHEMBL3045	Homo sapiens	Residual Activity	%	103.0
	12268111	CHEMBL2219403	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	O=C(c1cc2cc(O)ccc2[nH]1)c1cc2cc(O)ccc2[nH]1		CHEMBL377193	=	Residual Activity	%	93.0	CHEMBL3045	Homo sapiens	Residual Activity	%	93.0
	12268112	CHEMBL2219403	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	COc1cc2ncnc(Nc3ccc(O)c(Br)c3)c2cc1OC		CHEMBL473773	=	Residual Activity	%	97.0	CHEMBL3045	Homo sapiens	Residual Activity	%	97.0
	12268113	CHEMBL2219403	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	COc1cc2ncnc(N3CCN(C(=O)Nc4ccc(Oc5ccccc5)cc4)CC3)c2cc1OC		CHEMBL102346	=	Residual Activity	%	102.0	CHEMBL3045	Homo sapiens	Residual Activity	%	102.0
	12268114	CHEMBL2219403	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	O=C1NC(=O)C(c2cn(CCCn3ccnc3)c3ccccc23)=C1Nc1ccccc1		CHEMBL366266	=	Residual Activity	%	6.0	CHEMBL3045	Homo sapiens	Residual Activity	%	6.0
	12268115	CHEMBL2219403	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	c1ccc(-c2n[nH]cc2-c2ccnc3ccccc23)nc1		CHEMBL261454	=	Residual Activity	%	94.0	CHEMBL3045	Homo sapiens	Residual Activity	%	94.0
	12268116	CHEMBL2219403	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC		CHEMBL1289494	=	Residual Activity	%	104.0	CHEMBL3045	Homo sapiens	Residual Activity	%	104.0
	12268117	CHEMBL2219403	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	O=c1[nH]c2ccccc2n1C1CCN(Cc2ccc(-c3nc4cc5[nH]cnc5cc4nc3-c3ccccc3)cc2)CC1		CHEMBL258844	=	Residual Activity	%	93.0	CHEMBL3045	Homo sapiens	Residual Activity	%	93.0
	12268118	CHEMBL2219403	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	O=c1cc(N2CCOCC2)oc2c1ccc1ccccc12		CHEMBL104468	=	Residual Activity	%	92.0	CHEMBL3045	Homo sapiens	Residual Activity	%	92.0
	12268119	CHEMBL2219403	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	COc1ccc(COc2ccc(Cc3cnc(N)nc3N)cc2OC)cc1		CHEMBL261849	=	Residual Activity	%	96.0	CHEMBL3045	Homo sapiens	Residual Activity	%	96.0
	12268120	CHEMBL2219403	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	CC(C)N(CCC(=O)c1ccc2ccccc2c1)Cc1ccccc1		CHEMBL596674	=	Residual Activity	%	88.0	CHEMBL3045	Homo sapiens	Residual Activity	%	88.0
	12268121	CHEMBL2219403	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	COc1cc2c(cc1OC)-c1n[nH]c(Nc3cccc(F)c3)c1C2		CHEMBL120077	=	Residual Activity	%	105.0	CHEMBL3045	Homo sapiens	Residual Activity	%	105.0
	12268122	CHEMBL2219403	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](O)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C		CHEMBL413	=	Residual Activity	%	103.0	CHEMBL3045	Homo sapiens	Residual Activity	%	103.0
	12268123	CHEMBL2219403	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	Cc1cccc(-c2[nH]c(C(C)(C)C)nc2-c2ccc3c(c2)OCO3)n1		CHEMBL226838	=	Residual Activity	%	105.0	CHEMBL3045	Homo sapiens	Residual Activity	%	105.0
	12268124	CHEMBL2219403	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	O=C1Nc2ccc(Br)cc2/C1=C\c1cc2c([nH]1)CCCC2		CHEMBL2218925	=	Residual Activity	%	97.0	CHEMBL3045	Homo sapiens	Residual Activity	%	97.0
	12268125	CHEMBL2219403	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	CCN(CC)CCCCN1c2ccccc2Oc2ccc(Cl)cc21		CHEMBL1398474	=	Residual Activity	%	95.0	CHEMBL3045	Homo sapiens	Residual Activity	%	95.0
	12268126	CHEMBL2219403	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	CC(=O)c1ccc(N2CCOCC2)cc1O		CHEMBL1317546	=	Residual Activity	%	93.0	CHEMBL3045	Homo sapiens	Residual Activity	%	93.0
	12268127	CHEMBL2219403	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	Cn1c2ccccc2c2c3c(c4c5ccccc5n(CCC#N)c4c21)CNC3=O		CHEMBL302449	=	Residual Activity	%	29.0	CHEMBL3045	Homo sapiens	Residual Activity	%	29.0
	12268128	CHEMBL2219403	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	O=C1Nc2ccc(-c3cccnc3)cc2/C1=C\c1ccc[nH]1		CHEMBL2218929	=	Residual Activity	%	50.0	CHEMBL3045	Homo sapiens	Residual Activity	%	50.0
	12268129	CHEMBL2219403	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	COc1cc2nccc(Oc3ccc(NC(=S)NC(=O)c4ccccc4C)cc3)c2cc1OC		CHEMBL2218930	=	Residual Activity	%	101.0	CHEMBL3045	Homo sapiens	Residual Activity	%	101.0
	12268130	CHEMBL2219403	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	c1ccc2c(-c3ccncc3)c[nH]c2c1		CHEMBL380071	=	Residual Activity	%	65.0	CHEMBL3045	Homo sapiens	Residual Activity	%	65.0
	12268131	CHEMBL2219403	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	COc1ccc(C=C(C#N)C#N)cc1		CHEMBL77456	=	Residual Activity	%	93.0	CHEMBL3045	Homo sapiens	Residual Activity	%	93.0
	12268132	CHEMBL2219403	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	Cc1cc(C)c(/C=C2\C(=O)Nc3ccccc32)[nH]1		CHEMBL276711	=	Residual Activity	%	103.0	CHEMBL3045	Homo sapiens	Residual Activity	%	103.0
	12268133	CHEMBL2219403	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	O=C1c2ccccc2-c2nc3nnnn3nc21		CHEMBL599894	=	Residual Activity	%	88.0	CHEMBL3045	Homo sapiens	Residual Activity	%	88.0
	12268134	CHEMBL2219403	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	Oc1cccc(-c2nc(N3CCOCC3)c3oc4ncccc4c3n2)c1		CHEMBL573339	=	Residual Activity	%	96.0	CHEMBL3045	Homo sapiens	Residual Activity	%	96.0
	12268135	CHEMBL2219403	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	COc1ccc2c(c1)c(C1=C(c3c[nH]c4ccccc34)C(=O)NC1=O)cn2CCCN(C)C		CHEMBL261491	=	Residual Activity	%	3.0	CHEMBL3045	Homo sapiens	Residual Activity	%	3.0
	12268136	CHEMBL2219403	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	Nc1ncnc2c1c(-c1ccc(Oc3ccccc3)cc1)cn2C1CCCC1		CHEMBL47940	=	Residual Activity	%	91.0	CHEMBL3045	Homo sapiens	Residual Activity	%	91.0
	12268137	CHEMBL2219403	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	O=C1Nc2ccc3ncsc3c2/C1=C/c1c[nH]cn1		CHEMBL235641	=	Residual Activity	%	43.0	CHEMBL3045	Homo sapiens	Residual Activity	%	43.0
	12268138	CHEMBL2219403	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	Cc1cncc2cccc(S(=O)(=O)N3CCCN(C(=O)CN)C[C@H]3C)c12		CHEMBL2218931	=	Residual Activity	%	51.0	CHEMBL3045	Homo sapiens	Residual Activity	%	51.0
	12268139	CHEMBL2219403	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	N#C/C(=C\c1ccc(O)c(O)c1)C(=O)NCc1ccccc1		CHEMBL56543	=	Residual Activity	%	97.0	CHEMBL3045	Homo sapiens	Residual Activity	%	97.0
	12268140	CHEMBL2219403	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	COc1ccc(-c2cnc3c(-c4ccsc4)cnn3c2)cc1		CHEMBL92461	=	Residual Activity	%	92.0	CHEMBL3045	Homo sapiens	Residual Activity	%	92.0
	12268141	CHEMBL2219403	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	COc1cc2ncnc(Nc3ccc(NC(=O)c4ccccc4)cc3)c2cc1OC		CHEMBL382590	=	Residual Activity	%	94.0	CHEMBL3045	Homo sapiens	Residual Activity	%	94.0
	12268142	CHEMBL2219403	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	O=c1c2ccccc2[nH]c(=S)n1CCN1CCC(=C(c2ccc(F)cc2)c2ccc(F)cc2)CC1		CHEMBL261131	=	Residual Activity	%	104.0	CHEMBL3045	Homo sapiens	Residual Activity	%	104.0
	12268143	CHEMBL2219403	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	c1ccc(-c2n[nH]c3c2oc2ccccc23)cc1		CHEMBL406375	=	Residual Activity	%	98.0	CHEMBL3045	Homo sapiens	Residual Activity	%	98.0
	12268144	CHEMBL2219403	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	O=c1cc(N2CCOCC2)oc2c(-c3ccccc3)cccc12		CHEMBL98350	=	Residual Activity	%	90.0	CHEMBL3045	Homo sapiens	Residual Activity	%	90.0
	12268145	CHEMBL2219403	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	O=C1Nc2ccc(Cl)cc2/C1=C/c1cc(Cl)c(O)c(Cl)c1		CHEMBL2218932	=	Residual Activity	%	90.0	CHEMBL3045	Homo sapiens	Residual Activity	%	90.0
	12268146	CHEMBL2219403	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL608533	=	Residual Activity	%	45.0	CHEMBL3045	Homo sapiens	Residual Activity	%	45.0
	12268147	CHEMBL2219403	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	N#CC(C#N)=C(N)/C(C#N)=C/c1ccc(O)cc1		CHEMBL76589	=	Residual Activity	%	90.0	CHEMBL3045	Homo sapiens	Residual Activity	%	90.0
	12268148	CHEMBL2219403	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	O=C(c1ccccc1)c1ccc(N2CCOCC2)cc1O		CHEMBL478980	=	Residual Activity	%	101.0	CHEMBL3045	Homo sapiens	Residual Activity	%	101.0
	12268149	CHEMBL2219403	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	NC(=O)c1cccc(-c2cc(Nc3ccc(OC(F)(F)F)cc3)ncn2)c1		CHEMBL483847	=	Residual Activity	%	96.0	CHEMBL3045	Homo sapiens	Residual Activity	%	96.0
	12268150	CHEMBL2219403	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	CN(C)c1ccc(/C=C2\C(=O)Nc3ccccc32)cc1		CHEMBL328710	=	Residual Activity	%	98.0	CHEMBL3045	Homo sapiens	Residual Activity	%	98.0
	12268151	CHEMBL2219403	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	CO[C@H]1/C=C/C=C(\C)C(=O)NC2=CC(=O)C=C(C2=O)[C@H](OC)[C@@H](C)C[C@H](OC)[C@H](OC)[C@@H](C)/C=C(\C)[C@@H]1OC(N)=O		CHEMBL479533	=	Residual Activity	%	97.0	CHEMBL3045	Homo sapiens	Residual Activity	%	97.0
	12268152	CHEMBL2219403	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	O=c1cc(N2CCNCC2)oc2c(-c3ccccc3)cccc12		CHEMBL1363184	=	Residual Activity	%	95.0	CHEMBL3045	Homo sapiens	Residual Activity	%	95.0
	12268153	CHEMBL2219403	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	O=C1NC(=O)/C(=C\c2ccc3nccnc3c2)S1		CHEMBL2218934	=	Residual Activity	%	100.0	CHEMBL3045	Homo sapiens	Residual Activity	%	100.0
	12268154	CHEMBL2219403	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	COc1cc2ncnc(Nc3ccc(Oc4ccccc4)cc3)c2cc1OC		CHEMBL97771	=	Residual Activity	%	104.0	CHEMBL3045	Homo sapiens	Residual Activity	%	104.0
	12268155	CHEMBL2219403	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	Cc1cc2ncc(-c3ccccc3)nc2cc1C		CHEMBL7724	=	Residual Activity	%	107.0	CHEMBL3045	Homo sapiens	Residual Activity	%	107.0
	12268156	CHEMBL2219403	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	O=C(Nc1cccc(Nc2nccc(Nc3cccc(C(F)(F)F)c3)n2)c1)C1CC1		CHEMBL383899	=	Residual Activity	%	102.0	CHEMBL3045	Homo sapiens	Residual Activity	%	102.0
	12268157	CHEMBL2219403	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	CN(C)CCCn1cc(C2=C(c3c[nH]c4ccccc34)C(=O)NC2=O)c2ccccc21		CHEMBL7463	=	Residual Activity	%	2.0	CHEMBL3045	Homo sapiens	Residual Activity	%	2.0
	12268158	CHEMBL2219403	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	COc1cc2ncnc(Nc3ccc(OCc4ccccc4)cc3)c2cc1OC		CHEMBL563845	=	Residual Activity	%	101.0	CHEMBL3045	Homo sapiens	Residual Activity	%	101.0
	12268159	CHEMBL2219403	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	c1ccc(-c2cnc(Nc3ccc(OCCN4CCCC4)cc3)s2)cc1		CHEMBL2218935	=	Residual Activity	%	92.0	CHEMBL3045	Homo sapiens	Residual Activity	%	92.0
	12268160	CHEMBL2219403	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	CC1=C(C(=O)N2CCN(C)CC2)C(C)=C(/C=C2\C(=O)Nc3ccc(S(=O)(=O)N(C)c4cccc(Cl)c4)cc32)C1		CHEMBL2218936	=	Residual Activity	%	95.0	CHEMBL3045	Homo sapiens	Residual Activity	%	95.0
	12268161	CHEMBL2219403	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	O=C1NC(=O)/C(=C/c2ccc3c(c2)OC(F)(F)O3)S1		CHEMBL1231533	=	Residual Activity	%	102.0	CHEMBL3045	Homo sapiens	Residual Activity	%	102.0
	12268162	CHEMBL2219403	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(Cl)cc32)c1C		CHEMBL13485	=	Residual Activity	%	94.0	CHEMBL3045	Homo sapiens	Residual Activity	%	94.0
	12268163	CHEMBL2219403	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	COc1cc2ncc(-c3ccccc3)nc2cc1OC		CHEMBL71191	=	Residual Activity	%	96.0	CHEMBL3045	Homo sapiens	Residual Activity	%	96.0
	12268164	CHEMBL2219403	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL388978	=	Residual Activity	%	2.0	CHEMBL3045	Homo sapiens	Residual Activity	%	2.0
	12268165	CHEMBL2219403	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	CN([C@@H](Cc1ccc(OS(=O)(=O)c2cccc3cnccc23)cc1)C(=O)N1CCN(c2ccccc2)CC1)S(=O)(=O)c1cccc2cnccc12		CHEMBL28324	=	Residual Activity	%	101.0	CHEMBL3045	Homo sapiens	Residual Activity	%	101.0
	12268166	CHEMBL2219403	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	Nc1nc(Nc2ccc(S(N)(=O)=O)cc2)nn1C(=O)c1c(F)cccc1F		CHEMBL191003	=	Residual Activity	%	54.0	CHEMBL3045	Homo sapiens	Residual Activity	%	54.0
	12268167	CHEMBL2219403	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	O=C1NC(=O)c2c1c1c3ccccc3[nH]c1c1[nH]c3cc(Br)ccc3c21		CHEMBL64758	=	Residual Activity	%	95.0	CHEMBL3045	Homo sapiens	Residual Activity	%	95.0
	12268168	CHEMBL2219403	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	C[C@@H](N)[C@H]1CC[C@H](C(=O)Nc2ccncc2)CC1		CHEMBL559147	=	Residual Activity	%	34.0	CHEMBL3045	Homo sapiens	Residual Activity	%	34.0
	12268169	CHEMBL2219403	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	CN(C)S(=O)(=O)c1ccc2c(c1)/C(=C/c1cc3c([nH]1)CCCC3)C(=O)N2		CHEMBL605003	=	Residual Activity	%	96.0	CHEMBL3045	Homo sapiens	Residual Activity	%	96.0
	12268170	CHEMBL2219403	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	O=C(CCCc1ccc(-c2ccccc2F)cc1)Nc1ccc(O)cc1		CHEMBL235658	=	Residual Activity	%	101.0	CHEMBL3045	Homo sapiens	Residual Activity	%	101.0
	12268171	CHEMBL2219403	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	CSc1nc(-c2ccc(F)cc2)c(-c2ccnc(NC(C)c3ccccc3)c2)[nH]1		CHEMBL111364	=	Residual Activity	%	112.0	CHEMBL3045	Homo sapiens	Residual Activity	%	112.0
	12268172	CHEMBL2219403	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	C[S+]([O-])c1ccc(-c2nc(-c3ccc(F)cc3)c(-c3ccncc3)[nH]2)cc1		CHEMBL10	=	Residual Activity	%	75.0	CHEMBL3045	Homo sapiens	Residual Activity	%	75.0
	12268173	CHEMBL2219403	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	O=c1cc(-c2cccc3c2Sc2ccccc2S3)oc(N2CCOCC2)c1		CHEMBL222102	=	Residual Activity	%	101.0	CHEMBL3045	Homo sapiens	Residual Activity	%	101.0
	12268174	CHEMBL2219403	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	O=Nc1c(-c2c(O)[nH]c3ccccc23)[nH]c2ccccc12		CHEMBL126077	=	Residual Activity	%	102.0	CHEMBL3045	Homo sapiens	Residual Activity	%	102.0
	12268175	CHEMBL2219403	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	COc1ccc(OC)c2c(=S)c3ccccc3[nH]c12		CHEMBL1331734	=	Residual Activity	%	97.0	CHEMBL3045	Homo sapiens	Residual Activity	%	97.0
	12268176	CHEMBL2219403	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	Nc1n[nH]c2nnc(-c3c(-c4ccccc4)nn4ccccc34)cc12		CHEMBL259551	=	Residual Activity	%	93.0	CHEMBL3045	Homo sapiens	Residual Activity	%	93.0
	12268177	CHEMBL2219403	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	Cc1cc(Nc2nc(-c3ccccc3)nc3ccccc23)n[nH]1		CHEMBL359482	=	Residual Activity	%	95.0	CHEMBL3045	Homo sapiens	Residual Activity	%	95.0
	12268178	CHEMBL2219403	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	CCOc1nc(NC(=O)Cc2cc(OC)ccc2OC)cc(N)c1C#N		CHEMBL210618	=	Residual Activity	%	102.0	CHEMBL3045	Homo sapiens	Residual Activity	%	102.0
	12268179	CHEMBL2219403	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	Oc1c(-c2ccc(F)cc2)c(-c2ccncc2)nn1-c1ccc(Cl)cc1		CHEMBL91730	=	Residual Activity	%	97.0	CHEMBL3045	Homo sapiens	Residual Activity	%	97.0
	12268180	CHEMBL2219403	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	O=S(=O)(c1cccc2cnccc12)N1CCCNCC1		CHEMBL38380	=	Residual Activity	%	67.0	CHEMBL3045	Homo sapiens	Residual Activity	%	67.0
	12268181	CHEMBL2219403	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	O=C(NC(NC(=S)Nc1ccc(F)c([N+](=O)[O-])c1)C(Cl)(Cl)Cl)C(c1ccccc1)c1ccccc1		CHEMBL1221601	=	Residual Activity	%	103.0	CHEMBL3045	Homo sapiens	Residual Activity	%	103.0
	12268182	CHEMBL2219403	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	Cc1ccc(S(=O)(=O)/C=C/C#N)cc1		CHEMBL403183	=	Residual Activity	%	103.0	CHEMBL3045	Homo sapiens	Residual Activity	%	103.0
	12268183	CHEMBL2219403	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	Cc1ccc(NC2=CC(=O)c3sc(C)nc3C2=O)cc1		CHEMBL290904	=	Residual Activity	%	101.0	CHEMBL3045	Homo sapiens	Residual Activity	%	101.0
	12268184	CHEMBL2219403	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	Oc1n[nH]c2nnc(-c3c(-c4ccccc4)nn4ccccc34)cc12		CHEMBL2218938	=	Residual Activity	%	97.0	CHEMBL3045	Homo sapiens	Residual Activity	%	97.0
	12268185	CHEMBL2219403	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	O=C1NC(=O)c2c1c1c3ccccc3[nH]c1n1cncc21		CHEMBL413188	=	Residual Activity	%	111.0	CHEMBL3045	Homo sapiens	Residual Activity	%	111.0
	12268186	CHEMBL2219403	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	COC(=O)[C@@]1(O)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL281948	=	Residual Activity	%	18.0	CHEMBL3045	Homo sapiens	Residual Activity	%	18.0
	12268187	CHEMBL2219403	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	COc1cccc(-c2cc(=O)c3ccccc3o2)c1N		CHEMBL35482	=	Residual Activity	%	108.0	CHEMBL3045	Homo sapiens	Residual Activity	%	108.0
	12268188	CHEMBL2219403	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	O=C1NC(=O)c2c1c1c3ccccc3n3c1c1c2c2ccccc2n1C1CCC3O1		CHEMBL304428	=	Residual Activity	%	108.0	CHEMBL3045	Homo sapiens	Residual Activity	%	108.0
	12268189	CHEMBL2219403	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	O=C1Cc2c([nH]c3ccc([N+](=O)[O-])cc23)-c2ccccc2N1		CHEMBL50894	=	Residual Activity	%	99.0	CHEMBL3045	Homo sapiens	Residual Activity	%	99.0
	12268190	CHEMBL2219403	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	CC(C)n1cnc2c(NCc3ccccc3)nc(NCCCO)nc21		CHEMBL83980	=	Residual Activity	%	104.0	CHEMBL3045	Homo sapiens	Residual Activity	%	104.0
	12268191	CHEMBL2219403	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	CCN1/C(=C/C(C)=O)Sc2ccc(OC)cc21		CHEMBL408982	=	Residual Activity	%	82.0	CHEMBL3045	Homo sapiens	Residual Activity	%	82.0
	12268192	CHEMBL2219403	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	O=C1c2ccccc2-[n+]2ccc3c([nH]c4ccccc43)c21		CHEMBL602937	=	Residual Activity	%	88.0	CHEMBL3045	Homo sapiens	Residual Activity	%	88.0
	12268193	CHEMBL2219403	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	COc1cc(OC)c(/C=C2\C(=O)Nc3ccccc32)c(OC)c1		CHEMBL404941	=	Residual Activity	%	101.0	CHEMBL3045	Homo sapiens	Residual Activity	%	101.0
	12268194	CHEMBL2219403	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	O=C1Cc2c([nH]c3ccc(Br)cc23)-c2ccccc2N1		CHEMBL296586	=	Residual Activity	%	88.0	CHEMBL3045	Homo sapiens	Residual Activity	%	88.0
	12268195	CHEMBL2219403	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	O=[N+]([O-])c1ccc(-c2nc(-c3ccc(F)cc3)c(-c3ccncc3)[nH]2)cc1		CHEMBL17331	=	Residual Activity	%	96.0	CHEMBL3045	Homo sapiens	Residual Activity	%	96.0
	12268196	CHEMBL2219403	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	Cc1nc(-c2ccccc2)c(-c2ccncc2)o1		CHEMBL36450	=	Residual Activity	%	101.0	CHEMBL3045	Homo sapiens	Residual Activity	%	101.0
	12268197	CHEMBL2219403	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	N#CCCc1ccc2c(c1)-c1[nH]c3ccc([N+](=O)[O-])cc3c1CC(=O)N2		CHEMBL260138	=	Residual Activity	%	92.0	CHEMBL3045	Homo sapiens	Residual Activity	%	92.0
	12268198	CHEMBL2219403	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	O=C1Nc2ccccc2/C1=C\c1c(Cl)[nH]c2ccccc12		CHEMBL261425	=	Residual Activity	%	99.0	CHEMBL3045	Homo sapiens	Residual Activity	%	99.0
	12268199	CHEMBL2219403	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	NC(=O)c1ccc2[nH]c(-c3ccc(Oc4ccc(Cl)cc4)cc3)nc2c1		CHEMBL179583	=	Residual Activity	%	100.0	CHEMBL3045	Homo sapiens	Residual Activity	%	100.0
	12268200	CHEMBL2219403	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	Cn1sc(=O)n(Cc2ccccc2)c1=O		CHEMBL284861	=	Residual Activity	%	43.0	CHEMBL3045	Homo sapiens	Residual Activity	%	43.0
	12268201	CHEMBL2219403	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	NC(=O)Nc1sc(-c2ccc(F)cc2)cc1C(N)=O		CHEMBL257167	=	Residual Activity	%	89.0	CHEMBL3045	Homo sapiens	Residual Activity	%	89.0
	12268202	CHEMBL2219403	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	COc1ccc(S(=O)(=O)N(CCO)c2ccccc2CN(C)C/C=C/c2ccc(Cl)cc2)cc1		CHEMBL155333	=	Residual Activity	%	96.0	CHEMBL3045	Homo sapiens	Residual Activity	%	96.0
	12268203	CHEMBL2219403	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	Nc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCNCC2)n1		CHEMBL274064	=	Residual Activity	%	59.0	CHEMBL3045	Homo sapiens	Residual Activity	%	59.0
	12268204	CHEMBL2219403	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	Fc1ccc(-c2nc3n(c2-c2ccncc2)CCS3)cc1		CHEMBL313417	=	Residual Activity	%	92.0	CHEMBL3045	Homo sapiens	Residual Activity	%	92.0
	12268205	CHEMBL2219403	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	CCCCc1c(-c2ccc(O)cc2)[nH]c2nccnc12		CHEMBL75680	=	Residual Activity	%	91.0	CHEMBL3045	Homo sapiens	Residual Activity	%	91.0
	12268206	CHEMBL2219403	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	CCn1cnc2c(Nc3cccc(Cl)c3)nc(N[C@@H]3CCCC[C@@H]3N)nc21		CHEMBL367625	=	Residual Activity	%	92.0	CHEMBL3045	Homo sapiens	Residual Activity	%	92.0
	12268207	CHEMBL2219403	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	CC(C)n1cnc2/c(=N/c3cccc(Cl)c3)nc(NCCO)[nH]c21		CHEMBL311228	=	Residual Activity	%	100.0	CHEMBL3045	Homo sapiens	Residual Activity	%	100.0
	12268208	CHEMBL2219403	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	Ic1cccc(CSc2nnc(-c3ccncc3)o2)c1		CHEMBL288064	=	Residual Activity	%	92.0	CHEMBL3045	Homo sapiens	Residual Activity	%	92.0
	12268209	CHEMBL2219403	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	O=C1Nc2ccccc2/C1=C1/Nc2ccccc2/C1=N\OCCC(O)CO		CHEMBL1802727	=	Residual Activity	%	99.0	CHEMBL3045	Homo sapiens	Residual Activity	%	99.0
	12268210	CHEMBL2219403	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	N#C/C(=C(/N)SC1C=CC=CC1)c1cccc(C(O)c2ccncc2)c1		CHEMBL2218939	=	Residual Activity	%	103.0	CHEMBL3045	Homo sapiens	Residual Activity	%	103.0
	12268211	CHEMBL2219403	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	CC(C)[C@H](CO)Nc1nc(Nc2cccc(Cl)c2)c2ncn(C(C)C)c2n1		CHEMBL23327	=	Residual Activity	%	96.0	CHEMBL3045	Homo sapiens	Residual Activity	%	96.0
	12268212	CHEMBL2219403	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	Oc1ccc(Nc2nc(-c3ccc(Cl)cc3)cs2)cc1		CHEMBL1076555	=	Residual Activity	%	101.0	CHEMBL3045	Homo sapiens	Residual Activity	%	101.0
	12268213	CHEMBL2219403	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	CCCCc1c(-c2ccc(OC)cc2)[nH]c2nccnc12		CHEMBL306498	=	Residual Activity	%	102.0	CHEMBL3045	Homo sapiens	Residual Activity	%	102.0
	12268214	CHEMBL2219403	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	Nc1nc(Nc2ccc(S(N)(=O)=O)cc2)nn1C(=S)Nc1c(F)cccc1F		CHEMBL261720	=	Residual Activity	%	78.0	CHEMBL3045	Homo sapiens	Residual Activity	%	78.0
	12268215	CHEMBL2219403	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	COc1ccc(CNc2nc(N(CCO)CCO)nc3c2ncn3C(C)C)cc1		CHEMBL80713	=	Residual Activity	%	79.0	CHEMBL3045	Homo sapiens	Residual Activity	%	79.0
	12268216	CHEMBL2219403	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	COc1ccc(CNC(=O)Nc2ncc([N+](=O)[O-])s2)cc1		CHEMBL259850	=	Residual Activity	%	99.0	CHEMBL3045	Homo sapiens	Residual Activity	%	99.0
	12268217	CHEMBL2219403	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	Oc1c2ccccc2c2c3c(cccc13)N=N2		CHEMBL1725279	=	Residual Activity	%	102.0	CHEMBL3045	Homo sapiens	Residual Activity	%	102.0
	12268218	CHEMBL2219403	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	O=C1C(Cl)=C(N2C(=O)CCC2=O)C(=O)c2ccccc21		CHEMBL404939	=	Residual Activity	%	97.0	CHEMBL3045	Homo sapiens	Residual Activity	%	97.0
	12268219	CHEMBL2219403	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	Nc1cccc(-c2cc3c(Oc4cccc(O)c4)ncnc3[nH]2)c1		CHEMBL405759	=	Residual Activity	%	95.0	CHEMBL3045	Homo sapiens	Residual Activity	%	95.0
	12268220	CHEMBL2219403	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	CC(C)[C@H](CO)Nc1nc(Nc2cc(N)cc(Cl)c2)c2ncn(C(C)C)c2n1		CHEMBL286721	=	Residual Activity	%	94.0	CHEMBL3045	Homo sapiens	Residual Activity	%	94.0
	12268221	CHEMBL2219403	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	Nc1n[nH]c2nc3ccccc3nc12		CHEMBL259389	=	Residual Activity	%	105.0	CHEMBL3045	Homo sapiens	Residual Activity	%	105.0
	12268222	CHEMBL2219403	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	CCN(CC)C(=O)c1ccc(Nc2nc(OCC3CCCCC3)c3nc[nH]c3n2)cc1		CHEMBL1802728	=	Residual Activity	%	87.0	CHEMBL3045	Homo sapiens	Residual Activity	%	87.0
	12268223	CHEMBL2219403	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	O=C1Nc2cc(Br)ccc2/C1=C1/Nc2ccccc2/C1=N\O		CHEMBL409450	=	Residual Activity	%	95.0	CHEMBL3045	Homo sapiens	Residual Activity	%	95.0
	12268224	CHEMBL2219403	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	Cn1nc2c3c(cccc31)C(=O)c1ccccc1-2		CHEMBL1802485	=	Residual Activity	%	103.0	CHEMBL3045	Homo sapiens	Residual Activity	%	103.0
	12268225	CHEMBL2219403	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	N#C/C(=C(\N)Sc1ccc(N)cc1)c1ccccc1C(F)(F)F		CHEMBL2218940	=	Residual Activity	%	99.0	CHEMBL3045	Homo sapiens	Residual Activity	%	99.0
	12268226	CHEMBL2219403	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	O=S(=O)(NCCNC/C=C/c1ccc(Br)cc1)c1cccc2cnccc12		CHEMBL104264	=	Residual Activity	%	55.0	CHEMBL3045	Homo sapiens	Residual Activity	%	55.0
	12268227	CHEMBL2219403	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	O=C(O)c1ccc2c3c1cccc3c(=O)n1c3ccccc3nc21		CHEMBL1182777	=	Residual Activity	%	100.0	CHEMBL3045	Homo sapiens	Residual Activity	%	100.0
	12268228	CHEMBL2219403	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	c1cc(-c2cnn3cc(-c4ccc(OCCN5CCCCC5)cc4)cnc23)ccn1		CHEMBL478629	=	Residual Activity	%	95.0	CHEMBL3045	Homo sapiens	Residual Activity	%	95.0
	12268229	CHEMBL2219403	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	NC(=O)c1ccc(-c2nc(-c3ccc4c(c3)OCCO4)c(-c3ccccn3)[nH]2)cc1		CHEMBL410456	=	Residual Activity	%	78.0	CHEMBL3045	Homo sapiens	Residual Activity	%	78.0
	12268230	CHEMBL2219403	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	CC(C)c1nn(-c2c(Cl)cccc2Cl)c2nc(Cc3ccc(OCCO)cc3)[nH]c(=O)c12		CHEMBL258721	=	Residual Activity	%	95.0	CHEMBL3045	Homo sapiens	Residual Activity	%	95.0
	12268231	CHEMBL2219403	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	CC(=O)O/N=C1C(=C2\C(=O)Nc3cc(Br)ccc32)\Nc2ccccc2\1		CHEMBL2218941	=	Residual Activity	%	94.0	CHEMBL3045	Homo sapiens	Residual Activity	%	94.0
	12268232	CHEMBL2219403	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	N#C/C(=C1/Nc2ccccc2S1)c1ccnc(NCCc2cccnc2)n1		CHEMBL191384	=	Residual Activity	%	102.0	CHEMBL3045	Homo sapiens	Residual Activity	%	102.0
	12268233	CHEMBL2219403	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	Nc1ncnc2[nH]nc(Nc3ccc(F)cc3)c12		CHEMBL1240885	=	Residual Activity	%	99.0	CHEMBL3045	Homo sapiens	Residual Activity	%	99.0
	12268234	CHEMBL2219403	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	CCc1nc(-c2ccc(OC)cc2)[nH]c1-c1ccncc1		CHEMBL278724	=	Residual Activity	%	96.0	CHEMBL3045	Homo sapiens	Residual Activity	%	96.0
	12268235	CHEMBL2219403	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	COc1ccc2c(c1)/C(=C/c1cnc[nH]1)C(=O)N2		CHEMBL258805	=	Residual Activity	%	90.0	CHEMBL3045	Homo sapiens	Residual Activity	%	90.0
	12268236	CHEMBL2219403	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	O=C(O)/C=C/c1cc(Br)c(Br)c(Br)c1Br		CHEMBL270724	=	Residual Activity	%	101.0	CHEMBL3045	Homo sapiens	Residual Activity	%	101.0
	12268237	CHEMBL2219403	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	N/C(=N\[N+](=O)[O-])N/N=C\c1ccc(-c2cccc([N+](=O)[O-])c2)o1		CHEMBL221271	=	Residual Activity	%	92.0	CHEMBL3045	Homo sapiens	Residual Activity	%	92.0
	12268238	CHEMBL2219403	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	O=C1NC(=O)C(c2cn(CCCO)c3ncccc23)=C1c1cnccn1		CHEMBL272629	=	Residual Activity	%	94.0	CHEMBL3045	Homo sapiens	Residual Activity	%	94.0
	12268239	CHEMBL2219403	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	N#Cc1c(NC(=O)c2cccc3ccccc23)sc2c1CCCC2		CHEMBL233001	=	Residual Activity	%	115.0	CHEMBL3045	Homo sapiens	Residual Activity	%	115.0
	12268240	CHEMBL2219403	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	Nc1ccc2ncnc(NCCc3ccc(Oc4ccccc4)cc3)c2c1		CHEMBL522502	=	Residual Activity	%	104.0	CHEMBL3045	Homo sapiens	Residual Activity	%	104.0
	12268241	CHEMBL2219403	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	Oc1ccc(-c2nc(-c3ccc(F)cc3)c(-c3ccncc3)[nH]2)cc1		CHEMBL278041	=	Residual Activity	%	81.0	CHEMBL3045	Homo sapiens	Residual Activity	%	81.0
	12268242	CHEMBL2219403	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	B	N#Cc1cnc2cnc(NCc3cccnc3)cc2c1Nc1ccc(F)c(Cl)c1		CHEMBL200381	=	Residual Activity	%	83.0	CHEMBL3045	Homo sapiens	Residual Activity	%	83.0
	12421432	CHEMBL3063098	Inhibition of PKCbeta2 (unknown origin)	B	O=C1NC(=O)C(c2cn(CCCn3ccnc3)c3ccccc23)=C1Nc1ccccc1		CHEMBL366266	=	IC50	nM	5.012	CHEMBL3045	Homo sapiens	pIC50		8.3
	12421433	CHEMBL3063098	Inhibition of PKCbeta2 (unknown origin)	B	Br.N=C(N)SCCCn1cc(C2=C(Nc3ccccc3)C(=O)NC2=O)c2ccccc21		CHEMBL540357	=	IC50	nM	2.042	CHEMBL3045	Homo sapiens	pIC50		8.69
	12421434	CHEMBL3063098	Inhibition of PKCbeta2 (unknown origin)	B	CN1CCN(CCCn2cc(C3=C(Nc4ccccc4)C(=O)NC3=O)c3ccccc32)CC1		CHEMBL184146	=	IC50	nM	23.44	CHEMBL3045	Homo sapiens	pIC50		7.63
	12421435	CHEMBL3063098	Inhibition of PKCbeta2 (unknown origin)	B	O=C1NC(=O)C(c2cn(CCCN3CCCCC3)c3ccccc23)=C1Nc1ccccc1		CHEMBL187235	=	IC50	nM	17.38	CHEMBL3045	Homo sapiens	pIC50		7.76
	12421436	CHEMBL3063098	Inhibition of PKCbeta2 (unknown origin)	B	O=C1NC(=O)C(c2cn(CCCN3CCCC3)c3ccccc23)=C1Nc1ccccc1		CHEMBL184042	=	IC50	nM	18.2	CHEMBL3045	Homo sapiens	pIC50		7.74
	12421437	CHEMBL3063098	Inhibition of PKCbeta2 (unknown origin)	B	CN(C)CCCn1cc(C2=C(Nc3cccc(Cl)c3)C(=O)NC2=O)c2ccccc21		CHEMBL364337	=	IC50	nM	10.0	CHEMBL3045	Homo sapiens	pIC50		8.0
	12421438	CHEMBL3063098	Inhibition of PKCbeta2 (unknown origin)	B	Cc1cccc(NC2=C(c3cn(CCCN(C)C)c4ccccc34)C(=O)NC2=O)c1		CHEMBL369114	=	IC50	nM	15.14	CHEMBL3045	Homo sapiens	pIC50		7.82
	12421439	CHEMBL3063098	Inhibition of PKCbeta2 (unknown origin)	B	CN(C)CCCCCn1cc(C2=C(Nc3ccccc3)C(=O)NC2=O)c2ccccc21		CHEMBL184647	=	IC50	nM	41.69	CHEMBL3045	Homo sapiens	pIC50		7.38
	12421440	CHEMBL3063098	Inhibition of PKCbeta2 (unknown origin)	B	CN(C)CCCCn1cc(C2=C(Nc3ccccc3)C(=O)NC2=O)c2ccccc21		CHEMBL184548	=	IC50	nM	15.14	CHEMBL3045	Homo sapiens	pIC50		7.82
	12421441	CHEMBL3063098	Inhibition of PKCbeta2 (unknown origin)	B	CN(C)CCn1cc(C2=C(Nc3ccccc3)C(=O)NC2=O)c2ccccc21		CHEMBL184649	=	IC50	nM	28.18	CHEMBL3045	Homo sapiens	pIC50		7.55
	12421442	CHEMBL3063098	Inhibition of PKCbeta2 (unknown origin)	B	CC(C)c1cccc(NC2=C(c3c[nH]c4ccccc34)C(=O)NC2=O)c1		CHEMBL184269	=	IC50	nM	2884.03	CHEMBL3045	Homo sapiens	pIC50		5.54
	12421443	CHEMBL3063098	Inhibition of PKCbeta2 (unknown origin)	B	O=C1NC(=O)C(c2c[nH]c3ccccc23)=C1Nc1cccc(C(F)(F)F)c1		CHEMBL424809	=	IC50	nM	1479.11	CHEMBL3045	Homo sapiens	pIC50		5.83
	12421444	CHEMBL3063098	Inhibition of PKCbeta2 (unknown origin)	B	COc1cccc(NC2=C(c3c[nH]c4ccccc34)C(=O)NC2=O)c1		CHEMBL186901	=	IC50	nM	758.58	CHEMBL3045	Homo sapiens	pIC50		6.12
	12421445	CHEMBL3063098	Inhibition of PKCbeta2 (unknown origin)	B	O=C1NC(=O)C(c2c[nH]c3ccccc23)=C1Nc1cccc(Cl)c1		CHEMBL187325	=	IC50	nM	199.53	CHEMBL3045	Homo sapiens	pIC50		6.7
	12421446	CHEMBL3063098	Inhibition of PKCbeta2 (unknown origin)	B	O=C1NC(=O)C(c2c[nH]c3ccccc23)=C1Nc1cccc(F)c1		CHEMBL186981	=	IC50	nM	251.19	CHEMBL3045	Homo sapiens	pIC50		6.6
	12421447	CHEMBL3063098	Inhibition of PKCbeta2 (unknown origin)	B	Cc1ccc(NC2=C(c3c[nH]c4ccccc34)C(=O)NC2=O)cc1		CHEMBL186980	=	IC50	nM	489.78	CHEMBL3045	Homo sapiens	pIC50		6.31
	12421448	CHEMBL3063098	Inhibition of PKCbeta2 (unknown origin)	B	Cc1cccc(NC2=C(c3c[nH]c4ccccc34)C(=O)NC2=O)c1		CHEMBL185573	=	IC50	nM	151.36	CHEMBL3045	Homo sapiens	pIC50		6.82
	12421449	CHEMBL3063098	Inhibition of PKCbeta2 (unknown origin)	B	Cc1ccccc1NC1=C(c2c[nH]c3ccccc23)C(=O)NC1=O		CHEMBL435104	=	IC50	nM	2187.76	CHEMBL3045	Homo sapiens	pIC50		5.66
	12421450	CHEMBL3063098	Inhibition of PKCbeta2 (unknown origin)	B	O=C1NC(=O)C(c2c[nH]c3ccccc23)=C1Nc1ccccc1		CHEMBL183310	=	IC50	nM	223.87	CHEMBL3045	Homo sapiens	pIC50		6.65
	12421451	CHEMBL3063098	Inhibition of PKCbeta2 (unknown origin)	B	O=C1NC(=O)C(c2c[nH]c3ccccc23)=C1NC1CCCCC1		CHEMBL184826	=	IC50	nM	2454.71	CHEMBL3045	Homo sapiens	pIC50		5.61
	12421452	CHEMBL3063098	Inhibition of PKCbeta2 (unknown origin)	B	O=C1NC(=O)C(c2cn(CCCO)c3ccccc23)=C1Nc1ccccc1		CHEMBL185221	=	IC50	nM	30.2	CHEMBL3045	Homo sapiens	pIC50		7.52
	12421453	CHEMBL3063098	Inhibition of PKCbeta2 (unknown origin)	B	CN(C)CCCn1cc(C2=C(Nc3ccccc3)C(=O)NC2=O)c2ccccc21		CHEMBL365656	=	IC50	nM	12.02	CHEMBL3045	Homo sapiens	pIC50		7.92
	12421454	CHEMBL3063098	Inhibition of PKCbeta2 (unknown origin)	B	CN(C)C[C@@H]1Cc2c(C3=C(Nc4ccccc4)C(=O)NC3=O)c3ccccc3n2C1		CHEMBL2236797	=	IC50	nM	8.128	CHEMBL3045	Homo sapiens	pIC50		8.09
	12421455	CHEMBL3063098	Inhibition of PKCbeta2 (unknown origin)	B	O=C1NC(=O)C(c2c3n(c4ccccc24)C[C@H](CO)C3)=C1Nc1ccccc1		CHEMBL2236796	=	IC50	nM	14.13	CHEMBL3045	Homo sapiens	pIC50		7.85
	12421456	CHEMBL3063098	Inhibition of PKCbeta2 (unknown origin)	B	CC(=O)NC[C@H]1Cc2c(C3=C(Nc4ccccc4)C(=O)NC3=O)c3ccccc3n2C1		CHEMBL2236795	=	IC50	nM	7.943	CHEMBL3045	Homo sapiens	pIC50		8.1
	12421457	CHEMBL3063098	Inhibition of PKCbeta2 (unknown origin)	B	NC[C@H]1Cc2c(C3=C(Nc4ccccc4)C(=O)NC3=O)c3ccccc3n2C1		CHEMBL2236794	=	IC50	nM	1.413	CHEMBL3045	Homo sapiens	pIC50		8.85
	12421458	CHEMBL3063098	Inhibition of PKCbeta2 (unknown origin)	B	CCNC[C@H]1Cc2c(C3=C(Nc4ccccc4)C(=O)NC3=O)c3ccccc3n2C1		CHEMBL2236793	=	IC50	nM	2.455	CHEMBL3045	Homo sapiens	pIC50		8.61
	12421459	CHEMBL3063098	Inhibition of PKCbeta2 (unknown origin)	B	CNC[C@H]1Cc2c(C3=C(Nc4ccccc4)C(=O)NC3=O)c3ccccc3n2C1		CHEMBL2236809	=	IC50	nM	2.239	CHEMBL3045	Homo sapiens	pIC50		8.65
	12421460	CHEMBL3063098	Inhibition of PKCbeta2 (unknown origin)	B	O=C1NC(=O)C(c2c3n(c4ccccc24)C[C@@H](CN2CCCC2)C3)=C1Nc1ccccc1		CHEMBL2236808	=	IC50	nM	8.128	CHEMBL3045	Homo sapiens	pIC50		8.09
	12421461	CHEMBL3063098	Inhibition of PKCbeta2 (unknown origin)	B	CCN(C)C[C@H]1Cc2c(C3=C(Nc4ccccc4)C(=O)NC3=O)c3ccccc3n2C1		CHEMBL2236807	=	IC50	nM	5.012	CHEMBL3045	Homo sapiens	pIC50		8.3
	12421462	CHEMBL3063098	Inhibition of PKCbeta2 (unknown origin)	B	CCN(CC)C[C@H]1Cc2c(C3=C(Nc4ccccc4)C(=O)NC3=O)c3ccccc3n2C1		CHEMBL2236806	=	IC50	nM	32.36	CHEMBL3045	Homo sapiens	pIC50		7.49
	12421463	CHEMBL3063098	Inhibition of PKCbeta2 (unknown origin)	B	CN(C)C[C@H]1Cc2c(C3=C(Nc4ccccc4)C(=O)NC3=O)c3ccccc3n2C1		CHEMBL2236805	=	IC50	nM	4.074	CHEMBL3045	Homo sapiens	pIC50		8.39
	12421464	CHEMBL3063098	Inhibition of PKCbeta2 (unknown origin)	B	O=C1NC(=O)C(c2c3n(c4ccccc24)C[C@@H](CO)C3)=C1Nc1ccccc1		CHEMBL2236804	=	IC50	nM	4.074	CHEMBL3045	Homo sapiens	pIC50		8.39
	12421465	CHEMBL3063098	Inhibition of PKCbeta2 (unknown origin)	B	CN(C)C[C@@H]1CCc2c(C3=C(Nc4ccccc4)C(=O)NC3=O)c3ccccc3n2C1		CHEMBL2236803	=	IC50	nM	6.026	CHEMBL3045	Homo sapiens	pIC50		8.22
	12421466	CHEMBL3063098	Inhibition of PKCbeta2 (unknown origin)	B	CN(C)C[C@H]1CCc2c(C3=C(Nc4ccccc4)C(=O)NC3=O)c3ccccc3n2C1		CHEMBL2236802	=	IC50	nM	4.074	CHEMBL3045	Homo sapiens	pIC50		8.39
	12421467	CHEMBL3063098	Inhibition of PKCbeta2 (unknown origin)	B	CN(C)C[C@@H]1CCn2c(c(C3=C(Nc4ccccc4)C(=O)NC3=O)c3ccccc32)C1		CHEMBL2236801	=	IC50	nM	25.12	CHEMBL3045	Homo sapiens	pIC50		7.6
	12421468	CHEMBL3063098	Inhibition of PKCbeta2 (unknown origin)	B	O=C1NC(=O)C(c2c3n(c4ccccc24)CC[C@@H](CO)C3)=C1Nc1ccccc1		CHEMBL2236800	=	IC50	nM	17.38	CHEMBL3045	Homo sapiens	pIC50		7.76
	12421469	CHEMBL3063098	Inhibition of PKCbeta2 (unknown origin)	B	CN(C)C[C@H]1CCn2c(c(C3=C(Nc4ccccc4)C(=O)NC3=O)c3ccccc32)C1		CHEMBL2236799	=	IC50	nM	2.042	CHEMBL3045	Homo sapiens	pIC50		8.69
	12421470	CHEMBL3063098	Inhibition of PKCbeta2 (unknown origin)	B	O=C1NC(=O)C(c2c3n(c4ccccc24)CC[C@H](CO)C3)=C1Nc1ccccc1		CHEMBL2236798	=	IC50	nM	6.026	CHEMBL3045	Homo sapiens	pIC50		8.22
	12421471	CHEMBL3063098	Inhibition of PKCbeta2 (unknown origin)	B	O=C1NC(=O)C(c2cn(CCCn3ccnc3)c3ccccc23)=C1Nc1ccccc1		CHEMBL366266	=	IC50	nM	5.0	CHEMBL3045	Homo sapiens	IC50	nM	5.0
	12421472	CHEMBL3063098	Inhibition of PKCbeta2 (unknown origin)	B	Br.N=C(N)SCCCn1cc(C2=C(Nc3ccccc3)C(=O)NC2=O)c2ccccc21		CHEMBL540357	=	IC50	nM	2.0	CHEMBL3045	Homo sapiens	IC50	nM	2.0
	12421473	CHEMBL3063098	Inhibition of PKCbeta2 (unknown origin)	B	CN1CCN(CCCn2cc(C3=C(Nc4ccccc4)C(=O)NC3=O)c3ccccc32)CC1		CHEMBL184146	=	IC50	nM	23.0	CHEMBL3045	Homo sapiens	IC50	nM	23.0
	12421474	CHEMBL3063098	Inhibition of PKCbeta2 (unknown origin)	B	O=C1NC(=O)C(c2cn(CCCN3CCCCC3)c3ccccc23)=C1Nc1ccccc1		CHEMBL187235	=	IC50	nM	17.0	CHEMBL3045	Homo sapiens	IC50	nM	17.0
	12421475	CHEMBL3063098	Inhibition of PKCbeta2 (unknown origin)	B	O=C1NC(=O)C(c2cn(CCCN3CCCC3)c3ccccc23)=C1Nc1ccccc1		CHEMBL184042	=	IC50	nM	18.0	CHEMBL3045	Homo sapiens	IC50	nM	18.0
	12421476	CHEMBL3063098	Inhibition of PKCbeta2 (unknown origin)	B	CN(C)CCCn1cc(C2=C(Nc3cccc(Cl)c3)C(=O)NC2=O)c2ccccc21		CHEMBL364337	=	IC50	nM	10.0	CHEMBL3045	Homo sapiens	IC50	nM	10.0
	12421477	CHEMBL3063098	Inhibition of PKCbeta2 (unknown origin)	B	Cc1cccc(NC2=C(c3cn(CCCN(C)C)c4ccccc34)C(=O)NC2=O)c1		CHEMBL369114	=	IC50	nM	15.0	CHEMBL3045	Homo sapiens	IC50	nM	15.0
	12421478	CHEMBL3063098	Inhibition of PKCbeta2 (unknown origin)	B	CN(C)CCCCCn1cc(C2=C(Nc3ccccc3)C(=O)NC2=O)c2ccccc21		CHEMBL184647	=	IC50	nM	41.0	CHEMBL3045	Homo sapiens	IC50	nM	41.0
	12421479	CHEMBL3063098	Inhibition of PKCbeta2 (unknown origin)	B	CN(C)CCCCn1cc(C2=C(Nc3ccccc3)C(=O)NC2=O)c2ccccc21		CHEMBL184548	=	IC50	nM	15.0	CHEMBL3045	Homo sapiens	IC50	nM	15.0
	12421480	CHEMBL3063098	Inhibition of PKCbeta2 (unknown origin)	B	CN(C)CCn1cc(C2=C(Nc3ccccc3)C(=O)NC2=O)c2ccccc21		CHEMBL184649	=	IC50	nM	28.0	CHEMBL3045	Homo sapiens	IC50	nM	28.0
	12421481	CHEMBL3063098	Inhibition of PKCbeta2 (unknown origin)	B	CC(C)c1cccc(NC2=C(c3c[nH]c4ccccc34)C(=O)NC2=O)c1		CHEMBL184269	=	IC50	nM	2863.0	CHEMBL3045	Homo sapiens	IC50	nM	2863.0
	12421482	CHEMBL3063098	Inhibition of PKCbeta2 (unknown origin)	B	O=C1NC(=O)C(c2c[nH]c3ccccc23)=C1Nc1cccc(C(F)(F)F)c1		CHEMBL424809	=	IC50	nM	1450.0	CHEMBL3045	Homo sapiens	IC50	nM	1450.0
	12421483	CHEMBL3063098	Inhibition of PKCbeta2 (unknown origin)	B	COc1cccc(NC2=C(c3c[nH]c4ccccc34)C(=O)NC2=O)c1		CHEMBL186901	=	IC50	nM	747.0	CHEMBL3045	Homo sapiens	IC50	nM	747.0
	12421484	CHEMBL3063098	Inhibition of PKCbeta2 (unknown origin)	B	O=C1NC(=O)C(c2c[nH]c3ccccc23)=C1Nc1cccc(Cl)c1		CHEMBL187325	=	IC50	nM	198.0	CHEMBL3045	Homo sapiens	IC50	nM	198.0
	12421485	CHEMBL3063098	Inhibition of PKCbeta2 (unknown origin)	B	O=C1NC(=O)C(c2c[nH]c3ccccc23)=C1Nc1cccc(F)c1		CHEMBL186981	=	IC50	nM	249.0	CHEMBL3045	Homo sapiens	IC50	nM	249.0
	12421486	CHEMBL3063098	Inhibition of PKCbeta2 (unknown origin)	B	Cc1ccc(NC2=C(c3c[nH]c4ccccc34)C(=O)NC2=O)cc1		CHEMBL186980	=	IC50	nM	480.0	CHEMBL3045	Homo sapiens	IC50	nM	480.0
	12421783	CHEMBL3063098	Inhibition of PKCbeta2 (unknown origin)	B	Cc1cccc(NC2=C(c3c[nH]c4ccccc34)C(=O)NC2=O)c1		CHEMBL185573	=	IC50	nM	151.0	CHEMBL3045	Homo sapiens	IC50	nM	151.0
	12421784	CHEMBL3063098	Inhibition of PKCbeta2 (unknown origin)	B	Cc1ccccc1NC1=C(c2c[nH]c3ccccc23)C(=O)NC1=O		CHEMBL435104	=	IC50	nM	2146.0	CHEMBL3045	Homo sapiens	IC50	nM	2146.0
	12421785	CHEMBL3063098	Inhibition of PKCbeta2 (unknown origin)	B	O=C1NC(=O)C(c2c[nH]c3ccccc23)=C1Nc1ccccc1		CHEMBL183310	=	IC50	nM	223.0	CHEMBL3045	Homo sapiens	IC50	nM	223.0
	12421786	CHEMBL3063098	Inhibition of PKCbeta2 (unknown origin)	B	O=C1NC(=O)C(c2c[nH]c3ccccc23)=C1NC1CCCCC1		CHEMBL184826	=	IC50	nM	2448.0	CHEMBL3045	Homo sapiens	IC50	nM	2448.0
	12421787	CHEMBL3063098	Inhibition of PKCbeta2 (unknown origin)	B	O=C1NC(=O)C(c2c[nH]c3ccccc23)=C1NCc1ccccc1		CHEMBL364374	>	IC50	nM	10000.0	CHEMBL3045	Homo sapiens	IC50	nM	10000.0
	12421788	CHEMBL3063098	Inhibition of PKCbeta2 (unknown origin)	B	O=C1NC(=O)C(c2cn(CCCO)c3ccccc23)=C1Nc1ccccc1		CHEMBL185221	=	IC50	nM	30.0	CHEMBL3045	Homo sapiens	IC50	nM	30.0
	12421789	CHEMBL3063098	Inhibition of PKCbeta2 (unknown origin)	B	CN(C)CCCn1cc(C2=C(Nc3ccccc3)C(=O)NC2=O)c2ccccc21		CHEMBL365656	=	IC50	nM	12.0	CHEMBL3045	Homo sapiens	IC50	nM	12.0
	12421790	CHEMBL3063098	Inhibition of PKCbeta2 (unknown origin)	B	CN(C)C[C@@H]1Cc2c(C3=C(Nc4ccccc4)C(=O)NC3=O)c3ccccc3n2C1		CHEMBL2236797	=	IC50	nM	8.0	CHEMBL3045	Homo sapiens	IC50	nM	8.0
	12421791	CHEMBL3063098	Inhibition of PKCbeta2 (unknown origin)	B	O=C1NC(=O)C(c2c3n(c4ccccc24)C[C@H](CO)C3)=C1Nc1ccccc1		CHEMBL2236796	=	IC50	nM	14.0	CHEMBL3045	Homo sapiens	IC50	nM	14.0
	12421792	CHEMBL3063098	Inhibition of PKCbeta2 (unknown origin)	B	CC(=O)NC[C@H]1Cc2c(C3=C(Nc4ccccc4)C(=O)NC3=O)c3ccccc3n2C1		CHEMBL2236795	=	IC50	nM	7.9	CHEMBL3045	Homo sapiens	IC50	nM	7.9
	12421793	CHEMBL3063098	Inhibition of PKCbeta2 (unknown origin)	B	NC[C@H]1Cc2c(C3=C(Nc4ccccc4)C(=O)NC3=O)c3ccccc3n2C1		CHEMBL2236794	=	IC50	nM	1.4	CHEMBL3045	Homo sapiens	IC50	nM	1.4
	12421794	CHEMBL3063098	Inhibition of PKCbeta2 (unknown origin)	B	CCNC[C@H]1Cc2c(C3=C(Nc4ccccc4)C(=O)NC3=O)c3ccccc3n2C1		CHEMBL2236793	=	IC50	nM	2.4	CHEMBL3045	Homo sapiens	IC50	nM	2.4
	12421795	CHEMBL3063098	Inhibition of PKCbeta2 (unknown origin)	B	CNC[C@H]1Cc2c(C3=C(Nc4ccccc4)C(=O)NC3=O)c3ccccc3n2C1		CHEMBL2236809	=	IC50	nM	2.2	CHEMBL3045	Homo sapiens	IC50	nM	2.2
	12421796	CHEMBL3063098	Inhibition of PKCbeta2 (unknown origin)	B	O=C1NC(=O)C(c2c3n(c4ccccc24)C[C@@H](CN2CCCC2)C3)=C1Nc1ccccc1		CHEMBL2236808	=	IC50	nM	8.0	CHEMBL3045	Homo sapiens	IC50	nM	8.0
	12421797	CHEMBL3063098	Inhibition of PKCbeta2 (unknown origin)	B	CCN(C)C[C@H]1Cc2c(C3=C(Nc4ccccc4)C(=O)NC3=O)c3ccccc3n2C1		CHEMBL2236807	=	IC50	nM	5.0	CHEMBL3045	Homo sapiens	IC50	nM	5.0
	12421798	CHEMBL3063098	Inhibition of PKCbeta2 (unknown origin)	B	CCN(CC)C[C@H]1Cc2c(C3=C(Nc4ccccc4)C(=O)NC3=O)c3ccccc3n2C1		CHEMBL2236806	=	IC50	nM	32.0	CHEMBL3045	Homo sapiens	IC50	nM	32.0
	12421799	CHEMBL3063098	Inhibition of PKCbeta2 (unknown origin)	B	CN(C)C[C@H]1Cc2c(C3=C(Nc4ccccc4)C(=O)NC3=O)c3ccccc3n2C1		CHEMBL2236805	=	IC50	nM	4.0	CHEMBL3045	Homo sapiens	IC50	nM	4.0
	12421800	CHEMBL3063098	Inhibition of PKCbeta2 (unknown origin)	B	O=C1NC(=O)C(c2c3n(c4ccccc24)C[C@@H](CO)C3)=C1Nc1ccccc1		CHEMBL2236804	=	IC50	nM	4.0	CHEMBL3045	Homo sapiens	IC50	nM	4.0
	12421801	CHEMBL3063098	Inhibition of PKCbeta2 (unknown origin)	B	CN(C)C[C@@H]1CCc2c(C3=C(Nc4ccccc4)C(=O)NC3=O)c3ccccc3n2C1		CHEMBL2236803	=	IC50	nM	6.0	CHEMBL3045	Homo sapiens	IC50	nM	6.0
	12421802	CHEMBL3063098	Inhibition of PKCbeta2 (unknown origin)	B	CN(C)C[C@H]1CCc2c(C3=C(Nc4ccccc4)C(=O)NC3=O)c3ccccc3n2C1		CHEMBL2236802	=	IC50	nM	4.0	CHEMBL3045	Homo sapiens	IC50	nM	4.0
	12421803	CHEMBL3063098	Inhibition of PKCbeta2 (unknown origin)	B	CN(C)C[C@@H]1CCn2c(c(C3=C(Nc4ccccc4)C(=O)NC3=O)c3ccccc32)C1		CHEMBL2236801	=	IC50	nM	25.0	CHEMBL3045	Homo sapiens	IC50	nM	25.0
	12421804	CHEMBL3063098	Inhibition of PKCbeta2 (unknown origin)	B	O=C1NC(=O)C(c2c3n(c4ccccc24)CC[C@@H](CO)C3)=C1Nc1ccccc1		CHEMBL2236800	=	IC50	nM	17.0	CHEMBL3045	Homo sapiens	IC50	nM	17.0
	12421805	CHEMBL3063098	Inhibition of PKCbeta2 (unknown origin)	B	CN(C)C[C@H]1CCn2c(c(C3=C(Nc4ccccc4)C(=O)NC3=O)c3ccccc32)C1		CHEMBL2236799	=	IC50	nM	2.0	CHEMBL3045	Homo sapiens	IC50	nM	2.0
	12421806	CHEMBL3063098	Inhibition of PKCbeta2 (unknown origin)	B	O=C1NC(=O)C(c2c3n(c4ccccc24)CC[C@H](CO)C3)=C1Nc1ccccc1		CHEMBL2236798	=	IC50	nM	6.0	CHEMBL3045	Homo sapiens	IC50	nM	6.0
	12647883	CHEMBL2329063	Inhibition of PKCbeta (unknown origin) at 1 uM	B	CC(C)(C)[C@@H](NC(=O)c1c[nH]c2ncc(C3CC3)nc12)C(=O)N1CC(C#N)C1	Outside typical range	CHEMBL2325895	=	Inhibition	%	-18.0	CHEMBL3045	Homo sapiens	INH	%	-18.0
	12647884	CHEMBL2329063	Inhibition of PKCbeta (unknown origin) at 1 uM	B	C[C@@H](NC(=O)c1c[nH]c2ncc(C3CC3)nc12)C(=O)N1CC(C#N)C1		CHEMBL2325894	=	Inhibition	%	1.0	CHEMBL3045	Homo sapiens	INH	%	1.0
	12647885	CHEMBL2329063	Inhibition of PKCbeta (unknown origin) at 1 uM	B	C[C@H](NC(=O)c1c[nH]c2ncc(C3CC3)nc12)C(C)(C)C#N		CHEMBL2325906	=	Inhibition	%	9.0	CHEMBL3045	Homo sapiens	INH	%	9.0
	12647886	CHEMBL2329063	Inhibition of PKCbeta (unknown origin) at 1 uM	B	C[C@H](NC(=O)c1c[nH]c2ncc(C3CC3)nc12)C(C)(C)C		CHEMBL2325903	=	Inhibition	%	1.0	CHEMBL3045	Homo sapiens	INH	%	1.0
	12649573	CHEMBL2329525	Inhibition of PKCbeta (unknown origin) at 10 uM	B	C[C@@H](NC(=O)c1c[nH]c2ncc(C3CC3)nc12)C(=O)N1CC(C#N)C1		CHEMBL2325894	=	Inhibition	%	3.0	CHEMBL3045	Homo sapiens	INH	%	3.0
	12649574	CHEMBL2329525	Inhibition of PKCbeta (unknown origin) at 10 uM	B	C[C@H](NC(=O)c1c[nH]c2ncc(C3CC3)nc12)C(C)(C)O		CHEMBL2325904	=	Inhibition	%	10.0	CHEMBL3045	Homo sapiens	INH	%	10.0
	12649575	CHEMBL2329525	Inhibition of PKCbeta (unknown origin) at 10 uM	B	CC(C)NC(=O)c1c[nH]c2ncc(C3CC3)nc12	Outside typical range	CHEMBL2325901	=	Inhibition	%	-22.0	CHEMBL3045	Homo sapiens	INH	%	-22.0
	12662202	CHEMBL2330900	Inhibition of PKC beta2 (unknown origin)	B	CC(C)[C@@](C)(O)[C@@H]1CN(c2nc(-c3n[nH]c4ncccc34)c(F)cc2Cl)CCN1		CHEMBL2326002	=	Ki	nM	393.0	CHEMBL3045	Homo sapiens	Ki	nM	393.0
	12662203	CHEMBL2330899	Inhibition of PKC beta1 (unknown origin)	B	CC(C)[C@@](C)(O)[C@@H]1CN(c2nc(-c3n[nH]c4ncccc34)c(F)cc2Cl)CCN1		CHEMBL2326002	=	Ki	nM	15.0	CHEMBL3045	Homo sapiens	Ki	nM	15.0
	12668261	CHEMBL2345064	Inhibition of PRKCbeta1 (unknown origin) at 10 uM relative to control	B	CC(C)Nc1c(C(N)=O)nnc2cc(N3CCOCC3)ccc12		CHEMBL2333120	=	Inhibition	%	0.0	CHEMBL3045	Homo sapiens	INH	%	0.0
	12668262	CHEMBL2345064	Inhibition of PRKCbeta1 (unknown origin) at 10 uM relative to control	B	CC(C)Nc1c(C(N)=O)nnc2ccc(-c3cn[nH]c3)cc12		CHEMBL2333115	=	Inhibition	%	40.0	CHEMBL3045	Homo sapiens	INH	%	40.0
	12668263	CHEMBL2345064	Inhibition of PRKCbeta1 (unknown origin) at 10 uM relative to control	B	CC(C)Nc1c(C(N)=O)nnc2ccc(-c3ccncc3)cc12		CHEMBL2333114	=	Inhibition	%	43.0	CHEMBL3045	Homo sapiens	INH	%	43.0
	12668264	CHEMBL2345064	Inhibition of PRKCbeta1 (unknown origin) at 10 uM relative to control	B	CC(C)Nc1c(C(N)=O)nnc2cc(-c3ccncc3)ccc12		CHEMBL2333112	=	Inhibition	%	15.0	CHEMBL3045	Homo sapiens	INH	%	15.0
	12668265	CHEMBL2345064	Inhibition of PRKCbeta1 (unknown origin) at 10 uM relative to control	B	CS(=O)(=O)c1ccc(-c2ccc3c(NC4CCC4)c(C(N)=O)nnc3c2)cc1		CHEMBL2333129	=	Inhibition	%	-2.0	CHEMBL3045	Homo sapiens	INH	%	-2.0
	12668266	CHEMBL2345064	Inhibition of PRKCbeta1 (unknown origin) at 10 uM relative to control	B	C[C@@H](Nc1c(C(N)=O)nnc2cc(-c3ccc(S(C)(=O)=O)cc3)ccc12)C1CC1		CHEMBL2333128	=	Inhibition	%	0.0	CHEMBL3045	Homo sapiens	INH	%	0.0
	12668267	CHEMBL2345064	Inhibition of PRKCbeta1 (unknown origin) at 10 uM relative to control	B	CC(C)Nc1c(C(N)=O)cnc2cc(-c3ccc(S(C)(=O)=O)cc3)ccc12		CHEMBL2333125	=	Inhibition	%	8.0	CHEMBL3045	Homo sapiens	INH	%	8.0
	12679719	CHEMBL2345829	Inhibition of PRKCB2 (unknown origin) at 1 uM	B	Cc1ccc(-c2ccc3ncc4c(c3n2)n(C2CCN(C(=O)[C@H](C)O)CC2)c(=O)n4C)cn1		CHEMBL2331664	=	Inhibition	%	0.25	CHEMBL3045	Homo sapiens	INH	%	0.25
	12693192	CHEMBL2343433	Inhibition of PKCbeta2 (unknown origin)	B	Cc1c(C(=O)N2CCOc3ccc(-c4ccc(N)nc4)cc3C2)ccc(S(C)(=O)=O)c1F		CHEMBL2333365	>	IC50	nM	10000.0	CHEMBL3045	Homo sapiens	IC50	nM	10000.0
	12693193	CHEMBL2343435	Inhibition of PKCbeta1 (unknown origin)	B	Cc1c(C(=O)N2CCOc3ccc(-c4ccc(N)nc4)cc3C2)ccc(S(C)(=O)=O)c1F		CHEMBL2333365	>	IC50	nM	10000.0	CHEMBL3045	Homo sapiens	IC50	nM	10000.0
	12700154	CHEMBL2342692	Inhibition of recombinant PRKCB1 (unknown origin) at 5 uM by FRET-based Z'-LYTE assay	B	O=C1/C(=C/c2ccccn2)CNC/C1=C\c1ccccn1		CHEMBL574646	=	Inhibition	%	91.0	CHEMBL3045	Homo sapiens	INH	%	91.0
	12723645	CHEMBL2350476	Inhibition of PKCbeta1 (unknown origin) at 10 uM by single point assay	B	C[C@@H](Nc1c(C#N)cnc2cc(-c3ccc(-n4ccoc4=O)cc3)ccc12)C1CC1		CHEMBL2347818	=	Inhibition	%	-2.0	CHEMBL3045	Homo sapiens	INH	%	-2.0
	12724732	CHEMBL2350783	Inhibition of PKCbeta1 (unknown origin) at 1 uM by single point assay	B	CC(C)Nc1c(C#N)cnc2cc(-c3cnn(C)c3)ccc12		CHEMBL2347824	=	Inhibition	%	-7.0	CHEMBL3045	Homo sapiens	INH	%	-7.0
	12724733	CHEMBL2350783	Inhibition of PKCbeta1 (unknown origin) at 1 uM by single point assay	B	CC(C)Nc1c(C#N)cnc2cc(-c3ccc(S(C)(=O)=O)cc3)ccc12		CHEMBL2347823	=	Inhibition	%	19.0	CHEMBL3045	Homo sapiens	INH	%	19.0
	12727689	CHEMBL2351402	Inhibition of PKCbeta2 (unknown origin) assessed as remaining activity at 10 uM relative to control	B	O=c1[nH]c2ncc(-c3ccc(-c4nc[nH]n4)cc3)nc2n1CCC1CCOCC1		CHEMBL2348865	=	Activity	%	84.0	CHEMBL3045	Homo sapiens	Activity	%	84.0
	12727690	CHEMBL2351403	Inhibition of PKCbeta1 (unknown origin) assessed as remaining activity at 10 uM relative to control	B	O=c1[nH]c2ncc(-c3ccc(-c4nc[nH]n4)cc3)nc2n1CCC1CCOCC1		CHEMBL2348865	=	Activity	%	93.0	CHEMBL3045	Homo sapiens	Activity	%	93.0
	12728975	CHEMBL2350152	Inhibition of PKCbeta2 (unknown origin) assessed as remaining activity at 1 uM relative to control	B	CC(C)(O)c1ccc(-c2cnc3c(n2)N(CC2CCOCC2)CC(=O)N3)cn1		CHEMBL2348862	=	Activity	%	110.0	CHEMBL3045	Homo sapiens	Activity	%	110.0
	12728976	CHEMBL2350153	Inhibition of PKCbeta1 (unknown origin) assessed as remaining activity at 1 uM relative to control	B	CC(C)(O)c1ccc(-c2cnc3c(n2)N(CC2CCOCC2)CC(=O)N3)cn1		CHEMBL2348862	=	Activity	%	93.0	CHEMBL3045	Homo sapiens	Activity	%	93.0
	12729856	CHEMBL2352443	Inhibition of PKCb2 (unknown origin) using [gamma-33P]ATP assessed as residual activity at 3 uM	B	CCc1ccc(-c2ccc3c(c2)-c2[nH]ncc2S(=O)(=O)N3C)cc1		CHEMBL2333445	=	Activity	%	86.0	CHEMBL3045	Homo sapiens	Activity	%	86.0
	12729857	CHEMBL2352442	Inhibition of PKCb1 (unknown origin) using [gamma-33P]ATP assessed as residual activity at 3 uM	B	CCc1ccc(-c2ccc3c(c2)-c2[nH]ncc2S(=O)(=O)N3C)cc1		CHEMBL2333445	=	Activity	%	101.0	CHEMBL3045	Homo sapiens	Activity	%	101.0
	12730118	CHEMBL2351402	Inhibition of PKCbeta2 (unknown origin) assessed as remaining activity at 10 uM relative to control	B	CC(C)(O)c1ccc(-c2cnc3c(n2)N(CC2CCOCC2)CC(=O)N3)cn1		CHEMBL2348862	=	Activity	%	93.0	CHEMBL3045	Homo sapiens	Activity	%	93.0
	12730119	CHEMBL2351403	Inhibition of PKCbeta1 (unknown origin) assessed as remaining activity at 10 uM relative to control	B	CC(C)(O)c1ccc(-c2cnc3c(n2)N(CC2CCOCC2)CC(=O)N3)cn1		CHEMBL2348862	=	Activity	%	96.0	CHEMBL3045	Homo sapiens	Activity	%	96.0
	13281305	CHEMBL2378210	Inhibition of protein kinase C beta (unknown origin) at 10 uM relative to control	B	C[C@@H](NC(=O)c1c[nH]c2ncc(-c3ncn4cc(F)cc(F)c34)nc12)C(=O)N1CC(C#N)C1		CHEMBL2376158	=	Inhibition	%	9.0	CHEMBL3045	Homo sapiens	INH	%	9.0
	13281306	CHEMBL2378210	Inhibition of protein kinase C beta (unknown origin) at 10 uM relative to control	B	Cn1nc(-c2cnc3[nH]cc(C(=O)N[C@@H](C(=O)N4CC(C#N)C4)C4CC4)c3n2)c2ccc(Cl)cc21		CHEMBL2376154	=	Inhibition	%	46.0	CHEMBL3045	Homo sapiens	INH	%	46.0
	13281307	CHEMBL2378210	Inhibition of protein kinase C beta (unknown origin) at 10 uM relative to control	B	CC[C@@H](NC(=O)c1c[nH]c2ncc(-c3nn(C)c4cc(Cl)ccc34)nc12)C(=O)N1CC(C#N)C1		CHEMBL2376153	=	Inhibition	%	13.0	CHEMBL3045	Homo sapiens	INH	%	13.0
	13281308	CHEMBL2378210	Inhibition of protein kinase C beta (unknown origin) at 10 uM relative to control	B	C[C@@H](NC(=O)c1c[nH]c2ncc(-c3nn(C)c4cc(Cl)cc(F)c34)nc12)C(=O)N1CC(C#N)C1		CHEMBL2376152	=	Inhibition	%	1.0	CHEMBL3045	Homo sapiens	INH	%	1.0
	13281309	CHEMBL2378210	Inhibition of protein kinase C beta (unknown origin) at 10 uM relative to control	B	C[C@@H](NC(=O)c1c[nH]c2ncc(-c3nn(C)c4cc(Cl)ccc34)nc12)C(=O)N1CC(C#N)C1		CHEMBL2376144	=	Inhibition	%	-5.0	CHEMBL3045	Homo sapiens	INH	%	-5.0
	13281310	CHEMBL2378210	Inhibition of protein kinase C beta (unknown origin) at 10 uM relative to control	B	C[C@@H](NC(=O)c1c[nH]c2ncc(-c3cn(C)c4cc(Cl)ccc34)nc12)C(=O)N1CC(C#N)C1		CHEMBL2376143	=	Inhibition	%	-5.0	CHEMBL3045	Homo sapiens	INH	%	-5.0
Not Active	13328752	CHEMBL2388477	Inhibition of PRKCB2 (unknown origin)	B	Cc1cccc2nc(Cn3cnc4ccccc43)cc(=O)n12		CHEMBL2386917		Inhibition	%		CHEMBL3045	Homo sapiens	INH		
	13374382	CHEMBL2406514	Inhibition of PKCbeta2 (unknown origin) at 10 uM relative to control	B	CC[C@@H]1C(=O)N(C)c2cnc(-n3ccnc3-c3ccc(F)cc3)nc2N1c1ccn(C)n1		CHEMBL2402081	=	Inhibition	%	5.0	CHEMBL3045	Homo sapiens	INH	%	5.0
	13374383	CHEMBL2406516	Inhibition of PKCbeta1 (unknown origin) at 10 uM relative to control	B	CC[C@@H]1C(=O)N(C)c2cnc(-n3ccnc3-c3ccc(F)cc3)nc2N1c1ccn(C)n1		CHEMBL2402081	=	Inhibition	%	12.0	CHEMBL3045	Homo sapiens	INH	%	12.0
	13413166	CHEMBL2421508	Displacement of [3H]PDBu from PKCbeta C1A domain (unknown origin)	B	C[C@@H](CCCc1cccc(O)c1)[C@H]1O[C@@]23C[C@H](OC(=O)C[C@H]([C@@H](C)O)OC(=O)C[C@](O)(O2)[C@H](C)CC3(C)C)[C@@H]1C		CHEMBL2418196	=	Ki	nM	1.5	CHEMBL3045	Homo sapiens	Ki	nM	1.5
	13419748	CHEMBL2422282	Inhibition of PKCbeta-2 (unknown origin) at 30 uM by microfluidic mobility shift assay relative to control	B	c1ccc(CC2CCC3(CCN(c4ncnc5[nH]cnc45)CC3)NC2)cc1		CHEMBL2420901	=	Inhibition	%	13.0	CHEMBL3045	Homo sapiens	INH	%	13.0
	13419749	CHEMBL2422282	Inhibition of PKCbeta-2 (unknown origin) at 30 uM by microfluidic mobility shift assay relative to control	B	c1ccc(CC2CCNC3(CCN(c4ncnc5[nH]cnc45)CC3)C2)cc1		CHEMBL2420900	=	Inhibition	%	60.0	CHEMBL3045	Homo sapiens	INH	%	60.0
	13419750	CHEMBL2422282	Inhibition of PKCbeta-2 (unknown origin) at 30 uM by microfluidic mobility shift assay relative to control	B	c1ccc(C2CCNC3(CCN(c4ncnc5[nH]cnc45)CC3)C2)cc1		CHEMBL2420899	=	Inhibition	%	36.0	CHEMBL3045	Homo sapiens	INH	%	36.0
	13419751	CHEMBL2422283	Inhibition of PKCbeta-1 (unknown origin) at 30 uM by microfluidic mobility shift assay relative to control	B	c1ccc(CC2CCC3(CCN(c4ncnc5[nH]cnc45)CC3)NC2)cc1		CHEMBL2420901	=	Inhibition	%	38.0	CHEMBL3045	Homo sapiens	INH	%	38.0
	13419752	CHEMBL2422283	Inhibition of PKCbeta-1 (unknown origin) at 30 uM by microfluidic mobility shift assay relative to control	B	c1ccc(CC2CCNC3(CCN(c4ncnc5[nH]cnc45)CC3)C2)cc1		CHEMBL2420900	=	Inhibition	%	76.0	CHEMBL3045	Homo sapiens	INH	%	76.0
	13419753	CHEMBL2422283	Inhibition of PKCbeta-1 (unknown origin) at 30 uM by microfluidic mobility shift assay relative to control	B	c1ccc(C2CCNC3(CCN(c4ncnc5[nH]cnc45)CC3)C2)cc1		CHEMBL2420899	=	Inhibition	%	65.0	CHEMBL3045	Homo sapiens	INH	%	65.0
	13434546	CHEMBL2424235	Inhibition of PKCbeta in human PC3 cell lysates at 10 uM using desthiobiotin-tagged ATP probe AX9989 followed by trypsinization by LC/MS analysis	B	O=C(NC1(Cc2ccc(F)cc2)CC1)c1ccc2nc(N[C@H]3CC[C@H](O)CC3)c3nccn3c2c1		CHEMBL2420551	<	Inhibition	%	35.0	CHEMBL3045	Homo sapiens	INH	%	35.0
	13434547	CHEMBL2424235	Inhibition of PKCbeta in human PC3 cell lysates at 10 uM using desthiobiotin-tagged ATP probe AX9989 followed by trypsinization by LC/MS analysis	B	O=C(NC1(c2ccc(F)cc2)CC1)c1ccc2nc(N[C@H]3CC[C@H](O)CC3)c3nccn3c2c1		CHEMBL2420555	<	Inhibition	%	35.0	CHEMBL3045	Homo sapiens	INH	%	35.0
	13434548	CHEMBL2424235	Inhibition of PKCbeta in human PC3 cell lysates at 10 uM using desthiobiotin-tagged ATP probe AX9989 followed by trypsinization by LC/MS analysis	B	O=C(NC1(c2ccccc2)CCC1)c1ccc2nc(N[C@H]3CC[C@H](O)CC3)c3nccn3c2c1		CHEMBL2420573	<	Inhibition	%	35.0	CHEMBL3045	Homo sapiens	INH	%	35.0
	13434549	CHEMBL2424235	Inhibition of PKCbeta in human PC3 cell lysates at 10 uM using desthiobiotin-tagged ATP probe AX9989 followed by trypsinization by LC/MS analysis	B	O=C(NC1(c2ccccc2)CC1)c1ccc2nc(N[C@H]3CC[C@H](O)CC3)c3nccn3c2c1		CHEMBL2420572	<	Inhibition	%	35.0	CHEMBL3045	Homo sapiens	INH	%	35.0
	13434550	CHEMBL2424235	Inhibition of PKCbeta in human PC3 cell lysates at 10 uM using desthiobiotin-tagged ATP probe AX9989 followed by trypsinization by LC/MS analysis	B	CC(C)(NC(=O)c1ccc2nc(N[C@H]3CC[C@H](O)CC3)c3nccn3c2c1)c1ccccc1		CHEMBL2420570	<	Inhibition	%	35.0	CHEMBL3045	Homo sapiens	INH	%	35.0
	13434551	CHEMBL2424235	Inhibition of PKCbeta in human PC3 cell lysates at 10 uM using desthiobiotin-tagged ATP probe AX9989 followed by trypsinization by LC/MS analysis	B	CCC[C@@H](NC(=O)c1ccc2nc(N[C@H]3CC[C@H](O)CC3)c3nccn3c2c1)c1ccccc1		CHEMBL2420565	<	Inhibition	%	35.0	CHEMBL3045	Homo sapiens	INH	%	35.0
	13434552	CHEMBL2424235	Inhibition of PKCbeta in human PC3 cell lysates at 10 uM using desthiobiotin-tagged ATP probe AX9989 followed by trypsinization by LC/MS analysis	B	O=C(N[C@H](CO)c1ccccc1)c1ccc2nc(N[C@H]3CC[C@H](O)CC3)c3nccn3c2c1		CHEMBL2420564	<	Inhibition	%	35.0	CHEMBL3045	Homo sapiens	INH	%	35.0
	13434553	CHEMBL2424235	Inhibition of PKCbeta in human PC3 cell lysates at 10 uM using desthiobiotin-tagged ATP probe AX9989 followed by trypsinization by LC/MS analysis	B	CC[C@@H](NC(=O)c1ccc2nc(N[C@H]3CC[C@H](O)CC3)c3nccn3c2c1)c1ccccc1		CHEMBL2420562	<	Inhibition	%	35.0	CHEMBL3045	Homo sapiens	INH	%	35.0
	13434554	CHEMBL2424235	Inhibition of PKCbeta in human PC3 cell lysates at 10 uM using desthiobiotin-tagged ATP probe AX9989 followed by trypsinization by LC/MS analysis	B	C[C@H](NC(=O)c1ccc2nc(N[C@H]3CC[C@H](O)CC3)c3nccn3c2c1)c1ccccc1		CHEMBL2420560	<	Inhibition	%	35.0	CHEMBL3045	Homo sapiens	INH	%	35.0
	13434555	CHEMBL2424235	Inhibition of PKCbeta in human PC3 cell lysates at 10 uM using desthiobiotin-tagged ATP probe AX9989 followed by trypsinization by LC/MS analysis	B	C[C@@H](NC(=O)c1ccc2nc(N[C@H]3CC[C@H](O)CC3)c3nccn3c2c1)c1ccccc1		CHEMBL2420556	<	Inhibition	%	35.0	CHEMBL3045	Homo sapiens	INH	%	35.0
	13434556	CHEMBL2424235	Inhibition of PKCbeta in human PC3 cell lysates at 10 uM using desthiobiotin-tagged ATP probe AX9989 followed by trypsinization by LC/MS analysis	B	NC(=O)c1ccc2nc(N[C@H]3CC[C@H](O)CC3)c3nccn3c2c1		CHEMBL2420587	<	Inhibition	%	35.0	CHEMBL3045	Homo sapiens	INH	%	35.0
	13434557	CHEMBL2424235	Inhibition of PKCbeta in human PC3 cell lysates at 10 uM using desthiobiotin-tagged ATP probe AX9989 followed by trypsinization by LC/MS analysis	B	O=C(O)c1ccc2nc(N[C@H]3CC[C@H](O)CC3)c3nccn3c2c1		CHEMBL2420585	<	Inhibition	%	35.0	CHEMBL3045	Homo sapiens	INH	%	35.0
	13506625	CHEMBL2443980	Inhibition of PKCbeta2 (unknown origin)	B	CN(C)c1ccc(Oc2cc(O)cc(O)c2-c2cc(C(=O)NC3CCN(C4CCC5(CC4)OCCO5)CC3)no2)cc1		CHEMBL2443026	>	IC50	nM	10.0	CHEMBL3045	Homo sapiens	IC50	nM	10.0
	13506626	CHEMBL2443980	Inhibition of PKCbeta2 (unknown origin)	B	CC(C)Nc1ccc(Oc2cc(O)cc(O)c2-c2cc(C(=O)NC3CCN(C)CC3)no2)cc1		CHEMBL2443139	>	IC50	nM	10.0	CHEMBL3045	Homo sapiens	IC50	nM	10.0
	13506627	CHEMBL2443980	Inhibition of PKCbeta2 (unknown origin)	B	CN1CCC(NC(=O)c2cc(-c3c(O)cc(O)cc3Oc3ccc(N(C)C)cc3)on2)CC1		CHEMBL2443138	>	IC50	nM	10.0	CHEMBL3045	Homo sapiens	IC50	nM	10.0
	13506628	CHEMBL2443980	Inhibition of PKCbeta2 (unknown origin)	B	CN1CCC(NC(=O)c2cc(-c3c(O)cc(O)cc3Oc3ccc([N+](=O)[O-])cc3)on2)CC1		CHEMBL2443044	>	IC50	nM	10.0	CHEMBL3045	Homo sapiens	IC50	nM	10.0
Not Active	13508479	CHEMBL2447353	Inhibition of PKCbeta (unknown origin) at 30 uM	B	O=C(Nc1ccc2c(c1)B(O)OC2)c1c(C(F)(F)F)ccc(Cl)c1F		CHEMBL2441375		Inhibition	%		CHEMBL3045	Homo sapiens	INH		
	13871778	CHEMBL3101239	Inhibition of human PKCbeta2 assessed as residual activity at 1 uM relative to control	B	O=C1Nc2ncccc2/C1=C1/Nc2ncccc2C1=O		CHEMBL3099673	=	Activity	%	101.0	CHEMBL3045	Homo sapiens	Activity	%	101.0
	13871779	CHEMBL3101240	Inhibition of human PKCbeta1 assessed as residual activity at 1 uM relative to control	B	O=C1Nc2ncccc2/C1=C1/Nc2ncccc2C1=O		CHEMBL3099673	=	Activity	%	105.0	CHEMBL3045	Homo sapiens	Activity	%	105.0
	13965684	CHEMBL3135234	Inhibition of human full length PKC beta2 expressed in baculovirus assessed as substrate phosphorylation using fluorescence-labelled peptides as substrate at 70 uM after 90 mins by microfluidic peptide phosphorylation assay	B	CNCc1ccc(-c2ncnc3[nH]cnc23)cc1		CHEMBL376388	=	Inhibition	%	0.0	CHEMBL3045	Homo sapiens	INH	%	0.0
	13965685	CHEMBL3135235	Inhibition of human truncated PKC beta1 expressed in baculovirus assessed as substrate phosphorylation using fluorescence-labelled peptides as substrate at 70 uM after 90 mins by microfluidic peptide phosphorylation assay	B	CNCc1ccc(-c2ncnc3[nH]cnc23)cc1		CHEMBL376388	=	Inhibition	%	73.5	CHEMBL3045	Homo sapiens	INH	%	73.5
	13966062	CHEMBL3136899	Inhibition of human full length PKC beta2 expressed in baculovirus assessed as substrate phosphorylation using fluorescence-labelled peptides as substrate at 1000 uM after 90 mins by microfluidic peptide phosphorylation assay	B	c1cnc2[nH]ccc2c1		CHEMBL389685	=	Inhibition	%	21.0	CHEMBL3045	Homo sapiens	INH	%	21.0
	13966063	CHEMBL3136900	Inhibition of human truncated PKC beta1 expressed in baculovirus assessed as substrate phosphorylation using fluorescence-labelled peptides as substrate at 1000 uM after 90 mins by microfluidic peptide phosphorylation assay	B	c1cnc2[nH]ccc2c1		CHEMBL389685	=	Inhibition	%	46.0	CHEMBL3045	Homo sapiens	INH	%	46.0
	13973337	CHEMBL3135206	Inhibition of human full length PKC beta2 expressed in baculovirus assessed as substrate phosphorylation using fluorescence-labelled peptides as substrate at 0.1 uM after 90 mins by microfluidic peptide phosphorylation assay	B	C[C@H](CN(C)C)Oc1nc(Nc2cc3cccc(Cl)c3cn2)cnc1C#N		CHEMBL1928705	=	Inhibition	%	0.0	CHEMBL3045	Homo sapiens	INH	%	0.0
	13973338	CHEMBL3135207	Inhibition of human truncated PKC beta1 expressed in baculovirus assessed as substrate phosphorylation using fluorescence-labelled peptides as substrate at 0.1 uM after 90 mins by microfluidic peptide phosphorylation assay	B	C[C@H](CN(C)C)Oc1nc(Nc2cc3cccc(Cl)c3cn2)cnc1C#N		CHEMBL1928705	=	Inhibition	%	3.0	CHEMBL3045	Homo sapiens	INH	%	3.0
	13974055	CHEMBL3134715	Inhibition of human full length PKC beta2 expressed in baculovirus assessed as substrate phosphorylation using fluorescence-labelled peptides as substrate at 0.35 uM after 90 mins by microfluidic peptide phosphorylation assay	B	COC(=O)c1cnc(Nc2cnc(C#N)cn2)cc1NCC1CCNCC1		CHEMBL1928692	=	Inhibition	%	0.0	CHEMBL3045	Homo sapiens	INH	%	0.0
	13974056	CHEMBL3134716	Inhibition of human truncated PKC beta1 expressed in baculovirus assessed as substrate phosphorylation using fluorescence-labelled peptides as substrate at 0.35 uM after 90 mins by microfluidic peptide phosphorylation assay	B	COC(=O)c1cnc(Nc2cnc(C#N)cn2)cc1NCC1CCNCC1		CHEMBL1928692	=	Inhibition	%	2.0	CHEMBL3045	Homo sapiens	INH	%	2.0
	13974146	CHEMBL3136360	Inhibition of human full length PKC beta2 expressed in baculovirus assessed as substrate phosphorylation using fluorescence-labelled peptides as substrate at 9 uM after 90 mins by microfluidic peptide phosphorylation assay	B	NCC1CN(c2ncnc3[nH]c4cnccc4c23)CCO1		CHEMBL1928677	=	Inhibition	%	23.5	CHEMBL3045	Homo sapiens	INH	%	23.5
	13974147	CHEMBL3136361	Inhibition of human truncated PKC beta1 expressed in baculovirus assessed as substrate phosphorylation using fluorescence-labelled peptides as substrate at 9 uM after 90 mins by microfluidic peptide phosphorylation assay	B	NCC1CN(c2ncnc3[nH]c4cnccc4c23)CCO1		CHEMBL1928677	=	Inhibition	%	22.5	CHEMBL3045	Homo sapiens	INH	%	22.5
	13974237	CHEMBL3135462	Inhibition of human full length PKC beta2 expressed in baculovirus assessed as substrate phosphorylation using fluorescence-labelled peptides as substrate at 90 uM after 90 mins by microfluidic peptide phosphorylation assay	B	NCC1CN(c2ncnc3[nH]cnc23)CCO1		CHEMBL560373	=	Inhibition	%	0.0	CHEMBL3045	Homo sapiens	INH	%	0.0
	13974238	CHEMBL3135463	Inhibition of human truncated PKC beta1 expressed in baculovirus assessed as substrate phosphorylation using fluorescence-labelled peptides as substrate at 90 uM after 90 mins by microfluidic peptide phosphorylation assay	B	NCC1CN(c2ncnc3[nH]cnc23)CCO1		CHEMBL560373	=	Inhibition	%	68.5	CHEMBL3045	Homo sapiens	INH	%	68.5
	13974975	CHEMBL3137139	Inhibition of human full length PKC beta2 expressed in baculovirus assessed as substrate phosphorylation using fluorescence-labelled peptides as substrate at 420 uM after 90 mins by microfluidic peptide phosphorylation assay	B	c1nc(N2CCOCC2)c2nc[nH]c2n1		CHEMBL271138	=	Inhibition	%	38.0	CHEMBL3045	Homo sapiens	INH	%	38.0
	13974976	CHEMBL3137140	Inhibition of human truncated PKC beta1 expressed in baculovirus assessed as substrate phosphorylation using fluorescence-labelled peptides as substrate at 420 uM after 90 mins by microfluidic peptide phosphorylation assay	B	c1nc(N2CCOCC2)c2nc[nH]c2n1		CHEMBL271138	=	Inhibition	%	70.0	CHEMBL3045	Homo sapiens	INH	%	70.0
	13975066	CHEMBL3136711	Inhibition of human full length PKC beta2 expressed in baculovirus assessed as substrate phosphorylation using fluorescence-labelled peptides as substrate at 0.02 uM after 90 mins by microfluidic peptide phosphorylation assay	B	NC1(C(=O)NCc2ccc(Cl)cc2)CCN(c2ncnc3[nH]ccc23)CC1		CHEMBL598194	=	Inhibition	%	2.0	CHEMBL3045	Homo sapiens	INH	%	2.0
	13975067	CHEMBL3136712	Inhibition of human truncated PKC beta1 expressed in baculovirus assessed as substrate phosphorylation using fluorescence-labelled peptides as substrate at 0.02 uM after 90 mins by microfluidic peptide phosphorylation assay	B	NC1(C(=O)NCc2ccc(Cl)cc2)CCN(c2ncnc3[nH]ccc23)CC1		CHEMBL598194	=	Inhibition	%	0.0	CHEMBL3045	Homo sapiens	INH	%	0.0
	13975157	CHEMBL3134940	Inhibition of human full length PKC beta2 expressed in baculovirus assessed as substrate phosphorylation using fluorescence-labelled peptides as substrate at 0.06 uM after 90 mins by microfluidic peptide phosphorylation assay	B	NC1(Cc2ccc(Cl)cc2)CCN(c2ncnc3[nH]ccc23)CC1		CHEMBL263664	=	Inhibition	%	0.0	CHEMBL3045	Homo sapiens	INH	%	0.0
	13975158	CHEMBL3134941	Inhibition of human truncated PKC beta1 expressed in baculovirus assessed as substrate phosphorylation using fluorescence-labelled peptides as substrate at 0.06 uM after 90 mins by microfluidic peptide phosphorylation assay	B	NC1(Cc2ccc(Cl)cc2)CCN(c2ncnc3[nH]ccc23)CC1		CHEMBL263664	=	Inhibition	%	3.5	CHEMBL3045	Homo sapiens	INH	%	3.5
	13975248	CHEMBL3136529	Inhibition of human full length PKC beta2 expressed in baculovirus assessed as substrate phosphorylation using fluorescence-labelled peptides as substrate at 2 uM after 90 mins by microfluidic peptide phosphorylation assay	B	NC1CCN(c2ncnc3[nH]ccc23)CC1		CHEMBL259141	=	Inhibition	%	62.5	CHEMBL3045	Homo sapiens	INH	%	62.5
	13975249	CHEMBL3136530	Inhibition of human truncated PKC beta1 expressed in baculovirus assessed as substrate phosphorylation using fluorescence-labelled peptides as substrate at 2 uM after 90 mins by microfluidic peptide phosphorylation assay	B	NC1CCN(c2ncnc3[nH]ccc23)CC1		CHEMBL259141	=	Inhibition	%	16.5	CHEMBL3045	Homo sapiens	INH	%	16.5
	13975891	CHEMBL3136136	Inhibition of human full length PKC beta2 expressed in baculovirus assessed as substrate phosphorylation using fluorescence-labelled peptides as substrate at 8 uM after 90 mins by microfluidic peptide phosphorylation assay	B	NCC1CCN(c2ncnc3[nH]ccc23)CC1		CHEMBL261249	=	Inhibition	%	88.5	CHEMBL3045	Homo sapiens	INH	%	88.5
	13975892	CHEMBL3136137	Inhibition of human truncated PKC beta1 expressed in baculovirus assessed as substrate phosphorylation using fluorescence-labelled peptides as substrate at 8 uM after 90 mins by microfluidic peptide phosphorylation assay	B	NCC1CCN(c2ncnc3[nH]ccc23)CC1		CHEMBL261249	=	Inhibition	%	50.5	CHEMBL3045	Homo sapiens	INH	%	50.5
	13975984	CHEMBL3136293	Inhibition of human full length PKC beta2 expressed in baculovirus assessed as substrate phosphorylation using fluorescence-labelled peptides as substrate at 0.2 uM after 90 mins by microfluidic peptide phosphorylation assay	B	Clc1ccc(C2(c3ccc(-c4ncnc5[nH]cnc45)cc3)CCNCC2)cc1		CHEMBL228133	=	Inhibition	%	38.5	CHEMBL3045	Homo sapiens	INH	%	38.5
	13975985	CHEMBL3136294	Inhibition of human truncated PKC beta1 expressed in baculovirus assessed as substrate phosphorylation using fluorescence-labelled peptides as substrate at 0.2 uM after 90 mins by microfluidic peptide phosphorylation assay	B	Clc1ccc(C2(c3ccc(-c4ncnc5[nH]cnc45)cc3)CCNCC2)cc1		CHEMBL228133	=	Inhibition	%	53.0	CHEMBL3045	Homo sapiens	INH	%	53.0
	13976075	CHEMBL3136175	Inhibition of human full length PKC beta2 expressed in baculovirus assessed as substrate phosphorylation using fluorescence-labelled peptides as substrate at 95 uM after 90 mins by microfluidic peptide phosphorylation assay	B	NCCc1ccc(-c2ncnc3[nH]cnc23)cc1		CHEMBL227727	=	Inhibition	%	0.0	CHEMBL3045	Homo sapiens	INH	%	0.0
	13976076	CHEMBL3136176	Inhibition of human truncated PKC beta1 expressed in baculovirus assessed as substrate phosphorylation using fluorescence-labelled peptides as substrate at 95 uM after 90 mins by microfluidic peptide phosphorylation assay	B	NCCc1ccc(-c2ncnc3[nH]cnc23)cc1		CHEMBL227727	=	Inhibition	%	77.0	CHEMBL3045	Homo sapiens	INH	%	77.0
	14582584	CHEMBL3241648	Inhibition of human PKCbeta1 assessed as enzyme activity at 1 uM relative to control	B	CCCS(=O)(=O)Nc1cccc(Nc2ccc3ncn(C)c(=O)c3c2)c1C#N		CHEMBL3236464	=	Activity	%	87.0	CHEMBL3045	Homo sapiens	Activity	%	87.0
	14582585	CHEMBL3241649	Inhibition of human PKCbeta2 assessed as enzyme activity at 1 uM relative to control	B	CCCS(=O)(=O)Nc1cccc(Nc2ccc3ncn(C)c(=O)c3c2)c1C#N		CHEMBL3236464	=	Activity	%	100.5	CHEMBL3045	Homo sapiens	Activity	%	100.5
Not Active	14652726	CHEMBL3270633	Inhibition of human PKCbeta1 at 1 uM	B	CCN(Cc1ccc(C)cc1)C(=O)c1nc(-c2ccccc2Cl)c2ccccc2n1		CHEMBL3261905		Inhibition	%		CHEMBL3045	Homo sapiens	INH		
Not Active	14652729	CHEMBL3270634	Inhibition of human PKCbeta1 at 10 uM	B	CCN(Cc1ccc(C)cc1)C(=O)c1nc(-c2ccccc2Cl)c2ccccc2n1		CHEMBL3261905		Inhibition	%		CHEMBL3045	Homo sapiens	INH		
Not Active	14652730	CHEMBL3270635	Inhibition of human PKCbeta2 at 1 uM	B	CCN(Cc1ccc(C)cc1)C(=O)c1nc(-c2ccccc2Cl)c2ccccc2n1		CHEMBL3261905		Inhibition	%		CHEMBL3045	Homo sapiens	INH		
Not Active	14652731	CHEMBL3270636	Inhibition of human PKCbeta2 at 10 uM	B	CCN(Cc1ccc(C)cc1)C(=O)c1nc(-c2ccccc2Cl)c2ccccc2n1		CHEMBL3261905		Inhibition	%		CHEMBL3045	Homo sapiens	INH		
Not Active	14659135	CHEMBL3268162	Inhibition of recombinant GST-tagged PKCbeta2 (unknown origin)-His-tagged RACK1 interaction after 1 hr by ELISA-based assay relative to untreated control	B	CC(=O)c1cccc(NC(=O)c2sc3nc4cc5c(cc4cc3c2N)OCCO5)c1		CHEMBL3261343		Inhibition	%		CHEMBL3045	Homo sapiens	INH		
	14659150	CHEMBL3269725	Inhibition of PKCbeta1 (unknown origin) at 50 uM	B	CC(=O)c1cccc(NC(=O)c2sc3nc4cc5c(cc4cc3c2N)OCCO5)c1		CHEMBL3261343	=	Inhibition	%	80.0	CHEMBL3045	Homo sapiens	INH	%	80.0
	14751811	CHEMBL3300859	Inhibition of PKC-beta (unknown origin)	B	CC(C)(C)CNC(=O)CC1CNC(=O)c2cc(-c3ccsc3)cn21		CHEMBL3298400	>	IC50	nM	10000.0	CHEMBL3045	Homo sapiens	IC50	uM	10.0
	14751812	CHEMBL3300859	Inhibition of PKC-beta (unknown origin)	B	CN1CCN(C[C@@H](NC(=O)C[C@H]2CNC(=O)c3cc(-c4cccc(Cl)c4)cn32)C2CCCCC2)CC1		CHEMBL3297762	>	IC50	nM	10000.0	CHEMBL3045	Homo sapiens	IC50	uM	10.0
	14983171	CHEMBL3385028	Inhibition of PKC beta1 (unknown origin) at 1 uM	B	CN1CCN(c2ccc(-c3cnc4[nH]c5cnc(C#N)cc5c4c3)cc2)CC1		CHEMBL3359895	=	Inhibition	%	16.0	CHEMBL3045	Homo sapiens	INH	%	16.0
	14984413	CHEMBL3384378	Inhibition of PKC beta1 (unknown origin) at 0.1 uM	B	CN1CCN(c2ccc(-c3cnc4[nH]c5cnc(C#N)cc5c4c3)cc2)CC1		CHEMBL3359895	=	Inhibition	%	1.0	CHEMBL3045	Homo sapiens	INH	%	1.0
Not Active	14999363	CHEMBL3368454	Inhibition of human PKCbeta2 at 10 uM relative to control	B	CC(C)(C)C1=NN(c2ccc(Cl)cc2)C(c2ccc(O)cc2)C1		CHEMBL3323314		Inhibition	%		CHEMBL3045	Homo sapiens	INH		
Active	14999364	CHEMBL3368454	Inhibition of human PKCbeta2 at 10 uM relative to control	B	Cn1cc(C2=C(c3cn(CCCSC(=N)N)c4ccccc34)C(=O)NC2=O)c2ccccc21		CHEMBL6291		Inhibition	%		CHEMBL3045	Homo sapiens	INH		
Not Active	14999382	CHEMBL3368460	Inhibition of human PKCbeta1 at 10 uM relative to control	B	CC(C)(C)C1=NN(c2cccc(Cl)c2)C(c2ccc(F)c(O)c2)C1		CHEMBL3323358		Inhibition	%		CHEMBL3045	Homo sapiens	INH		
	15008093	CHEMBL3369108	Inhibition of human PKCbeta1 at 1 uM by radiometric Assay	B	NS(=O)(=O)c1cccc(-c2n[nH]c3ccc(NC(=O)Cc4ccccc4)cc23)c1		CHEMBL3330255	=	Inhibition	%	0.0	CHEMBL3045	Homo sapiens	INH	%	0.0
	15008094	CHEMBL3369108	Inhibition of human PKCbeta1 at 1 uM by radiometric Assay	B	COC(C(=O)Nc1ccc2[nH]nc(-c3cccc(S(N)(=O)=O)c3)c2c1)c1ccccc1		CHEMBL3330401	=	Inhibition	%	-6.0	CHEMBL3045	Homo sapiens	INH	%	-6.0
	15008095	CHEMBL3369108	Inhibition of human PKCbeta1 at 1 uM by radiometric Assay	B	NS(=O)(=O)c1cccc(-c2n[nH]c3ccc(NC(=O)C(c4ccsc4)N4CCCC4)cc23)c1		CHEMBL3330410	=	Inhibition	%	2.0	CHEMBL3045	Homo sapiens	INH	%	2.0
	15008096	CHEMBL3369109	Inhibition of human PKCbeta2 at 1 uM by radiometric Assay	B	NS(=O)(=O)c1cccc(-c2n[nH]c3ccc(NC(=O)Cc4ccccc4)cc23)c1		CHEMBL3330255	=	Inhibition	%	0.0	CHEMBL3045	Homo sapiens	INH	%	0.0
	15008097	CHEMBL3369109	Inhibition of human PKCbeta2 at 1 uM by radiometric Assay	B	COC(C(=O)Nc1ccc2[nH]nc(-c3cccc(S(N)(=O)=O)c3)c2c1)c1ccccc1		CHEMBL3330401	=	Inhibition	%	-4.0	CHEMBL3045	Homo sapiens	INH	%	-4.0
	15008098	CHEMBL3369109	Inhibition of human PKCbeta2 at 1 uM by radiometric Assay	B	NS(=O)(=O)c1cccc(-c2n[nH]c3ccc(NC(=O)C(c4ccsc4)N4CCCC4)cc23)c1		CHEMBL3330410	=	Inhibition	%	1.0	CHEMBL3045	Homo sapiens	INH	%	1.0
	15020533	CHEMBL3362926	Inhibition of human recombinant PKCbeta expressed in Sf21 cells using Bio-cdc peptide substrate and ATP after 60 mins by time-resolved fluorescence in-vitro kinase assay	B	Cc1cc2c(cc1NC1CNC1)N1C(=NNC(=O)[C@H]1C)CO2		CHEMBL3356470	=	IC50	nM	520.0	CHEMBL3045	Homo sapiens	IC50	uM	0.52
	15020534	CHEMBL3362926	Inhibition of human recombinant PKCbeta expressed in Sf21 cells using Bio-cdc peptide substrate and ATP after 60 mins by time-resolved fluorescence in-vitro kinase assay	B	C[C@@H]1C(=O)NN=C2COc3cc(-c4ccccc4)c(NC4CNC4)cc3N21		CHEMBL3356472	=	IC50	nM	87.0	CHEMBL3045	Homo sapiens	IC50	uM	0.087
	15020535	CHEMBL3362926	Inhibition of human recombinant PKCbeta expressed in Sf21 cells using Bio-cdc peptide substrate and ATP after 60 mins by time-resolved fluorescence in-vitro kinase assay	B	C[C@@H]1C(=O)NN=C2COc3cc(C(F)(F)F)c(NC4CNC4)cc3N21		CHEMBL3356474	=	IC50	nM	1500.0	CHEMBL3045	Homo sapiens	IC50	uM	1.5
	15036923	CHEMBL3381100	Inhibition of PKCbeta (unknown origin)	B	Nc1nc2c3c(F)cccc3nc(Cc3ccc4c(c3)OCO4)n2n1		CHEMBL3309990	>	IC50	nM	10000.0	CHEMBL3045	Homo sapiens	IC50	uM	10.0
	15036924	CHEMBL3381100	Inhibition of PKCbeta (unknown origin)	B	Nc1ccc2c(c1)nc(Cc1ccc3c(c1)OCO3)n1nc(N)nc21		CHEMBL3309995	>	IC50	nM	10000.0	CHEMBL3045	Homo sapiens	IC50	uM	10.0
	15036925	CHEMBL3381100	Inhibition of PKCbeta (unknown origin)	B	OCCCNc1ccc2c(c1)nc(-c1ccc3c(c1)OCO3)n1ncnc21		CHEMBL3309997	>	IC50	nM	10000.0	CHEMBL3045	Homo sapiens	IC50	uM	10.0
	15036926	CHEMBL3381100	Inhibition of PKCbeta (unknown origin)	B	Nc1nc2c3ccc(NCCO)cc3nc(Cc3ccc4c(c3)OCO4)n2n1		CHEMBL3309998	>	IC50	nM	10000.0	CHEMBL3045	Homo sapiens	IC50	uM	10.0
	15036927	CHEMBL3381100	Inhibition of PKCbeta (unknown origin)	B	CN1CCN(c2cc(F)c3c(c2)nc(Cc2ccc4c(c2)OCO4)n2nc(N)nc32)CC1		CHEMBL3310151	>	IC50	nM	10000.0	CHEMBL3045	Homo sapiens	IC50	uM	10.0
	15091072	CHEMBL3382230	Inhibition of human recombinant PKCbeta2 using CREBtide (CKRREILSRRPSYRK) substrate assessed as remaining enzyme activity at 1 uM after 15 mins relative to control	B	O=C1Nc2ccc(Cl)cc2/C1=C/c1cc(Br)c(O)c(Br)c1		CHEMBL2206014	=	Activity	%	85.0	CHEMBL3045	Homo sapiens	Activity	%	85.0
	15685914	CHEMBL3606457	Inhibition of human PKCbeta	B	NC(=O)c1cc(F)cc2c1C(=O)N(C1CCN(C3CCC(F)(F)CC3)CC1)C2		CHEMBL3606021	>	IC50	nM	10000.0	CHEMBL3045	Homo sapiens	IC50	uM	10.0
	15747328	CHEMBL3624079	Inhibition of PKCbeta2 (unknown origin) assessed as residual enzyme activity at 10 uM by kinaseprolier assay	B	NCCn1c(C2CCNCC2)nc2cc(C(N)=O)ccc21		CHEMBL3622826	>	Activity	%	65.0	CHEMBL3045	Homo sapiens	Activity	%	65.0
	15754262	CHEMBL3631688	Inhibition of PKCbeta1 (unknown origin) at 1 uM by FRET method	B	N#Cc1ccnc(Nc2cc(C3CCN(C4COC4)CC3)n(C3CCCC3)n2)c1		CHEMBL3629013	=	Inhibition	%	15.9	CHEMBL3045	Homo sapiens	INH	%	15.9
	16376474	CHEMBL3734498	Inhibition of recombinant human PKCb2 using fluorescein-labeled peptide as substrate by fluorescence-electrophoretic mobility shift assay	B	Cl.NCCN1C(=O)S/C(=C\CCC2CCCCC2)C1=O		CHEMBL3732044	=	Inhibition	%	16.0	CHEMBL3045	Homo sapiens	INH	%	16.0
	16425283	CHEMBL3751101	Inhibition of PKC beta1 (unknown origin) at 1 uM	B	Cc1c(-c2cc(Nc3cc4n(n3)CCN(C)C4)c(=O)[nH]n2)ccc(F)c1NC(=O)c1cc2ccccc2s1		CHEMBL3746293	=	Inhibition	%	0.2	CHEMBL3045	Homo sapiens	INH	%	0.2
	16431963	CHEMBL3748056	Inhibition of human PKCb2 using histone H1 as substrate	B	Cn1c(=O)c(S(=O)(=O)c2ccc(F)cc2F)cc2cnc(Nc3ccc4[nH]ccc4c3)nc21		CHEMBL3745885	>	IC50	nM	10000.0	CHEMBL3045	Homo sapiens	IC50	uM	10.0
	16451572	CHEMBL3760869	Inhibition of PKCbeta2 (unknown origin) at 100 nM	B	CC1(C)OCc2c(Nc3n[nH]c4ccccc34)nc(-c3cn[nH]c3)nc21		CHEMBL3758502	=	Inhibition	%	11.4	CHEMBL3045	Homo sapiens	INH	%	11.4
	16458603	CHEMBL3761599	Inhibition of PRKCB1 (unknown origin) at 500 nM	B	C[C@@H](Nc1ncnc2sc(-c3ccccc3C(N)=O)cc12)c1ccccc1		CHEMBL3759085	=	Inhibition	%	3.0	CHEMBL3045	Homo sapiens	INH	%	3.0
	16458604	CHEMBL3761599	Inhibition of PRKCB1 (unknown origin) at 500 nM	B	C[C@@H](Nc1ncnc2sc(-c3ccc(C(=O)NCCN(C)C)cc3)cc12)c1ccccc1		CHEMBL3758800	=	Inhibition	%	2.0	CHEMBL3045	Homo sapiens	INH	%	2.0
	16458605	CHEMBL3761599	Inhibition of PRKCB1 (unknown origin) at 500 nM	B	CN(C)CCNC(=O)c1ccc(-c2cc3c(N[C@H](CO)c4ccccc4)ncnc3s2)cc1		CHEMBL3758376	=	Inhibition	%	18.0	CHEMBL3045	Homo sapiens	INH	%	18.0
	16458606	CHEMBL3761599	Inhibition of PRKCB1 (unknown origin) at 500 nM	B	COc1cc(C(N)=O)ccc1-c1cc2c(N[C@H](CO)c3ccccc3)ncnc2s1		CHEMBL3759480	=	Inhibition	%	5.0	CHEMBL3045	Homo sapiens	INH	%	5.0
	16458607	CHEMBL3761599	Inhibition of PRKCB1 (unknown origin) at 500 nM	B	COc1ccc(C(=O)NCCN(C)C)cc1-c1cc2c(N[C@H](C)c3ccccc3)ncnc2s1		CHEMBL3758582	=	Inhibition	%	-2.0	CHEMBL3045	Homo sapiens	INH	%	-2.0
	16458608	CHEMBL3761599	Inhibition of PRKCB1 (unknown origin) at 500 nM	B	COc1cc(CO)ccc1-c1cc2c(N[C@H](C)c3ccccc3)ncnc2s1		CHEMBL3759559	=	Inhibition	%	1.0	CHEMBL3045	Homo sapiens	INH	%	1.0
	16458609	CHEMBL3761599	Inhibition of PRKCB1 (unknown origin) at 500 nM	B	COc1cc(CO)ccc1-c1cc2c(N[C@H](CO)c3ccccc3)ncnc2s1		CHEMBL3758682	=	Inhibition	%	4.0	CHEMBL3045	Homo sapiens	INH	%	4.0
	16458610	CHEMBL3761599	Inhibition of PRKCB1 (unknown origin) at 500 nM	B	COc1cc(CO)ccc1-c1cc2c(Nc3ccccc3)ncnc2s1		CHEMBL3758768	=	Inhibition	%	-7.0	CHEMBL3045	Homo sapiens	INH	%	-7.0
	16458611	CHEMBL3761599	Inhibition of PRKCB1 (unknown origin) at 500 nM	B	C#Cc1cccc(Nc2ncnc3sc(-c4ccc(CO)cc4OC)cc23)c1		CHEMBL3758802	=	Inhibition	%	-2.0	CHEMBL3045	Homo sapiens	INH	%	-2.0
	16458612	CHEMBL3761599	Inhibition of PRKCB1 (unknown origin) at 500 nM	B	COc1cc(CO)ccc1-c1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2s1		CHEMBL3758351	=	Inhibition	%	-2.0	CHEMBL3045	Homo sapiens	INH	%	-2.0
	16458613	CHEMBL3761599	Inhibition of PRKCB1 (unknown origin) at 500 nM	B	C#Cc1cccc(Nc2ncnc3cc(OCCOC)c(OCCOC)cc23)c1		CHEMBL553	=	Inhibition	%	-2.0	CHEMBL3045	Homo sapiens	INH	%	-2.0
	16495184	CHEMBL3777512	Inhibition of N-terminal His6-tagged recombinant human PKCbeta1expressed in baculovirus infected insect Sf9 cells assessed as remaining activity at 1 uM relative to control	B	Cn1cc(-c2ccc(Cc3n[nH]c4ccc(C(=O)N5CC[C@@H](O)C5)cc34)cc2)cn1		CHEMBL3775317	=	Activity	%	15.0	CHEMBL3045	Homo sapiens	Activity	%	15.0
	16495185	CHEMBL3777513	Inhibition of N-terminal His6-tagged recombinant human PKCB2 expressed in baculovirus infected insect Sf9 cells assessed as remaining activity at 1 uM relative to control	B	Cn1cc(-c2ccc(Cc3n[nH]c4ccc(C(=O)N5CC[C@@H](O)C5)cc34)cc2)cn1		CHEMBL3775317	=	Activity	%	-5.0	CHEMBL3045	Homo sapiens	Activity	%	-5.0
	16496103	CHEMBL3777512	Inhibition of N-terminal His6-tagged recombinant human PKCbeta1expressed in baculovirus infected insect Sf9 cells assessed as remaining activity at 1 uM relative to control	B	Cn1cc(-c2ccc(Cc3n[nH]c4ccc(C(=O)N5CCOCC5)cc34)cc2)cn1		CHEMBL3774885	=	Activity	%	-10.0	CHEMBL3045	Homo sapiens	Activity	%	-10.0
	16496104	CHEMBL3777513	Inhibition of N-terminal His6-tagged recombinant human PKCB2 expressed in baculovirus infected insect Sf9 cells assessed as remaining activity at 1 uM relative to control	B	Cn1cc(-c2ccc(Cc3n[nH]c4ccc(C(=O)N5CCOCC5)cc34)cc2)cn1		CHEMBL3774885	=	Activity	%	-3.0	CHEMBL3045	Homo sapiens	Activity	%	-3.0
Not Active	16506411	CHEMBL3778249	Inhibition of PKCbeta (unknown origin) incubated for 15 mins in presence of [gamma-32P]ATP	B	COc1ccc(/C=C2\CCOC2=O)cc1		CHEMBL1612487		IC50			CHEMBL3045	Homo sapiens	IC50		
Not Active	16506412	CHEMBL3778249	Inhibition of PKCbeta (unknown origin) incubated for 15 mins in presence of [gamma-32P]ATP	B	O=C1OCC/C1=C\c1ccc2c(c1)CCCO2		CHEMBL3775193		IC50			CHEMBL3045	Homo sapiens	IC50		
Not Active	16506413	CHEMBL3778249	Inhibition of PKCbeta (unknown origin) incubated for 15 mins in presence of [gamma-32P]ATP	B	COc1ccc(/C=C2\CCCOC2=O)cc1		CHEMBL3774736		IC50			CHEMBL3045	Homo sapiens	IC50		
Not Active	16506414	CHEMBL3778249	Inhibition of PKCbeta (unknown origin) incubated for 15 mins in presence of [gamma-32P]ATP	B	COc1ccc(/C=C2\CC(C)OC2=O)cc1		CHEMBL3775969		IC50			CHEMBL3045	Homo sapiens	IC50		
Not Active	16506415	CHEMBL3778249	Inhibition of PKCbeta (unknown origin) incubated for 15 mins in presence of [gamma-32P]ATP	B	O=C1OCC/C1=C\c1ccc2c(c1)CCO2		CHEMBL3775821		IC50			CHEMBL3045	Homo sapiens	IC50		
Not Active	16506416	CHEMBL3778249	Inhibition of PKCbeta (unknown origin) incubated for 15 mins in presence of [gamma-32P]ATP	B	CC1C/C(=C\c2ccc3c(c2)CCO3)C(=O)O1		CHEMBL3775111		IC50			CHEMBL3045	Homo sapiens	IC50		
Not Active	16506417	CHEMBL3778249	Inhibition of PKCbeta (unknown origin) incubated for 15 mins in presence of [gamma-32P]ATP	B	O=C1OCC/C1=C\c1ccc2ncsc2c1		CHEMBL3774704		IC50			CHEMBL3045	Homo sapiens	IC50		
Not Active	16506418	CHEMBL3778249	Inhibition of PKCbeta (unknown origin) incubated for 15 mins in presence of [gamma-32P]ATP	B	O=C1OCC/C1=C\c1ccc2c(c1)OCCO2		CHEMBL3774696		IC50			CHEMBL3045	Homo sapiens	IC50		
Not Active	16506419	CHEMBL3778249	Inhibition of PKCbeta (unknown origin) incubated for 15 mins in presence of [gamma-32P]ATP	B	O=C1OCC/C1=C\c1ccc2c(c1)OCO2		CHEMBL3193172		IC50			CHEMBL3045	Homo sapiens	IC50		
Not Active	16506420	CHEMBL3778249	Inhibition of PKCbeta (unknown origin) incubated for 15 mins in presence of [gamma-32P]ATP	B	CC1C/C(=C\c2ccc3ncsc3c2)C(=O)O1		CHEMBL3775538		IC50			CHEMBL3045	Homo sapiens	IC50		
Not Determined	16506421	CHEMBL3778249	Inhibition of PKCbeta (unknown origin) incubated for 15 mins in presence of [gamma-32P]ATP	B	COc1ccc(/C=C2\CC(=O)NC2=O)cc1		CHEMBL571292		IC50			CHEMBL3045	Homo sapiens	IC50		
Not Active	16506422	CHEMBL3778249	Inhibition of PKCbeta (unknown origin) incubated for 15 mins in presence of [gamma-32P]ATP	B	COc1ccc(/C=C2\NC(=O)NC2=O)cc1		CHEMBL38043		IC50			CHEMBL3045	Homo sapiens	IC50		
Not Active	16506423	CHEMBL3778249	Inhibition of PKCbeta (unknown origin) incubated for 15 mins in presence of [gamma-32P]ATP	B	COc1ccc(/C=C2\NC(=O)SC2=O)cc1		CHEMBL3774667		IC50			CHEMBL3045	Homo sapiens	IC50		
Not Active	16506424	CHEMBL3778249	Inhibition of PKCbeta (unknown origin) incubated for 15 mins in presence of [gamma-32P]ATP	B	COc1ccc(/C=C2/SC(=S)NC2=O)cc1		CHEMBL3775949		IC50			CHEMBL3045	Homo sapiens	IC50		
	16506425	CHEMBL3778249	Inhibition of PKCbeta (unknown origin) incubated for 15 mins in presence of [gamma-32P]ATP	B	O=C1NC(=S)S/C1=C\c1ccc2c(c1)CCO2		CHEMBL3774830	>	IC50	nM	10000.0	CHEMBL3045	Homo sapiens	IC50	uM	10.0
	16506426	CHEMBL3778249	Inhibition of PKCbeta (unknown origin) incubated for 15 mins in presence of [gamma-32P]ATP	B	O=C1NC(=S)S/C1=C\c1ccc2ncsc2c1		CHEMBL3775393	=	IC50	nM	9200.0	CHEMBL3045	Homo sapiens	IC50	uM	9.2
	16506427	CHEMBL3778249	Inhibition of PKCbeta (unknown origin) incubated for 15 mins in presence of [gamma-32P]ATP	B	O=C1NC(=S)S/C1=C\c1ccc2ncccc2c1		CHEMBL3774448	>	IC50	nM	10000.0	CHEMBL3045	Homo sapiens	IC50	uM	10.0
	16506428	CHEMBL3778249	Inhibition of PKCbeta (unknown origin) incubated for 15 mins in presence of [gamma-32P]ATP	B	O=C1NC(=S)N/C1=C\c1ccc2ncsc2c1		CHEMBL3775754	>	IC50	nM	10000.0	CHEMBL3045	Homo sapiens	IC50	uM	10.0
Not Determined	16506429	CHEMBL3778249	Inhibition of PKCbeta (unknown origin) incubated for 15 mins in presence of [gamma-32P]ATP	B	COc1ccc2c(c1)[nH]c1c(C)nccc12		CHEMBL269538		IC50			CHEMBL3045	Homo sapiens	IC50		
Not Active	16506430	CHEMBL3778249	Inhibition of PKCbeta (unknown origin) incubated for 15 mins in presence of [gamma-32P]ATP	B	O=C1NC(=O)/C(=C/c2ccc3nccnc3c2)S1		CHEMBL568150		IC50			CHEMBL3045	Homo sapiens	IC50		
	16508893	CHEMBL3777512	Inhibition of N-terminal His6-tagged recombinant human PKCbeta1expressed in baculovirus infected insect Sf9 cells assessed as remaining activity at 1 uM relative to control	B	CNC(=O)c1ccc2[nH]nc(Cc3ccc4c(cnn4C)c3)c2c1		CHEMBL3775576	=	Activity	%	11.0	CHEMBL3045	Homo sapiens	Activity	%	11.0
	16508894	CHEMBL3777513	Inhibition of N-terminal His6-tagged recombinant human PKCB2 expressed in baculovirus infected insect Sf9 cells assessed as remaining activity at 1 uM relative to control	B	CNC(=O)c1ccc2[nH]nc(Cc3ccc4c(cnn4C)c3)c2c1		CHEMBL3775576	=	Activity	%	0.0	CHEMBL3045	Homo sapiens	Activity	%	0.0
	16565456	CHEMBL3802857	Inhibition of N-terminal FLAG-tagged PKCbeta (unknown origin) expressed in baculovirus preincubated for 5 mins using fluorescein-PKC substrate measured after 60 mins in presence of ATP by TR-FRET assay	B	C[C@H](c1ccccc1)N1c2cc(-n3c(=O)[nH]c4ncccc43)ccc2C(=O)NC1(C)C		CHEMBL3798011	>	IC50	nM	10.0	CHEMBL3045	Homo sapiens	IC50	nM	10.0
	16587017	CHEMBL3807429	Inhibition of PKCbeta (unknown origin) in presence of gamma33-ATP	B	CN1CCN(c2ccc(C(=O)Nc3n[nH]c4ccc(Cc5cc(F)cc(F)c5)cc34)c(NC3CCOCC3)c2)CC1		CHEMBL1983268	>	IC50	nM	1000.0	CHEMBL3045	Homo sapiens	IC50	uM	1.0
	16614593	CHEMBL3815949	Inhibition of human PKCb2 at 1 uM using histone H1 as substrate	B	CNS(=O)(=O)c1ccc(N(C)C)c(Nc2ncnc3cc(OC)c(OC)cc23)c1		CHEMBL3815093	=	Inhibition	%	26.0	CHEMBL3045	Homo sapiens	INH	%	26.0
	16618109	CHEMBL3816495	Inhibition of full length recombinant human PKC-beta1 expressed in baculovirus expression system at 1 uM relative to control	B	CC1(C)OCCn2c1nc1c(N3CCOCC3)nc(-c3cnc(N)nc3)nc12		CHEMBL3813842	<	Inhibition	%	50.0	CHEMBL3045	Homo sapiens	INH	%	50.0
	16618110	CHEMBL3816496	Inhibition of full length recombinant human PKC-beta2 expressed in baculovirus expression system at 1 uM relative to control	B	CC1(C)OCCn2c1nc1c(N3CCOCC3)nc(-c3cnc(N)nc3)nc12		CHEMBL3813842	<	Inhibition	%	50.0	CHEMBL3045	Homo sapiens	INH	%	50.0
	16627564	CHEMBL3820358	Inhibition of recombinant human N-terminal His6-tagged PKC-beta1 (2-end residues) expressed in Sf21 cells at 1 uM by radiometric assay relative to control	B	Cc1cc(-c2cnn3c(NCC4CCOCC4)nc(Oc4ccccc4)nc23)ccc1C(=O)NC1CC1	Outside typical range	CHEMBL3819210	=	Inhibition	%	-14.0	CHEMBL3045	Homo sapiens	INH	%	-14.0
	16627565	CHEMBL3820358	Inhibition of recombinant human N-terminal His6-tagged PKC-beta1 (2-end residues) expressed in Sf21 cells at 1 uM by radiometric assay relative to control	B	O=C(N[C@@H](c1ccccn1)C1CC1)c1ccc2[nH]nc(-c3ccc(N4C5CCC4CC(O)C5)cc3)c2c1	Outside typical range	CHEMBL3818239	=	Inhibition	%	-11.0	CHEMBL3045	Homo sapiens	INH	%	-11.0
	16627566	CHEMBL3820359	Inhibition of recombinant human N-terminal His6-tagged PKC-beta2 (2-end residues) expressed in Sf21 cells at 1 uM by radiometric assay relative to control	B	Cc1cc(-c2cnn3c(NCC4CCOCC4)nc(Oc4ccccc4)nc23)ccc1C(=O)NC1CC1		CHEMBL3819210	=	Inhibition	%	-2.0	CHEMBL3045	Homo sapiens	INH	%	-2.0
	16627567	CHEMBL3820359	Inhibition of recombinant human N-terminal His6-tagged PKC-beta2 (2-end residues) expressed in Sf21 cells at 1 uM by radiometric assay relative to control	B	O=C(N[C@@H](c1ccccn1)C1CC1)c1ccc2[nH]nc(-c3ccc(N4C5CCC4CC(O)C5)cc3)c2c1		CHEMBL3818239	=	Inhibition	%	1.0	CHEMBL3045	Homo sapiens	INH	%	1.0
	16642012	CHEMBL3826423	Inhibition of full-length human PRKCB1 expressed in baculovirus system at 100 nM by Z-lyte assay	B	O=C(CNC(=O)c1cccn(Cc2ccc(F)c(F)c2)c1=O)Nc1ccc2c(c1)/C(=C/c1cnc[nH]1)C(=O)N2		CHEMBL3824119	=	Inhibition	%	-10.0	CHEMBL3045	Homo sapiens	INH	%	-10.0
	16667607	CHEMBL3854611	Binding affinity to PKCbeta2 (unknown origin) using Lys-Arg-Thr-Leu-Arg-Arg as substrate after 8 mins in presence of [gamma-32P]ATP by liquid scintillation spectrometry	B	O=C(N[C@@H]1CNCCC[C@H]1OC(=O)c1cc(O)c(C(=O)c2c(O)cccc2C(=O)O)c(O)c1)c1ccc(O)cc1		CHEMBL60254	=	Kd	nM	1.8	CHEMBL3045	Homo sapiens	Kd	nM	1.8
	16739525	CHEMBL3857074	Inhibition of recombinant full length human PRKCB1 expressed in baculovirus at 500 nM by Z'-LYTE assay	B	C[C@@H](Nc1ncnc2oc(-c3ccc(NCCN(C)C)cc3)cc12)c1ccccc1		CHEMBL3901622	=	Inhibition	%	-10.0	CHEMBL3045	Homo sapiens	INH	%	-10.0
	16739526	CHEMBL3857074	Inhibition of recombinant full length human PRKCB1 expressed in baculovirus at 500 nM by Z'-LYTE assay	B	C[C@@H](Nc1ncnc2oc(-c3ccc(NCCN4CCCCC4)cc3)cc12)c1ccccc1	Outside typical range	CHEMBL3891846	=	Inhibition	%	-14.0	CHEMBL3045	Homo sapiens	INH	%	-14.0
	16739527	CHEMBL3857074	Inhibition of recombinant full length human PRKCB1 expressed in baculovirus at 500 nM by Z'-LYTE assay	B	C#Cc1cccc(Nc2ncnc3cc(OCCOC)c(OCCOC)cc23)c1		CHEMBL553	=	Inhibition	%	-2.0	CHEMBL3045	Homo sapiens	INH	%	-2.0
295205	17676440	CHEMBL3705825	Inhibition Assay: Protein Kinase C beta 2 (PKC beta II) catalyzes the production of ADP from ATP that accompanies the phosphoryl transfer to the PKC Pseudosubstrate peptide (A->S, RFARKGSLRQKNV). This transfer is coupled to the oxidation of p-NADH through the activities of Pyruvate Kinase (PK) and Lactate Dehydrogenase (LDH). (3-NADH conversion to NAD+ is monitored by the decrease in absorbance at 340 nm (e=6.22 cm-1 mM-1) using a Molecular Devices SPECTRA max PLUS spectrophotometer.A typical assay was carried out on a 96-well, clear microtiter plate in a Molecular Devices spectrophotometer for 20 minutes at 30 C. in 0.1 mL of assay buffer containing 50 mM HEPES, pH 7.4, 5 nM PKC, 23 units of pyruvate kinase, 33 units of lactate dehydrogenase, 0.15 mM peptide, 0.1 mM ATP, 1 mM DTT, 4 mM PEP, 8 mM MgCl2, 0.3 mM NADH, 60 mM CaCl2, 10 mg/mL PS, 50 ng/mL PMA, 7.5% DMSO and from about 10,000 nM to 0.169 nM compound inhibitor.	B	C[C@H]1CN2CCC[C@H]2CN1C(=O)N1Cc2c(CC(=O)c3ccccn3)n[nH]c2C1(C)C		CHEMBL3658622	=	Ki	nM	29.2	CHEMBL3045	Homo sapiens	Ki	nM	29.2
295206	17676441	CHEMBL3705825	Inhibition Assay: Protein Kinase C beta 2 (PKC beta II) catalyzes the production of ADP from ATP that accompanies the phosphoryl transfer to the PKC Pseudosubstrate peptide (A->S, RFARKGSLRQKNV). This transfer is coupled to the oxidation of p-NADH through the activities of Pyruvate Kinase (PK) and Lactate Dehydrogenase (LDH). (3-NADH conversion to NAD+ is monitored by the decrease in absorbance at 340 nm (e=6.22 cm-1 mM-1) using a Molecular Devices SPECTRA max PLUS spectrophotometer.A typical assay was carried out on a 96-well, clear microtiter plate in a Molecular Devices spectrophotometer for 20 minutes at 30 C. in 0.1 mL of assay buffer containing 50 mM HEPES, pH 7.4, 5 nM PKC, 23 units of pyruvate kinase, 33 units of lactate dehydrogenase, 0.15 mM peptide, 0.1 mM ATP, 1 mM DTT, 4 mM PEP, 8 mM MgCl2, 0.3 mM NADH, 60 mM CaCl2, 10 mg/mL PS, 50 ng/mL PMA, 7.5% DMSO and from about 10,000 nM to 0.169 nM compound inhibitor.	B	C[C@H]1CN(C)C2(CCCC2)CN1C(=O)N1Cc2c(NC(=O)c3ccccn3)n[nH]c2C1(C)C		CHEMBL3658623	=	Ki	nM	3.05	CHEMBL3045	Homo sapiens	Ki	nM	3.05
295207	17676442	CHEMBL3705825	Inhibition Assay: Protein Kinase C beta 2 (PKC beta II) catalyzes the production of ADP from ATP that accompanies the phosphoryl transfer to the PKC Pseudosubstrate peptide (A->S, RFARKGSLRQKNV). This transfer is coupled to the oxidation of p-NADH through the activities of Pyruvate Kinase (PK) and Lactate Dehydrogenase (LDH). (3-NADH conversion to NAD+ is monitored by the decrease in absorbance at 340 nm (e=6.22 cm-1 mM-1) using a Molecular Devices SPECTRA max PLUS spectrophotometer.A typical assay was carried out on a 96-well, clear microtiter plate in a Molecular Devices spectrophotometer for 20 minutes at 30 C. in 0.1 mL of assay buffer containing 50 mM HEPES, pH 7.4, 5 nM PKC, 23 units of pyruvate kinase, 33 units of lactate dehydrogenase, 0.15 mM peptide, 0.1 mM ATP, 1 mM DTT, 4 mM PEP, 8 mM MgCl2, 0.3 mM NADH, 60 mM CaCl2, 10 mg/mL PS, 50 ng/mL PMA, 7.5% DMSO and from about 10,000 nM to 0.169 nM compound inhibitor.	B	CC1(C)c2[nH]nc(NC(=O)c3cccc(Oc4ccccc4)c3)c2CN1C(=O)N1C[C@@H]2CCCN2C[C@@H]1Cc1ccccc1		CHEMBL3658624	=	Ki	nM	36.8	CHEMBL3045	Homo sapiens	Ki	nM	36.8
295208	17676443	CHEMBL3705825	Inhibition Assay: Protein Kinase C beta 2 (PKC beta II) catalyzes the production of ADP from ATP that accompanies the phosphoryl transfer to the PKC Pseudosubstrate peptide (A->S, RFARKGSLRQKNV). This transfer is coupled to the oxidation of p-NADH through the activities of Pyruvate Kinase (PK) and Lactate Dehydrogenase (LDH). (3-NADH conversion to NAD+ is monitored by the decrease in absorbance at 340 nm (e=6.22 cm-1 mM-1) using a Molecular Devices SPECTRA max PLUS spectrophotometer.A typical assay was carried out on a 96-well, clear microtiter plate in a Molecular Devices spectrophotometer for 20 minutes at 30 C. in 0.1 mL of assay buffer containing 50 mM HEPES, pH 7.4, 5 nM PKC, 23 units of pyruvate kinase, 33 units of lactate dehydrogenase, 0.15 mM peptide, 0.1 mM ATP, 1 mM DTT, 4 mM PEP, 8 mM MgCl2, 0.3 mM NADH, 60 mM CaCl2, 10 mg/mL PS, 50 ng/mL PMA, 7.5% DMSO and from about 10,000 nM to 0.169 nM compound inhibitor.	B	CN1CCN(C(=O)N2Cc3c(n[nH]c3NC(=O)c3cc4ccccc4s3)C2(C)C)[C@@H](Cc2ccccc2)C1		CHEMBL3658625	=	Ki	nM	146.0	CHEMBL3045	Homo sapiens	Ki	nM	146.0
295209	17676444	CHEMBL3705825	Inhibition Assay: Protein Kinase C beta 2 (PKC beta II) catalyzes the production of ADP from ATP that accompanies the phosphoryl transfer to the PKC Pseudosubstrate peptide (A->S, RFARKGSLRQKNV). This transfer is coupled to the oxidation of p-NADH through the activities of Pyruvate Kinase (PK) and Lactate Dehydrogenase (LDH). (3-NADH conversion to NAD+ is monitored by the decrease in absorbance at 340 nm (e=6.22 cm-1 mM-1) using a Molecular Devices SPECTRA max PLUS spectrophotometer.A typical assay was carried out on a 96-well, clear microtiter plate in a Molecular Devices spectrophotometer for 20 minutes at 30 C. in 0.1 mL of assay buffer containing 50 mM HEPES, pH 7.4, 5 nM PKC, 23 units of pyruvate kinase, 33 units of lactate dehydrogenase, 0.15 mM peptide, 0.1 mM ATP, 1 mM DTT, 4 mM PEP, 8 mM MgCl2, 0.3 mM NADH, 60 mM CaCl2, 10 mg/mL PS, 50 ng/mL PMA, 7.5% DMSO and from about 10,000 nM to 0.169 nM compound inhibitor.	B	C.CC1c2[nH]nc(NC(=O)c3ccccc3)c2CN1C(=O)N1CCN(C)C[C@@H]1Cc1ccccc1		CHEMBL3901971	=	Ki	nM	189.0	CHEMBL3045	Homo sapiens	Ki	nM	189.0
295210	17676445	CHEMBL3705825	Inhibition Assay: Protein Kinase C beta 2 (PKC beta II) catalyzes the production of ADP from ATP that accompanies the phosphoryl transfer to the PKC Pseudosubstrate peptide (A->S, RFARKGSLRQKNV). This transfer is coupled to the oxidation of p-NADH through the activities of Pyruvate Kinase (PK) and Lactate Dehydrogenase (LDH). (3-NADH conversion to NAD+ is monitored by the decrease in absorbance at 340 nm (e=6.22 cm-1 mM-1) using a Molecular Devices SPECTRA max PLUS spectrophotometer.A typical assay was carried out on a 96-well, clear microtiter plate in a Molecular Devices spectrophotometer for 20 minutes at 30 C. in 0.1 mL of assay buffer containing 50 mM HEPES, pH 7.4, 5 nM PKC, 23 units of pyruvate kinase, 33 units of lactate dehydrogenase, 0.15 mM peptide, 0.1 mM ATP, 1 mM DTT, 4 mM PEP, 8 mM MgCl2, 0.3 mM NADH, 60 mM CaCl2, 10 mg/mL PS, 50 ng/mL PMA, 7.5% DMSO and from about 10,000 nM to 0.169 nM compound inhibitor.	B	CN1CCN(C(=O)N2Cc3c(NC(=O)c4cccs4)n[nH]c3C2(C)C)[C@@H](Cc2ccccc2)C1		CHEMBL3658627	=	Ki	nM	187.0	CHEMBL3045	Homo sapiens	Ki	nM	187.0
295211	17676446	CHEMBL3705825	Inhibition Assay: Protein Kinase C beta 2 (PKC beta II) catalyzes the production of ADP from ATP that accompanies the phosphoryl transfer to the PKC Pseudosubstrate peptide (A->S, RFARKGSLRQKNV). This transfer is coupled to the oxidation of p-NADH through the activities of Pyruvate Kinase (PK) and Lactate Dehydrogenase (LDH). (3-NADH conversion to NAD+ is monitored by the decrease in absorbance at 340 nm (e=6.22 cm-1 mM-1) using a Molecular Devices SPECTRA max PLUS spectrophotometer.A typical assay was carried out on a 96-well, clear microtiter plate in a Molecular Devices spectrophotometer for 20 minutes at 30 C. in 0.1 mL of assay buffer containing 50 mM HEPES, pH 7.4, 5 nM PKC, 23 units of pyruvate kinase, 33 units of lactate dehydrogenase, 0.15 mM peptide, 0.1 mM ATP, 1 mM DTT, 4 mM PEP, 8 mM MgCl2, 0.3 mM NADH, 60 mM CaCl2, 10 mg/mL PS, 50 ng/mL PMA, 7.5% DMSO and from about 10,000 nM to 0.169 nM compound inhibitor.	B	CN1CCN(C(=O)N2Cc3c(NC(=O)c4cc5ccccc5o4)n[nH]c3C2(C)C)[C@@H](Cc2ccccc2)C1		CHEMBL3658628	=	Ki	nM	124.0	CHEMBL3045	Homo sapiens	Ki	nM	124.0
295212	17676447	CHEMBL3705825	Inhibition Assay: Protein Kinase C beta 2 (PKC beta II) catalyzes the production of ADP from ATP that accompanies the phosphoryl transfer to the PKC Pseudosubstrate peptide (A->S, RFARKGSLRQKNV). This transfer is coupled to the oxidation of p-NADH through the activities of Pyruvate Kinase (PK) and Lactate Dehydrogenase (LDH). (3-NADH conversion to NAD+ is monitored by the decrease in absorbance at 340 nm (e=6.22 cm-1 mM-1) using a Molecular Devices SPECTRA max PLUS spectrophotometer.A typical assay was carried out on a 96-well, clear microtiter plate in a Molecular Devices spectrophotometer for 20 minutes at 30 C. in 0.1 mL of assay buffer containing 50 mM HEPES, pH 7.4, 5 nM PKC, 23 units of pyruvate kinase, 33 units of lactate dehydrogenase, 0.15 mM peptide, 0.1 mM ATP, 1 mM DTT, 4 mM PEP, 8 mM MgCl2, 0.3 mM NADH, 60 mM CaCl2, 10 mg/mL PS, 50 ng/mL PMA, 7.5% DMSO and from about 10,000 nM to 0.169 nM compound inhibitor.	B	CN1CCN(C(=O)N2Cc3c(NC(=O)c4ccc5ccccc5n4)n[nH]c3C2(C)C)[C@@H](Cc2ccccc2)C1		CHEMBL3658629	=	Ki	nM	78.1	CHEMBL3045	Homo sapiens	Ki	nM	78.1
295213	17676448	CHEMBL3705825	Inhibition Assay: Protein Kinase C beta 2 (PKC beta II) catalyzes the production of ADP from ATP that accompanies the phosphoryl transfer to the PKC Pseudosubstrate peptide (A->S, RFARKGSLRQKNV). This transfer is coupled to the oxidation of p-NADH through the activities of Pyruvate Kinase (PK) and Lactate Dehydrogenase (LDH). (3-NADH conversion to NAD+ is monitored by the decrease in absorbance at 340 nm (e=6.22 cm-1 mM-1) using a Molecular Devices SPECTRA max PLUS spectrophotometer.A typical assay was carried out on a 96-well, clear microtiter plate in a Molecular Devices spectrophotometer for 20 minutes at 30 C. in 0.1 mL of assay buffer containing 50 mM HEPES, pH 7.4, 5 nM PKC, 23 units of pyruvate kinase, 33 units of lactate dehydrogenase, 0.15 mM peptide, 0.1 mM ATP, 1 mM DTT, 4 mM PEP, 8 mM MgCl2, 0.3 mM NADH, 60 mM CaCl2, 10 mg/mL PS, 50 ng/mL PMA, 7.5% DMSO and from about 10,000 nM to 0.169 nM compound inhibitor.	B	CN1CCN(C(=O)N2Cc3c(NC(=O)c4cccc(Oc5ccccc5)c4)n[nH]c3C2(C)C)C(c2ccccc2)C1		CHEMBL3658630	=	Ki	nM	159.0	CHEMBL3045	Homo sapiens	Ki	nM	159.0
295214	17676449	CHEMBL3705825	Inhibition Assay: Protein Kinase C beta 2 (PKC beta II) catalyzes the production of ADP from ATP that accompanies the phosphoryl transfer to the PKC Pseudosubstrate peptide (A->S, RFARKGSLRQKNV). This transfer is coupled to the oxidation of p-NADH through the activities of Pyruvate Kinase (PK) and Lactate Dehydrogenase (LDH). (3-NADH conversion to NAD+ is monitored by the decrease in absorbance at 340 nm (e=6.22 cm-1 mM-1) using a Molecular Devices SPECTRA max PLUS spectrophotometer.A typical assay was carried out on a 96-well, clear microtiter plate in a Molecular Devices spectrophotometer for 20 minutes at 30 C. in 0.1 mL of assay buffer containing 50 mM HEPES, pH 7.4, 5 nM PKC, 23 units of pyruvate kinase, 33 units of lactate dehydrogenase, 0.15 mM peptide, 0.1 mM ATP, 1 mM DTT, 4 mM PEP, 8 mM MgCl2, 0.3 mM NADH, 60 mM CaCl2, 10 mg/mL PS, 50 ng/mL PMA, 7.5% DMSO and from about 10,000 nM to 0.169 nM compound inhibitor.	B	CC1(C)c2[nH]nc(NC(=O)c3cccc(Oc4ccccc4)c3)c2CN1C(=O)N1CCNCC1c1ccccc1		CHEMBL3658631	=	Ki	nM	55.9	CHEMBL3045	Homo sapiens	Ki	nM	55.9
295215	17676450	CHEMBL3705825	Inhibition Assay: Protein Kinase C beta 2 (PKC beta II) catalyzes the production of ADP from ATP that accompanies the phosphoryl transfer to the PKC Pseudosubstrate peptide (A->S, RFARKGSLRQKNV). This transfer is coupled to the oxidation of p-NADH through the activities of Pyruvate Kinase (PK) and Lactate Dehydrogenase (LDH). (3-NADH conversion to NAD+ is monitored by the decrease in absorbance at 340 nm (e=6.22 cm-1 mM-1) using a Molecular Devices SPECTRA max PLUS spectrophotometer.A typical assay was carried out on a 96-well, clear microtiter plate in a Molecular Devices spectrophotometer for 20 minutes at 30 C. in 0.1 mL of assay buffer containing 50 mM HEPES, pH 7.4, 5 nM PKC, 23 units of pyruvate kinase, 33 units of lactate dehydrogenase, 0.15 mM peptide, 0.1 mM ATP, 1 mM DTT, 4 mM PEP, 8 mM MgCl2, 0.3 mM NADH, 60 mM CaCl2, 10 mg/mL PS, 50 ng/mL PMA, 7.5% DMSO and from about 10,000 nM to 0.169 nM compound inhibitor.	B	CC1(C)c2[nH]nc(NC(=O)c3ccc4ccccc4n3)c2CN1C(=O)N1CCN2CCCC2C1		CHEMBL3662727	=	Ki	nM	73.9	CHEMBL3045	Homo sapiens	Ki	nM	73.9
295216	17676451	CHEMBL3705825	Inhibition Assay: Protein Kinase C beta 2 (PKC beta II) catalyzes the production of ADP from ATP that accompanies the phosphoryl transfer to the PKC Pseudosubstrate peptide (A->S, RFARKGSLRQKNV). This transfer is coupled to the oxidation of p-NADH through the activities of Pyruvate Kinase (PK) and Lactate Dehydrogenase (LDH). (3-NADH conversion to NAD+ is monitored by the decrease in absorbance at 340 nm (e=6.22 cm-1 mM-1) using a Molecular Devices SPECTRA max PLUS spectrophotometer.A typical assay was carried out on a 96-well, clear microtiter plate in a Molecular Devices spectrophotometer for 20 minutes at 30 C. in 0.1 mL of assay buffer containing 50 mM HEPES, pH 7.4, 5 nM PKC, 23 units of pyruvate kinase, 33 units of lactate dehydrogenase, 0.15 mM peptide, 0.1 mM ATP, 1 mM DTT, 4 mM PEP, 8 mM MgCl2, 0.3 mM NADH, 60 mM CaCl2, 10 mg/mL PS, 50 ng/mL PMA, 7.5% DMSO and from about 10,000 nM to 0.169 nM compound inhibitor.	B	CC(C)C[C@H]1CN2CCC[C@H]2CN1C(=O)N1Cc2c(NC(=O)c3ccc4ccccc4n3)n[nH]c2C1(C)C		CHEMBL3662728	=	Ki	nM	103.0	CHEMBL3045	Homo sapiens	Ki	nM	103.0
295217	17676452	CHEMBL3705825	Inhibition Assay: Protein Kinase C beta 2 (PKC beta II) catalyzes the production of ADP from ATP that accompanies the phosphoryl transfer to the PKC Pseudosubstrate peptide (A->S, RFARKGSLRQKNV). This transfer is coupled to the oxidation of p-NADH through the activities of Pyruvate Kinase (PK) and Lactate Dehydrogenase (LDH). (3-NADH conversion to NAD+ is monitored by the decrease in absorbance at 340 nm (e=6.22 cm-1 mM-1) using a Molecular Devices SPECTRA max PLUS spectrophotometer.A typical assay was carried out on a 96-well, clear microtiter plate in a Molecular Devices spectrophotometer for 20 minutes at 30 C. in 0.1 mL of assay buffer containing 50 mM HEPES, pH 7.4, 5 nM PKC, 23 units of pyruvate kinase, 33 units of lactate dehydrogenase, 0.15 mM peptide, 0.1 mM ATP, 1 mM DTT, 4 mM PEP, 8 mM MgCl2, 0.3 mM NADH, 60 mM CaCl2, 10 mg/mL PS, 50 ng/mL PMA, 7.5% DMSO and from about 10,000 nM to 0.169 nM compound inhibitor.	B	CC1(C)c2[nH]nc(NC(=O)c3ccc4ccccc4n3)c2CN1C(=O)N1C[C@@H]2CCCN2C[C@@H]1Cc1ccccc1		CHEMBL3662729	=	Ki	nM	27.7	CHEMBL3045	Homo sapiens	Ki	nM	27.7
295218	17676453	CHEMBL3705825	Inhibition Assay: Protein Kinase C beta 2 (PKC beta II) catalyzes the production of ADP from ATP that accompanies the phosphoryl transfer to the PKC Pseudosubstrate peptide (A->S, RFARKGSLRQKNV). This transfer is coupled to the oxidation of p-NADH through the activities of Pyruvate Kinase (PK) and Lactate Dehydrogenase (LDH). (3-NADH conversion to NAD+ is monitored by the decrease in absorbance at 340 nm (e=6.22 cm-1 mM-1) using a Molecular Devices SPECTRA max PLUS spectrophotometer.A typical assay was carried out on a 96-well, clear microtiter plate in a Molecular Devices spectrophotometer for 20 minutes at 30 C. in 0.1 mL of assay buffer containing 50 mM HEPES, pH 7.4, 5 nM PKC, 23 units of pyruvate kinase, 33 units of lactate dehydrogenase, 0.15 mM peptide, 0.1 mM ATP, 1 mM DTT, 4 mM PEP, 8 mM MgCl2, 0.3 mM NADH, 60 mM CaCl2, 10 mg/mL PS, 50 ng/mL PMA, 7.5% DMSO and from about 10,000 nM to 0.169 nM compound inhibitor.	B	CC1(C)c2[nH]nc(NC(=O)c3ccc4ccccc4n3)c2CN1C(=O)N1C[C@@H]2CCCN2C[C@@H]1Cc1ccccc1		CHEMBL3662729	=	Ki	nM	16.1	CHEMBL3045	Homo sapiens	Ki	nM	16.1
295219	17676454	CHEMBL3705825	Inhibition Assay: Protein Kinase C beta 2 (PKC beta II) catalyzes the production of ADP from ATP that accompanies the phosphoryl transfer to the PKC Pseudosubstrate peptide (A->S, RFARKGSLRQKNV). This transfer is coupled to the oxidation of p-NADH through the activities of Pyruvate Kinase (PK) and Lactate Dehydrogenase (LDH). (3-NADH conversion to NAD+ is monitored by the decrease in absorbance at 340 nm (e=6.22 cm-1 mM-1) using a Molecular Devices SPECTRA max PLUS spectrophotometer.A typical assay was carried out on a 96-well, clear microtiter plate in a Molecular Devices spectrophotometer for 20 minutes at 30 C. in 0.1 mL of assay buffer containing 50 mM HEPES, pH 7.4, 5 nM PKC, 23 units of pyruvate kinase, 33 units of lactate dehydrogenase, 0.15 mM peptide, 0.1 mM ATP, 1 mM DTT, 4 mM PEP, 8 mM MgCl2, 0.3 mM NADH, 60 mM CaCl2, 10 mg/mL PS, 50 ng/mL PMA, 7.5% DMSO and from about 10,000 nM to 0.169 nM compound inhibitor.	B	CC1(C)c2[nH]nc(NC(=O)c3cccs3)c2CN1C(=O)N1CCN2CCCC2C1		CHEMBL3662730	=	Ki	nM	136.0	CHEMBL3045	Homo sapiens	Ki	nM	136.0
295220	17676455	CHEMBL3705825	Inhibition Assay: Protein Kinase C beta 2 (PKC beta II) catalyzes the production of ADP from ATP that accompanies the phosphoryl transfer to the PKC Pseudosubstrate peptide (A->S, RFARKGSLRQKNV). This transfer is coupled to the oxidation of p-NADH through the activities of Pyruvate Kinase (PK) and Lactate Dehydrogenase (LDH). (3-NADH conversion to NAD+ is monitored by the decrease in absorbance at 340 nm (e=6.22 cm-1 mM-1) using a Molecular Devices SPECTRA max PLUS spectrophotometer.A typical assay was carried out on a 96-well, clear microtiter plate in a Molecular Devices spectrophotometer for 20 minutes at 30 C. in 0.1 mL of assay buffer containing 50 mM HEPES, pH 7.4, 5 nM PKC, 23 units of pyruvate kinase, 33 units of lactate dehydrogenase, 0.15 mM peptide, 0.1 mM ATP, 1 mM DTT, 4 mM PEP, 8 mM MgCl2, 0.3 mM NADH, 60 mM CaCl2, 10 mg/mL PS, 50 ng/mL PMA, 7.5% DMSO and from about 10,000 nM to 0.169 nM compound inhibitor.	B	CC1(C)c2[nH]nc(NC(=O)c3ccccc3)c2CN1C(=O)N1CCN2CCCC2C1		CHEMBL3662731	=	Ki	nM	113.0	CHEMBL3045	Homo sapiens	Ki	nM	113.0
295221	17676456	CHEMBL3705825	Inhibition Assay: Protein Kinase C beta 2 (PKC beta II) catalyzes the production of ADP from ATP that accompanies the phosphoryl transfer to the PKC Pseudosubstrate peptide (A->S, RFARKGSLRQKNV). This transfer is coupled to the oxidation of p-NADH through the activities of Pyruvate Kinase (PK) and Lactate Dehydrogenase (LDH). (3-NADH conversion to NAD+ is monitored by the decrease in absorbance at 340 nm (e=6.22 cm-1 mM-1) using a Molecular Devices SPECTRA max PLUS spectrophotometer.A typical assay was carried out on a 96-well, clear microtiter plate in a Molecular Devices spectrophotometer for 20 minutes at 30 C. in 0.1 mL of assay buffer containing 50 mM HEPES, pH 7.4, 5 nM PKC, 23 units of pyruvate kinase, 33 units of lactate dehydrogenase, 0.15 mM peptide, 0.1 mM ATP, 1 mM DTT, 4 mM PEP, 8 mM MgCl2, 0.3 mM NADH, 60 mM CaCl2, 10 mg/mL PS, 50 ng/mL PMA, 7.5% DMSO and from about 10,000 nM to 0.169 nM compound inhibitor.	B	COc1cccc(C(=O)Nc2n[nH]c3c2CN(C(=O)N2C[C@@H]4CCCN4C[C@@H]2Cc2ccccc2)C3(C)C)c1		CHEMBL3662732	=	Ki	nM	16.1	CHEMBL3045	Homo sapiens	Ki	nM	16.1
295222	17676457	CHEMBL3705825	Inhibition Assay: Protein Kinase C beta 2 (PKC beta II) catalyzes the production of ADP from ATP that accompanies the phosphoryl transfer to the PKC Pseudosubstrate peptide (A->S, RFARKGSLRQKNV). This transfer is coupled to the oxidation of p-NADH through the activities of Pyruvate Kinase (PK) and Lactate Dehydrogenase (LDH). (3-NADH conversion to NAD+ is monitored by the decrease in absorbance at 340 nm (e=6.22 cm-1 mM-1) using a Molecular Devices SPECTRA max PLUS spectrophotometer.A typical assay was carried out on a 96-well, clear microtiter plate in a Molecular Devices spectrophotometer for 20 minutes at 30 C. in 0.1 mL of assay buffer containing 50 mM HEPES, pH 7.4, 5 nM PKC, 23 units of pyruvate kinase, 33 units of lactate dehydrogenase, 0.15 mM peptide, 0.1 mM ATP, 1 mM DTT, 4 mM PEP, 8 mM MgCl2, 0.3 mM NADH, 60 mM CaCl2, 10 mg/mL PS, 50 ng/mL PMA, 7.5% DMSO and from about 10,000 nM to 0.169 nM compound inhibitor.	B	COc1ccc(C(=O)Nc2n[nH]c3c2CN(C(=O)N2C[C@@H]4CCCN4C[C@@H]2Cc2ccccc2)C3(C)C)cc1		CHEMBL3662733	=	Ki	nM	30.2	CHEMBL3045	Homo sapiens	Ki	nM	30.2
295223	17676458	CHEMBL3705825	Inhibition Assay: Protein Kinase C beta 2 (PKC beta II) catalyzes the production of ADP from ATP that accompanies the phosphoryl transfer to the PKC Pseudosubstrate peptide (A->S, RFARKGSLRQKNV). This transfer is coupled to the oxidation of p-NADH through the activities of Pyruvate Kinase (PK) and Lactate Dehydrogenase (LDH). (3-NADH conversion to NAD+ is monitored by the decrease in absorbance at 340 nm (e=6.22 cm-1 mM-1) using a Molecular Devices SPECTRA max PLUS spectrophotometer.A typical assay was carried out on a 96-well, clear microtiter plate in a Molecular Devices spectrophotometer for 20 minutes at 30 C. in 0.1 mL of assay buffer containing 50 mM HEPES, pH 7.4, 5 nM PKC, 23 units of pyruvate kinase, 33 units of lactate dehydrogenase, 0.15 mM peptide, 0.1 mM ATP, 1 mM DTT, 4 mM PEP, 8 mM MgCl2, 0.3 mM NADH, 60 mM CaCl2, 10 mg/mL PS, 50 ng/mL PMA, 7.5% DMSO and from about 10,000 nM to 0.169 nM compound inhibitor.	B	CC1(C)c2[nH]nc(NC(=O)c3ccccc3Cl)c2CN1C(=O)N1C[C@@H]2CCCN2C[C@@H]1Cc1ccccc1		CHEMBL3662734	=	Ki	nM	91.4	CHEMBL3045	Homo sapiens	Ki	nM	91.4
295224	17676459	CHEMBL3705825	Inhibition Assay: Protein Kinase C beta 2 (PKC beta II) catalyzes the production of ADP from ATP that accompanies the phosphoryl transfer to the PKC Pseudosubstrate peptide (A->S, RFARKGSLRQKNV). This transfer is coupled to the oxidation of p-NADH through the activities of Pyruvate Kinase (PK) and Lactate Dehydrogenase (LDH). (3-NADH conversion to NAD+ is monitored by the decrease in absorbance at 340 nm (e=6.22 cm-1 mM-1) using a Molecular Devices SPECTRA max PLUS spectrophotometer.A typical assay was carried out on a 96-well, clear microtiter plate in a Molecular Devices spectrophotometer for 20 minutes at 30 C. in 0.1 mL of assay buffer containing 50 mM HEPES, pH 7.4, 5 nM PKC, 23 units of pyruvate kinase, 33 units of lactate dehydrogenase, 0.15 mM peptide, 0.1 mM ATP, 1 mM DTT, 4 mM PEP, 8 mM MgCl2, 0.3 mM NADH, 60 mM CaCl2, 10 mg/mL PS, 50 ng/mL PMA, 7.5% DMSO and from about 10,000 nM to 0.169 nM compound inhibitor.	B	CC1(C)c2[nH]nc(NC(=O)c3cccc(F)c3F)c2CN1C(=O)N1C[C@@H]2CCCN2C[C@@H]1Cc1ccccc1		CHEMBL3662735	=	Ki	nM	50.8	CHEMBL3045	Homo sapiens	Ki	nM	50.8
295225	17676460	CHEMBL3705825	Inhibition Assay: Protein Kinase C beta 2 (PKC beta II) catalyzes the production of ADP from ATP that accompanies the phosphoryl transfer to the PKC Pseudosubstrate peptide (A->S, RFARKGSLRQKNV). This transfer is coupled to the oxidation of p-NADH through the activities of Pyruvate Kinase (PK) and Lactate Dehydrogenase (LDH). (3-NADH conversion to NAD+ is monitored by the decrease in absorbance at 340 nm (e=6.22 cm-1 mM-1) using a Molecular Devices SPECTRA max PLUS spectrophotometer.A typical assay was carried out on a 96-well, clear microtiter plate in a Molecular Devices spectrophotometer for 20 minutes at 30 C. in 0.1 mL of assay buffer containing 50 mM HEPES, pH 7.4, 5 nM PKC, 23 units of pyruvate kinase, 33 units of lactate dehydrogenase, 0.15 mM peptide, 0.1 mM ATP, 1 mM DTT, 4 mM PEP, 8 mM MgCl2, 0.3 mM NADH, 60 mM CaCl2, 10 mg/mL PS, 50 ng/mL PMA, 7.5% DMSO and from about 10,000 nM to 0.169 nM compound inhibitor.	B	C.CC1c2[nH]nc(NC(=O)c3ccccc3F)c2CN1C(=O)N1C[C@@H]2CCCN2C[C@@H]1Cc1ccccc1		CHEMBL3949655	=	Ki	nM	53.2	CHEMBL3045	Homo sapiens	Ki	nM	53.2
295226	17676461	CHEMBL3705825	Inhibition Assay: Protein Kinase C beta 2 (PKC beta II) catalyzes the production of ADP from ATP that accompanies the phosphoryl transfer to the PKC Pseudosubstrate peptide (A->S, RFARKGSLRQKNV). This transfer is coupled to the oxidation of p-NADH through the activities of Pyruvate Kinase (PK) and Lactate Dehydrogenase (LDH). (3-NADH conversion to NAD+ is monitored by the decrease in absorbance at 340 nm (e=6.22 cm-1 mM-1) using a Molecular Devices SPECTRA max PLUS spectrophotometer.A typical assay was carried out on a 96-well, clear microtiter plate in a Molecular Devices spectrophotometer for 20 minutes at 30 C. in 0.1 mL of assay buffer containing 50 mM HEPES, pH 7.4, 5 nM PKC, 23 units of pyruvate kinase, 33 units of lactate dehydrogenase, 0.15 mM peptide, 0.1 mM ATP, 1 mM DTT, 4 mM PEP, 8 mM MgCl2, 0.3 mM NADH, 60 mM CaCl2, 10 mg/mL PS, 50 ng/mL PMA, 7.5% DMSO and from about 10,000 nM to 0.169 nM compound inhibitor.	B	CC1(C)c2[nH]nc(NC(=O)c3cccc(Cl)c3)c2CN1C(=O)N1CCN2CCCC2C1		CHEMBL3662737	=	Ki	nM	28.9	CHEMBL3045	Homo sapiens	Ki	nM	28.9
295227	17676462	CHEMBL3705825	Inhibition Assay: Protein Kinase C beta 2 (PKC beta II) catalyzes the production of ADP from ATP that accompanies the phosphoryl transfer to the PKC Pseudosubstrate peptide (A->S, RFARKGSLRQKNV). This transfer is coupled to the oxidation of p-NADH through the activities of Pyruvate Kinase (PK) and Lactate Dehydrogenase (LDH). (3-NADH conversion to NAD+ is monitored by the decrease in absorbance at 340 nm (e=6.22 cm-1 mM-1) using a Molecular Devices SPECTRA max PLUS spectrophotometer.A typical assay was carried out on a 96-well, clear microtiter plate in a Molecular Devices spectrophotometer for 20 minutes at 30 C. in 0.1 mL of assay buffer containing 50 mM HEPES, pH 7.4, 5 nM PKC, 23 units of pyruvate kinase, 33 units of lactate dehydrogenase, 0.15 mM peptide, 0.1 mM ATP, 1 mM DTT, 4 mM PEP, 8 mM MgCl2, 0.3 mM NADH, 60 mM CaCl2, 10 mg/mL PS, 50 ng/mL PMA, 7.5% DMSO and from about 10,000 nM to 0.169 nM compound inhibitor.	B	CC1(C)c2[nH]nc(NC(=O)c3cccc(Cl)n3)c2CN1C(=O)N1CCN2CCCC2C1		CHEMBL3662738	=	Ki	nM	55.9	CHEMBL3045	Homo sapiens	Ki	nM	55.9
295228	17676463	CHEMBL3705825	Inhibition Assay: Protein Kinase C beta 2 (PKC beta II) catalyzes the production of ADP from ATP that accompanies the phosphoryl transfer to the PKC Pseudosubstrate peptide (A->S, RFARKGSLRQKNV). This transfer is coupled to the oxidation of p-NADH through the activities of Pyruvate Kinase (PK) and Lactate Dehydrogenase (LDH). (3-NADH conversion to NAD+ is monitored by the decrease in absorbance at 340 nm (e=6.22 cm-1 mM-1) using a Molecular Devices SPECTRA max PLUS spectrophotometer.A typical assay was carried out on a 96-well, clear microtiter plate in a Molecular Devices spectrophotometer for 20 minutes at 30 C. in 0.1 mL of assay buffer containing 50 mM HEPES, pH 7.4, 5 nM PKC, 23 units of pyruvate kinase, 33 units of lactate dehydrogenase, 0.15 mM peptide, 0.1 mM ATP, 1 mM DTT, 4 mM PEP, 8 mM MgCl2, 0.3 mM NADH, 60 mM CaCl2, 10 mg/mL PS, 50 ng/mL PMA, 7.5% DMSO and from about 10,000 nM to 0.169 nM compound inhibitor.	B	CC1(C)c2[nH]nc(NC(=O)c3cccc(Cl)n3)c2CN1C(=O)N1CCN2CCCC2C1		CHEMBL3662738	=	Ki	nM	42.9	CHEMBL3045	Homo sapiens	Ki	nM	42.9
295229	17676464	CHEMBL3705825	Inhibition Assay: Protein Kinase C beta 2 (PKC beta II) catalyzes the production of ADP from ATP that accompanies the phosphoryl transfer to the PKC Pseudosubstrate peptide (A->S, RFARKGSLRQKNV). This transfer is coupled to the oxidation of p-NADH through the activities of Pyruvate Kinase (PK) and Lactate Dehydrogenase (LDH). (3-NADH conversion to NAD+ is monitored by the decrease in absorbance at 340 nm (e=6.22 cm-1 mM-1) using a Molecular Devices SPECTRA max PLUS spectrophotometer.A typical assay was carried out on a 96-well, clear microtiter plate in a Molecular Devices spectrophotometer for 20 minutes at 30 C. in 0.1 mL of assay buffer containing 50 mM HEPES, pH 7.4, 5 nM PKC, 23 units of pyruvate kinase, 33 units of lactate dehydrogenase, 0.15 mM peptide, 0.1 mM ATP, 1 mM DTT, 4 mM PEP, 8 mM MgCl2, 0.3 mM NADH, 60 mM CaCl2, 10 mg/mL PS, 50 ng/mL PMA, 7.5% DMSO and from about 10,000 nM to 0.169 nM compound inhibitor.	B	CC1(C)c2[nH]nc(NC(=O)c3ccc4ccncc4n3)c2CN1C(=O)N1C[C@@H]2CCCN2C[C@@H]1Cc1ccccc1		CHEMBL3662739	=	Ki	nM	28.8	CHEMBL3045	Homo sapiens	Ki	nM	28.8
295230	17676465	CHEMBL3705825	Inhibition Assay: Protein Kinase C beta 2 (PKC beta II) catalyzes the production of ADP from ATP that accompanies the phosphoryl transfer to the PKC Pseudosubstrate peptide (A->S, RFARKGSLRQKNV). This transfer is coupled to the oxidation of p-NADH through the activities of Pyruvate Kinase (PK) and Lactate Dehydrogenase (LDH). (3-NADH conversion to NAD+ is monitored by the decrease in absorbance at 340 nm (e=6.22 cm-1 mM-1) using a Molecular Devices SPECTRA max PLUS spectrophotometer.A typical assay was carried out on a 96-well, clear microtiter plate in a Molecular Devices spectrophotometer for 20 minutes at 30 C. in 0.1 mL of assay buffer containing 50 mM HEPES, pH 7.4, 5 nM PKC, 23 units of pyruvate kinase, 33 units of lactate dehydrogenase, 0.15 mM peptide, 0.1 mM ATP, 1 mM DTT, 4 mM PEP, 8 mM MgCl2, 0.3 mM NADH, 60 mM CaCl2, 10 mg/mL PS, 50 ng/mL PMA, 7.5% DMSO and from about 10,000 nM to 0.169 nM compound inhibitor.	B	Cn1ccnc1C(=O)Nc1n[nH]c2c1CN(C(=O)N1C[C@@H]3CCCN3C[C@@H]1Cc1ccccc1)C2(C)C		CHEMBL3662740	=	Ki	nM	69.3	CHEMBL3045	Homo sapiens	Ki	nM	69.3
295231	17676466	CHEMBL3705825	Inhibition Assay: Protein Kinase C beta 2 (PKC beta II) catalyzes the production of ADP from ATP that accompanies the phosphoryl transfer to the PKC Pseudosubstrate peptide (A->S, RFARKGSLRQKNV). This transfer is coupled to the oxidation of p-NADH through the activities of Pyruvate Kinase (PK) and Lactate Dehydrogenase (LDH). (3-NADH conversion to NAD+ is monitored by the decrease in absorbance at 340 nm (e=6.22 cm-1 mM-1) using a Molecular Devices SPECTRA max PLUS spectrophotometer.A typical assay was carried out on a 96-well, clear microtiter plate in a Molecular Devices spectrophotometer for 20 minutes at 30 C. in 0.1 mL of assay buffer containing 50 mM HEPES, pH 7.4, 5 nM PKC, 23 units of pyruvate kinase, 33 units of lactate dehydrogenase, 0.15 mM peptide, 0.1 mM ATP, 1 mM DTT, 4 mM PEP, 8 mM MgCl2, 0.3 mM NADH, 60 mM CaCl2, 10 mg/mL PS, 50 ng/mL PMA, 7.5% DMSO and from about 10,000 nM to 0.169 nM compound inhibitor.	B	C[C@H]1CN2CCC[C@H]2CN1C(=O)N1Cc2c(NC(=O)c3ccccc3)n[nH]c2C1(C)C		CHEMBL3662741	=	Ki	nM	35.1	CHEMBL3045	Homo sapiens	Ki	nM	35.1
295232	17676467	CHEMBL3705825	Inhibition Assay: Protein Kinase C beta 2 (PKC beta II) catalyzes the production of ADP from ATP that accompanies the phosphoryl transfer to the PKC Pseudosubstrate peptide (A->S, RFARKGSLRQKNV). This transfer is coupled to the oxidation of p-NADH through the activities of Pyruvate Kinase (PK) and Lactate Dehydrogenase (LDH). (3-NADH conversion to NAD+ is monitored by the decrease in absorbance at 340 nm (e=6.22 cm-1 mM-1) using a Molecular Devices SPECTRA max PLUS spectrophotometer.A typical assay was carried out on a 96-well, clear microtiter plate in a Molecular Devices spectrophotometer for 20 minutes at 30 C. in 0.1 mL of assay buffer containing 50 mM HEPES, pH 7.4, 5 nM PKC, 23 units of pyruvate kinase, 33 units of lactate dehydrogenase, 0.15 mM peptide, 0.1 mM ATP, 1 mM DTT, 4 mM PEP, 8 mM MgCl2, 0.3 mM NADH, 60 mM CaCl2, 10 mg/mL PS, 50 ng/mL PMA, 7.5% DMSO and from about 10,000 nM to 0.169 nM compound inhibitor.	B	CCC[C@H]1CN2CCC[C@H]2CN1C(=O)N1Cc2c(NC(=O)c3ccccc3)n[nH]c2C1(C)C		CHEMBL3662742	=	Ki	nM	96.1	CHEMBL3045	Homo sapiens	Ki	nM	96.1
295233	17676468	CHEMBL3705825	Inhibition Assay: Protein Kinase C beta 2 (PKC beta II) catalyzes the production of ADP from ATP that accompanies the phosphoryl transfer to the PKC Pseudosubstrate peptide (A->S, RFARKGSLRQKNV). This transfer is coupled to the oxidation of p-NADH through the activities of Pyruvate Kinase (PK) and Lactate Dehydrogenase (LDH). (3-NADH conversion to NAD+ is monitored by the decrease in absorbance at 340 nm (e=6.22 cm-1 mM-1) using a Molecular Devices SPECTRA max PLUS spectrophotometer.A typical assay was carried out on a 96-well, clear microtiter plate in a Molecular Devices spectrophotometer for 20 minutes at 30 C. in 0.1 mL of assay buffer containing 50 mM HEPES, pH 7.4, 5 nM PKC, 23 units of pyruvate kinase, 33 units of lactate dehydrogenase, 0.15 mM peptide, 0.1 mM ATP, 1 mM DTT, 4 mM PEP, 8 mM MgCl2, 0.3 mM NADH, 60 mM CaCl2, 10 mg/mL PS, 50 ng/mL PMA, 7.5% DMSO and from about 10,000 nM to 0.169 nM compound inhibitor.	B	C[C@H]1CN(C(=O)N2Cc3c(NC(=O)c4ccccn4)n[nH]c3C2(C)C)C[C@@H](C)N1		CHEMBL3662743	=	Ki	nM	77.6	CHEMBL3045	Homo sapiens	Ki	nM	77.6
295234	17676469	CHEMBL3705825	Inhibition Assay: Protein Kinase C beta 2 (PKC beta II) catalyzes the production of ADP from ATP that accompanies the phosphoryl transfer to the PKC Pseudosubstrate peptide (A->S, RFARKGSLRQKNV). This transfer is coupled to the oxidation of p-NADH through the activities of Pyruvate Kinase (PK) and Lactate Dehydrogenase (LDH). (3-NADH conversion to NAD+ is monitored by the decrease in absorbance at 340 nm (e=6.22 cm-1 mM-1) using a Molecular Devices SPECTRA max PLUS spectrophotometer.A typical assay was carried out on a 96-well, clear microtiter plate in a Molecular Devices spectrophotometer for 20 minutes at 30 C. in 0.1 mL of assay buffer containing 50 mM HEPES, pH 7.4, 5 nM PKC, 23 units of pyruvate kinase, 33 units of lactate dehydrogenase, 0.15 mM peptide, 0.1 mM ATP, 1 mM DTT, 4 mM PEP, 8 mM MgCl2, 0.3 mM NADH, 60 mM CaCl2, 10 mg/mL PS, 50 ng/mL PMA, 7.5% DMSO and from about 10,000 nM to 0.169 nM compound inhibitor.	B	C[C@H]1CN2CCC[C@H]2CN1C(=O)C1Cc2c(NC(=O)c3cc(Cl)cc(Cl)c3)n[nH]c2C1(C)C		CHEMBL3662744	=	Ki	nM	22.9	CHEMBL3045	Homo sapiens	Ki	nM	22.9
295235	17676470	CHEMBL3705825	Inhibition Assay: Protein Kinase C beta 2 (PKC beta II) catalyzes the production of ADP from ATP that accompanies the phosphoryl transfer to the PKC Pseudosubstrate peptide (A->S, RFARKGSLRQKNV). This transfer is coupled to the oxidation of p-NADH through the activities of Pyruvate Kinase (PK) and Lactate Dehydrogenase (LDH). (3-NADH conversion to NAD+ is monitored by the decrease in absorbance at 340 nm (e=6.22 cm-1 mM-1) using a Molecular Devices SPECTRA max PLUS spectrophotometer.A typical assay was carried out on a 96-well, clear microtiter plate in a Molecular Devices spectrophotometer for 20 minutes at 30 C. in 0.1 mL of assay buffer containing 50 mM HEPES, pH 7.4, 5 nM PKC, 23 units of pyruvate kinase, 33 units of lactate dehydrogenase, 0.15 mM peptide, 0.1 mM ATP, 1 mM DTT, 4 mM PEP, 8 mM MgCl2, 0.3 mM NADH, 60 mM CaCl2, 10 mg/mL PS, 50 ng/mL PMA, 7.5% DMSO and from about 10,000 nM to 0.169 nM compound inhibitor.	B	C[C@H]1CN2CCC[C@H]2CN1C(=O)N1Cc2c(NC(=O)c3cccc(Cl)c3)n[nH]c2C1(C)C		CHEMBL3662745	=	Ki	nM	21.3	CHEMBL3045	Homo sapiens	Ki	nM	21.3
295236	17676471	CHEMBL3705825	Inhibition Assay: Protein Kinase C beta 2 (PKC beta II) catalyzes the production of ADP from ATP that accompanies the phosphoryl transfer to the PKC Pseudosubstrate peptide (A->S, RFARKGSLRQKNV). This transfer is coupled to the oxidation of p-NADH through the activities of Pyruvate Kinase (PK) and Lactate Dehydrogenase (LDH). (3-NADH conversion to NAD+ is monitored by the decrease in absorbance at 340 nm (e=6.22 cm-1 mM-1) using a Molecular Devices SPECTRA max PLUS spectrophotometer.A typical assay was carried out on a 96-well, clear microtiter plate in a Molecular Devices spectrophotometer for 20 minutes at 30 C. in 0.1 mL of assay buffer containing 50 mM HEPES, pH 7.4, 5 nM PKC, 23 units of pyruvate kinase, 33 units of lactate dehydrogenase, 0.15 mM peptide, 0.1 mM ATP, 1 mM DTT, 4 mM PEP, 8 mM MgCl2, 0.3 mM NADH, 60 mM CaCl2, 10 mg/mL PS, 50 ng/mL PMA, 7.5% DMSO and from about 10,000 nM to 0.169 nM compound inhibitor.	B	C[C@H]1CN2CCC[C@H]2CN1C(=O)N1Cc2c(NC(=O)c3ccccc3F)n[nH]c2C1(C)C		CHEMBL3662746	=	Ki	nM	92.4	CHEMBL3045	Homo sapiens	Ki	nM	92.4
295237	17676472	CHEMBL3705825	Inhibition Assay: Protein Kinase C beta 2 (PKC beta II) catalyzes the production of ADP from ATP that accompanies the phosphoryl transfer to the PKC Pseudosubstrate peptide (A->S, RFARKGSLRQKNV). This transfer is coupled to the oxidation of p-NADH through the activities of Pyruvate Kinase (PK) and Lactate Dehydrogenase (LDH). (3-NADH conversion to NAD+ is monitored by the decrease in absorbance at 340 nm (e=6.22 cm-1 mM-1) using a Molecular Devices SPECTRA max PLUS spectrophotometer.A typical assay was carried out on a 96-well, clear microtiter plate in a Molecular Devices spectrophotometer for 20 minutes at 30 C. in 0.1 mL of assay buffer containing 50 mM HEPES, pH 7.4, 5 nM PKC, 23 units of pyruvate kinase, 33 units of lactate dehydrogenase, 0.15 mM peptide, 0.1 mM ATP, 1 mM DTT, 4 mM PEP, 8 mM MgCl2, 0.3 mM NADH, 60 mM CaCl2, 10 mg/mL PS, 50 ng/mL PMA, 7.5% DMSO and from about 10,000 nM to 0.169 nM compound inhibitor.	B	C[C@H]1CN2CCC[C@H]2CN1C(=O)N1Cc2c(NC(=O)c3cc(Cl)ccc3F)n[nH]c2C1(C)C		CHEMBL3662747	=	Ki	nM	82.7	CHEMBL3045	Homo sapiens	Ki	nM	82.7
295238	17676473	CHEMBL3705825	Inhibition Assay: Protein Kinase C beta 2 (PKC beta II) catalyzes the production of ADP from ATP that accompanies the phosphoryl transfer to the PKC Pseudosubstrate peptide (A->S, RFARKGSLRQKNV). This transfer is coupled to the oxidation of p-NADH through the activities of Pyruvate Kinase (PK) and Lactate Dehydrogenase (LDH). (3-NADH conversion to NAD+ is monitored by the decrease in absorbance at 340 nm (e=6.22 cm-1 mM-1) using a Molecular Devices SPECTRA max PLUS spectrophotometer.A typical assay was carried out on a 96-well, clear microtiter plate in a Molecular Devices spectrophotometer for 20 minutes at 30 C. in 0.1 mL of assay buffer containing 50 mM HEPES, pH 7.4, 5 nM PKC, 23 units of pyruvate kinase, 33 units of lactate dehydrogenase, 0.15 mM peptide, 0.1 mM ATP, 1 mM DTT, 4 mM PEP, 8 mM MgCl2, 0.3 mM NADH, 60 mM CaCl2, 10 mg/mL PS, 50 ng/mL PMA, 7.5% DMSO and from about 10,000 nM to 0.169 nM compound inhibitor.	B	C[C@H]1CN2CCC[C@H]2CN1C(=O)N1Cc2c(NC(=O)c3ccc(F)c(Cl)c3)n[nH]c2C1(C)C		CHEMBL3662748	=	Ki	nM	21.9	CHEMBL3045	Homo sapiens	Ki	nM	21.9
295239	17676474	CHEMBL3705825	Inhibition Assay: Protein Kinase C beta 2 (PKC beta II) catalyzes the production of ADP from ATP that accompanies the phosphoryl transfer to the PKC Pseudosubstrate peptide (A->S, RFARKGSLRQKNV). This transfer is coupled to the oxidation of p-NADH through the activities of Pyruvate Kinase (PK) and Lactate Dehydrogenase (LDH). (3-NADH conversion to NAD+ is monitored by the decrease in absorbance at 340 nm (e=6.22 cm-1 mM-1) using a Molecular Devices SPECTRA max PLUS spectrophotometer.A typical assay was carried out on a 96-well, clear microtiter plate in a Molecular Devices spectrophotometer for 20 minutes at 30 C. in 0.1 mL of assay buffer containing 50 mM HEPES, pH 7.4, 5 nM PKC, 23 units of pyruvate kinase, 33 units of lactate dehydrogenase, 0.15 mM peptide, 0.1 mM ATP, 1 mM DTT, 4 mM PEP, 8 mM MgCl2, 0.3 mM NADH, 60 mM CaCl2, 10 mg/mL PS, 50 ng/mL PMA, 7.5% DMSO and from about 10,000 nM to 0.169 nM compound inhibitor.	B	C[C@H]1CN2CCC[C@H]2CN1C(=O)N1Cc2c(NC(=O)c3cc(C(F)(F)F)ccc3F)n[nH]c2C1(C)C		CHEMBL3662749	=	Ki	nM	176.0	CHEMBL3045	Homo sapiens	Ki	nM	176.0
295240	17676475	CHEMBL3705825	Inhibition Assay: Protein Kinase C beta 2 (PKC beta II) catalyzes the production of ADP from ATP that accompanies the phosphoryl transfer to the PKC Pseudosubstrate peptide (A->S, RFARKGSLRQKNV). This transfer is coupled to the oxidation of p-NADH through the activities of Pyruvate Kinase (PK) and Lactate Dehydrogenase (LDH). (3-NADH conversion to NAD+ is monitored by the decrease in absorbance at 340 nm (e=6.22 cm-1 mM-1) using a Molecular Devices SPECTRA max PLUS spectrophotometer.A typical assay was carried out on a 96-well, clear microtiter plate in a Molecular Devices spectrophotometer for 20 minutes at 30 C. in 0.1 mL of assay buffer containing 50 mM HEPES, pH 7.4, 5 nM PKC, 23 units of pyruvate kinase, 33 units of lactate dehydrogenase, 0.15 mM peptide, 0.1 mM ATP, 1 mM DTT, 4 mM PEP, 8 mM MgCl2, 0.3 mM NADH, 60 mM CaCl2, 10 mg/mL PS, 50 ng/mL PMA, 7.5% DMSO and from about 10,000 nM to 0.169 nM compound inhibitor.	B	C[C@H]1CN2CCC[C@H]2CN1C(=O)N1Cc2c(NC(=O)c3ccc(Cl)c(Cl)c3)n[nH]c2C1(C)C		CHEMBL3662750	=	Ki	nM	13.9	CHEMBL3045	Homo sapiens	Ki	nM	13.9
295241	17676476	CHEMBL3705825	Inhibition Assay: Protein Kinase C beta 2 (PKC beta II) catalyzes the production of ADP from ATP that accompanies the phosphoryl transfer to the PKC Pseudosubstrate peptide (A->S, RFARKGSLRQKNV). This transfer is coupled to the oxidation of p-NADH through the activities of Pyruvate Kinase (PK) and Lactate Dehydrogenase (LDH). (3-NADH conversion to NAD+ is monitored by the decrease in absorbance at 340 nm (e=6.22 cm-1 mM-1) using a Molecular Devices SPECTRA max PLUS spectrophotometer.A typical assay was carried out on a 96-well, clear microtiter plate in a Molecular Devices spectrophotometer for 20 minutes at 30 C. in 0.1 mL of assay buffer containing 50 mM HEPES, pH 7.4, 5 nM PKC, 23 units of pyruvate kinase, 33 units of lactate dehydrogenase, 0.15 mM peptide, 0.1 mM ATP, 1 mM DTT, 4 mM PEP, 8 mM MgCl2, 0.3 mM NADH, 60 mM CaCl2, 10 mg/mL PS, 50 ng/mL PMA, 7.5% DMSO and from about 10,000 nM to 0.169 nM compound inhibitor.	B	C[C@H]1CN2CCC[C@H]2CN1C(=O)N1Cc2c(NC(=O)c3c(F)cccc3C(F)(F)F)n[nH]c2C1(C)C		CHEMBL3662751	=	Ki	nM	155.0	CHEMBL3045	Homo sapiens	Ki	nM	155.0
295242	17676477	CHEMBL3705825	Inhibition Assay: Protein Kinase C beta 2 (PKC beta II) catalyzes the production of ADP from ATP that accompanies the phosphoryl transfer to the PKC Pseudosubstrate peptide (A->S, RFARKGSLRQKNV). This transfer is coupled to the oxidation of p-NADH through the activities of Pyruvate Kinase (PK) and Lactate Dehydrogenase (LDH). (3-NADH conversion to NAD+ is monitored by the decrease in absorbance at 340 nm (e=6.22 cm-1 mM-1) using a Molecular Devices SPECTRA max PLUS spectrophotometer.A typical assay was carried out on a 96-well, clear microtiter plate in a Molecular Devices spectrophotometer for 20 minutes at 30 C. in 0.1 mL of assay buffer containing 50 mM HEPES, pH 7.4, 5 nM PKC, 23 units of pyruvate kinase, 33 units of lactate dehydrogenase, 0.15 mM peptide, 0.1 mM ATP, 1 mM DTT, 4 mM PEP, 8 mM MgCl2, 0.3 mM NADH, 60 mM CaCl2, 10 mg/mL PS, 50 ng/mL PMA, 7.5% DMSO and from about 10,000 nM to 0.169 nM compound inhibitor.	B	C[C@H]1CN2CCC[C@H]2CN1C(=O)N1Cc2c(NC(=O)c3c(F)cccc3Cl)n[nH]c2C1(C)C		CHEMBL3662752	=	Ki	nM	181.0	CHEMBL3045	Homo sapiens	Ki	nM	181.0
295243	17676478	CHEMBL3705825	Inhibition Assay: Protein Kinase C beta 2 (PKC beta II) catalyzes the production of ADP from ATP that accompanies the phosphoryl transfer to the PKC Pseudosubstrate peptide (A->S, RFARKGSLRQKNV). This transfer is coupled to the oxidation of p-NADH through the activities of Pyruvate Kinase (PK) and Lactate Dehydrogenase (LDH). (3-NADH conversion to NAD+ is monitored by the decrease in absorbance at 340 nm (e=6.22 cm-1 mM-1) using a Molecular Devices SPECTRA max PLUS spectrophotometer.A typical assay was carried out on a 96-well, clear microtiter plate in a Molecular Devices spectrophotometer for 20 minutes at 30 C. in 0.1 mL of assay buffer containing 50 mM HEPES, pH 7.4, 5 nM PKC, 23 units of pyruvate kinase, 33 units of lactate dehydrogenase, 0.15 mM peptide, 0.1 mM ATP, 1 mM DTT, 4 mM PEP, 8 mM MgCl2, 0.3 mM NADH, 60 mM CaCl2, 10 mg/mL PS, 50 ng/mL PMA, 7.5% DMSO and from about 10,000 nM to 0.169 nM compound inhibitor.	B	C.COc1cccc(C(=O)Nc2n[nH]c3c2CN(C(=O)N2C[C@@H]4CCCN4C[C@@H]2C)C3(C)C)c1		CHEMBL3939506	=	Ki	nM	47.4	CHEMBL3045	Homo sapiens	Ki	nM	47.4
295244	17676479	CHEMBL3705825	Inhibition Assay: Protein Kinase C beta 2 (PKC beta II) catalyzes the production of ADP from ATP that accompanies the phosphoryl transfer to the PKC Pseudosubstrate peptide (A->S, RFARKGSLRQKNV). This transfer is coupled to the oxidation of p-NADH through the activities of Pyruvate Kinase (PK) and Lactate Dehydrogenase (LDH). (3-NADH conversion to NAD+ is monitored by the decrease in absorbance at 340 nm (e=6.22 cm-1 mM-1) using a Molecular Devices SPECTRA max PLUS spectrophotometer.A typical assay was carried out on a 96-well, clear microtiter plate in a Molecular Devices spectrophotometer for 20 minutes at 30 C. in 0.1 mL of assay buffer containing 50 mM HEPES, pH 7.4, 5 nM PKC, 23 units of pyruvate kinase, 33 units of lactate dehydrogenase, 0.15 mM peptide, 0.1 mM ATP, 1 mM DTT, 4 mM PEP, 8 mM MgCl2, 0.3 mM NADH, 60 mM CaCl2, 10 mg/mL PS, 50 ng/mL PMA, 7.5% DMSO and from about 10,000 nM to 0.169 nM compound inhibitor.	B	COc1ccc(C(=O)Nc2n[nH]c3c2CN(C(=O)N2C[C@@H]4CCCN4C[C@@H]2C)C3(C)C)cc1		CHEMBL3662754	=	Ki	nM	32.7	CHEMBL3045	Homo sapiens	Ki	nM	32.7
295245	17676480	CHEMBL3705825	Inhibition Assay: Protein Kinase C beta 2 (PKC beta II) catalyzes the production of ADP from ATP that accompanies the phosphoryl transfer to the PKC Pseudosubstrate peptide (A->S, RFARKGSLRQKNV). This transfer is coupled to the oxidation of p-NADH through the activities of Pyruvate Kinase (PK) and Lactate Dehydrogenase (LDH). (3-NADH conversion to NAD+ is monitored by the decrease in absorbance at 340 nm (e=6.22 cm-1 mM-1) using a Molecular Devices SPECTRA max PLUS spectrophotometer.A typical assay was carried out on a 96-well, clear microtiter plate in a Molecular Devices spectrophotometer for 20 minutes at 30 C. in 0.1 mL of assay buffer containing 50 mM HEPES, pH 7.4, 5 nM PKC, 23 units of pyruvate kinase, 33 units of lactate dehydrogenase, 0.15 mM peptide, 0.1 mM ATP, 1 mM DTT, 4 mM PEP, 8 mM MgCl2, 0.3 mM NADH, 60 mM CaCl2, 10 mg/mL PS, 50 ng/mL PMA, 7.5% DMSO and from about 10,000 nM to 0.169 nM compound inhibitor.	B	C[C@H]1CN2CCC[C@H]2CN1C(=O)N1Cc2c(NC(=O)c3ccc(OC(F)(F)F)cc3)n[nH]c2C1(C)C		CHEMBL3662755	=	Ki	nM	45.4	CHEMBL3045	Homo sapiens	Ki	nM	45.4
295246	17676481	CHEMBL3705825	Inhibition Assay: Protein Kinase C beta 2 (PKC beta II) catalyzes the production of ADP from ATP that accompanies the phosphoryl transfer to the PKC Pseudosubstrate peptide (A->S, RFARKGSLRQKNV). This transfer is coupled to the oxidation of p-NADH through the activities of Pyruvate Kinase (PK) and Lactate Dehydrogenase (LDH). (3-NADH conversion to NAD+ is monitored by the decrease in absorbance at 340 nm (e=6.22 cm-1 mM-1) using a Molecular Devices SPECTRA max PLUS spectrophotometer.A typical assay was carried out on a 96-well, clear microtiter plate in a Molecular Devices spectrophotometer for 20 minutes at 30 C. in 0.1 mL of assay buffer containing 50 mM HEPES, pH 7.4, 5 nM PKC, 23 units of pyruvate kinase, 33 units of lactate dehydrogenase, 0.15 mM peptide, 0.1 mM ATP, 1 mM DTT, 4 mM PEP, 8 mM MgCl2, 0.3 mM NADH, 60 mM CaCl2, 10 mg/mL PS, 50 ng/mL PMA, 7.5% DMSO and from about 10,000 nM to 0.169 nM compound inhibitor.	B	Cc1cc(C(=O)Nc2n[nH]c3c2CN(C(=O)N2C[C@@H]4CCCN4C[C@@H]2C)C3(C)C)n(C)n1		CHEMBL3662756	=	Ki	nM	67.9	CHEMBL3045	Homo sapiens	Ki	nM	67.9
295247	17676482	CHEMBL3705825	Inhibition Assay: Protein Kinase C beta 2 (PKC beta II) catalyzes the production of ADP from ATP that accompanies the phosphoryl transfer to the PKC Pseudosubstrate peptide (A->S, RFARKGSLRQKNV). This transfer is coupled to the oxidation of p-NADH through the activities of Pyruvate Kinase (PK) and Lactate Dehydrogenase (LDH). (3-NADH conversion to NAD+ is monitored by the decrease in absorbance at 340 nm (e=6.22 cm-1 mM-1) using a Molecular Devices SPECTRA max PLUS spectrophotometer.A typical assay was carried out on a 96-well, clear microtiter plate in a Molecular Devices spectrophotometer for 20 minutes at 30 C. in 0.1 mL of assay buffer containing 50 mM HEPES, pH 7.4, 5 nM PKC, 23 units of pyruvate kinase, 33 units of lactate dehydrogenase, 0.15 mM peptide, 0.1 mM ATP, 1 mM DTT, 4 mM PEP, 8 mM MgCl2, 0.3 mM NADH, 60 mM CaCl2, 10 mg/mL PS, 50 ng/mL PMA, 7.5% DMSO and from about 10,000 nM to 0.169 nM compound inhibitor.	B	C[C@H]1CN2CCC[C@H]2CN1C(=O)N1Cc2c(NC(=O)c3cncs3)n[nH]c2C1(C)C		CHEMBL3662757	=	Ki	nM	135.0	CHEMBL3045	Homo sapiens	Ki	nM	135.0
295248	17676483	CHEMBL3705825	Inhibition Assay: Protein Kinase C beta 2 (PKC beta II) catalyzes the production of ADP from ATP that accompanies the phosphoryl transfer to the PKC Pseudosubstrate peptide (A->S, RFARKGSLRQKNV). This transfer is coupled to the oxidation of p-NADH through the activities of Pyruvate Kinase (PK) and Lactate Dehydrogenase (LDH). (3-NADH conversion to NAD+ is monitored by the decrease in absorbance at 340 nm (e=6.22 cm-1 mM-1) using a Molecular Devices SPECTRA max PLUS spectrophotometer.A typical assay was carried out on a 96-well, clear microtiter plate in a Molecular Devices spectrophotometer for 20 minutes at 30 C. in 0.1 mL of assay buffer containing 50 mM HEPES, pH 7.4, 5 nM PKC, 23 units of pyruvate kinase, 33 units of lactate dehydrogenase, 0.15 mM peptide, 0.1 mM ATP, 1 mM DTT, 4 mM PEP, 8 mM MgCl2, 0.3 mM NADH, 60 mM CaCl2, 10 mg/mL PS, 50 ng/mL PMA, 7.5% DMSO and from about 10,000 nM to 0.169 nM compound inhibitor.	B	C[C@H]1CN2CCC[C@H]2CN1C(=O)N1Cc2c(NC(=O)c3cscn3)n[nH]c2C1(C)C		CHEMBL3662758	=	Ki	nM	43.5	CHEMBL3045	Homo sapiens	Ki	nM	43.5
295249	17676484	CHEMBL3705825	Inhibition Assay: Protein Kinase C beta 2 (PKC beta II) catalyzes the production of ADP from ATP that accompanies the phosphoryl transfer to the PKC Pseudosubstrate peptide (A->S, RFARKGSLRQKNV). This transfer is coupled to the oxidation of p-NADH through the activities of Pyruvate Kinase (PK) and Lactate Dehydrogenase (LDH). (3-NADH conversion to NAD+ is monitored by the decrease in absorbance at 340 nm (e=6.22 cm-1 mM-1) using a Molecular Devices SPECTRA max PLUS spectrophotometer.A typical assay was carried out on a 96-well, clear microtiter plate in a Molecular Devices spectrophotometer for 20 minutes at 30 C. in 0.1 mL of assay buffer containing 50 mM HEPES, pH 7.4, 5 nM PKC, 23 units of pyruvate kinase, 33 units of lactate dehydrogenase, 0.15 mM peptide, 0.1 mM ATP, 1 mM DTT, 4 mM PEP, 8 mM MgCl2, 0.3 mM NADH, 60 mM CaCl2, 10 mg/mL PS, 50 ng/mL PMA, 7.5% DMSO and from about 10,000 nM to 0.169 nM compound inhibitor.	B	C[C@H]1CN2CCC[C@H]2CN1C(=O)N1Cc2c(NC(=O)c3cccc(OC(F)(F)F)c3)n[nH]c2C1(C)C		CHEMBL3662759	=	Ki	nM	104.0	CHEMBL3045	Homo sapiens	Ki	nM	104.0
295250	17676485	CHEMBL3705825	Inhibition Assay: Protein Kinase C beta 2 (PKC beta II) catalyzes the production of ADP from ATP that accompanies the phosphoryl transfer to the PKC Pseudosubstrate peptide (A->S, RFARKGSLRQKNV). This transfer is coupled to the oxidation of p-NADH through the activities of Pyruvate Kinase (PK) and Lactate Dehydrogenase (LDH). (3-NADH conversion to NAD+ is monitored by the decrease in absorbance at 340 nm (e=6.22 cm-1 mM-1) using a Molecular Devices SPECTRA max PLUS spectrophotometer.A typical assay was carried out on a 96-well, clear microtiter plate in a Molecular Devices spectrophotometer for 20 minutes at 30 C. in 0.1 mL of assay buffer containing 50 mM HEPES, pH 7.4, 5 nM PKC, 23 units of pyruvate kinase, 33 units of lactate dehydrogenase, 0.15 mM peptide, 0.1 mM ATP, 1 mM DTT, 4 mM PEP, 8 mM MgCl2, 0.3 mM NADH, 60 mM CaCl2, 10 mg/mL PS, 50 ng/mL PMA, 7.5% DMSO and from about 10,000 nM to 0.169 nM compound inhibitor.	B	CC1CN(C(=O)N2Cc3c(NC(=O)c4ccccn4)n[nH]c3C2(C)C)C(C)CN1		CHEMBL3662760	=	Ki	nM	36.2	CHEMBL3045	Homo sapiens	Ki	nM	36.2
295251	17676486	CHEMBL3705825	Inhibition Assay: Protein Kinase C beta 2 (PKC beta II) catalyzes the production of ADP from ATP that accompanies the phosphoryl transfer to the PKC Pseudosubstrate peptide (A->S, RFARKGSLRQKNV). This transfer is coupled to the oxidation of p-NADH through the activities of Pyruvate Kinase (PK) and Lactate Dehydrogenase (LDH). (3-NADH conversion to NAD+ is monitored by the decrease in absorbance at 340 nm (e=6.22 cm-1 mM-1) using a Molecular Devices SPECTRA max PLUS spectrophotometer.A typical assay was carried out on a 96-well, clear microtiter plate in a Molecular Devices spectrophotometer for 20 minutes at 30 C. in 0.1 mL of assay buffer containing 50 mM HEPES, pH 7.4, 5 nM PKC, 23 units of pyruvate kinase, 33 units of lactate dehydrogenase, 0.15 mM peptide, 0.1 mM ATP, 1 mM DTT, 4 mM PEP, 8 mM MgCl2, 0.3 mM NADH, 60 mM CaCl2, 10 mg/mL PS, 50 ng/mL PMA, 7.5% DMSO and from about 10,000 nM to 0.169 nM compound inhibitor.	B	COc1ccc(C(=O)Nc2n[nH]c3c2CN(C(=O)N2C[C@@H]4CCCN4C[C@@H]2C)C3(C)C)nc1		CHEMBL3662761	=	Ki	nM	65.5	CHEMBL3045	Homo sapiens	Ki	nM	65.5
295252	17676487	CHEMBL3705825	Inhibition Assay: Protein Kinase C beta 2 (PKC beta II) catalyzes the production of ADP from ATP that accompanies the phosphoryl transfer to the PKC Pseudosubstrate peptide (A->S, RFARKGSLRQKNV). This transfer is coupled to the oxidation of p-NADH through the activities of Pyruvate Kinase (PK) and Lactate Dehydrogenase (LDH). (3-NADH conversion to NAD+ is monitored by the decrease in absorbance at 340 nm (e=6.22 cm-1 mM-1) using a Molecular Devices SPECTRA max PLUS spectrophotometer.A typical assay was carried out on a 96-well, clear microtiter plate in a Molecular Devices spectrophotometer for 20 minutes at 30 C. in 0.1 mL of assay buffer containing 50 mM HEPES, pH 7.4, 5 nM PKC, 23 units of pyruvate kinase, 33 units of lactate dehydrogenase, 0.15 mM peptide, 0.1 mM ATP, 1 mM DTT, 4 mM PEP, 8 mM MgCl2, 0.3 mM NADH, 60 mM CaCl2, 10 mg/mL PS, 50 ng/mL PMA, 7.5% DMSO and from about 10,000 nM to 0.169 nM compound inhibitor.	B	COc1cc(C(=O)Nc2n[nH]c3c2CN(C(=O)N2C[C@@H]4CCCN4C[C@@H]2C)C3(C)C)ccc1Cl		CHEMBL3662762	=	Ki	nM	68.8	CHEMBL3045	Homo sapiens	Ki	nM	68.8
295253	17676488	CHEMBL3705825	Inhibition Assay: Protein Kinase C beta 2 (PKC beta II) catalyzes the production of ADP from ATP that accompanies the phosphoryl transfer to the PKC Pseudosubstrate peptide (A->S, RFARKGSLRQKNV). This transfer is coupled to the oxidation of p-NADH through the activities of Pyruvate Kinase (PK) and Lactate Dehydrogenase (LDH). (3-NADH conversion to NAD+ is monitored by the decrease in absorbance at 340 nm (e=6.22 cm-1 mM-1) using a Molecular Devices SPECTRA max PLUS spectrophotometer.A typical assay was carried out on a 96-well, clear microtiter plate in a Molecular Devices spectrophotometer for 20 minutes at 30 C. in 0.1 mL of assay buffer containing 50 mM HEPES, pH 7.4, 5 nM PKC, 23 units of pyruvate kinase, 33 units of lactate dehydrogenase, 0.15 mM peptide, 0.1 mM ATP, 1 mM DTT, 4 mM PEP, 8 mM MgCl2, 0.3 mM NADH, 60 mM CaCl2, 10 mg/mL PS, 50 ng/mL PMA, 7.5% DMSO and from about 10,000 nM to 0.169 nM compound inhibitor.	B	C[C@H]1CN2CCC[C@H]2CN1C(=O)N1Cc2c(NC(=O)c3ccc(F)c(Cl)c3)n[nH]c2C1(C)C		CHEMBL3662748	=	Ki	nM	53.6	CHEMBL3045	Homo sapiens	Ki	nM	53.6
295254	17676489	CHEMBL3705825	Inhibition Assay: Protein Kinase C beta 2 (PKC beta II) catalyzes the production of ADP from ATP that accompanies the phosphoryl transfer to the PKC Pseudosubstrate peptide (A->S, RFARKGSLRQKNV). This transfer is coupled to the oxidation of p-NADH through the activities of Pyruvate Kinase (PK) and Lactate Dehydrogenase (LDH). (3-NADH conversion to NAD+ is monitored by the decrease in absorbance at 340 nm (e=6.22 cm-1 mM-1) using a Molecular Devices SPECTRA max PLUS spectrophotometer.A typical assay was carried out on a 96-well, clear microtiter plate in a Molecular Devices spectrophotometer for 20 minutes at 30 C. in 0.1 mL of assay buffer containing 50 mM HEPES, pH 7.4, 5 nM PKC, 23 units of pyruvate kinase, 33 units of lactate dehydrogenase, 0.15 mM peptide, 0.1 mM ATP, 1 mM DTT, 4 mM PEP, 8 mM MgCl2, 0.3 mM NADH, 60 mM CaCl2, 10 mg/mL PS, 50 ng/mL PMA, 7.5% DMSO and from about 10,000 nM to 0.169 nM compound inhibitor.	B	CCc1ccc(C(=O)Nc2n[nH]c3c2CN(C(=O)N2C[C@@H]4CCCN4C[C@@H]2C)C3(C)C)nc1		CHEMBL3662763	=	Ki	nM	82.1	CHEMBL3045	Homo sapiens	Ki	nM	82.1
295255	17676490	CHEMBL3705825	Inhibition Assay: Protein Kinase C beta 2 (PKC beta II) catalyzes the production of ADP from ATP that accompanies the phosphoryl transfer to the PKC Pseudosubstrate peptide (A->S, RFARKGSLRQKNV). This transfer is coupled to the oxidation of p-NADH through the activities of Pyruvate Kinase (PK) and Lactate Dehydrogenase (LDH). (3-NADH conversion to NAD+ is monitored by the decrease in absorbance at 340 nm (e=6.22 cm-1 mM-1) using a Molecular Devices SPECTRA max PLUS spectrophotometer.A typical assay was carried out on a 96-well, clear microtiter plate in a Molecular Devices spectrophotometer for 20 minutes at 30 C. in 0.1 mL of assay buffer containing 50 mM HEPES, pH 7.4, 5 nM PKC, 23 units of pyruvate kinase, 33 units of lactate dehydrogenase, 0.15 mM peptide, 0.1 mM ATP, 1 mM DTT, 4 mM PEP, 8 mM MgCl2, 0.3 mM NADH, 60 mM CaCl2, 10 mg/mL PS, 50 ng/mL PMA, 7.5% DMSO and from about 10,000 nM to 0.169 nM compound inhibitor.	B	Cc1cc(C)nc(C(=O)Nc2n[nH]c3c2CN(C(=O)N2C[C@@H]4CCCN4C[C@@H]2C)C3(C)C)c1		CHEMBL3662764	=	Ki	nM	20.9	CHEMBL3045	Homo sapiens	Ki	nM	20.9
295256	17676491	CHEMBL3705825	Inhibition Assay: Protein Kinase C beta 2 (PKC beta II) catalyzes the production of ADP from ATP that accompanies the phosphoryl transfer to the PKC Pseudosubstrate peptide (A->S, RFARKGSLRQKNV). This transfer is coupled to the oxidation of p-NADH through the activities of Pyruvate Kinase (PK) and Lactate Dehydrogenase (LDH). (3-NADH conversion to NAD+ is monitored by the decrease in absorbance at 340 nm (e=6.22 cm-1 mM-1) using a Molecular Devices SPECTRA max PLUS spectrophotometer.A typical assay was carried out on a 96-well, clear microtiter plate in a Molecular Devices spectrophotometer for 20 minutes at 30 C. in 0.1 mL of assay buffer containing 50 mM HEPES, pH 7.4, 5 nM PKC, 23 units of pyruvate kinase, 33 units of lactate dehydrogenase, 0.15 mM peptide, 0.1 mM ATP, 1 mM DTT, 4 mM PEP, 8 mM MgCl2, 0.3 mM NADH, 60 mM CaCl2, 10 mg/mL PS, 50 ng/mL PMA, 7.5% DMSO and from about 10,000 nM to 0.169 nM compound inhibitor.	B	Cc1cc(C(=O)Nc2n[nH]c3c2CN(C(=O)N2C[C@@H]4CCCN4C[C@@H]2C)C3(C)C)nn1C		CHEMBL3662765	=	Ki	nM	149.0	CHEMBL3045	Homo sapiens	Ki	nM	149.0
295257	17676492	CHEMBL3705825	Inhibition Assay: Protein Kinase C beta 2 (PKC beta II) catalyzes the production of ADP from ATP that accompanies the phosphoryl transfer to the PKC Pseudosubstrate peptide (A->S, RFARKGSLRQKNV). This transfer is coupled to the oxidation of p-NADH through the activities of Pyruvate Kinase (PK) and Lactate Dehydrogenase (LDH). (3-NADH conversion to NAD+ is monitored by the decrease in absorbance at 340 nm (e=6.22 cm-1 mM-1) using a Molecular Devices SPECTRA max PLUS spectrophotometer.A typical assay was carried out on a 96-well, clear microtiter plate in a Molecular Devices spectrophotometer for 20 minutes at 30 C. in 0.1 mL of assay buffer containing 50 mM HEPES, pH 7.4, 5 nM PKC, 23 units of pyruvate kinase, 33 units of lactate dehydrogenase, 0.15 mM peptide, 0.1 mM ATP, 1 mM DTT, 4 mM PEP, 8 mM MgCl2, 0.3 mM NADH, 60 mM CaCl2, 10 mg/mL PS, 50 ng/mL PMA, 7.5% DMSO and from about 10,000 nM to 0.169 nM compound inhibitor.	B	CCc1ccnc(C(=O)Nc2n[nH]c3c2CN(C(=O)N2C[C@@H]4CCCN4C[C@@H]2C)C3(C)C)c1		CHEMBL3662766	=	Ki	nM	66.3	CHEMBL3045	Homo sapiens	Ki	nM	66.3
295258	17676493	CHEMBL3705825	Inhibition Assay: Protein Kinase C beta 2 (PKC beta II) catalyzes the production of ADP from ATP that accompanies the phosphoryl transfer to the PKC Pseudosubstrate peptide (A->S, RFARKGSLRQKNV). This transfer is coupled to the oxidation of p-NADH through the activities of Pyruvate Kinase (PK) and Lactate Dehydrogenase (LDH). (3-NADH conversion to NAD+ is monitored by the decrease in absorbance at 340 nm (e=6.22 cm-1 mM-1) using a Molecular Devices SPECTRA max PLUS spectrophotometer.A typical assay was carried out on a 96-well, clear microtiter plate in a Molecular Devices spectrophotometer for 20 minutes at 30 C. in 0.1 mL of assay buffer containing 50 mM HEPES, pH 7.4, 5 nM PKC, 23 units of pyruvate kinase, 33 units of lactate dehydrogenase, 0.15 mM peptide, 0.1 mM ATP, 1 mM DTT, 4 mM PEP, 8 mM MgCl2, 0.3 mM NADH, 60 mM CaCl2, 10 mg/mL PS, 50 ng/mL PMA, 7.5% DMSO and from about 10,000 nM to 0.169 nM compound inhibitor.	B	C[C@H]1CN2CCC[C@H]2CN1C(=O)N1Cc2c(NC(=O)c3nc4ccccc4s3)n[nH]c2C1(C)C		CHEMBL3662767	=	Ki	nM	49.9	CHEMBL3045	Homo sapiens	Ki	nM	49.9
295259	17676494	CHEMBL3705825	Inhibition Assay: Protein Kinase C beta 2 (PKC beta II) catalyzes the production of ADP from ATP that accompanies the phosphoryl transfer to the PKC Pseudosubstrate peptide (A->S, RFARKGSLRQKNV). This transfer is coupled to the oxidation of p-NADH through the activities of Pyruvate Kinase (PK) and Lactate Dehydrogenase (LDH). (3-NADH conversion to NAD+ is monitored by the decrease in absorbance at 340 nm (e=6.22 cm-1 mM-1) using a Molecular Devices SPECTRA max PLUS spectrophotometer.A typical assay was carried out on a 96-well, clear microtiter plate in a Molecular Devices spectrophotometer for 20 minutes at 30 C. in 0.1 mL of assay buffer containing 50 mM HEPES, pH 7.4, 5 nM PKC, 23 units of pyruvate kinase, 33 units of lactate dehydrogenase, 0.15 mM peptide, 0.1 mM ATP, 1 mM DTT, 4 mM PEP, 8 mM MgCl2, 0.3 mM NADH, 60 mM CaCl2, 10 mg/mL PS, 50 ng/mL PMA, 7.5% DMSO and from about 10,000 nM to 0.169 nM compound inhibitor.	B	CC(C)c1csc(C(=O)Nc2n[nH]c3c2CN(C(=O)N2C[C@@H]4CCCN4C[C@@H]2C)C3(C)C)n1		CHEMBL3662768	=	Ki	nM	177.0	CHEMBL3045	Homo sapiens	Ki	nM	177.0
295260	17676495	CHEMBL3705825	Inhibition Assay: Protein Kinase C beta 2 (PKC beta II) catalyzes the production of ADP from ATP that accompanies the phosphoryl transfer to the PKC Pseudosubstrate peptide (A->S, RFARKGSLRQKNV). This transfer is coupled to the oxidation of p-NADH through the activities of Pyruvate Kinase (PK) and Lactate Dehydrogenase (LDH). (3-NADH conversion to NAD+ is monitored by the decrease in absorbance at 340 nm (e=6.22 cm-1 mM-1) using a Molecular Devices SPECTRA max PLUS spectrophotometer.A typical assay was carried out on a 96-well, clear microtiter plate in a Molecular Devices spectrophotometer for 20 minutes at 30 C. in 0.1 mL of assay buffer containing 50 mM HEPES, pH 7.4, 5 nM PKC, 23 units of pyruvate kinase, 33 units of lactate dehydrogenase, 0.15 mM peptide, 0.1 mM ATP, 1 mM DTT, 4 mM PEP, 8 mM MgCl2, 0.3 mM NADH, 60 mM CaCl2, 10 mg/mL PS, 50 ng/mL PMA, 7.5% DMSO and from about 10,000 nM to 0.169 nM compound inhibitor.	B	CC1(C)c2[nH]nc(NC(=O)c3ccccn3)c2CN1C(=O)N1C[C@@H]2CCCN2C[C@@H]1CC1CCCCC1		CHEMBL3662769	=	Ki	nM	18.1	CHEMBL3045	Homo sapiens	Ki	nM	18.1
295261	17676496	CHEMBL3705825	Inhibition Assay: Protein Kinase C beta 2 (PKC beta II) catalyzes the production of ADP from ATP that accompanies the phosphoryl transfer to the PKC Pseudosubstrate peptide (A->S, RFARKGSLRQKNV). This transfer is coupled to the oxidation of p-NADH through the activities of Pyruvate Kinase (PK) and Lactate Dehydrogenase (LDH). (3-NADH conversion to NAD+ is monitored by the decrease in absorbance at 340 nm (e=6.22 cm-1 mM-1) using a Molecular Devices SPECTRA max PLUS spectrophotometer.A typical assay was carried out on a 96-well, clear microtiter plate in a Molecular Devices spectrophotometer for 20 minutes at 30 C. in 0.1 mL of assay buffer containing 50 mM HEPES, pH 7.4, 5 nM PKC, 23 units of pyruvate kinase, 33 units of lactate dehydrogenase, 0.15 mM peptide, 0.1 mM ATP, 1 mM DTT, 4 mM PEP, 8 mM MgCl2, 0.3 mM NADH, 60 mM CaCl2, 10 mg/mL PS, 50 ng/mL PMA, 7.5% DMSO and from about 10,000 nM to 0.169 nM compound inhibitor.	B	CC1(C)CN2CCC[C@H]2CN1C(=O)N1Cc2c(NC(=O)c3cccc(Cl)c3)n[nH]c2C1(C)C		CHEMBL3662770	=	Ki	nM	87.4	CHEMBL3045	Homo sapiens	Ki	nM	87.4
295262	17676497	CHEMBL3705825	Inhibition Assay: Protein Kinase C beta 2 (PKC beta II) catalyzes the production of ADP from ATP that accompanies the phosphoryl transfer to the PKC Pseudosubstrate peptide (A->S, RFARKGSLRQKNV). This transfer is coupled to the oxidation of p-NADH through the activities of Pyruvate Kinase (PK) and Lactate Dehydrogenase (LDH). (3-NADH conversion to NAD+ is monitored by the decrease in absorbance at 340 nm (e=6.22 cm-1 mM-1) using a Molecular Devices SPECTRA max PLUS spectrophotometer.A typical assay was carried out on a 96-well, clear microtiter plate in a Molecular Devices spectrophotometer for 20 minutes at 30 C. in 0.1 mL of assay buffer containing 50 mM HEPES, pH 7.4, 5 nM PKC, 23 units of pyruvate kinase, 33 units of lactate dehydrogenase, 0.15 mM peptide, 0.1 mM ATP, 1 mM DTT, 4 mM PEP, 8 mM MgCl2, 0.3 mM NADH, 60 mM CaCl2, 10 mg/mL PS, 50 ng/mL PMA, 7.5% DMSO and from about 10,000 nM to 0.169 nM compound inhibitor.	B	Cc1cc(C(=O)Nc2n[nH]c3c2CN(C(=O)N2C[C@@H]4CCCN4C[C@@H]2C)C3(C)C)nc(Cl)n1		CHEMBL3662771	=	Ki	nM	35.3	CHEMBL3045	Homo sapiens	Ki	nM	35.3
295263	17676498	CHEMBL3705825	Inhibition Assay: Protein Kinase C beta 2 (PKC beta II) catalyzes the production of ADP from ATP that accompanies the phosphoryl transfer to the PKC Pseudosubstrate peptide (A->S, RFARKGSLRQKNV). This transfer is coupled to the oxidation of p-NADH through the activities of Pyruvate Kinase (PK) and Lactate Dehydrogenase (LDH). (3-NADH conversion to NAD+ is monitored by the decrease in absorbance at 340 nm (e=6.22 cm-1 mM-1) using a Molecular Devices SPECTRA max PLUS spectrophotometer.A typical assay was carried out on a 96-well, clear microtiter plate in a Molecular Devices spectrophotometer for 20 minutes at 30 C. in 0.1 mL of assay buffer containing 50 mM HEPES, pH 7.4, 5 nM PKC, 23 units of pyruvate kinase, 33 units of lactate dehydrogenase, 0.15 mM peptide, 0.1 mM ATP, 1 mM DTT, 4 mM PEP, 8 mM MgCl2, 0.3 mM NADH, 60 mM CaCl2, 10 mg/mL PS, 50 ng/mL PMA, 7.5% DMSO and from about 10,000 nM to 0.169 nM compound inhibitor.	B	COc1cc(C(=O)Nc2n[nH]c3c2CN(C(=O)N2C[C@@H]4CCCN4C[C@@H]2C)C3(C)C)nc(OC)n1		CHEMBL3662772	=	Ki	nM	94.5	CHEMBL3045	Homo sapiens	Ki	nM	94.5
295264	17676499	CHEMBL3705825	Inhibition Assay: Protein Kinase C beta 2 (PKC beta II) catalyzes the production of ADP from ATP that accompanies the phosphoryl transfer to the PKC Pseudosubstrate peptide (A->S, RFARKGSLRQKNV). This transfer is coupled to the oxidation of p-NADH through the activities of Pyruvate Kinase (PK) and Lactate Dehydrogenase (LDH). (3-NADH conversion to NAD+ is monitored by the decrease in absorbance at 340 nm (e=6.22 cm-1 mM-1) using a Molecular Devices SPECTRA max PLUS spectrophotometer.A typical assay was carried out on a 96-well, clear microtiter plate in a Molecular Devices spectrophotometer for 20 minutes at 30 C. in 0.1 mL of assay buffer containing 50 mM HEPES, pH 7.4, 5 nM PKC, 23 units of pyruvate kinase, 33 units of lactate dehydrogenase, 0.15 mM peptide, 0.1 mM ATP, 1 mM DTT, 4 mM PEP, 8 mM MgCl2, 0.3 mM NADH, 60 mM CaCl2, 10 mg/mL PS, 50 ng/mL PMA, 7.5% DMSO and from about 10,000 nM to 0.169 nM compound inhibitor.	B	C[C@H]1CN2CCC[C@H]2CN1C(=O)N1Cc2c(NC(=O)c3cccc(C#N)c3)n[nH]c2C1(C)C		CHEMBL3662773	=	Ki	nM	17.1	CHEMBL3045	Homo sapiens	Ki	nM	17.1
295265	17676500	CHEMBL3705825	Inhibition Assay: Protein Kinase C beta 2 (PKC beta II) catalyzes the production of ADP from ATP that accompanies the phosphoryl transfer to the PKC Pseudosubstrate peptide (A->S, RFARKGSLRQKNV). This transfer is coupled to the oxidation of p-NADH through the activities of Pyruvate Kinase (PK) and Lactate Dehydrogenase (LDH). (3-NADH conversion to NAD+ is monitored by the decrease in absorbance at 340 nm (e=6.22 cm-1 mM-1) using a Molecular Devices SPECTRA max PLUS spectrophotometer.A typical assay was carried out on a 96-well, clear microtiter plate in a Molecular Devices spectrophotometer for 20 minutes at 30 C. in 0.1 mL of assay buffer containing 50 mM HEPES, pH 7.4, 5 nM PKC, 23 units of pyruvate kinase, 33 units of lactate dehydrogenase, 0.15 mM peptide, 0.1 mM ATP, 1 mM DTT, 4 mM PEP, 8 mM MgCl2, 0.3 mM NADH, 60 mM CaCl2, 10 mg/mL PS, 50 ng/mL PMA, 7.5% DMSO and from about 10,000 nM to 0.169 nM compound inhibitor.	B	CCc1ccc(C(=O)Nc2n[nH]c3c2CN(C(=O)N2C[C@@H]4CCCN4C[C@@H]2C)C3(C)C)cc1		CHEMBL3662774	=	Ki	nM	23.8	CHEMBL3045	Homo sapiens	Ki	nM	23.8
295266	17676501	CHEMBL3705825	Inhibition Assay: Protein Kinase C beta 2 (PKC beta II) catalyzes the production of ADP from ATP that accompanies the phosphoryl transfer to the PKC Pseudosubstrate peptide (A->S, RFARKGSLRQKNV). This transfer is coupled to the oxidation of p-NADH through the activities of Pyruvate Kinase (PK) and Lactate Dehydrogenase (LDH). (3-NADH conversion to NAD+ is monitored by the decrease in absorbance at 340 nm (e=6.22 cm-1 mM-1) using a Molecular Devices SPECTRA max PLUS spectrophotometer.A typical assay was carried out on a 96-well, clear microtiter plate in a Molecular Devices spectrophotometer for 20 minutes at 30 C. in 0.1 mL of assay buffer containing 50 mM HEPES, pH 7.4, 5 nM PKC, 23 units of pyruvate kinase, 33 units of lactate dehydrogenase, 0.15 mM peptide, 0.1 mM ATP, 1 mM DTT, 4 mM PEP, 8 mM MgCl2, 0.3 mM NADH, 60 mM CaCl2, 10 mg/mL PS, 50 ng/mL PMA, 7.5% DMSO and from about 10,000 nM to 0.169 nM compound inhibitor.	B	Cc1cc(C(=O)Nc2n[nH]c3c2CN(C(=O)N2C[C@@H]4CCCN4C[C@@H]2C)C3(C)C)ccc1F		CHEMBL3662775	=	Ki	nM	50.8	CHEMBL3045	Homo sapiens	Ki	nM	50.8
295267	17676502	CHEMBL3705825	Inhibition Assay: Protein Kinase C beta 2 (PKC beta II) catalyzes the production of ADP from ATP that accompanies the phosphoryl transfer to the PKC Pseudosubstrate peptide (A->S, RFARKGSLRQKNV). This transfer is coupled to the oxidation of p-NADH through the activities of Pyruvate Kinase (PK) and Lactate Dehydrogenase (LDH). (3-NADH conversion to NAD+ is monitored by the decrease in absorbance at 340 nm (e=6.22 cm-1 mM-1) using a Molecular Devices SPECTRA max PLUS spectrophotometer.A typical assay was carried out on a 96-well, clear microtiter plate in a Molecular Devices spectrophotometer for 20 minutes at 30 C. in 0.1 mL of assay buffer containing 50 mM HEPES, pH 7.4, 5 nM PKC, 23 units of pyruvate kinase, 33 units of lactate dehydrogenase, 0.15 mM peptide, 0.1 mM ATP, 1 mM DTT, 4 mM PEP, 8 mM MgCl2, 0.3 mM NADH, 60 mM CaCl2, 10 mg/mL PS, 50 ng/mL PMA, 7.5% DMSO and from about 10,000 nM to 0.169 nM compound inhibitor.	B	C[C@H]1CN2CCC[C@H]2CN1C(=O)N1Cc2c(NC(=O)c3cccc(F)c3F)n[nH]c2C1(C)C		CHEMBL3662776	=	Ki	nM	65.4	CHEMBL3045	Homo sapiens	Ki	nM	65.4
295268	17676503	CHEMBL3705825	Inhibition Assay: Protein Kinase C beta 2 (PKC beta II) catalyzes the production of ADP from ATP that accompanies the phosphoryl transfer to the PKC Pseudosubstrate peptide (A->S, RFARKGSLRQKNV). This transfer is coupled to the oxidation of p-NADH through the activities of Pyruvate Kinase (PK) and Lactate Dehydrogenase (LDH). (3-NADH conversion to NAD+ is monitored by the decrease in absorbance at 340 nm (e=6.22 cm-1 mM-1) using a Molecular Devices SPECTRA max PLUS spectrophotometer.A typical assay was carried out on a 96-well, clear microtiter plate in a Molecular Devices spectrophotometer for 20 minutes at 30 C. in 0.1 mL of assay buffer containing 50 mM HEPES, pH 7.4, 5 nM PKC, 23 units of pyruvate kinase, 33 units of lactate dehydrogenase, 0.15 mM peptide, 0.1 mM ATP, 1 mM DTT, 4 mM PEP, 8 mM MgCl2, 0.3 mM NADH, 60 mM CaCl2, 10 mg/mL PS, 50 ng/mL PMA, 7.5% DMSO and from about 10,000 nM to 0.169 nM compound inhibitor.	B	C[C@H]1CN2CCC[C@H]2CN1C(=O)N1Cc2c(NC(=O)c3ccc4c(c3)CCO4)n[nH]c2C1(C)C		CHEMBL3639616	=	Ki	nM	15.9	CHEMBL3045	Homo sapiens	Ki	nM	15.9
295269	17676504	CHEMBL3705825	Inhibition Assay: Protein Kinase C beta 2 (PKC beta II) catalyzes the production of ADP from ATP that accompanies the phosphoryl transfer to the PKC Pseudosubstrate peptide (A->S, RFARKGSLRQKNV). This transfer is coupled to the oxidation of p-NADH through the activities of Pyruvate Kinase (PK) and Lactate Dehydrogenase (LDH). (3-NADH conversion to NAD+ is monitored by the decrease in absorbance at 340 nm (e=6.22 cm-1 mM-1) using a Molecular Devices SPECTRA max PLUS spectrophotometer.A typical assay was carried out on a 96-well, clear microtiter plate in a Molecular Devices spectrophotometer for 20 minutes at 30 C. in 0.1 mL of assay buffer containing 50 mM HEPES, pH 7.4, 5 nM PKC, 23 units of pyruvate kinase, 33 units of lactate dehydrogenase, 0.15 mM peptide, 0.1 mM ATP, 1 mM DTT, 4 mM PEP, 8 mM MgCl2, 0.3 mM NADH, 60 mM CaCl2, 10 mg/mL PS, 50 ng/mL PMA, 7.5% DMSO and from about 10,000 nM to 0.169 nM compound inhibitor.	B	Cc1cccc(C(=O)Nc2n[nH]c3c2CN(C(=O)N2C[C@@H]4CCCN4C[C@@H]2C)C3(C)C)c1		CHEMBL3662777	=	Ki	nM	54.5	CHEMBL3045	Homo sapiens	Ki	nM	54.5
295270	17676505	CHEMBL3705825	Inhibition Assay: Protein Kinase C beta 2 (PKC beta II) catalyzes the production of ADP from ATP that accompanies the phosphoryl transfer to the PKC Pseudosubstrate peptide (A->S, RFARKGSLRQKNV). This transfer is coupled to the oxidation of p-NADH through the activities of Pyruvate Kinase (PK) and Lactate Dehydrogenase (LDH). (3-NADH conversion to NAD+ is monitored by the decrease in absorbance at 340 nm (e=6.22 cm-1 mM-1) using a Molecular Devices SPECTRA max PLUS spectrophotometer.A typical assay was carried out on a 96-well, clear microtiter plate in a Molecular Devices spectrophotometer for 20 minutes at 30 C. in 0.1 mL of assay buffer containing 50 mM HEPES, pH 7.4, 5 nM PKC, 23 units of pyruvate kinase, 33 units of lactate dehydrogenase, 0.15 mM peptide, 0.1 mM ATP, 1 mM DTT, 4 mM PEP, 8 mM MgCl2, 0.3 mM NADH, 60 mM CaCl2, 10 mg/mL PS, 50 ng/mL PMA, 7.5% DMSO and from about 10,000 nM to 0.169 nM compound inhibitor.	B	C[C@H]1CN2CCC[C@H]2CN1C(=O)N1Cc2c(NC(=O)c3ccc(C#N)cc3F)n[nH]c2C1(C)C		CHEMBL3662778	=	Ki	nM	122.0	CHEMBL3045	Homo sapiens	Ki	nM	122.0
295271	17676506	CHEMBL3705825	Inhibition Assay: Protein Kinase C beta 2 (PKC beta II) catalyzes the production of ADP from ATP that accompanies the phosphoryl transfer to the PKC Pseudosubstrate peptide (A->S, RFARKGSLRQKNV). This transfer is coupled to the oxidation of p-NADH through the activities of Pyruvate Kinase (PK) and Lactate Dehydrogenase (LDH). (3-NADH conversion to NAD+ is monitored by the decrease in absorbance at 340 nm (e=6.22 cm-1 mM-1) using a Molecular Devices SPECTRA max PLUS spectrophotometer.A typical assay was carried out on a 96-well, clear microtiter plate in a Molecular Devices spectrophotometer for 20 minutes at 30 C. in 0.1 mL of assay buffer containing 50 mM HEPES, pH 7.4, 5 nM PKC, 23 units of pyruvate kinase, 33 units of lactate dehydrogenase, 0.15 mM peptide, 0.1 mM ATP, 1 mM DTT, 4 mM PEP, 8 mM MgCl2, 0.3 mM NADH, 60 mM CaCl2, 10 mg/mL PS, 50 ng/mL PMA, 7.5% DMSO and from about 10,000 nM to 0.169 nM compound inhibitor.	B	C[C@H]1CN2CCC[C@H]2CN1C(=O)N1Cc2c(NC(=O)c3ccc(Cl)cn3)n[nH]c2C1(C)C		CHEMBL3662779	=	Ki	nM	24.3	CHEMBL3045	Homo sapiens	Ki	nM	24.3
295272	17676507	CHEMBL3705825	Inhibition Assay: Protein Kinase C beta 2 (PKC beta II) catalyzes the production of ADP from ATP that accompanies the phosphoryl transfer to the PKC Pseudosubstrate peptide (A->S, RFARKGSLRQKNV). This transfer is coupled to the oxidation of p-NADH through the activities of Pyruvate Kinase (PK) and Lactate Dehydrogenase (LDH). (3-NADH conversion to NAD+ is monitored by the decrease in absorbance at 340 nm (e=6.22 cm-1 mM-1) using a Molecular Devices SPECTRA max PLUS spectrophotometer.A typical assay was carried out on a 96-well, clear microtiter plate in a Molecular Devices spectrophotometer for 20 minutes at 30 C. in 0.1 mL of assay buffer containing 50 mM HEPES, pH 7.4, 5 nM PKC, 23 units of pyruvate kinase, 33 units of lactate dehydrogenase, 0.15 mM peptide, 0.1 mM ATP, 1 mM DTT, 4 mM PEP, 8 mM MgCl2, 0.3 mM NADH, 60 mM CaCl2, 10 mg/mL PS, 50 ng/mL PMA, 7.5% DMSO and from about 10,000 nM to 0.169 nM compound inhibitor.	B	C[C@H]1CN2CCC[C@H]2CN1C(=O)N1Cc2c(NC(=O)c3cc(Cl)ccn3)n[nH]c2C1(C)C		CHEMBL3662780	=	Ki	nM	21.3	CHEMBL3045	Homo sapiens	Ki	nM	21.3
295273	17676508	CHEMBL3705825	Inhibition Assay: Protein Kinase C beta 2 (PKC beta II) catalyzes the production of ADP from ATP that accompanies the phosphoryl transfer to the PKC Pseudosubstrate peptide (A->S, RFARKGSLRQKNV). This transfer is coupled to the oxidation of p-NADH through the activities of Pyruvate Kinase (PK) and Lactate Dehydrogenase (LDH). (3-NADH conversion to NAD+ is monitored by the decrease in absorbance at 340 nm (e=6.22 cm-1 mM-1) using a Molecular Devices SPECTRA max PLUS spectrophotometer.A typical assay was carried out on a 96-well, clear microtiter plate in a Molecular Devices spectrophotometer for 20 minutes at 30 C. in 0.1 mL of assay buffer containing 50 mM HEPES, pH 7.4, 5 nM PKC, 23 units of pyruvate kinase, 33 units of lactate dehydrogenase, 0.15 mM peptide, 0.1 mM ATP, 1 mM DTT, 4 mM PEP, 8 mM MgCl2, 0.3 mM NADH, 60 mM CaCl2, 10 mg/mL PS, 50 ng/mL PMA, 7.5% DMSO and from about 10,000 nM to 0.169 nM compound inhibitor.	B	CC[C@H]1CN2CCC[C@H]2CN1C(=O)N1Cc2c(NC(=O)c3ccccc3)n[nH]c2C1(C)C		CHEMBL3662781	=	Ki	nM	67.8	CHEMBL3045	Homo sapiens	Ki	nM	67.8
295274	17676509	CHEMBL3705825	Inhibition Assay: Protein Kinase C beta 2 (PKC beta II) catalyzes the production of ADP from ATP that accompanies the phosphoryl transfer to the PKC Pseudosubstrate peptide (A->S, RFARKGSLRQKNV). This transfer is coupled to the oxidation of p-NADH through the activities of Pyruvate Kinase (PK) and Lactate Dehydrogenase (LDH). (3-NADH conversion to NAD+ is monitored by the decrease in absorbance at 340 nm (e=6.22 cm-1 mM-1) using a Molecular Devices SPECTRA max PLUS spectrophotometer.A typical assay was carried out on a 96-well, clear microtiter plate in a Molecular Devices spectrophotometer for 20 minutes at 30 C. in 0.1 mL of assay buffer containing 50 mM HEPES, pH 7.4, 5 nM PKC, 23 units of pyruvate kinase, 33 units of lactate dehydrogenase, 0.15 mM peptide, 0.1 mM ATP, 1 mM DTT, 4 mM PEP, 8 mM MgCl2, 0.3 mM NADH, 60 mM CaCl2, 10 mg/mL PS, 50 ng/mL PMA, 7.5% DMSO and from about 10,000 nM to 0.169 nM compound inhibitor.	B	CC[C@H]1CN2CCC[C@H]2CN1C(=O)N1Cc2c(NC(=O)c3ccccn3)n[nH]c2C1(C)C		CHEMBL3662782	=	Ki	nM	46.2	CHEMBL3045	Homo sapiens	Ki	nM	46.2
295275	17676510	CHEMBL3705825	Inhibition Assay: Protein Kinase C beta 2 (PKC beta II) catalyzes the production of ADP from ATP that accompanies the phosphoryl transfer to the PKC Pseudosubstrate peptide (A->S, RFARKGSLRQKNV). This transfer is coupled to the oxidation of p-NADH through the activities of Pyruvate Kinase (PK) and Lactate Dehydrogenase (LDH). (3-NADH conversion to NAD+ is monitored by the decrease in absorbance at 340 nm (e=6.22 cm-1 mM-1) using a Molecular Devices SPECTRA max PLUS spectrophotometer.A typical assay was carried out on a 96-well, clear microtiter plate in a Molecular Devices spectrophotometer for 20 minutes at 30 C. in 0.1 mL of assay buffer containing 50 mM HEPES, pH 7.4, 5 nM PKC, 23 units of pyruvate kinase, 33 units of lactate dehydrogenase, 0.15 mM peptide, 0.1 mM ATP, 1 mM DTT, 4 mM PEP, 8 mM MgCl2, 0.3 mM NADH, 60 mM CaCl2, 10 mg/mL PS, 50 ng/mL PMA, 7.5% DMSO and from about 10,000 nM to 0.169 nM compound inhibitor.	B	CC[C@H]1CN2CCC[C@H]2CN1C(=O)N1Cc2c(NC(=O)c3cccc(Cl)c3)n[nH]c2C1(C)C		CHEMBL3662783	=	Ki	nM	49.9	CHEMBL3045	Homo sapiens	Ki	nM	49.9
295276	17676511	CHEMBL3705825	Inhibition Assay: Protein Kinase C beta 2 (PKC beta II) catalyzes the production of ADP from ATP that accompanies the phosphoryl transfer to the PKC Pseudosubstrate peptide (A->S, RFARKGSLRQKNV). This transfer is coupled to the oxidation of p-NADH through the activities of Pyruvate Kinase (PK) and Lactate Dehydrogenase (LDH). (3-NADH conversion to NAD+ is monitored by the decrease in absorbance at 340 nm (e=6.22 cm-1 mM-1) using a Molecular Devices SPECTRA max PLUS spectrophotometer.A typical assay was carried out on a 96-well, clear microtiter plate in a Molecular Devices spectrophotometer for 20 minutes at 30 C. in 0.1 mL of assay buffer containing 50 mM HEPES, pH 7.4, 5 nM PKC, 23 units of pyruvate kinase, 33 units of lactate dehydrogenase, 0.15 mM peptide, 0.1 mM ATP, 1 mM DTT, 4 mM PEP, 8 mM MgCl2, 0.3 mM NADH, 60 mM CaCl2, 10 mg/mL PS, 50 ng/mL PMA, 7.5% DMSO and from about 10,000 nM to 0.169 nM compound inhibitor.	B	CC[C@H]1CN2CCC[C@H]2CN1C(=O)N1Cc2c(NC(=O)c3ccccc3F)n[nH]c2C1(C)C		CHEMBL3662784	=	Ki	nM	105.0	CHEMBL3045	Homo sapiens	Ki	nM	105.0
295277	17676512	CHEMBL3705825	Inhibition Assay: Protein Kinase C beta 2 (PKC beta II) catalyzes the production of ADP from ATP that accompanies the phosphoryl transfer to the PKC Pseudosubstrate peptide (A->S, RFARKGSLRQKNV). This transfer is coupled to the oxidation of p-NADH through the activities of Pyruvate Kinase (PK) and Lactate Dehydrogenase (LDH). (3-NADH conversion to NAD+ is monitored by the decrease in absorbance at 340 nm (e=6.22 cm-1 mM-1) using a Molecular Devices SPECTRA max PLUS spectrophotometer.A typical assay was carried out on a 96-well, clear microtiter plate in a Molecular Devices spectrophotometer for 20 minutes at 30 C. in 0.1 mL of assay buffer containing 50 mM HEPES, pH 7.4, 5 nM PKC, 23 units of pyruvate kinase, 33 units of lactate dehydrogenase, 0.15 mM peptide, 0.1 mM ATP, 1 mM DTT, 4 mM PEP, 8 mM MgCl2, 0.3 mM NADH, 60 mM CaCl2, 10 mg/mL PS, 50 ng/mL PMA, 7.5% DMSO and from about 10,000 nM to 0.169 nM compound inhibitor.	B	CC[C@H]1CN2CCC[C@H]2CN1C(=O)N1Cc2c(NC(=O)c3ccc(F)cc3)n[nH]c2C1(C)C		CHEMBL3662785	=	Ki	nM	115.0	CHEMBL3045	Homo sapiens	Ki	nM	115.0
295278	17676513	CHEMBL3705825	Inhibition Assay: Protein Kinase C beta 2 (PKC beta II) catalyzes the production of ADP from ATP that accompanies the phosphoryl transfer to the PKC Pseudosubstrate peptide (A->S, RFARKGSLRQKNV). This transfer is coupled to the oxidation of p-NADH through the activities of Pyruvate Kinase (PK) and Lactate Dehydrogenase (LDH). (3-NADH conversion to NAD+ is monitored by the decrease in absorbance at 340 nm (e=6.22 cm-1 mM-1) using a Molecular Devices SPECTRA max PLUS spectrophotometer.A typical assay was carried out on a 96-well, clear microtiter plate in a Molecular Devices spectrophotometer for 20 minutes at 30 C. in 0.1 mL of assay buffer containing 50 mM HEPES, pH 7.4, 5 nM PKC, 23 units of pyruvate kinase, 33 units of lactate dehydrogenase, 0.15 mM peptide, 0.1 mM ATP, 1 mM DTT, 4 mM PEP, 8 mM MgCl2, 0.3 mM NADH, 60 mM CaCl2, 10 mg/mL PS, 50 ng/mL PMA, 7.5% DMSO and from about 10,000 nM to 0.169 nM compound inhibitor.	B	C[C@H]1CN2CCC[C@H]2CN1C(=O)N1Cc2c(NC(=O)c3nc(Cl)c(Cl)s3)n[nH]c2C1(C)C		CHEMBL3662786	=	Ki	nM	10.4	CHEMBL3045	Homo sapiens	Ki	nM	10.4
295279	17676514	CHEMBL3705825	Inhibition Assay: Protein Kinase C beta 2 (PKC beta II) catalyzes the production of ADP from ATP that accompanies the phosphoryl transfer to the PKC Pseudosubstrate peptide (A->S, RFARKGSLRQKNV). This transfer is coupled to the oxidation of p-NADH through the activities of Pyruvate Kinase (PK) and Lactate Dehydrogenase (LDH). (3-NADH conversion to NAD+ is monitored by the decrease in absorbance at 340 nm (e=6.22 cm-1 mM-1) using a Molecular Devices SPECTRA max PLUS spectrophotometer.A typical assay was carried out on a 96-well, clear microtiter plate in a Molecular Devices spectrophotometer for 20 minutes at 30 C. in 0.1 mL of assay buffer containing 50 mM HEPES, pH 7.4, 5 nM PKC, 23 units of pyruvate kinase, 33 units of lactate dehydrogenase, 0.15 mM peptide, 0.1 mM ATP, 1 mM DTT, 4 mM PEP, 8 mM MgCl2, 0.3 mM NADH, 60 mM CaCl2, 10 mg/mL PS, 50 ng/mL PMA, 7.5% DMSO and from about 10,000 nM to 0.169 nM compound inhibitor.	B	Cc1cc(C(=O)Nc2n[nH]c3c2CN(C(=O)N2C[C@@H]4CCCN4C[C@@H]2C)C3(C)C)nc(C)n1		CHEMBL3662787	=	Ki	nM	56.9	CHEMBL3045	Homo sapiens	Ki	nM	56.9
295280	17676515	CHEMBL3705825	Inhibition Assay: Protein Kinase C beta 2 (PKC beta II) catalyzes the production of ADP from ATP that accompanies the phosphoryl transfer to the PKC Pseudosubstrate peptide (A->S, RFARKGSLRQKNV). This transfer is coupled to the oxidation of p-NADH through the activities of Pyruvate Kinase (PK) and Lactate Dehydrogenase (LDH). (3-NADH conversion to NAD+ is monitored by the decrease in absorbance at 340 nm (e=6.22 cm-1 mM-1) using a Molecular Devices SPECTRA max PLUS spectrophotometer.A typical assay was carried out on a 96-well, clear microtiter plate in a Molecular Devices spectrophotometer for 20 minutes at 30 C. in 0.1 mL of assay buffer containing 50 mM HEPES, pH 7.4, 5 nM PKC, 23 units of pyruvate kinase, 33 units of lactate dehydrogenase, 0.15 mM peptide, 0.1 mM ATP, 1 mM DTT, 4 mM PEP, 8 mM MgCl2, 0.3 mM NADH, 60 mM CaCl2, 10 mg/mL PS, 50 ng/mL PMA, 7.5% DMSO and from about 10,000 nM to 0.169 nM compound inhibitor.	B	C[C@H]1CN2CCC[C@H]2CN1C(=O)N1Cc2c(NC(=O)c3cc4cccn4cn3)n[nH]c2C1(C)C		CHEMBL3662788	=	Ki	nM	13.9	CHEMBL3045	Homo sapiens	Ki	nM	13.9
295281	17676516	CHEMBL3705825	Inhibition Assay: Protein Kinase C beta 2 (PKC beta II) catalyzes the production of ADP from ATP that accompanies the phosphoryl transfer to the PKC Pseudosubstrate peptide (A->S, RFARKGSLRQKNV). This transfer is coupled to the oxidation of p-NADH through the activities of Pyruvate Kinase (PK) and Lactate Dehydrogenase (LDH). (3-NADH conversion to NAD+ is monitored by the decrease in absorbance at 340 nm (e=6.22 cm-1 mM-1) using a Molecular Devices SPECTRA max PLUS spectrophotometer.A typical assay was carried out on a 96-well, clear microtiter plate in a Molecular Devices spectrophotometer for 20 minutes at 30 C. in 0.1 mL of assay buffer containing 50 mM HEPES, pH 7.4, 5 nM PKC, 23 units of pyruvate kinase, 33 units of lactate dehydrogenase, 0.15 mM peptide, 0.1 mM ATP, 1 mM DTT, 4 mM PEP, 8 mM MgCl2, 0.3 mM NADH, 60 mM CaCl2, 10 mg/mL PS, 50 ng/mL PMA, 7.5% DMSO and from about 10,000 nM to 0.169 nM compound inhibitor.	B	C[C@H]1CN2CCC[C@@H]2CN1C(=O)N1Cc2c(NC(=O)c3ccccn3)n[nH]c2C1(C)C		CHEMBL3662789	=	Ki	nM	77.8	CHEMBL3045	Homo sapiens	Ki	nM	77.8
295282	17676517	CHEMBL3705825	Inhibition Assay: Protein Kinase C beta 2 (PKC beta II) catalyzes the production of ADP from ATP that accompanies the phosphoryl transfer to the PKC Pseudosubstrate peptide (A->S, RFARKGSLRQKNV). This transfer is coupled to the oxidation of p-NADH through the activities of Pyruvate Kinase (PK) and Lactate Dehydrogenase (LDH). (3-NADH conversion to NAD+ is monitored by the decrease in absorbance at 340 nm (e=6.22 cm-1 mM-1) using a Molecular Devices SPECTRA max PLUS spectrophotometer.A typical assay was carried out on a 96-well, clear microtiter plate in a Molecular Devices spectrophotometer for 20 minutes at 30 C. in 0.1 mL of assay buffer containing 50 mM HEPES, pH 7.4, 5 nM PKC, 23 units of pyruvate kinase, 33 units of lactate dehydrogenase, 0.15 mM peptide, 0.1 mM ATP, 1 mM DTT, 4 mM PEP, 8 mM MgCl2, 0.3 mM NADH, 60 mM CaCl2, 10 mg/mL PS, 50 ng/mL PMA, 7.5% DMSO and from about 10,000 nM to 0.169 nM compound inhibitor.	B	CC1(C)c2[nH]nc(NC(=O)c3ccccn3)c2CN1C(=O)N1C[C@@H]2CCCN2C[C@@H]1CO		CHEMBL3662790	=	Ki	nM	165.0	CHEMBL3045	Homo sapiens	Ki	nM	165.0
295283	17676518	CHEMBL3705825	Inhibition Assay: Protein Kinase C beta 2 (PKC beta II) catalyzes the production of ADP from ATP that accompanies the phosphoryl transfer to the PKC Pseudosubstrate peptide (A->S, RFARKGSLRQKNV). This transfer is coupled to the oxidation of p-NADH through the activities of Pyruvate Kinase (PK) and Lactate Dehydrogenase (LDH). (3-NADH conversion to NAD+ is monitored by the decrease in absorbance at 340 nm (e=6.22 cm-1 mM-1) using a Molecular Devices SPECTRA max PLUS spectrophotometer.A typical assay was carried out on a 96-well, clear microtiter plate in a Molecular Devices spectrophotometer for 20 minutes at 30 C. in 0.1 mL of assay buffer containing 50 mM HEPES, pH 7.4, 5 nM PKC, 23 units of pyruvate kinase, 33 units of lactate dehydrogenase, 0.15 mM peptide, 0.1 mM ATP, 1 mM DTT, 4 mM PEP, 8 mM MgCl2, 0.3 mM NADH, 60 mM CaCl2, 10 mg/mL PS, 50 ng/mL PMA, 7.5% DMSO and from about 10,000 nM to 0.169 nM compound inhibitor.	B	CCC1CN(C(=O)N2Cc3c(NC(=O)c4ccccn4)n[nH]c3C2(C)C)CCN1C		CHEMBL3662791	=	Ki	nM	79.6	CHEMBL3045	Homo sapiens	Ki	nM	79.6
295284	17676519	CHEMBL3705825	Inhibition Assay: Protein Kinase C beta 2 (PKC beta II) catalyzes the production of ADP from ATP that accompanies the phosphoryl transfer to the PKC Pseudosubstrate peptide (A->S, RFARKGSLRQKNV). This transfer is coupled to the oxidation of p-NADH through the activities of Pyruvate Kinase (PK) and Lactate Dehydrogenase (LDH). (3-NADH conversion to NAD+ is monitored by the decrease in absorbance at 340 nm (e=6.22 cm-1 mM-1) using a Molecular Devices SPECTRA max PLUS spectrophotometer.A typical assay was carried out on a 96-well, clear microtiter plate in a Molecular Devices spectrophotometer for 20 minutes at 30 C. in 0.1 mL of assay buffer containing 50 mM HEPES, pH 7.4, 5 nM PKC, 23 units of pyruvate kinase, 33 units of lactate dehydrogenase, 0.15 mM peptide, 0.1 mM ATP, 1 mM DTT, 4 mM PEP, 8 mM MgCl2, 0.3 mM NADH, 60 mM CaCl2, 10 mg/mL PS, 50 ng/mL PMA, 7.5% DMSO and from about 10,000 nM to 0.169 nM compound inhibitor.	B	CC[C@H](C)[C@H]1CN2CCC[C@@H]2CN1C(=O)N1Cc2c(NC(=O)c3ccccn3)n[nH]c2C1(C)C		CHEMBL3662792	=	Ki	nM	129.0	CHEMBL3045	Homo sapiens	Ki	nM	129.0
295285	17676520	CHEMBL3705825	Inhibition Assay: Protein Kinase C beta 2 (PKC beta II) catalyzes the production of ADP from ATP that accompanies the phosphoryl transfer to the PKC Pseudosubstrate peptide (A->S, RFARKGSLRQKNV). This transfer is coupled to the oxidation of p-NADH through the activities of Pyruvate Kinase (PK) and Lactate Dehydrogenase (LDH). (3-NADH conversion to NAD+ is monitored by the decrease in absorbance at 340 nm (e=6.22 cm-1 mM-1) using a Molecular Devices SPECTRA max PLUS spectrophotometer.A typical assay was carried out on a 96-well, clear microtiter plate in a Molecular Devices spectrophotometer for 20 minutes at 30 C. in 0.1 mL of assay buffer containing 50 mM HEPES, pH 7.4, 5 nM PKC, 23 units of pyruvate kinase, 33 units of lactate dehydrogenase, 0.15 mM peptide, 0.1 mM ATP, 1 mM DTT, 4 mM PEP, 8 mM MgCl2, 0.3 mM NADH, 60 mM CaCl2, 10 mg/mL PS, 50 ng/mL PMA, 7.5% DMSO and from about 10,000 nM to 0.169 nM compound inhibitor.	B	CC1(C)CN2CCC[C@H]2CN1C(=O)N1Cc2c(NC(=O)c3ccccn3)n[nH]c2C1(C)C		CHEMBL3662793	=	Ki	nM	125.0	CHEMBL3045	Homo sapiens	Ki	nM	125.0
295286	17676521	CHEMBL3705825	Inhibition Assay: Protein Kinase C beta 2 (PKC beta II) catalyzes the production of ADP from ATP that accompanies the phosphoryl transfer to the PKC Pseudosubstrate peptide (A->S, RFARKGSLRQKNV). This transfer is coupled to the oxidation of p-NADH through the activities of Pyruvate Kinase (PK) and Lactate Dehydrogenase (LDH). (3-NADH conversion to NAD+ is monitored by the decrease in absorbance at 340 nm (e=6.22 cm-1 mM-1) using a Molecular Devices SPECTRA max PLUS spectrophotometer.A typical assay was carried out on a 96-well, clear microtiter plate in a Molecular Devices spectrophotometer for 20 minutes at 30 C. in 0.1 mL of assay buffer containing 50 mM HEPES, pH 7.4, 5 nM PKC, 23 units of pyruvate kinase, 33 units of lactate dehydrogenase, 0.15 mM peptide, 0.1 mM ATP, 1 mM DTT, 4 mM PEP, 8 mM MgCl2, 0.3 mM NADH, 60 mM CaCl2, 10 mg/mL PS, 50 ng/mL PMA, 7.5% DMSO and from about 10,000 nM to 0.169 nM compound inhibitor.	B	CC1(C)CN2CCC[C@H]2CN1C(=O)N1Cc2c(NC(=O)c3ccccn3)n[nH]c2C1(C)C		CHEMBL3662793	=	Ki	nM	81.8	CHEMBL3045	Homo sapiens	Ki	nM	81.8
295287	17676522	CHEMBL3705825	Inhibition Assay: Protein Kinase C beta 2 (PKC beta II) catalyzes the production of ADP from ATP that accompanies the phosphoryl transfer to the PKC Pseudosubstrate peptide (A->S, RFARKGSLRQKNV). This transfer is coupled to the oxidation of p-NADH through the activities of Pyruvate Kinase (PK) and Lactate Dehydrogenase (LDH). (3-NADH conversion to NAD+ is monitored by the decrease in absorbance at 340 nm (e=6.22 cm-1 mM-1) using a Molecular Devices SPECTRA max PLUS spectrophotometer.A typical assay was carried out on a 96-well, clear microtiter plate in a Molecular Devices spectrophotometer for 20 minutes at 30 C. in 0.1 mL of assay buffer containing 50 mM HEPES, pH 7.4, 5 nM PKC, 23 units of pyruvate kinase, 33 units of lactate dehydrogenase, 0.15 mM peptide, 0.1 mM ATP, 1 mM DTT, 4 mM PEP, 8 mM MgCl2, 0.3 mM NADH, 60 mM CaCl2, 10 mg/mL PS, 50 ng/mL PMA, 7.5% DMSO and from about 10,000 nM to 0.169 nM compound inhibitor.	B	CCCN1C[C@H](C)N(C(=O)N2Cc3c(NC(=O)c4ccccn4)n[nH]c3C2(C)C)C[C@H]1CCO		CHEMBL3662794	=	Ki	nM	9.53	CHEMBL3045	Homo sapiens	Ki	nM	9.53
295288	17676523	CHEMBL3705825	Inhibition Assay: Protein Kinase C beta 2 (PKC beta II) catalyzes the production of ADP from ATP that accompanies the phosphoryl transfer to the PKC Pseudosubstrate peptide (A->S, RFARKGSLRQKNV). This transfer is coupled to the oxidation of p-NADH through the activities of Pyruvate Kinase (PK) and Lactate Dehydrogenase (LDH). (3-NADH conversion to NAD+ is monitored by the decrease in absorbance at 340 nm (e=6.22 cm-1 mM-1) using a Molecular Devices SPECTRA max PLUS spectrophotometer.A typical assay was carried out on a 96-well, clear microtiter plate in a Molecular Devices spectrophotometer for 20 minutes at 30 C. in 0.1 mL of assay buffer containing 50 mM HEPES, pH 7.4, 5 nM PKC, 23 units of pyruvate kinase, 33 units of lactate dehydrogenase, 0.15 mM peptide, 0.1 mM ATP, 1 mM DTT, 4 mM PEP, 8 mM MgCl2, 0.3 mM NADH, 60 mM CaCl2, 10 mg/mL PS, 50 ng/mL PMA, 7.5% DMSO and from about 10,000 nM to 0.169 nM compound inhibitor.	B	CC[C@H](C)[C@H]1CN2C[C@H](O)C[C@H]2CN1C(=O)N1Cc2c(NC(=O)c3ccccn3)n[nH]c2C1(C)C		CHEMBL3662795	=	Ki	nM	139.0	CHEMBL3045	Homo sapiens	Ki	nM	139.0
295289	17676524	CHEMBL3705825	Inhibition Assay: Protein Kinase C beta 2 (PKC beta II) catalyzes the production of ADP from ATP that accompanies the phosphoryl transfer to the PKC Pseudosubstrate peptide (A->S, RFARKGSLRQKNV). This transfer is coupled to the oxidation of p-NADH through the activities of Pyruvate Kinase (PK) and Lactate Dehydrogenase (LDH). (3-NADH conversion to NAD+ is monitored by the decrease in absorbance at 340 nm (e=6.22 cm-1 mM-1) using a Molecular Devices SPECTRA max PLUS spectrophotometer.A typical assay was carried out on a 96-well, clear microtiter plate in a Molecular Devices spectrophotometer for 20 minutes at 30 C. in 0.1 mL of assay buffer containing 50 mM HEPES, pH 7.4, 5 nM PKC, 23 units of pyruvate kinase, 33 units of lactate dehydrogenase, 0.15 mM peptide, 0.1 mM ATP, 1 mM DTT, 4 mM PEP, 8 mM MgCl2, 0.3 mM NADH, 60 mM CaCl2, 10 mg/mL PS, 50 ng/mL PMA, 7.5% DMSO and from about 10,000 nM to 0.169 nM compound inhibitor.	B	CC[C@H](C)[C@H]1CN2C[C@H](O)C[C@H]2CN1C(=O)N1Cc2c(NC(=O)c3ccccn3)n[nH]c2C1(C)C		CHEMBL3662795	=	Ki	nM	15.2	CHEMBL3045	Homo sapiens	Ki	nM	15.2
295290	17676525	CHEMBL3705825	Inhibition Assay: Protein Kinase C beta 2 (PKC beta II) catalyzes the production of ADP from ATP that accompanies the phosphoryl transfer to the PKC Pseudosubstrate peptide (A->S, RFARKGSLRQKNV). This transfer is coupled to the oxidation of p-NADH through the activities of Pyruvate Kinase (PK) and Lactate Dehydrogenase (LDH). (3-NADH conversion to NAD+ is monitored by the decrease in absorbance at 340 nm (e=6.22 cm-1 mM-1) using a Molecular Devices SPECTRA max PLUS spectrophotometer.A typical assay was carried out on a 96-well, clear microtiter plate in a Molecular Devices spectrophotometer for 20 minutes at 30 C. in 0.1 mL of assay buffer containing 50 mM HEPES, pH 7.4, 5 nM PKC, 23 units of pyruvate kinase, 33 units of lactate dehydrogenase, 0.15 mM peptide, 0.1 mM ATP, 1 mM DTT, 4 mM PEP, 8 mM MgCl2, 0.3 mM NADH, 60 mM CaCl2, 10 mg/mL PS, 50 ng/mL PMA, 7.5% DMSO and from about 10,000 nM to 0.169 nM compound inhibitor.	B	CCC1(C)c2[nH]nc(NC(=O)c3ncc(F)cc3F)c2CN1C(=O)C1C[C@@H]2CCCN2C[C@@H]1C		CHEMBL3662796	=	Ki	nM	74.1	CHEMBL3045	Homo sapiens	Ki	nM	74.1
295291	17676526	CHEMBL3705825	Inhibition Assay: Protein Kinase C beta 2 (PKC beta II) catalyzes the production of ADP from ATP that accompanies the phosphoryl transfer to the PKC Pseudosubstrate peptide (A->S, RFARKGSLRQKNV). This transfer is coupled to the oxidation of p-NADH through the activities of Pyruvate Kinase (PK) and Lactate Dehydrogenase (LDH). (3-NADH conversion to NAD+ is monitored by the decrease in absorbance at 340 nm (e=6.22 cm-1 mM-1) using a Molecular Devices SPECTRA max PLUS spectrophotometer.A typical assay was carried out on a 96-well, clear microtiter plate in a Molecular Devices spectrophotometer for 20 minutes at 30 C. in 0.1 mL of assay buffer containing 50 mM HEPES, pH 7.4, 5 nM PKC, 23 units of pyruvate kinase, 33 units of lactate dehydrogenase, 0.15 mM peptide, 0.1 mM ATP, 1 mM DTT, 4 mM PEP, 8 mM MgCl2, 0.3 mM NADH, 60 mM CaCl2, 10 mg/mL PS, 50 ng/mL PMA, 7.5% DMSO and from about 10,000 nM to 0.169 nM compound inhibitor.	B	C[C@H]1CN2CCC[C@H]2CN1C(=O)N1Cc2c(NC(=O)c3cc(N(C)C)ccn3)n[nH]c2C1(C)C		CHEMBL3662797	=	Ki	nM	32.3	CHEMBL3045	Homo sapiens	Ki	nM	32.3
295292	17676527	CHEMBL3705825	Inhibition Assay: Protein Kinase C beta 2 (PKC beta II) catalyzes the production of ADP from ATP that accompanies the phosphoryl transfer to the PKC Pseudosubstrate peptide (A->S, RFARKGSLRQKNV). This transfer is coupled to the oxidation of p-NADH through the activities of Pyruvate Kinase (PK) and Lactate Dehydrogenase (LDH). (3-NADH conversion to NAD+ is monitored by the decrease in absorbance at 340 nm (e=6.22 cm-1 mM-1) using a Molecular Devices SPECTRA max PLUS spectrophotometer.A typical assay was carried out on a 96-well, clear microtiter plate in a Molecular Devices spectrophotometer for 20 minutes at 30 C. in 0.1 mL of assay buffer containing 50 mM HEPES, pH 7.4, 5 nM PKC, 23 units of pyruvate kinase, 33 units of lactate dehydrogenase, 0.15 mM peptide, 0.1 mM ATP, 1 mM DTT, 4 mM PEP, 8 mM MgCl2, 0.3 mM NADH, 60 mM CaCl2, 10 mg/mL PS, 50 ng/mL PMA, 7.5% DMSO and from about 10,000 nM to 0.169 nM compound inhibitor.	B	C[C@H]1CN2CCC[C@H]2CN1C(=O)N1Cc2c(NC(=O)c3ccc4ccccc4n3)n[nH]c2C1(C)C		CHEMBL3662798	=	Ki	nM	17.8	CHEMBL3045	Homo sapiens	Ki	nM	17.8
295293	17676528	CHEMBL3705825	Inhibition Assay: Protein Kinase C beta 2 (PKC beta II) catalyzes the production of ADP from ATP that accompanies the phosphoryl transfer to the PKC Pseudosubstrate peptide (A->S, RFARKGSLRQKNV). This transfer is coupled to the oxidation of p-NADH through the activities of Pyruvate Kinase (PK) and Lactate Dehydrogenase (LDH). (3-NADH conversion to NAD+ is monitored by the decrease in absorbance at 340 nm (e=6.22 cm-1 mM-1) using a Molecular Devices SPECTRA max PLUS spectrophotometer.A typical assay was carried out on a 96-well, clear microtiter plate in a Molecular Devices spectrophotometer for 20 minutes at 30 C. in 0.1 mL of assay buffer containing 50 mM HEPES, pH 7.4, 5 nM PKC, 23 units of pyruvate kinase, 33 units of lactate dehydrogenase, 0.15 mM peptide, 0.1 mM ATP, 1 mM DTT, 4 mM PEP, 8 mM MgCl2, 0.3 mM NADH, 60 mM CaCl2, 10 mg/mL PS, 50 ng/mL PMA, 7.5% DMSO and from about 10,000 nM to 0.169 nM compound inhibitor.	B	C=CCN1C[C@H](C)N(C(=O)N2Cc3c(NC(=O)c4ccccn4)n[nH]c3C2(C)C)C[C@H]1C		CHEMBL3662799	=	Ki	nM	15.7	CHEMBL3045	Homo sapiens	Ki	nM	15.7
295294	17676529	CHEMBL3705825	Inhibition Assay: Protein Kinase C beta 2 (PKC beta II) catalyzes the production of ADP from ATP that accompanies the phosphoryl transfer to the PKC Pseudosubstrate peptide (A->S, RFARKGSLRQKNV). This transfer is coupled to the oxidation of p-NADH through the activities of Pyruvate Kinase (PK) and Lactate Dehydrogenase (LDH). (3-NADH conversion to NAD+ is monitored by the decrease in absorbance at 340 nm (e=6.22 cm-1 mM-1) using a Molecular Devices SPECTRA max PLUS spectrophotometer.A typical assay was carried out on a 96-well, clear microtiter plate in a Molecular Devices spectrophotometer for 20 minutes at 30 C. in 0.1 mL of assay buffer containing 50 mM HEPES, pH 7.4, 5 nM PKC, 23 units of pyruvate kinase, 33 units of lactate dehydrogenase, 0.15 mM peptide, 0.1 mM ATP, 1 mM DTT, 4 mM PEP, 8 mM MgCl2, 0.3 mM NADH, 60 mM CaCl2, 10 mg/mL PS, 50 ng/mL PMA, 7.5% DMSO and from about 10,000 nM to 0.169 nM compound inhibitor.	B	CC[C@H]1CN2CCC[C@@H]2CN1C(=O)N1Cc2c(CC(=O)c3ccccn3)n[nH]c2C1(C)C		CHEMBL3662800	=	Ki	nM	107.0	CHEMBL3045	Homo sapiens	Ki	nM	107.0
295295	17676530	CHEMBL3705825	Inhibition Assay: Protein Kinase C beta 2 (PKC beta II) catalyzes the production of ADP from ATP that accompanies the phosphoryl transfer to the PKC Pseudosubstrate peptide (A->S, RFARKGSLRQKNV). This transfer is coupled to the oxidation of p-NADH through the activities of Pyruvate Kinase (PK) and Lactate Dehydrogenase (LDH). (3-NADH conversion to NAD+ is monitored by the decrease in absorbance at 340 nm (e=6.22 cm-1 mM-1) using a Molecular Devices SPECTRA max PLUS spectrophotometer.A typical assay was carried out on a 96-well, clear microtiter plate in a Molecular Devices spectrophotometer for 20 minutes at 30 C. in 0.1 mL of assay buffer containing 50 mM HEPES, pH 7.4, 5 nM PKC, 23 units of pyruvate kinase, 33 units of lactate dehydrogenase, 0.15 mM peptide, 0.1 mM ATP, 1 mM DTT, 4 mM PEP, 8 mM MgCl2, 0.3 mM NADH, 60 mM CaCl2, 10 mg/mL PS, 50 ng/mL PMA, 7.5% DMSO and from about 10,000 nM to 0.169 nM compound inhibitor.	B	C[C@H]1CN2CCC[C@H]2CN1C(=O)N1Cc2c(NC(=O)c3ccc(Br)cn3)n[nH]c2C1(C)C		CHEMBL3662801	=	Ki	nM	20.3	CHEMBL3045	Homo sapiens	Ki	nM	20.3
295296	17676531	CHEMBL3705825	Inhibition Assay: Protein Kinase C beta 2 (PKC beta II) catalyzes the production of ADP from ATP that accompanies the phosphoryl transfer to the PKC Pseudosubstrate peptide (A->S, RFARKGSLRQKNV). This transfer is coupled to the oxidation of p-NADH through the activities of Pyruvate Kinase (PK) and Lactate Dehydrogenase (LDH). (3-NADH conversion to NAD+ is monitored by the decrease in absorbance at 340 nm (e=6.22 cm-1 mM-1) using a Molecular Devices SPECTRA max PLUS spectrophotometer.A typical assay was carried out on a 96-well, clear microtiter plate in a Molecular Devices spectrophotometer for 20 minutes at 30 C. in 0.1 mL of assay buffer containing 50 mM HEPES, pH 7.4, 5 nM PKC, 23 units of pyruvate kinase, 33 units of lactate dehydrogenase, 0.15 mM peptide, 0.1 mM ATP, 1 mM DTT, 4 mM PEP, 8 mM MgCl2, 0.3 mM NADH, 60 mM CaCl2, 10 mg/mL PS, 50 ng/mL PMA, 7.5% DMSO and from about 10,000 nM to 0.169 nM compound inhibitor.	B	C[C@H]1CN2CCC[C@H]2CN1C(=O)N1Cc2c(NC(=O)c3ccc(F)cn3)n[nH]c2C1(C)C		CHEMBL3662802	=	Ki	nM	20.3	CHEMBL3045	Homo sapiens	Ki	nM	20.3
295297	17676532	CHEMBL3705825	Inhibition Assay: Protein Kinase C beta 2 (PKC beta II) catalyzes the production of ADP from ATP that accompanies the phosphoryl transfer to the PKC Pseudosubstrate peptide (A->S, RFARKGSLRQKNV). This transfer is coupled to the oxidation of p-NADH through the activities of Pyruvate Kinase (PK) and Lactate Dehydrogenase (LDH). (3-NADH conversion to NAD+ is monitored by the decrease in absorbance at 340 nm (e=6.22 cm-1 mM-1) using a Molecular Devices SPECTRA max PLUS spectrophotometer.A typical assay was carried out on a 96-well, clear microtiter plate in a Molecular Devices spectrophotometer for 20 minutes at 30 C. in 0.1 mL of assay buffer containing 50 mM HEPES, pH 7.4, 5 nM PKC, 23 units of pyruvate kinase, 33 units of lactate dehydrogenase, 0.15 mM peptide, 0.1 mM ATP, 1 mM DTT, 4 mM PEP, 8 mM MgCl2, 0.3 mM NADH, 60 mM CaCl2, 10 mg/mL PS, 50 ng/mL PMA, 7.5% DMSO and from about 10,000 nM to 0.169 nM compound inhibitor.	B	COCCN1C[C@H](C)N(C(=O)N2Cc3c(NC(=O)c4ccccn4)n[nH]c3C2(C)C)C[C@H]1C		CHEMBL3662803	=	Ki	nM	63.6	CHEMBL3045	Homo sapiens	Ki	nM	63.6
295298	17676533	CHEMBL3705825	Inhibition Assay: Protein Kinase C beta 2 (PKC beta II) catalyzes the production of ADP from ATP that accompanies the phosphoryl transfer to the PKC Pseudosubstrate peptide (A->S, RFARKGSLRQKNV). This transfer is coupled to the oxidation of p-NADH through the activities of Pyruvate Kinase (PK) and Lactate Dehydrogenase (LDH). (3-NADH conversion to NAD+ is monitored by the decrease in absorbance at 340 nm (e=6.22 cm-1 mM-1) using a Molecular Devices SPECTRA max PLUS spectrophotometer.A typical assay was carried out on a 96-well, clear microtiter plate in a Molecular Devices spectrophotometer for 20 minutes at 30 C. in 0.1 mL of assay buffer containing 50 mM HEPES, pH 7.4, 5 nM PKC, 23 units of pyruvate kinase, 33 units of lactate dehydrogenase, 0.15 mM peptide, 0.1 mM ATP, 1 mM DTT, 4 mM PEP, 8 mM MgCl2, 0.3 mM NADH, 60 mM CaCl2, 10 mg/mL PS, 50 ng/mL PMA, 7.5% DMSO and from about 10,000 nM to 0.169 nM compound inhibitor.	B	C.COCCCN1CCN(C(=O)N2Cc3c(NC(=O)c4ccccn4)n[nH]c3C2(C)C)[C@@H](C)C1		CHEMBL3931196	=	Ki	nM	23.8	CHEMBL3045	Homo sapiens	Ki	nM	23.8
295299	17676534	CHEMBL3705825	Inhibition Assay: Protein Kinase C beta 2 (PKC beta II) catalyzes the production of ADP from ATP that accompanies the phosphoryl transfer to the PKC Pseudosubstrate peptide (A->S, RFARKGSLRQKNV). This transfer is coupled to the oxidation of p-NADH through the activities of Pyruvate Kinase (PK) and Lactate Dehydrogenase (LDH). (3-NADH conversion to NAD+ is monitored by the decrease in absorbance at 340 nm (e=6.22 cm-1 mM-1) using a Molecular Devices SPECTRA max PLUS spectrophotometer.A typical assay was carried out on a 96-well, clear microtiter plate in a Molecular Devices spectrophotometer for 20 minutes at 30 C. in 0.1 mL of assay buffer containing 50 mM HEPES, pH 7.4, 5 nM PKC, 23 units of pyruvate kinase, 33 units of lactate dehydrogenase, 0.15 mM peptide, 0.1 mM ATP, 1 mM DTT, 4 mM PEP, 8 mM MgCl2, 0.3 mM NADH, 60 mM CaCl2, 10 mg/mL PS, 50 ng/mL PMA, 7.5% DMSO and from about 10,000 nM to 0.169 nM compound inhibitor.	B	CCN1C[C@H](C)N(C(=O)N2Cc3c(NC(=O)c4ccccn4)n[nH]c3C2(C)C)C[C@H]1C		CHEMBL3662805	=	Ki	nM	9.11	CHEMBL3045	Homo sapiens	Ki	nM	9.11
295300	17676535	CHEMBL3705825	Inhibition Assay: Protein Kinase C beta 2 (PKC beta II) catalyzes the production of ADP from ATP that accompanies the phosphoryl transfer to the PKC Pseudosubstrate peptide (A->S, RFARKGSLRQKNV). This transfer is coupled to the oxidation of p-NADH through the activities of Pyruvate Kinase (PK) and Lactate Dehydrogenase (LDH). (3-NADH conversion to NAD+ is monitored by the decrease in absorbance at 340 nm (e=6.22 cm-1 mM-1) using a Molecular Devices SPECTRA max PLUS spectrophotometer.A typical assay was carried out on a 96-well, clear microtiter plate in a Molecular Devices spectrophotometer for 20 minutes at 30 C. in 0.1 mL of assay buffer containing 50 mM HEPES, pH 7.4, 5 nM PKC, 23 units of pyruvate kinase, 33 units of lactate dehydrogenase, 0.15 mM peptide, 0.1 mM ATP, 1 mM DTT, 4 mM PEP, 8 mM MgCl2, 0.3 mM NADH, 60 mM CaCl2, 10 mg/mL PS, 50 ng/mL PMA, 7.5% DMSO and from about 10,000 nM to 0.169 nM compound inhibitor.	B	C.C[C@H]1CN(C)CCN1C(=O)N1Cc2c(NC(=O)c3ccccn3)n[nH]c2C1(C)C		CHEMBL3914339	=	Ki	nM	28.2	CHEMBL3045	Homo sapiens	Ki	nM	28.2
295301	17676536	CHEMBL3705825	Inhibition Assay: Protein Kinase C beta 2 (PKC beta II) catalyzes the production of ADP from ATP that accompanies the phosphoryl transfer to the PKC Pseudosubstrate peptide (A->S, RFARKGSLRQKNV). This transfer is coupled to the oxidation of p-NADH through the activities of Pyruvate Kinase (PK) and Lactate Dehydrogenase (LDH). (3-NADH conversion to NAD+ is monitored by the decrease in absorbance at 340 nm (e=6.22 cm-1 mM-1) using a Molecular Devices SPECTRA max PLUS spectrophotometer.A typical assay was carried out on a 96-well, clear microtiter plate in a Molecular Devices spectrophotometer for 20 minutes at 30 C. in 0.1 mL of assay buffer containing 50 mM HEPES, pH 7.4, 5 nM PKC, 23 units of pyruvate kinase, 33 units of lactate dehydrogenase, 0.15 mM peptide, 0.1 mM ATP, 1 mM DTT, 4 mM PEP, 8 mM MgCl2, 0.3 mM NADH, 60 mM CaCl2, 10 mg/mL PS, 50 ng/mL PMA, 7.5% DMSO and from about 10,000 nM to 0.169 nM compound inhibitor.	B	C.CC(C)N1CCN(C(=O)N2Cc3c(NC(=O)c4ccccn4)n[nH]c3C2(C)C)[C@@H](C)C1		CHEMBL3929842	=	Ki	nM	69.2	CHEMBL3045	Homo sapiens	Ki	nM	69.2
295302	17676537	CHEMBL3705825	Inhibition Assay: Protein Kinase C beta 2 (PKC beta II) catalyzes the production of ADP from ATP that accompanies the phosphoryl transfer to the PKC Pseudosubstrate peptide (A->S, RFARKGSLRQKNV). This transfer is coupled to the oxidation of p-NADH through the activities of Pyruvate Kinase (PK) and Lactate Dehydrogenase (LDH). (3-NADH conversion to NAD+ is monitored by the decrease in absorbance at 340 nm (e=6.22 cm-1 mM-1) using a Molecular Devices SPECTRA max PLUS spectrophotometer.A typical assay was carried out on a 96-well, clear microtiter plate in a Molecular Devices spectrophotometer for 20 minutes at 30 C. in 0.1 mL of assay buffer containing 50 mM HEPES, pH 7.4, 5 nM PKC, 23 units of pyruvate kinase, 33 units of lactate dehydrogenase, 0.15 mM peptide, 0.1 mM ATP, 1 mM DTT, 4 mM PEP, 8 mM MgCl2, 0.3 mM NADH, 60 mM CaCl2, 10 mg/mL PS, 50 ng/mL PMA, 7.5% DMSO and from about 10,000 nM to 0.169 nM compound inhibitor.	B	C.C[C@H]1CN(CC2CC2)CCN1C(=O)N1Cc2c(NC(=O)c3ccccn3)n[nH]c2C1(C)C		CHEMBL3901906	=	Ki	nM	19.1	CHEMBL3045	Homo sapiens	Ki	nM	19.1
295303	17676538	CHEMBL3705825	Inhibition Assay: Protein Kinase C beta 2 (PKC beta II) catalyzes the production of ADP from ATP that accompanies the phosphoryl transfer to the PKC Pseudosubstrate peptide (A->S, RFARKGSLRQKNV). This transfer is coupled to the oxidation of p-NADH through the activities of Pyruvate Kinase (PK) and Lactate Dehydrogenase (LDH). (3-NADH conversion to NAD+ is monitored by the decrease in absorbance at 340 nm (e=6.22 cm-1 mM-1) using a Molecular Devices SPECTRA max PLUS spectrophotometer.A typical assay was carried out on a 96-well, clear microtiter plate in a Molecular Devices spectrophotometer for 20 minutes at 30 C. in 0.1 mL of assay buffer containing 50 mM HEPES, pH 7.4, 5 nM PKC, 23 units of pyruvate kinase, 33 units of lactate dehydrogenase, 0.15 mM peptide, 0.1 mM ATP, 1 mM DTT, 4 mM PEP, 8 mM MgCl2, 0.3 mM NADH, 60 mM CaCl2, 10 mg/mL PS, 50 ng/mL PMA, 7.5% DMSO and from about 10,000 nM to 0.169 nM compound inhibitor.	B	CC1CN(C(=O)N2Cc3c(NC(=O)c4ccccn4)n[nH]c3C2(C)C)C(C)CN1CCCO		CHEMBL3662809	=	Ki	nM	19.9	CHEMBL3045	Homo sapiens	Ki	nM	19.9
295304	17676539	CHEMBL3705825	Inhibition Assay: Protein Kinase C beta 2 (PKC beta II) catalyzes the production of ADP from ATP that accompanies the phosphoryl transfer to the PKC Pseudosubstrate peptide (A->S, RFARKGSLRQKNV). This transfer is coupled to the oxidation of p-NADH through the activities of Pyruvate Kinase (PK) and Lactate Dehydrogenase (LDH). (3-NADH conversion to NAD+ is monitored by the decrease in absorbance at 340 nm (e=6.22 cm-1 mM-1) using a Molecular Devices SPECTRA max PLUS spectrophotometer.A typical assay was carried out on a 96-well, clear microtiter plate in a Molecular Devices spectrophotometer for 20 minutes at 30 C. in 0.1 mL of assay buffer containing 50 mM HEPES, pH 7.4, 5 nM PKC, 23 units of pyruvate kinase, 33 units of lactate dehydrogenase, 0.15 mM peptide, 0.1 mM ATP, 1 mM DTT, 4 mM PEP, 8 mM MgCl2, 0.3 mM NADH, 60 mM CaCl2, 10 mg/mL PS, 50 ng/mL PMA, 7.5% DMSO and from about 10,000 nM to 0.169 nM compound inhibitor.	B	CC(C)[C@H]1CN2CCC[C@H]2CN1C(=O)N1Cc2c(NC(=O)c3ccccn3)n[nH]c2C1(C)C		CHEMBL3662810	=	Ki	nM	14.1	CHEMBL3045	Homo sapiens	Ki	nM	14.1
295305	17676540	CHEMBL3705825	Inhibition Assay: Protein Kinase C beta 2 (PKC beta II) catalyzes the production of ADP from ATP that accompanies the phosphoryl transfer to the PKC Pseudosubstrate peptide (A->S, RFARKGSLRQKNV). This transfer is coupled to the oxidation of p-NADH through the activities of Pyruvate Kinase (PK) and Lactate Dehydrogenase (LDH). (3-NADH conversion to NAD+ is monitored by the decrease in absorbance at 340 nm (e=6.22 cm-1 mM-1) using a Molecular Devices SPECTRA max PLUS spectrophotometer.A typical assay was carried out on a 96-well, clear microtiter plate in a Molecular Devices spectrophotometer for 20 minutes at 30 C. in 0.1 mL of assay buffer containing 50 mM HEPES, pH 7.4, 5 nM PKC, 23 units of pyruvate kinase, 33 units of lactate dehydrogenase, 0.15 mM peptide, 0.1 mM ATP, 1 mM DTT, 4 mM PEP, 8 mM MgCl2, 0.3 mM NADH, 60 mM CaCl2, 10 mg/mL PS, 50 ng/mL PMA, 7.5% DMSO and from about 10,000 nM to 0.169 nM compound inhibitor.	B	CC(C)[C@H]1CN2CCC[C@H]2CN1C(=O)N1Cc2c(NC(=O)c3ccc(F)cc3F)n[nH]c2C1(C)C		CHEMBL3662811	=	Ki	nM	148.0	CHEMBL3045	Homo sapiens	Ki	nM	148.0
295306	17676541	CHEMBL3705825	Inhibition Assay: Protein Kinase C beta 2 (PKC beta II) catalyzes the production of ADP from ATP that accompanies the phosphoryl transfer to the PKC Pseudosubstrate peptide (A->S, RFARKGSLRQKNV). This transfer is coupled to the oxidation of p-NADH through the activities of Pyruvate Kinase (PK) and Lactate Dehydrogenase (LDH). (3-NADH conversion to NAD+ is monitored by the decrease in absorbance at 340 nm (e=6.22 cm-1 mM-1) using a Molecular Devices SPECTRA max PLUS spectrophotometer.A typical assay was carried out on a 96-well, clear microtiter plate in a Molecular Devices spectrophotometer for 20 minutes at 30 C. in 0.1 mL of assay buffer containing 50 mM HEPES, pH 7.4, 5 nM PKC, 23 units of pyruvate kinase, 33 units of lactate dehydrogenase, 0.15 mM peptide, 0.1 mM ATP, 1 mM DTT, 4 mM PEP, 8 mM MgCl2, 0.3 mM NADH, 60 mM CaCl2, 10 mg/mL PS, 50 ng/mL PMA, 7.5% DMSO and from about 10,000 nM to 0.169 nM compound inhibitor.	B	CCCN1C[C@H](C)N(C(=O)N2Cc3c(NC(=O)c4ccc(F)cc4F)n[nH]c3C2(C)C)C[C@H]1CCO		CHEMBL3662812	=	Ki	nM	45.9	CHEMBL3045	Homo sapiens	Ki	nM	45.9
295307	17676542	CHEMBL3705825	Inhibition Assay: Protein Kinase C beta 2 (PKC beta II) catalyzes the production of ADP from ATP that accompanies the phosphoryl transfer to the PKC Pseudosubstrate peptide (A->S, RFARKGSLRQKNV). This transfer is coupled to the oxidation of p-NADH through the activities of Pyruvate Kinase (PK) and Lactate Dehydrogenase (LDH). (3-NADH conversion to NAD+ is monitored by the decrease in absorbance at 340 nm (e=6.22 cm-1 mM-1) using a Molecular Devices SPECTRA max PLUS spectrophotometer.A typical assay was carried out on a 96-well, clear microtiter plate in a Molecular Devices spectrophotometer for 20 minutes at 30 C. in 0.1 mL of assay buffer containing 50 mM HEPES, pH 7.4, 5 nM PKC, 23 units of pyruvate kinase, 33 units of lactate dehydrogenase, 0.15 mM peptide, 0.1 mM ATP, 1 mM DTT, 4 mM PEP, 8 mM MgCl2, 0.3 mM NADH, 60 mM CaCl2, 10 mg/mL PS, 50 ng/mL PMA, 7.5% DMSO and from about 10,000 nM to 0.169 nM compound inhibitor.	B	C[C@H]1CN2CCC[C@H]2CC1C(=O)N1Cc2c(NC(=O)c3csc(Br)n3)n[nH]c2C1(C)C		CHEMBL3662813	=	Ki	nM	12.9	CHEMBL3045	Homo sapiens	Ki	nM	12.9
295308	17676543	CHEMBL3705825	Inhibition Assay: Protein Kinase C beta 2 (PKC beta II) catalyzes the production of ADP from ATP that accompanies the phosphoryl transfer to the PKC Pseudosubstrate peptide (A->S, RFARKGSLRQKNV). This transfer is coupled to the oxidation of p-NADH through the activities of Pyruvate Kinase (PK) and Lactate Dehydrogenase (LDH). (3-NADH conversion to NAD+ is monitored by the decrease in absorbance at 340 nm (e=6.22 cm-1 mM-1) using a Molecular Devices SPECTRA max PLUS spectrophotometer.A typical assay was carried out on a 96-well, clear microtiter plate in a Molecular Devices spectrophotometer for 20 minutes at 30 C. in 0.1 mL of assay buffer containing 50 mM HEPES, pH 7.4, 5 nM PKC, 23 units of pyruvate kinase, 33 units of lactate dehydrogenase, 0.15 mM peptide, 0.1 mM ATP, 1 mM DTT, 4 mM PEP, 8 mM MgCl2, 0.3 mM NADH, 60 mM CaCl2, 10 mg/mL PS, 50 ng/mL PMA, 7.5% DMSO and from about 10,000 nM to 0.169 nM compound inhibitor.	B	C[C@H]1CN2C[C@H]3CC3[C@H]2CN1C(=O)N1Cc2c(NC(=O)c3ccccn3)n[nH]c2C1(C)C		CHEMBL3662814	=	Ki	nM	83.7	CHEMBL3045	Homo sapiens	Ki	nM	83.7
295309	17676544	CHEMBL3705825	Inhibition Assay: Protein Kinase C beta 2 (PKC beta II) catalyzes the production of ADP from ATP that accompanies the phosphoryl transfer to the PKC Pseudosubstrate peptide (A->S, RFARKGSLRQKNV). This transfer is coupled to the oxidation of p-NADH through the activities of Pyruvate Kinase (PK) and Lactate Dehydrogenase (LDH). (3-NADH conversion to NAD+ is monitored by the decrease in absorbance at 340 nm (e=6.22 cm-1 mM-1) using a Molecular Devices SPECTRA max PLUS spectrophotometer.A typical assay was carried out on a 96-well, clear microtiter plate in a Molecular Devices spectrophotometer for 20 minutes at 30 C. in 0.1 mL of assay buffer containing 50 mM HEPES, pH 7.4, 5 nM PKC, 23 units of pyruvate kinase, 33 units of lactate dehydrogenase, 0.15 mM peptide, 0.1 mM ATP, 1 mM DTT, 4 mM PEP, 8 mM MgCl2, 0.3 mM NADH, 60 mM CaCl2, 10 mg/mL PS, 50 ng/mL PMA, 7.5% DMSO and from about 10,000 nM to 0.169 nM compound inhibitor.	B	C[C@H]1CN2C[C@@H](F)C[C@H]2CN1C(=O)N1Cc2c(NC(=O)c3ccccn3)n[nH]c2C1(C)C		CHEMBL3662815	=	Ki	nM	109.0	CHEMBL3045	Homo sapiens	Ki	nM	109.0
295310	17676545	CHEMBL3705825	Inhibition Assay: Protein Kinase C beta 2 (PKC beta II) catalyzes the production of ADP from ATP that accompanies the phosphoryl transfer to the PKC Pseudosubstrate peptide (A->S, RFARKGSLRQKNV). This transfer is coupled to the oxidation of p-NADH through the activities of Pyruvate Kinase (PK) and Lactate Dehydrogenase (LDH). (3-NADH conversion to NAD+ is monitored by the decrease in absorbance at 340 nm (e=6.22 cm-1 mM-1) using a Molecular Devices SPECTRA max PLUS spectrophotometer.A typical assay was carried out on a 96-well, clear microtiter plate in a Molecular Devices spectrophotometer for 20 minutes at 30 C. in 0.1 mL of assay buffer containing 50 mM HEPES, pH 7.4, 5 nM PKC, 23 units of pyruvate kinase, 33 units of lactate dehydrogenase, 0.15 mM peptide, 0.1 mM ATP, 1 mM DTT, 4 mM PEP, 8 mM MgCl2, 0.3 mM NADH, 60 mM CaCl2, 10 mg/mL PS, 50 ng/mL PMA, 7.5% DMSO and from about 10,000 nM to 0.169 nM compound inhibitor.	B	C.CCCN1CCN(C(=O)N2Cc3c(NC(=O)c4ccccn4)n[nH]c3C2(C)CC)[C@@H](C)C1		CHEMBL3933186	=	Ki	nM	39.5	CHEMBL3045	Homo sapiens	Ki	nM	39.5
295311	17676546	CHEMBL3705825	Inhibition Assay: Protein Kinase C beta 2 (PKC beta II) catalyzes the production of ADP from ATP that accompanies the phosphoryl transfer to the PKC Pseudosubstrate peptide (A->S, RFARKGSLRQKNV). This transfer is coupled to the oxidation of p-NADH through the activities of Pyruvate Kinase (PK) and Lactate Dehydrogenase (LDH). (3-NADH conversion to NAD+ is monitored by the decrease in absorbance at 340 nm (e=6.22 cm-1 mM-1) using a Molecular Devices SPECTRA max PLUS spectrophotometer.A typical assay was carried out on a 96-well, clear microtiter plate in a Molecular Devices spectrophotometer for 20 minutes at 30 C. in 0.1 mL of assay buffer containing 50 mM HEPES, pH 7.4, 5 nM PKC, 23 units of pyruvate kinase, 33 units of lactate dehydrogenase, 0.15 mM peptide, 0.1 mM ATP, 1 mM DTT, 4 mM PEP, 8 mM MgCl2, 0.3 mM NADH, 60 mM CaCl2, 10 mg/mL PS, 50 ng/mL PMA, 7.5% DMSO and from about 10,000 nM to 0.169 nM compound inhibitor.	B	C.C[C@H]1CN(CC2CC2)CCN1C(=O)N1Cc2c(NC(=O)c3ccc(F)cc3F)n[nH]c2C1(C)C		CHEMBL3896223	=	Ki	nM	68.9	CHEMBL3045	Homo sapiens	Ki	nM	68.9
295312	17676547	CHEMBL3705825	Inhibition Assay: Protein Kinase C beta 2 (PKC beta II) catalyzes the production of ADP from ATP that accompanies the phosphoryl transfer to the PKC Pseudosubstrate peptide (A->S, RFARKGSLRQKNV). This transfer is coupled to the oxidation of p-NADH through the activities of Pyruvate Kinase (PK) and Lactate Dehydrogenase (LDH). (3-NADH conversion to NAD+ is monitored by the decrease in absorbance at 340 nm (e=6.22 cm-1 mM-1) using a Molecular Devices SPECTRA max PLUS spectrophotometer.A typical assay was carried out on a 96-well, clear microtiter plate in a Molecular Devices spectrophotometer for 20 minutes at 30 C. in 0.1 mL of assay buffer containing 50 mM HEPES, pH 7.4, 5 nM PKC, 23 units of pyruvate kinase, 33 units of lactate dehydrogenase, 0.15 mM peptide, 0.1 mM ATP, 1 mM DTT, 4 mM PEP, 8 mM MgCl2, 0.3 mM NADH, 60 mM CaCl2, 10 mg/mL PS, 50 ng/mL PMA, 7.5% DMSO and from about 10,000 nM to 0.169 nM compound inhibitor.	B	C.C[C@H]1CN(C2CCC2)CCN1C(=O)N1Cc2c(NC(=O)c3ccc(F)cc3F)n[nH]c2C1(C)C		CHEMBL3924237	=	Ki	nM	74.2	CHEMBL3045	Homo sapiens	Ki	nM	74.2
295313	17676548	CHEMBL3705825	Inhibition Assay: Protein Kinase C beta 2 (PKC beta II) catalyzes the production of ADP from ATP that accompanies the phosphoryl transfer to the PKC Pseudosubstrate peptide (A->S, RFARKGSLRQKNV). This transfer is coupled to the oxidation of p-NADH through the activities of Pyruvate Kinase (PK) and Lactate Dehydrogenase (LDH). (3-NADH conversion to NAD+ is monitored by the decrease in absorbance at 340 nm (e=6.22 cm-1 mM-1) using a Molecular Devices SPECTRA max PLUS spectrophotometer.A typical assay was carried out on a 96-well, clear microtiter plate in a Molecular Devices spectrophotometer for 20 minutes at 30 C. in 0.1 mL of assay buffer containing 50 mM HEPES, pH 7.4, 5 nM PKC, 23 units of pyruvate kinase, 33 units of lactate dehydrogenase, 0.15 mM peptide, 0.1 mM ATP, 1 mM DTT, 4 mM PEP, 8 mM MgCl2, 0.3 mM NADH, 60 mM CaCl2, 10 mg/mL PS, 50 ng/mL PMA, 7.5% DMSO and from about 10,000 nM to 0.169 nM compound inhibitor.	B	C.CCCCN1CCN(C(=O)N2Cc3c(NC(=O)c4ccc(F)cc4F)n[nH]c3C2(C)C)[C@@H](C)C1		CHEMBL3985036	=	Ki	nM	54.9	CHEMBL3045	Homo sapiens	Ki	nM	54.9
295314	17676549	CHEMBL3705825	Inhibition Assay: Protein Kinase C beta 2 (PKC beta II) catalyzes the production of ADP from ATP that accompanies the phosphoryl transfer to the PKC Pseudosubstrate peptide (A->S, RFARKGSLRQKNV). This transfer is coupled to the oxidation of p-NADH through the activities of Pyruvate Kinase (PK) and Lactate Dehydrogenase (LDH). (3-NADH conversion to NAD+ is monitored by the decrease in absorbance at 340 nm (e=6.22 cm-1 mM-1) using a Molecular Devices SPECTRA max PLUS spectrophotometer.A typical assay was carried out on a 96-well, clear microtiter plate in a Molecular Devices spectrophotometer for 20 minutes at 30 C. in 0.1 mL of assay buffer containing 50 mM HEPES, pH 7.4, 5 nM PKC, 23 units of pyruvate kinase, 33 units of lactate dehydrogenase, 0.15 mM peptide, 0.1 mM ATP, 1 mM DTT, 4 mM PEP, 8 mM MgCl2, 0.3 mM NADH, 60 mM CaCl2, 10 mg/mL PS, 50 ng/mL PMA, 7.5% DMSO and from about 10,000 nM to 0.169 nM compound inhibitor.	B	C.C[C@H]1CN(CC2CCCC2)CCN1C(=O)N1Cc2c(NC(=O)c3ccc(F)cc3F)n[nH]c2C1(C)C		CHEMBL3918822	=	Ki	nM	81.3	CHEMBL3045	Homo sapiens	Ki	nM	81.3
295315	17676550	CHEMBL3705825	Inhibition Assay: Protein Kinase C beta 2 (PKC beta II) catalyzes the production of ADP from ATP that accompanies the phosphoryl transfer to the PKC Pseudosubstrate peptide (A->S, RFARKGSLRQKNV). This transfer is coupled to the oxidation of p-NADH through the activities of Pyruvate Kinase (PK) and Lactate Dehydrogenase (LDH). (3-NADH conversion to NAD+ is monitored by the decrease in absorbance at 340 nm (e=6.22 cm-1 mM-1) using a Molecular Devices SPECTRA max PLUS spectrophotometer.A typical assay was carried out on a 96-well, clear microtiter plate in a Molecular Devices spectrophotometer for 20 minutes at 30 C. in 0.1 mL of assay buffer containing 50 mM HEPES, pH 7.4, 5 nM PKC, 23 units of pyruvate kinase, 33 units of lactate dehydrogenase, 0.15 mM peptide, 0.1 mM ATP, 1 mM DTT, 4 mM PEP, 8 mM MgCl2, 0.3 mM NADH, 60 mM CaCl2, 10 mg/mL PS, 50 ng/mL PMA, 7.5% DMSO and from about 10,000 nM to 0.169 nM compound inhibitor.	B	C.CO[C@@H]1CN2C[C@H](C)N(C(=O)N3Cc4c(NC(=O)c5ccccn5)n[nH]c4C3(C)C)C[C@@H]2C1C		CHEMBL3941144	=	Ki	nM	177.0	CHEMBL3045	Homo sapiens	Ki	nM	177.0
295316	17676551	CHEMBL3705825	Inhibition Assay: Protein Kinase C beta 2 (PKC beta II) catalyzes the production of ADP from ATP that accompanies the phosphoryl transfer to the PKC Pseudosubstrate peptide (A->S, RFARKGSLRQKNV). This transfer is coupled to the oxidation of p-NADH through the activities of Pyruvate Kinase (PK) and Lactate Dehydrogenase (LDH). (3-NADH conversion to NAD+ is monitored by the decrease in absorbance at 340 nm (e=6.22 cm-1 mM-1) using a Molecular Devices SPECTRA max PLUS spectrophotometer.A typical assay was carried out on a 96-well, clear microtiter plate in a Molecular Devices spectrophotometer for 20 minutes at 30 C. in 0.1 mL of assay buffer containing 50 mM HEPES, pH 7.4, 5 nM PKC, 23 units of pyruvate kinase, 33 units of lactate dehydrogenase, 0.15 mM peptide, 0.1 mM ATP, 1 mM DTT, 4 mM PEP, 8 mM MgCl2, 0.3 mM NADH, 60 mM CaCl2, 10 mg/mL PS, 50 ng/mL PMA, 7.5% DMSO and from about 10,000 nM to 0.169 nM compound inhibitor.	B	C[C@H]1CN2CCC[C@H]2CN1C(=O)N1Cc2c(NC(=O)C3CCCCO3)n[nH]c2C1(C)C		CHEMBL3662822	=	Ki	nM	186.0	CHEMBL3045	Homo sapiens	Ki	nM	186.0
295317	17676552	CHEMBL3705825	Inhibition Assay: Protein Kinase C beta 2 (PKC beta II) catalyzes the production of ADP from ATP that accompanies the phosphoryl transfer to the PKC Pseudosubstrate peptide (A->S, RFARKGSLRQKNV). This transfer is coupled to the oxidation of p-NADH through the activities of Pyruvate Kinase (PK) and Lactate Dehydrogenase (LDH). (3-NADH conversion to NAD+ is monitored by the decrease in absorbance at 340 nm (e=6.22 cm-1 mM-1) using a Molecular Devices SPECTRA max PLUS spectrophotometer.A typical assay was carried out on a 96-well, clear microtiter plate in a Molecular Devices spectrophotometer for 20 minutes at 30 C. in 0.1 mL of assay buffer containing 50 mM HEPES, pH 7.4, 5 nM PKC, 23 units of pyruvate kinase, 33 units of lactate dehydrogenase, 0.15 mM peptide, 0.1 mM ATP, 1 mM DTT, 4 mM PEP, 8 mM MgCl2, 0.3 mM NADH, 60 mM CaCl2, 10 mg/mL PS, 50 ng/mL PMA, 7.5% DMSO and from about 10,000 nM to 0.169 nM compound inhibitor.	B	C[C@H]1CN(C)[C@H](C)CN1C(=O)N1Cc2c(NC(=O)c3ccccn3)n[nH]c2C1(C)C		CHEMBL3662823	=	Ki	nM	13.9	CHEMBL3045	Homo sapiens	Ki	nM	13.9
295318	17676553	CHEMBL3705825	Inhibition Assay: Protein Kinase C beta 2 (PKC beta II) catalyzes the production of ADP from ATP that accompanies the phosphoryl transfer to the PKC Pseudosubstrate peptide (A->S, RFARKGSLRQKNV). This transfer is coupled to the oxidation of p-NADH through the activities of Pyruvate Kinase (PK) and Lactate Dehydrogenase (LDH). (3-NADH conversion to NAD+ is monitored by the decrease in absorbance at 340 nm (e=6.22 cm-1 mM-1) using a Molecular Devices SPECTRA max PLUS spectrophotometer.A typical assay was carried out on a 96-well, clear microtiter plate in a Molecular Devices spectrophotometer for 20 minutes at 30 C. in 0.1 mL of assay buffer containing 50 mM HEPES, pH 7.4, 5 nM PKC, 23 units of pyruvate kinase, 33 units of lactate dehydrogenase, 0.15 mM peptide, 0.1 mM ATP, 1 mM DTT, 4 mM PEP, 8 mM MgCl2, 0.3 mM NADH, 60 mM CaCl2, 10 mg/mL PS, 50 ng/mL PMA, 7.5% DMSO and from about 10,000 nM to 0.169 nM compound inhibitor.	B	C[C@H]1CN(C)C(C)(C)CN1C(=O)N1Cc2c(NC(=O)c3ccc(F)cc3F)n[nH]c2C1(C)C		CHEMBL3662824	=	Ki	nM	87.1	CHEMBL3045	Homo sapiens	Ki	nM	87.1
295319	17676554	CHEMBL3705825	Inhibition Assay: Protein Kinase C beta 2 (PKC beta II) catalyzes the production of ADP from ATP that accompanies the phosphoryl transfer to the PKC Pseudosubstrate peptide (A->S, RFARKGSLRQKNV). This transfer is coupled to the oxidation of p-NADH through the activities of Pyruvate Kinase (PK) and Lactate Dehydrogenase (LDH). (3-NADH conversion to NAD+ is monitored by the decrease in absorbance at 340 nm (e=6.22 cm-1 mM-1) using a Molecular Devices SPECTRA max PLUS spectrophotometer.A typical assay was carried out on a 96-well, clear microtiter plate in a Molecular Devices spectrophotometer for 20 minutes at 30 C. in 0.1 mL of assay buffer containing 50 mM HEPES, pH 7.4, 5 nM PKC, 23 units of pyruvate kinase, 33 units of lactate dehydrogenase, 0.15 mM peptide, 0.1 mM ATP, 1 mM DTT, 4 mM PEP, 8 mM MgCl2, 0.3 mM NADH, 60 mM CaCl2, 10 mg/mL PS, 50 ng/mL PMA, 7.5% DMSO and from about 10,000 nM to 0.169 nM compound inhibitor.	B	C.C[C@H]1CN(C)CCN1C(=O)N1Cc2c(NC(=O)c3ccc(F)cc3F)n[nH]c2C1(C)C		CHEMBL3920342	=	Ki	nM	83.1	CHEMBL3045	Homo sapiens	Ki	nM	83.1
295320	17676555	CHEMBL3705825	Inhibition Assay: Protein Kinase C beta 2 (PKC beta II) catalyzes the production of ADP from ATP that accompanies the phosphoryl transfer to the PKC Pseudosubstrate peptide (A->S, RFARKGSLRQKNV). This transfer is coupled to the oxidation of p-NADH through the activities of Pyruvate Kinase (PK) and Lactate Dehydrogenase (LDH). (3-NADH conversion to NAD+ is monitored by the decrease in absorbance at 340 nm (e=6.22 cm-1 mM-1) using a Molecular Devices SPECTRA max PLUS spectrophotometer.A typical assay was carried out on a 96-well, clear microtiter plate in a Molecular Devices spectrophotometer for 20 minutes at 30 C. in 0.1 mL of assay buffer containing 50 mM HEPES, pH 7.4, 5 nM PKC, 23 units of pyruvate kinase, 33 units of lactate dehydrogenase, 0.15 mM peptide, 0.1 mM ATP, 1 mM DTT, 4 mM PEP, 8 mM MgCl2, 0.3 mM NADH, 60 mM CaCl2, 10 mg/mL PS, 50 ng/mL PMA, 7.5% DMSO and from about 10,000 nM to 0.169 nM compound inhibitor.	B	C.CCCN1CCN(C(=O)N2Cc3c(NC(=O)c4ccc(F)cc4F)n[nH]c3C2(C)C)[C@@H](C)C1		CHEMBL3964302	=	Ki	nM	87.3	CHEMBL3045	Homo sapiens	Ki	nM	87.3
295321	17676556	CHEMBL3705825	Inhibition Assay: Protein Kinase C beta 2 (PKC beta II) catalyzes the production of ADP from ATP that accompanies the phosphoryl transfer to the PKC Pseudosubstrate peptide (A->S, RFARKGSLRQKNV). This transfer is coupled to the oxidation of p-NADH through the activities of Pyruvate Kinase (PK) and Lactate Dehydrogenase (LDH). (3-NADH conversion to NAD+ is monitored by the decrease in absorbance at 340 nm (e=6.22 cm-1 mM-1) using a Molecular Devices SPECTRA max PLUS spectrophotometer.A typical assay was carried out on a 96-well, clear microtiter plate in a Molecular Devices spectrophotometer for 20 minutes at 30 C. in 0.1 mL of assay buffer containing 50 mM HEPES, pH 7.4, 5 nM PKC, 23 units of pyruvate kinase, 33 units of lactate dehydrogenase, 0.15 mM peptide, 0.1 mM ATP, 1 mM DTT, 4 mM PEP, 8 mM MgCl2, 0.3 mM NADH, 60 mM CaCl2, 10 mg/mL PS, 50 ng/mL PMA, 7.5% DMSO and from about 10,000 nM to 0.169 nM compound inhibitor.	B	C.COCCCN1CCN(C(=O)N2Cc3c(NC(=O)c4ccc(F)cc4F)n[nH]c3C2(C)C)[C@@H](C)C1		CHEMBL3940515	=	Ki	nM	131.0	CHEMBL3045	Homo sapiens	Ki	nM	131.0
295322	17676557	CHEMBL3705825	Inhibition Assay: Protein Kinase C beta 2 (PKC beta II) catalyzes the production of ADP from ATP that accompanies the phosphoryl transfer to the PKC Pseudosubstrate peptide (A->S, RFARKGSLRQKNV). This transfer is coupled to the oxidation of p-NADH through the activities of Pyruvate Kinase (PK) and Lactate Dehydrogenase (LDH). (3-NADH conversion to NAD+ is monitored by the decrease in absorbance at 340 nm (e=6.22 cm-1 mM-1) using a Molecular Devices SPECTRA max PLUS spectrophotometer.A typical assay was carried out on a 96-well, clear microtiter plate in a Molecular Devices spectrophotometer for 20 minutes at 30 C. in 0.1 mL of assay buffer containing 50 mM HEPES, pH 7.4, 5 nM PKC, 23 units of pyruvate kinase, 33 units of lactate dehydrogenase, 0.15 mM peptide, 0.1 mM ATP, 1 mM DTT, 4 mM PEP, 8 mM MgCl2, 0.3 mM NADH, 60 mM CaCl2, 10 mg/mL PS, 50 ng/mL PMA, 7.5% DMSO and from about 10,000 nM to 0.169 nM compound inhibitor.	B	C.CCN1CCN(C(=O)N2Cc3c(NC(=O)c4ccccn4)n[nH]c3C2(C)C)[C@@H](C)C1		CHEMBL3915993	=	Ki	nM	149.0	CHEMBL3045	Homo sapiens	Ki	nM	149.0
295323	17676558	CHEMBL3705825	Inhibition Assay: Protein Kinase C beta 2 (PKC beta II) catalyzes the production of ADP from ATP that accompanies the phosphoryl transfer to the PKC Pseudosubstrate peptide (A->S, RFARKGSLRQKNV). This transfer is coupled to the oxidation of p-NADH through the activities of Pyruvate Kinase (PK) and Lactate Dehydrogenase (LDH). (3-NADH conversion to NAD+ is monitored by the decrease in absorbance at 340 nm (e=6.22 cm-1 mM-1) using a Molecular Devices SPECTRA max PLUS spectrophotometer.A typical assay was carried out on a 96-well, clear microtiter plate in a Molecular Devices spectrophotometer for 20 minutes at 30 C. in 0.1 mL of assay buffer containing 50 mM HEPES, pH 7.4, 5 nM PKC, 23 units of pyruvate kinase, 33 units of lactate dehydrogenase, 0.15 mM peptide, 0.1 mM ATP, 1 mM DTT, 4 mM PEP, 8 mM MgCl2, 0.3 mM NADH, 60 mM CaCl2, 10 mg/mL PS, 50 ng/mL PMA, 7.5% DMSO and from about 10,000 nM to 0.169 nM compound inhibitor.	B	C.CCCN1CCN(C(=O)N2Cc3c(NC(=O)c4ccccn4)n[nH]c3C2(C)C)[C@@H](C)C1		CHEMBL3917094	=	Ki	nM	52.5	CHEMBL3045	Homo sapiens	Ki	nM	52.5
295324	17676559	CHEMBL3705825	Inhibition Assay: Protein Kinase C beta 2 (PKC beta II) catalyzes the production of ADP from ATP that accompanies the phosphoryl transfer to the PKC Pseudosubstrate peptide (A->S, RFARKGSLRQKNV). This transfer is coupled to the oxidation of p-NADH through the activities of Pyruvate Kinase (PK) and Lactate Dehydrogenase (LDH). (3-NADH conversion to NAD+ is monitored by the decrease in absorbance at 340 nm (e=6.22 cm-1 mM-1) using a Molecular Devices SPECTRA max PLUS spectrophotometer.A typical assay was carried out on a 96-well, clear microtiter plate in a Molecular Devices spectrophotometer for 20 minutes at 30 C. in 0.1 mL of assay buffer containing 50 mM HEPES, pH 7.4, 5 nM PKC, 23 units of pyruvate kinase, 33 units of lactate dehydrogenase, 0.15 mM peptide, 0.1 mM ATP, 1 mM DTT, 4 mM PEP, 8 mM MgCl2, 0.3 mM NADH, 60 mM CaCl2, 10 mg/mL PS, 50 ng/mL PMA, 7.5% DMSO and from about 10,000 nM to 0.169 nM compound inhibitor.	B	C.C[C@H]1CN(C)CCN1C(=O)N1Cc2c(NC(=O)c3ccccn3)n[nH]c2C1(C)C		CHEMBL3914339	=	Ki	nM	19.5	CHEMBL3045	Homo sapiens	Ki	nM	19.5
295325	17676560	CHEMBL3705825	Inhibition Assay: Protein Kinase C beta 2 (PKC beta II) catalyzes the production of ADP from ATP that accompanies the phosphoryl transfer to the PKC Pseudosubstrate peptide (A->S, RFARKGSLRQKNV). This transfer is coupled to the oxidation of p-NADH through the activities of Pyruvate Kinase (PK) and Lactate Dehydrogenase (LDH). (3-NADH conversion to NAD+ is monitored by the decrease in absorbance at 340 nm (e=6.22 cm-1 mM-1) using a Molecular Devices SPECTRA max PLUS spectrophotometer.A typical assay was carried out on a 96-well, clear microtiter plate in a Molecular Devices spectrophotometer for 20 minutes at 30 C. in 0.1 mL of assay buffer containing 50 mM HEPES, pH 7.4, 5 nM PKC, 23 units of pyruvate kinase, 33 units of lactate dehydrogenase, 0.15 mM peptide, 0.1 mM ATP, 1 mM DTT, 4 mM PEP, 8 mM MgCl2, 0.3 mM NADH, 60 mM CaCl2, 10 mg/mL PS, 50 ng/mL PMA, 7.5% DMSO and from about 10,000 nM to 0.169 nM compound inhibitor.	B	C.CCCN1CCN(C(=O)N2Cc3c(NC(=O)c4ccccn4)n[nH]c3C2(C)C)[C@@H](C)C1		CHEMBL3917094	=	Ki	nM	14.6	CHEMBL3045	Homo sapiens	Ki	nM	14.6
295326	17676561	CHEMBL3705825	Inhibition Assay: Protein Kinase C beta 2 (PKC beta II) catalyzes the production of ADP from ATP that accompanies the phosphoryl transfer to the PKC Pseudosubstrate peptide (A->S, RFARKGSLRQKNV). This transfer is coupled to the oxidation of p-NADH through the activities of Pyruvate Kinase (PK) and Lactate Dehydrogenase (LDH). (3-NADH conversion to NAD+ is monitored by the decrease in absorbance at 340 nm (e=6.22 cm-1 mM-1) using a Molecular Devices SPECTRA max PLUS spectrophotometer.A typical assay was carried out on a 96-well, clear microtiter plate in a Molecular Devices spectrophotometer for 20 minutes at 30 C. in 0.1 mL of assay buffer containing 50 mM HEPES, pH 7.4, 5 nM PKC, 23 units of pyruvate kinase, 33 units of lactate dehydrogenase, 0.15 mM peptide, 0.1 mM ATP, 1 mM DTT, 4 mM PEP, 8 mM MgCl2, 0.3 mM NADH, 60 mM CaCl2, 10 mg/mL PS, 50 ng/mL PMA, 7.5% DMSO and from about 10,000 nM to 0.169 nM compound inhibitor.	B	C.C[C@H]1CN(CC2CC2)CCN1C(=O)N1Cc2c(NC(=O)c3ccccn3)n[nH]c2C1(C)C		CHEMBL3901906	=	Ki	nM	13.3	CHEMBL3045	Homo sapiens	Ki	nM	13.3
295327	17676562	CHEMBL3705825	Inhibition Assay: Protein Kinase C beta 2 (PKC beta II) catalyzes the production of ADP from ATP that accompanies the phosphoryl transfer to the PKC Pseudosubstrate peptide (A->S, RFARKGSLRQKNV). This transfer is coupled to the oxidation of p-NADH through the activities of Pyruvate Kinase (PK) and Lactate Dehydrogenase (LDH). (3-NADH conversion to NAD+ is monitored by the decrease in absorbance at 340 nm (e=6.22 cm-1 mM-1) using a Molecular Devices SPECTRA max PLUS spectrophotometer.A typical assay was carried out on a 96-well, clear microtiter plate in a Molecular Devices spectrophotometer for 20 minutes at 30 C. in 0.1 mL of assay buffer containing 50 mM HEPES, pH 7.4, 5 nM PKC, 23 units of pyruvate kinase, 33 units of lactate dehydrogenase, 0.15 mM peptide, 0.1 mM ATP, 1 mM DTT, 4 mM PEP, 8 mM MgCl2, 0.3 mM NADH, 60 mM CaCl2, 10 mg/mL PS, 50 ng/mL PMA, 7.5% DMSO and from about 10,000 nM to 0.169 nM compound inhibitor.	B	C.CCCCN1CCN(C(=O)N2Cc3c(NC(=O)c4ccccn4)n[nH]c3C2(C)C)[C@@H](C)C1		CHEMBL3923758	=	Ki	nM	13.3	CHEMBL3045	Homo sapiens	Ki	nM	13.3
295328	17676563	CHEMBL3705825	Inhibition Assay: Protein Kinase C beta 2 (PKC beta II) catalyzes the production of ADP from ATP that accompanies the phosphoryl transfer to the PKC Pseudosubstrate peptide (A->S, RFARKGSLRQKNV). This transfer is coupled to the oxidation of p-NADH through the activities of Pyruvate Kinase (PK) and Lactate Dehydrogenase (LDH). (3-NADH conversion to NAD+ is monitored by the decrease in absorbance at 340 nm (e=6.22 cm-1 mM-1) using a Molecular Devices SPECTRA max PLUS spectrophotometer.A typical assay was carried out on a 96-well, clear microtiter plate in a Molecular Devices spectrophotometer for 20 minutes at 30 C. in 0.1 mL of assay buffer containing 50 mM HEPES, pH 7.4, 5 nM PKC, 23 units of pyruvate kinase, 33 units of lactate dehydrogenase, 0.15 mM peptide, 0.1 mM ATP, 1 mM DTT, 4 mM PEP, 8 mM MgCl2, 0.3 mM NADH, 60 mM CaCl2, 10 mg/mL PS, 50 ng/mL PMA, 7.5% DMSO and from about 10,000 nM to 0.169 nM compound inhibitor.	B	C.COCCCN1CCN(C(=O)N2Cc3c(NC(=O)c4ccccn4)n[nH]c3C2(C)C)[C@@H](C)C1		CHEMBL3931196	=	Ki	nM	143.0	CHEMBL3045	Homo sapiens	Ki	nM	143.0
295329	17676564	CHEMBL3705825	Inhibition Assay: Protein Kinase C beta 2 (PKC beta II) catalyzes the production of ADP from ATP that accompanies the phosphoryl transfer to the PKC Pseudosubstrate peptide (A->S, RFARKGSLRQKNV). This transfer is coupled to the oxidation of p-NADH through the activities of Pyruvate Kinase (PK) and Lactate Dehydrogenase (LDH). (3-NADH conversion to NAD+ is monitored by the decrease in absorbance at 340 nm (e=6.22 cm-1 mM-1) using a Molecular Devices SPECTRA max PLUS spectrophotometer.A typical assay was carried out on a 96-well, clear microtiter plate in a Molecular Devices spectrophotometer for 20 minutes at 30 C. in 0.1 mL of assay buffer containing 50 mM HEPES, pH 7.4, 5 nM PKC, 23 units of pyruvate kinase, 33 units of lactate dehydrogenase, 0.15 mM peptide, 0.1 mM ATP, 1 mM DTT, 4 mM PEP, 8 mM MgCl2, 0.3 mM NADH, 60 mM CaCl2, 10 mg/mL PS, 50 ng/mL PMA, 7.5% DMSO and from about 10,000 nM to 0.169 nM compound inhibitor.	B	CC[C@H]1CN(C(=O)N2Cc3c(NC(=O)c4ccccn4)n[nH]c3C2(C)C)[C@@H](C)CN1C		CHEMBL3662831	=	Ki	nM	93.9	CHEMBL3045	Homo sapiens	Ki	nM	93.9
295330	17676565	CHEMBL3705825	Inhibition Assay: Protein Kinase C beta 2 (PKC beta II) catalyzes the production of ADP from ATP that accompanies the phosphoryl transfer to the PKC Pseudosubstrate peptide (A->S, RFARKGSLRQKNV). This transfer is coupled to the oxidation of p-NADH through the activities of Pyruvate Kinase (PK) and Lactate Dehydrogenase (LDH). (3-NADH conversion to NAD+ is monitored by the decrease in absorbance at 340 nm (e=6.22 cm-1 mM-1) using a Molecular Devices SPECTRA max PLUS spectrophotometer.A typical assay was carried out on a 96-well, clear microtiter plate in a Molecular Devices spectrophotometer for 20 minutes at 30 C. in 0.1 mL of assay buffer containing 50 mM HEPES, pH 7.4, 5 nM PKC, 23 units of pyruvate kinase, 33 units of lactate dehydrogenase, 0.15 mM peptide, 0.1 mM ATP, 1 mM DTT, 4 mM PEP, 8 mM MgCl2, 0.3 mM NADH, 60 mM CaCl2, 10 mg/mL PS, 50 ng/mL PMA, 7.5% DMSO and from about 10,000 nM to 0.169 nM compound inhibitor.	B	CCN1C[C@H](C)N(C(=O)N2Cc3c(NC(=O)c4ccc(F)cn4)n[nH]c3C2(C)C)C[C@@H]1C		CHEMBL3662832	=	Ki	nM	22.2	CHEMBL3045	Homo sapiens	Ki	nM	22.2
295331	17676566	CHEMBL3705825	Inhibition Assay: Protein Kinase C beta 2 (PKC beta II) catalyzes the production of ADP from ATP that accompanies the phosphoryl transfer to the PKC Pseudosubstrate peptide (A->S, RFARKGSLRQKNV). This transfer is coupled to the oxidation of p-NADH through the activities of Pyruvate Kinase (PK) and Lactate Dehydrogenase (LDH). (3-NADH conversion to NAD+ is monitored by the decrease in absorbance at 340 nm (e=6.22 cm-1 mM-1) using a Molecular Devices SPECTRA max PLUS spectrophotometer.A typical assay was carried out on a 96-well, clear microtiter plate in a Molecular Devices spectrophotometer for 20 minutes at 30 C. in 0.1 mL of assay buffer containing 50 mM HEPES, pH 7.4, 5 nM PKC, 23 units of pyruvate kinase, 33 units of lactate dehydrogenase, 0.15 mM peptide, 0.1 mM ATP, 1 mM DTT, 4 mM PEP, 8 mM MgCl2, 0.3 mM NADH, 60 mM CaCl2, 10 mg/mL PS, 50 ng/mL PMA, 7.5% DMSO and from about 10,000 nM to 0.169 nM compound inhibitor.	B	CC1CN(C(=O)N2Cc3c(NC(=O)c4ccccn4)n[nH]c3C2(C)C)CCN1CC1CC1		CHEMBL3662833	=	Ki	nM	134.0	CHEMBL3045	Homo sapiens	Ki	nM	134.0
295332	17676567	CHEMBL3705825	Inhibition Assay: Protein Kinase C beta 2 (PKC beta II) catalyzes the production of ADP from ATP that accompanies the phosphoryl transfer to the PKC Pseudosubstrate peptide (A->S, RFARKGSLRQKNV). This transfer is coupled to the oxidation of p-NADH through the activities of Pyruvate Kinase (PK) and Lactate Dehydrogenase (LDH). (3-NADH conversion to NAD+ is monitored by the decrease in absorbance at 340 nm (e=6.22 cm-1 mM-1) using a Molecular Devices SPECTRA max PLUS spectrophotometer.A typical assay was carried out on a 96-well, clear microtiter plate in a Molecular Devices spectrophotometer for 20 minutes at 30 C. in 0.1 mL of assay buffer containing 50 mM HEPES, pH 7.4, 5 nM PKC, 23 units of pyruvate kinase, 33 units of lactate dehydrogenase, 0.15 mM peptide, 0.1 mM ATP, 1 mM DTT, 4 mM PEP, 8 mM MgCl2, 0.3 mM NADH, 60 mM CaCl2, 10 mg/mL PS, 50 ng/mL PMA, 7.5% DMSO and from about 10,000 nM to 0.169 nM compound inhibitor.	B	CCN1CCN(C(=O)N2Cc3c(NC(=O)c4ccccn4)n[nH]c3C2(C)C)CC1C		CHEMBL3662834	=	Ki	nM	156.0	CHEMBL3045	Homo sapiens	Ki	nM	156.0
295333	17676568	CHEMBL3705825	Inhibition Assay: Protein Kinase C beta 2 (PKC beta II) catalyzes the production of ADP from ATP that accompanies the phosphoryl transfer to the PKC Pseudosubstrate peptide (A->S, RFARKGSLRQKNV). This transfer is coupled to the oxidation of p-NADH through the activities of Pyruvate Kinase (PK) and Lactate Dehydrogenase (LDH). (3-NADH conversion to NAD+ is monitored by the decrease in absorbance at 340 nm (e=6.22 cm-1 mM-1) using a Molecular Devices SPECTRA max PLUS spectrophotometer.A typical assay was carried out on a 96-well, clear microtiter plate in a Molecular Devices spectrophotometer for 20 minutes at 30 C. in 0.1 mL of assay buffer containing 50 mM HEPES, pH 7.4, 5 nM PKC, 23 units of pyruvate kinase, 33 units of lactate dehydrogenase, 0.15 mM peptide, 0.1 mM ATP, 1 mM DTT, 4 mM PEP, 8 mM MgCl2, 0.3 mM NADH, 60 mM CaCl2, 10 mg/mL PS, 50 ng/mL PMA, 7.5% DMSO and from about 10,000 nM to 0.169 nM compound inhibitor.	B	C[C@H]1CN(C)C(C)(C)CN1C(=O)N1Cc2c(NC(=O)c3ccccn3)n[nH]c2C1(C)C		CHEMBL3662835	=	Ki	nM	18.1	CHEMBL3045	Homo sapiens	Ki	nM	18.1
295334	17676569	CHEMBL3705825	Inhibition Assay: Protein Kinase C beta 2 (PKC beta II) catalyzes the production of ADP from ATP that accompanies the phosphoryl transfer to the PKC Pseudosubstrate peptide (A->S, RFARKGSLRQKNV). This transfer is coupled to the oxidation of p-NADH through the activities of Pyruvate Kinase (PK) and Lactate Dehydrogenase (LDH). (3-NADH conversion to NAD+ is monitored by the decrease in absorbance at 340 nm (e=6.22 cm-1 mM-1) using a Molecular Devices SPECTRA max PLUS spectrophotometer.A typical assay was carried out on a 96-well, clear microtiter plate in a Molecular Devices spectrophotometer for 20 minutes at 30 C. in 0.1 mL of assay buffer containing 50 mM HEPES, pH 7.4, 5 nM PKC, 23 units of pyruvate kinase, 33 units of lactate dehydrogenase, 0.15 mM peptide, 0.1 mM ATP, 1 mM DTT, 4 mM PEP, 8 mM MgCl2, 0.3 mM NADH, 60 mM CaCl2, 10 mg/mL PS, 50 ng/mL PMA, 7.5% DMSO and from about 10,000 nM to 0.169 nM compound inhibitor.	B	C[C@H]1CN2CCC[C@H]2CN1C(=O)N1Cc2c(NC(=O)c3ccc(C(F)(F)F)cn3)n[nH]c2C1(C)C		CHEMBL3662836	=	Ki	nM	31.5	CHEMBL3045	Homo sapiens	Ki	nM	31.5
295335	17676570	CHEMBL3705825	Inhibition Assay: Protein Kinase C beta 2 (PKC beta II) catalyzes the production of ADP from ATP that accompanies the phosphoryl transfer to the PKC Pseudosubstrate peptide (A->S, RFARKGSLRQKNV). This transfer is coupled to the oxidation of p-NADH through the activities of Pyruvate Kinase (PK) and Lactate Dehydrogenase (LDH). (3-NADH conversion to NAD+ is monitored by the decrease in absorbance at 340 nm (e=6.22 cm-1 mM-1) using a Molecular Devices SPECTRA max PLUS spectrophotometer.A typical assay was carried out on a 96-well, clear microtiter plate in a Molecular Devices spectrophotometer for 20 minutes at 30 C. in 0.1 mL of assay buffer containing 50 mM HEPES, pH 7.4, 5 nM PKC, 23 units of pyruvate kinase, 33 units of lactate dehydrogenase, 0.15 mM peptide, 0.1 mM ATP, 1 mM DTT, 4 mM PEP, 8 mM MgCl2, 0.3 mM NADH, 60 mM CaCl2, 10 mg/mL PS, 50 ng/mL PMA, 7.5% DMSO and from about 10,000 nM to 0.169 nM compound inhibitor.	B	CC[C@@H]1CN(C(=O)N2Cc3c(NC(=O)c4ccccn4)n[nH]c3C2(C)C)[C@@H](C)CN1C		CHEMBL3662837	=	Ki	nM	37.2	CHEMBL3045	Homo sapiens	Ki	nM	37.2
295336	17676571	CHEMBL3705825	Inhibition Assay: Protein Kinase C beta 2 (PKC beta II) catalyzes the production of ADP from ATP that accompanies the phosphoryl transfer to the PKC Pseudosubstrate peptide (A->S, RFARKGSLRQKNV). This transfer is coupled to the oxidation of p-NADH through the activities of Pyruvate Kinase (PK) and Lactate Dehydrogenase (LDH). (3-NADH conversion to NAD+ is monitored by the decrease in absorbance at 340 nm (e=6.22 cm-1 mM-1) using a Molecular Devices SPECTRA max PLUS spectrophotometer.A typical assay was carried out on a 96-well, clear microtiter plate in a Molecular Devices spectrophotometer for 20 minutes at 30 C. in 0.1 mL of assay buffer containing 50 mM HEPES, pH 7.4, 5 nM PKC, 23 units of pyruvate kinase, 33 units of lactate dehydrogenase, 0.15 mM peptide, 0.1 mM ATP, 1 mM DTT, 4 mM PEP, 8 mM MgCl2, 0.3 mM NADH, 60 mM CaCl2, 10 mg/mL PS, 50 ng/mL PMA, 7.5% DMSO and from about 10,000 nM to 0.169 nM compound inhibitor.	B	CCC1(CC)c2[nH]nc(NC(=O)c3ccccn3)c2CN1C(=O)N1C[C@@H]2CCCN2C[C@@H]1C		CHEMBL3662838	=	Ki	nM	61.9	CHEMBL3045	Homo sapiens	Ki	nM	61.9
295337	17676572	CHEMBL3705825	Inhibition Assay: Protein Kinase C beta 2 (PKC beta II) catalyzes the production of ADP from ATP that accompanies the phosphoryl transfer to the PKC Pseudosubstrate peptide (A->S, RFARKGSLRQKNV). This transfer is coupled to the oxidation of p-NADH through the activities of Pyruvate Kinase (PK) and Lactate Dehydrogenase (LDH). (3-NADH conversion to NAD+ is monitored by the decrease in absorbance at 340 nm (e=6.22 cm-1 mM-1) using a Molecular Devices SPECTRA max PLUS spectrophotometer.A typical assay was carried out on a 96-well, clear microtiter plate in a Molecular Devices spectrophotometer for 20 minutes at 30 C. in 0.1 mL of assay buffer containing 50 mM HEPES, pH 7.4, 5 nM PKC, 23 units of pyruvate kinase, 33 units of lactate dehydrogenase, 0.15 mM peptide, 0.1 mM ATP, 1 mM DTT, 4 mM PEP, 8 mM MgCl2, 0.3 mM NADH, 60 mM CaCl2, 10 mg/mL PS, 50 ng/mL PMA, 7.5% DMSO and from about 10,000 nM to 0.169 nM compound inhibitor.	B	C[C@H]1CN(C)C2(CCC2)CN1C(=O)N1Cc2c(NC(=O)c3ccccn3)n[nH]c2C1(C)C		CHEMBL3662839	=	Ki	nM	8.58	CHEMBL3045	Homo sapiens	Ki	nM	8.58
295338	17676573	CHEMBL3705825	Inhibition Assay: Protein Kinase C beta 2 (PKC beta II) catalyzes the production of ADP from ATP that accompanies the phosphoryl transfer to the PKC Pseudosubstrate peptide (A->S, RFARKGSLRQKNV). This transfer is coupled to the oxidation of p-NADH through the activities of Pyruvate Kinase (PK) and Lactate Dehydrogenase (LDH). (3-NADH conversion to NAD+ is monitored by the decrease in absorbance at 340 nm (e=6.22 cm-1 mM-1) using a Molecular Devices SPECTRA max PLUS spectrophotometer.A typical assay was carried out on a 96-well, clear microtiter plate in a Molecular Devices spectrophotometer for 20 minutes at 30 C. in 0.1 mL of assay buffer containing 50 mM HEPES, pH 7.4, 5 nM PKC, 23 units of pyruvate kinase, 33 units of lactate dehydrogenase, 0.15 mM peptide, 0.1 mM ATP, 1 mM DTT, 4 mM PEP, 8 mM MgCl2, 0.3 mM NADH, 60 mM CaCl2, 10 mg/mL PS, 50 ng/mL PMA, 7.5% DMSO and from about 10,000 nM to 0.169 nM compound inhibitor.	B	CC(C)[C@H]1CN(C)C(C)(C)CN1C(=O)N1Cc2c(NC(=O)c3ccccn3)n[nH]c2C1(C)C		CHEMBL3662840	=	Ki	nM	90.1	CHEMBL3045	Homo sapiens	Ki	nM	90.1
295339	17676574	CHEMBL3705825	Inhibition Assay: Protein Kinase C beta 2 (PKC beta II) catalyzes the production of ADP from ATP that accompanies the phosphoryl transfer to the PKC Pseudosubstrate peptide (A->S, RFARKGSLRQKNV). This transfer is coupled to the oxidation of p-NADH through the activities of Pyruvate Kinase (PK) and Lactate Dehydrogenase (LDH). (3-NADH conversion to NAD+ is monitored by the decrease in absorbance at 340 nm (e=6.22 cm-1 mM-1) using a Molecular Devices SPECTRA max PLUS spectrophotometer.A typical assay was carried out on a 96-well, clear microtiter plate in a Molecular Devices spectrophotometer for 20 minutes at 30 C. in 0.1 mL of assay buffer containing 50 mM HEPES, pH 7.4, 5 nM PKC, 23 units of pyruvate kinase, 33 units of lactate dehydrogenase, 0.15 mM peptide, 0.1 mM ATP, 1 mM DTT, 4 mM PEP, 8 mM MgCl2, 0.3 mM NADH, 60 mM CaCl2, 10 mg/mL PS, 50 ng/mL PMA, 7.5% DMSO and from about 10,000 nM to 0.169 nM compound inhibitor.	B	C.CC(C)[C@H]1CN(C)C(C)CN1C(=O)N1Cc2c(NC(=O)c3ccc(Cl)cn3)n[nH]c2C1(C)C		CHEMBL4111227	=	Ki	nM	51.2	CHEMBL3045	Homo sapiens	Ki	nM	51.2
295340	17676575	CHEMBL3705825	Inhibition Assay: Protein Kinase C beta 2 (PKC beta II) catalyzes the production of ADP from ATP that accompanies the phosphoryl transfer to the PKC Pseudosubstrate peptide (A->S, RFARKGSLRQKNV). This transfer is coupled to the oxidation of p-NADH through the activities of Pyruvate Kinase (PK) and Lactate Dehydrogenase (LDH). (3-NADH conversion to NAD+ is monitored by the decrease in absorbance at 340 nm (e=6.22 cm-1 mM-1) using a Molecular Devices SPECTRA max PLUS spectrophotometer.A typical assay was carried out on a 96-well, clear microtiter plate in a Molecular Devices spectrophotometer for 20 minutes at 30 C. in 0.1 mL of assay buffer containing 50 mM HEPES, pH 7.4, 5 nM PKC, 23 units of pyruvate kinase, 33 units of lactate dehydrogenase, 0.15 mM peptide, 0.1 mM ATP, 1 mM DTT, 4 mM PEP, 8 mM MgCl2, 0.3 mM NADH, 60 mM CaCl2, 10 mg/mL PS, 50 ng/mL PMA, 7.5% DMSO and from about 10,000 nM to 0.169 nM compound inhibitor.	B	C.C.CC1c2[nH]nc(NC(=O)c3ccccn3)c2CN1C(=O)N1C[C@@H]2CCCN2C[C@@H]1C		CHEMBL3934903	=	Ki	nM	57.6	CHEMBL3045	Homo sapiens	Ki	nM	57.6
295341	17676576	CHEMBL3705825	Inhibition Assay: Protein Kinase C beta 2 (PKC beta II) catalyzes the production of ADP from ATP that accompanies the phosphoryl transfer to the PKC Pseudosubstrate peptide (A->S, RFARKGSLRQKNV). This transfer is coupled to the oxidation of p-NADH through the activities of Pyruvate Kinase (PK) and Lactate Dehydrogenase (LDH). (3-NADH conversion to NAD+ is monitored by the decrease in absorbance at 340 nm (e=6.22 cm-1 mM-1) using a Molecular Devices SPECTRA max PLUS spectrophotometer.A typical assay was carried out on a 96-well, clear microtiter plate in a Molecular Devices spectrophotometer for 20 minutes at 30 C. in 0.1 mL of assay buffer containing 50 mM HEPES, pH 7.4, 5 nM PKC, 23 units of pyruvate kinase, 33 units of lactate dehydrogenase, 0.15 mM peptide, 0.1 mM ATP, 1 mM DTT, 4 mM PEP, 8 mM MgCl2, 0.3 mM NADH, 60 mM CaCl2, 10 mg/mL PS, 50 ng/mL PMA, 7.5% DMSO and from about 10,000 nM to 0.169 nM compound inhibitor.	B	C.COCCCN1CCN(C(=O)N2Cc3c(NC(=O)c4ccccn4)n[nH]c3C2(C)C)[C@@H](C)C1		CHEMBL3931196	=	Ki	nM	19.5	CHEMBL3045	Homo sapiens	Ki	nM	19.5
295342	17676577	CHEMBL3705825	Inhibition Assay: Protein Kinase C beta 2 (PKC beta II) catalyzes the production of ADP from ATP that accompanies the phosphoryl transfer to the PKC Pseudosubstrate peptide (A->S, RFARKGSLRQKNV). This transfer is coupled to the oxidation of p-NADH through the activities of Pyruvate Kinase (PK) and Lactate Dehydrogenase (LDH). (3-NADH conversion to NAD+ is monitored by the decrease in absorbance at 340 nm (e=6.22 cm-1 mM-1) using a Molecular Devices SPECTRA max PLUS spectrophotometer.A typical assay was carried out on a 96-well, clear microtiter plate in a Molecular Devices spectrophotometer for 20 minutes at 30 C. in 0.1 mL of assay buffer containing 50 mM HEPES, pH 7.4, 5 nM PKC, 23 units of pyruvate kinase, 33 units of lactate dehydrogenase, 0.15 mM peptide, 0.1 mM ATP, 1 mM DTT, 4 mM PEP, 8 mM MgCl2, 0.3 mM NADH, 60 mM CaCl2, 10 mg/mL PS, 50 ng/mL PMA, 7.5% DMSO and from about 10,000 nM to 0.169 nM compound inhibitor.	B	C[C@H]1CN2CCC[C@@]2(C)CN1C(=O)N1Cc2c(NC(=O)c3ccc(F)cn3)n[nH]c2C1(C)C		CHEMBL3662843	=	Ki	nM	29.3	CHEMBL3045	Homo sapiens	Ki	nM	29.3
295343	17676578	CHEMBL3705825	Inhibition Assay: Protein Kinase C beta 2 (PKC beta II) catalyzes the production of ADP from ATP that accompanies the phosphoryl transfer to the PKC Pseudosubstrate peptide (A->S, RFARKGSLRQKNV). This transfer is coupled to the oxidation of p-NADH through the activities of Pyruvate Kinase (PK) and Lactate Dehydrogenase (LDH). (3-NADH conversion to NAD+ is monitored by the decrease in absorbance at 340 nm (e=6.22 cm-1 mM-1) using a Molecular Devices SPECTRA max PLUS spectrophotometer.A typical assay was carried out on a 96-well, clear microtiter plate in a Molecular Devices spectrophotometer for 20 minutes at 30 C. in 0.1 mL of assay buffer containing 50 mM HEPES, pH 7.4, 5 nM PKC, 23 units of pyruvate kinase, 33 units of lactate dehydrogenase, 0.15 mM peptide, 0.1 mM ATP, 1 mM DTT, 4 mM PEP, 8 mM MgCl2, 0.3 mM NADH, 60 mM CaCl2, 10 mg/mL PS, 50 ng/mL PMA, 7.5% DMSO and from about 10,000 nM to 0.169 nM compound inhibitor.	B	CC[C@H]1CN2CCC[C@@]2(C)CN1C(=O)N1Cc2c(NC(=O)c3ccc(F)cn3)n[nH]c2C1(C)C		CHEMBL3662844	=	Ki	nM	75.2	CHEMBL3045	Homo sapiens	Ki	nM	75.2
295344	17676579	CHEMBL3705825	Inhibition Assay: Protein Kinase C beta 2 (PKC beta II) catalyzes the production of ADP from ATP that accompanies the phosphoryl transfer to the PKC Pseudosubstrate peptide (A->S, RFARKGSLRQKNV). This transfer is coupled to the oxidation of p-NADH through the activities of Pyruvate Kinase (PK) and Lactate Dehydrogenase (LDH). (3-NADH conversion to NAD+ is monitored by the decrease in absorbance at 340 nm (e=6.22 cm-1 mM-1) using a Molecular Devices SPECTRA max PLUS spectrophotometer.A typical assay was carried out on a 96-well, clear microtiter plate in a Molecular Devices spectrophotometer for 20 minutes at 30 C. in 0.1 mL of assay buffer containing 50 mM HEPES, pH 7.4, 5 nM PKC, 23 units of pyruvate kinase, 33 units of lactate dehydrogenase, 0.15 mM peptide, 0.1 mM ATP, 1 mM DTT, 4 mM PEP, 8 mM MgCl2, 0.3 mM NADH, 60 mM CaCl2, 10 mg/mL PS, 50 ng/mL PMA, 7.5% DMSO and from about 10,000 nM to 0.169 nM compound inhibitor.	B	C[C@H]1CN(C)[C@H](C)CN1C(=O)N1Cc2c(NC(=O)c3cc(C4CC4)on3)n[nH]c2C1(C)C		CHEMBL3662845	=	Ki	nM	26.8	CHEMBL3045	Homo sapiens	Ki	nM	26.8
295345	17676580	CHEMBL3705825	Inhibition Assay: Protein Kinase C beta 2 (PKC beta II) catalyzes the production of ADP from ATP that accompanies the phosphoryl transfer to the PKC Pseudosubstrate peptide (A->S, RFARKGSLRQKNV). This transfer is coupled to the oxidation of p-NADH through the activities of Pyruvate Kinase (PK) and Lactate Dehydrogenase (LDH). (3-NADH conversion to NAD+ is monitored by the decrease in absorbance at 340 nm (e=6.22 cm-1 mM-1) using a Molecular Devices SPECTRA max PLUS spectrophotometer.A typical assay was carried out on a 96-well, clear microtiter plate in a Molecular Devices spectrophotometer for 20 minutes at 30 C. in 0.1 mL of assay buffer containing 50 mM HEPES, pH 7.4, 5 nM PKC, 23 units of pyruvate kinase, 33 units of lactate dehydrogenase, 0.15 mM peptide, 0.1 mM ATP, 1 mM DTT, 4 mM PEP, 8 mM MgCl2, 0.3 mM NADH, 60 mM CaCl2, 10 mg/mL PS, 50 ng/mL PMA, 7.5% DMSO and from about 10,000 nM to 0.169 nM compound inhibitor.	B	C[C@H]1CN(CCCC#N)[C@H](C)CN1C(=O)N1Cc2c(NC(=O)c3ccccn3)n[nH]c2C1(C)C		CHEMBL3662846	=	Ki	nM	23.6	CHEMBL3045	Homo sapiens	Ki	nM	23.6
295346	17676581	CHEMBL3705825	Inhibition Assay: Protein Kinase C beta 2 (PKC beta II) catalyzes the production of ADP from ATP that accompanies the phosphoryl transfer to the PKC Pseudosubstrate peptide (A->S, RFARKGSLRQKNV). This transfer is coupled to the oxidation of p-NADH through the activities of Pyruvate Kinase (PK) and Lactate Dehydrogenase (LDH). (3-NADH conversion to NAD+ is monitored by the decrease in absorbance at 340 nm (e=6.22 cm-1 mM-1) using a Molecular Devices SPECTRA max PLUS spectrophotometer.A typical assay was carried out on a 96-well, clear microtiter plate in a Molecular Devices spectrophotometer for 20 minutes at 30 C. in 0.1 mL of assay buffer containing 50 mM HEPES, pH 7.4, 5 nM PKC, 23 units of pyruvate kinase, 33 units of lactate dehydrogenase, 0.15 mM peptide, 0.1 mM ATP, 1 mM DTT, 4 mM PEP, 8 mM MgCl2, 0.3 mM NADH, 60 mM CaCl2, 10 mg/mL PS, 50 ng/mL PMA, 7.5% DMSO and from about 10,000 nM to 0.169 nM compound inhibitor.	B	C[C@H]1CN(CCCF)[C@H](C)CN1C(=O)N1Cc2c(NC(=O)c3ccccn3)n[nH]c2C1(C)C		CHEMBL3662847	=	Ki	nM	43.4	CHEMBL3045	Homo sapiens	Ki	nM	43.4
295347	17676582	CHEMBL3705825	Inhibition Assay: Protein Kinase C beta 2 (PKC beta II) catalyzes the production of ADP from ATP that accompanies the phosphoryl transfer to the PKC Pseudosubstrate peptide (A->S, RFARKGSLRQKNV). This transfer is coupled to the oxidation of p-NADH through the activities of Pyruvate Kinase (PK) and Lactate Dehydrogenase (LDH). (3-NADH conversion to NAD+ is monitored by the decrease in absorbance at 340 nm (e=6.22 cm-1 mM-1) using a Molecular Devices SPECTRA max PLUS spectrophotometer.A typical assay was carried out on a 96-well, clear microtiter plate in a Molecular Devices spectrophotometer for 20 minutes at 30 C. in 0.1 mL of assay buffer containing 50 mM HEPES, pH 7.4, 5 nM PKC, 23 units of pyruvate kinase, 33 units of lactate dehydrogenase, 0.15 mM peptide, 0.1 mM ATP, 1 mM DTT, 4 mM PEP, 8 mM MgCl2, 0.3 mM NADH, 60 mM CaCl2, 10 mg/mL PS, 50 ng/mL PMA, 7.5% DMSO and from about 10,000 nM to 0.169 nM compound inhibitor.	B	C[C@H]1CN(CC2CCOCC2)[C@H](C)CN1C(=O)N1Cc2c(NC(=O)c3ccccn3)n[nH]c2C1(C)C		CHEMBL3662848	=	Ki	nM	1.9	CHEMBL3045	Homo sapiens	Ki	nM	1.9
295348	17676583	CHEMBL3705825	Inhibition Assay: Protein Kinase C beta 2 (PKC beta II) catalyzes the production of ADP from ATP that accompanies the phosphoryl transfer to the PKC Pseudosubstrate peptide (A->S, RFARKGSLRQKNV). This transfer is coupled to the oxidation of p-NADH through the activities of Pyruvate Kinase (PK) and Lactate Dehydrogenase (LDH). (3-NADH conversion to NAD+ is monitored by the decrease in absorbance at 340 nm (e=6.22 cm-1 mM-1) using a Molecular Devices SPECTRA max PLUS spectrophotometer.A typical assay was carried out on a 96-well, clear microtiter plate in a Molecular Devices spectrophotometer for 20 minutes at 30 C. in 0.1 mL of assay buffer containing 50 mM HEPES, pH 7.4, 5 nM PKC, 23 units of pyruvate kinase, 33 units of lactate dehydrogenase, 0.15 mM peptide, 0.1 mM ATP, 1 mM DTT, 4 mM PEP, 8 mM MgCl2, 0.3 mM NADH, 60 mM CaCl2, 10 mg/mL PS, 50 ng/mL PMA, 7.5% DMSO and from about 10,000 nM to 0.169 nM compound inhibitor.	B	C[C@H]1CN(CCCCC#N)[C@H](C)CN1C(=O)N1Cc2c(NC(=O)c3ccccn3)n[nH]c2C1(C)C		CHEMBL3662849	=	Ki	nM	38.3	CHEMBL3045	Homo sapiens	Ki	nM	38.3
295349	17676584	CHEMBL3705825	Inhibition Assay: Protein Kinase C beta 2 (PKC beta II) catalyzes the production of ADP from ATP that accompanies the phosphoryl transfer to the PKC Pseudosubstrate peptide (A->S, RFARKGSLRQKNV). This transfer is coupled to the oxidation of p-NADH through the activities of Pyruvate Kinase (PK) and Lactate Dehydrogenase (LDH). (3-NADH conversion to NAD+ is monitored by the decrease in absorbance at 340 nm (e=6.22 cm-1 mM-1) using a Molecular Devices SPECTRA max PLUS spectrophotometer.A typical assay was carried out on a 96-well, clear microtiter plate in a Molecular Devices spectrophotometer for 20 minutes at 30 C. in 0.1 mL of assay buffer containing 50 mM HEPES, pH 7.4, 5 nM PKC, 23 units of pyruvate kinase, 33 units of lactate dehydrogenase, 0.15 mM peptide, 0.1 mM ATP, 1 mM DTT, 4 mM PEP, 8 mM MgCl2, 0.3 mM NADH, 60 mM CaCl2, 10 mg/mL PS, 50 ng/mL PMA, 7.5% DMSO and from about 10,000 nM to 0.169 nM compound inhibitor.	B	C[C@H]1CN(CCC2CCOCC2)[C@H](C)CN1C(=O)N1Cc2c(NC(=O)c3ccccn3)n[nH]c2C1(C)C		CHEMBL3662850	=	Ki	nM	17.6	CHEMBL3045	Homo sapiens	Ki	nM	17.6
295350	17676585	CHEMBL3705825	Inhibition Assay: Protein Kinase C beta 2 (PKC beta II) catalyzes the production of ADP from ATP that accompanies the phosphoryl transfer to the PKC Pseudosubstrate peptide (A->S, RFARKGSLRQKNV). This transfer is coupled to the oxidation of p-NADH through the activities of Pyruvate Kinase (PK) and Lactate Dehydrogenase (LDH). (3-NADH conversion to NAD+ is monitored by the decrease in absorbance at 340 nm (e=6.22 cm-1 mM-1) using a Molecular Devices SPECTRA max PLUS spectrophotometer.A typical assay was carried out on a 96-well, clear microtiter plate in a Molecular Devices spectrophotometer for 20 minutes at 30 C. in 0.1 mL of assay buffer containing 50 mM HEPES, pH 7.4, 5 nM PKC, 23 units of pyruvate kinase, 33 units of lactate dehydrogenase, 0.15 mM peptide, 0.1 mM ATP, 1 mM DTT, 4 mM PEP, 8 mM MgCl2, 0.3 mM NADH, 60 mM CaCl2, 10 mg/mL PS, 50 ng/mL PMA, 7.5% DMSO and from about 10,000 nM to 0.169 nM compound inhibitor.	B	C[C@H]1CN(C2CCOCC2)[C@H](C)CN1C(=O)N1Cc2c(NC(=O)c3ccccn3)n[nH]c2C1(C)C		CHEMBL3662851	=	Ki	nM	1.7	CHEMBL3045	Homo sapiens	Ki	nM	1.7
295351	17676586	CHEMBL3705825	Inhibition Assay: Protein Kinase C beta 2 (PKC beta II) catalyzes the production of ADP from ATP that accompanies the phosphoryl transfer to the PKC Pseudosubstrate peptide (A->S, RFARKGSLRQKNV). This transfer is coupled to the oxidation of p-NADH through the activities of Pyruvate Kinase (PK) and Lactate Dehydrogenase (LDH). (3-NADH conversion to NAD+ is monitored by the decrease in absorbance at 340 nm (e=6.22 cm-1 mM-1) using a Molecular Devices SPECTRA max PLUS spectrophotometer.A typical assay was carried out on a 96-well, clear microtiter plate in a Molecular Devices spectrophotometer for 20 minutes at 30 C. in 0.1 mL of assay buffer containing 50 mM HEPES, pH 7.4, 5 nM PKC, 23 units of pyruvate kinase, 33 units of lactate dehydrogenase, 0.15 mM peptide, 0.1 mM ATP, 1 mM DTT, 4 mM PEP, 8 mM MgCl2, 0.3 mM NADH, 60 mM CaCl2, 10 mg/mL PS, 50 ng/mL PMA, 7.5% DMSO and from about 10,000 nM to 0.169 nM compound inhibitor.	B	C[C@H]1CN(CC2CCOC2)[C@H](C)CN1C(=O)N1Cc2c(NC(=O)c3ccccn3)n[nH]c2C1(C)C		CHEMBL3662852	<	Ki	nM	10.0	CHEMBL3045	Homo sapiens	Ki	nM	10.0
295352	17676587	CHEMBL3705825	Inhibition Assay: Protein Kinase C beta 2 (PKC beta II) catalyzes the production of ADP from ATP that accompanies the phosphoryl transfer to the PKC Pseudosubstrate peptide (A->S, RFARKGSLRQKNV). This transfer is coupled to the oxidation of p-NADH through the activities of Pyruvate Kinase (PK) and Lactate Dehydrogenase (LDH). (3-NADH conversion to NAD+ is monitored by the decrease in absorbance at 340 nm (e=6.22 cm-1 mM-1) using a Molecular Devices SPECTRA max PLUS spectrophotometer.A typical assay was carried out on a 96-well, clear microtiter plate in a Molecular Devices spectrophotometer for 20 minutes at 30 C. in 0.1 mL of assay buffer containing 50 mM HEPES, pH 7.4, 5 nM PKC, 23 units of pyruvate kinase, 33 units of lactate dehydrogenase, 0.15 mM peptide, 0.1 mM ATP, 1 mM DTT, 4 mM PEP, 8 mM MgCl2, 0.3 mM NADH, 60 mM CaCl2, 10 mg/mL PS, 50 ng/mL PMA, 7.5% DMSO and from about 10,000 nM to 0.169 nM compound inhibitor.	B	C[C@H]1CN(Cc2cocn2)[C@H](C)CN1C(=O)N1Cc2c(NC(=O)c3ccccn3)n[nH]c2C1(C)C		CHEMBL3662853	=	Ki	nM	48.3	CHEMBL3045	Homo sapiens	Ki	nM	48.3
295353	17676588	CHEMBL3705825	Inhibition Assay: Protein Kinase C beta 2 (PKC beta II) catalyzes the production of ADP from ATP that accompanies the phosphoryl transfer to the PKC Pseudosubstrate peptide (A->S, RFARKGSLRQKNV). This transfer is coupled to the oxidation of p-NADH through the activities of Pyruvate Kinase (PK) and Lactate Dehydrogenase (LDH). (3-NADH conversion to NAD+ is monitored by the decrease in absorbance at 340 nm (e=6.22 cm-1 mM-1) using a Molecular Devices SPECTRA max PLUS spectrophotometer.A typical assay was carried out on a 96-well, clear microtiter plate in a Molecular Devices spectrophotometer for 20 minutes at 30 C. in 0.1 mL of assay buffer containing 50 mM HEPES, pH 7.4, 5 nM PKC, 23 units of pyruvate kinase, 33 units of lactate dehydrogenase, 0.15 mM peptide, 0.1 mM ATP, 1 mM DTT, 4 mM PEP, 8 mM MgCl2, 0.3 mM NADH, 60 mM CaCl2, 10 mg/mL PS, 50 ng/mL PMA, 7.5% DMSO and from about 10,000 nM to 0.169 nM compound inhibitor.	B	C[C@H]1CN(C2CCOCC2)[C@H](C)CN1C(=O)N1Cc2c(NC(=O)c3ccc(F)cn3)n[nH]c2C1(C)C		CHEMBL3662854	<	Ki	nM	10.0	CHEMBL3045	Homo sapiens	Ki	nM	10.0
295354	17676589	CHEMBL3705825	Inhibition Assay: Protein Kinase C beta 2 (PKC beta II) catalyzes the production of ADP from ATP that accompanies the phosphoryl transfer to the PKC Pseudosubstrate peptide (A->S, RFARKGSLRQKNV). This transfer is coupled to the oxidation of p-NADH through the activities of Pyruvate Kinase (PK) and Lactate Dehydrogenase (LDH). (3-NADH conversion to NAD+ is monitored by the decrease in absorbance at 340 nm (e=6.22 cm-1 mM-1) using a Molecular Devices SPECTRA max PLUS spectrophotometer.A typical assay was carried out on a 96-well, clear microtiter plate in a Molecular Devices spectrophotometer for 20 minutes at 30 C. in 0.1 mL of assay buffer containing 50 mM HEPES, pH 7.4, 5 nM PKC, 23 units of pyruvate kinase, 33 units of lactate dehydrogenase, 0.15 mM peptide, 0.1 mM ATP, 1 mM DTT, 4 mM PEP, 8 mM MgCl2, 0.3 mM NADH, 60 mM CaCl2, 10 mg/mL PS, 50 ng/mL PMA, 7.5% DMSO and from about 10,000 nM to 0.169 nM compound inhibitor.	B	C[C@H]1CN(C)[C@H](CCO)CN1C(=O)N1Cc2c(NC(=O)c3ccccn3)n[nH]c2C1(C)C		CHEMBL3662855	=	Ki	nM	42.0	CHEMBL3045	Homo sapiens	Ki	nM	42.0
295355	17676590	CHEMBL3705825	Inhibition Assay: Protein Kinase C beta 2 (PKC beta II) catalyzes the production of ADP from ATP that accompanies the phosphoryl transfer to the PKC Pseudosubstrate peptide (A->S, RFARKGSLRQKNV). This transfer is coupled to the oxidation of p-NADH through the activities of Pyruvate Kinase (PK) and Lactate Dehydrogenase (LDH). (3-NADH conversion to NAD+ is monitored by the decrease in absorbance at 340 nm (e=6.22 cm-1 mM-1) using a Molecular Devices SPECTRA max PLUS spectrophotometer.A typical assay was carried out on a 96-well, clear microtiter plate in a Molecular Devices spectrophotometer for 20 minutes at 30 C. in 0.1 mL of assay buffer containing 50 mM HEPES, pH 7.4, 5 nM PKC, 23 units of pyruvate kinase, 33 units of lactate dehydrogenase, 0.15 mM peptide, 0.1 mM ATP, 1 mM DTT, 4 mM PEP, 8 mM MgCl2, 0.3 mM NADH, 60 mM CaCl2, 10 mg/mL PS, 50 ng/mL PMA, 7.5% DMSO and from about 10,000 nM to 0.169 nM compound inhibitor.	B	C[C@H]1CN(C)[C@@H](CCO)CN1C(=O)N1Cc2c(NC(=O)c3ccccn3)n[nH]c2C1(C)C		CHEMBL3662856	=	Ki	nM	152.0	CHEMBL3045	Homo sapiens	Ki	nM	152.0
295356	17676591	CHEMBL3705825	Inhibition Assay: Protein Kinase C beta 2 (PKC beta II) catalyzes the production of ADP from ATP that accompanies the phosphoryl transfer to the PKC Pseudosubstrate peptide (A->S, RFARKGSLRQKNV). This transfer is coupled to the oxidation of p-NADH through the activities of Pyruvate Kinase (PK) and Lactate Dehydrogenase (LDH). (3-NADH conversion to NAD+ is monitored by the decrease in absorbance at 340 nm (e=6.22 cm-1 mM-1) using a Molecular Devices SPECTRA max PLUS spectrophotometer.A typical assay was carried out on a 96-well, clear microtiter plate in a Molecular Devices spectrophotometer for 20 minutes at 30 C. in 0.1 mL of assay buffer containing 50 mM HEPES, pH 7.4, 5 nM PKC, 23 units of pyruvate kinase, 33 units of lactate dehydrogenase, 0.15 mM peptide, 0.1 mM ATP, 1 mM DTT, 4 mM PEP, 8 mM MgCl2, 0.3 mM NADH, 60 mM CaCl2, 10 mg/mL PS, 50 ng/mL PMA, 7.5% DMSO and from about 10,000 nM to 0.169 nM compound inhibitor.	B	C[C@H]1CN(CC2CCOCC2)[C@H](C)CN1C(=O)N1Cc2c(NC(=O)c3ccccn3)n[nH]c2C12CC2		CHEMBL3662857	=	Ki	nM	76.2	CHEMBL3045	Homo sapiens	Ki	nM	76.2
295357	17676592	CHEMBL3705825	Inhibition Assay: Protein Kinase C beta 2 (PKC beta II) catalyzes the production of ADP from ATP that accompanies the phosphoryl transfer to the PKC Pseudosubstrate peptide (A->S, RFARKGSLRQKNV). This transfer is coupled to the oxidation of p-NADH through the activities of Pyruvate Kinase (PK) and Lactate Dehydrogenase (LDH). (3-NADH conversion to NAD+ is monitored by the decrease in absorbance at 340 nm (e=6.22 cm-1 mM-1) using a Molecular Devices SPECTRA max PLUS spectrophotometer.A typical assay was carried out on a 96-well, clear microtiter plate in a Molecular Devices spectrophotometer for 20 minutes at 30 C. in 0.1 mL of assay buffer containing 50 mM HEPES, pH 7.4, 5 nM PKC, 23 units of pyruvate kinase, 33 units of lactate dehydrogenase, 0.15 mM peptide, 0.1 mM ATP, 1 mM DTT, 4 mM PEP, 8 mM MgCl2, 0.3 mM NADH, 60 mM CaCl2, 10 mg/mL PS, 50 ng/mL PMA, 7.5% DMSO and from about 10,000 nM to 0.169 nM compound inhibitor.	B	C[C@H]1CN(CC2(C)COC2)[C@H](C)CN1C(=O)N1Cc2c(NC(=O)c3ccccn3)n[nH]c2C1(C)C		CHEMBL3662858	=	Ki	nM	37.0	CHEMBL3045	Homo sapiens	Ki	nM	37.0
295358	17676593	CHEMBL3705825	Inhibition Assay: Protein Kinase C beta 2 (PKC beta II) catalyzes the production of ADP from ATP that accompanies the phosphoryl transfer to the PKC Pseudosubstrate peptide (A->S, RFARKGSLRQKNV). This transfer is coupled to the oxidation of p-NADH through the activities of Pyruvate Kinase (PK) and Lactate Dehydrogenase (LDH). (3-NADH conversion to NAD+ is monitored by the decrease in absorbance at 340 nm (e=6.22 cm-1 mM-1) using a Molecular Devices SPECTRA max PLUS spectrophotometer.A typical assay was carried out on a 96-well, clear microtiter plate in a Molecular Devices spectrophotometer for 20 minutes at 30 C. in 0.1 mL of assay buffer containing 50 mM HEPES, pH 7.4, 5 nM PKC, 23 units of pyruvate kinase, 33 units of lactate dehydrogenase, 0.15 mM peptide, 0.1 mM ATP, 1 mM DTT, 4 mM PEP, 8 mM MgCl2, 0.3 mM NADH, 60 mM CaCl2, 10 mg/mL PS, 50 ng/mL PMA, 7.5% DMSO and from about 10,000 nM to 0.169 nM compound inhibitor.	B	C[C@H]1CN([C@H](C)CCO)[C@H](C)CN1C(=O)N1Cc2c(NC(=O)c3ccccn3)n[nH]c2C1(C)C		CHEMBL3662859	=	Ki	nM	25.1	CHEMBL3045	Homo sapiens	Ki	nM	25.1
295359	17676594	CHEMBL3705825	Inhibition Assay: Protein Kinase C beta 2 (PKC beta II) catalyzes the production of ADP from ATP that accompanies the phosphoryl transfer to the PKC Pseudosubstrate peptide (A->S, RFARKGSLRQKNV). This transfer is coupled to the oxidation of p-NADH through the activities of Pyruvate Kinase (PK) and Lactate Dehydrogenase (LDH). (3-NADH conversion to NAD+ is monitored by the decrease in absorbance at 340 nm (e=6.22 cm-1 mM-1) using a Molecular Devices SPECTRA max PLUS spectrophotometer.A typical assay was carried out on a 96-well, clear microtiter plate in a Molecular Devices spectrophotometer for 20 minutes at 30 C. in 0.1 mL of assay buffer containing 50 mM HEPES, pH 7.4, 5 nM PKC, 23 units of pyruvate kinase, 33 units of lactate dehydrogenase, 0.15 mM peptide, 0.1 mM ATP, 1 mM DTT, 4 mM PEP, 8 mM MgCl2, 0.3 mM NADH, 60 mM CaCl2, 10 mg/mL PS, 50 ng/mL PMA, 7.5% DMSO and from about 10,000 nM to 0.169 nM compound inhibitor.	B	C[C@H]1CN([C@@H](C)CCO)[C@H](C)CN1C(=O)N1Cc2c(NC(=O)c3ccccn3)n[nH]c2C1(C)C		CHEMBL3662860	=	Ki	nM	43.3	CHEMBL3045	Homo sapiens	Ki	nM	43.3
295360	17676595	CHEMBL3705825	Inhibition Assay: Protein Kinase C beta 2 (PKC beta II) catalyzes the production of ADP from ATP that accompanies the phosphoryl transfer to the PKC Pseudosubstrate peptide (A->S, RFARKGSLRQKNV). This transfer is coupled to the oxidation of p-NADH through the activities of Pyruvate Kinase (PK) and Lactate Dehydrogenase (LDH). (3-NADH conversion to NAD+ is monitored by the decrease in absorbance at 340 nm (e=6.22 cm-1 mM-1) using a Molecular Devices SPECTRA max PLUS spectrophotometer.A typical assay was carried out on a 96-well, clear microtiter plate in a Molecular Devices spectrophotometer for 20 minutes at 30 C. in 0.1 mL of assay buffer containing 50 mM HEPES, pH 7.4, 5 nM PKC, 23 units of pyruvate kinase, 33 units of lactate dehydrogenase, 0.15 mM peptide, 0.1 mM ATP, 1 mM DTT, 4 mM PEP, 8 mM MgCl2, 0.3 mM NADH, 60 mM CaCl2, 10 mg/mL PS, 50 ng/mL PMA, 7.5% DMSO and from about 10,000 nM to 0.169 nM compound inhibitor.	B	C[C@H]1CN(CCOCCO)[C@H](C)CN1C(=O)N1Cc2c(NC(=O)c3ccccn3)n[nH]c2C1(C)C		CHEMBL3662861	=	Ki	nM	108.0	CHEMBL3045	Homo sapiens	Ki	nM	108.0
295361	17676596	CHEMBL3705825	Inhibition Assay: Protein Kinase C beta 2 (PKC beta II) catalyzes the production of ADP from ATP that accompanies the phosphoryl transfer to the PKC Pseudosubstrate peptide (A->S, RFARKGSLRQKNV). This transfer is coupled to the oxidation of p-NADH through the activities of Pyruvate Kinase (PK) and Lactate Dehydrogenase (LDH). (3-NADH conversion to NAD+ is monitored by the decrease in absorbance at 340 nm (e=6.22 cm-1 mM-1) using a Molecular Devices SPECTRA max PLUS spectrophotometer.A typical assay was carried out on a 96-well, clear microtiter plate in a Molecular Devices spectrophotometer for 20 minutes at 30 C. in 0.1 mL of assay buffer containing 50 mM HEPES, pH 7.4, 5 nM PKC, 23 units of pyruvate kinase, 33 units of lactate dehydrogenase, 0.15 mM peptide, 0.1 mM ATP, 1 mM DTT, 4 mM PEP, 8 mM MgCl2, 0.3 mM NADH, 60 mM CaCl2, 10 mg/mL PS, 50 ng/mL PMA, 7.5% DMSO and from about 10,000 nM to 0.169 nM compound inhibitor.	B	C.C[C@H]1CN(CCO)CCN1C(=O)N1Cc2c(NC(=O)c3ccccn3)n[nH]c2C1(C)C		CHEMBL3984847	=	Ki	nM	38.8	CHEMBL3045	Homo sapiens	Ki	nM	38.8
295362	17676597	CHEMBL3705825	Inhibition Assay: Protein Kinase C beta 2 (PKC beta II) catalyzes the production of ADP from ATP that accompanies the phosphoryl transfer to the PKC Pseudosubstrate peptide (A->S, RFARKGSLRQKNV). This transfer is coupled to the oxidation of p-NADH through the activities of Pyruvate Kinase (PK) and Lactate Dehydrogenase (LDH). (3-NADH conversion to NAD+ is monitored by the decrease in absorbance at 340 nm (e=6.22 cm-1 mM-1) using a Molecular Devices SPECTRA max PLUS spectrophotometer.A typical assay was carried out on a 96-well, clear microtiter plate in a Molecular Devices spectrophotometer for 20 minutes at 30 C. in 0.1 mL of assay buffer containing 50 mM HEPES, pH 7.4, 5 nM PKC, 23 units of pyruvate kinase, 33 units of lactate dehydrogenase, 0.15 mM peptide, 0.1 mM ATP, 1 mM DTT, 4 mM PEP, 8 mM MgCl2, 0.3 mM NADH, 60 mM CaCl2, 10 mg/mL PS, 50 ng/mL PMA, 7.5% DMSO and from about 10,000 nM to 0.169 nM compound inhibitor.	B	C.C[C@H](CO)CN1CCN(C(=O)N2Cc3c(NC(=O)c4ccccn4)n[nH]c3C2(C)C)[C@@H](C)C1		CHEMBL3945458	=	Ki	nM	50.4	CHEMBL3045	Homo sapiens	Ki	nM	50.4
295363	17676598	CHEMBL3705825	Inhibition Assay: Protein Kinase C beta 2 (PKC beta II) catalyzes the production of ADP from ATP that accompanies the phosphoryl transfer to the PKC Pseudosubstrate peptide (A->S, RFARKGSLRQKNV). This transfer is coupled to the oxidation of p-NADH through the activities of Pyruvate Kinase (PK) and Lactate Dehydrogenase (LDH). (3-NADH conversion to NAD+ is monitored by the decrease in absorbance at 340 nm (e=6.22 cm-1 mM-1) using a Molecular Devices SPECTRA max PLUS spectrophotometer.A typical assay was carried out on a 96-well, clear microtiter plate in a Molecular Devices spectrophotometer for 20 minutes at 30 C. in 0.1 mL of assay buffer containing 50 mM HEPES, pH 7.4, 5 nM PKC, 23 units of pyruvate kinase, 33 units of lactate dehydrogenase, 0.15 mM peptide, 0.1 mM ATP, 1 mM DTT, 4 mM PEP, 8 mM MgCl2, 0.3 mM NADH, 60 mM CaCl2, 10 mg/mL PS, 50 ng/mL PMA, 7.5% DMSO and from about 10,000 nM to 0.169 nM compound inhibitor.	B	C.C[C@H]1CN(C[C@@H](C)CO)CCN1C(=O)N1Cc2c(NC(=O)c3ccccn3)n[nH]c2C1(C)C		CHEMBL4114009	=	Ki	nM	49.6	CHEMBL3045	Homo sapiens	Ki	nM	49.6
295364	17676599	CHEMBL3705825	Inhibition Assay: Protein Kinase C beta 2 (PKC beta II) catalyzes the production of ADP from ATP that accompanies the phosphoryl transfer to the PKC Pseudosubstrate peptide (A->S, RFARKGSLRQKNV). This transfer is coupled to the oxidation of p-NADH through the activities of Pyruvate Kinase (PK) and Lactate Dehydrogenase (LDH). (3-NADH conversion to NAD+ is monitored by the decrease in absorbance at 340 nm (e=6.22 cm-1 mM-1) using a Molecular Devices SPECTRA max PLUS spectrophotometer.A typical assay was carried out on a 96-well, clear microtiter plate in a Molecular Devices spectrophotometer for 20 minutes at 30 C. in 0.1 mL of assay buffer containing 50 mM HEPES, pH 7.4, 5 nM PKC, 23 units of pyruvate kinase, 33 units of lactate dehydrogenase, 0.15 mM peptide, 0.1 mM ATP, 1 mM DTT, 4 mM PEP, 8 mM MgCl2, 0.3 mM NADH, 60 mM CaCl2, 10 mg/mL PS, 50 ng/mL PMA, 7.5% DMSO and from about 10,000 nM to 0.169 nM compound inhibitor.	B	Cc1nc(C)c(C(=O)Nc2n[nH]c3c2CN(C(=O)N2C[C@@H](C)N(CCCO)C[C@@H]2C)C3(C)C)o1		CHEMBL3662865	=	Ki	nM	24.9	CHEMBL3045	Homo sapiens	Ki	nM	24.9
295365	17676600	CHEMBL3705825	Inhibition Assay: Protein Kinase C beta 2 (PKC beta II) catalyzes the production of ADP from ATP that accompanies the phosphoryl transfer to the PKC Pseudosubstrate peptide (A->S, RFARKGSLRQKNV). This transfer is coupled to the oxidation of p-NADH through the activities of Pyruvate Kinase (PK) and Lactate Dehydrogenase (LDH). (3-NADH conversion to NAD+ is monitored by the decrease in absorbance at 340 nm (e=6.22 cm-1 mM-1) using a Molecular Devices SPECTRA max PLUS spectrophotometer.A typical assay was carried out on a 96-well, clear microtiter plate in a Molecular Devices spectrophotometer for 20 minutes at 30 C. in 0.1 mL of assay buffer containing 50 mM HEPES, pH 7.4, 5 nM PKC, 23 units of pyruvate kinase, 33 units of lactate dehydrogenase, 0.15 mM peptide, 0.1 mM ATP, 1 mM DTT, 4 mM PEP, 8 mM MgCl2, 0.3 mM NADH, 60 mM CaCl2, 10 mg/mL PS, 50 ng/mL PMA, 7.5% DMSO and from about 10,000 nM to 0.169 nM compound inhibitor.	B	C[C@H]1CN(CCO)[C@H](C)CN1C(=O)N1Cc2c(NC(=O)c3ccc(F)cn3)n[nH]c2C1(C)C		CHEMBL3662866	=	Ki	nM	38.8	CHEMBL3045	Homo sapiens	Ki	nM	38.8
295366	17676601	CHEMBL3705825	Inhibition Assay: Protein Kinase C beta 2 (PKC beta II) catalyzes the production of ADP from ATP that accompanies the phosphoryl transfer to the PKC Pseudosubstrate peptide (A->S, RFARKGSLRQKNV). This transfer is coupled to the oxidation of p-NADH through the activities of Pyruvate Kinase (PK) and Lactate Dehydrogenase (LDH). (3-NADH conversion to NAD+ is monitored by the decrease in absorbance at 340 nm (e=6.22 cm-1 mM-1) using a Molecular Devices SPECTRA max PLUS spectrophotometer.A typical assay was carried out on a 96-well, clear microtiter plate in a Molecular Devices spectrophotometer for 20 minutes at 30 C. in 0.1 mL of assay buffer containing 50 mM HEPES, pH 7.4, 5 nM PKC, 23 units of pyruvate kinase, 33 units of lactate dehydrogenase, 0.15 mM peptide, 0.1 mM ATP, 1 mM DTT, 4 mM PEP, 8 mM MgCl2, 0.3 mM NADH, 60 mM CaCl2, 10 mg/mL PS, 50 ng/mL PMA, 7.5% DMSO and from about 10,000 nM to 0.169 nM compound inhibitor.	B	C[C@H]1CN(CCCO)[C@H](C)CN1C(=O)N1Cc2c(NC(=O)c3ccc(F)cn3)n[nH]c2C1(C)C		CHEMBL3662867	=	Ki	nM	21.7	CHEMBL3045	Homo sapiens	Ki	nM	21.7
295367	17676602	CHEMBL3705825	Inhibition Assay: Protein Kinase C beta 2 (PKC beta II) catalyzes the production of ADP from ATP that accompanies the phosphoryl transfer to the PKC Pseudosubstrate peptide (A->S, RFARKGSLRQKNV). This transfer is coupled to the oxidation of p-NADH through the activities of Pyruvate Kinase (PK) and Lactate Dehydrogenase (LDH). (3-NADH conversion to NAD+ is monitored by the decrease in absorbance at 340 nm (e=6.22 cm-1 mM-1) using a Molecular Devices SPECTRA max PLUS spectrophotometer.A typical assay was carried out on a 96-well, clear microtiter plate in a Molecular Devices spectrophotometer for 20 minutes at 30 C. in 0.1 mL of assay buffer containing 50 mM HEPES, pH 7.4, 5 nM PKC, 23 units of pyruvate kinase, 33 units of lactate dehydrogenase, 0.15 mM peptide, 0.1 mM ATP, 1 mM DTT, 4 mM PEP, 8 mM MgCl2, 0.3 mM NADH, 60 mM CaCl2, 10 mg/mL PS, 50 ng/mL PMA, 7.5% DMSO and from about 10,000 nM to 0.169 nM compound inhibitor.	B	COCCCN1C[C@H](C)N(C(=O)N2Cc3c(NC(=O)c4ccc(F)cn4)n[nH]c3C2(C)C)C[C@H]1C		CHEMBL3662868	=	Ki	nM	24.5	CHEMBL3045	Homo sapiens	Ki	nM	24.5
295368	17676603	CHEMBL3705825	Inhibition Assay: Protein Kinase C beta 2 (PKC beta II) catalyzes the production of ADP from ATP that accompanies the phosphoryl transfer to the PKC Pseudosubstrate peptide (A->S, RFARKGSLRQKNV). This transfer is coupled to the oxidation of p-NADH through the activities of Pyruvate Kinase (PK) and Lactate Dehydrogenase (LDH). (3-NADH conversion to NAD+ is monitored by the decrease in absorbance at 340 nm (e=6.22 cm-1 mM-1) using a Molecular Devices SPECTRA max PLUS spectrophotometer.A typical assay was carried out on a 96-well, clear microtiter plate in a Molecular Devices spectrophotometer for 20 minutes at 30 C. in 0.1 mL of assay buffer containing 50 mM HEPES, pH 7.4, 5 nM PKC, 23 units of pyruvate kinase, 33 units of lactate dehydrogenase, 0.15 mM peptide, 0.1 mM ATP, 1 mM DTT, 4 mM PEP, 8 mM MgCl2, 0.3 mM NADH, 60 mM CaCl2, 10 mg/mL PS, 50 ng/mL PMA, 7.5% DMSO and from about 10,000 nM to 0.169 nM compound inhibitor.	B	COCCN1C[C@H](C)N(C(=O)N2Cc3c(NC(=O)c4ccc(F)cn4)n[nH]c3C2(C)C)C[C@H]1C		CHEMBL3662869	=	Ki	nM	56.9	CHEMBL3045	Homo sapiens	Ki	nM	56.9
295369	17676604	CHEMBL3705825	Inhibition Assay: Protein Kinase C beta 2 (PKC beta II) catalyzes the production of ADP from ATP that accompanies the phosphoryl transfer to the PKC Pseudosubstrate peptide (A->S, RFARKGSLRQKNV). This transfer is coupled to the oxidation of p-NADH through the activities of Pyruvate Kinase (PK) and Lactate Dehydrogenase (LDH). (3-NADH conversion to NAD+ is monitored by the decrease in absorbance at 340 nm (e=6.22 cm-1 mM-1) using a Molecular Devices SPECTRA max PLUS spectrophotometer.A typical assay was carried out on a 96-well, clear microtiter plate in a Molecular Devices spectrophotometer for 20 minutes at 30 C. in 0.1 mL of assay buffer containing 50 mM HEPES, pH 7.4, 5 nM PKC, 23 units of pyruvate kinase, 33 units of lactate dehydrogenase, 0.15 mM peptide, 0.1 mM ATP, 1 mM DTT, 4 mM PEP, 8 mM MgCl2, 0.3 mM NADH, 60 mM CaCl2, 10 mg/mL PS, 50 ng/mL PMA, 7.5% DMSO and from about 10,000 nM to 0.169 nM compound inhibitor.	B	CC1(C)c2n[nH]c(NC(=O)c3ccccn3)c2CN1C(=O)C1(F)CCN(C2CCC2)CC1		CHEMBL3662870	=	Ki	nM	75.3	CHEMBL3045	Homo sapiens	Ki	nM	75.3
295370	17676605	CHEMBL3705825	Inhibition Assay: Protein Kinase C beta 2 (PKC beta II) catalyzes the production of ADP from ATP that accompanies the phosphoryl transfer to the PKC Pseudosubstrate peptide (A->S, RFARKGSLRQKNV). This transfer is coupled to the oxidation of p-NADH through the activities of Pyruvate Kinase (PK) and Lactate Dehydrogenase (LDH). (3-NADH conversion to NAD+ is monitored by the decrease in absorbance at 340 nm (e=6.22 cm-1 mM-1) using a Molecular Devices SPECTRA max PLUS spectrophotometer.A typical assay was carried out on a 96-well, clear microtiter plate in a Molecular Devices spectrophotometer for 20 minutes at 30 C. in 0.1 mL of assay buffer containing 50 mM HEPES, pH 7.4, 5 nM PKC, 23 units of pyruvate kinase, 33 units of lactate dehydrogenase, 0.15 mM peptide, 0.1 mM ATP, 1 mM DTT, 4 mM PEP, 8 mM MgCl2, 0.3 mM NADH, 60 mM CaCl2, 10 mg/mL PS, 50 ng/mL PMA, 7.5% DMSO and from about 10,000 nM to 0.169 nM compound inhibitor.	B	CC1(C)c2[nH]nc(NC(=O)c3ccccn3)c2CN1C(=O)C1(F)CCN(C2CCOCC2)CC1		CHEMBL3662871	=	Ki	nM	89.8	CHEMBL3045	Homo sapiens	Ki	nM	89.8
295371	17676606	CHEMBL3705825	Inhibition Assay: Protein Kinase C beta 2 (PKC beta II) catalyzes the production of ADP from ATP that accompanies the phosphoryl transfer to the PKC Pseudosubstrate peptide (A->S, RFARKGSLRQKNV). This transfer is coupled to the oxidation of p-NADH through the activities of Pyruvate Kinase (PK) and Lactate Dehydrogenase (LDH). (3-NADH conversion to NAD+ is monitored by the decrease in absorbance at 340 nm (e=6.22 cm-1 mM-1) using a Molecular Devices SPECTRA max PLUS spectrophotometer.A typical assay was carried out on a 96-well, clear microtiter plate in a Molecular Devices spectrophotometer for 20 minutes at 30 C. in 0.1 mL of assay buffer containing 50 mM HEPES, pH 7.4, 5 nM PKC, 23 units of pyruvate kinase, 33 units of lactate dehydrogenase, 0.15 mM peptide, 0.1 mM ATP, 1 mM DTT, 4 mM PEP, 8 mM MgCl2, 0.3 mM NADH, 60 mM CaCl2, 10 mg/mL PS, 50 ng/mL PMA, 7.5% DMSO and from about 10,000 nM to 0.169 nM compound inhibitor.	B	CN1CCC(F)(C(=O)N2Cc3c(NC(=O)c4ccc(Cl)c(Cl)c4)n[nH]c3C2(C)C)CC1		CHEMBL3662872	=	Ki	nM	67.4	CHEMBL3045	Homo sapiens	Ki	nM	67.4
295372	17676607	CHEMBL3705825	Inhibition Assay: Protein Kinase C beta 2 (PKC beta II) catalyzes the production of ADP from ATP that accompanies the phosphoryl transfer to the PKC Pseudosubstrate peptide (A->S, RFARKGSLRQKNV). This transfer is coupled to the oxidation of p-NADH through the activities of Pyruvate Kinase (PK) and Lactate Dehydrogenase (LDH). (3-NADH conversion to NAD+ is monitored by the decrease in absorbance at 340 nm (e=6.22 cm-1 mM-1) using a Molecular Devices SPECTRA max PLUS spectrophotometer.A typical assay was carried out on a 96-well, clear microtiter plate in a Molecular Devices spectrophotometer for 20 minutes at 30 C. in 0.1 mL of assay buffer containing 50 mM HEPES, pH 7.4, 5 nM PKC, 23 units of pyruvate kinase, 33 units of lactate dehydrogenase, 0.15 mM peptide, 0.1 mM ATP, 1 mM DTT, 4 mM PEP, 8 mM MgCl2, 0.3 mM NADH, 60 mM CaCl2, 10 mg/mL PS, 50 ng/mL PMA, 7.5% DMSO and from about 10,000 nM to 0.169 nM compound inhibitor.	B	CCN1C[C@H](C)N(C(=O)N2Cc3c(NC(=O)c4cnccn4)n[nH]c3C2(C)C)C[C@H]1C		CHEMBL3662873	=	Ki	nM	28.6	CHEMBL3045	Homo sapiens	Ki	nM	28.6
295373	17676608	CHEMBL3705825	Inhibition Assay: Protein Kinase C beta 2 (PKC beta II) catalyzes the production of ADP from ATP that accompanies the phosphoryl transfer to the PKC Pseudosubstrate peptide (A->S, RFARKGSLRQKNV). This transfer is coupled to the oxidation of p-NADH through the activities of Pyruvate Kinase (PK) and Lactate Dehydrogenase (LDH). (3-NADH conversion to NAD+ is monitored by the decrease in absorbance at 340 nm (e=6.22 cm-1 mM-1) using a Molecular Devices SPECTRA max PLUS spectrophotometer.A typical assay was carried out on a 96-well, clear microtiter plate in a Molecular Devices spectrophotometer for 20 minutes at 30 C. in 0.1 mL of assay buffer containing 50 mM HEPES, pH 7.4, 5 nM PKC, 23 units of pyruvate kinase, 33 units of lactate dehydrogenase, 0.15 mM peptide, 0.1 mM ATP, 1 mM DTT, 4 mM PEP, 8 mM MgCl2, 0.3 mM NADH, 60 mM CaCl2, 10 mg/mL PS, 50 ng/mL PMA, 7.5% DMSO and from about 10,000 nM to 0.169 nM compound inhibitor.	B	Cc1nc(C)c(C(=O)Nc2n[nH]c3c2CN(C(=O)N2C[C@@H](C)N(C)C[C@@H]2C)C3(C)C)o1		CHEMBL3662874	=	Ki	nM	50.3	CHEMBL3045	Homo sapiens	Ki	nM	50.3
295374	17676609	CHEMBL3705825	Inhibition Assay: Protein Kinase C beta 2 (PKC beta II) catalyzes the production of ADP from ATP that accompanies the phosphoryl transfer to the PKC Pseudosubstrate peptide (A->S, RFARKGSLRQKNV). This transfer is coupled to the oxidation of p-NADH through the activities of Pyruvate Kinase (PK) and Lactate Dehydrogenase (LDH). (3-NADH conversion to NAD+ is monitored by the decrease in absorbance at 340 nm (e=6.22 cm-1 mM-1) using a Molecular Devices SPECTRA max PLUS spectrophotometer.A typical assay was carried out on a 96-well, clear microtiter plate in a Molecular Devices spectrophotometer for 20 minutes at 30 C. in 0.1 mL of assay buffer containing 50 mM HEPES, pH 7.4, 5 nM PKC, 23 units of pyruvate kinase, 33 units of lactate dehydrogenase, 0.15 mM peptide, 0.1 mM ATP, 1 mM DTT, 4 mM PEP, 8 mM MgCl2, 0.3 mM NADH, 60 mM CaCl2, 10 mg/mL PS, 50 ng/mL PMA, 7.5% DMSO and from about 10,000 nM to 0.169 nM compound inhibitor.	B	Cc1nc(C(=O)Nc2n[nH]c3c2CN(C(=O)N2C[C@@H](C)N(C)C[C@@H]2C)C3(C)C)cs1		CHEMBL3662875	=	Ki	nM	35.1	CHEMBL3045	Homo sapiens	Ki	nM	35.1
295375	17676610	CHEMBL3705825	Inhibition Assay: Protein Kinase C beta 2 (PKC beta II) catalyzes the production of ADP from ATP that accompanies the phosphoryl transfer to the PKC Pseudosubstrate peptide (A->S, RFARKGSLRQKNV). This transfer is coupled to the oxidation of p-NADH through the activities of Pyruvate Kinase (PK) and Lactate Dehydrogenase (LDH). (3-NADH conversion to NAD+ is monitored by the decrease in absorbance at 340 nm (e=6.22 cm-1 mM-1) using a Molecular Devices SPECTRA max PLUS spectrophotometer.A typical assay was carried out on a 96-well, clear microtiter plate in a Molecular Devices spectrophotometer for 20 minutes at 30 C. in 0.1 mL of assay buffer containing 50 mM HEPES, pH 7.4, 5 nM PKC, 23 units of pyruvate kinase, 33 units of lactate dehydrogenase, 0.15 mM peptide, 0.1 mM ATP, 1 mM DTT, 4 mM PEP, 8 mM MgCl2, 0.3 mM NADH, 60 mM CaCl2, 10 mg/mL PS, 50 ng/mL PMA, 7.5% DMSO and from about 10,000 nM to 0.169 nM compound inhibitor.	B	Cc1ocnc1C(=O)Nc1n[nH]c2c1CN(C(=O)N1C[C@@H](C)N(C)C[C@@H]1C)C2(C)C		CHEMBL3639617	=	Ki	nM	45.1	CHEMBL3045	Homo sapiens	Ki	nM	45.1
295376	17676611	CHEMBL3705825	Inhibition Assay: Protein Kinase C beta 2 (PKC beta II) catalyzes the production of ADP from ATP that accompanies the phosphoryl transfer to the PKC Pseudosubstrate peptide (A->S, RFARKGSLRQKNV). This transfer is coupled to the oxidation of p-NADH through the activities of Pyruvate Kinase (PK) and Lactate Dehydrogenase (LDH). (3-NADH conversion to NAD+ is monitored by the decrease in absorbance at 340 nm (e=6.22 cm-1 mM-1) using a Molecular Devices SPECTRA max PLUS spectrophotometer.A typical assay was carried out on a 96-well, clear microtiter plate in a Molecular Devices spectrophotometer for 20 minutes at 30 C. in 0.1 mL of assay buffer containing 50 mM HEPES, pH 7.4, 5 nM PKC, 23 units of pyruvate kinase, 33 units of lactate dehydrogenase, 0.15 mM peptide, 0.1 mM ATP, 1 mM DTT, 4 mM PEP, 8 mM MgCl2, 0.3 mM NADH, 60 mM CaCl2, 10 mg/mL PS, 50 ng/mL PMA, 7.5% DMSO and from about 10,000 nM to 0.169 nM compound inhibitor.	B	Cc1ncoc1C(=O)Nc1n[nH]c2c1CN(C(=O)N1C[C@@H](C)N(C)C[C@@H]1C)C2(C)C		CHEMBL3662876	=	Ki	nM	46.5	CHEMBL3045	Homo sapiens	Ki	nM	46.5
295377	17676612	CHEMBL3705825	Inhibition Assay: Protein Kinase C beta 2 (PKC beta II) catalyzes the production of ADP from ATP that accompanies the phosphoryl transfer to the PKC Pseudosubstrate peptide (A->S, RFARKGSLRQKNV). This transfer is coupled to the oxidation of p-NADH through the activities of Pyruvate Kinase (PK) and Lactate Dehydrogenase (LDH). (3-NADH conversion to NAD+ is monitored by the decrease in absorbance at 340 nm (e=6.22 cm-1 mM-1) using a Molecular Devices SPECTRA max PLUS spectrophotometer.A typical assay was carried out on a 96-well, clear microtiter plate in a Molecular Devices spectrophotometer for 20 minutes at 30 C. in 0.1 mL of assay buffer containing 50 mM HEPES, pH 7.4, 5 nM PKC, 23 units of pyruvate kinase, 33 units of lactate dehydrogenase, 0.15 mM peptide, 0.1 mM ATP, 1 mM DTT, 4 mM PEP, 8 mM MgCl2, 0.3 mM NADH, 60 mM CaCl2, 10 mg/mL PS, 50 ng/mL PMA, 7.5% DMSO and from about 10,000 nM to 0.169 nM compound inhibitor.	B	CCc1nc(C)c(C(=O)Nc2n[nH]c3c2CN(C(=O)N2C[C@@H](C)N(C)C[C@@H]2C)C3(C)C)o1		CHEMBL3662877	=	Ki	nM	25.7	CHEMBL3045	Homo sapiens	Ki	nM	25.7
295378	17676613	CHEMBL3705825	Inhibition Assay: Protein Kinase C beta 2 (PKC beta II) catalyzes the production of ADP from ATP that accompanies the phosphoryl transfer to the PKC Pseudosubstrate peptide (A->S, RFARKGSLRQKNV). This transfer is coupled to the oxidation of p-NADH through the activities of Pyruvate Kinase (PK) and Lactate Dehydrogenase (LDH). (3-NADH conversion to NAD+ is monitored by the decrease in absorbance at 340 nm (e=6.22 cm-1 mM-1) using a Molecular Devices SPECTRA max PLUS spectrophotometer.A typical assay was carried out on a 96-well, clear microtiter plate in a Molecular Devices spectrophotometer for 20 minutes at 30 C. in 0.1 mL of assay buffer containing 50 mM HEPES, pH 7.4, 5 nM PKC, 23 units of pyruvate kinase, 33 units of lactate dehydrogenase, 0.15 mM peptide, 0.1 mM ATP, 1 mM DTT, 4 mM PEP, 8 mM MgCl2, 0.3 mM NADH, 60 mM CaCl2, 10 mg/mL PS, 50 ng/mL PMA, 7.5% DMSO and from about 10,000 nM to 0.169 nM compound inhibitor.	B	CCc1ocnc1C(=O)Nc1n[nH]c2c1CN(C(=O)N1C[C@@H](C)N(C)C[C@@H]1C)C2(C)C		CHEMBL3662878	=	Ki	nM	66.4	CHEMBL3045	Homo sapiens	Ki	nM	66.4
295379	17676614	CHEMBL3705825	Inhibition Assay: Protein Kinase C beta 2 (PKC beta II) catalyzes the production of ADP from ATP that accompanies the phosphoryl transfer to the PKC Pseudosubstrate peptide (A->S, RFARKGSLRQKNV). This transfer is coupled to the oxidation of p-NADH through the activities of Pyruvate Kinase (PK) and Lactate Dehydrogenase (LDH). (3-NADH conversion to NAD+ is monitored by the decrease in absorbance at 340 nm (e=6.22 cm-1 mM-1) using a Molecular Devices SPECTRA max PLUS spectrophotometer.A typical assay was carried out on a 96-well, clear microtiter plate in a Molecular Devices spectrophotometer for 20 minutes at 30 C. in 0.1 mL of assay buffer containing 50 mM HEPES, pH 7.4, 5 nM PKC, 23 units of pyruvate kinase, 33 units of lactate dehydrogenase, 0.15 mM peptide, 0.1 mM ATP, 1 mM DTT, 4 mM PEP, 8 mM MgCl2, 0.3 mM NADH, 60 mM CaCl2, 10 mg/mL PS, 50 ng/mL PMA, 7.5% DMSO and from about 10,000 nM to 0.169 nM compound inhibitor.	B	C[C@H]1CN(C)[C@H](C)CN1C(=O)N1Cc2c(NC(=O)c3coc(C4CC4)n3)n[nH]c2C1(C)C		CHEMBL3662879	=	Ki	nM	25.0	CHEMBL3045	Homo sapiens	Ki	nM	25.0
295380	17676615	CHEMBL3705825	Inhibition Assay: Protein Kinase C beta 2 (PKC beta II) catalyzes the production of ADP from ATP that accompanies the phosphoryl transfer to the PKC Pseudosubstrate peptide (A->S, RFARKGSLRQKNV). This transfer is coupled to the oxidation of p-NADH through the activities of Pyruvate Kinase (PK) and Lactate Dehydrogenase (LDH). (3-NADH conversion to NAD+ is monitored by the decrease in absorbance at 340 nm (e=6.22 cm-1 mM-1) using a Molecular Devices SPECTRA max PLUS spectrophotometer.A typical assay was carried out on a 96-well, clear microtiter plate in a Molecular Devices spectrophotometer for 20 minutes at 30 C. in 0.1 mL of assay buffer containing 50 mM HEPES, pH 7.4, 5 nM PKC, 23 units of pyruvate kinase, 33 units of lactate dehydrogenase, 0.15 mM peptide, 0.1 mM ATP, 1 mM DTT, 4 mM PEP, 8 mM MgCl2, 0.3 mM NADH, 60 mM CaCl2, 10 mg/mL PS, 50 ng/mL PMA, 7.5% DMSO and from about 10,000 nM to 0.169 nM compound inhibitor.	B	CCc1cc(C(=O)Nc2n[nH]c3c2CN(C(=O)N2C[C@@H]4CCCN4C[C@@H]2C)C3(C)C)no1		CHEMBL3662880	=	Ki	nM	61.6	CHEMBL3045	Homo sapiens	Ki	nM	61.6
295381	17676616	CHEMBL3705825	Inhibition Assay: Protein Kinase C beta 2 (PKC beta II) catalyzes the production of ADP from ATP that accompanies the phosphoryl transfer to the PKC Pseudosubstrate peptide (A->S, RFARKGSLRQKNV). This transfer is coupled to the oxidation of p-NADH through the activities of Pyruvate Kinase (PK) and Lactate Dehydrogenase (LDH). (3-NADH conversion to NAD+ is monitored by the decrease in absorbance at 340 nm (e=6.22 cm-1 mM-1) using a Molecular Devices SPECTRA max PLUS spectrophotometer.A typical assay was carried out on a 96-well, clear microtiter plate in a Molecular Devices spectrophotometer for 20 minutes at 30 C. in 0.1 mL of assay buffer containing 50 mM HEPES, pH 7.4, 5 nM PKC, 23 units of pyruvate kinase, 33 units of lactate dehydrogenase, 0.15 mM peptide, 0.1 mM ATP, 1 mM DTT, 4 mM PEP, 8 mM MgCl2, 0.3 mM NADH, 60 mM CaCl2, 10 mg/mL PS, 50 ng/mL PMA, 7.5% DMSO and from about 10,000 nM to 0.169 nM compound inhibitor.	B	Cc1cnc(C(=O)Nc2n[nH]c3c2CN(C(=O)N2C[C@@H]4CCCN4C[C@@H]2C)C3(C)C)cn1		CHEMBL3662881	=	Ki	nM	72.9	CHEMBL3045	Homo sapiens	Ki	nM	72.9
295382	17676617	CHEMBL3705825	Inhibition Assay: Protein Kinase C beta 2 (PKC beta II) catalyzes the production of ADP from ATP that accompanies the phosphoryl transfer to the PKC Pseudosubstrate peptide (A->S, RFARKGSLRQKNV). This transfer is coupled to the oxidation of p-NADH through the activities of Pyruvate Kinase (PK) and Lactate Dehydrogenase (LDH). (3-NADH conversion to NAD+ is monitored by the decrease in absorbance at 340 nm (e=6.22 cm-1 mM-1) using a Molecular Devices SPECTRA max PLUS spectrophotometer.A typical assay was carried out on a 96-well, clear microtiter plate in a Molecular Devices spectrophotometer for 20 minutes at 30 C. in 0.1 mL of assay buffer containing 50 mM HEPES, pH 7.4, 5 nM PKC, 23 units of pyruvate kinase, 33 units of lactate dehydrogenase, 0.15 mM peptide, 0.1 mM ATP, 1 mM DTT, 4 mM PEP, 8 mM MgCl2, 0.3 mM NADH, 60 mM CaCl2, 10 mg/mL PS, 50 ng/mL PMA, 7.5% DMSO and from about 10,000 nM to 0.169 nM compound inhibitor.	B	C[C@H]1CN2CCC[C@H]2CN1C(=O)N1Cc2c(NC(=O)c3cc4ccccc4cn3)n[nH]c2C1(C)C		CHEMBL3662882	=	Ki	nM	5.51	CHEMBL3045	Homo sapiens	Ki	nM	5.51
295383	17676618	CHEMBL3705825	Inhibition Assay: Protein Kinase C beta 2 (PKC beta II) catalyzes the production of ADP from ATP that accompanies the phosphoryl transfer to the PKC Pseudosubstrate peptide (A->S, RFARKGSLRQKNV). This transfer is coupled to the oxidation of p-NADH through the activities of Pyruvate Kinase (PK) and Lactate Dehydrogenase (LDH). (3-NADH conversion to NAD+ is monitored by the decrease in absorbance at 340 nm (e=6.22 cm-1 mM-1) using a Molecular Devices SPECTRA max PLUS spectrophotometer.A typical assay was carried out on a 96-well, clear microtiter plate in a Molecular Devices spectrophotometer for 20 minutes at 30 C. in 0.1 mL of assay buffer containing 50 mM HEPES, pH 7.4, 5 nM PKC, 23 units of pyruvate kinase, 33 units of lactate dehydrogenase, 0.15 mM peptide, 0.1 mM ATP, 1 mM DTT, 4 mM PEP, 8 mM MgCl2, 0.3 mM NADH, 60 mM CaCl2, 10 mg/mL PS, 50 ng/mL PMA, 7.5% DMSO and from about 10,000 nM to 0.169 nM compound inhibitor.	B	C[C@H]1CN2CCC[C@H]2CN1C(=O)N1Cc2c(NC(=O)c3ccc4cnccc4n3)n[nH]c2C1(C)C		CHEMBL3662883	=	Ki	nM	6.17	CHEMBL3045	Homo sapiens	Ki	nM	6.17
295384	17676619	CHEMBL3705825	Inhibition Assay: Protein Kinase C beta 2 (PKC beta II) catalyzes the production of ADP from ATP that accompanies the phosphoryl transfer to the PKC Pseudosubstrate peptide (A->S, RFARKGSLRQKNV). This transfer is coupled to the oxidation of p-NADH through the activities of Pyruvate Kinase (PK) and Lactate Dehydrogenase (LDH). (3-NADH conversion to NAD+ is monitored by the decrease in absorbance at 340 nm (e=6.22 cm-1 mM-1) using a Molecular Devices SPECTRA max PLUS spectrophotometer.A typical assay was carried out on a 96-well, clear microtiter plate in a Molecular Devices spectrophotometer for 20 minutes at 30 C. in 0.1 mL of assay buffer containing 50 mM HEPES, pH 7.4, 5 nM PKC, 23 units of pyruvate kinase, 33 units of lactate dehydrogenase, 0.15 mM peptide, 0.1 mM ATP, 1 mM DTT, 4 mM PEP, 8 mM MgCl2, 0.3 mM NADH, 60 mM CaCl2, 10 mg/mL PS, 50 ng/mL PMA, 7.5% DMSO and from about 10,000 nM to 0.169 nM compound inhibitor.	B	COc1cccc(C(=O)Nc2n[nH]c3c2CN(C(=O)N2C[C@@H]4CCCN4C[C@@H]2C)C3(C)C)c1		CHEMBL3662753	=	Ki	nM	37.5	CHEMBL3045	Homo sapiens	Ki	nM	37.5
295385	17676620	CHEMBL3705825	Inhibition Assay: Protein Kinase C beta 2 (PKC beta II) catalyzes the production of ADP from ATP that accompanies the phosphoryl transfer to the PKC Pseudosubstrate peptide (A->S, RFARKGSLRQKNV). This transfer is coupled to the oxidation of p-NADH through the activities of Pyruvate Kinase (PK) and Lactate Dehydrogenase (LDH). (3-NADH conversion to NAD+ is monitored by the decrease in absorbance at 340 nm (e=6.22 cm-1 mM-1) using a Molecular Devices SPECTRA max PLUS spectrophotometer.A typical assay was carried out on a 96-well, clear microtiter plate in a Molecular Devices spectrophotometer for 20 minutes at 30 C. in 0.1 mL of assay buffer containing 50 mM HEPES, pH 7.4, 5 nM PKC, 23 units of pyruvate kinase, 33 units of lactate dehydrogenase, 0.15 mM peptide, 0.1 mM ATP, 1 mM DTT, 4 mM PEP, 8 mM MgCl2, 0.3 mM NADH, 60 mM CaCl2, 10 mg/mL PS, 50 ng/mL PMA, 7.5% DMSO and from about 10,000 nM to 0.169 nM compound inhibitor.	B	C[C@H]1CN2CCC[C@H]2CN1C(=O)N1Cc2c(NC(=O)c3cc(C4CC4)n[nH]3)n[nH]c2C1(C)C		CHEMBL3662884	=	Ki	nM	6.81	CHEMBL3045	Homo sapiens	Ki	nM	6.81
295386	17676621	CHEMBL3705825	Inhibition Assay: Protein Kinase C beta 2 (PKC beta II) catalyzes the production of ADP from ATP that accompanies the phosphoryl transfer to the PKC Pseudosubstrate peptide (A->S, RFARKGSLRQKNV). This transfer is coupled to the oxidation of p-NADH through the activities of Pyruvate Kinase (PK) and Lactate Dehydrogenase (LDH). (3-NADH conversion to NAD+ is monitored by the decrease in absorbance at 340 nm (e=6.22 cm-1 mM-1) using a Molecular Devices SPECTRA max PLUS spectrophotometer.A typical assay was carried out on a 96-well, clear microtiter plate in a Molecular Devices spectrophotometer for 20 minutes at 30 C. in 0.1 mL of assay buffer containing 50 mM HEPES, pH 7.4, 5 nM PKC, 23 units of pyruvate kinase, 33 units of lactate dehydrogenase, 0.15 mM peptide, 0.1 mM ATP, 1 mM DTT, 4 mM PEP, 8 mM MgCl2, 0.3 mM NADH, 60 mM CaCl2, 10 mg/mL PS, 50 ng/mL PMA, 7.5% DMSO and from about 10,000 nM to 0.169 nM compound inhibitor.	B	C[C@H]1CN2CCC[C@H]2CN1C(=O)N1Cc2c(NC(=O)c3cnc4ccccc4n3)n[nH]c2C1(C)C		CHEMBL3662885	=	Ki	nM	12.5	CHEMBL3045	Homo sapiens	Ki	nM	12.5
295387	17676622	CHEMBL3705825	Inhibition Assay: Protein Kinase C beta 2 (PKC beta II) catalyzes the production of ADP from ATP that accompanies the phosphoryl transfer to the PKC Pseudosubstrate peptide (A->S, RFARKGSLRQKNV). This transfer is coupled to the oxidation of p-NADH through the activities of Pyruvate Kinase (PK) and Lactate Dehydrogenase (LDH). (3-NADH conversion to NAD+ is monitored by the decrease in absorbance at 340 nm (e=6.22 cm-1 mM-1) using a Molecular Devices SPECTRA max PLUS spectrophotometer.A typical assay was carried out on a 96-well, clear microtiter plate in a Molecular Devices spectrophotometer for 20 minutes at 30 C. in 0.1 mL of assay buffer containing 50 mM HEPES, pH 7.4, 5 nM PKC, 23 units of pyruvate kinase, 33 units of lactate dehydrogenase, 0.15 mM peptide, 0.1 mM ATP, 1 mM DTT, 4 mM PEP, 8 mM MgCl2, 0.3 mM NADH, 60 mM CaCl2, 10 mg/mL PS, 50 ng/mL PMA, 7.5% DMSO and from about 10,000 nM to 0.169 nM compound inhibitor.	B	C[C@H]1CN2CCC[C@H]2CN1C(=O)N1Cc2c(NC(=O)c3ccnn3C)n[nH]c2C1(C)C		CHEMBL3662886	=	Ki	nM	118.0	CHEMBL3045	Homo sapiens	Ki	nM	118.0
295388	17676623	CHEMBL3705825	Inhibition Assay: Protein Kinase C beta 2 (PKC beta II) catalyzes the production of ADP from ATP that accompanies the phosphoryl transfer to the PKC Pseudosubstrate peptide (A->S, RFARKGSLRQKNV). This transfer is coupled to the oxidation of p-NADH through the activities of Pyruvate Kinase (PK) and Lactate Dehydrogenase (LDH). (3-NADH conversion to NAD+ is monitored by the decrease in absorbance at 340 nm (e=6.22 cm-1 mM-1) using a Molecular Devices SPECTRA max PLUS spectrophotometer.A typical assay was carried out on a 96-well, clear microtiter plate in a Molecular Devices spectrophotometer for 20 minutes at 30 C. in 0.1 mL of assay buffer containing 50 mM HEPES, pH 7.4, 5 nM PKC, 23 units of pyruvate kinase, 33 units of lactate dehydrogenase, 0.15 mM peptide, 0.1 mM ATP, 1 mM DTT, 4 mM PEP, 8 mM MgCl2, 0.3 mM NADH, 60 mM CaCl2, 10 mg/mL PS, 50 ng/mL PMA, 7.5% DMSO and from about 10,000 nM to 0.169 nM compound inhibitor.	B	Cc1nc(C(=O)Nc2n[nH]c3c2CN(C(=O)N2C[C@@H]4CCCN4C[C@@H]2C)C3(C)C)cs1		CHEMBL3662887	=	Ki	nM	31.3	CHEMBL3045	Homo sapiens	Ki	nM	31.3
295389	17676624	CHEMBL3705825	Inhibition Assay: Protein Kinase C beta 2 (PKC beta II) catalyzes the production of ADP from ATP that accompanies the phosphoryl transfer to the PKC Pseudosubstrate peptide (A->S, RFARKGSLRQKNV). This transfer is coupled to the oxidation of p-NADH through the activities of Pyruvate Kinase (PK) and Lactate Dehydrogenase (LDH). (3-NADH conversion to NAD+ is monitored by the decrease in absorbance at 340 nm (e=6.22 cm-1 mM-1) using a Molecular Devices SPECTRA max PLUS spectrophotometer.A typical assay was carried out on a 96-well, clear microtiter plate in a Molecular Devices spectrophotometer for 20 minutes at 30 C. in 0.1 mL of assay buffer containing 50 mM HEPES, pH 7.4, 5 nM PKC, 23 units of pyruvate kinase, 33 units of lactate dehydrogenase, 0.15 mM peptide, 0.1 mM ATP, 1 mM DTT, 4 mM PEP, 8 mM MgCl2, 0.3 mM NADH, 60 mM CaCl2, 10 mg/mL PS, 50 ng/mL PMA, 7.5% DMSO and from about 10,000 nM to 0.169 nM compound inhibitor.	B	C[C@H]1CN2CCC[C@H]2CN1C(=O)N1Cc2c(NC(=O)c3cc(C(C)(C)C)nn3C)n[nH]c2C1(C)C		CHEMBL3662888	=	Ki	nM	10.6	CHEMBL3045	Homo sapiens	Ki	nM	10.6
295390	17676625	CHEMBL3705825	Inhibition Assay: Protein Kinase C beta 2 (PKC beta II) catalyzes the production of ADP from ATP that accompanies the phosphoryl transfer to the PKC Pseudosubstrate peptide (A->S, RFARKGSLRQKNV). This transfer is coupled to the oxidation of p-NADH through the activities of Pyruvate Kinase (PK) and Lactate Dehydrogenase (LDH). (3-NADH conversion to NAD+ is monitored by the decrease in absorbance at 340 nm (e=6.22 cm-1 mM-1) using a Molecular Devices SPECTRA max PLUS spectrophotometer.A typical assay was carried out on a 96-well, clear microtiter plate in a Molecular Devices spectrophotometer for 20 minutes at 30 C. in 0.1 mL of assay buffer containing 50 mM HEPES, pH 7.4, 5 nM PKC, 23 units of pyruvate kinase, 33 units of lactate dehydrogenase, 0.15 mM peptide, 0.1 mM ATP, 1 mM DTT, 4 mM PEP, 8 mM MgCl2, 0.3 mM NADH, 60 mM CaCl2, 10 mg/mL PS, 50 ng/mL PMA, 7.5% DMSO and from about 10,000 nM to 0.169 nM compound inhibitor.	B	Cc1nc(C)c(C(=O)Nc2n[nH]c3c2CN(C(=O)N2C[C@@H]4CCCN4C[C@@H]2C)C3(C)C)o1		CHEMBL3662889	=	Ki	nM	28.9	CHEMBL3045	Homo sapiens	Ki	nM	28.9
295391	17676626	CHEMBL3705825	Inhibition Assay: Protein Kinase C beta 2 (PKC beta II) catalyzes the production of ADP from ATP that accompanies the phosphoryl transfer to the PKC Pseudosubstrate peptide (A->S, RFARKGSLRQKNV). This transfer is coupled to the oxidation of p-NADH through the activities of Pyruvate Kinase (PK) and Lactate Dehydrogenase (LDH). (3-NADH conversion to NAD+ is monitored by the decrease in absorbance at 340 nm (e=6.22 cm-1 mM-1) using a Molecular Devices SPECTRA max PLUS spectrophotometer.A typical assay was carried out on a 96-well, clear microtiter plate in a Molecular Devices spectrophotometer for 20 minutes at 30 C. in 0.1 mL of assay buffer containing 50 mM HEPES, pH 7.4, 5 nM PKC, 23 units of pyruvate kinase, 33 units of lactate dehydrogenase, 0.15 mM peptide, 0.1 mM ATP, 1 mM DTT, 4 mM PEP, 8 mM MgCl2, 0.3 mM NADH, 60 mM CaCl2, 10 mg/mL PS, 50 ng/mL PMA, 7.5% DMSO and from about 10,000 nM to 0.169 nM compound inhibitor.	B	C[C@H]1CN2CCC[C@H]2CN1C(=O)N1Cc2c(NC(=O)c3cc(C4CC4)on3)n[nH]c2C1(C)C		CHEMBL3662890	=	Ki	nM	58.6	CHEMBL3045	Homo sapiens	Ki	nM	58.6
295392	17676627	CHEMBL3705825	Inhibition Assay: Protein Kinase C beta 2 (PKC beta II) catalyzes the production of ADP from ATP that accompanies the phosphoryl transfer to the PKC Pseudosubstrate peptide (A->S, RFARKGSLRQKNV). This transfer is coupled to the oxidation of p-NADH through the activities of Pyruvate Kinase (PK) and Lactate Dehydrogenase (LDH). (3-NADH conversion to NAD+ is monitored by the decrease in absorbance at 340 nm (e=6.22 cm-1 mM-1) using a Molecular Devices SPECTRA max PLUS spectrophotometer.A typical assay was carried out on a 96-well, clear microtiter plate in a Molecular Devices spectrophotometer for 20 minutes at 30 C. in 0.1 mL of assay buffer containing 50 mM HEPES, pH 7.4, 5 nM PKC, 23 units of pyruvate kinase, 33 units of lactate dehydrogenase, 0.15 mM peptide, 0.1 mM ATP, 1 mM DTT, 4 mM PEP, 8 mM MgCl2, 0.3 mM NADH, 60 mM CaCl2, 10 mg/mL PS, 50 ng/mL PMA, 7.5% DMSO and from about 10,000 nM to 0.169 nM compound inhibitor.	B	C[C@H]1CN2CCC[C@H]2CN1C(=O)N1Cc2c(NC(=O)c3c(F)ccc(F)c3F)n[nH]c2C1(C)C		CHEMBL3662891	=	Ki	nM	135.0	CHEMBL3045	Homo sapiens	Ki	nM	135.0
295393	17676628	CHEMBL3705825	Inhibition Assay: Protein Kinase C beta 2 (PKC beta II) catalyzes the production of ADP from ATP that accompanies the phosphoryl transfer to the PKC Pseudosubstrate peptide (A->S, RFARKGSLRQKNV). This transfer is coupled to the oxidation of p-NADH through the activities of Pyruvate Kinase (PK) and Lactate Dehydrogenase (LDH). (3-NADH conversion to NAD+ is monitored by the decrease in absorbance at 340 nm (e=6.22 cm-1 mM-1) using a Molecular Devices SPECTRA max PLUS spectrophotometer.A typical assay was carried out on a 96-well, clear microtiter plate in a Molecular Devices spectrophotometer for 20 minutes at 30 C. in 0.1 mL of assay buffer containing 50 mM HEPES, pH 7.4, 5 nM PKC, 23 units of pyruvate kinase, 33 units of lactate dehydrogenase, 0.15 mM peptide, 0.1 mM ATP, 1 mM DTT, 4 mM PEP, 8 mM MgCl2, 0.3 mM NADH, 60 mM CaCl2, 10 mg/mL PS, 50 ng/mL PMA, 7.5% DMSO and from about 10,000 nM to 0.169 nM compound inhibitor.	B	C[C@H]1CN(CC2CCOCC2)[C@H](C)CN1C(=O)N1Cc2c(NC(=O)c3cn(C)cn3)n[nH]c2C1(C)C		CHEMBL3662892	=	Ki	nM	157.0	CHEMBL3045	Homo sapiens	Ki	nM	157.0
295394	17676629	CHEMBL3705825	Inhibition Assay: Protein Kinase C beta 2 (PKC beta II) catalyzes the production of ADP from ATP that accompanies the phosphoryl transfer to the PKC Pseudosubstrate peptide (A->S, RFARKGSLRQKNV). This transfer is coupled to the oxidation of p-NADH through the activities of Pyruvate Kinase (PK) and Lactate Dehydrogenase (LDH). (3-NADH conversion to NAD+ is monitored by the decrease in absorbance at 340 nm (e=6.22 cm-1 mM-1) using a Molecular Devices SPECTRA max PLUS spectrophotometer.A typical assay was carried out on a 96-well, clear microtiter plate in a Molecular Devices spectrophotometer for 20 minutes at 30 C. in 0.1 mL of assay buffer containing 50 mM HEPES, pH 7.4, 5 nM PKC, 23 units of pyruvate kinase, 33 units of lactate dehydrogenase, 0.15 mM peptide, 0.1 mM ATP, 1 mM DTT, 4 mM PEP, 8 mM MgCl2, 0.3 mM NADH, 60 mM CaCl2, 10 mg/mL PS, 50 ng/mL PMA, 7.5% DMSO and from about 10,000 nM to 0.169 nM compound inhibitor.	B	CCc1nc(C)c(C(=O)Nc2n[nH]c3c2CN(C(=O)N2C[C@@H](C)N(CC4CCOCC4)C[C@@H]2C)C3(C)C)o1		CHEMBL3662893	=	Ki	nM	22.4	CHEMBL3045	Homo sapiens	Ki	nM	22.4
295395	17676630	CHEMBL3705825	Inhibition Assay: Protein Kinase C beta 2 (PKC beta II) catalyzes the production of ADP from ATP that accompanies the phosphoryl transfer to the PKC Pseudosubstrate peptide (A->S, RFARKGSLRQKNV). This transfer is coupled to the oxidation of p-NADH through the activities of Pyruvate Kinase (PK) and Lactate Dehydrogenase (LDH). (3-NADH conversion to NAD+ is monitored by the decrease in absorbance at 340 nm (e=6.22 cm-1 mM-1) using a Molecular Devices SPECTRA max PLUS spectrophotometer.A typical assay was carried out on a 96-well, clear microtiter plate in a Molecular Devices spectrophotometer for 20 minutes at 30 C. in 0.1 mL of assay buffer containing 50 mM HEPES, pH 7.4, 5 nM PKC, 23 units of pyruvate kinase, 33 units of lactate dehydrogenase, 0.15 mM peptide, 0.1 mM ATP, 1 mM DTT, 4 mM PEP, 8 mM MgCl2, 0.3 mM NADH, 60 mM CaCl2, 10 mg/mL PS, 50 ng/mL PMA, 7.5% DMSO and from about 10,000 nM to 0.169 nM compound inhibitor.	B	COCCCN1C[C@H](C)N(C(=O)N2Cc3c(NC(=O)c4cc(C)nc(C)n4)n[nH]c3C2(C)C)C[C@H]1C		CHEMBL3662894	=	Ki	nM	78.4	CHEMBL3045	Homo sapiens	Ki	nM	78.4
295396	17676631	CHEMBL3705825	Inhibition Assay: Protein Kinase C beta 2 (PKC beta II) catalyzes the production of ADP from ATP that accompanies the phosphoryl transfer to the PKC Pseudosubstrate peptide (A->S, RFARKGSLRQKNV). This transfer is coupled to the oxidation of p-NADH through the activities of Pyruvate Kinase (PK) and Lactate Dehydrogenase (LDH). (3-NADH conversion to NAD+ is monitored by the decrease in absorbance at 340 nm (e=6.22 cm-1 mM-1) using a Molecular Devices SPECTRA max PLUS spectrophotometer.A typical assay was carried out on a 96-well, clear microtiter plate in a Molecular Devices spectrophotometer for 20 minutes at 30 C. in 0.1 mL of assay buffer containing 50 mM HEPES, pH 7.4, 5 nM PKC, 23 units of pyruvate kinase, 33 units of lactate dehydrogenase, 0.15 mM peptide, 0.1 mM ATP, 1 mM DTT, 4 mM PEP, 8 mM MgCl2, 0.3 mM NADH, 60 mM CaCl2, 10 mg/mL PS, 50 ng/mL PMA, 7.5% DMSO and from about 10,000 nM to 0.169 nM compound inhibitor.	B	COCCCN1C[C@H](C)N(C(=O)N2Cc3c(NC(=O)c4cnccn4)n[nH]c3C2(C)C)C[C@H]1C		CHEMBL3662895	=	Ki	nM	625.0	CHEMBL3045	Homo sapiens	Ki	nM	625.0
295397	17676632	CHEMBL3705825	Inhibition Assay: Protein Kinase C beta 2 (PKC beta II) catalyzes the production of ADP from ATP that accompanies the phosphoryl transfer to the PKC Pseudosubstrate peptide (A->S, RFARKGSLRQKNV). This transfer is coupled to the oxidation of p-NADH through the activities of Pyruvate Kinase (PK) and Lactate Dehydrogenase (LDH). (3-NADH conversion to NAD+ is monitored by the decrease in absorbance at 340 nm (e=6.22 cm-1 mM-1) using a Molecular Devices SPECTRA max PLUS spectrophotometer.A typical assay was carried out on a 96-well, clear microtiter plate in a Molecular Devices spectrophotometer for 20 minutes at 30 C. in 0.1 mL of assay buffer containing 50 mM HEPES, pH 7.4, 5 nM PKC, 23 units of pyruvate kinase, 33 units of lactate dehydrogenase, 0.15 mM peptide, 0.1 mM ATP, 1 mM DTT, 4 mM PEP, 8 mM MgCl2, 0.3 mM NADH, 60 mM CaCl2, 10 mg/mL PS, 50 ng/mL PMA, 7.5% DMSO and from about 10,000 nM to 0.169 nM compound inhibitor.	B	CCc1cc(C(=O)Nc2n[nH]c3c2CN(C(=O)N2C[C@@H](C)N(CCCOC)C[C@@H]2C)C3(C)C)n(C)n1		CHEMBL3662896	=	Ki	nM	37.3	CHEMBL3045	Homo sapiens	Ki	nM	37.3
295398	17676633	CHEMBL3705825	Inhibition Assay: Protein Kinase C beta 2 (PKC beta II) catalyzes the production of ADP from ATP that accompanies the phosphoryl transfer to the PKC Pseudosubstrate peptide (A->S, RFARKGSLRQKNV). This transfer is coupled to the oxidation of p-NADH through the activities of Pyruvate Kinase (PK) and Lactate Dehydrogenase (LDH). (3-NADH conversion to NAD+ is monitored by the decrease in absorbance at 340 nm (e=6.22 cm-1 mM-1) using a Molecular Devices SPECTRA max PLUS spectrophotometer.A typical assay was carried out on a 96-well, clear microtiter plate in a Molecular Devices spectrophotometer for 20 minutes at 30 C. in 0.1 mL of assay buffer containing 50 mM HEPES, pH 7.4, 5 nM PKC, 23 units of pyruvate kinase, 33 units of lactate dehydrogenase, 0.15 mM peptide, 0.1 mM ATP, 1 mM DTT, 4 mM PEP, 8 mM MgCl2, 0.3 mM NADH, 60 mM CaCl2, 10 mg/mL PS, 50 ng/mL PMA, 7.5% DMSO and from about 10,000 nM to 0.169 nM compound inhibitor.	B	COCCCN1C[C@H](C)N(C(=O)N2Cc3c(NC(=O)c4oc(C)cc4C)n[nH]c3C2(C)C)C[C@H]1C		CHEMBL3662897	=	Ki	nM	71.8	CHEMBL3045	Homo sapiens	Ki	nM	71.8
295399	17676634	CHEMBL3705825	Inhibition Assay: Protein Kinase C beta 2 (PKC beta II) catalyzes the production of ADP from ATP that accompanies the phosphoryl transfer to the PKC Pseudosubstrate peptide (A->S, RFARKGSLRQKNV). This transfer is coupled to the oxidation of p-NADH through the activities of Pyruvate Kinase (PK) and Lactate Dehydrogenase (LDH). (3-NADH conversion to NAD+ is monitored by the decrease in absorbance at 340 nm (e=6.22 cm-1 mM-1) using a Molecular Devices SPECTRA max PLUS spectrophotometer.A typical assay was carried out on a 96-well, clear microtiter plate in a Molecular Devices spectrophotometer for 20 minutes at 30 C. in 0.1 mL of assay buffer containing 50 mM HEPES, pH 7.4, 5 nM PKC, 23 units of pyruvate kinase, 33 units of lactate dehydrogenase, 0.15 mM peptide, 0.1 mM ATP, 1 mM DTT, 4 mM PEP, 8 mM MgCl2, 0.3 mM NADH, 60 mM CaCl2, 10 mg/mL PS, 50 ng/mL PMA, 7.5% DMSO and from about 10,000 nM to 0.169 nM compound inhibitor.	B	CCc1nc(C)c(C(=O)Nc2n[nH]c3c2CN(C(=O)N2C[C@@H](C)N(CCCOC)C[C@@H]2C)C3(C)C)o1		CHEMBL3662898	=	Ki	nM	83.6	CHEMBL3045	Homo sapiens	Ki	nM	83.6
295400	17676635	CHEMBL3705825	Inhibition Assay: Protein Kinase C beta 2 (PKC beta II) catalyzes the production of ADP from ATP that accompanies the phosphoryl transfer to the PKC Pseudosubstrate peptide (A->S, RFARKGSLRQKNV). This transfer is coupled to the oxidation of p-NADH through the activities of Pyruvate Kinase (PK) and Lactate Dehydrogenase (LDH). (3-NADH conversion to NAD+ is monitored by the decrease in absorbance at 340 nm (e=6.22 cm-1 mM-1) using a Molecular Devices SPECTRA max PLUS spectrophotometer.A typical assay was carried out on a 96-well, clear microtiter plate in a Molecular Devices spectrophotometer for 20 minutes at 30 C. in 0.1 mL of assay buffer containing 50 mM HEPES, pH 7.4, 5 nM PKC, 23 units of pyruvate kinase, 33 units of lactate dehydrogenase, 0.15 mM peptide, 0.1 mM ATP, 1 mM DTT, 4 mM PEP, 8 mM MgCl2, 0.3 mM NADH, 60 mM CaCl2, 10 mg/mL PS, 50 ng/mL PMA, 7.5% DMSO and from about 10,000 nM to 0.169 nM compound inhibitor.	B	COCCCN1C[C@H](C)N(C(=O)N2Cc3c(NC(=O)Cc4c(C)noc4C)n[nH]c3C2(C)C)C[C@H]1C		CHEMBL3662899	=	Ki	nM	67.1	CHEMBL3045	Homo sapiens	Ki	nM	67.1
295401	17676636	CHEMBL3705825	Inhibition Assay: Protein Kinase C beta 2 (PKC beta II) catalyzes the production of ADP from ATP that accompanies the phosphoryl transfer to the PKC Pseudosubstrate peptide (A->S, RFARKGSLRQKNV). This transfer is coupled to the oxidation of p-NADH through the activities of Pyruvate Kinase (PK) and Lactate Dehydrogenase (LDH). (3-NADH conversion to NAD+ is monitored by the decrease in absorbance at 340 nm (e=6.22 cm-1 mM-1) using a Molecular Devices SPECTRA max PLUS spectrophotometer.A typical assay was carried out on a 96-well, clear microtiter plate in a Molecular Devices spectrophotometer for 20 minutes at 30 C. in 0.1 mL of assay buffer containing 50 mM HEPES, pH 7.4, 5 nM PKC, 23 units of pyruvate kinase, 33 units of lactate dehydrogenase, 0.15 mM peptide, 0.1 mM ATP, 1 mM DTT, 4 mM PEP, 8 mM MgCl2, 0.3 mM NADH, 60 mM CaCl2, 10 mg/mL PS, 50 ng/mL PMA, 7.5% DMSO and from about 10,000 nM to 0.169 nM compound inhibitor.	B	COCCCN1C[C@H](C)N(C(=O)N2Cc3c(NC(=O)c4ocnc4C)n[nH]c3C2(C)C)C[C@H]1C		CHEMBL3662900	=	Ki	nM	95.6	CHEMBL3045	Homo sapiens	Ki	nM	95.6
295402	17676637	CHEMBL3705825	Inhibition Assay: Protein Kinase C beta 2 (PKC beta II) catalyzes the production of ADP from ATP that accompanies the phosphoryl transfer to the PKC Pseudosubstrate peptide (A->S, RFARKGSLRQKNV). This transfer is coupled to the oxidation of p-NADH through the activities of Pyruvate Kinase (PK) and Lactate Dehydrogenase (LDH). (3-NADH conversion to NAD+ is monitored by the decrease in absorbance at 340 nm (e=6.22 cm-1 mM-1) using a Molecular Devices SPECTRA max PLUS spectrophotometer.A typical assay was carried out on a 96-well, clear microtiter plate in a Molecular Devices spectrophotometer for 20 minutes at 30 C. in 0.1 mL of assay buffer containing 50 mM HEPES, pH 7.4, 5 nM PKC, 23 units of pyruvate kinase, 33 units of lactate dehydrogenase, 0.15 mM peptide, 0.1 mM ATP, 1 mM DTT, 4 mM PEP, 8 mM MgCl2, 0.3 mM NADH, 60 mM CaCl2, 10 mg/mL PS, 50 ng/mL PMA, 7.5% DMSO and from about 10,000 nM to 0.169 nM compound inhibitor.	B	C[C@H]1CN(CC2CCOCC2)[C@H](C)CN1C(=O)N1Cc2c(NC(=O)c3cn(C)cn3)n[nH]c2C1(C)C		CHEMBL3662892	=	Ki	nM	62.4	CHEMBL3045	Homo sapiens	Ki	nM	62.4
295403	17676638	CHEMBL3705825	Inhibition Assay: Protein Kinase C beta 2 (PKC beta II) catalyzes the production of ADP from ATP that accompanies the phosphoryl transfer to the PKC Pseudosubstrate peptide (A->S, RFARKGSLRQKNV). This transfer is coupled to the oxidation of p-NADH through the activities of Pyruvate Kinase (PK) and Lactate Dehydrogenase (LDH). (3-NADH conversion to NAD+ is monitored by the decrease in absorbance at 340 nm (e=6.22 cm-1 mM-1) using a Molecular Devices SPECTRA max PLUS spectrophotometer.A typical assay was carried out on a 96-well, clear microtiter plate in a Molecular Devices spectrophotometer for 20 minutes at 30 C. in 0.1 mL of assay buffer containing 50 mM HEPES, pH 7.4, 5 nM PKC, 23 units of pyruvate kinase, 33 units of lactate dehydrogenase, 0.15 mM peptide, 0.1 mM ATP, 1 mM DTT, 4 mM PEP, 8 mM MgCl2, 0.3 mM NADH, 60 mM CaCl2, 10 mg/mL PS, 50 ng/mL PMA, 7.5% DMSO and from about 10,000 nM to 0.169 nM compound inhibitor.	B	Cc1nc(C)c(C(=O)Nc2n[nH]c3c2CN(C(=O)N2C[C@@H](C)N(CC4CCOCC4)C[C@@H]2C)C3(C)C)s1		CHEMBL3662901	=	Ki	nM	22.6	CHEMBL3045	Homo sapiens	Ki	nM	22.6
295404	17676639	CHEMBL3705825	Inhibition Assay: Protein Kinase C beta 2 (PKC beta II) catalyzes the production of ADP from ATP that accompanies the phosphoryl transfer to the PKC Pseudosubstrate peptide (A->S, RFARKGSLRQKNV). This transfer is coupled to the oxidation of p-NADH through the activities of Pyruvate Kinase (PK) and Lactate Dehydrogenase (LDH). (3-NADH conversion to NAD+ is monitored by the decrease in absorbance at 340 nm (e=6.22 cm-1 mM-1) using a Molecular Devices SPECTRA max PLUS spectrophotometer.A typical assay was carried out on a 96-well, clear microtiter plate in a Molecular Devices spectrophotometer for 20 minutes at 30 C. in 0.1 mL of assay buffer containing 50 mM HEPES, pH 7.4, 5 nM PKC, 23 units of pyruvate kinase, 33 units of lactate dehydrogenase, 0.15 mM peptide, 0.1 mM ATP, 1 mM DTT, 4 mM PEP, 8 mM MgCl2, 0.3 mM NADH, 60 mM CaCl2, 10 mg/mL PS, 50 ng/mL PMA, 7.5% DMSO and from about 10,000 nM to 0.169 nM compound inhibitor.	B	C[C@H]1CN(CC2CCOCC2)[C@H](C)CN1C(=O)N1Cc2c(NC(=O)c3cc(C4CC4)on3)n[nH]c2C1(C)C		CHEMBL3662902	=	Ki	nM	29.8	CHEMBL3045	Homo sapiens	Ki	nM	29.8
295405	17676640	CHEMBL3705825	Inhibition Assay: Protein Kinase C beta 2 (PKC beta II) catalyzes the production of ADP from ATP that accompanies the phosphoryl transfer to the PKC Pseudosubstrate peptide (A->S, RFARKGSLRQKNV). This transfer is coupled to the oxidation of p-NADH through the activities of Pyruvate Kinase (PK) and Lactate Dehydrogenase (LDH). (3-NADH conversion to NAD+ is monitored by the decrease in absorbance at 340 nm (e=6.22 cm-1 mM-1) using a Molecular Devices SPECTRA max PLUS spectrophotometer.A typical assay was carried out on a 96-well, clear microtiter plate in a Molecular Devices spectrophotometer for 20 minutes at 30 C. in 0.1 mL of assay buffer containing 50 mM HEPES, pH 7.4, 5 nM PKC, 23 units of pyruvate kinase, 33 units of lactate dehydrogenase, 0.15 mM peptide, 0.1 mM ATP, 1 mM DTT, 4 mM PEP, 8 mM MgCl2, 0.3 mM NADH, 60 mM CaCl2, 10 mg/mL PS, 50 ng/mL PMA, 7.5% DMSO and from about 10,000 nM to 0.169 nM compound inhibitor.	B	Cc1cc(C(=O)Nc2n[nH]c3c2CN(C(=O)N2C[C@@H](C)N(CC4CCOCC4)C[C@@H]2C)C3(C)C)n(C)n1		CHEMBL3662903	=	Ki	nM	33.0	CHEMBL3045	Homo sapiens	Ki	nM	33.0
295406	17676641	CHEMBL3705825	Inhibition Assay: Protein Kinase C beta 2 (PKC beta II) catalyzes the production of ADP from ATP that accompanies the phosphoryl transfer to the PKC Pseudosubstrate peptide (A->S, RFARKGSLRQKNV). This transfer is coupled to the oxidation of p-NADH through the activities of Pyruvate Kinase (PK) and Lactate Dehydrogenase (LDH). (3-NADH conversion to NAD+ is monitored by the decrease in absorbance at 340 nm (e=6.22 cm-1 mM-1) using a Molecular Devices SPECTRA max PLUS spectrophotometer.A typical assay was carried out on a 96-well, clear microtiter plate in a Molecular Devices spectrophotometer for 20 minutes at 30 C. in 0.1 mL of assay buffer containing 50 mM HEPES, pH 7.4, 5 nM PKC, 23 units of pyruvate kinase, 33 units of lactate dehydrogenase, 0.15 mM peptide, 0.1 mM ATP, 1 mM DTT, 4 mM PEP, 8 mM MgCl2, 0.3 mM NADH, 60 mM CaCl2, 10 mg/mL PS, 50 ng/mL PMA, 7.5% DMSO and from about 10,000 nM to 0.169 nM compound inhibitor.	B	Cc1cc(C(=O)Nc2n[nH]c3c2CN(C(=O)N2C[C@@H](C)N(CC4CCOCC4)C[C@@H]2C)C3(C)C)no1		CHEMBL3662904	=	Ki	nM	41.1	CHEMBL3045	Homo sapiens	Ki	nM	41.1
295407	17676642	CHEMBL3705825	Inhibition Assay: Protein Kinase C beta 2 (PKC beta II) catalyzes the production of ADP from ATP that accompanies the phosphoryl transfer to the PKC Pseudosubstrate peptide (A->S, RFARKGSLRQKNV). This transfer is coupled to the oxidation of p-NADH through the activities of Pyruvate Kinase (PK) and Lactate Dehydrogenase (LDH). (3-NADH conversion to NAD+ is monitored by the decrease in absorbance at 340 nm (e=6.22 cm-1 mM-1) using a Molecular Devices SPECTRA max PLUS spectrophotometer.A typical assay was carried out on a 96-well, clear microtiter plate in a Molecular Devices spectrophotometer for 20 minutes at 30 C. in 0.1 mL of assay buffer containing 50 mM HEPES, pH 7.4, 5 nM PKC, 23 units of pyruvate kinase, 33 units of lactate dehydrogenase, 0.15 mM peptide, 0.1 mM ATP, 1 mM DTT, 4 mM PEP, 8 mM MgCl2, 0.3 mM NADH, 60 mM CaCl2, 10 mg/mL PS, 50 ng/mL PMA, 7.5% DMSO and from about 10,000 nM to 0.169 nM compound inhibitor.	B	CCn1nc(C)cc1C(=O)Nc1n[nH]c2c1CN(C(=O)N1C[C@@H](C)N(CC3CCOCC3)C[C@@H]1C)C2(C)C		CHEMBL3662905	=	Ki	nM	20.0	CHEMBL3045	Homo sapiens	Ki	nM	20.0
295408	17676643	CHEMBL3705825	Inhibition Assay: Protein Kinase C beta 2 (PKC beta II) catalyzes the production of ADP from ATP that accompanies the phosphoryl transfer to the PKC Pseudosubstrate peptide (A->S, RFARKGSLRQKNV). This transfer is coupled to the oxidation of p-NADH through the activities of Pyruvate Kinase (PK) and Lactate Dehydrogenase (LDH). (3-NADH conversion to NAD+ is monitored by the decrease in absorbance at 340 nm (e=6.22 cm-1 mM-1) using a Molecular Devices SPECTRA max PLUS spectrophotometer.A typical assay was carried out on a 96-well, clear microtiter plate in a Molecular Devices spectrophotometer for 20 minutes at 30 C. in 0.1 mL of assay buffer containing 50 mM HEPES, pH 7.4, 5 nM PKC, 23 units of pyruvate kinase, 33 units of lactate dehydrogenase, 0.15 mM peptide, 0.1 mM ATP, 1 mM DTT, 4 mM PEP, 8 mM MgCl2, 0.3 mM NADH, 60 mM CaCl2, 10 mg/mL PS, 50 ng/mL PMA, 7.5% DMSO and from about 10,000 nM to 0.169 nM compound inhibitor.	B	CCc1ocnc1C(=O)Nc1n[nH]c2c1CN(C(=O)N1C[C@@H](C)N(CC3CCOCC3)C[C@@H]1C)C2(C)C		CHEMBL3662906	=	Ki	nM	52.1	CHEMBL3045	Homo sapiens	Ki	nM	52.1
295409	17676644	CHEMBL3705825	Inhibition Assay: Protein Kinase C beta 2 (PKC beta II) catalyzes the production of ADP from ATP that accompanies the phosphoryl transfer to the PKC Pseudosubstrate peptide (A->S, RFARKGSLRQKNV). This transfer is coupled to the oxidation of p-NADH through the activities of Pyruvate Kinase (PK) and Lactate Dehydrogenase (LDH). (3-NADH conversion to NAD+ is monitored by the decrease in absorbance at 340 nm (e=6.22 cm-1 mM-1) using a Molecular Devices SPECTRA max PLUS spectrophotometer.A typical assay was carried out on a 96-well, clear microtiter plate in a Molecular Devices spectrophotometer for 20 minutes at 30 C. in 0.1 mL of assay buffer containing 50 mM HEPES, pH 7.4, 5 nM PKC, 23 units of pyruvate kinase, 33 units of lactate dehydrogenase, 0.15 mM peptide, 0.1 mM ATP, 1 mM DTT, 4 mM PEP, 8 mM MgCl2, 0.3 mM NADH, 60 mM CaCl2, 10 mg/mL PS, 50 ng/mL PMA, 7.5% DMSO and from about 10,000 nM to 0.169 nM compound inhibitor.	B	C[C@H]1CN(CC2CCOCC2)[C@H](C)CN1C(=O)N1Cc2c(NC(=O)c3ccn(C)n3)n[nH]c2C1(C)C		CHEMBL3662907	=	Ki	nM	25.8	CHEMBL3045	Homo sapiens	Ki	nM	25.8
295410	17676645	CHEMBL3705825	Inhibition Assay: Protein Kinase C beta 2 (PKC beta II) catalyzes the production of ADP from ATP that accompanies the phosphoryl transfer to the PKC Pseudosubstrate peptide (A->S, RFARKGSLRQKNV). This transfer is coupled to the oxidation of p-NADH through the activities of Pyruvate Kinase (PK) and Lactate Dehydrogenase (LDH). (3-NADH conversion to NAD+ is monitored by the decrease in absorbance at 340 nm (e=6.22 cm-1 mM-1) using a Molecular Devices SPECTRA max PLUS spectrophotometer.A typical assay was carried out on a 96-well, clear microtiter plate in a Molecular Devices spectrophotometer for 20 minutes at 30 C. in 0.1 mL of assay buffer containing 50 mM HEPES, pH 7.4, 5 nM PKC, 23 units of pyruvate kinase, 33 units of lactate dehydrogenase, 0.15 mM peptide, 0.1 mM ATP, 1 mM DTT, 4 mM PEP, 8 mM MgCl2, 0.3 mM NADH, 60 mM CaCl2, 10 mg/mL PS, 50 ng/mL PMA, 7.5% DMSO and from about 10,000 nM to 0.169 nM compound inhibitor.	B	C[C@H]1CN(CC2CCOCC2)[C@H](C)CN1C(=O)N1Cc2c(NC(=O)c3cc(C4CC4)n[nH]3)n[nH]c2C1(C)C		CHEMBL3662908	=	Ki	nM	19.4	CHEMBL3045	Homo sapiens	Ki	nM	19.4
295411	17676646	CHEMBL3705825	Inhibition Assay: Protein Kinase C beta 2 (PKC beta II) catalyzes the production of ADP from ATP that accompanies the phosphoryl transfer to the PKC Pseudosubstrate peptide (A->S, RFARKGSLRQKNV). This transfer is coupled to the oxidation of p-NADH through the activities of Pyruvate Kinase (PK) and Lactate Dehydrogenase (LDH). (3-NADH conversion to NAD+ is monitored by the decrease in absorbance at 340 nm (e=6.22 cm-1 mM-1) using a Molecular Devices SPECTRA max PLUS spectrophotometer.A typical assay was carried out on a 96-well, clear microtiter plate in a Molecular Devices spectrophotometer for 20 minutes at 30 C. in 0.1 mL of assay buffer containing 50 mM HEPES, pH 7.4, 5 nM PKC, 23 units of pyruvate kinase, 33 units of lactate dehydrogenase, 0.15 mM peptide, 0.1 mM ATP, 1 mM DTT, 4 mM PEP, 8 mM MgCl2, 0.3 mM NADH, 60 mM CaCl2, 10 mg/mL PS, 50 ng/mL PMA, 7.5% DMSO and from about 10,000 nM to 0.169 nM compound inhibitor.	B	CCc1cc(C(=O)Nc2n[nH]c3c2CN(C(=O)N2C[C@@H](C)N(CC4CCOCC4)C[C@@H]2C)C3(C)C)on1		CHEMBL3662909	=	Ki	nM	32.1	CHEMBL3045	Homo sapiens	Ki	nM	32.1
295412	17676647	CHEMBL3705825	Inhibition Assay: Protein Kinase C beta 2 (PKC beta II) catalyzes the production of ADP from ATP that accompanies the phosphoryl transfer to the PKC Pseudosubstrate peptide (A->S, RFARKGSLRQKNV). This transfer is coupled to the oxidation of p-NADH through the activities of Pyruvate Kinase (PK) and Lactate Dehydrogenase (LDH). (3-NADH conversion to NAD+ is monitored by the decrease in absorbance at 340 nm (e=6.22 cm-1 mM-1) using a Molecular Devices SPECTRA max PLUS spectrophotometer.A typical assay was carried out on a 96-well, clear microtiter plate in a Molecular Devices spectrophotometer for 20 minutes at 30 C. in 0.1 mL of assay buffer containing 50 mM HEPES, pH 7.4, 5 nM PKC, 23 units of pyruvate kinase, 33 units of lactate dehydrogenase, 0.15 mM peptide, 0.1 mM ATP, 1 mM DTT, 4 mM PEP, 8 mM MgCl2, 0.3 mM NADH, 60 mM CaCl2, 10 mg/mL PS, 50 ng/mL PMA, 7.5% DMSO and from about 10,000 nM to 0.169 nM compound inhibitor.	B	CCc1cc(C(=O)Nc2n[nH]c3c2CN(C(=O)N2C[C@@H](C)N(CC4CCOCC4)C[C@@H]2C)C3(C)C)no1		CHEMBL3662910	=	Ki	nM	26.5	CHEMBL3045	Homo sapiens	Ki	nM	26.5
295413	17676648	CHEMBL3705825	Inhibition Assay: Protein Kinase C beta 2 (PKC beta II) catalyzes the production of ADP from ATP that accompanies the phosphoryl transfer to the PKC Pseudosubstrate peptide (A->S, RFARKGSLRQKNV). This transfer is coupled to the oxidation of p-NADH through the activities of Pyruvate Kinase (PK) and Lactate Dehydrogenase (LDH). (3-NADH conversion to NAD+ is monitored by the decrease in absorbance at 340 nm (e=6.22 cm-1 mM-1) using a Molecular Devices SPECTRA max PLUS spectrophotometer.A typical assay was carried out on a 96-well, clear microtiter plate in a Molecular Devices spectrophotometer for 20 minutes at 30 C. in 0.1 mL of assay buffer containing 50 mM HEPES, pH 7.4, 5 nM PKC, 23 units of pyruvate kinase, 33 units of lactate dehydrogenase, 0.15 mM peptide, 0.1 mM ATP, 1 mM DTT, 4 mM PEP, 8 mM MgCl2, 0.3 mM NADH, 60 mM CaCl2, 10 mg/mL PS, 50 ng/mL PMA, 7.5% DMSO and from about 10,000 nM to 0.169 nM compound inhibitor.	B	Cc1nc(C)c(C(=O)Nc2n[nH]c3c2CN(C(=O)N2C[C@@H](C)N(CC4CCOCC4)C[C@@H]2C)C3(C)C)o1		CHEMBL3662911	=	Ki	nM	19.7	CHEMBL3045	Homo sapiens	Ki	nM	19.7
295414	17676649	CHEMBL3705825	Inhibition Assay: Protein Kinase C beta 2 (PKC beta II) catalyzes the production of ADP from ATP that accompanies the phosphoryl transfer to the PKC Pseudosubstrate peptide (A->S, RFARKGSLRQKNV). This transfer is coupled to the oxidation of p-NADH through the activities of Pyruvate Kinase (PK) and Lactate Dehydrogenase (LDH). (3-NADH conversion to NAD+ is monitored by the decrease in absorbance at 340 nm (e=6.22 cm-1 mM-1) using a Molecular Devices SPECTRA max PLUS spectrophotometer.A typical assay was carried out on a 96-well, clear microtiter plate in a Molecular Devices spectrophotometer for 20 minutes at 30 C. in 0.1 mL of assay buffer containing 50 mM HEPES, pH 7.4, 5 nM PKC, 23 units of pyruvate kinase, 33 units of lactate dehydrogenase, 0.15 mM peptide, 0.1 mM ATP, 1 mM DTT, 4 mM PEP, 8 mM MgCl2, 0.3 mM NADH, 60 mM CaCl2, 10 mg/mL PS, 50 ng/mL PMA, 7.5% DMSO and from about 10,000 nM to 0.169 nM compound inhibitor.	B	Cc1cc(C(=O)Nc2n[nH]c3c2CN(C(=O)N2C[C@@H](C)N(CC4CCOCC4)C[C@@H]2C)C3(C)C)on1		CHEMBL3662912	=	Ki	nM	38.1	CHEMBL3045	Homo sapiens	Ki	nM	38.1
295415	17676650	CHEMBL3705825	Inhibition Assay: Protein Kinase C beta 2 (PKC beta II) catalyzes the production of ADP from ATP that accompanies the phosphoryl transfer to the PKC Pseudosubstrate peptide (A->S, RFARKGSLRQKNV). This transfer is coupled to the oxidation of p-NADH through the activities of Pyruvate Kinase (PK) and Lactate Dehydrogenase (LDH). (3-NADH conversion to NAD+ is monitored by the decrease in absorbance at 340 nm (e=6.22 cm-1 mM-1) using a Molecular Devices SPECTRA max PLUS spectrophotometer.A typical assay was carried out on a 96-well, clear microtiter plate in a Molecular Devices spectrophotometer for 20 minutes at 30 C. in 0.1 mL of assay buffer containing 50 mM HEPES, pH 7.4, 5 nM PKC, 23 units of pyruvate kinase, 33 units of lactate dehydrogenase, 0.15 mM peptide, 0.1 mM ATP, 1 mM DTT, 4 mM PEP, 8 mM MgCl2, 0.3 mM NADH, 60 mM CaCl2, 10 mg/mL PS, 50 ng/mL PMA, 7.5% DMSO and from about 10,000 nM to 0.169 nM compound inhibitor.	B	Cc1nonc1C(=O)Nc1n[nH]c2c1CN(C(=O)N1C[C@@H](C)N(CC3CCOCC3)C[C@@H]1C)C2(C)C		CHEMBL3662913	=	Ki	nM	47.3	CHEMBL3045	Homo sapiens	Ki	nM	47.3
295416	17676651	CHEMBL3705825	Inhibition Assay: Protein Kinase C beta 2 (PKC beta II) catalyzes the production of ADP from ATP that accompanies the phosphoryl transfer to the PKC Pseudosubstrate peptide (A->S, RFARKGSLRQKNV). This transfer is coupled to the oxidation of p-NADH through the activities of Pyruvate Kinase (PK) and Lactate Dehydrogenase (LDH). (3-NADH conversion to NAD+ is monitored by the decrease in absorbance at 340 nm (e=6.22 cm-1 mM-1) using a Molecular Devices SPECTRA max PLUS spectrophotometer.A typical assay was carried out on a 96-well, clear microtiter plate in a Molecular Devices spectrophotometer for 20 minutes at 30 C. in 0.1 mL of assay buffer containing 50 mM HEPES, pH 7.4, 5 nM PKC, 23 units of pyruvate kinase, 33 units of lactate dehydrogenase, 0.15 mM peptide, 0.1 mM ATP, 1 mM DTT, 4 mM PEP, 8 mM MgCl2, 0.3 mM NADH, 60 mM CaCl2, 10 mg/mL PS, 50 ng/mL PMA, 7.5% DMSO and from about 10,000 nM to 0.169 nM compound inhibitor.	B	Cc1nc(C(=O)Nc2n[nH]c3c2CN(C(=O)N2C[C@@H](C)N(CC4CCOCC4)C[C@@H]2C)C3(C)C)c(C)o1		CHEMBL3662914	=	Ki	nM	31.3	CHEMBL3045	Homo sapiens	Ki	nM	31.3
295417	17676652	CHEMBL3705825	Inhibition Assay: Protein Kinase C beta 2 (PKC beta II) catalyzes the production of ADP from ATP that accompanies the phosphoryl transfer to the PKC Pseudosubstrate peptide (A->S, RFARKGSLRQKNV). This transfer is coupled to the oxidation of p-NADH through the activities of Pyruvate Kinase (PK) and Lactate Dehydrogenase (LDH). (3-NADH conversion to NAD+ is monitored by the decrease in absorbance at 340 nm (e=6.22 cm-1 mM-1) using a Molecular Devices SPECTRA max PLUS spectrophotometer.A typical assay was carried out on a 96-well, clear microtiter plate in a Molecular Devices spectrophotometer for 20 minutes at 30 C. in 0.1 mL of assay buffer containing 50 mM HEPES, pH 7.4, 5 nM PKC, 23 units of pyruvate kinase, 33 units of lactate dehydrogenase, 0.15 mM peptide, 0.1 mM ATP, 1 mM DTT, 4 mM PEP, 8 mM MgCl2, 0.3 mM NADH, 60 mM CaCl2, 10 mg/mL PS, 50 ng/mL PMA, 7.5% DMSO and from about 10,000 nM to 0.169 nM compound inhibitor.	B	CCCc1cc(C(=O)Nc2n[nH]c3c2CN(C(=O)N2C[C@@H](C)N(CC4CCOCC4)C[C@@H]2C)C3(C)C)no1		CHEMBL3662915	=	Ki	nM	59.4	CHEMBL3045	Homo sapiens	Ki	nM	59.4
295418	17676653	CHEMBL3705825	Inhibition Assay: Protein Kinase C beta 2 (PKC beta II) catalyzes the production of ADP from ATP that accompanies the phosphoryl transfer to the PKC Pseudosubstrate peptide (A->S, RFARKGSLRQKNV). This transfer is coupled to the oxidation of p-NADH through the activities of Pyruvate Kinase (PK) and Lactate Dehydrogenase (LDH). (3-NADH conversion to NAD+ is monitored by the decrease in absorbance at 340 nm (e=6.22 cm-1 mM-1) using a Molecular Devices SPECTRA max PLUS spectrophotometer.A typical assay was carried out on a 96-well, clear microtiter plate in a Molecular Devices spectrophotometer for 20 minutes at 30 C. in 0.1 mL of assay buffer containing 50 mM HEPES, pH 7.4, 5 nM PKC, 23 units of pyruvate kinase, 33 units of lactate dehydrogenase, 0.15 mM peptide, 0.1 mM ATP, 1 mM DTT, 4 mM PEP, 8 mM MgCl2, 0.3 mM NADH, 60 mM CaCl2, 10 mg/mL PS, 50 ng/mL PMA, 7.5% DMSO and from about 10,000 nM to 0.169 nM compound inhibitor.	B	CCc1nc(C(=O)Nc2n[nH]c3c2CN(C(=O)N2C[C@@H](C)N(CC4CCOCC4)C[C@@H]2C)C3(C)C)cs1		CHEMBL3662916	=	Ki	nM	33.3	CHEMBL3045	Homo sapiens	Ki	nM	33.3
295419	17676654	CHEMBL3705825	Inhibition Assay: Protein Kinase C beta 2 (PKC beta II) catalyzes the production of ADP from ATP that accompanies the phosphoryl transfer to the PKC Pseudosubstrate peptide (A->S, RFARKGSLRQKNV). This transfer is coupled to the oxidation of p-NADH through the activities of Pyruvate Kinase (PK) and Lactate Dehydrogenase (LDH). (3-NADH conversion to NAD+ is monitored by the decrease in absorbance at 340 nm (e=6.22 cm-1 mM-1) using a Molecular Devices SPECTRA max PLUS spectrophotometer.A typical assay was carried out on a 96-well, clear microtiter plate in a Molecular Devices spectrophotometer for 20 minutes at 30 C. in 0.1 mL of assay buffer containing 50 mM HEPES, pH 7.4, 5 nM PKC, 23 units of pyruvate kinase, 33 units of lactate dehydrogenase, 0.15 mM peptide, 0.1 mM ATP, 1 mM DTT, 4 mM PEP, 8 mM MgCl2, 0.3 mM NADH, 60 mM CaCl2, 10 mg/mL PS, 50 ng/mL PMA, 7.5% DMSO and from about 10,000 nM to 0.169 nM compound inhibitor.	B	C.C[C@H]1CN(CC2CCOCC2)CCN1C(=O)N1Cc2c(NC(=O)c3ccc(F)cn3)n[nH]c2C1(C)C		CHEMBL3960180	=	Ki	nM	12.8	CHEMBL3045	Homo sapiens	Ki	nM	12.8
295420	17676655	CHEMBL3705825	Inhibition Assay: Protein Kinase C beta 2 (PKC beta II) catalyzes the production of ADP from ATP that accompanies the phosphoryl transfer to the PKC Pseudosubstrate peptide (A->S, RFARKGSLRQKNV). This transfer is coupled to the oxidation of p-NADH through the activities of Pyruvate Kinase (PK) and Lactate Dehydrogenase (LDH). (3-NADH conversion to NAD+ is monitored by the decrease in absorbance at 340 nm (e=6.22 cm-1 mM-1) using a Molecular Devices SPECTRA max PLUS spectrophotometer.A typical assay was carried out on a 96-well, clear microtiter plate in a Molecular Devices spectrophotometer for 20 minutes at 30 C. in 0.1 mL of assay buffer containing 50 mM HEPES, pH 7.4, 5 nM PKC, 23 units of pyruvate kinase, 33 units of lactate dehydrogenase, 0.15 mM peptide, 0.1 mM ATP, 1 mM DTT, 4 mM PEP, 8 mM MgCl2, 0.3 mM NADH, 60 mM CaCl2, 10 mg/mL PS, 50 ng/mL PMA, 7.5% DMSO and from about 10,000 nM to 0.169 nM compound inhibitor.	B	C.Cc1ccnc(C(=O)Nc2n[nH]c3c2CN(C(=O)N2CCN(CC4CCOCC4)C[C@@H]2C)C3(C)C)c1		CHEMBL3933521	=	Ki	nM	21.7	CHEMBL3045	Homo sapiens	Ki	nM	21.7
295421	17676656	CHEMBL3705825	Inhibition Assay: Protein Kinase C beta 2 (PKC beta II) catalyzes the production of ADP from ATP that accompanies the phosphoryl transfer to the PKC Pseudosubstrate peptide (A->S, RFARKGSLRQKNV). This transfer is coupled to the oxidation of p-NADH through the activities of Pyruvate Kinase (PK) and Lactate Dehydrogenase (LDH). (3-NADH conversion to NAD+ is monitored by the decrease in absorbance at 340 nm (e=6.22 cm-1 mM-1) using a Molecular Devices SPECTRA max PLUS spectrophotometer.A typical assay was carried out on a 96-well, clear microtiter plate in a Molecular Devices spectrophotometer for 20 minutes at 30 C. in 0.1 mL of assay buffer containing 50 mM HEPES, pH 7.4, 5 nM PKC, 23 units of pyruvate kinase, 33 units of lactate dehydrogenase, 0.15 mM peptide, 0.1 mM ATP, 1 mM DTT, 4 mM PEP, 8 mM MgCl2, 0.3 mM NADH, 60 mM CaCl2, 10 mg/mL PS, 50 ng/mL PMA, 7.5% DMSO and from about 10,000 nM to 0.169 nM compound inhibitor.	B	C.COc1cccc(C(=O)Nc2n[nH]c3c2CN(C(=O)N2CCN(CC4CCOCC4)C[C@@H]2C)C3(C)C)n1		CHEMBL3914445	=	Ki	nM	46.7	CHEMBL3045	Homo sapiens	Ki	nM	46.7
295422	17676657	CHEMBL3705825	Inhibition Assay: Protein Kinase C beta 2 (PKC beta II) catalyzes the production of ADP from ATP that accompanies the phosphoryl transfer to the PKC Pseudosubstrate peptide (A->S, RFARKGSLRQKNV). This transfer is coupled to the oxidation of p-NADH through the activities of Pyruvate Kinase (PK) and Lactate Dehydrogenase (LDH). (3-NADH conversion to NAD+ is monitored by the decrease in absorbance at 340 nm (e=6.22 cm-1 mM-1) using a Molecular Devices SPECTRA max PLUS spectrophotometer.A typical assay was carried out on a 96-well, clear microtiter plate in a Molecular Devices spectrophotometer for 20 minutes at 30 C. in 0.1 mL of assay buffer containing 50 mM HEPES, pH 7.4, 5 nM PKC, 23 units of pyruvate kinase, 33 units of lactate dehydrogenase, 0.15 mM peptide, 0.1 mM ATP, 1 mM DTT, 4 mM PEP, 8 mM MgCl2, 0.3 mM NADH, 60 mM CaCl2, 10 mg/mL PS, 50 ng/mL PMA, 7.5% DMSO and from about 10,000 nM to 0.169 nM compound inhibitor.	B	C.COc1ccc(C(=O)Nc2n[nH]c3c2CN(C(=O)N2CCN(CC4CCOCC4)C[C@@H]2C)C3(C)C)nc1		CHEMBL3942662	<	Ki	nM	10.0	CHEMBL3045	Homo sapiens	Ki	nM	10.0
295423	17676658	CHEMBL3705825	Inhibition Assay: Protein Kinase C beta 2 (PKC beta II) catalyzes the production of ADP from ATP that accompanies the phosphoryl transfer to the PKC Pseudosubstrate peptide (A->S, RFARKGSLRQKNV). This transfer is coupled to the oxidation of p-NADH through the activities of Pyruvate Kinase (PK) and Lactate Dehydrogenase (LDH). (3-NADH conversion to NAD+ is monitored by the decrease in absorbance at 340 nm (e=6.22 cm-1 mM-1) using a Molecular Devices SPECTRA max PLUS spectrophotometer.A typical assay was carried out on a 96-well, clear microtiter plate in a Molecular Devices spectrophotometer for 20 minutes at 30 C. in 0.1 mL of assay buffer containing 50 mM HEPES, pH 7.4, 5 nM PKC, 23 units of pyruvate kinase, 33 units of lactate dehydrogenase, 0.15 mM peptide, 0.1 mM ATP, 1 mM DTT, 4 mM PEP, 8 mM MgCl2, 0.3 mM NADH, 60 mM CaCl2, 10 mg/mL PS, 50 ng/mL PMA, 7.5% DMSO and from about 10,000 nM to 0.169 nM compound inhibitor.	B	C.C[C@H]1CN(CC2CCOCC2)CCN1C(=O)N1Cc2c(NC(=O)c3ccc(Cl)cn3)n[nH]c2C1(C)C		CHEMBL3969799	=	Ki	nM	11.9	CHEMBL3045	Homo sapiens	Ki	nM	11.9
295424	17676659	CHEMBL3705825	Inhibition Assay: Protein Kinase C beta 2 (PKC beta II) catalyzes the production of ADP from ATP that accompanies the phosphoryl transfer to the PKC Pseudosubstrate peptide (A->S, RFARKGSLRQKNV). This transfer is coupled to the oxidation of p-NADH through the activities of Pyruvate Kinase (PK) and Lactate Dehydrogenase (LDH). (3-NADH conversion to NAD+ is monitored by the decrease in absorbance at 340 nm (e=6.22 cm-1 mM-1) using a Molecular Devices SPECTRA max PLUS spectrophotometer.A typical assay was carried out on a 96-well, clear microtiter plate in a Molecular Devices spectrophotometer for 20 minutes at 30 C. in 0.1 mL of assay buffer containing 50 mM HEPES, pH 7.4, 5 nM PKC, 23 units of pyruvate kinase, 33 units of lactate dehydrogenase, 0.15 mM peptide, 0.1 mM ATP, 1 mM DTT, 4 mM PEP, 8 mM MgCl2, 0.3 mM NADH, 60 mM CaCl2, 10 mg/mL PS, 50 ng/mL PMA, 7.5% DMSO and from about 10,000 nM to 0.169 nM compound inhibitor.	B	C.Cc1cccc(C(=O)Nc2n[nH]c3c2CN(C(=O)N2CCN(CC4CCOCC4)C[C@@H]2C)C3(C)C)n1		CHEMBL3947241	=	Ki	nM	15.0	CHEMBL3045	Homo sapiens	Ki	nM	15.0
295425	17676660	CHEMBL3705825	Inhibition Assay: Protein Kinase C beta 2 (PKC beta II) catalyzes the production of ADP from ATP that accompanies the phosphoryl transfer to the PKC Pseudosubstrate peptide (A->S, RFARKGSLRQKNV). This transfer is coupled to the oxidation of p-NADH through the activities of Pyruvate Kinase (PK) and Lactate Dehydrogenase (LDH). (3-NADH conversion to NAD+ is monitored by the decrease in absorbance at 340 nm (e=6.22 cm-1 mM-1) using a Molecular Devices SPECTRA max PLUS spectrophotometer.A typical assay was carried out on a 96-well, clear microtiter plate in a Molecular Devices spectrophotometer for 20 minutes at 30 C. in 0.1 mL of assay buffer containing 50 mM HEPES, pH 7.4, 5 nM PKC, 23 units of pyruvate kinase, 33 units of lactate dehydrogenase, 0.15 mM peptide, 0.1 mM ATP, 1 mM DTT, 4 mM PEP, 8 mM MgCl2, 0.3 mM NADH, 60 mM CaCl2, 10 mg/mL PS, 50 ng/mL PMA, 7.5% DMSO and from about 10,000 nM to 0.169 nM compound inhibitor.	B	C.Cc1nc(C(=O)Nc2n[nH]c3c2CN(C(=O)N2CCN(CC4CCOCC4)C[C@@H]2C)C3(C)C)cs1		CHEMBL3965116	=	Ki	nM	12.8	CHEMBL3045	Homo sapiens	Ki	nM	12.8
295426	17676661	CHEMBL3705825	Inhibition Assay: Protein Kinase C beta 2 (PKC beta II) catalyzes the production of ADP from ATP that accompanies the phosphoryl transfer to the PKC Pseudosubstrate peptide (A->S, RFARKGSLRQKNV). This transfer is coupled to the oxidation of p-NADH through the activities of Pyruvate Kinase (PK) and Lactate Dehydrogenase (LDH). (3-NADH conversion to NAD+ is monitored by the decrease in absorbance at 340 nm (e=6.22 cm-1 mM-1) using a Molecular Devices SPECTRA max PLUS spectrophotometer.A typical assay was carried out on a 96-well, clear microtiter plate in a Molecular Devices spectrophotometer for 20 minutes at 30 C. in 0.1 mL of assay buffer containing 50 mM HEPES, pH 7.4, 5 nM PKC, 23 units of pyruvate kinase, 33 units of lactate dehydrogenase, 0.15 mM peptide, 0.1 mM ATP, 1 mM DTT, 4 mM PEP, 8 mM MgCl2, 0.3 mM NADH, 60 mM CaCl2, 10 mg/mL PS, 50 ng/mL PMA, 7.5% DMSO and from about 10,000 nM to 0.169 nM compound inhibitor.	B	C.Cc1ccc(C(=O)Nc2n[nH]c3c2CN(C(=O)N2CCN(CC4CCOCC4)C[C@@H]2C)C3(C)C)nc1		CHEMBL3960003	=	Ki	nM	26.4	CHEMBL3045	Homo sapiens	Ki	nM	26.4
295427	17676662	CHEMBL3705825	Inhibition Assay: Protein Kinase C beta 2 (PKC beta II) catalyzes the production of ADP from ATP that accompanies the phosphoryl transfer to the PKC Pseudosubstrate peptide (A->S, RFARKGSLRQKNV). This transfer is coupled to the oxidation of p-NADH through the activities of Pyruvate Kinase (PK) and Lactate Dehydrogenase (LDH). (3-NADH conversion to NAD+ is monitored by the decrease in absorbance at 340 nm (e=6.22 cm-1 mM-1) using a Molecular Devices SPECTRA max PLUS spectrophotometer.A typical assay was carried out on a 96-well, clear microtiter plate in a Molecular Devices spectrophotometer for 20 minutes at 30 C. in 0.1 mL of assay buffer containing 50 mM HEPES, pH 7.4, 5 nM PKC, 23 units of pyruvate kinase, 33 units of lactate dehydrogenase, 0.15 mM peptide, 0.1 mM ATP, 1 mM DTT, 4 mM PEP, 8 mM MgCl2, 0.3 mM NADH, 60 mM CaCl2, 10 mg/mL PS, 50 ng/mL PMA, 7.5% DMSO and from about 10,000 nM to 0.169 nM compound inhibitor.	B	C.Cc1cc(C(=O)Nc2n[nH]c3c2CN(C(=O)N2CCN(CC4CCOCC4)C[C@@H]2C)C3(C)C)n(C)n1		CHEMBL3941605	<	Ki	nM	10.0	CHEMBL3045	Homo sapiens	Ki	nM	10.0
295428	17676663	CHEMBL3705825	Inhibition Assay: Protein Kinase C beta 2 (PKC beta II) catalyzes the production of ADP from ATP that accompanies the phosphoryl transfer to the PKC Pseudosubstrate peptide (A->S, RFARKGSLRQKNV). This transfer is coupled to the oxidation of p-NADH through the activities of Pyruvate Kinase (PK) and Lactate Dehydrogenase (LDH). (3-NADH conversion to NAD+ is monitored by the decrease in absorbance at 340 nm (e=6.22 cm-1 mM-1) using a Molecular Devices SPECTRA max PLUS spectrophotometer.A typical assay was carried out on a 96-well, clear microtiter plate in a Molecular Devices spectrophotometer for 20 minutes at 30 C. in 0.1 mL of assay buffer containing 50 mM HEPES, pH 7.4, 5 nM PKC, 23 units of pyruvate kinase, 33 units of lactate dehydrogenase, 0.15 mM peptide, 0.1 mM ATP, 1 mM DTT, 4 mM PEP, 8 mM MgCl2, 0.3 mM NADH, 60 mM CaCl2, 10 mg/mL PS, 50 ng/mL PMA, 7.5% DMSO and from about 10,000 nM to 0.169 nM compound inhibitor.	B	C.C[C@H]1CN(CC2CCOCC2)CCN1C(=O)N1Cc2c(NC(=O)c3cncn3C)n[nH]c2C1(C)C		CHEMBL3971197	=	Ki	nM	47.9	CHEMBL3045	Homo sapiens	Ki	nM	47.9
295429	17676664	CHEMBL3705825	Inhibition Assay: Protein Kinase C beta 2 (PKC beta II) catalyzes the production of ADP from ATP that accompanies the phosphoryl transfer to the PKC Pseudosubstrate peptide (A->S, RFARKGSLRQKNV). This transfer is coupled to the oxidation of p-NADH through the activities of Pyruvate Kinase (PK) and Lactate Dehydrogenase (LDH). (3-NADH conversion to NAD+ is monitored by the decrease in absorbance at 340 nm (e=6.22 cm-1 mM-1) using a Molecular Devices SPECTRA max PLUS spectrophotometer.A typical assay was carried out on a 96-well, clear microtiter plate in a Molecular Devices spectrophotometer for 20 minutes at 30 C. in 0.1 mL of assay buffer containing 50 mM HEPES, pH 7.4, 5 nM PKC, 23 units of pyruvate kinase, 33 units of lactate dehydrogenase, 0.15 mM peptide, 0.1 mM ATP, 1 mM DTT, 4 mM PEP, 8 mM MgCl2, 0.3 mM NADH, 60 mM CaCl2, 10 mg/mL PS, 50 ng/mL PMA, 7.5% DMSO and from about 10,000 nM to 0.169 nM compound inhibitor.	B	C.C[C@H]1CN(CC2CCOCC2)CCN1C(=O)N1Cc2c(NC(=O)c3cn(C)cn3)n[nH]c2C1(C)C		CHEMBL3948813	=	Ki	nM	62.4	CHEMBL3045	Homo sapiens	Ki	nM	62.4
295430	17676665	CHEMBL3705825	Inhibition Assay: Protein Kinase C beta 2 (PKC beta II) catalyzes the production of ADP from ATP that accompanies the phosphoryl transfer to the PKC Pseudosubstrate peptide (A->S, RFARKGSLRQKNV). This transfer is coupled to the oxidation of p-NADH through the activities of Pyruvate Kinase (PK) and Lactate Dehydrogenase (LDH). (3-NADH conversion to NAD+ is monitored by the decrease in absorbance at 340 nm (e=6.22 cm-1 mM-1) using a Molecular Devices SPECTRA max PLUS spectrophotometer.A typical assay was carried out on a 96-well, clear microtiter plate in a Molecular Devices spectrophotometer for 20 minutes at 30 C. in 0.1 mL of assay buffer containing 50 mM HEPES, pH 7.4, 5 nM PKC, 23 units of pyruvate kinase, 33 units of lactate dehydrogenase, 0.15 mM peptide, 0.1 mM ATP, 1 mM DTT, 4 mM PEP, 8 mM MgCl2, 0.3 mM NADH, 60 mM CaCl2, 10 mg/mL PS, 50 ng/mL PMA, 7.5% DMSO and from about 10,000 nM to 0.169 nM compound inhibitor.	B	C.C[C@H]1CN(CC2CCOCC2)CCN1C(=O)N1Cc2c(NC(=O)c3cn(C4CCC4)cn3)n[nH]c2C1(C)C		CHEMBL3921008	=	Ki	nM	14.1	CHEMBL3045	Homo sapiens	Ki	nM	14.1
295431	17676666	CHEMBL3705825	Inhibition Assay: Protein Kinase C beta 2 (PKC beta II) catalyzes the production of ADP from ATP that accompanies the phosphoryl transfer to the PKC Pseudosubstrate peptide (A->S, RFARKGSLRQKNV). This transfer is coupled to the oxidation of p-NADH through the activities of Pyruvate Kinase (PK) and Lactate Dehydrogenase (LDH). (3-NADH conversion to NAD+ is monitored by the decrease in absorbance at 340 nm (e=6.22 cm-1 mM-1) using a Molecular Devices SPECTRA max PLUS spectrophotometer.A typical assay was carried out on a 96-well, clear microtiter plate in a Molecular Devices spectrophotometer for 20 minutes at 30 C. in 0.1 mL of assay buffer containing 50 mM HEPES, pH 7.4, 5 nM PKC, 23 units of pyruvate kinase, 33 units of lactate dehydrogenase, 0.15 mM peptide, 0.1 mM ATP, 1 mM DTT, 4 mM PEP, 8 mM MgCl2, 0.3 mM NADH, 60 mM CaCl2, 10 mg/mL PS, 50 ng/mL PMA, 7.5% DMSO and from about 10,000 nM to 0.169 nM compound inhibitor.	B	C.C.CCn1cnc(C(=O)Nc2n[nH]c3c2CN(C(=O)N2CCN(CC4CCOCC4)C[C@@H]2C)C3(C)C)c1		CHEMBL3986299	=	Ki	nM	23.8	CHEMBL3045	Homo sapiens	Ki	nM	23.8
295432	17676667	CHEMBL3705825	Inhibition Assay: Protein Kinase C beta 2 (PKC beta II) catalyzes the production of ADP from ATP that accompanies the phosphoryl transfer to the PKC Pseudosubstrate peptide (A->S, RFARKGSLRQKNV). This transfer is coupled to the oxidation of p-NADH through the activities of Pyruvate Kinase (PK) and Lactate Dehydrogenase (LDH). (3-NADH conversion to NAD+ is monitored by the decrease in absorbance at 340 nm (e=6.22 cm-1 mM-1) using a Molecular Devices SPECTRA max PLUS spectrophotometer.A typical assay was carried out on a 96-well, clear microtiter plate in a Molecular Devices spectrophotometer for 20 minutes at 30 C. in 0.1 mL of assay buffer containing 50 mM HEPES, pH 7.4, 5 nM PKC, 23 units of pyruvate kinase, 33 units of lactate dehydrogenase, 0.15 mM peptide, 0.1 mM ATP, 1 mM DTT, 4 mM PEP, 8 mM MgCl2, 0.3 mM NADH, 60 mM CaCl2, 10 mg/mL PS, 50 ng/mL PMA, 7.5% DMSO and from about 10,000 nM to 0.169 nM compound inhibitor.	B	C.CCC1NC(C(=O)Nc2n[nH]c3c2CN(C(=O)N2CCN(CC4CCOCC4)C[C@@H]2C)C3(C)C)=CO1		CHEMBL3961038	=	Ki	nM	14.9	CHEMBL3045	Homo sapiens	Ki	nM	14.9
295433	17676668	CHEMBL3705825	Inhibition Assay: Protein Kinase C beta 2 (PKC beta II) catalyzes the production of ADP from ATP that accompanies the phosphoryl transfer to the PKC Pseudosubstrate peptide (A->S, RFARKGSLRQKNV). This transfer is coupled to the oxidation of p-NADH through the activities of Pyruvate Kinase (PK) and Lactate Dehydrogenase (LDH). (3-NADH conversion to NAD+ is monitored by the decrease in absorbance at 340 nm (e=6.22 cm-1 mM-1) using a Molecular Devices SPECTRA max PLUS spectrophotometer.A typical assay was carried out on a 96-well, clear microtiter plate in a Molecular Devices spectrophotometer for 20 minutes at 30 C. in 0.1 mL of assay buffer containing 50 mM HEPES, pH 7.4, 5 nM PKC, 23 units of pyruvate kinase, 33 units of lactate dehydrogenase, 0.15 mM peptide, 0.1 mM ATP, 1 mM DTT, 4 mM PEP, 8 mM MgCl2, 0.3 mM NADH, 60 mM CaCl2, 10 mg/mL PS, 50 ng/mL PMA, 7.5% DMSO and from about 10,000 nM to 0.169 nM compound inhibitor.	B	C.C[C@H]1CN(CC2CCOCC2)CCN1C(=O)N1Cc2c(NC(=O)c3coc(C4CC4)n3)n[nH]c2C1(C)C		CHEMBL3934515	=	Ki	nM	15.7	CHEMBL3045	Homo sapiens	Ki	nM	15.7
295434	17676669	CHEMBL3705825	Inhibition Assay: Protein Kinase C beta 2 (PKC beta II) catalyzes the production of ADP from ATP that accompanies the phosphoryl transfer to the PKC Pseudosubstrate peptide (A->S, RFARKGSLRQKNV). This transfer is coupled to the oxidation of p-NADH through the activities of Pyruvate Kinase (PK) and Lactate Dehydrogenase (LDH). (3-NADH conversion to NAD+ is monitored by the decrease in absorbance at 340 nm (e=6.22 cm-1 mM-1) using a Molecular Devices SPECTRA max PLUS spectrophotometer.A typical assay was carried out on a 96-well, clear microtiter plate in a Molecular Devices spectrophotometer for 20 minutes at 30 C. in 0.1 mL of assay buffer containing 50 mM HEPES, pH 7.4, 5 nM PKC, 23 units of pyruvate kinase, 33 units of lactate dehydrogenase, 0.15 mM peptide, 0.1 mM ATP, 1 mM DTT, 4 mM PEP, 8 mM MgCl2, 0.3 mM NADH, 60 mM CaCl2, 10 mg/mL PS, 50 ng/mL PMA, 7.5% DMSO and from about 10,000 nM to 0.169 nM compound inhibitor.	B	C.C.C[C@H]1CN(CC2CCOCC2)CCN1C(=O)N1Cc2c(NC(=O)c3cocn3)n[nH]c2C1(C)C		CHEMBL3906555	=	Ki	nM	117.0	CHEMBL3045	Homo sapiens	Ki	nM	117.0
295435	17676670	CHEMBL3705825	Inhibition Assay: Protein Kinase C beta 2 (PKC beta II) catalyzes the production of ADP from ATP that accompanies the phosphoryl transfer to the PKC Pseudosubstrate peptide (A->S, RFARKGSLRQKNV). This transfer is coupled to the oxidation of p-NADH through the activities of Pyruvate Kinase (PK) and Lactate Dehydrogenase (LDH). (3-NADH conversion to NAD+ is monitored by the decrease in absorbance at 340 nm (e=6.22 cm-1 mM-1) using a Molecular Devices SPECTRA max PLUS spectrophotometer.A typical assay was carried out on a 96-well, clear microtiter plate in a Molecular Devices spectrophotometer for 20 minutes at 30 C. in 0.1 mL of assay buffer containing 50 mM HEPES, pH 7.4, 5 nM PKC, 23 units of pyruvate kinase, 33 units of lactate dehydrogenase, 0.15 mM peptide, 0.1 mM ATP, 1 mM DTT, 4 mM PEP, 8 mM MgCl2, 0.3 mM NADH, 60 mM CaCl2, 10 mg/mL PS, 50 ng/mL PMA, 7.5% DMSO and from about 10,000 nM to 0.169 nM compound inhibitor.	B	C.C[C@H]1CN(CC2CCOCC2)CCN1C(=O)N1Cc2c(NC(=O)c3ccccc3)n[nH]c2C1(C)C		CHEMBL3943487	=	Ki	nM	30.1	CHEMBL3045	Homo sapiens	Ki	nM	30.1
295436	17676671	CHEMBL3705825	Inhibition Assay: Protein Kinase C beta 2 (PKC beta II) catalyzes the production of ADP from ATP that accompanies the phosphoryl transfer to the PKC Pseudosubstrate peptide (A->S, RFARKGSLRQKNV). This transfer is coupled to the oxidation of p-NADH through the activities of Pyruvate Kinase (PK) and Lactate Dehydrogenase (LDH). (3-NADH conversion to NAD+ is monitored by the decrease in absorbance at 340 nm (e=6.22 cm-1 mM-1) using a Molecular Devices SPECTRA max PLUS spectrophotometer.A typical assay was carried out on a 96-well, clear microtiter plate in a Molecular Devices spectrophotometer for 20 minutes at 30 C. in 0.1 mL of assay buffer containing 50 mM HEPES, pH 7.4, 5 nM PKC, 23 units of pyruvate kinase, 33 units of lactate dehydrogenase, 0.15 mM peptide, 0.1 mM ATP, 1 mM DTT, 4 mM PEP, 8 mM MgCl2, 0.3 mM NADH, 60 mM CaCl2, 10 mg/mL PS, 50 ng/mL PMA, 7.5% DMSO and from about 10,000 nM to 0.169 nM compound inhibitor.	B	C.CCn1ccc(C(=O)Nc2n[nH]c3c2CN(C(=O)N2CCN(CC4CCOCC4)C[C@@H]2C)C3(C)C)n1		CHEMBL3912065	=	Ki	nM	26.9	CHEMBL3045	Homo sapiens	Ki	nM	26.9
295437	17676672	CHEMBL3705825	Inhibition Assay: Protein Kinase C beta 2 (PKC beta II) catalyzes the production of ADP from ATP that accompanies the phosphoryl transfer to the PKC Pseudosubstrate peptide (A->S, RFARKGSLRQKNV). This transfer is coupled to the oxidation of p-NADH through the activities of Pyruvate Kinase (PK) and Lactate Dehydrogenase (LDH). (3-NADH conversion to NAD+ is monitored by the decrease in absorbance at 340 nm (e=6.22 cm-1 mM-1) using a Molecular Devices SPECTRA max PLUS spectrophotometer.A typical assay was carried out on a 96-well, clear microtiter plate in a Molecular Devices spectrophotometer for 20 minutes at 30 C. in 0.1 mL of assay buffer containing 50 mM HEPES, pH 7.4, 5 nM PKC, 23 units of pyruvate kinase, 33 units of lactate dehydrogenase, 0.15 mM peptide, 0.1 mM ATP, 1 mM DTT, 4 mM PEP, 8 mM MgCl2, 0.3 mM NADH, 60 mM CaCl2, 10 mg/mL PS, 50 ng/mL PMA, 7.5% DMSO and from about 10,000 nM to 0.169 nM compound inhibitor.	B	C.Cc1cccc(C(=O)Nc2n[nH]c3c2CN(C(=O)N2CCN(CC4CCOCC4)C[C@@H]2C)C3(C)C)c1		CHEMBL3915428	<	Ki	nM	10.0	CHEMBL3045	Homo sapiens	Ki	nM	10.0
295438	17676673	CHEMBL3705825	Inhibition Assay: Protein Kinase C beta 2 (PKC beta II) catalyzes the production of ADP from ATP that accompanies the phosphoryl transfer to the PKC Pseudosubstrate peptide (A->S, RFARKGSLRQKNV). This transfer is coupled to the oxidation of p-NADH through the activities of Pyruvate Kinase (PK) and Lactate Dehydrogenase (LDH). (3-NADH conversion to NAD+ is monitored by the decrease in absorbance at 340 nm (e=6.22 cm-1 mM-1) using a Molecular Devices SPECTRA max PLUS spectrophotometer.A typical assay was carried out on a 96-well, clear microtiter plate in a Molecular Devices spectrophotometer for 20 minutes at 30 C. in 0.1 mL of assay buffer containing 50 mM HEPES, pH 7.4, 5 nM PKC, 23 units of pyruvate kinase, 33 units of lactate dehydrogenase, 0.15 mM peptide, 0.1 mM ATP, 1 mM DTT, 4 mM PEP, 8 mM MgCl2, 0.3 mM NADH, 60 mM CaCl2, 10 mg/mL PS, 50 ng/mL PMA, 7.5% DMSO and from about 10,000 nM to 0.169 nM compound inhibitor.	B	C.Cc1ccccc1C(=O)Nc1n[nH]c2c1CN(C(=O)N1CCN(CC3CCOCC3)C[C@@H]1C)C2(C)C		CHEMBL3985199	=	Ki	nM	67.1	CHEMBL3045	Homo sapiens	Ki	nM	67.1
295439	17676674	CHEMBL3705825	Inhibition Assay: Protein Kinase C beta 2 (PKC beta II) catalyzes the production of ADP from ATP that accompanies the phosphoryl transfer to the PKC Pseudosubstrate peptide (A->S, RFARKGSLRQKNV). This transfer is coupled to the oxidation of p-NADH through the activities of Pyruvate Kinase (PK) and Lactate Dehydrogenase (LDH). (3-NADH conversion to NAD+ is monitored by the decrease in absorbance at 340 nm (e=6.22 cm-1 mM-1) using a Molecular Devices SPECTRA max PLUS spectrophotometer.A typical assay was carried out on a 96-well, clear microtiter plate in a Molecular Devices spectrophotometer for 20 minutes at 30 C. in 0.1 mL of assay buffer containing 50 mM HEPES, pH 7.4, 5 nM PKC, 23 units of pyruvate kinase, 33 units of lactate dehydrogenase, 0.15 mM peptide, 0.1 mM ATP, 1 mM DTT, 4 mM PEP, 8 mM MgCl2, 0.3 mM NADH, 60 mM CaCl2, 10 mg/mL PS, 50 ng/mL PMA, 7.5% DMSO and from about 10,000 nM to 0.169 nM compound inhibitor.	B	C.C[C@H]1CN(CC2CCOCC2)CCN1C(=O)N1Cc2c(NC(=O)c3ccc(F)cc3)n[nH]c2C1(C)C		CHEMBL3929905	=	Ki	nM	11.2	CHEMBL3045	Homo sapiens	Ki	nM	11.2
295440	17676675	CHEMBL3705825	Inhibition Assay: Protein Kinase C beta 2 (PKC beta II) catalyzes the production of ADP from ATP that accompanies the phosphoryl transfer to the PKC Pseudosubstrate peptide (A->S, RFARKGSLRQKNV). This transfer is coupled to the oxidation of p-NADH through the activities of Pyruvate Kinase (PK) and Lactate Dehydrogenase (LDH). (3-NADH conversion to NAD+ is monitored by the decrease in absorbance at 340 nm (e=6.22 cm-1 mM-1) using a Molecular Devices SPECTRA max PLUS spectrophotometer.A typical assay was carried out on a 96-well, clear microtiter plate in a Molecular Devices spectrophotometer for 20 minutes at 30 C. in 0.1 mL of assay buffer containing 50 mM HEPES, pH 7.4, 5 nM PKC, 23 units of pyruvate kinase, 33 units of lactate dehydrogenase, 0.15 mM peptide, 0.1 mM ATP, 1 mM DTT, 4 mM PEP, 8 mM MgCl2, 0.3 mM NADH, 60 mM CaCl2, 10 mg/mL PS, 50 ng/mL PMA, 7.5% DMSO and from about 10,000 nM to 0.169 nM compound inhibitor.	B	C.C[C@H]1CN(CC2CCOCC2)CCN1C(=O)N1Cc2c(NC(=O)c3cccc(F)c3)n[nH]c2C1(C)C		CHEMBL3954093	<	Ki	nM	10.0	CHEMBL3045	Homo sapiens	Ki	nM	10.0
295441	17676676	CHEMBL3705825	Inhibition Assay: Protein Kinase C beta 2 (PKC beta II) catalyzes the production of ADP from ATP that accompanies the phosphoryl transfer to the PKC Pseudosubstrate peptide (A->S, RFARKGSLRQKNV). This transfer is coupled to the oxidation of p-NADH through the activities of Pyruvate Kinase (PK) and Lactate Dehydrogenase (LDH). (3-NADH conversion to NAD+ is monitored by the decrease in absorbance at 340 nm (e=6.22 cm-1 mM-1) using a Molecular Devices SPECTRA max PLUS spectrophotometer.A typical assay was carried out on a 96-well, clear microtiter plate in a Molecular Devices spectrophotometer for 20 minutes at 30 C. in 0.1 mL of assay buffer containing 50 mM HEPES, pH 7.4, 5 nM PKC, 23 units of pyruvate kinase, 33 units of lactate dehydrogenase, 0.15 mM peptide, 0.1 mM ATP, 1 mM DTT, 4 mM PEP, 8 mM MgCl2, 0.3 mM NADH, 60 mM CaCl2, 10 mg/mL PS, 50 ng/mL PMA, 7.5% DMSO and from about 10,000 nM to 0.169 nM compound inhibitor.	B	C.C[C@H]1CN(CC2CCOCC2)CCN1C(=O)N1Cc2c(NC(=O)c3ccc(C#N)cc3)n[nH]c2C1(C)C		CHEMBL3987088	=	Ki	nM	24.3	CHEMBL3045	Homo sapiens	Ki	nM	24.3
295442	17676677	CHEMBL3705825	Inhibition Assay: Protein Kinase C beta 2 (PKC beta II) catalyzes the production of ADP from ATP that accompanies the phosphoryl transfer to the PKC Pseudosubstrate peptide (A->S, RFARKGSLRQKNV). This transfer is coupled to the oxidation of p-NADH through the activities of Pyruvate Kinase (PK) and Lactate Dehydrogenase (LDH). (3-NADH conversion to NAD+ is monitored by the decrease in absorbance at 340 nm (e=6.22 cm-1 mM-1) using a Molecular Devices SPECTRA max PLUS spectrophotometer.A typical assay was carried out on a 96-well, clear microtiter plate in a Molecular Devices spectrophotometer for 20 minutes at 30 C. in 0.1 mL of assay buffer containing 50 mM HEPES, pH 7.4, 5 nM PKC, 23 units of pyruvate kinase, 33 units of lactate dehydrogenase, 0.15 mM peptide, 0.1 mM ATP, 1 mM DTT, 4 mM PEP, 8 mM MgCl2, 0.3 mM NADH, 60 mM CaCl2, 10 mg/mL PS, 50 ng/mL PMA, 7.5% DMSO and from about 10,000 nM to 0.169 nM compound inhibitor.	B	C.C[C@H]1CN(CC2CCOCC2)CCN1C(=O)N1Cc2c(NC(=O)c3cccc(C#N)c3)n[nH]c2C1(C)C		CHEMBL3967714	=	Ki	nM	25.6	CHEMBL3045	Homo sapiens	Ki	nM	25.6
295443	17676678	CHEMBL3705825	Inhibition Assay: Protein Kinase C beta 2 (PKC beta II) catalyzes the production of ADP from ATP that accompanies the phosphoryl transfer to the PKC Pseudosubstrate peptide (A->S, RFARKGSLRQKNV). This transfer is coupled to the oxidation of p-NADH through the activities of Pyruvate Kinase (PK) and Lactate Dehydrogenase (LDH). (3-NADH conversion to NAD+ is monitored by the decrease in absorbance at 340 nm (e=6.22 cm-1 mM-1) using a Molecular Devices SPECTRA max PLUS spectrophotometer.A typical assay was carried out on a 96-well, clear microtiter plate in a Molecular Devices spectrophotometer for 20 minutes at 30 C. in 0.1 mL of assay buffer containing 50 mM HEPES, pH 7.4, 5 nM PKC, 23 units of pyruvate kinase, 33 units of lactate dehydrogenase, 0.15 mM peptide, 0.1 mM ATP, 1 mM DTT, 4 mM PEP, 8 mM MgCl2, 0.3 mM NADH, 60 mM CaCl2, 10 mg/mL PS, 50 ng/mL PMA, 7.5% DMSO and from about 10,000 nM to 0.169 nM compound inhibitor.	B	C.C[C@H]1CN(CC2(O)CCOCC2)CCN1C(=O)N1Cc2c(NC(=O)c3ccccn3)n[nH]c2C1(C)C		CHEMBL3932340	=	Ki	nM	96.1	CHEMBL3045	Homo sapiens	Ki	nM	96.1
295444	17676679	CHEMBL3705825	Inhibition Assay: Protein Kinase C beta 2 (PKC beta II) catalyzes the production of ADP from ATP that accompanies the phosphoryl transfer to the PKC Pseudosubstrate peptide (A->S, RFARKGSLRQKNV). This transfer is coupled to the oxidation of p-NADH through the activities of Pyruvate Kinase (PK) and Lactate Dehydrogenase (LDH). (3-NADH conversion to NAD+ is monitored by the decrease in absorbance at 340 nm (e=6.22 cm-1 mM-1) using a Molecular Devices SPECTRA max PLUS spectrophotometer.A typical assay was carried out on a 96-well, clear microtiter plate in a Molecular Devices spectrophotometer for 20 minutes at 30 C. in 0.1 mL of assay buffer containing 50 mM HEPES, pH 7.4, 5 nM PKC, 23 units of pyruvate kinase, 33 units of lactate dehydrogenase, 0.15 mM peptide, 0.1 mM ATP, 1 mM DTT, 4 mM PEP, 8 mM MgCl2, 0.3 mM NADH, 60 mM CaCl2, 10 mg/mL PS, 50 ng/mL PMA, 7.5% DMSO and from about 10,000 nM to 0.169 nM compound inhibitor.	B	CCc1ccc(C(=O)Nc2n[nH]c3c2CN(C(=O)N2C[C@@H](C)N(C4CCOCC4)C[C@@H]2C)C3(C)C)nc1		CHEMBL3662942	<	Ki	nM	10.0	CHEMBL3045	Homo sapiens	Ki	nM	10.0
295445	17676680	CHEMBL3705825	Inhibition Assay: Protein Kinase C beta 2 (PKC beta II) catalyzes the production of ADP from ATP that accompanies the phosphoryl transfer to the PKC Pseudosubstrate peptide (A->S, RFARKGSLRQKNV). This transfer is coupled to the oxidation of p-NADH through the activities of Pyruvate Kinase (PK) and Lactate Dehydrogenase (LDH). (3-NADH conversion to NAD+ is monitored by the decrease in absorbance at 340 nm (e=6.22 cm-1 mM-1) using a Molecular Devices SPECTRA max PLUS spectrophotometer.A typical assay was carried out on a 96-well, clear microtiter plate in a Molecular Devices spectrophotometer for 20 minutes at 30 C. in 0.1 mL of assay buffer containing 50 mM HEPES, pH 7.4, 5 nM PKC, 23 units of pyruvate kinase, 33 units of lactate dehydrogenase, 0.15 mM peptide, 0.1 mM ATP, 1 mM DTT, 4 mM PEP, 8 mM MgCl2, 0.3 mM NADH, 60 mM CaCl2, 10 mg/mL PS, 50 ng/mL PMA, 7.5% DMSO and from about 10,000 nM to 0.169 nM compound inhibitor.	B	C[C@H]1CN(C2CCOCC2)[C@H](C)CN1C(=O)N1Cc2c(NC(=O)c3ccc(N4CCOCC4)cn3)n[nH]c2C1(C)C		CHEMBL3662943	<	Ki	nM	10.0	CHEMBL3045	Homo sapiens	Ki	nM	10.0
295446	17676681	CHEMBL3705825	Inhibition Assay: Protein Kinase C beta 2 (PKC beta II) catalyzes the production of ADP from ATP that accompanies the phosphoryl transfer to the PKC Pseudosubstrate peptide (A->S, RFARKGSLRQKNV). This transfer is coupled to the oxidation of p-NADH through the activities of Pyruvate Kinase (PK) and Lactate Dehydrogenase (LDH). (3-NADH conversion to NAD+ is monitored by the decrease in absorbance at 340 nm (e=6.22 cm-1 mM-1) using a Molecular Devices SPECTRA max PLUS spectrophotometer.A typical assay was carried out on a 96-well, clear microtiter plate in a Molecular Devices spectrophotometer for 20 minutes at 30 C. in 0.1 mL of assay buffer containing 50 mM HEPES, pH 7.4, 5 nM PKC, 23 units of pyruvate kinase, 33 units of lactate dehydrogenase, 0.15 mM peptide, 0.1 mM ATP, 1 mM DTT, 4 mM PEP, 8 mM MgCl2, 0.3 mM NADH, 60 mM CaCl2, 10 mg/mL PS, 50 ng/mL PMA, 7.5% DMSO and from about 10,000 nM to 0.169 nM compound inhibitor.	B	C[C@H]1CN(C2CCOCC2)[C@H](C)CN1C(=O)N1Cc2c(NC(=O)c3ccncn3)n[nH]c2C1(C)C		CHEMBL3662944	=	Ki	nM	24.0	CHEMBL3045	Homo sapiens	Ki	nM	24.0
295447	17676682	CHEMBL3705825	Inhibition Assay: Protein Kinase C beta 2 (PKC beta II) catalyzes the production of ADP from ATP that accompanies the phosphoryl transfer to the PKC Pseudosubstrate peptide (A->S, RFARKGSLRQKNV). This transfer is coupled to the oxidation of p-NADH through the activities of Pyruvate Kinase (PK) and Lactate Dehydrogenase (LDH). (3-NADH conversion to NAD+ is monitored by the decrease in absorbance at 340 nm (e=6.22 cm-1 mM-1) using a Molecular Devices SPECTRA max PLUS spectrophotometer.A typical assay was carried out on a 96-well, clear microtiter plate in a Molecular Devices spectrophotometer for 20 minutes at 30 C. in 0.1 mL of assay buffer containing 50 mM HEPES, pH 7.4, 5 nM PKC, 23 units of pyruvate kinase, 33 units of lactate dehydrogenase, 0.15 mM peptide, 0.1 mM ATP, 1 mM DTT, 4 mM PEP, 8 mM MgCl2, 0.3 mM NADH, 60 mM CaCl2, 10 mg/mL PS, 50 ng/mL PMA, 7.5% DMSO and from about 10,000 nM to 0.169 nM compound inhibitor.	B	Cc1ccc(C(=O)Nc2n[nH]c3c2CN(C(=O)N2C[C@@H](C)N(C4CCOCC4)C[C@@H]2C)C3(C)C)nc1		CHEMBL3662945	=	Ki	nM	12.2	CHEMBL3045	Homo sapiens	Ki	nM	12.2
295448	17676683	CHEMBL3705825	Inhibition Assay: Protein Kinase C beta 2 (PKC beta II) catalyzes the production of ADP from ATP that accompanies the phosphoryl transfer to the PKC Pseudosubstrate peptide (A->S, RFARKGSLRQKNV). This transfer is coupled to the oxidation of p-NADH through the activities of Pyruvate Kinase (PK) and Lactate Dehydrogenase (LDH). (3-NADH conversion to NAD+ is monitored by the decrease in absorbance at 340 nm (e=6.22 cm-1 mM-1) using a Molecular Devices SPECTRA max PLUS spectrophotometer.A typical assay was carried out on a 96-well, clear microtiter plate in a Molecular Devices spectrophotometer for 20 minutes at 30 C. in 0.1 mL of assay buffer containing 50 mM HEPES, pH 7.4, 5 nM PKC, 23 units of pyruvate kinase, 33 units of lactate dehydrogenase, 0.15 mM peptide, 0.1 mM ATP, 1 mM DTT, 4 mM PEP, 8 mM MgCl2, 0.3 mM NADH, 60 mM CaCl2, 10 mg/mL PS, 50 ng/mL PMA, 7.5% DMSO and from about 10,000 nM to 0.169 nM compound inhibitor.	B	COc1ccc(C(=O)Nc2n[nH]c3c2CN(C(=O)N2C[C@@H](C)N(C4CCOCC4)C[C@@H]2C)C3(C)C)nc1		CHEMBL3662946	<	Ki	nM	10.0	CHEMBL3045	Homo sapiens	Ki	nM	10.0
295449	17676684	CHEMBL3705825	Inhibition Assay: Protein Kinase C beta 2 (PKC beta II) catalyzes the production of ADP from ATP that accompanies the phosphoryl transfer to the PKC Pseudosubstrate peptide (A->S, RFARKGSLRQKNV). This transfer is coupled to the oxidation of p-NADH through the activities of Pyruvate Kinase (PK) and Lactate Dehydrogenase (LDH). (3-NADH conversion to NAD+ is monitored by the decrease in absorbance at 340 nm (e=6.22 cm-1 mM-1) using a Molecular Devices SPECTRA max PLUS spectrophotometer.A typical assay was carried out on a 96-well, clear microtiter plate in a Molecular Devices spectrophotometer for 20 minutes at 30 C. in 0.1 mL of assay buffer containing 50 mM HEPES, pH 7.4, 5 nM PKC, 23 units of pyruvate kinase, 33 units of lactate dehydrogenase, 0.15 mM peptide, 0.1 mM ATP, 1 mM DTT, 4 mM PEP, 8 mM MgCl2, 0.3 mM NADH, 60 mM CaCl2, 10 mg/mL PS, 50 ng/mL PMA, 7.5% DMSO and from about 10,000 nM to 0.169 nM compound inhibitor.	B	C[C@H]1CN(C2CCOCC2)[C@H](C)CN1C(=O)N1Cc2c(NC(=O)c3ccc(Cl)cn3)n[nH]c2C1(C)C		CHEMBL3667487	<	Ki	nM	10.0	CHEMBL3045	Homo sapiens	Ki	nM	10.0
295450	17676685	CHEMBL3705825	Inhibition Assay: Protein Kinase C beta 2 (PKC beta II) catalyzes the production of ADP from ATP that accompanies the phosphoryl transfer to the PKC Pseudosubstrate peptide (A->S, RFARKGSLRQKNV). This transfer is coupled to the oxidation of p-NADH through the activities of Pyruvate Kinase (PK) and Lactate Dehydrogenase (LDH). (3-NADH conversion to NAD+ is monitored by the decrease in absorbance at 340 nm (e=6.22 cm-1 mM-1) using a Molecular Devices SPECTRA max PLUS spectrophotometer.A typical assay was carried out on a 96-well, clear microtiter plate in a Molecular Devices spectrophotometer for 20 minutes at 30 C. in 0.1 mL of assay buffer containing 50 mM HEPES, pH 7.4, 5 nM PKC, 23 units of pyruvate kinase, 33 units of lactate dehydrogenase, 0.15 mM peptide, 0.1 mM ATP, 1 mM DTT, 4 mM PEP, 8 mM MgCl2, 0.3 mM NADH, 60 mM CaCl2, 10 mg/mL PS, 50 ng/mL PMA, 7.5% DMSO and from about 10,000 nM to 0.169 nM compound inhibitor.	B	C[C@H]1CN(CC2CCOCC2)[C@H](C)CN1C(=O)N1Cc2c(NC(=O)c3cnccn3)n[nH]c2C1(C)C		CHEMBL3667488	=	Ki	nM	52.7	CHEMBL3045	Homo sapiens	Ki	nM	52.7
295451	17676686	CHEMBL3705825	Inhibition Assay: Protein Kinase C beta 2 (PKC beta II) catalyzes the production of ADP from ATP that accompanies the phosphoryl transfer to the PKC Pseudosubstrate peptide (A->S, RFARKGSLRQKNV). This transfer is coupled to the oxidation of p-NADH through the activities of Pyruvate Kinase (PK) and Lactate Dehydrogenase (LDH). (3-NADH conversion to NAD+ is monitored by the decrease in absorbance at 340 nm (e=6.22 cm-1 mM-1) using a Molecular Devices SPECTRA max PLUS spectrophotometer.A typical assay was carried out on a 96-well, clear microtiter plate in a Molecular Devices spectrophotometer for 20 minutes at 30 C. in 0.1 mL of assay buffer containing 50 mM HEPES, pH 7.4, 5 nM PKC, 23 units of pyruvate kinase, 33 units of lactate dehydrogenase, 0.15 mM peptide, 0.1 mM ATP, 1 mM DTT, 4 mM PEP, 8 mM MgCl2, 0.3 mM NADH, 60 mM CaCl2, 10 mg/mL PS, 50 ng/mL PMA, 7.5% DMSO and from about 10,000 nM to 0.169 nM compound inhibitor.	B	C[C@H]1CN(CC2CCOCC2)[C@H](C)CN1C(=O)N1Cc2c(NC(=O)c3ncccn3)n[nH]c2C1(C)C		CHEMBL3667489	=	Ki	nM	133.0	CHEMBL3045	Homo sapiens	Ki	nM	133.0
295452	17676687	CHEMBL3705825	Inhibition Assay: Protein Kinase C beta 2 (PKC beta II) catalyzes the production of ADP from ATP that accompanies the phosphoryl transfer to the PKC Pseudosubstrate peptide (A->S, RFARKGSLRQKNV). This transfer is coupled to the oxidation of p-NADH through the activities of Pyruvate Kinase (PK) and Lactate Dehydrogenase (LDH). (3-NADH conversion to NAD+ is monitored by the decrease in absorbance at 340 nm (e=6.22 cm-1 mM-1) using a Molecular Devices SPECTRA max PLUS spectrophotometer.A typical assay was carried out on a 96-well, clear microtiter plate in a Molecular Devices spectrophotometer for 20 minutes at 30 C. in 0.1 mL of assay buffer containing 50 mM HEPES, pH 7.4, 5 nM PKC, 23 units of pyruvate kinase, 33 units of lactate dehydrogenase, 0.15 mM peptide, 0.1 mM ATP, 1 mM DTT, 4 mM PEP, 8 mM MgCl2, 0.3 mM NADH, 60 mM CaCl2, 10 mg/mL PS, 50 ng/mL PMA, 7.5% DMSO and from about 10,000 nM to 0.169 nM compound inhibitor.	B	Cc1noc(C)c1CC(=O)Nc1n[nH]c2c1CN(C(=O)N1C[C@@H](C)N(CC3CCOCC3)C[C@@H]1C)C2(C)C		CHEMBL3667490	=	Ki	nM	20.0	CHEMBL3045	Homo sapiens	Ki	nM	20.0
295453	17676688	CHEMBL3705825	Inhibition Assay: Protein Kinase C beta 2 (PKC beta II) catalyzes the production of ADP from ATP that accompanies the phosphoryl transfer to the PKC Pseudosubstrate peptide (A->S, RFARKGSLRQKNV). This transfer is coupled to the oxidation of p-NADH through the activities of Pyruvate Kinase (PK) and Lactate Dehydrogenase (LDH). (3-NADH conversion to NAD+ is monitored by the decrease in absorbance at 340 nm (e=6.22 cm-1 mM-1) using a Molecular Devices SPECTRA max PLUS spectrophotometer.A typical assay was carried out on a 96-well, clear microtiter plate in a Molecular Devices spectrophotometer for 20 minutes at 30 C. in 0.1 mL of assay buffer containing 50 mM HEPES, pH 7.4, 5 nM PKC, 23 units of pyruvate kinase, 33 units of lactate dehydrogenase, 0.15 mM peptide, 0.1 mM ATP, 1 mM DTT, 4 mM PEP, 8 mM MgCl2, 0.3 mM NADH, 60 mM CaCl2, 10 mg/mL PS, 50 ng/mL PMA, 7.5% DMSO and from about 10,000 nM to 0.169 nM compound inhibitor.	B	C[C@H]1CN(CC2CCOCC2)[C@H](C)CN1C(=O)N1Cc2c(NC(=O)c3ccc(C(F)(F)F)cn3)n[nH]c2C1(C)C		CHEMBL3667491	=	Ki	nM	4.17	CHEMBL3045	Homo sapiens	Ki	nM	4.17
295454	17676689	CHEMBL3705825	Inhibition Assay: Protein Kinase C beta 2 (PKC beta II) catalyzes the production of ADP from ATP that accompanies the phosphoryl transfer to the PKC Pseudosubstrate peptide (A->S, RFARKGSLRQKNV). This transfer is coupled to the oxidation of p-NADH through the activities of Pyruvate Kinase (PK) and Lactate Dehydrogenase (LDH). (3-NADH conversion to NAD+ is monitored by the decrease in absorbance at 340 nm (e=6.22 cm-1 mM-1) using a Molecular Devices SPECTRA max PLUS spectrophotometer.A typical assay was carried out on a 96-well, clear microtiter plate in a Molecular Devices spectrophotometer for 20 minutes at 30 C. in 0.1 mL of assay buffer containing 50 mM HEPES, pH 7.4, 5 nM PKC, 23 units of pyruvate kinase, 33 units of lactate dehydrogenase, 0.15 mM peptide, 0.1 mM ATP, 1 mM DTT, 4 mM PEP, 8 mM MgCl2, 0.3 mM NADH, 60 mM CaCl2, 10 mg/mL PS, 50 ng/mL PMA, 7.5% DMSO and from about 10,000 nM to 0.169 nM compound inhibitor.	B	C[C@H]1CN(CC2CCOCC2)[C@H](C)CN1C(=O)N1Cc2c(NC(=O)c3ccc(C#N)cn3)n[nH]c2C1(C)C		CHEMBL3667492	<	Ki	nM	10.0	CHEMBL3045	Homo sapiens	Ki	nM	10.0
295455	17676690	CHEMBL3705825	Inhibition Assay: Protein Kinase C beta 2 (PKC beta II) catalyzes the production of ADP from ATP that accompanies the phosphoryl transfer to the PKC Pseudosubstrate peptide (A->S, RFARKGSLRQKNV). This transfer is coupled to the oxidation of p-NADH through the activities of Pyruvate Kinase (PK) and Lactate Dehydrogenase (LDH). (3-NADH conversion to NAD+ is monitored by the decrease in absorbance at 340 nm (e=6.22 cm-1 mM-1) using a Molecular Devices SPECTRA max PLUS spectrophotometer.A typical assay was carried out on a 96-well, clear microtiter plate in a Molecular Devices spectrophotometer for 20 minutes at 30 C. in 0.1 mL of assay buffer containing 50 mM HEPES, pH 7.4, 5 nM PKC, 23 units of pyruvate kinase, 33 units of lactate dehydrogenase, 0.15 mM peptide, 0.1 mM ATP, 1 mM DTT, 4 mM PEP, 8 mM MgCl2, 0.3 mM NADH, 60 mM CaCl2, 10 mg/mL PS, 50 ng/mL PMA, 7.5% DMSO and from about 10,000 nM to 0.169 nM compound inhibitor.	B	C[C@H]1CN(C)[C@H](C)CN1C(=O)N1Cc2c(NC(=O)c3ccc(C#N)cn3)n[nH]c2C1(C)C		CHEMBL3667493	=	Ki	nM	28.7	CHEMBL3045	Homo sapiens	Ki	nM	28.7
295456	17676691	CHEMBL3705825	Inhibition Assay: Protein Kinase C beta 2 (PKC beta II) catalyzes the production of ADP from ATP that accompanies the phosphoryl transfer to the PKC Pseudosubstrate peptide (A->S, RFARKGSLRQKNV). This transfer is coupled to the oxidation of p-NADH through the activities of Pyruvate Kinase (PK) and Lactate Dehydrogenase (LDH). (3-NADH conversion to NAD+ is monitored by the decrease in absorbance at 340 nm (e=6.22 cm-1 mM-1) using a Molecular Devices SPECTRA max PLUS spectrophotometer.A typical assay was carried out on a 96-well, clear microtiter plate in a Molecular Devices spectrophotometer for 20 minutes at 30 C. in 0.1 mL of assay buffer containing 50 mM HEPES, pH 7.4, 5 nM PKC, 23 units of pyruvate kinase, 33 units of lactate dehydrogenase, 0.15 mM peptide, 0.1 mM ATP, 1 mM DTT, 4 mM PEP, 8 mM MgCl2, 0.3 mM NADH, 60 mM CaCl2, 10 mg/mL PS, 50 ng/mL PMA, 7.5% DMSO and from about 10,000 nM to 0.169 nM compound inhibitor.	B	C[C@H]1CN(CC2CCOCC2)[C@H](C)CN1C(=O)N1Cc2c(NC(=O)c3ccc(C#N)cn3)n[nH]c2C1(C)C		CHEMBL3667492	<	Ki	nM	10.0	CHEMBL3045	Homo sapiens	Ki	nM	10.0
417341	17780802	CHEMBL3888822	Binding Assay: On the day at experiment Human Protein Kinase C betaII (PKCbII, Millipore cat#14-496) was incubated with 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 0.1 mg/mL histone H1, 10 mM MgAcetate. Amount of enzyme in each assay was 1.8 ng (final assay volume is 25 L). The compounds were then diluted to 500 M, and then serially diluted in 100% DMSO in semi-logarithmic decrements for 12 points. 0.5 L of each concentration, in duplicate, was pipetted into a dry 96 well assay plate using a TIP Mosquito. Control and blank wells received 0.5 L of 100% DMSO instead of compound. 14.5 l kinase in assay buffer was added to each well. The assay was started with the addition of 10 L ATP containing -33P-ATP] (specific activity approx. 500 cpm/pmol), to a final assay concentration of 70 M. The reaction was allowed to proceed at room temperature for 40 minutes before the addition of 5 L 3% ortho-phosphoric acid. Blank wells were acid blanks, and had 5 L 3% ortho-phosphoric acid added before the addition of ATP. 10 L of the stopped reaction products was transferred to a P30 filtermat which was then washed 4 times in 75 mM ortho-phosphoric acid, and once in methanol before drying. The filter was read by liquid scintillation counting using a Wallac Trilux.	B	CC1=C[C@]23C(=O)[C@@H](C=C(CO)C[C@@H]2[C@H]1OC(=O)C1(C)CCCCC1)[C@H]1[C@@H](C[C@H]3C)C1(C)C		CHEMBL4111556	=	EC50	nM	6.0	CHEMBL3045	Homo sapiens	EC50	nM	6.0
417342	17780803	CHEMBL3888822	Binding Assay: On the day at experiment Human Protein Kinase C betaII (PKCbII, Millipore cat#14-496) was incubated with 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 0.1 mg/mL histone H1, 10 mM MgAcetate. Amount of enzyme in each assay was 1.8 ng (final assay volume is 25 L). The compounds were then diluted to 500 M, and then serially diluted in 100% DMSO in semi-logarithmic decrements for 12 points. 0.5 L of each concentration, in duplicate, was pipetted into a dry 96 well assay plate using a TIP Mosquito. Control and blank wells received 0.5 L of 100% DMSO instead of compound. 14.5 l kinase in assay buffer was added to each well. The assay was started with the addition of 10 L ATP containing -33P-ATP] (specific activity approx. 500 cpm/pmol), to a final assay concentration of 70 M. The reaction was allowed to proceed at room temperature for 40 minutes before the addition of 5 L 3% ortho-phosphoric acid. Blank wells were acid blanks, and had 5 L 3% ortho-phosphoric acid added before the addition of ATP. 10 L of the stopped reaction products was transferred to a P30 filtermat which was then washed 4 times in 75 mM ortho-phosphoric acid, and once in methanol before drying. The filter was read by liquid scintillation counting using a Wallac Trilux.	B	CC1=C[C@]23C(=O)[C@@H](C=C(CO)C[C@]2(O)[C@H]1OC(=O)C1(C)CCCCC1)[C@H]1[C@@H](C[C@H]3C)C1(C)C		CHEMBL4115540	=	EC50	nM	0.8	CHEMBL3045	Homo sapiens	EC50	nM	0.8
417343	17780804	CHEMBL3888822	Binding Assay: On the day at experiment Human Protein Kinase C betaII (PKCbII, Millipore cat#14-496) was incubated with 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 0.1 mg/mL histone H1, 10 mM MgAcetate. Amount of enzyme in each assay was 1.8 ng (final assay volume is 25 L). The compounds were then diluted to 500 M, and then serially diluted in 100% DMSO in semi-logarithmic decrements for 12 points. 0.5 L of each concentration, in duplicate, was pipetted into a dry 96 well assay plate using a TIP Mosquito. Control and blank wells received 0.5 L of 100% DMSO instead of compound. 14.5 l kinase in assay buffer was added to each well. The assay was started with the addition of 10 L ATP containing -33P-ATP] (specific activity approx. 500 cpm/pmol), to a final assay concentration of 70 M. The reaction was allowed to proceed at room temperature for 40 minutes before the addition of 5 L 3% ortho-phosphoric acid. Blank wells were acid blanks, and had 5 L 3% ortho-phosphoric acid added before the addition of ATP. 10 L of the stopped reaction products was transferred to a P30 filtermat which was then washed 4 times in 75 mM ortho-phosphoric acid, and once in methanol before drying. The filter was read by liquid scintillation counting using a Wallac Trilux.	B	CC1=CC23C(=O)[C@@H](C=C(CO)[C@@H](O)[C@@H]2[C@H]1OC(=O)C1(C)CCCCC1)[C@H]1[C@@H](C[C@H]3C)C1(C)C		CHEMBL4113544	=	EC50	nM	0.2	CHEMBL3045	Homo sapiens	EC50	nM	0.2
417344	17780805	CHEMBL3888822	Binding Assay: On the day at experiment Human Protein Kinase C betaII (PKCbII, Millipore cat#14-496) was incubated with 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 0.1 mg/mL histone H1, 10 mM MgAcetate. Amount of enzyme in each assay was 1.8 ng (final assay volume is 25 L). The compounds were then diluted to 500 M, and then serially diluted in 100% DMSO in semi-logarithmic decrements for 12 points. 0.5 L of each concentration, in duplicate, was pipetted into a dry 96 well assay plate using a TIP Mosquito. Control and blank wells received 0.5 L of 100% DMSO instead of compound. 14.5 l kinase in assay buffer was added to each well. The assay was started with the addition of 10 L ATP containing -33P-ATP] (specific activity approx. 500 cpm/pmol), to a final assay concentration of 70 M. The reaction was allowed to proceed at room temperature for 40 minutes before the addition of 5 L 3% ortho-phosphoric acid. Blank wells were acid blanks, and had 5 L 3% ortho-phosphoric acid added before the addition of ATP. 10 L of the stopped reaction products was transferred to a P30 filtermat which was then washed 4 times in 75 mM ortho-phosphoric acid, and once in methanol before drying. The filter was read by liquid scintillation counting using a Wallac Trilux.	B	CC1=C[C@@]23CC[C@@H]4[C@H]([C@H](C=C(CO)[C@@H](O)[C@]2(O)[C@H]1OC(=O)C1(C)CCCCC1)C3=O)C4(C)C		CHEMBL3926213	=	EC50	nM	0.1	CHEMBL3045	Homo sapiens	EC50	nM	0.1
Inactive	17929980	CHEMBL3991843	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C		CHEMBL535	>	Kd	nM	30000.0	CHEMBL3045	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17929981	CHEMBL3991843	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COC(=O)N[C@@H](C)CNc1nccc(-c2cn(C(C)C)nc2-c2cc(Cl)cc(NS(C)(=O)=O)c2F)n1		CHEMBL3301612	>	Kd	nM	30000.0	CHEMBL3045	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17929982	CHEMBL3991843	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=C(NC[C@H](O)CO)c1ccncc1Nc1ccc(I)cc1F		CHEMBL2107832	>	Kd	nM	30000.0	CHEMBL3045	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17929983	CHEMBL3991843	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=S(=O)(c1cccc2cnccc12)N1CCCNCC1		CHEMBL38380	>	Kd	nM	30000.0	CHEMBL3045	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17929984	CHEMBL3991843	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1		CHEMBL1287853	>	Kd	nM	30000.0	CHEMBL3045	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17929985	CHEMBL3991843	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc(OC)c(/C=C/S(=O)(=O)Cc2ccc(OC)c(NCC(=O)O)c2)c(OC)c1		CHEMBL1241855	>	Kd	nM	30000.0	CHEMBL3045	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17929986	CHEMBL3991843	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=C(Nc1cccc(Cl)c1)Nc1ncc(CCN=c2[nH]cnc3ccsc23)s1		CHEMBL482767	>	Kd	nM	30000.0	CHEMBL3045	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17929987	CHEMBL3991843	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1cn(-c2cc(NC(=O)c3ccc(C)c(Nc4nccc(-c5cccnc5)n4)c3)cc(C(F)(F)F)c2)cn1		CHEMBL255863	>	Kd	nM	30000.0	CHEMBL3045	Homo sapiens	Kd apparent	nM	30000.0
Active	17929988	CHEMBL3991843	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CN(C)C[C@@H]1CCn2cc(c3ccccc32)C2=C(C(=O)NC2=O)c2cn(c3ccccc23)CCO1		CHEMBL91829	=	Kd	nM	198.0	CHEMBL3045	Homo sapiens	Kd apparent	nM	198.0
Inactive	17929989	CHEMBL3991843	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cn1cc(-c2cnc3ccc4ccc(CS(=O)(=O)NCc5ccccn5)cc4c(=O)c3c2)cn1		CHEMBL2323775	>	Kd	nM	30000.0	CHEMBL3045	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17929990	CHEMBL3991843	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCN(CCO)CCCOc1ccc2c(Nc3cc(CC(=O)Nc4cccc(F)c4)[nH]n3)ncnc2c1		CHEMBL215152	>	Kd	nM	30000.0	CHEMBL3045	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17929991	CHEMBL3991843	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cccc2cc(-c3nc([C@H]4CC[C@H](C(=O)O)CC4)n4ncnc(N)c34)[nH]c12		CHEMBL3120215	>	Kd	nM	30000.0	CHEMBL3045	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17929992	CHEMBL3991843	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCS(=O)(=O)c1cccc(-c2cc(C(=O)NC3CCN(C)CC3)c(C)c3[nH]c4ncc(C)cc4c23)c1		CHEMBL3544932	>	Kd	nM	30000.0	CHEMBL3045	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17929993	CHEMBL3991843	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Nc1ncnc2c1c(-c1cccc(OCc3ccccc3)c1)cn2[C@H]1C[C@H](N2CCC2)C1		CHEMBL551064	>	Kd	nM	30000.0	CHEMBL3045	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17929994	CHEMBL3991843	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C[C@@H]1COC(Nc2ccc3ncnc(Nc4ccc(OCc5nccs5)c(Cl)c4)c3c2)=N1		CHEMBL2103842	>	Kd	nM	30000.0	CHEMBL3045	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17929995	CHEMBL3991843	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=C(NC1CCNCC1)c1n[nH]cc1NC(=O)c1c(Cl)cccc1Cl		CHEMBL445813	>	Kd	nM	30000.0	CHEMBL3045	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17929996	CHEMBL3991843	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CN1CC[C@@H](c2c(O)cc(O)c3c(=O)cc(-c4ccccc4Cl)oc23)[C@@H]1CO.Cl		CHEMBL3991935	>	Kd	nM	30000.0	CHEMBL3045	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17929997	CHEMBL3991843	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1cc(C(=O)NOCCO)c(Nc2ccc(I)cc2F)n(C)c1=O		CHEMBL3182621	>	Kd	nM	30000.0	CHEMBL3045	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17929998	CHEMBL3991843	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=C(Nc1cc(C(F)(F)F)cc(C(F)(F)F)c1)c1cc(Cl)ccc1O		CHEMBL536151	>	Kd	nM	30000.0	CHEMBL3045	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17929999	CHEMBL3991843	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C		CHEMBL1908360	>	Kd	nM	30000.0	CHEMBL3045	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17930000	CHEMBL3991843	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1		CHEMBL939	>	Kd	nM	30000.0	CHEMBL3045	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17930001	CHEMBL3991843	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Clc1ccc(Nc2nnc(Cc3ccncc3)c3ccccc23)cc1		CHEMBL101253	>	Kd	nM	30000.0	CHEMBL3045	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17930002	CHEMBL3991843	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CN1CCN(CCOc2cc(OC3CCOCC3)c3c(Nc4c(Cl)ccc5c4OCO5)ncnc3c2)CC1		CHEMBL217092	>	Kd	nM	30000.0	CHEMBL3045	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17930003	CHEMBL3991843	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CNC(=O)c1nn(C)c2c1C(C)(C)Cc1cnc(Nc3ccc(N4CCN(C)CC4)cc3)nc1-2		CHEMBL564829	>	Kd	nM	30000.0	CHEMBL3045	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17930004	CHEMBL3991843	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=C(Nc1ccc(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)cc1)C1CCCN1		CHEMBL3545328	>	Kd	nM	30000.0	CHEMBL3045	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17930005	CHEMBL3991843	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1csc(-c2nnc(Nc3ccc(Oc4ncccc4-c4ccnc(N)n4)cc3)c3ccccc23)c1		CHEMBL2140408	>	Kd	nM	30000.0	CHEMBL3045	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17930006	CHEMBL3991843	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cn1cc(-c2ccc3nnc(Sc4ccc5ncccc5c4)n3n2)cn1		CHEMBL1236107	>	Kd	nM	30000.0	CHEMBL3045	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17930007	CHEMBL3991843	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cn1c(=O)c(F)c(Nc2ccc(I)cc2F)c2c(=O)n(C[C@@H](O)CO)cnc21		CHEMBL1615025	>	Kd	nM	30000.0	CHEMBL3045	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17930008	CHEMBL3991843	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	FC(F)(F)c1ccc(/C=C/c2nc(COc3ccc(CCCCn4ccnn4)cc3)co2)cc1		CHEMBL1614707	>	Kd	nM	30000.0	CHEMBL3045	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17930009	CHEMBL3991843	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	NC(=O)c1ccc(N(C(N)=O)c2c(F)cccc2F)nc1-c1ccc(F)cc1F		CHEMBL1090090	>	Kd	nM	30000.0	CHEMBL3045	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17930010	CHEMBL3991843	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	NC(=O)c1c(OCc2c(F)cc(Br)cc2F)nsc1NC(=O)NCCCCN1CCCC1		CHEMBL253969	>	Kd	nM	30000.0	CHEMBL3045	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17930011	CHEMBL3991843	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCN1CCN(Cc2ccc(-c3cc4c(N[C@H](C)c5ccccc5)ncnc4[nH]3)cc2)CC1		CHEMBL587723	>	Kd	nM	30000.0	CHEMBL3045	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17930012	CHEMBL3991843	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C#Cc1cccc(Nc2ncnc3cc(OC)c(OCCCCCCC(=O)NO)cc23)c1		CHEMBL598797	>	Kd	nM	30000.0	CHEMBL3045	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17930013	CHEMBL3991843	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CNC(=O)c1cc(COc2nnc(Nc3ccc(Cl)cc3)c3ccoc23)ccn1		CHEMBL2079588	>	Kd	nM	30000.0	CHEMBL3045	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17930014	CHEMBL3991843	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc2c(N3CCN(C(=O)Nc4ccc(OC(C)C)cc4)CC3)ncnc2cc1OCCCN1CCCCC1		CHEMBL124660	>	Kd	nM	30000.0	CHEMBL3045	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17930015	CHEMBL3991843	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc2nccc(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3)c2cc1OC		CHEMBL2105717	>	Kd	nM	30000.0	CHEMBL3045	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17930016	CHEMBL3991843	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CN1CCN(C2CCN(C(=O)Nc3cc(Oc4ccc(NC(=O)C5(C(=O)Nc6ccc(F)cc6)CC5)c(F)c4)ccn3)CC2)CC1		CHEMBL3039525	>	Kd	nM	30000.0	CHEMBL3045	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17930017	CHEMBL3991843	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CC[C@H](Nc1ncnc2[nH]cnc12)c1nc2cccc(F)c2c(=O)n1-c1ccccc1		CHEMBL2216870	>	Kd	nM	30000.0	CHEMBL3045	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17930018	CHEMBL3991843	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCNC(=O)C#Cc1ccc2c(c1)NC(=O)/C2=C(\Nc1ccc(CN(C)C)cc1)c1ccccc1		CHEMBL3699142	>	Kd	nM	30000.0	CHEMBL3045	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17930019	CHEMBL3991843	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCC1CCN(C)CC1		CHEMBL24828	>	Kd	nM	30000.0	CHEMBL3045	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17930020	CHEMBL3991843	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CNC(=O)c1cccc(-c2ccc3c(N4CCOC[C@@H]4C)nc(N4CCOC[C@@H]4C)nc3n2)c1		CHEMBL2336325	>	Kd	nM	30000.0	CHEMBL3045	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17930021	CHEMBL3991843	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1		CHEMBL1421	>	Kd	nM	30000.0	CHEMBL3045	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17930022	CHEMBL3991843	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1cc(Nc2ncc(Cl)c(Nc3ccccc3S(=O)(=O)C(C)C)n2)c(OC(C)C)cc1C1CCNCC1		CHEMBL2403108	>	Kd	nM	30000.0	CHEMBL3045	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17930023	CHEMBL3991843	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=C(O)c1ccc(Nc2ncc3c(n2)-c2ccc(Cl)cc2C(c2c(F)cccc2F)=NC3)cc1		CHEMBL259084	>	Kd	nM	30000.0	CHEMBL3045	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17930024	CHEMBL3991843	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=C(Cc1ccc(-c2ccc(OCCN3CCOCC3)cc2)cn1)NCc1ccccc1		CHEMBL571546	>	Kd	nM	30000.0	CHEMBL3045	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17930025	CHEMBL3991843	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CC(C)c1cc(CNc2nc(Nc3cc(C4CC4)[nH]n3)cc(N3CCN(C)CC3)n2)on1		CHEMBL3545085	>	Kd	nM	30000.0	CHEMBL3045	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17930026	CHEMBL3991843	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCOc1cc2ncc(C#N)c(Nc3ccc(OCc4ccccn4)c(Cl)c3)c2cc1NC(=O)/C=C/CN(C)C		CHEMBL180022	>	Kd	nM	30000.0	CHEMBL3045	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17930027	CHEMBL3991843	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCn1cc(-c2ccnc3[nH]c(-c4cccc(CN(C)C)c4)cc23)c(-c2ccc(NC(=O)N(C)C)cc2)n1		CHEMBL1090479	>	Kd	nM	30000.0	CHEMBL3045	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17930028	CHEMBL3991843	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1ncc(-c2ccnc(Nc3ccc(S(C)(=O)=O)cc3)n2)n1C(C)C		CHEMBL488436	>	Kd	nM	30000.0	CHEMBL3045	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17930029	CHEMBL3991843	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CC[C@@H]1C(=O)N(C)c2cnc(Nc3ccc(C(=O)N[C@H]4CC[C@H](N5CCN(CC6CC6)CC5)CC4)cc3OC)nc2N1C(C)C		CHEMBL1233528	>	Kd	nM	30000.0	CHEMBL3045	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17930030	CHEMBL3991843	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CN(C)C/C=C/C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1		CHEMBL1173655	>	Kd	nM	30000.0	CHEMBL3045	Homo sapiens	Kd apparent	nM	30000.0
Active	17930031	CHEMBL3991843	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CC(=O)c1cnc2ccc(-c3cc(Cl)c(O)c(Cl)c3)nc2c1N[C@H]1CC[C@H](CN(C)C)CC1		CHEMBL3688339	=	Kd	nM	233.0	CHEMBL3045	Homo sapiens	Kd apparent	nM	233.0
Inactive	17930032	CHEMBL3991843	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CC(=O)c1c(C)c2cnc(Nc3ccc(N4CCNCC4)cn3)nc2n(C2CCCC2)c1=O		CHEMBL189963	>	Kd	nM	30000.0	CHEMBL3045	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17930033	CHEMBL3991843	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1		CHEMBL1873475	>	Kd	nM	30000.0	CHEMBL3045	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17930034	CHEMBL3991843	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	c1cc(OCCN2CCCCC2)cc(-c2n[nH]c3ccc(-c4nnc[nH]4)cc23)c1		CHEMBL1614713	>	Kd	nM	30000.0	CHEMBL3045	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17930035	CHEMBL3991843	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CNC(=O)c1ccc(-c2cnc3ncc(Cc4ccc5ncccc5c4)n3n2)cc1F		CHEMBL3188267	>	Kd	nM	30000.0	CHEMBL3045	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17930036	CHEMBL3991843	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CNS(=O)(=O)Nc1nccc(Cc2c(C)c3ccc(Oc4ncccn4)cc3oc2=O)c1F		CHEMBL3264002	>	Kd	nM	30000.0	CHEMBL3045	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17930037	CHEMBL3991843	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CC(=O)Nc1cccc(-n2c(=O)n(C3CC3)c(=O)c3c(Nc4ccc(I)cc4F)n(C)c(=O)c(C)c32)c1		CHEMBL2103875	>	Kd	nM	30000.0	CHEMBL3045	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17930038	CHEMBL3991843	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1cc2c(F)c(Oc3ncnn4cc(OC[C@@H](C)OC(=O)[C@H](C)N)c(C)c34)ccc2[nH]1		CHEMBL270995	>	Kd	nM	30000.0	CHEMBL3045	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17930039	CHEMBL3991843	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCOc1cc2ncc(C#N)c(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)/C=C/CN(C)C		CHEMBL607707	>	Kd	nM	30000.0	CHEMBL3045	Homo sapiens	Kd apparent	nM	30000.0
Active	17930040	CHEMBL3991843	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCS(=O)(=O)N1CC(CC#N)(n2cc(-c3ncnc4[nH]ccc34)cn2)C1		CHEMBL2105759	=	Kd	nM	26324.0	CHEMBL3045	Homo sapiens	Kd apparent	nM	26324.0
Inactive	17930041	CHEMBL3991843	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CN(C)C1CCN(C(=O)c2ccc(NC(=O)Nc3ccc(-c4nc(N5CCOCC5)nc(N5CCOCC5)n4)cc3)cc2)CC1		CHEMBL592445	>	Kd	nM	30000.0	CHEMBL3045	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17930042	CHEMBL3991843	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CN1CCC(CNc2ccc3ncc(-c4cccc(OC(F)(F)F)c4)n3n2)CC1		CHEMBL1952329	>	Kd	nM	30000.0	CHEMBL3045	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17930043	CHEMBL3991843	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1ccc(-c2cc3c(C)nc(N)nc3n([C@H]3CC[C@H](OCCO)CC3)c2=O)cn1		CHEMBL1234354	>	Kd	nM	30000.0	CHEMBL3045	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17930044	CHEMBL3991843	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B			CHEMBL4084193	>	Kd	nM	30000.0	CHEMBL3045	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17930045	CHEMBL3991843	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OP(C)(C)=O)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C		CHEMBL2103839	>	Kd	nM	30000.0	CHEMBL3045	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17930046	CHEMBL3991843	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc(Nc2c(C#N)cnc3cc(OCCCN4CCN(C)CC4)c(OC)cc23)c(Cl)cc1Cl		CHEMBL288441	>	Kd	nM	30000.0	CHEMBL3045	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17930047	CHEMBL3991843	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCc1nc(C(N)=O)c(Nc2ccc(N3CCC(N4CCN(C)CC4)CC3)c(OC)c2)nc1NC1CCOCC1		CHEMBL3301622	>	Kd	nM	30000.0	CHEMBL3045	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17930048	CHEMBL3991843	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3cc(C(C)(C)C)nn3-c3ccc4ncccc4c3)c(F)c2)ccn1		CHEMBL1738757	>	Kd	nM	30000.0	CHEMBL3045	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17930049	CHEMBL3991843	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(-c4ccc(Cl)cc4)cc23)c1F		CHEMBL1229517	>	Kd	nM	30000.0	CHEMBL3045	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17930050	CHEMBL3991843	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C=CC(=O)N1CCC(Oc2cc3c(Nc4ccc(Cl)c(Cl)c4F)ncnc3cc2OC)CC1		CHEMBL3545154	>	Kd	nM	30000.0	CHEMBL3045	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17930051	CHEMBL3991843	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C[C@@H](Oc1cc(-n2cnc3ccc(CN4CCN(C)CC4)cc32)sc1C(N)=O)c1ccccc1C(F)(F)F		CHEMBL1908394	>	Kd	nM	30000.0	CHEMBL3045	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17930052	CHEMBL3991843	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C=CCN(/C=C1/C(=O)O[C@H](COC)[C@@]2(C)C1=C(O)C(=O)C1=C2[C@H](OC(C)=O)C[C@]2(C)C(=O)CC[C@@H]12)CC=C		CHEMBL411907	>	Kd	nM	30000.0	CHEMBL3045	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17930053	CHEMBL3991843	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCN(CCCOc1ccc2c(Nc3cc(CC(=O)Nc4cccc(F)c4)[nH]n3)ncnc2c1)CCOP(=O)(O)O		CHEMBL415049	>	Kd	nM	30000.0	CHEMBL3045	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17930054	CHEMBL3991843	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cn1cnc2c(F)c(Nc3ccc(Br)cc3F)c(C(=O)NOCCO)cc21		CHEMBL3187723	>	Kd	nM	30000.0	CHEMBL3045	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17930055	CHEMBL3991843	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cn1c(Nc2ccc(C(F)(F)F)cc2)nc2cc(Oc3ccnc(-c4ncc(C(F)(F)F)[nH]4)c3)ccc21		CHEMBL558752	>	Kd	nM	30000.0	CHEMBL3045	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17930056	CHEMBL3991843	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1		CHEMBL1789941	>	Kd	nM	30000.0	CHEMBL3045	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17930057	CHEMBL3991843	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1ccc(S(=O)(=O)N(C(C)=O)c2ccccc2/C=C/c2cc[n+]([O-])cc2)cc1		CHEMBL3991927	>	Kd	nM	30000.0	CHEMBL3045	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17930058	CHEMBL3991843	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C[C@@H](NC(=O)c1ncnc(N)c1Cl)c1ncc(C(=O)Nc2cc(C(F)(F)F)c(Cl)cn2)s1		CHEMBL3348923	>	Kd	nM	30000.0	CHEMBL3045	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17930059	CHEMBL3991843	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1cc(C(=O)Nc2cc(Oc3ccc4nc(NC(=O)C5CC5)cn4n3)ccc2C)n(C)n1		CHEMBL2180604	>	Kd	nM	30000.0	CHEMBL3045	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17930060	CHEMBL3991843	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C=CC(=O)Nc1cc(Nc2nccc(-c3cn(C)c4ccccc34)n2)c(OC)cc1N(C)CCN(C)C		CHEMBL3353410	>	Kd	nM	30000.0	CHEMBL3045	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17930061	CHEMBL3991843	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C=CC(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1C#CC(C)(C)N1CCN(C)CC1		CHEMBL2138625	>	Kd	nM	30000.0	CHEMBL3045	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17930062	CHEMBL3991843	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c(C)c1C(=O)NC[C@H](O)CN1CCOCC1		CHEMBL1721885	>	Kd	nM	30000.0	CHEMBL3045	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17930063	CHEMBL3991843	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCn1c(=O)c(-c2cc[nH]n2)cc2c(C)nc(N)nc21		CHEMBL3545366	>	Kd	nM	30000.0	CHEMBL3045	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17930064	CHEMBL3991843	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CN1CCN(c2ccc3nc(-c4c(N)c5c(F)cccc5[nH]c4=O)[nH]c3c2)CC1		CHEMBL522892	>	Kd	nM	30000.0	CHEMBL3045	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17930065	CHEMBL3991843	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CN1N=C(N)c2cn([C@@H]3O[C@H](COP(=O)(O)O)[C@@H](O)[C@H]3O)c3ncnc1c23		CHEMBL462018	>	Kd	nM	30000.0	CHEMBL3045	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17930066	CHEMBL3991843	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](O)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C		CHEMBL413	>	Kd	nM	30000.0	CHEMBL3045	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17930067	CHEMBL3991843	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C[C@@H](c1ccc2nccn2c1)n1nnc2ncc(-c3cnn(C)c3)nc21		CHEMBL3334567	>	Kd	nM	30000.0	CHEMBL3045	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17930068	CHEMBL3991843	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cn1nccc1Nc1nccc(-c2ccn([C@H](CO)c3ccc(Cl)c(F)c3)c(=O)c2)n1		CHEMBL3544964	>	Kd	nM	30000.0	CHEMBL3045	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17930069	CHEMBL3991843	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	NC1(c2ccc(-c3nc4ccn5c(=O)[nH]nc5c4cc3-c3ccccc3)cc2)CCC1		CHEMBL1079175	>	Kd	nM	30000.0	CHEMBL3045	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17930070	CHEMBL3991843	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cn1cc(C2=Nc3cc(NC(=O)C(N)C4CCCCC4)cc4c3C2=CNNC4=O)cn1		CHEMBL3545137	>	Kd	nM	30000.0	CHEMBL3045	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17930071	CHEMBL3991843	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nc(-c2cccnc2)cs1		CHEMBL1908391	>	Kd	nM	30000.0	CHEMBL3045	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17930072	CHEMBL3991843	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1cc(-c2cc(O)ccc2Cl)cc2nnc(Nc3ccc(OCCN4CCCC4)cc3)nc12		CHEMBL400402	>	Kd	nM	30000.0	CHEMBL3045	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17930073	CHEMBL3991843	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=C1NC(=O)[C@@H](c2cn3c4c(cccc24)CCC3)[C@@H]1c1c[nH]c2ccccc12		CHEMBL2103882	>	Kd	nM	30000.0	CHEMBL3045	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17930074	CHEMBL3991843	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CS(=O)(=O)N1CCN(Cc2cc3nc(-c4cccc5[nH]ncc45)nc(N4CCOCC4)c3s2)CC1		CHEMBL521851	>	Kd	nM	30000.0	CHEMBL3045	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17930075	CHEMBL3991843	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CNC(=O)c1cccc2cc(Oc3ccnc4cc(OCC5(N)CC5)c(OC)cc34)ccc12		CHEMBL2220486	>	Kd	nM	30000.0	CHEMBL3045	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17930076	CHEMBL3991843	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CC[C@H](CO)Nc1nc(NCc2ccccc2)c2ncn(C(C)C)c2n1		CHEMBL14762	>	Kd	nM	30000.0	CHEMBL3045	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17930077	CHEMBL3991843	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	NC(=O)Nc1cc(-c2cccc(F)c2)sc1C(=O)N[C@H]1CCCNC1		CHEMBL2041933	>	Kd	nM	30000.0	CHEMBL3045	Homo sapiens	Kd apparent	nM	30000.0
Active	17930078	CHEMBL3991843	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)N[C@H]4O		CHEMBL574737	=	Kd	nM	19.0	CHEMBL3045	Homo sapiens	Kd apparent	nM	19.0
Inactive	17930079	CHEMBL3991843	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COCc1c(-c2ccc(NC(=O)Nc3cc(C(F)(F)F)ccc3F)c(F)c2)c2c(N)ncnn2c1CN1CCOCC1		CHEMBL3991934	>	Kd	nM	30000.0	CHEMBL3045	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17930080	CHEMBL3991843	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1ccc(S(=O)(=O)Nc2nc3ccccc3nc2Nc2ccc3nsnc3c2)cc1		CHEMBL3218575	>	Kd	nM	30000.0	CHEMBL3045	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17930081	CHEMBL3991843	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1cc(Nc2cc(N3CCN(C)CC3)nc(/C=C/c3ccccc3)n2)n[nH]1		CHEMBL482968	>	Kd	nM	30000.0	CHEMBL3045	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17930082	CHEMBL3991843	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=S(=O)(c1cccc2c(O)nccc12)N1CCCNCC1		CHEMBL1233300	>	Kd	nM	30000.0	CHEMBL3045	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17930083	CHEMBL3991843	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1cc(Nc2cc(N3CCN(C)CC3)nc(Sc3ccc(NC(=O)C4CC4)cc3)n2)n[nH]1		CHEMBL572878	>	Kd	nM	30000.0	CHEMBL3045	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17930084	CHEMBL3991843	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc2ncnc3c2cc1OCCCCCN(C)Cc1ccc(Br)cc1N3		CHEMBL3109738	>	Kd	nM	30000.0	CHEMBL3045	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17930085	CHEMBL3991843	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CC[C@@H]1C(=O)N(C)c2cnc(Nc3ccc(C(=O)NC4CCN(C)CC4)cc3OC)nc2N1C1CCCC1		CHEMBL513909	>	Kd	nM	30000.0	CHEMBL3045	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17930086	CHEMBL3991843	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCS(=O)(=O)N1CCN(c2ccc(Nc3ncc(C(N)=O)c(NC4CC4)n3)cc2)CC1.Cl		CHEMBL3991929	>	Kd	nM	30000.0	CHEMBL3045	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17930087	CHEMBL3991843	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CC(C)(C)c1cc(NC(=O)Nc2ccc(-c3cn4c(n3)sc3cc(OCCN5CCOCC5)ccc34)cc2)no1		CHEMBL576982	>	Kd	nM	30000.0	CHEMBL3045	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17930088	CHEMBL3991843	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc(Nc2ncc3c(n2)-c2ccc(Cl)cc2C(c2c(F)cccc2OC)=NC3)ccc1C(=O)O		CHEMBL483158	>	Kd	nM	30000.0	CHEMBL3045	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17930089	CHEMBL3991843	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CC(C)(O)CC(=O)NCCn1ccc2ncnc(Nc3ccc(Oc4cccc(C(F)(F)F)c4)c(Cl)c3)c21		CHEMBL1614725	>	Kd	nM	30000.0	CHEMBL3045	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17930090	CHEMBL3991843	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Nc1cc(C(F)(F)F)c(-c2cc(N3CCOCC3)nc(N3CCOCC3)n2)cn1		CHEMBL2017974	>	Kd	nM	30000.0	CHEMBL3045	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17930091	CHEMBL3991843	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=C(O)c1ccc2c(c1)nc(Nc1cccc(Cl)c1)c1ccncc12		CHEMBL1230165	>	Kd	nM	30000.0	CHEMBL3045	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17930092	CHEMBL3991843	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1c(OCCCN2CCOCC2)ccc2c1N=C(NC(=O)c1cnc(N)nc1)N1CCN=C21		CHEMBL3218576	>	Kd	nM	30000.0	CHEMBL3045	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17930093	CHEMBL3991843	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=C1NC(=O)/C(=C/c2ccc3nccc(-c4ccncc4)c3c2)S1		CHEMBL3544966	>	Kd	nM	30000.0	CHEMBL3045	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17930094	CHEMBL3991843	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	N#CCNC(=O)c1ccc(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)cc1		CHEMBL1078178	>	Kd	nM	30000.0	CHEMBL3045	Homo sapiens	Kd apparent	nM	30000.0
Active	17930095	CHEMBL3991843	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CN1C/C=C/CCOc2cccc(c2)-c2ccnc(n2)Nc2cccc(c2)C1		CHEMBL1944698	=	Kd	nM	4321.0	CHEMBL3045	Homo sapiens	Kd apparent	nM	4321.0
Inactive	17930096	CHEMBL3991843	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	S=C(NCc1ccc2c(c1)OCO2)N1CCN(c2ncnc3c2oc2ccccc23)CC1		CHEMBL2103851	>	Kd	nM	30000.0	CHEMBL3045	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17930097	CHEMBL3991843	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CNC(=O)c1ccccc1Sc1ccc2c(/C=C/c3ccccn3)n[nH]c2c1		CHEMBL1289926	>	Kd	nM	30000.0	CHEMBL3045	Homo sapiens	Kd apparent	nM	30000.0
Active	17930098	CHEMBL3991843	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CN1CCN(c2nc(C3=C(c4c[nH]c5ccccc45)C(=O)NC3=O)c3ccccc3n2)CC1		CHEMBL565612	=	Kd	nM	24.0	CHEMBL3045	Homo sapiens	Kd apparent	nM	24.0
Inactive	17930099	CHEMBL3991843	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1ccc(C(=O)Nc2ccc(CN3CCN(C)CC3)c(C(F)(F)F)c2)cc1C#Cc1cnc2cccnn12		CHEMBL1171837	>	Kd	nM	30000.0	CHEMBL3045	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17930100	CHEMBL3991843	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CN(c1ncccc1CNc1nc(Nc2ccc3c(c2)CC(=O)N3)ncc1C(F)(F)F)S(C)(=O)=O		CHEMBL1084546	>	Kd	nM	30000.0	CHEMBL3045	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17930101	CHEMBL3991843	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COCC(=O)NC/C=C/c1ccc2ncnc(Nc3ccc(Oc4ccc(C)nc4)c(C)c3)c2c1		CHEMBL483321	>	Kd	nM	30000.0	CHEMBL3045	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17930102	CHEMBL3991843	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1cc(Nc2ncnc3ccc(NC4=NC(C)(C)CO4)cc23)ccc1Oc1ccn2ncnc2c1		CHEMBL3989868	>	Kd	nM	30000.0	CHEMBL3045	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17930103	CHEMBL3991843	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CC(C)Nc1cc(-c2c[nH]c(C(=O)N[C@H](CO)c3cccc(Cl)c3)c2)c(Cl)cn1		CHEMBL3590106	>	Kd	nM	30000.0	CHEMBL3045	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17930104	CHEMBL3991843	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COCCN1CCN(Cc2ccc(-c3n[nH]c4c3C(=O)c3c(NC(=O)NN5CCOCC5)cccc3-4)cc2)CC1		CHEMBL3545083	>	Kd	nM	30000.0	CHEMBL3045	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17930105	CHEMBL3991843	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc21		CHEMBL572881	>	Kd	nM	30000.0	CHEMBL3045	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17930106	CHEMBL3991843	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc2ncnc(Oc3cccc(NC(=O)Nc4cc(C(C)(C)C(F)(F)F)on4)c3)c2cc1OC		CHEMBL2029988	>	Kd	nM	30000.0	CHEMBL3045	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17930107	CHEMBL3991843	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc(F)c(F)c(Nc2ccc(I)cc2F)c1NS(=O)(=O)C1(C[C@H](O)CO)CC1		CHEMBL1236682	>	Kd	nM	30000.0	CHEMBL3045	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17930108	CHEMBL3991843	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O[C@H]1CC[C@H](Nc2ncc3nc(Nc4c(F)cc(F)cc4F)n([C@H]4CCOC4)c3n2)CC1		CHEMBL1950289	>	Kd	nM	30000.0	CHEMBL3045	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17930109	CHEMBL3991843	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC		CHEMBL1289494	>	Kd	nM	30000.0	CHEMBL3045	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17930110	CHEMBL3991843	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CC(C)CC(=O)Nc1n[nH]c2c1CN(C(=O)C1CCN(C)CC1)C2(C)C		CHEMBL1230607	>	Kd	nM	30000.0	CHEMBL3045	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17930111	CHEMBL3991843	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1[nH]c(/C=C2\C(=O)Nc3ccccc32)c(C)c1CCC(=O)O		CHEMBL274654	>	Kd	nM	30000.0	CHEMBL3045	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17930112	CHEMBL3991843	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCOc1ccn(-c2ccc(F)cc2)c(=O)c1C(=O)Nc1ccc(Oc2ccnc(N)c2Cl)c(F)c1		CHEMBL460702	>	Kd	nM	30000.0	CHEMBL3045	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17930113	CHEMBL3991843	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C[C@@]1(C(=O)Nc2ccc(F)nc2)CCCN1c1nc(Nc2cc(C3CC3)n[nH]2)c2cccn2n1		CHEMBL575448	>	Kd	nM	30000.0	CHEMBL3045	Homo sapiens	Kd apparent	nM	30000.0
Active	17930114	CHEMBL3991843	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1nc(Nc2[nH]nc3c2CN(C(=O)N[C@H](CN(C)C)c2ccccc2)C3(C)C)c2sccc2n1		CHEMBL3128043	=	Kd	nM	5893.0	CHEMBL3045	Homo sapiens	Kd apparent	nM	5893.0
Active	17930115	CHEMBL3991843	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cn1cc(C2=C(c3cn(C4CCN(Cc5ccccn5)CC4)c4ccccc34)C(=O)NC2=O)c2ccccc21		CHEMBL300138	=	Kd	nM	2897.0	CHEMBL3045	Homo sapiens	Kd apparent	nM	2897.0
Inactive	17930116	CHEMBL3991843	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1ccc(NC(=O)c2ccc(CN3CC[C@H](N(C)C)C3)c(C(F)(F)F)c2)cc1Nc1nccc(-c2cncnc2)n1		CHEMBL206834	>	Kd	nM	30000.0	CHEMBL3045	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17930117	CHEMBL3991843	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CN1CCC(COc2cnc(-c3cccc(Cn4nc(-c5cccc(C#N)c5)ccc4=O)c3)nc2)CC1		CHEMBL3402762	>	Kd	nM	30000.0	CHEMBL3045	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17930118	CHEMBL3991843	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1c(F)cc(C(=O)NC2CC2)cc1-c1ccc(C(=O)NCC(C)(C)C)cn1		CHEMBL1088752	>	Kd	nM	30000.0	CHEMBL3045	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17930119	CHEMBL3991843	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=C(c1ccc(/C=C/c2n[nH]c3ccccc23)cc1)N1CCNCC1		CHEMBL1908397	>	Kd	nM	30000.0	CHEMBL3045	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17930120	CHEMBL3991843	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1		CHEMBL3813873	>	Kd	nM	30000.0	CHEMBL3045	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17930121	CHEMBL3991843	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ncnc2cc1OCCCN1CCCC1		CHEMBL491473	>	Kd	nM	30000.0	CHEMBL3045	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17930122	CHEMBL3991843	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COC(=O)c1ccc2c(c1)NC(=O)/C2=C(\Nc1ccc(N(C)C(=O)CN2CCN(C)CC2)cc1)c1ccccc1		CHEMBL502835	>	Kd	nM	30000.0	CHEMBL3045	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17930123	CHEMBL3991843	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12		CHEMBL221959	>	Kd	nM	30000.0	CHEMBL3045	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17930124	CHEMBL3991843	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C[C@]1(O)C[C@@H](c2nc(-c3ccc4ccc(-c5ccccc5)nc4c3)c3c(N)nccn32)C1		CHEMBL1091644	>	Kd	nM	30000.0	CHEMBL3045	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17930125	CHEMBL3991843	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1c(NC(=O)OC[C@@H]2COCCN2)cn2ncnc(Nc3ccc4c(cnn4Cc4cccc(F)c4)c3)c12		CHEMBL1645462	>	Kd	nM	30000.0	CHEMBL3045	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17930126	CHEMBL3991843	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=C(NOC[C@H](O)CO)c1ccc(F)c(F)c1Nc1ccc(I)cc1F		CHEMBL507361	>	Kd	nM	30000.0	CHEMBL3045	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17930127	CHEMBL3991843	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc(Nc2ncc(F)c(Nc3ccc4c(n3)N(COP(=O)(O)O)C(=O)C(C)(C)O4)n2)cc(OC)c1OC		CHEMBL2103830	>	Kd	nM	30000.0	CHEMBL3045	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17930128	CHEMBL3991843	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1ccc(C(=O)Nc2ccc(Oc3cc4cnn(C)c4cc3-c3cn[nH]c3)c(F)c2)c(=O)n1-c1ccc(F)cc1		CHEMBL3545307	>	Kd	nM	30000.0	CHEMBL3045	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17930129	CHEMBL3991843	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C=CC(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1OCCCN1CCOCC1		CHEMBL31965	>	Kd	nM	30000.0	CHEMBL3045	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17930130	CHEMBL3991843	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C=CC(=O)N1CCC[C@H](n2c(=O)n(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1		CHEMBL3991931	>	Kd	nM	30000.0	CHEMBL3045	Homo sapiens	Kd apparent	nM	30000.0
Active	17930131	CHEMBL3991843	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C[C@@H](N)c1ccc(C(=O)Nc2ccnc3[nH]ccc23)cc1		CHEMBL571948	=	Kd	nM	6032.0	CHEMBL3045	Homo sapiens	Kd apparent	nM	6032.0
Inactive	17930132	CHEMBL3991843	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1ccc(-n2nc(C(C)(C)C)cc2NC(=O)NCc2cc(F)ccc2Oc2ccc3c(cnn3CCO)c2)cc1		CHEMBL3991932	>	Kd	nM	30000.0	CHEMBL3045	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17930133	CHEMBL3991843	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cn1cc(-c2cnn3c(N)c(Br)c([C@@H]4CCCNC4)nc23)cn1		CHEMBL2386889	>	Kd	nM	30000.0	CHEMBL3045	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17930134	CHEMBL3991843	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1cc(-c2cc(OC(=O)c3ccccc3)ccc2Cl)cc2nnc(Nc3ccc(OCCN4CCCC4)cc3)nc12		CHEMBL403989	>	Kd	nM	30000.0	CHEMBL3045	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17930135	CHEMBL3991843	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1		CHEMBL554	>	Kd	nM	30000.0	CHEMBL3045	Homo sapiens	Kd apparent	nM	30000.0
Active	17930136	CHEMBL3991843	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cn1ncc(Cl)c1-c1cc(C(=O)N[C@H](CN)Cc2cccc(F)c2)sc1Cl		CHEMBL2219422	=	Kd	nM	4879.0	CHEMBL3045	Homo sapiens	Kd apparent	nM	4879.0
Inactive	17930137	CHEMBL3991843	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1c(Cn2c(C)nc3c(C(=O)O)cc(N4CCOCC4)cc32)cccc1C(F)(F)F		CHEMBL3188551	>	Kd	nM	30000.0	CHEMBL3045	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17930138	CHEMBL3991843	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=C(c1ccc(F)c(F)c1Nc1ccc(I)cc1F)N1CC(O)([C@@H]2CCCCN2)C1		CHEMBL2146883	>	Kd	nM	30000.0	CHEMBL3045	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17930139	CHEMBL3991843	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CO[C@@H](C(=O)N1Cc2n[nH]c(NC(=O)c3ccc(N4CCN(C)CC4)cc3)c2C1)c1ccccc1		CHEMBL402548	>	Kd	nM	30000.0	CHEMBL3045	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17930140	CHEMBL3991843	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1c(CN2CCN(C(=O)[C@H](C)O)CC2)sc2c(N3CCOCC3)nc(-c3cnc(N)nc3)nc12		CHEMBL1922094	>	Kd	nM	30000.0	CHEMBL3045	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17930141	CHEMBL3991843	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cn1cc(-c2ccc3nnc(C(F)(F)c4ccc5ncccc5c4)n3n2)cn1		CHEMBL2133806	>	Kd	nM	30000.0	CHEMBL3045	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17930142	CHEMBL3991843	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CNC(=O)CN1CCC(Oc2cc3c(Nc4cccc(Cl)c4F)ncnc3cc2OC)CC1		CHEMBL2408045	>	Kd	nM	30000.0	CHEMBL3045	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17930143	CHEMBL3991843	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C[C@@H](Oc1cc(C(=O)Nc2ccc(C(=O)N3CCN(C)CC3)cc2)nnc1N)c1c(Cl)ccc(F)c1Cl		CHEMBL2376648	>	Kd	nM	30000.0	CHEMBL3045	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17930144	CHEMBL3991843	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc(Nc2ncc(F)c(Nc3ccc4c(n3)NC(=O)C(C)(C)O4)n2)cc(OC)c1OC		CHEMBL475251	>	Kd	nM	30000.0	CHEMBL3045	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17930145	CHEMBL3991843	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc(CCc2cc(NC(=O)c3ccc(N4CC(C)NC(C)C4)cc3)n[nH]2)cc(OC)c1		CHEMBL3184679	>	Kd	nM	30000.0	CHEMBL3045	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17930146	CHEMBL3991843	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=c1[nH]ccc2cc(OC3CCNCC3)ccc12		CHEMBL1667969	>	Kd	nM	30000.0	CHEMBL3045	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17930147	CHEMBL3991843	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	NC[C@@](O)(c1ccc(Cl)cc1)c1ccc(-c2cn[nH]c2)cc1		CHEMBL3544960	>	Kd	nM	30000.0	CHEMBL3045	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17930148	CHEMBL3991843	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1nc(NC(=O)N2CCC[C@H]2C(N)=O)sc1-c1ccnc(C(C)(C)C(F)(F)F)c1		CHEMBL2396661	>	Kd	nM	30000.0	CHEMBL3045	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17930149	CHEMBL3991843	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CN(C[C@@H]1COCCO1)S(=O)(=O)Nc1ccc2ccc3ncc(-c4cnn(C)c4)cc3c(=O)c2c1		CHEMBL1822792	>	Kd	nM	30000.0	CHEMBL3045	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17930150	CHEMBL3991843	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C#Cc1cccc(Nc2ncnc3cc(OCCOC)c(OCCOC)cc23)c1		CHEMBL553	>	Kd	nM	30000.0	CHEMBL3045	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17930151	CHEMBL3991843	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CN(C)C(=O)c1cc2cnc(Nc3ccc(N4CCNCC4)cn3)nc2n1C1CCCC1		CHEMBL3545110	>	Kd	nM	30000.0	CHEMBL3045	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17930152	CHEMBL3991843	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1ccc2c(OCc3nnc4ccc(-c5ccccc5)nn34)ccnc2c1		CHEMBL496102	>	Kd	nM	30000.0	CHEMBL3045	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17930153	CHEMBL3991843	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C[C@]12O[C@H](C[C@]1(O)CO)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)CNC4=O		CHEMBL603469	>	Kd	nM	30000.0	CHEMBL3045	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17930154	CHEMBL3991843	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCn1c(C(=O)N(C2CC2)C2CC2)cc2c3c(ncn3C)c(Nc3cc(C)n(C)n3)nc21		CHEMBL3545215	>	Kd	nM	30000.0	CHEMBL3045	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17930155	CHEMBL3991843	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cn1cnc2c(F)c(Nc3ccc(Br)cc3Cl)c(C(=O)NOCCO)cc21		CHEMBL1614701	>	Kd	nM	30000.0	CHEMBL3045	Homo sapiens	Kd apparent	nM	30000.0
Active	17930156	CHEMBL3991843	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	NC1(C(=O)N[C@@H](CCO)c2ccc(Cl)cc2)CCN(c2ncnc3[nH]ccc23)CC1		CHEMBL2325741	=	Kd	nM	2431.0	CHEMBL3045	Homo sapiens	Kd apparent	nM	2431.0
Inactive	17930157	CHEMBL3991843	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CC1(COc2ccc3c(c2)ncn3-c2ccc3cccc(N4CCC(N)CC4)c3n2)COC1		CHEMBL2105728	>	Kd	nM	30000.0	CHEMBL3045	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17930158	CHEMBL3991843	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COC(=O)[C@@]1(O)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL281948	>	Kd	nM	30000.0	CHEMBL3045	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17930159	CHEMBL3991843	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc([C@@H]2c3cc4c(cc3[C@H](O)[C@H]3COC(=O)[C@@H]23)OCO4)cc(OC)c1OC		CHEMBL283120	>	Kd	nM	30000.0	CHEMBL3045	Homo sapiens	Kd apparent	nM	30000.0
Active	17930160	CHEMBL3991843	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=C(Nc1c[nH]nc1-c1nc2ccc(CN3CCOCC3)cc2[nH]1)NC1CC1		CHEMBL495727	=	Kd	nM	3380.0	CHEMBL3045	Homo sapiens	Kd apparent	nM	3380.0
Inactive	17930161	CHEMBL3991843	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1ccc(F)c(F)c1C(=O)c1cnc(NC2CCN(S(C)(=O)=O)CC2)nc1N		CHEMBL384304	>	Kd	nM	30000.0	CHEMBL3045	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17930162	CHEMBL3991843	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Nc1nc(N)c2nc(-c3cccc(O)c3)c(-c3cccc(O)c3)nc2n1		CHEMBL230011	>	Kd	nM	30000.0	CHEMBL3045	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17930163	CHEMBL3991843	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C#Cc1cccc(Nc2ncnc3cc4c(cc23)OCCOCCOCCO4)c1		CHEMBL2087361	>	Kd	nM	30000.0	CHEMBL3045	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17930164	CHEMBL3991843	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C[C@H]1CNCCCN1S(=O)(=O)c1cccc2cncc(F)c12		CHEMBL3426621	>	Kd	nM	30000.0	CHEMBL3045	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17930165	CHEMBL3991843	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1cnc(NC(=O)Nc2cc(Br)c(C)cc2OC[C@@H]2CNCCO2)cn1		CHEMBL3039517	>	Kd	nM	30000.0	CHEMBL3045	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17930166	CHEMBL3991843	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCc1cnn2c(NCc3ccc[n+]([O-])c3)cc(N3CCCC[C@H]3CCO)nc12		CHEMBL2103840	>	Kd	nM	30000.0	CHEMBL3045	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17930167	CHEMBL3991843	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=C(NOCCO)c1cc(CN2OCCCC2=O)c(F)c(F)c1Nc1ccc(I)cc1F		CHEMBL1614766	>	Kd	nM	30000.0	CHEMBL3045	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17930168	CHEMBL3991843	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CNC(=O)c1ccc(Nc2ncc(C(F)(F)F)c(NCc3nccnc3N(C)S(C)(=O)=O)n2)cc1		CHEMBL3137331	>	Kd	nM	30000.0	CHEMBL3045	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17930169	CHEMBL3991843	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=c1sn(-c2cccc3ccccc23)c(=O)n1Cc1ccccc1		CHEMBL3545157	>	Kd	nM	30000.0	CHEMBL3045	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17930170	CHEMBL3991843	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1nc2ccc(-n3ncc(C(=O)c4cc5ccccc5[nH]4)c3N)cc2[nH]1		CHEMBL3907479	>	Kd	nM	30000.0	CHEMBL3045	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17930171	CHEMBL3991843	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C[C@@H](Nc1cc(F)cc(F)c1)c1cc(C(=O)N(C)C)cc2c(=O)cc(N3CCOCC3)oc12		CHEMBL3408248	>	Kd	nM	30000.0	CHEMBL3045	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17930172	CHEMBL3991843	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1		CHEMBL941	>	Kd	nM	30000.0	CHEMBL3045	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17930173	CHEMBL3991843	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cn1c(=O)n(-c2ccc(C(C)(C)C#N)cc2)c2c3cc(-c4cnc5ccccc5c4)ccc3ncc21		CHEMBL1879463	>	Kd	nM	30000.0	CHEMBL3045	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17930174	CHEMBL3991843	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C[C@@H](Oc1cc(-c2cnn(C3CCNCC3)c2)cnc1N)c1c(Cl)ccc(F)c1Cl		CHEMBL601719	>	Kd	nM	30000.0	CHEMBL3045	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17930175	CHEMBL3991843	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc2c(Nc3ccc(Cl)c(Cl)c3F)ncnc2cc1OC[C@@H]1C[C@@H]2CN(C)C[C@@H]2C1		CHEMBL3544983	>	Kd	nM	30000.0	CHEMBL3045	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17930176	CHEMBL3991843	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1nc(N)sc1-c1ccnc(Nc2ccc(N3CCOCC3)cc2)n1		CHEMBL482967	>	Kd	nM	30000.0	CHEMBL3045	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17930177	CHEMBL3991843	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cn1cc(-c2ccc(F)c(C(F)(F)F)c2)nc1C1CCN(c2ncnc3[nH]ncc23)CC1		CHEMBL3545076	>	Kd	nM	30000.0	CHEMBL3045	Homo sapiens	Kd apparent	nM	30000.0
Active	17930178	CHEMBL3991843	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C1=C/COCc2cc(ccc2OCCN2CCCC2)Nc2nccc(n2)-c2cccc(c2)COC/1		CHEMBL2035187	=	Kd	nM	7244.0	CHEMBL3045	Homo sapiens	Kd apparent	nM	7244.0
Inactive	17930179	CHEMBL3991843	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1ccc(-c2ccc3c(N4CCOC[C@@H]4C)nc(N4CCOC[C@@H]4C)nc3n2)cc1CO		CHEMBL1801204	>	Kd	nM	30000.0	CHEMBL3045	Homo sapiens	Kd apparent	nM	30000.0
Active	17930180	CHEMBL3991843	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OC[C@H]3CCCNC3)c21		CHEMBL494089	=	Kd	nM	310.0	CHEMBL3045	Homo sapiens	Kd apparent	nM	310.0
Inactive	17930181	CHEMBL3991843	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc2c(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3F)ccnc2cc1OCCCN1CCOCC1		CHEMBL1230609	>	Kd	nM	30000.0	CHEMBL3045	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17930182	CHEMBL3991843	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1ccc(-c2ccc3ncc4c(c3c2)n(-c2ccc(N3CCNCC3)c(C(F)(F)F)c2)c(=O)n4C)cn1		CHEMBL3218578	>	Kd	nM	30000.0	CHEMBL3045	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17930183	CHEMBL3991843	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O		CHEMBL477772	>	Kd	nM	30000.0	CHEMBL3045	Homo sapiens	Kd apparent	nM	30000.0
Active	17930184	CHEMBL3991843	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cn1ncc(Cl)c1-c1cc(C(=O)N[C@H](CN)Cc2ccc(F)c(F)c2)oc1Cl		CHEMBL3137336	=	Kd	nM	1180.0	CHEMBL3045	Homo sapiens	Kd apparent	nM	1180.0
Inactive	17930185	CHEMBL3991843	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	N[C@@H]1CCCN(c2c(/C=C3\SC(=O)NC3=O)cccc2-c2ccccc2)C1		CHEMBL2048872	>	Kd	nM	30000.0	CHEMBL3045	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17930186	CHEMBL3991843	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OC(=O)C(C)(CO)CO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C		CHEMBL1201182	>	Kd	nM	30000.0	CHEMBL3045	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17930187	CHEMBL3991843	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CN1CCN(c2ccc(C(=O)Nc3n[nH]c4ccc(Cc5cc(F)cc(F)c5)cc34)c(NC3CCOCC3)c2)CC1		CHEMBL1983268	>	Kd	nM	30000.0	CHEMBL3045	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17930188	CHEMBL3991843	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CC(C)(C)c1nc(-c2cccc(NS(=O)(=O)c3c(F)cccc3F)c2F)c(-c2ccnc(N)n2)s1		CHEMBL2028663	>	Kd	nM	30000.0	CHEMBL3045	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17930189	CHEMBL3991843	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C=CCn1c(=O)c2cnc(Nc3ccc(N4CCN(C)CC4)cc3)nc2n1-c1cccc(C(C)(C)O)n1		CHEMBL1976040	>	Kd	nM	30000.0	CHEMBL3045	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17930190	CHEMBL3991843	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cccc(Nc2ncnn3ccc(CN4CC[C@@H](N)[C@H](O)C4)c23)c1		CHEMBL3545396	>	Kd	nM	30000.0	CHEMBL3045	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17930191	CHEMBL3991843	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=c1[nH]c(C2CCCN2)nc2c1oc1ccc(Cl)cc12		CHEMBL3544944	>	Kd	nM	30000.0	CHEMBL3045	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17930192	CHEMBL3991843	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cn1cnc(-c2cc3nccc(Oc4ccc(NC(=S)NC(=O)Cc5ccccc5)cc4F)c3s2)c1		CHEMBL254760	>	Kd	nM	30000.0	CHEMBL3045	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17930193	CHEMBL3991843	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c(F)c2)ccn1		CHEMBL1946170	>	Kd	nM	30000.0	CHEMBL3045	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17930194	CHEMBL3991843	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1cccc(-c2nn3c(c2-c2ccnc4ccc(C(N)=O)cc24)CCC3)n1		CHEMBL2364611	>	Kd	nM	30000.0	CHEMBL3045	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17930195	CHEMBL3991843	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=C(O)C1(Cc2cccc(Nc3nccs3)n2)CCC(Oc2cccc(Cl)c2F)CC1		CHEMBL3182444	>	Kd	nM	30000.0	CHEMBL3045	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17930196	CHEMBL3991843	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CC(=O)NCC(=O)N1C2CCC1c1cc(Nc3ncc(C(F)(F)F)c(NC4CCC4)n3)ccc12		CHEMBL1983111	>	Kd	nM	30000.0	CHEMBL3045	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17930197	CHEMBL3991843	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCCCCCCCCCCCCCCCCCOP(=O)([O-])OC1CC[N+](C)(C)CC1		CHEMBL372764	>	Kd	nM	30000.0	CHEMBL3045	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17930198	CHEMBL3991843	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1		CHEMBL3301607	>	Kd	nM	30000.0	CHEMBL3045	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17930199	CHEMBL3991843	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)/C=C/CN1CCCCC1		CHEMBL2110732	>	Kd	nM	30000.0	CHEMBL3045	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17930200	CHEMBL3991843	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1ccc(F)c(NC(=O)Nc2ccc(-c3cccc4[nH]nc(N)c34)cc2)c1		CHEMBL223360	>	Kd	nM	30000.0	CHEMBL3045	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17930201	CHEMBL3991843	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1cc2c(F)c(Oc3ncnn4cc(OC[C@@H](C)O)c(C)c34)ccc2[nH]1		CHEMBL377300	>	Kd	nM	30000.0	CHEMBL3045	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17930202	CHEMBL3991843	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	N#CC1(c2ccc(NC(=O)c3cccnc3NCc3ccncc3)cc2)CCCC1		CHEMBL3186534	>	Kd	nM	30000.0	CHEMBL3045	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17930203	CHEMBL3991843	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1cc([C@@H](C)Nc2ccccc2C(=O)O)c2nc(N3CCOCC3)cc(=O)n2c1		CHEMBL2165191	>	Kd	nM	30000.0	CHEMBL3045	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17930204	CHEMBL3991843	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1ccc(N2CCN(C)CC2)cc1Nc1ncc2c(n1)-c1c(c(C(N)=O)nn1C)CC2		CHEMBL1094408	>	Kd	nM	30000.0	CHEMBL3045	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17930205	CHEMBL3991843	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCc1cc2c(cc1N1CCC(N3CCOCC3)CC1)C(C)(C)c1[nH]c3cc(C#N)ccc3c1C2=O		CHEMBL1738797	>	Kd	nM	30000.0	CHEMBL3045	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17930206	CHEMBL3991843	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CN1CC[C@H](c2c(O)cc(O)c3c(=O)cc(-c4ccccc4Cl)oc23)[C@H](O)C1		CHEMBL428690	>	Kd	nM	30000.0	CHEMBL3045	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17930207	CHEMBL3991843	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CNC(=O)c1ccc(C)c(-n2c(C)cc(OCc3ccc(F)cc3F)c(Br)c2=O)c1		CHEMBL1088751	>	Kd	nM	30000.0	CHEMBL3045	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17930208	CHEMBL3991843	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=C(Nc1ccc(OC(F)(F)F)cc1)c1sccc1NCc1ccnc2ccccc12		CHEMBL1614710	>	Kd	nM	30000.0	CHEMBL3045	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17930209	CHEMBL3991843	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc2ncnc(Nc3ccc(O)cc3)c2cc1OC		CHEMBL405130	>	Kd	nM	30000.0	CHEMBL3045	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17930210	CHEMBL3991843	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc2nccc(Oc3ccc(NC(=O)NC4CC4)c(Cl)c3)c2cc1C(N)=O		CHEMBL1289601	>	Kd	nM	30000.0	CHEMBL3045	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17930211	CHEMBL3991843	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1nc2cc(-c3nn(C(C)C)c4ncnc(N)c34)ccc2o1		CHEMBL3991933	>	Kd	nM	30000.0	CHEMBL3045	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17930212	CHEMBL3991843	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1ncc(-c2ccc3nccc(-c4ccnnc4)c3c2)cc1NS(=O)(=O)c1ccc(F)cc1F		CHEMBL1236962	>	Kd	nM	30000.0	CHEMBL3045	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17930213	CHEMBL3991843	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1		CHEMBL1336	>	Kd	nM	30000.0	CHEMBL3045	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17930214	CHEMBL3991843	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc(N2CCC(N3CCN(C)CC3)CC2)ccc1Nc1ncnc(Nc2ccccc2S(=O)(=O)C(C)C)n1		CHEMBL3545360	>	Kd	nM	30000.0	CHEMBL3045	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17930215	CHEMBL3991843	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C=CC(=O)Nc1cccc(Nc2nc(Nc3ccc(N4CCN(C(C)=O)CC4)cc3OC)ncc2C(F)(F)F)c1		CHEMBL3545308	>	Kd	nM	30000.0	CHEMBL3045	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17930216	CHEMBL3991843	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1cc(Nc2nc(N[C@@H](C)c3ncc(F)cn3)ncc2Cl)[nH]n1		CHEMBL1231124	>	Kd	nM	30000.0	CHEMBL3045	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17930217	CHEMBL3991843	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C[C@H]1CN(C(=O)c2cc3c(C(=O)C(=O)N(C)C)cn(C)c3cc2Cl)[C@H](C)CN1Cc1ccc(F)cc1		CHEMBL514201	>	Kd	nM	30000.0	CHEMBL3045	Homo sapiens	Kd apparent	nM	30000.0
Active	17930218	CHEMBL3991843	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CC[C@@](C)(Nc1ccnc(-c2c[nH]c3ncccc23)n1)C(=O)NCC(F)(F)F		CHEMBL3039513	=	Kd	nM	426.0	CHEMBL3045	Homo sapiens	Kd apparent	nM	426.0
Inactive	17930219	CHEMBL3991843	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CC(C)(C)c1cnc(CSc2cnc(NC(=O)C3CCNCC3)s2)o1		CHEMBL296468	>	Kd	nM	30000.0	CHEMBL3045	Homo sapiens	Kd apparent	nM	30000.0
Active	17930220	CHEMBL3991843	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCN1CCN(Cc2ccc(Nc3ncc(F)c(-c4cc(F)c5nc(C)n(C(C)C)c5c4)n3)nc2)CC1		CHEMBL3301610	=	Kd	nM	1624.0	CHEMBL3045	Homo sapiens	Kd apparent	nM	1624.0
Inactive	17930221	CHEMBL3991843	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	OCCn1cc(-c2cnc3nnn(Cc4ccc5ncccc5c4)c3n2)cn1		CHEMBL2001019	>	Kd	nM	30000.0	CHEMBL3045	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17930222	CHEMBL3991843	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL608533	>	Kd	nM	30000.0	CHEMBL3045	Homo sapiens	Kd apparent	nM	30000.0
	17979269	CHEMBL3998073	Inhibition of full length recombinant human PKCbeta1 expressed in baculovirus expression system at 10 uM relative to control	B	CC1=Nc2c(Sc3ccccc3)ncnc2Sc2ccccc21		CHEMBL4061152	=	Inhibition	%	1.0	CHEMBL3045	Homo sapiens	INH	%	1.0
	18012412	CHEMBL4004232	Inhibition of recombinant full length human N-terminal GST-tagged PKCbeta1 (1 to 671 residues) expressed in baculovirus expression system	B	COc1cc2ncccc2cc1NC(=O)c1csc2cncnc12		CHEMBL3822972	>	IC50	nM	50000.0	CHEMBL3045	Homo sapiens	IC50	uM	50.0
	18012413	CHEMBL4004233	Inhibition of recombinant full length human N-terminal GST-tagged PKCbeta2 (1 to 673 residues) expressed in baculovirus expression system	B	COc1cc2ncccc2cc1NC(=O)c1csc2cncnc12		CHEMBL3822972	>	IC50	nM	50000.0	CHEMBL3045	Homo sapiens	IC50	uM	50.0
	18014604	CHEMBL4004541	Inhibition of PKCbeta1 (unknown origin) after 60 mins in presence of [gamma33P]ATP by scintillation proximity assay	B	Cn1cc(C2=C(c3cccc4ccc(CN)cc34)C(=O)NC2=O)c2ccccc21		CHEMBL4083182	=	IC50	nM	93.0	CHEMBL3045	Homo sapiens	IC50	nM	93.0
	18014605	CHEMBL4004541	Inhibition of PKCbeta1 (unknown origin) after 60 mins in presence of [gamma33P]ATP by scintillation proximity assay	B	NCc1ccc2cccc(C3=C(c4c[nH]c5ccccc45)C(=O)NC3=O)c2c1		CHEMBL4061321	=	IC50	nM	75.0	CHEMBL3045	Homo sapiens	IC50	nM	75.0
	18014606	CHEMBL4004541	Inhibition of PKCbeta1 (unknown origin) after 60 mins in presence of [gamma33P]ATP by scintillation proximity assay	B	Cn1cc(C2=C(c3cccc4cc(CN)ccc34)C(=O)NC2=O)c2ccccc21		CHEMBL4072709	=	IC50	nM	133.0	CHEMBL3045	Homo sapiens	IC50	nM	133.0
	18014607	CHEMBL4004541	Inhibition of PKCbeta1 (unknown origin) after 60 mins in presence of [gamma33P]ATP by scintillation proximity assay	B	Cc1ccc2ccc(CN)cc2c1C1=C(c2c[nH]c3ccccc23)C(=O)NC1=O		CHEMBL4099609	=	IC50	nM	43.0	CHEMBL3045	Homo sapiens	IC50	nM	43.0
	18014608	CHEMBL4004541	Inhibition of PKCbeta1 (unknown origin) after 60 mins in presence of [gamma33P]ATP by scintillation proximity assay	B	Cc1ccc2ccc(CN)cc2c1C1=C(c2cn(C)c3ccccc23)C(=O)NC1=O		CHEMBL4078759	=	IC50	nM	42.0	CHEMBL3045	Homo sapiens	IC50	nM	42.0
	18014609	CHEMBL4004541	Inhibition of PKCbeta1 (unknown origin) after 60 mins in presence of [gamma33P]ATP by scintillation proximity assay	B	Cn1cc(C2=C(c3c(Cl)ccc4ccc(CN)cc34)C(=O)NC2=O)c2ccccc21		CHEMBL4089665	=	IC50	nM	3.3	CHEMBL3045	Homo sapiens	IC50	nM	3.3
	18014610	CHEMBL4004541	Inhibition of PKCbeta1 (unknown origin) after 60 mins in presence of [gamma33P]ATP by scintillation proximity assay	B	CN(C)Cc1ccc2ccc(Cl)c(C3=C(c4cn(C)c5ccccc45)C(=O)NC3=O)c2c1		CHEMBL4077967	=	IC50	nM	3.7	CHEMBL3045	Homo sapiens	IC50	nM	3.7
	18014611	CHEMBL4004541	Inhibition of PKCbeta1 (unknown origin) after 60 mins in presence of [gamma33P]ATP by scintillation proximity assay	B	CN(C)Cc1ccc2ccc(Cl)c(C3=C(c4c[nH]c5ccccc45)C(=O)NC3=O)c2c1		CHEMBL4102228	=	IC50	nM	0.7	CHEMBL3045	Homo sapiens	IC50	nM	0.7
	18014612	CHEMBL4004541	Inhibition of PKCbeta1 (unknown origin) after 60 mins in presence of [gamma33P]ATP by scintillation proximity assay	B	CN(C)Cc1ccc2c(C3=C(c4c[nH]c5ccccc45)C(=O)NC3=O)c(Cl)ccc2c1		CHEMBL4085837	=	IC50	nM	3.4	CHEMBL3045	Homo sapiens	IC50	nM	3.4
	18014613	CHEMBL4004541	Inhibition of PKCbeta1 (unknown origin) after 60 mins in presence of [gamma33P]ATP by scintillation proximity assay	B	CN(C)Cc1ccc2c(C3=C(c4cn(C)c5ccccc45)C(=O)NC3=O)c(Cl)ccc2c1		CHEMBL4064291	=	IC50	nM	6.8	CHEMBL3045	Homo sapiens	IC50	nM	6.8
	18014614	CHEMBL4004541	Inhibition of PKCbeta1 (unknown origin) after 60 mins in presence of [gamma33P]ATP by scintillation proximity assay	B	CN1CCN(c2nc(C3=C(c4c[nH]c5ccccc45)C(=O)NC3=O)c3ccccc3n2)CC1		CHEMBL565612	=	IC50	nM	2.0	CHEMBL3045	Homo sapiens	IC50	nM	2.0
	18014615	CHEMBL4004541	Inhibition of PKCbeta1 (unknown origin) after 60 mins in presence of [gamma33P]ATP by scintillation proximity assay	B	CNCc1ccc2ccc(Cl)c(C3=C(c4cn(C)c5ccccc45)C(=O)NC3=O)c2c1		CHEMBL4072879	=	IC50	nM	1.4	CHEMBL3045	Homo sapiens	IC50	nM	1.4
	18014616	CHEMBL4004541	Inhibition of PKCbeta1 (unknown origin) after 60 mins in presence of [gamma33P]ATP by scintillation proximity assay	B	COCCNCc1ccc2ccc(Cl)c(C3=C(c4cn(C)c5ccccc45)C(=O)NC3=O)c2c1		CHEMBL4101316	=	IC50	nM	3.1	CHEMBL3045	Homo sapiens	IC50	nM	3.1
	18014617	CHEMBL4004541	Inhibition of PKCbeta1 (unknown origin) after 60 mins in presence of [gamma33P]ATP by scintillation proximity assay	B	CC(C)NCc1ccc2ccc(Cl)c(C3=C(c4cn(C)c5ccccc45)C(=O)NC3=O)c2c1		CHEMBL4083319	=	IC50	nM	2.9	CHEMBL3045	Homo sapiens	IC50	nM	2.9
	18014618	CHEMBL4004541	Inhibition of PKCbeta1 (unknown origin) after 60 mins in presence of [gamma33P]ATP by scintillation proximity assay	B	Cn1cc(C2=C(c3c(Cl)ccc4ccc(CN5CCC5)cc34)C(=O)NC2=O)c2ccccc21		CHEMBL4089217	=	IC50	nM	2.0	CHEMBL3045	Homo sapiens	IC50	nM	2.0
	18014619	CHEMBL4004541	Inhibition of PKCbeta1 (unknown origin) after 60 mins in presence of [gamma33P]ATP by scintillation proximity assay	B	CN1CCN(Cc2ccc3ccc(Cl)c(C4=C(c5cn(C)c6ccccc56)C(=O)NC4=O)c3c2)CC1		CHEMBL4068028	=	IC50	nM	15.0	CHEMBL3045	Homo sapiens	IC50	nM	15.0
	18014620	CHEMBL4004541	Inhibition of PKCbeta1 (unknown origin) after 60 mins in presence of [gamma33P]ATP by scintillation proximity assay	B	CC(=O)N(C)Cc1ccc2ccc(Cl)c(C3=C(c4cn(C)c5ccccc45)C(=O)NC3=O)c2c1		CHEMBL4100747	=	IC50	nM	41.0	CHEMBL3045	Homo sapiens	IC50	nM	41.0
	18014621	CHEMBL4004541	Inhibition of PKCbeta1 (unknown origin) after 60 mins in presence of [gamma33P]ATP by scintillation proximity assay	B	CN(Cc1ccc2ccc(Cl)c(C3=C(c4cn(C)c5ccccc45)C(=O)NC3=O)c2c1)C1CC1		CHEMBL4073977	=	IC50	nM	60.0	CHEMBL3045	Homo sapiens	IC50	nM	60.0
	18014703	CHEMBL4004554	Reversible competitive inhibition of PKCbeta1 (unknown origin)	B	CN(C)Cc1ccc2ccc(Cl)c(C3=C(c4cn(C)c5ccccc45)C(=O)NC3=O)c2c1		CHEMBL4077967	=	Ki	nM	0.5	CHEMBL3045	Homo sapiens	Ki	nM	0.5
	18096492	CHEMBL4021285	Inhibition of PKCbeta (unknown origin)	B	N#CCCn1c2ccccc2c2c3c(c4c5ccccc5[nH]c4c21)C(=O)NC3	Non standard unit for type	CHEMBL292746	=	INH	nM	6.2	CHEMBL3045	Homo sapiens	INH	nM	6.2
Active	18194802	CHEMBL4042043	Induction of PKC-beta1 translocation from cytosol to plasma membrane in human platelet at 0.1 uM measured after 1 min by Western blot analysis	B	C/C=C(/C)C(=O)O[C@H]1C(C)=C[C@]23C(=O)[C@@H](C=C(CO)[C@@H](O)[C@]12O)[C@H]1[C@@H](C[C@H]3C)C1(C)C		CHEMBL1863513		Activity			CHEMBL3045	Homo sapiens	Activity		
Active	18194803	CHEMBL4042043	Induction of PKC-beta1 translocation from cytosol to plasma membrane in human platelet at 0.1 uM measured after 1 min by Western blot analysis	B	CCCCCCCCCCCCCC(=O)O[C@@H]1[C@@H](C)[C@@]2(O)[C@@H](C=C(CO)C[C@]3(O)C(=O)C(C)=C[C@@H]23)[C@@H]2C(C)(C)[C@]12OC(C)=O		CHEMBL279115		Activity			CHEMBL3045	Homo sapiens	Activity		
Active	18194804	CHEMBL4042044	Induction of PKC-beta1 translocation from cytosol to plasma membrane in human platelet at 1 to 10 uM measured after 1 min by Western blot analysis	B	C/C=C(/C)C(=O)OC[C@]1(C)[C@H]2[C@@H]3C=C(COC(C)=O)C[C@]4(O)C(=O)C(C)=C[C@H]4[C@@]3(O)[C@H](C)C[C@]21OCC(C)C		CHEMBL4104319		Activity			CHEMBL3045	Homo sapiens	Activity		
Active	18194805	CHEMBL4042044	Induction of PKC-beta1 translocation from cytosol to plasma membrane in human platelet at 1 to 10 uM measured after 1 min by Western blot analysis	B	C/C=C(/C)C(=O)O[C@H]1C(C)=C[C@]23C(=O)[C@@H](C=C(C)[C@@H](O)[C@]12O)[C@H]1[C@@H](C[C@H]3C)C1(C)C		CHEMBL4071723		Activity			CHEMBL3045	Homo sapiens	Activity		
Active	18194806	CHEMBL4042044	Induction of PKC-beta1 translocation from cytosol to plasma membrane in human platelet at 1 to 10 uM measured after 1 min by Western blot analysis	B	CC(=O)O[C@@]12C[C@@H](C)[C@@]3(O)[C@@H](C=C(CO)C[C@]4(O)C(=O)C(C)=C[C@H]43)[C@@H]1C2(C)C		CHEMBL170518		Activity			CHEMBL3045	Homo sapiens	Activity		
Active	18194827	CHEMBL4042059	Induction of PKC-beta1 translocation from cytosol to plasma membrane in human platelet at 1 uM measured after 1 min by Western blot analysis	B	C/C=C(/C)C(=O)O[C@H]1C(C)=C[C@]23C(=O)[C@@H](C=C(CO)[C@@H](O)[C@]12O)[C@H]1[C@@H](C[C@H]3C)C1(C)C		CHEMBL1863513		Activity			CHEMBL3045	Homo sapiens	Activity		
	18211711	CHEMBL4045807	Inhibition of PKCb conserved Lys2 (DLKLDNVMLDSEGHIK) in human PBMC at 1 uM	B	CC(C)n1cc(-c2cc(-c3ccc(CN4CCOCC4)cc3)cnc2N)nn1		CHEMBL3971067	=	Inhibition	%	-7.4	CHEMBL3045	Homo sapiens	INH	%	-7.4
	18211952	CHEMBL4046048	Inhibition of PKCb conserved Lys2 (DLKLDNVMLDSEGHIK) in human PBMC at 0.1 uM	B	CC(C)n1cc(-c2cc(-c3ccc(CN4CCOCC4)cc3)cnc2N)nn1	Outside typical range	CHEMBL3971067	=	Inhibition	%	-19.8	CHEMBL3045	Homo sapiens	INH	%	-19.8
	18248615	CHEMBL4053898	Inhibition of PRKCB1 (unknown origin) at 1 uM relative to control	B	C=CC(=O)Nc1cc(Nc2nccc(-c3cn4c5c(cccc35)CCC4)n2)c(OC)cc1N(C)CCN(C)C		CHEMBL4104658	=	Inhibition	%	2.0	CHEMBL3045	Homo sapiens	INH	%	2.0
	18282114	CHEMBL4120069	Inhibition of PKCbeta1 (unknown origin) at 1 uM by FRET assay relative to control	B	CC(C)n1nc(-c2cnc(N)c(OC(F)(F)F)c2)cc1[C@@H]1[C@H]2CN(C3COC3)C[C@H]21		CHEMBL3719135	=	Inhibition	%	1.1	CHEMBL3045	Homo sapiens	INH	%	1.1
	18282433	CHEMBL4120069	Inhibition of PKCbeta1 (unknown origin) at 1 uM by FRET assay relative to control	B	Nc1ncc(-c2cc([C@@H]3[C@H]4CN(C5COC5)C[C@H]43)n(CC3CC3)n2)cc1C(F)(F)F		CHEMBL3715238	=	Inhibition	%	-7.3	CHEMBL3045	Homo sapiens	INH	%	-7.3
	18286348	CHEMBL4121598	Inhibition of PKCbeta1 (unknown origin) at 10 uM in presence of ATP relative to control	B	CC(C)(C)NS(=O)(=O)c1ccc(-c2sc(C(=O)N[C@H]3C[C@H](C(=O)O)C3)nc2CC2CCCCC2)c2ccccc12		CHEMBL4128926	=	Inhibition	%	-2.0	CHEMBL3045	Homo sapiens	INH	%	-2.0
	18288067	CHEMBL4121777	Inhibition of human PKCbeta2 measured at apparent ATP Km level	B	C[C@@H]1CC(=O)Nc2ncnc(N3CCC(c4nc(-c5ccc(F)c(C(F)(F)F)c5)cn4CCN4CCCC4)CC3)c21		CHEMBL4128457	=	IC50	nM	36.0	CHEMBL3045	Homo sapiens	IC50	uM	0.036
	18288068	CHEMBL4121777	Inhibition of human PKCbeta2 measured at apparent ATP Km level	B	C[C@@H]1CC(=O)Nc2ncnc(N3CCC(c4nc(C(F)(F)F)cn4CCN4CCCC4)CC3)c21		CHEMBL4129817	=	IC50	nM	16300.0	CHEMBL3045	Homo sapiens	IC50	uM	16.3
	18288069	CHEMBL4121777	Inhibition of human PKCbeta2 measured at apparent ATP Km level	B	C[C@@H]1CC(=O)Nc2ncnc(N3CCC(c4nc(C5CCOCC5)cn4CCN4CCCC4)CC3)c21		CHEMBL4126067	=	IC50	nM	20000.0	CHEMBL3045	Homo sapiens	IC50	uM	20.0
	18288070	CHEMBL4121777	Inhibition of human PKCbeta2 measured at apparent ATP Km level	B	C[C@@H]1CC(=O)Nc2ncnc(N3CCC(c4nc(CCC(F)(F)F)cn4CCN4CCCC4)CC3)c21		CHEMBL4129379	=	IC50	nM	3980.0	CHEMBL3045	Homo sapiens	IC50	uM	3.98
	18298999	CHEMBL4124327	Inhibition of human PKCbeta	B	CC(=O)C1=C(O)C=C2Oc3c(C(N)=O)c(O)cc(O)c3[C@]2(C)C1=O		CHEMBL475816	=	IC50	nM	300.0	CHEMBL3045	Homo sapiens	IC50	uM	0.3
	18420791	CHEMBL4153885	Inhibition of PCK-beta2 (unknown origin) at 10 uM by [33P]-ATP radiometric assay	B	Cc1ccc2nc3nc(NCc4ccc(CN5CCN(C)CC5)cc4)[nH]c(=O)c3cc2c1		CHEMBL4163273	=	Inhibition	%	3.0	CHEMBL3045	Homo sapiens	INH	%	3.0
	18420792	CHEMBL4153885	Inhibition of PCK-beta2 (unknown origin) at 10 uM by [33P]-ATP radiometric assay	B	CN1CCN(Cc2ccc(CNc3nc4nc5ccc(Cl)cc5cc4c(=O)[nH]3)cc2)CC1		CHEMBL4171176	=	Inhibition	%	5.0	CHEMBL3045	Homo sapiens	INH	%	5.0
	18420793	CHEMBL4153885	Inhibition of PCK-beta2 (unknown origin) at 10 uM by [33P]-ATP radiometric assay	B	O=c1[nH]c(NCc2ccc(CN3CCCCC3)cc2)nc2nc3ccccc3cc12		CHEMBL4160278	=	Inhibition	%	4.0	CHEMBL3045	Homo sapiens	INH	%	4.0
	18420794	CHEMBL4153885	Inhibition of PCK-beta2 (unknown origin) at 10 uM by [33P]-ATP radiometric assay	B	COc1ccc2nc3nc(NCc4ccc(CN5CCN(C)CC5)cc4)[nH]c(=O)c3nc2c1		CHEMBL4171939	=	Inhibition	%	-7.0	CHEMBL3045	Homo sapiens	INH	%	-7.0
	18420795	CHEMBL4153885	Inhibition of PCK-beta2 (unknown origin) at 10 uM by [33P]-ATP radiometric assay	B	COc1ccc(CCN2CCC(Nc3nc4nc5ccc(C)cc5nc4c(=O)[nH]3)CC2)cc1		CHEMBL4167512	=	Inhibition	%	7.0	CHEMBL3045	Homo sapiens	INH	%	7.0
	18420796	CHEMBL4153885	Inhibition of PCK-beta2 (unknown origin) at 10 uM by [33P]-ATP radiometric assay	B	Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1		CHEMBL941	=	Inhibition	%	10.0	CHEMBL3045	Homo sapiens	INH	%	10.0
	18434146	CHEMBL4156128	Inhibition of recombinant full length human GST-tagged PKCbeta-1 expressed in insect cells at 500 nM by Z-LYTE assay relative to control	B	OC[C@@H](Nc1ncnc2sc(-c3ccc(O)cc3)cc12)c1ccccc1		CHEMBL4177361	=	Inhibition	%	-9.0	CHEMBL3045	Homo sapiens	INH	%	-9.0
	18434198	CHEMBL4156128	Inhibition of recombinant full length human GST-tagged PKCbeta-1 expressed in insect cells at 500 nM by Z-LYTE assay relative to control	B	CCC(=O)Nc1ccc(-c2c[nH]c3ncnc(N[C@H](C)c4ccccc4)c23)cc1		CHEMBL4167749	=	Inhibition	%	14.0	CHEMBL3045	Homo sapiens	INH	%	14.0
	18434258	CHEMBL4156128	Inhibition of recombinant full length human GST-tagged PKCbeta-1 expressed in insect cells at 500 nM by Z-LYTE assay relative to control	B	CN(C)CCn1cc(-c2cccc(O)c2)c2c(N)ncnc21		CHEMBL4159505	=	Inhibition	%	8.0	CHEMBL3045	Homo sapiens	INH	%	8.0
	18434330	CHEMBL4156128	Inhibition of recombinant full length human GST-tagged PKCbeta-1 expressed in insect cells at 500 nM by Z-LYTE assay relative to control	B	OCc1ccc(-c2cc3c(N[C@H](CO)c4ccccc4)ncnc3[nH]2)cc1		CHEMBL4175024	=	Inhibition	%	-1.0	CHEMBL3045	Homo sapiens	INH	%	-1.0
	18463786	CHEMBL4181202	Inhibition of recombinant human N-terminal His6-tagged PKCbeta2 (2 to end residues) expressed in Sf21 cells at 10 uM by filter binding radioactive ATP transferase assay relative to control	B	C=C(C)n1c(=O)n(C(C)=O)c2cc(Br)cnc21		CHEMBL4212680	=	Inhibition	%	6.0	CHEMBL3045	Homo sapiens	INH	%	6.0
	18507652	CHEMBL4191139	Inhibition of recombinant human PKCbeta2 (2 to end residues) at 1 uM using histone H1 as substrate after 40 mins in presence of [gamma-33P]ATP by scintillation counting method	B	CS(=O)(=O)c1ccc(-n2nc(-c3cnc4[nH]ccc4c3)c3c(N)ncnc32)cc1		CHEMBL4207014	=	Inhibition	%	-4.0	CHEMBL3045	Homo sapiens	INH	%	-4.0
	18507653	CHEMBL4191138	Inhibition of recombinant human PKCbeta1 (2 to end residues) at 1 uM using histone H1 as substrate after 40 mins in presence of [gamma-33P]ATP by scintillation counting method	B	CS(=O)(=O)c1ccc(-n2nc(-c3cnc4[nH]ccc4c3)c3c(N)ncnc32)cc1		CHEMBL4207014	=	Inhibition	%	6.0	CHEMBL3045	Homo sapiens	INH	%	6.0
	18653427	CHEMBL4230190	Inhibition of PKC-beta2 (unknown origin) at 1 uM by mobility shift microfluidics platform based assay relative to control	B	CC(C)n1nc(C#Cc2cccc(NC(=O)c3cccc(C(F)(F)F)c3)c2)c2c(N)ncnc21		CHEMBL3736320	=	Inhibition	%	2.0	CHEMBL3045	Homo sapiens	INH	%	2.0
	18653428	CHEMBL4230190	Inhibition of PKC-beta2 (unknown origin) at 1 uM by mobility shift microfluidics platform based assay relative to control	B	CC(C)n1nc(C#Cc2cccc3cc(-c4cccc(C(F)(F)F)c4)ncc23)c2c(N)ncnc21		CHEMBL4247506	=	Inhibition	%	5.0	CHEMBL3045	Homo sapiens	INH	%	5.0
	18653429	CHEMBL4230189	Inhibition of PKC-beta1 (unknown origin) at 1 uM by mobility shift microfluidics platform based assay relative to control	B	CC(C)n1nc(C#Cc2cccc(NC(=O)c3cccc(C(F)(F)F)c3)c2)c2c(N)ncnc21		CHEMBL3736320	=	Inhibition	%	-3.0	CHEMBL3045	Homo sapiens	INH	%	-3.0
	18653430	CHEMBL4230189	Inhibition of PKC-beta1 (unknown origin) at 1 uM by mobility shift microfluidics platform based assay relative to control	B	CC(C)n1nc(C#Cc2cccc3cc(-c4cccc(C(F)(F)F)c4)ncc23)c2c(N)ncnc21		CHEMBL4247506	=	Inhibition	%	2.0	CHEMBL3045	Homo sapiens	INH	%	2.0
	18665507	CHEMBL4233383	Inhibition of PKC-beta1 (unknown origin)	B	O=C(Cc1cccc(OCCCN2CCNCC2)c1)Nc1nc(-c2ccncc2)cs1		CHEMBL4245507	>	IC50	nM	1000.0	CHEMBL3045	Homo sapiens	IC50	nM	1000.0
	18665510	CHEMBL4233386	Inhibition of PKCbeta2 (unknown origin)	B	O=C(Cc1cccc(OCCCN2CCNCC2)c1)Nc1nc(-c2ccncc2)cs1		CHEMBL4245507	>	IC50	nM	10000.0	CHEMBL3045	Homo sapiens	IC50	nM	10000.0
	18668763	CHEMBL4234426	Inhibition of DAG-activated human PKCbeta1 after 10 mins in presence of [32P]ATP by beta scintillation counting method	B	CN(C)C[C@@H]1CCn2cc(c3ccccc32)C2=C(C(=O)NC2=O)c2cn(c3ccccc23)CCO1		CHEMBL91829	=	IC50	nM	4.7	CHEMBL3045	Homo sapiens	IC50	nM	4.7
	18668764	CHEMBL4234425	Inhibition of DAG-activated human PKCbeta2 after 10 mins in presence of [32P]ATP by beta scintillation counting method	B	CN(C)C[C@@H]1CCn2cc(c3ccccc32)C2=C(C(=O)NC2=O)c2cn(c3ccccc23)CCO1		CHEMBL91829	=	IC50	nM	5.9	CHEMBL3045	Homo sapiens	IC50	nM	5.9
	18668770	CHEMBL4234419	Inhibition of PKCbeta (unknown origin)	B	Cn1cc(C2=C(c3cn(C4CCN(Cc5ccccn5)CC4)c4ccccc34)C(=O)NC2=O)c2ccccc21		CHEMBL300138	=	IC50	nM	6.0	CHEMBL3045	Homo sapiens	IC50	nM	6.0
	18674834	CHEMBL4235413	Inhibition of PKCbeta1 (unknown origin)	B	CS(=O)(=O)Nc1cccc(CC(=O)Nc2nc(-c3c[nH]c4ncccc34)cs2)c1		CHEMBL4249925	>	Ki	nM	2000.0	CHEMBL3045	Homo sapiens	Ki	nM	2000.0
	18674835	CHEMBL4235413	Inhibition of PKCbeta1 (unknown origin)	B	O=C(Cc1cccc(OCCCC2CCNCC2)c1)Nc1nc(-c2c[nH]c3ncccc23)cs1		CHEMBL4245242	>	Ki	nM	2000.0	CHEMBL3045	Homo sapiens	Ki	nM	2000.0
Not Determined	18674836	CHEMBL4235413	Inhibition of PKCbeta1 (unknown origin)	B	CN1CCN(CCCOc2cccc(CC(=O)Nc3nc(-c4c[nH]c5ncccc45)cs3)c2)CC1		CHEMBL4248525		Ki			CHEMBL3045	Homo sapiens	Ki		
	18674840	CHEMBL4235415	Inhibition of PKCbeta2 (unknown origin)	B	CS(=O)(=O)Nc1cccc(CC(=O)Nc2nc(-c3c[nH]c4ncccc34)cs2)c1		CHEMBL4249925	=	Ki	nM	2090.0	CHEMBL3045	Homo sapiens	Ki	nM	2090.0
Not Determined	18674841	CHEMBL4235415	Inhibition of PKCbeta2 (unknown origin)	B	O=C(Cc1cccc(OCCCC2CCNCC2)c1)Nc1nc(-c2c[nH]c3ncccc23)cs1		CHEMBL4245242		Ki			CHEMBL3045	Homo sapiens	Ki		
	18674842	CHEMBL4235415	Inhibition of PKCbeta2 (unknown origin)	B	CN1CCN(CCCOc2cccc(CC(=O)Nc3nc(-c4c[nH]c5ncccc45)cs3)c2)CC1		CHEMBL4248525	>	Ki	nM	10000.0	CHEMBL3045	Homo sapiens	Ki	nM	10000.0
	18694021	CHEMBL4253474	Inhibition of PKCbeta2 (unknown origin) at 0.1 uM by Z'-Lyte assay relative to control	B	CC1=Nc2c(F)cc(-c3nc(Nc4ccc(C5CCN(C)CC5)cn4)ncc3F)cc2C12CCCC2		CHEMBL4277900	=	Inhibition	%	3.0	CHEMBL3045	Homo sapiens	INH	%	3.0
	18694103	CHEMBL4253556	Inhibition of PKCbeta2 (unknown origin) at 1 uM by Z'-Lyte assay relative to control	B	CC1=Nc2c(F)cc(-c3nc(Nc4ccc(C5CCN(C)CC5)cn4)ncc3F)cc2C12CCCC2		CHEMBL4277900	=	Inhibition	%	52.0	CHEMBL3045	Homo sapiens	INH	%	52.0
	18702477	CHEMBL4255130	Inhibition of recombinant human full length GST-tagged PRKCB2 expressed in insect cells at 1 uM relative to control	B	COc1ccc(S(N)(=O)=O)cc1C(=O)Nc1cccc(-c2nncn2C(C)C)n1		CHEMBL4278211	=	Inhibition	%	12.0	CHEMBL3045	Homo sapiens	INH	%	12.0
	18702561	CHEMBL4255130	Inhibition of recombinant human full length GST-tagged PRKCB2 expressed in insect cells at 1 uM relative to control	B	COc1ccc(C(N)=O)cc1C(=O)Nc1cccc(-c2nncn2C(C)C)n1		CHEMBL4282644	=	Inhibition	%	9.0	CHEMBL3045	Homo sapiens	INH	%	9.0
	18702606	CHEMBL4255130	Inhibition of recombinant human full length GST-tagged PRKCB2 expressed in insect cells at 1 uM relative to control	B	COc1ccc(S(C)(=O)=O)cc1C(=O)Nc1cccc(-c2nncn2C(C)C)n1		CHEMBL4287097	=	Inhibition	%	5.0	CHEMBL3045	Homo sapiens	INH	%	5.0
	18702658	CHEMBL4255130	Inhibition of recombinant human full length GST-tagged PRKCB2 expressed in insect cells at 1 uM relative to control	B	COc1cc(C)c(S(N)(=O)=O)cc1C(=O)Nc1cccc(-c2nncn2C(C)C)n1		CHEMBL4283739	=	Inhibition	%	9.0	CHEMBL3045	Homo sapiens	INH	%	9.0
	18702701	CHEMBL4255130	Inhibition of recombinant human full length GST-tagged PRKCB2 expressed in insect cells at 1 uM relative to control	B	COc1cc(C)c(C(N)=O)cc1C(=O)Nc1cccc(-c2nncn2C(C)C)n1		CHEMBL4294318	=	Inhibition	%	3.0	CHEMBL3045	Homo sapiens	INH	%	3.0
	18702744	CHEMBL4255130	Inhibition of recombinant human full length GST-tagged PRKCB2 expressed in insect cells at 1 uM relative to control	B	COc1cc(C)c(S(C)(=O)=O)cc1C(=O)Nc1cccc(-c2nncn2C(C)C)n1		CHEMBL4289040	=	Inhibition	%	12.0	CHEMBL3045	Homo sapiens	INH	%	12.0
Not Active	18726722	CHEMBL4259281	Inhibition of PKCbeta2 (unknown origin) at 10 uM	B	Oc1ccc(C2=NN(c3ccc(Cl)cc3)C(c3ccc(Cl)cc3)C2)cc1O		CHEMBL4283413		Inhibition	%		CHEMBL3045	Homo sapiens	INH		
Not Active	18726723	CHEMBL4259280	Inhibition of PKCbeta1 (unknown origin) at 10 uM	B	Oc1ccc(C2=NN(c3ccc(Cl)cc3)C(c3ccc(Cl)cc3)C2)cc1O		CHEMBL4283413		Inhibition	%		CHEMBL3045	Homo sapiens	INH		
	18751201	CHEMBL4263910	Inhibition of PKC-BETA1 (unknown origin) at 1 uM relative to control	B	NC1(c2ccc(-c3cnc4c(-c5ccc(S(N)(=O)=O)c6ccccc56)cnn4c3)cc2)CCC1		CHEMBL4278763	=	Inhibition	%	3.0	CHEMBL3045	Homo sapiens	INH	%	3.0
	18751202	CHEMBL4263911	Inhibition of PKC-BETA2 (unknown origin) at 1 uM relative to control	B	NC1(c2ccc(-c3cnc4c(-c5ccc(S(N)(=O)=O)c6ccccc56)cnn4c3)cc2)CCC1		CHEMBL4278763	=	Inhibition	%	1.0	CHEMBL3045	Homo sapiens	INH	%	1.0
	18757966	CHEMBL4265580	Inhibition of recombinant human full length GST-tagged PRKCB2 expressed in insect cells at 1 uM in presence of 1 mM ATP by kinomescan assay relative to control	B	N#CN[C@H]1CCc2ccc(-c3ncnc4[nH]cc(-c5cccc(CO)c5)c34)cc21		CHEMBL4292341	=	Inhibition	%	52.0	CHEMBL3045	Homo sapiens	INH	%	52.0
	18811790	CHEMBL4276094	Inhibition of recombinant N-terminal GST-fused full-length human PKCbeta1 expressed in Baculovirus expression system using STK1-biotin as substrate after 1 hr in presence of ATP by TR-FRET analysis	B	N#Cc1cnc(NCc2ccccc2OC(F)(F)F)nc1NC[C@@]12C[C@H]3C[C@@H](C1)[C@H](NCCO)[C@H](C3)C2		CHEMBL4289707	=	IC50	nM	410.0	CHEMBL3045	Homo sapiens	IC50	nM	410.0
Not Active	18883539	CHEMBL4312752	Activity at human PKCbeta2 at 10 uM	B	CS(=O)(=O)c1ccc(Oc2cc(F)cc(C#N)c2)c2c1[C@H](O)[C@H](F)[C@@H]2F		CHEMBL4585668		Activity			CHEMBL3045	Homo sapiens	Activity		
Not Active	18883540	CHEMBL4312751	Activity at human PKCbeta1 at 10 uM	B	CS(=O)(=O)c1ccc(Oc2cc(F)cc(C#N)c2)c2c1[C@H](O)[C@H](F)[C@@H]2F		CHEMBL4585668		Activity			CHEMBL3045	Homo sapiens	Activity		
	18892687	CHEMBL4314562	Inhibition of recombinant human PKCbeta1 (2 to end residues) assessed as residual activity at 10 uM using histone H1 as substrate measured after 40 mins in presence of [gamma33P]ATP by scintillation counting method	B	Cc1cc(C)c(CNc2nc(Cl)nc3c2ncn3C2CCCC2)c(=O)[nH]1		CHEMBL4557538	=	Activity	%	96.0	CHEMBL3045	Homo sapiens	Activity	%	96.0
	18892688	CHEMBL4314561	Inhibition of recombinant human PKCbeta2 (2 to end residues) assessed as residual activity at 10 uM using histone H1 as substrate measured after 40 mins in presence of [gamma33P]ATP by scintillation counting method	B	Cc1cc(C)c(CNc2nc(Cl)nc3c2ncn3C2CCCC2)c(=O)[nH]1		CHEMBL4557538	=	Activity	%	106.5	CHEMBL3045	Homo sapiens	Activity	%	106.5
	18919565	CHEMBL4322921	Binding affinity to recombinant full-length N-terminal His-FLAG-tagged PRKCB (unknown origin) expressed in baculovirus infected Sf9 insect cells incubated for 1 hr by TR-FRET assay	B	CO[C@@H]1[C@H](NCCOCCOCCOCCNC(=O)CCC2=[N+]3C(=Cc4c(C)cc(C)n4[B-]3(F)F)C=C2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL4465866	=	Kd	nM	65.0	CHEMBL3045	Homo sapiens	Kd	nM	65.0
	18919753	CHEMBL4322921	Binding affinity to recombinant full-length N-terminal His-FLAG-tagged PRKCB (unknown origin) expressed in baculovirus infected Sf9 insect cells incubated for 1 hr by TR-FRET assay	B	CO[C@@H]1[C@H](N(C)CCOCCOCCOCCNC(=O)CCC2=[N+]3C(=Cc4c(C)cc(C)n4[B-]3(F)F)C=C2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL4576489	=	Kd	nM	17.0	CHEMBL3045	Homo sapiens	Kd	nM	17.0
	18938215	CHEMBL4327834	Inhibition of human PKCb1 assessed as residual activity at 1 uM using Histone H1 as substrate by [gamma-33P]-ATP assay relative to control	B	ClC/C=C/C[N+]12CN3CN(CN(C3)C1)C2.[Cl-]		CHEMBL4438024	=	Activity	%	86.54	CHEMBL3045	Homo sapiens	Activity	%	86.54
	18938216	CHEMBL4327834	Inhibition of human PKCb1 assessed as residual activity at 1 uM using Histone H1 as substrate by [gamma-33P]-ATP assay relative to control	B	C(=C/c1ccccc1)\C[N+]12CN3CN(CN(C3)C1)C2.[Cl-]		CHEMBL4446405	=	Activity	%	90.49	CHEMBL3045	Homo sapiens	Activity	%	90.49
	18938217	CHEMBL4327835	Inhibition of human PKCb2 assessed as residual activity at 1 uM using Histone H1 as substrate by [gamma-33P]-ATP assay relative to control	B	ClC/C=C/C[N+]12CN3CN(CN(C3)C1)C2.[Cl-]		CHEMBL4438024	=	Activity	%	105.74	CHEMBL3045	Homo sapiens	Activity	%	105.74
	18938218	CHEMBL4327835	Inhibition of human PKCb2 assessed as residual activity at 1 uM using Histone H1 as substrate by [gamma-33P]-ATP assay relative to control	B	C(=C/c1ccccc1)\C[N+]12CN3CN(CN(C3)C1)C2.[Cl-]		CHEMBL4446405	=	Activity	%	97.66	CHEMBL3045	Homo sapiens	Activity	%	97.66
	18938679	CHEMBL4328198	Inhibition of human PKCb1 assessed as residual activity at 100 uM using Histone H1 as substrate by [gamma-33P]-ATP assay relative to control	B	CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL388978	<	Activity	%	65.0	CHEMBL3045	Homo sapiens	Activity	%	65.0
	18938680	CHEMBL4328199	Inhibition of human PKCb2 assessed as residual activity at 100 uM using Histone H1 as substrate by [gamma-33P]-ATP assay relative to control	B	CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL388978	<	Activity	%	65.0	CHEMBL3045	Homo sapiens	Activity	%	65.0
	18939063	CHEMBL4328562	Inhibition of human PKCb1 using Histone H1 as substrate by [gamma-33P]-ATP assay	B	CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL388978	=	IC50	nM	12.0	CHEMBL3045	Homo sapiens	IC50	10'-8M	1.2
	18939064	CHEMBL4328563	Inhibition of human PKCb2 using Histone H1 as substrate by [gamma-33P]-ATP assay	B	CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL388978	=	IC50	nM	2.78	CHEMBL3045	Homo sapiens	IC50	10'-9M	2.78
	18964594	CHEMBL4335238	Inhibition of recombinant human PKCbeta1 (2 to end residues) assessed as residual activity at 1 uM using histone H1 as substrate measured after 40 mins in presence of [gamma33P]ATP by scintillation counting method relative to control	B	N=C1NC(=O)/C(=C\c2ccc(-c3cccc([N+](=O)[O-])c3)o2)S1		CHEMBL4455512	=	Activity	%	100.0	CHEMBL3045	Homo sapiens	Activity	%	100.0
	18964595	CHEMBL4335238	Inhibition of recombinant human PKCbeta1 (2 to end residues) assessed as residual activity at 1 uM using histone H1 as substrate measured after 40 mins in presence of [gamma33P]ATP by scintillation counting method relative to control	B	C=CCOC(=O)c1cc(-c2ccc(/C=C3/NC(=S)NC3=O)o2)ccc1Cl		CHEMBL4568120	=	Activity	%	113.0	CHEMBL3045	Homo sapiens	Activity	%	113.0
	18964596	CHEMBL4335239	Inhibition of recombinant human PKCbeta2 (2 to end residues) assessed as residual activity at 1 uM using histone H1 as substrate measured after 40 mins in presence of [gamma33P]ATP by scintillation counting method relative to control	B	N=C1NC(=O)/C(=C\c2ccc(-c3cccc([N+](=O)[O-])c3)o2)S1		CHEMBL4455512	=	Activity	%	92.0	CHEMBL3045	Homo sapiens	Activity	%	92.0
	18964597	CHEMBL4335239	Inhibition of recombinant human PKCbeta2 (2 to end residues) assessed as residual activity at 1 uM using histone H1 as substrate measured after 40 mins in presence of [gamma33P]ATP by scintillation counting method relative to control	B	C=CCOC(=O)c1cc(-c2ccc(/C=C3/NC(=S)NC3=O)o2)ccc1Cl		CHEMBL4568120	=	Activity	%	100.0	CHEMBL3045	Homo sapiens	Activity	%	100.0
	18972051	CHEMBL4337061	Inhibition of recombinant human PKCbeta1 (2 to end residues) assessed as residual activity at 10 uM using histone H1 as substrate incubated for 40 mins in presence of [gamma33P]ATP by scintillation counting based radiometry assay relative to control	B	C[C@@H](c1ccccc1)n1nnc2cnc3ccc(-c4cnc5[nH]ccc5c4)cc3c21		CHEMBL4472294	=	Activity	%	110.0	CHEMBL3045	Homo sapiens	Activity	%	110.0
	18972052	CHEMBL4337062	Inhibition of recombinant human PKCbeta2 (2 to end residues) assessed as residual activity at 10 uM using histone H1 as substrate incubated for 40 mins in presence of [gamma33P]ATP by scintillation counting based radiometry assay relative to control	B	C[C@@H](c1ccccc1)n1nnc2cnc3ccc(-c4cnc5[nH]ccc5c4)cc3c21		CHEMBL4472294	=	Activity	%	93.0	CHEMBL3045	Homo sapiens	Activity	%	93.0
	19032207	CHEMBL4349800	Inhibition of recombinant human full length N-terminal GST/His6-tagged PKC-beta2 (M1 to S673) expressed in Sf9 insect cells at 20 nM using phosphatidylserine as substrate incubated for 60 mins in presence of [33P]-ATP by scintillation counting method	B	Cn1cc(-c2n[nH]c3ccc(NCc4cc(F)ccc4S(C)(=O)=O)cc23)cn1		CHEMBL4555442	=	Inhibition	%	5.0	CHEMBL3045	Homo sapiens	INH	%	5.0
Not Active	19040109	CHEMBL4352013	Inhibition of recombinant human PKCbeta1 (2 to end residues) at 10 uM using histone H1 as substrate measured after 40 mins in presence of [gamma33P]ATP by scintillation counting method	B	CN1C[C@H](Nc2nc3cc[nH]c3c(=O)n2C)C[C@H](c2ccc3c(c2)OCCO3)C1		CHEMBL4574669		Inhibition	%		CHEMBL3045	Homo sapiens	INH		
Not Active	19040110	CHEMBL4352014	Inhibition of recombinant human PKCbeta2 (2 to end residues) at 10 uM using histone H1 as substrate measured after 40 mins in presence of [gamma33P]ATP by scintillation counting method	B	CN1C[C@H](Nc2nc3cc[nH]c3c(=O)n2C)C[C@H](c2ccc3c(c2)OCCO3)C1		CHEMBL4574669		Inhibition	%		CHEMBL3045	Homo sapiens	INH		
Active	19041240	CHEMBL4352501	Inhibition of human PKCb1 at 10 uM using Histone H1 as substrate in presence of [gamma-33P]-ATP	B	CC(C)(C)C(=O)N1N=CC[C@H]1c1ccccc1		CHEMBL4521353		Inhibition	%		CHEMBL3045	Homo sapiens	INH		
Active	19041241	CHEMBL4352502	Inhibition of human PKCb2 at 10 uM using Histone H1 as substrate in presence of [gamma-33P]-ATP	B	CC(C)(C)C(=O)N1N=CC[C@H]1c1ccccc1		CHEMBL4521353		Inhibition	%		CHEMBL3045	Homo sapiens	INH		
	19092072	CHEMBL4366546	Inhibition of human PKCb1 at 100 nM using Histone H1 as substrate by [gamma-33P]-ATP assay	B	COc1ccc(N2C(=O)COc3ccc(-c4cnc(OC)c(NS(=O)(=O)c5ccc(F)cc5)c4)cc32)cc1		CHEMBL4528675	=	Inhibition	%	7.83	CHEMBL3045	Homo sapiens	INH	%	7.83
	19092073	CHEMBL4366547	Inhibition of human PKCb2 at 100 nM using Histone H1 as substrate by [gamma-33P]-ATP assay	B	COc1ccc(N2C(=O)COc3ccc(-c4cnc(OC)c(NS(=O)(=O)c5ccc(F)cc5)c4)cc32)cc1		CHEMBL4528675	=	Inhibition	%	-6.74	CHEMBL3045	Homo sapiens	INH	%	-6.74
Not Active	19132746	CHEMBL4375138	Agonist activity at Protein kinase C beta in human MT4 cells infected with HIV-1 NL4-3 assessed as inhibition of viral replication at 2 nM measured on day 3 post-infection in presence of PKCbeta antagonist enzastaurin by Nano-Glo luciferase assay	B	C=C(C)[C@]12C[C@@H](COC(=O)c3ccccc3)[C@@]34OC5(O[C@@H]1[C@@H]3[C@@H]1O[C@]1(CO)[C@@H](O)[C@]1(O)[C@@H](OC(=O)c3ccncc3)[C@@H](C)[C@H]([C@H](C)CCCCCC[C@H]5O)[C@H]14)O2		CHEMBL4587471		Activity			CHEMBL3045	Homo sapiens	Activity		
Not Active	19132755	CHEMBL4375137	Agonist activity at Protein kinase C beta in human MT4 cells infected with HIV-1 NL4-3 assessed as inhibition of viral replication at 0.6 nM measured on day 3 post-infection in presence of PKCbeta antagonist enzastaurin by Nano-Glo luciferase assay	B	C=C(C)[C@]12C[C@@H](COC(=O)c3ccccc3)[C@@]34OC5(O[C@@H]1[C@@H]3[C@@H]1O[C@]1(CO)[C@@H](O)[C@]1(O)[C@@H](OC(=O)c3ccccc3)[C@@H](C)[C@H]([C@H](C)CCCCCC[C@H]5O)[C@H]14)O2		CHEMBL3741746		Activity			CHEMBL3045	Homo sapiens	Activity		
	19132764	CHEMBL4375136	Agonist activity at Protein kinase C beta in human MT4 cells infected with HIV-1 NL4-3 assessed as inhibition of viral replication at 0.6 nM measured on day 3 post-infection by Nano-Glo luciferase assay relative to control	B	C=C(C)[C@]12C[C@@H](COC(=O)c3ccccc3)[C@@]34OC5(O[C@@H]1[C@@H]3[C@@H]1O[C@]1(CO)[C@@H](O)[C@]1(O)[C@@H](OC(=O)c3ccccc3)[C@@H](C)[C@H]([C@H](C)CCCCCC[C@H]5O)[C@H]14)O2		CHEMBL3741746	=	Inhibition	%	90.0	CHEMBL3045	Homo sapiens	INH	%	90.0
	19144755	CHEMBL4377771	Inhibition of recombinant human PKCbeta1 (2 to end residues) at 1 uM using histone H1 as substrate measured after 40 mins in presence of [gamma33P]ATP by scintillation counting method relative to control	B	CN(C)C(=O)c1cc2cnc(Nc3ccc(NC(=O)CCCCCCCN=C=S)cc3)nc2n1C1CCCC1		CHEMBL4548580	=	Inhibition	%	20.0	CHEMBL3045	Homo sapiens	INH	%	20.0
	19144756	CHEMBL4377772	Inhibition of recombinant human PKCbeta2 (2 to end residues) at 1 uM using histone H1 as substrate measured after 40 mins in presence of [gamma33P]ATP by scintillation counting method relative to control	B	CN(C)C(=O)c1cc2cnc(Nc3ccc(NC(=O)CCCCCCCN=C=S)cc3)nc2n1C1CCCC1		CHEMBL4548580	=	Inhibition	%	72.0	CHEMBL3045	Homo sapiens	INH	%	72.0
	19146930	CHEMBL4378862	Inhibition of recombinant human PKCbeta1 (2 to end residues) at 10 uM using histone H1 as substrate after 40 mins by in presence of [gamma33P]ATP by scintillation counting method relative to control	B	C=CS(=O)(=O)Nc1ccc(Cc2ccc3ccccc3c2)cc1	Outside typical range	CHEMBL4459587	=	Inhibition	%	-11.0	CHEMBL3045	Homo sapiens	INH	%	-11.0
	19146931	CHEMBL4378861	Inhibition of recombinant human PKCbeta2 (2 to end residues) at 10 uM using histone H1 as substrate after 40 mins by in presence of [gamma33P]ATP by scintillation counting method relative to control	B	C=CS(=O)(=O)Nc1ccc(Cc2ccc3ccccc3c2)cc1		CHEMBL4459587	=	Inhibition	%	4.0	CHEMBL3045	Homo sapiens	INH	%	4.0
	19147995	CHEMBL4379235	Inhibition of recombinant human PKCbeta1 (2 to end residues) using histone H1 as substrate incubated for 40 mins in presence of [gamma33P]ATP by radiometric scintillation counting analysis	B	CN(C)c1ccc(C(=O)Nc2cccc(NC(=O)COc3ccc4c(=O)ccoc4c3)c2)cc1		CHEMBL4438748	>	IC50	nM	10000.0	CHEMBL3045	Homo sapiens	IC50	uM	10.0
	19147996	CHEMBL4379234	Inhibition of recombinant human PKCbeta2 (2 to end residues) using histone H1 as substrate incubated for 40 mins in presence of [gamma33P]ATP by radiometric scintillation counting analysis	B	CN(C)c1ccc(C(=O)Nc2cccc(NC(=O)COc3ccc4c(=O)ccoc4c3)c2)cc1		CHEMBL4438748	>	IC50	nM	10000.0	CHEMBL3045	Homo sapiens	IC50	uM	10.0
	19181115	CHEMBL4387326	Inhibition of recombinant full length human GST-tagged PKCbeta1 expressed in insect expression system at 0.1 uM using serine/threonine-7 peptide as substrate incubated for 60 mins by Z'-LYTE assay relative to control	B	CCN1CCN(Cc2ccc(Nc3ncc(F)c(-c4cc(F)c5nc(C)n(C(C)C)c5c4)n3)nc2)CC1		CHEMBL3301610	=	Inhibition	%	38.0	CHEMBL3045	Homo sapiens	INH	%	38.0
	19181340	CHEMBL4387326	Inhibition of recombinant full length human GST-tagged PKCbeta1 expressed in insect expression system at 0.1 uM using serine/threonine-7 peptide as substrate incubated for 60 mins by Z'-LYTE assay relative to control	B	CCN1CC2(C1)CN(c1ccc(Nc3ncc(F)c(-c4cnn5c4[C@H](C)CCCC5)n3)nc1)C2		CHEMBL4545456	=	Inhibition	%	4.5	CHEMBL3045	Homo sapiens	INH	%	4.5
	19225485	CHEMBL4395905	Inhibition of human recombinant PKCbeta at 1 uM using CREBtide as substrate measured after 15 mins in presence of ATP by LANCE assay relative to control	B	CCc1nc(-c2ccc(F)cc2)c(-c2ccnc(NC(=O)C3CC3)c2)[nH]1		CHEMBL4536012	=	Inhibition	%	10.68	CHEMBL3045	Homo sapiens	INH	%	10.68
	19240785	CHEMBL4399617	Inhibition of human PKC beta	B	NCC1(c2cccc(-c3ccnc4[nH]nc(C(F)(F)F)c34)c2)COC1		CHEMBL4461649	=	Ki	nM	1700.0	CHEMBL3045	Homo sapiens	Ki	uM	1.7
	19266568	CHEMBL4405518	Inhibition of PKCb1 (unknown origin) at 1 uM relative to control	B	CC[C@H](Nc1nc(N)nc(C)c1C#N)c1nc2cccc(NCc3ccc(C(=O)NO)cc3)c2c(=O)n1-c1ccccc1		CHEMBL4455923	<	Inhibition	%	50.0	CHEMBL3045	Homo sapiens	INH	%	50.0
	19266569	CHEMBL4405519	Inhibition of PKCb2 (unknown origin) at 1 uM relative to control	B	CC[C@H](Nc1nc(N)nc(C)c1C#N)c1nc2cccc(NCc3ccc(C(=O)NO)cc3)c2c(=O)n1-c1ccccc1		CHEMBL4455923	<	Inhibition	%	50.0	CHEMBL3045	Homo sapiens	INH	%	50.0
	19276098	CHEMBL4408101	Inhibition of recombinant human PKCbeta1 (2 to end residues) at 1 uM using histone H1 as substrate incubated for 40 mins in presence of [gamma-33P]-ATP by scintillation counting method relative to control	B	Cc1ccc(NC(=O)C2(C(=O)Nc3ccc(Nc4ncc(F)c(-c5cc(F)c6nc(C)n(C(C)C)c6c5)n4)cc3)CC2)cc1		CHEMBL4445335	=	Inhibition	%	36.0	CHEMBL3045	Homo sapiens	INH	%	36.0
	19276099	CHEMBL4408102	Inhibition of recombinant human PKCbeta2 (2 to end residues) at 1 uM using histone H1 as substrate incubated for 40 mins in presence of [gamma-33P]-ATP by scintillation counting method relative to control	B	Cc1ccc(NC(=O)C2(C(=O)Nc3ccc(Nc4ncc(F)c(-c5cc(F)c6nc(C)n(C(C)C)c6c5)n4)cc3)CC2)cc1		CHEMBL4445335	=	Inhibition	%	47.0	CHEMBL3045	Homo sapiens	INH	%	47.0
	19294331	CHEMBL4412088	Inhibition of human PKCb2 assessed as enzyme activity at 30 uM using Histone H1 as substrate by [gamma-33P]-ATP assay relative to control	B	O=C1C=CC2(C=C1)OCC(Cc1cc(C(F)(F)F)cc(C(F)(F)F)c1)C(=O)N2c1ccccc1		CHEMBL4476753	=	Activity	%	67.73	CHEMBL3045	Homo sapiens	Activity	%	67.73
	19294347	CHEMBL4412104	Inhibition of human PKCb2 using Histone H1 as substrate by [gamma-33P]-ATP assay	B	CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL388978	=	IC50	nM	1.44	CHEMBL3045	Homo sapiens	IC50	10'-9M	1.44
	19371152	CHEMBL4424904	Inhibition of human N-terminal His6-tagged (2 to end residues) PKCbeta expressed in baculovirus infected Sf21 insect cells using Histone H1 as substrate	A	COc1cc(C2CN(C(=O)c3cc(COC[C@@H](O)CO)ccn3)C2)ccc1OCc1ccc(C2CC2)cc1		CHEMBL4474690	>	IC50	nM	1000.0	CHEMBL3045	Homo sapiens	IC50	nM	1000.0
	19411436	CHEMBL4427729	Inhibition of PKCbeta1 (unknown origin)	B	Cc1cnc(-c2cc(Cl)ccc2F)cc1-n1c(=O)n(CC(N)=O)c2cnccc21		CHEMBL4564126	>=	IC50	nM	5000.0	CHEMBL3045	Homo sapiens	IC50	uM	5.0
	19411492	CHEMBL4427673	Inhibition of PKCbeta1 (unknown origin) at 1 uM relative to control	B	Cc1cnc(-c2cc(Cl)ccc2F)cc1-n1c(=O)n(CC(N)=O)c2cnccc21		CHEMBL4564126	<=	Inhibition	%	16.0	CHEMBL3045	Homo sapiens	INH	%	16.0
	20600638	CHEMBL4603590	Inhibition of recombinant full length human GST-tagged PKCbeta1 expressed in insect expression system using serine/threonine-7 peptide as substrate incubated for 60 mins in presence of ATP by Z'-LYTE assay	B	C[C@@H]1C[C@H]1C(=O)N1CCN(c2cnc(C#N)c(-c3cnn(C)c3)n2)C[C@H]1C		CHEMBL4634634	>	IC50	nM	100000.0	CHEMBL3045	Homo sapiens	IC50	uM	100.0
	20600639	CHEMBL4603591	Inhibition of recombinant full length human GST-tagged PKCbeta2 expressed in insect expression system using serine/threonine-7 peptide as substrate incubated for 60 mins in presence of ATP by Z'-LYTE assay	B	C[C@@H]1C[C@H]1C(=O)N1CCN(c2cnc(C#N)c(-c3cnn(C)c3)n2)C[C@H]1C		CHEMBL4634634	>	IC50	nM	100000.0	CHEMBL3045	Homo sapiens	IC50	uM	100.0
	20632856	CHEMBL4611127	Inhibition of recombinant full-length N-temrinal GST-tagged human PKC beta1 expressed in baculovirus infected Sf9 cells using TMB as substrate incubated for 4.5 hrs by colorimetric analysis	B	O=C1O/C(=C(/C(=O)O)c2ccc(O)c(O)c2)C(O)=C1c1ccc(O)c(O)c1		CHEMBL4636684	=	IC50	nM	36200.0	CHEMBL3045	Homo sapiens	IC50	uM	36.2
Dose-dependent effect	20632857	CHEMBL4611127	Inhibition of recombinant full-length N-temrinal GST-tagged human PKC beta1 expressed in baculovirus infected Sf9 cells using TMB as substrate incubated for 4.5 hrs by colorimetric analysis	B	O=C1O/C(=C(/C(=O)O)c2ccc(O)c(O)c2)C(O)=C1c1ccc(O)c(O)c1		CHEMBL4636684		Inhibition	%		CHEMBL3045	Homo sapiens	INH		
Active	20681776	CHEMBL4623325	Inhibition of PKCbeta1 (unknown origin) at 5 uM by radiometric kinase assay	B	NCC1CCN(c2nc(-c3ccncc3)nc3sc4c(c23)CCCC4)CC1		CHEMBL4637651		Inhibition	%		CHEMBL3045	Homo sapiens	INH		
	22391641	CHEMBL4666953	Inhibition of recombinant human His-tagged full length PKCbeta1 expressed in insect expression system using Ser/Thr 07 as substrate at 0.1 uM incubated for 60 mins by Z'-lyte assay relative to control	B	O=C(Nc1c[nH]nc1-c1cc(Cl)ccc1OC(F)F)c1cnn2cccnc12		CHEMBL4744172	=	Inhibition	%	24.0	CHEMBL3045	Homo sapiens	INH	%	24.0
	22391642	CHEMBL4666953	Inhibition of recombinant human His-tagged full length PKCbeta1 expressed in insect expression system using Ser/Thr 07 as substrate at 0.1 uM incubated for 60 mins by Z'-lyte assay relative to control	B	Cn1cc(NC(=O)c2cnn3cccnc23)c(-c2cc(Cl)ccc2OC(F)F)n1		CHEMBL4777342	=	Inhibition	%	2.0	CHEMBL3045	Homo sapiens	INH	%	2.0
	22391643	CHEMBL4666953	Inhibition of recombinant human His-tagged full length PKCbeta1 expressed in insect expression system using Ser/Thr 07 as substrate at 0.1 uM incubated for 60 mins by Z'-lyte assay relative to control	B	O=C(Nc1c[nH]nc1-c1cc2ccccc2cc1OC(F)F)c1cnn2cccnc12		CHEMBL4745474	=	Inhibition	%	13.0	CHEMBL3045	Homo sapiens	INH	%	13.0
	22391644	CHEMBL4666954	Inhibition of recombinant human GST-tagged full length PKCbeta2 expressed in insect expression system using Ser/Thr 07 as substrate at 0.1 uM incubated for 60 mins by Z'-lyte assay relative to control	B	O=C(Nc1c[nH]nc1-c1cc(Cl)ccc1OC(F)F)c1cnn2cccnc12		CHEMBL4744172	=	Inhibition	%	21.0	CHEMBL3045	Homo sapiens	INH	%	21.0
	22391645	CHEMBL4666954	Inhibition of recombinant human GST-tagged full length PKCbeta2 expressed in insect expression system using Ser/Thr 07 as substrate at 0.1 uM incubated for 60 mins by Z'-lyte assay relative to control	B	Cn1cc(NC(=O)c2cnn3cccnc23)c(-c2cc(Cl)ccc2OC(F)F)n1		CHEMBL4777342	=	Inhibition	%	12.0	CHEMBL3045	Homo sapiens	INH	%	12.0
	22391646	CHEMBL4666954	Inhibition of recombinant human GST-tagged full length PKCbeta2 expressed in insect expression system using Ser/Thr 07 as substrate at 0.1 uM incubated for 60 mins by Z'-lyte assay relative to control	B	O=C(Nc1c[nH]nc1-c1cc2ccccc2cc1OC(F)F)c1cnn2cccnc12		CHEMBL4745474	=	Inhibition	%	17.0	CHEMBL3045	Homo sapiens	INH	%	17.0
	22392135	CHEMBL4667230	Inhibition of recombinant human His-tagged full length PKCbeta1 expressed in insect expression system using Ser/Thr 07 as substrate at 10 uM incubated for 60 mins by Z'-lyte assay relative to control	B	CN1C(=O)[C@@H](NC(=O)c2n[nH]c3ncc(C(F)(F)C(F)(F)F)cc23)COc2ccccc21		CHEMBL4785812	=	Inhibition	%	5.5	CHEMBL3045	Homo sapiens	INH	%	5.5
Not Active	22417335	CHEMBL4672559	Inhibition of PKC(pan)/beta II phosphorylation at S660 residue in human BXPC-3 cells at 1 uM incubated for 4 hrs by Western blot analysis	B	CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4=O		CHEMBL4763675		Inhibition	%		CHEMBL3045	Homo sapiens	INH		
Not Active	22417545	CHEMBL4672625	Inhibition of PKCbeta phosphorylation at S660 residue in human BXPC-3 cells at 1 uM incubated for 4 hrs by Western blot analysis	B	CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4=O		CHEMBL4763675		Inhibition	%		CHEMBL3045	Homo sapiens	INH		
	22423327	CHEMBL4674239	Inhibition of human PKCb2 using Histone H1 as substrate assessed as residual activity at 1 uM by [gamma-33P]-ATP assay relative to control	B	Nc1ncc(-c2cnc(C3CCNCC3)s2)cc1OC1CCCCC1		CHEMBL4785602	=	Activity	%	94.95	CHEMBL3045	Homo sapiens	Activity	%	94.95
	22423328	CHEMBL4674239	Inhibition of human PKCb2 using Histone H1 as substrate assessed as residual activity at 1 uM by [gamma-33P]-ATP assay relative to control	B	Nc1ncc(-c2cnc(C3CCNCC3)s2)cc1OCc1ccncc1		CHEMBL4749141	=	Activity	%	67.06	CHEMBL3045	Homo sapiens	Activity	%	67.06
	22423331	CHEMBL4674241	Inhibition of human PKCb1 using Histone H1 as substrate assessed as residual activity at 1 uM by [gamma-33P]-ATP assay relative to control	B	Nc1ncc(-c2cnc(C3CCNCC3)s2)cc1OC1CCCCC1		CHEMBL4785602	=	Activity	%	95.1	CHEMBL3045	Homo sapiens	Activity	%	95.1
	22423332	CHEMBL4674241	Inhibition of human PKCb1 using Histone H1 as substrate assessed as residual activity at 1 uM by [gamma-33P]-ATP assay relative to control	B	Nc1ncc(-c2cnc(C3CCNCC3)s2)cc1OCc1ccncc1		CHEMBL4749141	=	Activity	%	93.15	CHEMBL3045	Homo sapiens	Activity	%	93.15
	22768260	CHEMBL4703623	Inhibition of human PKCbeta1	B	COc1cccc(Cn2cnc3ccc(-c4cn[nH]c4)cc3c2=O)c1		CHEMBL4742990	=	IC50	nM	9068.0	CHEMBL3045	Homo sapiens	IC50	nM	9068.0
	22768261	CHEMBL4703623	Inhibition of human PKCbeta1	B	COc1cccc(Cn2ncc3ccc(-c4cn[nH]c4)cc3c2=O)c1		CHEMBL4744858	>	IC50	nM	10000.0	CHEMBL3045	Homo sapiens	IC50	nM	10000.0
	22818123	CHEMBL4715346	Inhibition of recombinant human N-terminal His6-tagged PKCbeta2 (2 to end residues) expressed in Sf21 insect cells at 2 uM using Histone H1 as substrate relative to control	B	C[C@@H](c1ccc2ncccc2c1)c1nnc2sc(-c3cnn(C)c3)nn12		CHEMBL4791034	<	Inhibition	%	50.0	CHEMBL3045	Homo sapiens	INH	%	50.0
	22836378	CHEMBL4718885	Inhibition of human full length GST tagged PRKCB1 expressed in insect cells at 500 nM using Ser/Thr 07 as substrate incubated for 1 hr in presence of ATP at its Km concentration by Z'-LYTE assay relative to control	B	C#Cc1cccc(Nc2ncnc3cc(OCCOC)c(OCCOC)cc23)c1		CHEMBL553	=	Inhibition	%	-2.0	CHEMBL3045	Homo sapiens	INH	%	-2.0
	22836379	CHEMBL4718885	Inhibition of human full length GST tagged PRKCB1 expressed in insect cells at 500 nM using Ser/Thr 07 as substrate incubated for 1 hr in presence of ATP at its Km concentration by Z'-LYTE assay relative to control	B	OCC[C@@H](Nc1ncnc2[nH]c(-c3ccccc3)cc12)c1ccccc1		CHEMBL4786776	=	Inhibition	%	6.0	CHEMBL3045	Homo sapiens	INH	%	6.0
	22836380	CHEMBL4718885	Inhibition of human full length GST tagged PRKCB1 expressed in insect cells at 500 nM using Ser/Thr 07 as substrate incubated for 1 hr in presence of ATP at its Km concentration by Z'-LYTE assay relative to control	B	CN(C)CCNCc1ccc(-c2cc3c(N[C@H](CO)c4ccccc4)ncnc3[nH]2)cc1F		CHEMBL4748367	=	Inhibition	%	17.0	CHEMBL3045	Homo sapiens	INH	%	17.0
	22836381	CHEMBL4718885	Inhibition of human full length GST tagged PRKCB1 expressed in insect cells at 500 nM using Ser/Thr 07 as substrate incubated for 1 hr in presence of ATP at its Km concentration by Z'-LYTE assay relative to control	B	CCOc1ccccc1-c1cc2c(N[C@H](CO)c3ccccc3)ncnc2[nH]1		CHEMBL4776396	=	Inhibition	%	15.0	CHEMBL3045	Homo sapiens	INH	%	15.0
	22836382	CHEMBL4718885	Inhibition of human full length GST tagged PRKCB1 expressed in insect cells at 500 nM using Ser/Thr 07 as substrate incubated for 1 hr in presence of ATP at its Km concentration by Z'-LYTE assay relative to control	B	COc1ccccc1-c1cc2c(N[C@H](CO)c3ccccc3)ncnc2[nH]1		CHEMBL4783569	=	Inhibition	%	8.0	CHEMBL3045	Homo sapiens	INH	%	8.0
	22836383	CHEMBL4718885	Inhibition of human full length GST tagged PRKCB1 expressed in insect cells at 500 nM using Ser/Thr 07 as substrate incubated for 1 hr in presence of ATP at its Km concentration by Z'-LYTE assay relative to control	B	OC[C@@H](Nc1ncnc2[nH]c(-c3ccccc3)cc12)c1ccccc1		CHEMBL4780286	=	Inhibition	%	1.0	CHEMBL3045	Homo sapiens	INH	%	1.0
	22843608	CHEMBL4720594	Inhibition of human PKCb2 using Histone H1 as substrate by [gamma-33P]-ATP assay	B	CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL388978	=	IC50	nM	2.5	CHEMBL3045	Homo sapiens	IC50	10^-9M	2.5
	22843609	CHEMBL4720595	Inhibition of human PKCb1 using Histone H1 as substrate by [gamma-33P]-ATP assay	B	CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL388978	=	IC50	nM	7.26	CHEMBL3045	Homo sapiens	IC50	10^-9M	7.26
	22843953	CHEMBL4720939	Inhibition of human PKCb2 assessed as residual activity using Histone H1 as substrate at 1 uM by [gamma-33P]-ATP assay relative to control	B	O=C(Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1OCCCN1CCOCC1)c1cc([N+](=O)[O-])ccc1F		CHEMBL4750196	=	Activity	%	102.76	CHEMBL3045	Homo sapiens	Activity	%	102.76
	22843954	CHEMBL4720940	Inhibition of human PKCb1 assessed as residual activity using Histone H1 as substrate at 1 uM by [gamma-33P]-ATP assay relative to control	B	O=C(Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1OCCCN1CCOCC1)c1cc([N+](=O)[O-])ccc1F		CHEMBL4750196	=	Activity	%	98.7	CHEMBL3045	Homo sapiens	Activity	%	98.7
	22844827	CHEMBL4721502	Inhibition of PKCbeta1 (unknown origin) assessed as residual activity at 1 uM by Kinomescan method relative to control	B	CCOc1nc(Nc2ccc(C(=O)N3CCOCC3)cc2OC)nc2[nH]ccc12		CHEMBL4794578	=	Activity	%	100.13	CHEMBL3045	Homo sapiens	Activity	%	100.13
	22844828	CHEMBL4721503	Inhibition of PKCbeta2 (unknown origin) assessed as residual activity at 1 uM by Kinomescan method relative to control	B	CCOc1nc(Nc2ccc(C(=O)N3CCOCC3)cc2OC)nc2[nH]ccc12		CHEMBL4794578	=	Activity	%	89.11	CHEMBL3045	Homo sapiens	Activity	%	89.11
	22952958	CHEMBL4766895	Inhibition of recombinant human PKCbeta1 (2 to end residues) assessed as residual activity at 10 uM using histone H1 as substrate incubated for 40 mins in presence of [gamma33P]ATP by scintillation counting based radiometry assay relative to control	B	CC(C)(C)c1cc(NC(=O)Nc2ccc(Nc3ncnc4c3OCCCN4)cc2)no1		CHEMBL4793380	=	Activity	%	99.0	CHEMBL3045	Homo sapiens	Activity	%	99.0
	22952959	CHEMBL4766896	Inhibition of recombinant human PKCbeta2 (2 to end residues) assessed as residual activity at 10 uM using histone H1 as substrate incubated for 40 mins in presence of [gamma33P]ATP by scintillation counting based radiometry assay relative to control	B	CC(C)(C)c1cc(NC(=O)Nc2ccc(Nc3ncnc4c3OCCCN4)cc2)no1		CHEMBL4793380	=	Activity	%	105.0	CHEMBL3045	Homo sapiens	Activity	%	105.0
	23124271	CHEMBL4806344	Inhibition of PRKCB2 (unknown origin) at 10 uM relative to control	B	Cn1cc(-n2cnc3c(NCc4nc5cc(Cl)c(Cl)cc5[nH]4)nc(N4CCOCC4)nc32)cn1		CHEMBL4877117	=	Inhibition	%	46.0	CHEMBL3045	Homo sapiens	INH	%	46.0
	23128455	CHEMBL4807960	Inhibition of PKCbeta1 (unknown origin) assessed as residual activity measured at 1 uM	B	Cc1nc(Nc2ncc(C(=O)Nc3c(C)csc3Cl)s2)cc(N2CCN(CCO)CC2)n1		CHEMBL4867844	>	Activity	%	75.0	CHEMBL3045	Homo sapiens	Activity	%	75.0
	23128456	CHEMBL4807960	Inhibition of PKCbeta1 (unknown origin) assessed as residual activity measured at 1 uM	B	Cc1nc(Nc2ncc(C(=O)Nc3c(Cl)ccnc3C)s2)cc(NN2CCN(CCO)CC2)n1		CHEMBL4855726	>	Activity	%	75.0	CHEMBL3045	Homo sapiens	Activity	%	75.0
	23128457	CHEMBL4807960	Inhibition of PKCbeta1 (unknown origin) assessed as residual activity measured at 1 uM	B	Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1		CHEMBL1421	>	Activity	%	75.0	CHEMBL3045	Homo sapiens	Activity	%	75.0
	23128458	CHEMBL4807961	Inhibition of PKCbeta2 (unknown origin) assessed as residual activity measured at 1 uM	B	Cc1nc(Nc2ncc(C(=O)Nc3c(C)csc3Cl)s2)cc(N2CCN(CCO)CC2)n1		CHEMBL4867844	>	Activity	%	75.0	CHEMBL3045	Homo sapiens	Activity	%	75.0
	23128459	CHEMBL4807961	Inhibition of PKCbeta2 (unknown origin) assessed as residual activity measured at 1 uM	B	Cc1nc(Nc2ncc(C(=O)Nc3c(Cl)ccnc3C)s2)cc(NN2CCN(CCO)CC2)n1		CHEMBL4855726	>	Activity	%	75.0	CHEMBL3045	Homo sapiens	Activity	%	75.0
	23128460	CHEMBL4807961	Inhibition of PKCbeta2 (unknown origin) assessed as residual activity measured at 1 uM	B	Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1		CHEMBL1421	>	Activity	%	75.0	CHEMBL3045	Homo sapiens	Activity	%	75.0
	23248251	CHEMBL4830428	Inhibition of human PKCb1 using Histone H1 as substrate assessed as enzyme activity incubated for 2 hrs by [gamma-33P]-ATP assay relative to control	B	CC(C)c1c2cc(-c3ccnc(Nc4ccc5c(N6CCN(C)CC6)ccnc5c4)n3)ccc2nn1C		CHEMBL4856177	<	Activity	%	20.0	CHEMBL3045	Homo sapiens	Activity	%	20.0
Not Active	23324100	CHEMBL4880719	PKCbetaI (h) Millipore kinase activity assay	B	CC1=C(C#N)C(c2ccc3[nH]nc(C)c3c2)C(C#N)=C(C)N1		CHEMBL4593677		Inhibition	%	-4.0	CHEMBL3045	Homo sapiens	% inhibition	%	-4.0
Not Active	23324101	CHEMBL4880720	PKCbetaII (h) Millipore kinase activity assay	B	CC1=C(C#N)C(c2ccc3[nH]nc(C)c3c2)C(C#N)=C(C)N1		CHEMBL4593677		Inhibition	%	7.0	CHEMBL3045	Homo sapiens	% inhibition	%	7.0
Not Active	23329481	CHEMBL4881188	PKCbetaI (h) Eurofins Kinase panel	B	CN1CCN(c2cnc3c(C4CCN(C(=O)c5ccc(OC(F)(F)F)cc5N)CC4)ncnc3c2)CC1		CHEMBL4445670		% residual kinase activity	%	110.0	CHEMBL3045	Homo sapiens	% residual kinase activity	%	110.0
Not Active	23329482	CHEMBL4881189	PKCbetaII (h) Eurofins Kinase panel	B	CN1CCN(c2cnc3c(C4CCN(C(=O)c5ccc(OC(F)(F)F)cc5N)CC4)ncnc3c2)CC1		CHEMBL4445670		% residual kinase activity	%	112.0	CHEMBL3045	Homo sapiens	% residual kinase activity	%	112.0
Not Active	23334937	CHEMBL4881559	PKCBI (h) Upstate kinase activity assay	B	Cc1c[nH]c2nccc(Oc3c(F)cc(Nc4cc(Cl)nc(N)n4)cc3F)c12		CHEMBL1971943		Inhibition	%	8.0	CHEMBL3045	Homo sapiens	% inhibition	%	8.0
Not Active	23334938	CHEMBL4881560	PKCBII(h) Upstate kinase activity assay	B	Cc1c[nH]c2nccc(Oc3c(F)cc(Nc4cc(Cl)nc(N)n4)cc3F)c12		CHEMBL1971943		Inhibition	%	9.0	CHEMBL3045	Homo sapiens	% inhibition	%	9.0
Not Active	23337735	CHEMBL4882106	PRKCB1 Invitrogen selectivity data (BI)	B	CN(C)C(=O)Cn1cc(-c2nc([C@@](C)(c3ccc(-c4cnc(N)nc4)cc3)C3CC3)no2)cn1		CHEMBL3417525		% Ctrl	%	98.5	CHEMBL3045	Homo sapiens	% Ctrl	%	98.5
Not Active	23337736	CHEMBL4882107	PRKCB2 Invitrogen selectivity data (BI)	B	CN(C)C(=O)Cn1cc(-c2nc([C@@](C)(c3ccc(-c4cnc(N)nc4)cc3)C3CC3)no2)cn1		CHEMBL3417525		% Ctrl	%	100.0	CHEMBL3045	Homo sapiens	% Ctrl	%	100.0
Not Active	23343282	CHEMBL4882467	PRKCB1 Invitrogen selectivity data (BI)	B	CCOC(=O)c1cc2cc(-c3cc(C(=O)NCc4ccc(C(=O)O)cc4)nn3C)ccc2[nH]1		CHEMBL1939876		% Ctrl	%	97.0	CHEMBL3045	Homo sapiens	% Ctrl	%	97.0
Not Active	23352188	CHEMBL4882877	PRKCB1 (PKC beta I) Kinase screen	B	C[C@H]1CN(c2cc(-c3n[nH]c4ccc(OC5(C)CC5)cc34)ncn2)C[C@@H](C)O1		CHEMBL4098877		Inhibition	%	-7.69	CHEMBL3045	Homo sapiens	% Inhibition	%	-7.6896
Not Active	23367703	CHEMBL4884056	PKC-beta1 ProQinase selectivity panel	B	O=C1c2ccc(Nc3ccc(F)cc3F)cc2CCc2ccc(OC[C@H](O)CO)cc21		CHEMBL2152944		% Residual activity with Skepinone-L	%	103.0	CHEMBL3045	Homo sapiens	% Residual activity with Skepinone-L	%	103.0
Not Active	23367704	CHEMBL4884057	PKC-beta2 ProQinase selectivity panel	B	O=C1c2ccc(Nc3ccc(F)cc3F)cc2CCc2ccc(OC[C@H](O)CO)cc21		CHEMBL2152944		% Residual activity with Skepinone-L	%	97.0	CHEMBL3045	Homo sapiens	% Residual activity with Skepinone-L	%	97.0
Not Active	23370197	CHEMBL4884439	PKCbetaI (h) Eurofins kinase panel	B	CCc1ccccc1C(=O)Nc1n[nH]c2c(C)c(F)c(C3C(C#N)=C(C)N(C)C(C)=C3C#N)cc12		CHEMBL4580220		% residual kinase activity	%	55.0	CHEMBL3045	Homo sapiens	% residual kinase activity	%	55.0
Not Active	23370198	CHEMBL4884440	PKCbetaII (h) Eurofins kinase panel	B	CCc1ccccc1C(=O)Nc1n[nH]c2c(C)c(F)c(C3C(C#N)=C(C)N(C)C(C)=C3C#N)cc12		CHEMBL4580220		% residual kinase activity	%	42.0	CHEMBL3045	Homo sapiens	% residual kinase activity	%	42.0
	23372860	CHEMBL4884825	PKCbeta(PRKBPHY3) Takeda global kinase panel	B	CN1C(=O)[C@@H](N2CCc3cn(Cc4ccccc4)nc3C2=O)COc2ccccc21		CHEMBL4088216		IC50	nM	1000.0	CHEMBL3045	Homo sapiens	pIC50		6.0
	23373269	CHEMBL4885116	PKCbeta(PRKBPHY3) Takeda global kinase panel	B	CN1C(=O)[C@@H](N2CCc3c(nn(Cc4ccccc4)c3Br)C2=O)COc2ccccc21		CHEMBL4549667		IC50	nM	1000.0	CHEMBL3045	Homo sapiens	pIC50		6.0
	23373625	CHEMBL4885402	PKCbeta(PRKBPHY3) Takeda global kinase panel	B	CN1C(=O)[C@@H](N2CCc3cn(CC4CCS(=O)(=O)CC4)nc3C2=O)COc2ccccc21		CHEMBL4097778		IC50	nM	1000.0	CHEMBL3045	Homo sapiens	pIC50		6.0
Not Active	23375070	CHEMBL4886058	PKC_beta1 Kinase panel	B	CC(C)(O)[C@H](F)CN1Cc2cc(NC(=O)c3cnn4cccnc34)c(N3CCOCC3)cc2C1=O		CHEMBL4475494		Inhibition	%	4.0	CHEMBL3045	Homo sapiens	% Inhibition	%	4.0
Not Active	23375343	CHEMBL4886325	protein kinase C, beta 1 Millipore kinase panel	B	COCCc1ccc(-c2c(C)nc3c(N4CCOCC4)ccnn23)cn1		CHEMBL2180408		Inhibition	%	-5.0	CHEMBL3045	Homo sapiens	% inhibition	%	-5.0
Not Active	23382427	CHEMBL4887142	PKCbeta II Invitrogen kinase activity assay	B	CNC(=O)c1ccc(Nc2ncc(C(F)(F)F)c(NCc3nccnc3N(C)S(C)(=O)=O)n2)cc1		CHEMBL3137331		Inhibition	%	15.0	CHEMBL3045	Homo sapiens	% inhibition	%	15.0
Not Active	23383947	CHEMBL4887555	PRKCB1 Invitrogen Lab (UK) kinase screen (BI)	B	CCC(F)(F)c1cc(N2CCC(S(C)(=O)=O)CC2)nc2sc(C(N)=O)c(N)c12		CHEMBL4522930		% Ctrl	%	89.0	CHEMBL3045	Homo sapiens	% Ctrl	%	89.0
Not Active	23383948	CHEMBL4887555	PRKCB1 Invitrogen Lab (UK) kinase screen (BI)	B	CCC(F)(F)c1cc(N2CCC(S(C)(=O)=O)CC2)nc2sc(C(N)=O)c(N)c12		CHEMBL4522930		% Ctrl	%	102.0	CHEMBL3045	Homo sapiens	% Ctrl	%	102.0
Not Active	23383949	CHEMBL4887556	PRKCB2 Invitrogen Lab (UK) kinase screen (BI)	B	CCC(F)(F)c1cc(N2CCC(S(C)(=O)=O)CC2)nc2sc(C(N)=O)c(N)c12		CHEMBL4522930		% Ctrl	%	99.0	CHEMBL3045	Homo sapiens	% Ctrl	%	99.0
Not Active	23384418	CHEMBL4888013	PKCbetaI(h) Millipore kinase panel	B	CC[C@@H](Nc1c(C#N)c(-c2ccc(-c3cccc(C)c3F)cc2)nc2cnccc12)C(=O)O		CHEMBL4802045		Inhibition	%	16.52	CHEMBL3045	Homo sapiens	% inhibition	%	16.52
Not Active	23384419	CHEMBL4888014	PKCbetaII(h) Millipore kinase panel	B	CC[C@@H](Nc1c(C#N)c(-c2ccc(-c3cccc(C)c3F)cc2)nc2cnccc12)C(=O)O		CHEMBL4802045		Inhibition	%	-1.59	CHEMBL3045	Homo sapiens	% inhibition	%	-1.59
Not Active	23384689	CHEMBL4888215	PRKCB1 (PKC beta I) SelectScreen Kinase panel (LifeTechnologies)	B	C=CC(=O)Nc1ccc2[nH]c(=O)n(C3CCN(Cc4ccc(-c5nc6cc[nH]c(=O)c6cc5-c5ccccc5)cc4)CC3)c2c1		CHEMBL4795065		Inhibition	%	-7.0	CHEMBL3045	Homo sapiens	% Inhibition	%	-7.0
Not Active	23384690	CHEMBL4888216	PRKCB2 (PKC beta II) SelectScreen Kinase panel (LifeTechnologies)	B	C=CC(=O)Nc1ccc2[nH]c(=O)n(C3CCN(Cc4ccc(-c5nc6cc[nH]c(=O)c6cc5-c5ccccc5)cc4)CC3)c2c1		CHEMBL4795065		Inhibition	%	9.0	CHEMBL3045	Homo sapiens	% Inhibition	%	9.0
Not Active	23385904	CHEMBL4888377	PKCbetaI Invitrogen kinase panel	B	COc1nc2ccc([C@@](O)(c3ccccc3)C3CCN(C(C)=O)CC3)cc2c(Cl)c1Cc1ccc(-n2cccn2)cc1		CHEMBL4802042		Inhibition	%	1.0	CHEMBL3045	Homo sapiens	% inhibition	%	1.0
